<SEC-DOCUMENT>0001445305-14-003560.txt : 20140812
<SEC-HEADER>0001445305-14-003560.hdr.sgml : 20140811
<ACCEPTANCE-DATETIME>20140808170336
ACCESSION NUMBER:		0001445305-14-003560
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20140630
FILED AS OF DATE:		20140808
DATE AS OF CHANGE:		20140808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		141028246

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>q2201410q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Q2 2014 10Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sC76CFEAA2748B30C3141688378609FB5"></a><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: 001-33637</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified In Its Charter)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="3%"></td><td width="48%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">62-1765329</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or Other Jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2525 West End Avenue, Suite 950,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nashville, Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">37203</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(615) 255-0068</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="20%"></td><td width="3%"></td><td width="42%"></td><td width="3%"></td><td width="26%"></td><td width="3%"></td><td width="3%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168; </font><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="47%"></td><td width="21%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding&#160;at&#160;August 4,&#160;2014&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, no par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,577,699</font></div></td></tr></table></div></div><br><hr style="page-break-after:always"><a name="s2E38E370F886DD3A8EE1688379A9EB19"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="83%"></td><td width="17%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sB361B1CDAD7C67B4D2E0688379DB88A7"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">PART I &#8211; FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sB361B1CDAD7C67B4D2E0688379DB88A7">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s127AAB225589714DB18F688379FC73FB"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;1. Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s127AAB225589714DB18F688379FC73FB">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sABAB811E5CA91E8B2C1F6883769C9646"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sABAB811E5CA91E8B2C1F6883769C9646">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBC2CC8EAEE9EAECE80BD688376903B68"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations and Comprehensive Income</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sBC2CC8EAEE9EAECE80BD688376903B68">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sCB15A53EA180ABB43210688376597753"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sCB15A53EA180ABB43210688376597753">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sC530CEFC7B40930E26FF6883767F446A"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statement of Equity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sC530CEFC7B40930E26FF6883767F446A">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s0F52784E0FD2304443E568837AF644B6"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Notes to the Unaudited Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s0F52784E0FD2304443E568837AF644B6">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s07A2E73794404EBCCD4968837CEA341A"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s07A2E73794404EBCCD4968837CEA341A">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF026F9EFDCBD3D9E6E0568837DE4BAE6"><font style="font-family:inherit;font-size:10pt;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sF026F9EFDCBD3D9E6E0568837DE4BAE6">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sE3396F81BEFC7D37229268837E16204B"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sE3396F81BEFC7D37229268837E16204B">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s11226D916CF26B4E4A4B68837E38A9B2"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">PART II &#8211; OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s11226D916CF26B4E4A4B68837E38A9B2">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s78B1FD3BF78D90598D9168837E6A4997"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;1. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s78B1FD3BF78D90598D9168837E6A4997">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sEB24D15BFD0DB2D7198468837E8BEAA2"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sEB24D15BFD0DB2D7198468837E8BEAA2">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sE7DDA99ADC2D2E00D4DA688377EE6AE8"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sE7DDA99ADC2D2E00D4DA688377EE6AE8">22</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sD357D40459154F7D4AE868837EDF1C37"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Item&#160;6. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sD357D40459154F7D4AE868837EDF1C37">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s3BEBBAADEC090AAB752268837F1000E3"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s3BEBBAADEC090AAB752268837F1000E3">24</a></div></td></tr></table></div></div><br><hr style="page-break-after:always"><a name="sB361B1CDAD7C67B4D2E0688379DB88A7"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</font></div><a name="s127AAB225589714DB18F688379FC73FB"></a><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1. Financial Statements (Unaudited)</font></div><a name="sABAB811E5CA91E8B2C1F6883769C9646"></a><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,050,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,869,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,825,632</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net of allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,014,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,530,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,996,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,744,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,537,191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,632,037</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,679,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,073,458</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,498,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,036,301</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,554,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,468,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,613,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,220,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,035,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,642,960</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,509,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,863,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,545,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">776,125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,736,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,321,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock&#8212;no par value; 100,000,000 shares authorized; 17,660,367 and 17,985,503 shares issued and outstanding as of June 30, 2014 and December&#160;31, 2013, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,529,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,073,941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,403,430</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,394,540</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,933,074</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,468,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200,810</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(176,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,732,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,291,843</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,468,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,613,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="sBC2CC8EAEE9EAECE80BD688376903B68"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="42%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,750,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,843,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,339,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,154,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,263,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling and marketing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,930,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,542,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,544,013</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,215,988</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">861,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,386,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,687,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,835,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,140,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,037,466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,430,940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">598,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407,695</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,534,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,221,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,219,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,153,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,215,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,140,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,544</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,359</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,232,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,112,262</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,696,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(523,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(711,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,959</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648,854</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss at subsidiary attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">722,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(639,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings (loss) per share attributable to common shareholders</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,743,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,825,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,580,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,025,913</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,093,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,756,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648,854</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="sCB15A53EA180ABB43210688376597753"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800,231</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">325,344</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excess tax benefit derived from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(711,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,038</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,038</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncash investment losses </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net changes in assets and liabilities affecting operating activities, net of effect of business combination:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,484,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(701,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,165,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,707,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,479</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,818,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,792,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions to property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,119</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,254,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,371,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,267,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions to intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,829,693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investment activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,768,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,788,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net borrowings on line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,292</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excess tax benefit derived from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of subsidiary shares to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,005</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,580,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,162,302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,688,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,818,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,684,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,869,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,349,381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,050,841</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,664,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in unpaid additions to intangibles, property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="sC530CEFC7B40930E26FF6883767F446A"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statement of Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="35%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Retained earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,985,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,073,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,394,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(176,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,291,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options and related tax benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of subsidiary shares to noncontrolling interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,005</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,005</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase of common shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(340,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,580,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,580,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,660,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,529,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,403,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200,810</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,732,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s0F52784E0FD2304443E568837AF644B6"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><a name="s02E5A4D08BA13AA2CF95688376495626"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1) ORGANIZATION AND BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc. and its subsidiaries (the&#160;"Company" or "Cumberland") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland has both internal product development and commercial capabilities. The Company is focused on maximizing the commercial potential of its current brands, as well as expanding its product portfolio through select acquisitions and development of new product candidates.  Cumberland&#8217;s products are manufactured by third parties, which are overseen by the Company&#8217;s quality assurance professionals. The Company works closely with its distribution partners to ensure the delivery and availability of the Company's products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission, or the SEC, and omit certain information and footnote disclosure necessary to present the statements in accordance with U.S. generally accepted accounting principles. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total comprehensive income (loss) was comprised solely of net income (loss) for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Financial Accounting Standards Board (the "FASB") issued amended guidance in the form of a FASB Accounting Standards Update on "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity".  The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomes effective on January 1, 2015. Adoption is on a prospective basis. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued amended guidance in the form of a FASB Accounting Standards Update on, "Revenue from Contracts with Customers".  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process.  The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method by which we will adopt the standard in 2017.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Policies:</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual amounts could differ from those estimated at the time the condensed consolidated financial statements are prepared.  The Company's most significant estimates include: (1) its </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">allowances for chargebacks and accruals for rebates and product returns and (2) the  allowances for obsolescent or unmarketable inventory.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Operating Segments</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment, specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold.  Substantially all of the Company&#8217;s assets are located in the United States, and total revenues are primarily attributable to U.S.&#160;customers.</font></div><a name="s497C6A863CC3A6844F40688376849EAB"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2) MARKETABLE SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of U.S. Treasury notes and bonds, U.S. Government Agency notes and bonds and bank-guaranteed, variable rate demand notes ("VRDN").  At the time of purchase,  the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 1 -</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices for identical instruments in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 2 -</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 3 -</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant inputs to the valuation model are unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of these marketable securities, by level within the fair value hierarchy, as of each period end:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="200px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="62px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury notes and bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency issued mortgage-backed securities &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency notes and bonds &#8211; fixed rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SBA loan pools &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds &#8211; VRDN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of marketable  securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,692,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,133,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,825,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,724,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="sA0DB134133C2B0D8FB266883762CED16"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3) EARNINGS (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles the numerator and denominator used to calculate diluted earnings per share for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="65%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">722,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(639,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,743,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,025,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="441px"></td><td width="9px"></td><td width="102px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="103px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,825,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,580,891</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,093,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,756,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, restricted stock awards and options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">188,814</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">554,279</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, respectively, were outstanding but were not included in the computation of diluted EPS because the effect would be antidilutive.</font></div><a name="s0AD92C5BFA3F0B990DF16883763D7BD2"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4) REVENUES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s net revenues consisted of the following for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="39%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acetadote</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,063,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,784,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,398,968</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omeclamox-Pak</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,344,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristalose</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,559,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,041,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,935,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,158,293</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vaprisol</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,547</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,129,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,750,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081,088</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,843,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,339,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 10, the Company acquired rights to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;new products and both Omeclamox-Pak and Vaprisol contributed to Cumberland's net revenue during 2014. On October 28, 2013, Cumberland entered into an agreement with Pernix Therapeutics ("Pernix") to distribute and promote Omeclamox-Pak. Under the terms of the agreement, effective October 1, 2013, the Company began to record the revenue of this product and effective January 2014 Cumberland began distributing Omeclamox-Pak and promoting it to gastroenterologists across the United States.  On February 28, 2014, Cumberland entered into an agreement with Astellas Pharma US, Inc. ("Astellas") to acquire certain product rights, intellectual property and related assets of Vaprisol. The Company began selling Vaprisol in March 2014 and launched promotional efforts for the brand in May 2014.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2012, the Company entered into a settlement agreement with Paddock Laboratories, LLC ("Paddock") and Perrigo Company ("Perrigo") involving an Acetadote patent.  As part of the agreement, Cumberland supplies Perrigo with an </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized Generic version of the Company's Acetadote product.  The Company's revenue generated by sales of it's Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;agreements for the registration and commercialization of Caldolor outside the United States and amended its agreement with Harbin Gloria Pharmaceuticals Co., Ltd ("Gloria") to extend Gloria's territory.  Earlier in </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;agreements with international partners for commercialization of certain of its products into additional international territories. As a result of these agreements, Cumberland recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of non-refundable up-front payments as other revenue in the consolidated statement of operations during the first half of </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the full year of 2013, the Company entered into a total of </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;new agreements and amended </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;agreement with international partners.  The agreements entered into during 2013 provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, will handle ongoing distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulation.  Under the licensing agreements, Cumberland is entitled to receive additional milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company will recognize revenue for these substantive milestones using the milestone method. The 2013 agreements provide for up to  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in milestone payments related to regulatory approvals and up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in milestone payments related to total and annual product sales. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, Cumberland has not recognized any revenues related to milestones associated with the new agreements.  The Company is also entitled to receive royalties on future sales of the products under the agreements. </font></div><a name="s229028F966979118C436688376612DC4"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5) INVENTORIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor inventory on hand at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;had varying original expiration dates that began in the second quarter of 2014 and extend through January 2016. During 2013, the Company provided stability data to the Food and Drug Administration ("FDA") supporting that the Caldolor product expiration dates may be extended by up to a year.  In January 2014, the FDA notified the Company that it had approved its request to extend the original shelf life of the Caldolor 800mg vials from </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company has recognized cumulative charges for potential obsolescence and discontinuance losses, primarily for Caldolor, of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. If actual sales in future periods are less than projected sales, the Company may incur additional obsolescence losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient for Kristalose and maintains the inventory at the third-party manufacturer. As the ingredients are consumed in production, the value of the ingredients is transferred from raw materials to finished goods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, inventory was comprised of the following: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="65%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,228,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,697,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,996,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><a name="s18576820AF4DA2801A3968837644D897"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6) SHAREHOLDERS&#8217; EQUITY AND DEBT</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May&#160;13, 2010, the Company announced a share repurchase program to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2011, April 2012 and January 2013, the Company's Board of Directors replaced the prior authorizations with new </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;authorizations for repurchases of the Company's outstanding common stock.  During the first six months of </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">340,436</font><font style="font-family:inherit;font-size:10pt;">&#32;shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">676,551</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Grants </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first half of 2014, the Company issued approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">175,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one year</font><font style="font-family:inherit;font-size:10pt;">&#32;anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cumberland Emerging Technologies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company received approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from Gloria for its participation in Cumberland Emerging Technologies ("CET"). As a result, Gloria received shares in CET and will have the first right to negotiate a license to CET developed products for the Chinese market. Prior to April 2014, Cumberland owned </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of CET, with the balance of the enterprise being owned by Vanderbilt University and the Tennessee Technology Development Corporation.  In connection with Gloria&#8217;s investment in CET, the Company also provided an additional investment in CET.  Cumberland contributed </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and provided </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in loan foregiveness to CET in exchange for newly issued shares.   Upon completion of the additional investment by Gloria and Cumberland in April 2014, the Company&#8217;s ownership in CET is </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;">. As a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">New Debt Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, Cumberland entered into a Revolving Credit Loan Agreement (&#8220;Loan Agreement&#8221;) with SunTrust Bank. The new agreement replaced the August 2011 Fifth Amended and Restated Loan Agreement (the "Agreement") with its previous primary lender which was to expire on December 31, 2014.   There are no borrowings under the Loan Agreement at June 30, 2014 and it has a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year term expiring on June 26, 2017.  The Loan Agreement provides for an aggregate principal amount up to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">.  The initial revolving line of credit is up to </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;">, an increase from the </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the previous Agreement.  Similar to the previous Agreement, Cumberland has the ability to increase the borrowing amount up to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">, upon the satisfaction of certain conditions. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rate on the Loan Agreement is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">2.85%</font><font style="font-family:inherit;font-size:10pt;">.  In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of the Company&#8217;s assets.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Loan Agreement, Cumberland is subject to certain financial covenants, including, but not limited to, maintaining an EBIT to Interest Expense Ratio and a Funded Debt Ratio, as such terms are defined in the Loan Agreement and that are determined on a quarterly basis.  The Company is in compliance with all covenants at June 30, 2014. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred no early termination penalties upon termination of the previous Agreement and incurred less than $0.1 million in deferred financing costs related to the new Loan Agreement, which will be amortized to interest expense using the effective interest method over the term of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Previous Debt Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2011 Fifth Amended and Restated Loan Agreement carried an interest rate of the LIBOR Daily Floating Rate plus an applicable margin, as defined by the agreement (</font><font style="font-family:inherit;font-size:10pt;">2.17%</font><font style="font-family:inherit;font-size:10pt;">&#32;at December&#160;31, 2013). Interest and an unused line of credit fee (</font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per annum) were payable quarterly. There were no borrowings outstanding on the credit facility at December 31, 2013 or at any time during 2014.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the previous Agreement, the Company was subject to certain financial covenants including, but not limited to, maintaining a leverage ratio and interest coverage ratio, as defined in the Agreement.  In March&#160;2014 and May 2014, the previous Agreement was amended for certain provisions related to the aggregate ownership of the Company's common stock over 30% and certain other financial covenants.  As of March&#160;31, 2014 and December 31, 2013, the Company was in compliance with all covenants.  </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><a name="s2739BA8F6704C82BB28268837671F611"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(7) INCOME TAXES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company has unrecognized net operating loss carryforwards generated from the exercise of nonqualified options of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;">. These benefits occurred as a result of the actual tax benefit realized upon an employee's exercise exceeding the cumulative book compensation charge associated with the awards and will be recognized in the year in which they are able to reduce current income taxes payable.  Accordingly, deferred tax assets are not recognized for these net operating loss carryforwards or credit carryforwards resulting from the exercise of nonqualified options.  The Company's utilization of these net operating loss carryforwards and a net operating loss in 2013 resulted in it paying minimal income taxes in each of the years 2009 through 2013.  The Company expects to pay minimal income taxes in 2014 through utilization of these net operating loss carryforwards. </font></div><a name="sAF1835B4F96320F2986C6883763FCFEC"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8) COLLABORATIVE AGREEMENTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income.</font></div><a name="sB025A8622D1A6CA8DC8D6883763B8AFE"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9) COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received notices during 2012 and 2013, that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&#160; The Company is continuing to seek additional claims to protect its intellectual property associated with Acetadote and have additional pending patent applications relating to Acetadote.  The Company continues to consider its legal options and intends to continue to vigorously defend and protect its Acetadote product and related intellectual property rights.&#160; Also see the discussion of the Company's Acetadote patent defense legal proceedings contained in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part 1, Item 1, Business -Trademarks and Patents</font><font style="font-family:inherit;font-size:10pt;">, of the Company's Form 10-K for the year ended December&#160;31, 2013, which is incorporated by reference herein.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is unable to successfully defend the Acetadote patents and related intellectual property rights associated with its Acetadote product, its financial condition and results of operations could be adversely affected in the event of a loss of patent rights and lower sales volumes due to competition. </font></div><a name="s7CC4D6D222D04133AA53688376658F7A"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10) NEW PRODUCTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Omeclamox-Pak</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2013, the Company entered into an agreement with Pernix to distribute and promote Omeclamox-Pak. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:10pt;">) infection and duodenal ulcer disease. Under the terms of the agreement, the Company promotes the product to gastroenterologists across the United States and Pernix promotes the product through its specialty sales force focusing on select primary care physicians. The companies cooperate in the marketing and other activities needed to support the commercialization of the brand. The Company paid an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Pernix on October 29, 2013.  There are additional milestones at the first and second anniversary dates of the execution of the agreement totaling </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the aggregate. Royalty payments ranging from </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;based on tiered levels of gross profits are paid by Cumberland to Pernix.  The Company also makes royalty payments to Pernix to reflect their ongoing sales promotional efforts.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment that the Company paid to Pernix on October 29, 2013 is included in product and license rights and will be amortized over the remaining expected useful life of the acquired asset, currently the life of the agreement, which ends in June 2032.  Omeclamox-Pak contributed </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net revenues during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vaprisol</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 28, 2014, the Company acquired certain product rights, intellectual property and related assets of Vaprisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">  </sup></font><font style="font-family:inherit;font-size:10pt;">from Astellas. Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia.  The Company provided an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Astellas at closing. There is an additional milestone payment due forty-five days after the first anniversary date of the closing of the transaction of up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, dependent upon Cumberland achieving certain first year sales levels for the product.  Cumberland's acquisition of Vaprisol is accounted for as a business combination and the product is included in the results of operations since the acquisition date. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary allocation of the fair values of the assets acquired and liabilities assumed as of the acquisition date for Vaprisol:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="569px"></td><td width="9px"></td><td width="95px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,990,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent consideration obligation represents the additional milestone payment discussed above.  Cumberland prepared the valuations of the contingent consideration obligation and the intangible assets utilizing significant unobservable inputs. As a result, the valuations are classified as Level 3 fair value measurements.  Vaprisol contributed </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net revenues during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The pro-forma effects of the acquisition on the condensed consolidated financial statements were not material for disclosure.  </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><a name="s07A2E73794404EBCCD4968837CEA341A"></a><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; and management of our growth and integration of our acquisitions. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in &#8220;Risk Factors&#8221; on pages 19 through 34, and &#8220;Special Note Regarding Forward-Looking Statements&#8221; on page 34 of our Annual Report on Form 10-K for the year ended December&#160;31, 2013.  We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Form 10-Q.</font></div><a name="s47EA887BCA536B475E5168837D1C158B"></a><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  We market and sell our approved products through our hospital and gastroenterology sales forces in the United States and are establishing a network of international partners to bring our products to patients in their countries.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product portfolio includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acetadote</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:10pt;">) Injection, for the treatment of acetaminophen poisoning,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:10pt;">) Injection, for the treatment of pain and fever,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kristalose</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:10pt;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Omeclamox</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">-Pak</font><font style="font-family:inherit;font-size:10pt;">, (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">omeprazole, clarithromycin, amoxicillin</font><font style="font-family:inherit;font-size:10pt;">) for Helicobacter pylori (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:10pt;">) infection and duodenal ulcer disease,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vaprisol</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:10pt;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia,  and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hepatoren</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:10pt;">) Injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have both product development and commercial capabilities, and believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, in-licensing and out-licensing opportunities. Our product development team develops proprietary product formulations, manages our clinical trials, prepares all regulatory submissions and manages our medical call center. Our quality and manufacturing professionals oversee the manufacture and release of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Growth Strategy</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our growth strategy involves maximizing the potential of our existing products while continuing to build a portfolio of new, differentiated products. Specifically, we expect to grow by executing the following plans:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Continue to internally develop a line of late stage product candidates that address unmet medical needs. </font><font style="font-family:inherit;font-size:10pt;">&#32;Our development team that has successfully registered our Acetadote and Caldolor products is working to identify and </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:13px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">develop new late stage product candidates.  Those efforts have led to the advancement of Hepatoren into a multicenter Phase II study.  We will also continue to explore opportunities for label expansion to bring our marketed products to new patient populations.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expand our product portfolio by acquiring rights to additional marketed products and late stage product candidates.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs, which we believe helps mitigate our exposure to risk, cost and time associated with drug discovery and research. We plan to continue to target products that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. The addition of Omeclamox-Pak and Vaprisol reflects our strategy and commitment to selectively expanding our product portfolio as both met our acquisition criteria. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expand our global presence through select international partnerships.</font><font style="font-family:inherit;font-size:10pt;">&#32;We have established our own commercial capabilities, including a sales organization to cover the U.S. market for our products.  We are building a network of select international partners to register our products and make them available to patients in their countries.  We will continue to expand our network of international partners and continue to support our partners&#8217; registration and commercialization efforts in their respective territories. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Develop a pipeline of early-stage products through Cumberland Emerging Technologies.</font><font style="font-family:inherit;font-size:10pt;">&#32;In order to build our product pipeline, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities at Cumberland Emerging Technologies ("CET&#8221;), our majority-owned subsidiary. CET partners with universities and other research organizations to develop promising, early-stage product candidates, and Cumberland has the opportunity to negotiate rights to further develop and commercialize them in the U.S and other markets.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception.  In 2009, we completed an initial public offering of our common stock and listing of our shares on the NASDAQ exchange. Our website address is www.cumberlandpharma.com. We make available through our website our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and any amendments, as well as other documents following their filing with the SEC. These filings are also made available to the public by the SEC at www.sec.gov.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments and Highlights</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Omeclamox</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">-Pak</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Launch of Omeclamox-Pak</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched our promotion and distribution efforts to support Omeclamox-Pak in early 2014.  Our field sales force promotes Omeclamox-Pak to the gastroenterologist segment, which accounts for the largest component of the prescriber base for this product. Omeclamox-Pak is a branded prescription product used for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease.  This innovative product combines three well-known and widely prescribed medications: omeprazole, clarithromycin, and amoxicillin.  Omeclamox-Pak is the first FDA approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Clarithromycin and amoxicillin are both antibiotic agents which hinder the growth of H. pylori.  Interaction of these agents allows the stomach lining to heal effectively.  The medications are packaged together on convenient daily dosing cards, making it simple to follow the twice a day dosing before meals.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While there are competing products, Omeclamox-Pak is one of the few actively marketed products for this condition.  In addition, compared to the competing branded products, Omeclamox-Pak has the lowest pill burden, fewest days of therapy and the lowest cost.  Our involvement with Omeclamox-Pak was effective October 2013, through an agreement with Pernix Therapeutics ("Pernix").  Pernix continues to promote the product through its specialty sales force focusing on select primary care physicians. We are responsible for the marketing, sale and distribution of the product. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vaprisol</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Launch of Vaprisol</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, we entered into an agreement with Astellas Pharma US, Inc. ("Astellas") to acquire certain product rights, intellectual property and related assets of Vaprisol. Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the first and only intravenously administered branded treatment.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients.  These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We re-launched active promotion of the brand in early May 2014 utilizing our hospital sales force, which also features our Caldolor and Acetadote products.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cumberland Emerging Technologies</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, we received approximately $1.0 million from Harbin Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;) for their participation in CET. As a result, Gloria received shares in CET and joined the CET ownership group.  As part of this transaction, Gloria will have the first right to negotiate a license to CET developed products for the Chinese market. The funds from this new investment are being used to support and accelerate the development of CET product candidates. CET&#8217;s lead product candidate is ifetroban which is being developed by Cumberland under the brand name Hepatoren. During the second quarter of 2014 we also filed and cleared an amendment to the existing IND with the FDA to begin to evaluate an oral formulation of ifetroban.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to April 2014, we owned 85% of CET, with the balance of the enterprise being owned by Vanderbilt University and the Tennessee Technology Development Corporation.  In connection with Gloria&#8217;s investment in CET, we also provided an additional investment in CET through $1.0 million in cash and $2.4 million in loan foregiveness.  Upon completion of the additional investment by Gloria and Cumberland in April 2014, our ownership in CET is 80%. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Caldolor Pediatric Pain Study Published</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data from our Caldolor (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:10pt;">) pediatric pain study was published in the May 2014 edition of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pediatric Anesthesia. </font><font style="font-family:inherit;font-size:10pt;">The study was a multi-center, randomized, double-blind placebo-controlled, single dose trial of the safety and efficacy of intravenous ibuprofen for treatment of pain in pediatric patients undergoing tonsillectomy.   The objective of the study was to determine whether administration of Caldolor prior to pediatric tonsillectomy surgery can significantly decrease the number of doses of narcotic following surgery when compared with placebo.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the study a total of 161 pediatric patients undergoing tonsillectomy, ranging in age from 6 years to 17 years, were randomized to receive either a single dose of Caldolor or placebo prior to surgery.  Postoperative pain was managed with intravenous narcotic on an as needed basis based on the visual analog scale (VAS) as well as deemed appropriate by the recovery room nurses and physicians. The primary endpoint was the number of doses and amount of narcotic administered following surgery.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pediatric study indicated that there was a significant reduction in the number of postoperative doses and the amount of narcotic administered after surgery in the group that was administered Caldolor compared with the placebo group. There were no differences in the time to the first analgesia request or the number of patients who required analgesia after surgery. There were no significant differences in the incidence of serious adverse events.  The study concluded that the administration of Caldolor significantly reduced narcotic use in pediatric tonsillectomy patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Caldolor Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">On May 27, 2014, the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) issued U.S. Patent number 8,735,452 (the &#8220;452 Caldolor Patent&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">which is assigned to us.  The claims of the 452 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.  Following its issuance, the 452 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 23, 2014, we received a Notice of Allowance from the USPTO for a patent related to methods of treating pain using intravenous ibuprofen which is scheduled to expire in September 2029.  We also have additional patent applications related to Caldolor which are pending with the USPTO.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Caldolor Pediatric Presentation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data from our Caldolor pediatric fever study was presented at the Society of Pediatric Anesthesiology meeting in Ft. Lauderdale, Florida in March 2014.  The presentation entitled &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">A Multi-Center, Open-Label, Parallel, Active-Comparator, Multiple Dose Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Pediatric Patients</font><font style="font-family:inherit;font-size:10pt;">&#8221; was presented by Dr. Samia N. Khalil, M.D., Department of Anesthesiology, the University of Texas Medical School at Houston. The meeting was co-sponsored by the Society for Pediatric Anesthesia and the American Academy of Pediatrics Section on Anesthesiology and Pain Medicine.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pediatric study met its primary endpoint demonstrating that Caldolor was associated with a statistically significant reduction in temperature within the first 2 hours of dosing when compared to acetaminophen. Equally important, no safety concerns were observed during the study.  During the study, febrile hospitalized children ranging in age from less than 1 year to 16 years, were administered Caldolor injection or oral or rectal acetaminophen as a single or multiple dose therapy for up to five days.  One hundred and three patients were enrolled in this multi-center, randomized, open-label active comparator study. The pediatric patients received either 10 mg/kg intravenous ibuprofen (not to exceed 400 mg per dose) or 10 mg/kg acetaminophen (not to exceed 650 mg per dose).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acetadote</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acetadote Patents </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We developed a new formulation of Acetadote (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:10pt;">) Injection as part of the Phase IV commitment in response to a request by the FDA.  Since 2012, the USPTO has issued the following patents to us associated with Acetadote:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:660px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="86px"></td><td width="5px"></td><td width="126px"></td><td width="5px"></td><td width="82px"></td><td width="5px"></td><td width="348px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Patent number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent claims </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,148,356</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acetadote formulation and composition of matter</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,399,445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,653,061</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,722,738</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Administration method of acetylcysteine injection, without specification of the presence or lack of EDTA in the formulation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are continuing to seek additional claims to protect our intellectual property associated with Acetadote and have additional patent applications relating to Acetadote which are pending with the USPTO.  We intend to vigorously defend and protect our Acetadote product and related intellectual property rights.  Information and discussion regarding our Acetadote patent defense is contained in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part 1, Item 1, Business -Trademarks and Patents</font><font style="font-family:inherit;font-size:10pt;">, of our Form 10-K for the year ended December&#160;31, 2013, which is incorporated by reference herein.  We have no recent developments that would impact those disclosures.</font></div><a name="sFCA57846393AA9D1D14F68837D3E9A10"></a><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see a discussion of our critical accounting policies and significant judgments and estimates on pages 40 through 43 in &#8220;Management&#8217;s Discussion and Analysis&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2013.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Estimates and Judgments</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, share-based compensation, research and development expenses and intangible assets.</font></div><a name="sFC31F61A30CF8CA31A7668837D708E51"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">three months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Net revenues for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, representing an increase of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">37.7%</font><font style="font-family:inherit;font-size:10pt;">.   This significant revenue increase was driven primarily by increases in Kristalose product revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, Omeclamox-Pak revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and Vaprisol revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">.  A decrease in Acetadote product revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;partially offset this increase. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristalose revenue increased </font><font style="font-family:inherit;font-size:10pt;">74.4%</font><font style="font-family:inherit;font-size:10pt;">&#32;over the prior year primarily due to new positioning for the product.  We increased the price of Kristalose during the first quarter of 2014 to bring Kristalose more in line with the other marketed branded prescription products in its class.  Concurrent with the price increase, we increased our patient focused initiatives to enhance patient affordability and increase demand.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in Acetadote net revenue was due to decreased sales volume of the branded Acetadote product largely as a result of generic competition. In addition, our Acetadote product revenue for the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;included </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue resulting from sales of our Authorized Generic distributed by Perrigo, compared to </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period last year.   </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</font><font style="font-family:inherit;font-size:10pt;">. As a percentage of net revenues, cost of products sold decreased to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13.3%</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16.3%</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">.  The decrease in costs of sales as a percentage of revenue was attributable to a change in the product sales mix and increased pricing.  </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling and marketing</font><font style="font-family:inherit;font-size:10pt;">. Selling and marketing expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, which was an increase from the prior year's expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the $0.3 million increase in Omeclamox product royalties. Our selling and marketing efforts continue to be refined under our commercial strategy, including the incremental costs of promoting our recently added products.     </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</font><font style="font-family:inherit;font-size:10pt;">. Research and development costs for the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period last year, representing a decrease of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">37.9%</font><font style="font-family:inherit;font-size:10pt;">.   This change is a result of decreased product development and clinical study costs during 2014 compared to 2013 following the conclusion of clinical studies related to Caldolor. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative</font><font style="font-family:inherit;font-size:10pt;">.  General and administrative expense was </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">second quarter of 2013</font><font style="font-family:inherit;font-size:10pt;">.  The $0.2 million increase was driven by increases in salary wages and benefits costs during the quarter.  We continue to realign the organization to reflect the current mix of brands.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization.</font><font style="font-family:inherit;font-size:10pt;">&#32;Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was relatively consistent with the prior year. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax (expense) benefit</font><font style="font-family:inherit;font-size:10pt;">. Income tax expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, compared to an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">second quarter of 2013</font><font style="font-family:inherit;font-size:10pt;">, representing an increase in expense of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. The increase was the result of pretax income in the second quarter of 2014 compared to pretax loss in the prior year.  As a percentage of income before income taxes, income tax expense was </font><font style="font-family:inherit;font-size:10pt;">42.4%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">41.7%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we have approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized net operating loss carryforwards resulting from the exercise of nonqualified stock options in 2009 that will be used to significantly offset future income tax obligations.  These benefits will be recognized in the year in which they are able to reduce current income taxes payable. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compared to the </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Net revenues for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;">$17.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$17.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">, representing an increase of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2.9%</font><font style="font-family:inherit;font-size:10pt;">.  This revenue increase was driven primarily by increases in Kristalose product revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, Omeclamox-Pak revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and Vaprisol revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the first half of </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. A decrease in Acetadote product revenue of </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;partially offset this increase. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristalose revenue increased </font><font style="font-family:inherit;font-size:10pt;">66.8%</font><font style="font-family:inherit;font-size:10pt;">&#32;over the prior year primarily due to new positioning for the product.  We increased the price of Kristalose during the first quarter of 2014 to bring Kristalose more in line with the other marketed branded prescription products in its class.  Concurrent with the price increase, we increased our patient focused initiatives to enhance patient affordability and increase demand.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in Acetadote net revenue was due to decreased sales volume of the branded Acetadote product largely as a result of generic competition. In addition, our Acetadote product revenue for </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;included </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue resulting from sales of our Authorized Generic, compared to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of such revenue last year. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized $0.6 million of other revenue in the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;as the result of upfront payments we received in connection with out-licensing agreements with international commercial partners.   </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">products sold</font><font style="font-family:inherit;font-size:10pt;">. As a percentage of net revenues, cost of products sold was </font><font style="font-family:inherit;font-size:10pt;">13.2%</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, which was consistent with </font><font style="font-family:inherit;font-size:10pt;">13.1%</font><font style="font-family:inherit;font-size:10pt;">&#32;in the prior year.  The slight increase in costs of sales as a percentage of revenue was attributable to a change in the sales mix.  </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling and marketing</font><font style="font-family:inherit;font-size:10pt;">. Selling and marketing expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">, representing an increase of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">4.5%</font><font style="font-family:inherit;font-size:10pt;">.  This increase was primarily due to the $0.5 million increase in Omeclamox product royalties, offset by reductions in our salary expenses. Our selling and marketing efforts continue to be refined under our commercial strategy, including the incremental costs of promoting our recently added products.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</font><font style="font-family:inherit;font-size:10pt;">. Research and development costs for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period last year, representing a decrease of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">40.5%</font><font style="font-family:inherit;font-size:10pt;">.   This change is a result of decreased product development and clinical study costs during 2014 compared to 2013 following the conclusion of clinical studies related to Caldolor. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period last year. The </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;decrease was attributable to salary expenses and consulting fees.  We continue to realign the organization to reflect the current mix of brands. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization.</font><font style="font-family:inherit;font-size:10pt;">&#32;Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.   Amortization expense for the first half of </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the first half of </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, representing an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. The increase was primarily due to increased product rights, capitalized patents and patent defense costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax expense</font><font style="font-family:inherit;font-size:10pt;">. Income tax expense for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, representing an increase of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;over the </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">.  As a percentage of income before income taxes, income tax expense was </font><font style="font-family:inherit;font-size:10pt;">41.9%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the the first half of </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">33.3%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period last year. The decrease in income tax rate for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the reinstatement of the U.S. research and development tax credit during 2013.</font></div><a name="s5F934DE592AD97FA341A688377EE9E23"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary sources of liquidity are cash flows provided by our operations, the availability under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009.  For both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, we generated </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash flow from operations.  We believe that our internally generated cash flows and amounts available under our line of credit will be adequate to service existing debt, finance internal growth and fund capital expenditures. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest a portion of our cash reserves in variable rate demand notes ("VRDNs") and a portfolio of government-backed securities (including U.S. Treasuries, government-sponsored enterprise debentures and government-sponsored adjustable rate, mortgage-backed securities).  The VRDNs are generally issued by municipal governments and are backed by a financial institution letter of credit.&#160; We hold a put right on the VRDNs, which allows us to liquidate the investments relatively quickly (less than one week).&#160; The government-backed securities have an active secondary market that generally provides for liquidity in less than one week.  At </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, we had approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and  </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;invested in marketable securities, respectively.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our liquidity and working capital as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="68%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,050,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,869,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,825,632</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,876,473</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,889,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital (current assets less current liabilities)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-top:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,768,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,133,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current ratio (multiple of current assets to current liabilities)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving line of credit availability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our net changes in cash and cash equivalents for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="66%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,818,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,792,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,768,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,788,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,688,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,818,616</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,684,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in cash and cash equivalents for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was mainly attributable to our </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;acquisition of Vaprisol which is included in investing activities. We also used cash in investing activities as we increased our net investment in marketable securities by </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. Our financing activities include the </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;investment Gloria made in CET and the repurchase of shares of our common stock totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Cash provided by operating activities was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and included net income of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net decrease in cash and cash equivalents for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily attributable to the  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;net investment in certain government and government-backed securities. We also repurchased shares of our common stock totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the period. These decreases were partially offset by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net income.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, we have approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized net operating loss carryforwards resulting from the exercise of nonqualified stock options in 2009 that will be used to significantly offset future income tax obligations.  These benefits will be recognized in the year in which they are able to reduce current income taxes payable. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, we entered into a Revolving Credit Loan Agreement (&#8220;Loan Agreement&#8221;) with SunTrust Bank. The new agreement replaced the August 2011 Fifth Amended and Restated Loan Agreement with our previous primary lender which was to expire on December 31, 2014.   There are no borrowings under the Loan Agreement at June 30, 2014.  The Loan Agreement provides for an aggregate principal amount of up to $20 million and it has a three year term expiring on June 26, 2017.  The initial revolving line of credit is up to $12 million, an increase from the $10 million under the previous agreement.  We have the ability to increase the borrowing amount up to $20 million, upon the satisfaction of certain conditions.  Our interest rate is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.0% to 2.85%.  In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. Under the Loan Agreement, we are subject to certain financial covenants, including, but not limited to, maintaining an EBIT to Interest Expense Ratio and a Funded Debt Ratio, determined on a quarterly basis.  We are in compliance with all covenants at June 30, 2014. </font></div><a name="s88F110BAAB26F1E9195768837DC396CB"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OFF-BALANCE SHEET ARRANGEMENTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, we did not engage in any off-balance sheet arrangements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sF026F9EFDCBD3D9E6E0568837DE4BAE6"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. Our investment policy focuses on principal preservation and liquidity.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2012, we analyzed our return on our investments and determined investing in VRDNs and a portfolio of government backed securities (including U.S. Treasuries, government sponsored enterprise debentures and government sponsored adjustable rate mortgage backed securities),&#160;would yield a higher return with minimal additional risk.&#160;The VRDNs are generally issued by municipal governments and are backed by a financial institution letter of credit.&#160;The VRDNs allow us the ability to liquidate the investment relatively quickly (less than one week).&#160;The government backed securities have an active secondary market that generally provides for liquidity in less than one week.&#160;The risk related to interest rates for these accounts will produce less income than expected if market interest rates fall.  Based on the  </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in marketable securities outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, a 1% decrease in the fair value of the securities would result in a reduction in pretax net income of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rate related to our revolving credit facility is a variable rate based on LIBOR plus an interest rate spread.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, no borrowings were outstanding under our revolving credit facility. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exchange Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we operate primarily in the United States, we are exposed to foreign currency risk.  A portion of our research and development is performed abroad. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, our outstanding payables denominated in a foreign currency were less than $0.1 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange gains and losses were immaterial for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">. Neither a 10% increase nor decrease from current exchange rates would have a significant effect on our operating results or financial condition.</font></div><a name="sE3396F81BEFC7D37229268837E16204B"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4. Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive and principal financial officers evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Based on that evaluation, our disclosure controls and procedures are considered effective to ensure that material information relating to us and our consolidated subsidiaries is made known to officers within these entities in order to allow for timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><a name="s11226D916CF26B4E4A4B68837E38A9B2"></a><div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8211; OTHER INFORMATION</font></div><a name="s78B1FD3BF78D90598D9168837E6A4997"></a><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;April 14, 2014, we filed with the American Arbitration Association a request for arbitration with&#160;Mylan Inc., Mylan Institutional LLC, Mylan Pharma Group Limited, and Mylan Teoranta (collectively, &#8220;Mylan&#8221;).&#160;&#160;We are seeking to arbitrate claims against Mylan in connection with our Alliance Agreement dated January 15, 2002, and Manufacturing and Supply Agreement as amended April 25, 2011, which require that Mylan and its affiliates manufacture and supply acetylcysteine drug product, including Acetadote, for us exclusively until April 2016. &#160;We have asserted in the request for arbitration claims against Mylan for breach of contract, breach of implied covenant of good faith and fair dealing, and unjust enrichment and seek monetary damages or to enjoin Mylan and its affiliates from selling or supplying acetylcysteine drug product to another entity or person until April 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also see the discussion of our Acetadote patent defense legal proceedings contained in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part 1, Item 1, Business -Trademarks and Patents</font><font style="font-family:inherit;font-size:10pt;">, of our Form 10-K for the year ended December&#160;31, 2013, which is incorporated by reference herein.</font></div><a name="sEB24D15BFD0DB2D7198468837E8BEAA2"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1a. Risk Factors</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information Information regarding risk factors appears on pages 19 through 33 in our Annual Report on Form 10-K for the year ended December&#160;31, 2013 under the section titled &#8220;Risk Factors.&#8221; The following risk factor was included in our Form 10-K for the year ended December&#160;31, 2013 and has been updated for recent developments:</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our strategy to secure and extend marketing exclusivity or patent rights may provide only limited protection from competition. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek to secure and extend marketing exclusivity for our products through a variety of means, including FDA exclusivity and patent rights. Additional barriers for competitors seeking to enter the market include the time and cost associated with the development, regulatory approval and manufacturing of a similar product formulation. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acetadote is indicated to prevent or lessen hepatic (liver) injury when administered intravenously within eight to ten hours after ingesting quantities of acetaminophen that are potentially toxic to the liver. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2012, the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) issued U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to us. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO. Following the issuance of the 356 Acetadote Patent, we received separate Paragraph IV certification notices from InnoPharma, Inc., Paddock Laboratories, LLC ("Paddock") and Mylan Institutional LLC challenging the 356 Acetadote Patent on the basis of non-infringement and/or invalidity. On May&#160;17, 2012, we responded to the Paragraph IV certification notices by filing three separate lawsuits for infringement of the 356 Acetadote Patent. The first lawsuit was filed against Mylan Institutional LLC and Mylan Inc. ("Mylan") in the United States District Court for the Northern District of Illinois, Eastern Division.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">The second lawsuit was filed against InnoPharma, Inc. in the United States District Court for the District of Delaware. The third lawsuit was also filed in the United States District Court for the District of Delaware against Paddock and Perrigo Company ("Perrigo").  On May&#160;20, 2012, we received a Paragraph IV certification notice from Sagent Agila LLC challenging the 356 Acetadote Patent.  On June 26, 2012, we filed a lawsuit for infringement of the 356 Acetadote Patent against Sagent Agila LLC and Sagent Pharmaceuticals, Inc. ("Sagent") in the United States District Court for the District of Delaware.  On July 9, 2012, we received a Paragraph IV certification notice from Perrigo.  On August 9, 2012, we filed a lawsuit for infringement of the 356 Acetadote Patent against Perrigo in the United States District Court for the Northern District of Illinois, Eastern Division.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 12, 2012, we entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Paddock and Perrigo to resolve the challenges and the pending litigation with each of Paddock and Perrigo involving the 356 Acetadote Patent.  Under the Settlement Agreement, Paddock and Perrigo admit that the 356 Acetadote Patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote product (with or without EDTA) would infringe upon the 356 Acetadote Patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the 356 Acetadote Patent through its expiration currently scheduled for May 2026. On November 12, 2012, in connection with the execution of the Settlement Agreement, we entered into a License and Supply Agreement with Paddock and Perrigo (the &#8220;License and Supply Agreement&#8221;).  Under the terms of the License and Supply Agreement, if a third party receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party has made such generic version available for purchase in commercial quantities in the United States, we will supply Perrigo with an authorized generic version of our Acetadote product (the &#8220;Authorized Generic&#8221;).</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By statute, where the Paragraph IV certification is to a patent timely listed before an Abbreviated New Drug Application (&#8220;ANDA&#8221;) is filed, a company has 45 days to institute a patent infringement lawsuit during which period the FDA may not approve another application. In addition, such a lawsuit for patent infringement filed within such 45-day period may stay, or bar, the FDA from approving another product application for two and a half years or until a district court decision that is adverse to the asserted </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><br><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patents, whichever is earlier. On May&#160;18, 2012, we requested the aforementioned bar or stay in connection with the filing of the three lawsuits on May 17, 2012. The aforementioned bar or stay may or may not be available to us with respect to the remaining lawsuits.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May&#160;18, 2012, we also submitted a Citizen Petition to the FDA requesting that the FDA refrain from approving any applications for acetylcysteine injection that contain EDTA, based in part on the FDA's request that we evaluate the reduction or removal of EDTA from its original Acetadote formulation. On November 7, 2012, the FDA responded to the Citizen Petition denying our request and stating that ANDAs referencing Acetadote that contain EDTA may be accepted and approved  provided they meet all applicable requirements. We believe this response contradicts the FDA's request to evaluate the reduction or removal of EDTA. On November 8, 2012, we learned that the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc.  On November 13, 2012, we brought suit against the FDA in the United States District Court for the District of Columbia alleging that the FDA's denial of our Citizen Petition and acceptance for review and approval of any InnoPharma, Inc. product containing EDTA was arbitrary and in violation of law.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We found during the resulting legal proceedings that the FDA initially concluded that the original Acetadote formulation was withdrawn for safety reasons and no generic versions should be approved. The FDA later reversed its position based on the possibility of drug shortages and the presence of EDTA in other formulations. At the same time, the FDA noted that exclusively marketing a non-EDTA containing product would be preferable because it would eliminate the potential risk of EDTA.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 7, 2013, Perrigo announced initial distribution of our authorized generic acetylcysteine injection product.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 19, 2013, the USPTO issued U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;) which is also assigned to us. The claims of the 445 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose.   On April 8, 2013, the 445 Acetadote Patent was listed in the FDA Orange Book. The 445 Acetadote Patent is scheduled to expire in August 2025. Following the issuance of the 445 Acetadote Patent we have received separate Paragraph IV certification notices from Perrigo, Sagent, and Mylan challenging the 445 Acetadote Patent on the basis of non-infringement, unenforceability and/or invalidity.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 10, 2013, we became aware of a Paragraph IV certification notice from Akorn, Inc. challenging the 445 Acetadote Patent and the 356 Acetadote Patent on the basis of non-infringement. On July 12, 2013, we filed a lawsuit for infringement of the 356 Acetadote Patent against Akorn, Inc. in the United States District Court for the District of Delaware.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 10, 2013, we announced that the FDA approved updated labeling for Acetadote.  The new labeling revises the product's indication and offers new dosing guidance for specific patient populations.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the United States District Court for the District of Columbia filed an opinion granting a Summary Judgment&#160;in favor of the FDA regarding Cumberland&#8217;s November 13, 2012 suit. &#160;On November 1, 2013, the United States District Court for the District of Delaware filed opinions granting Sagent&#8217;s and InnoPharma&#8217;s motions to dismiss our May 2012 and June 2012 suits. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue to vigorously defend and protect our Acetadote product and related intellectual property.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February18, 2014, the USPTO issued U.S. Patent number 8,653,061 (the &#8220;061 Acetadote Patent&#8221;) which is assigned to us. The claims of the 061 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose.  Following its issuance, the 061 Acetadote Patent was listed in the FDA Orange Book. The 061 Acetadote Patent is scheduled to expire in August 2025.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 13, 2014, the USPTO issued U.S. Patent number 8,722,738 (the &#8220;738 Acetadote Patent&#8221;) which is assigned to us.  The claims of the 738 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 738 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in April 2032.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have additional patent applications relating to Acetadote which are pending with the USPTO and may or may not be issued.  As noted, we intend to continue to vigorously defend and protect our Acetadote product and related intellectual property rights. If we are unsuccessful in protecting our Acetadote intellectual property rights, our competitors may be able to introduce products into the marketplace that reduce the sales and market share of our Acetadote product which may require us to take measures such as reducing prices or increasing our marketing expense, any of which may result in a material adverse effect to our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have U.S.&#160;Patent number 6,727,286 (the &#8220;286 Caldolor Patent&#8221;)  and related international patents which include composition of matter claims that encompass the Caldolor formulation and claims directed to ibuprofen solution formulations, methods of making the same, and methods of using the same, and which are related to our formulation and manufacture of Caldolor. Additionally, the active ingredient in Caldolor, ibuprofen, is in the public domain, and a competitor could try to develop, test and seek FDA approval for a sufficiently distinct formulation for another ibuprofen product that competes with Caldolor.  The 286 Caldolor U.S.Patent is listed in the FDA Orange Book and expires in November of 2021.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><br><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">On May 27, 2014, the USPTO issued U.S. Patent number 8,735,452 (the &#8220;452 Caldolor Patent&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">which is assigned to us.  The claims of the 452 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.  Following its issuance, the 452 Caldolor Patent was listed in the FDA Orange Book. The 452 Caldolor Patent is scheduled to expire in September 2029.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 23, 2014, we received a Notice of Allowance from the USPTO for a patent relating to methods of treating pain using intravenous ibuprofen and which is scheduled to expire in September 2029.  We also have additional patent applications relating to Caldolor which are pending with the USPTO and may or may not be issued.  </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we consider patent protection when evaluating product acquisition opportunities, any products we acquire in the future may not have significant patent protection. Neither the USPTO nor the courts have a consistent policy regarding the breadth of claims allowed or the degree of protection afforded under many pharmaceutical patents. Patent applications in the U.S.&#160;and many foreign jurisdictions are typically not published until 18&#160;months following the filing date of the first related application, and in some cases not at all. In addition, publication of discoveries in scientific literature often lags significantly behind actual discoveries. Therefore, neither we nor our licensors can be certain that we or they were the first to make the inventions claimed in our issued patents or pending patent applications, or that we or they were the first to file for protection of the inventions set forth in these patent applications. In addition, changes in either patent laws or in interpretations of patent laws in the U.S.&#160;and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Furthermore, our competitors may independently develop similar technologies or duplicate technology developed by us in a manner that does not infringe our patents or other intellectual property. As a result of these factors, our patent rights may not provide any commercially valuable protection from competing products.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sE7DDA99ADC2D2E00D4DA688377EE6AE8"></a><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our purchase of Cumberland equity securities during the three months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="19%"></td><td width="19%"></td><td width="4%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="21%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares (or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price&#160;Paid</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(or Unit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares (or Units)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchased&#160;as&#160;Part</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Announced Plans</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">or Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maximum&#160;Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(or Approximate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollar Value) of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares&#160;(or&#160;Units)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">that May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchased&#160;Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">the Plans or</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,507,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,281</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,281</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,323,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,022,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,950</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,950</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><a name="sD357D40459154F7D4AE868837EDF1C37"></a><br><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6. Exhibits</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="10%"></td><td width="3%"></td><td width="87%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Credit Loan Agreement, dated June 26, 2014, by and between Cumberland Pharmaceuticals Inc. and SunTrust Bank.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL INSTANCE DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><a name="s3BEBBAADEC090AAB752268837F1000E3"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="37%"></td><td width="2%"></td><td width="5%"></td><td width="14%"></td><td width="4%"></td><td width="2%"></td><td width="36%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: August 8, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ A. J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A. J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>2
<FILENAME>a1033revolvingcreditloanag.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>10.33 Revolving Credit Loan Agreement - SunTrust bank - revised exh</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD0EDF5FF964EE8E9DE60F3B56D6F93EB"></a><div></div><br><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REVOLVING CREDIT LOAN AGREEMENT</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">dated as of June 26, 2014</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">between</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC.,</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">as Borrower</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">and</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SUNTRUST BANK</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">the Lender</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s392431AB4AEAA630CCB0F3B56D9CD5CC"></a><div></div><br><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LOAN</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Loan</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interest</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">1&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrowing Procedures for the Loan</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Use of Proceeds</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payments to Lender&#8217;s Office; Right of Offset</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fees</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Increase of Availability Under Note</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">2</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Usury</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">3</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">COLLATERAL AND GUARANTIES</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">4</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collateral</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">4</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Guaranties</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">4</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cross&#8209;Collateralization</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">4</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">REPRESENTATIONS AND WARRANTIES</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Existence and Qualification</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Power and Authorization</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Binding Obligations</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Legal Bar or Resultant Lien</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Consent</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Financial Condition</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">5</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Litigation</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Taxes; Governmental Charges</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title, Etc</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Intellectual Property</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Default</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Casualties; Taking of Properties, Etc</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance with Laws, Etc</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">6</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ERISA</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Trade Names</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><br><div></div><hr style="page-break-after:always"><a name="s392431AB4AEAA630CCB0F3B56D9CD5CC"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(continued)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subsidiaries</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Loans to Others</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.18</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Leases and/or Warehouse Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CONDITIONS PRECEDENT</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Initial Conditions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All Advances</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">8</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AFFIRMATIVE COVENANTS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Financial Statements and Reports</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Taxes and Other Liens</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">9</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Maintenance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Further Assurances</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Accounts and Records</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notice of Certain Events</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">10</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance with Laws</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ERISA Information and Compliance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insurance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">11</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NEGATIVE COVENANTS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nature of Business</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mergers, Etc</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Proceeds of Loan</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Change in Control</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notice of Additional Debt</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Liens</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EBIT to Interest Expense Ratio</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">12</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Funded Debt Ratio</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subsidiaries</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dividends, Loans, Advances to Others, Etc</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sale of Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Repurchase or Redemption of Stock</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acquisition</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Change in Business</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CEO</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><br><div></div><hr style="page-break-after:always"><a name="s392431AB4AEAA630CCB0F3B56D9CD5CC"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(continued)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Emerging Technologies, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EVENTS OF DEFAULT</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Events of Default</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Remedies</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">15</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Right of Set&#8209;off</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">16</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Default</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">16</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">GENERAL PROVISIONS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">16</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">16</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Invalidity</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Term of This Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Successors and Assigns</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Participation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waivers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amendments</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Fiduciary Relationship</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nature of Commitment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governance; Exhibits</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Time of Essence</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Costs, Expenses, and Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Counterparts</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">19</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Distribution of Information  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">19</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jurisdiction; Venue; Service of Process</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">19</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jury Waiver</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">19</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.18</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Certain Damages</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">19</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">8.19</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">20</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DEFINITIONS AND USAGE</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">20</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Defined Terms  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">20</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Computations; Accounting Principles</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">25</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General Construction; Captions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">UCC Terms</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">References to Documents and Laws</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><br><div></div><hr style="page-break-after:always"><a name="s0C6A8EA467ED71F2F99CF3B56DF0519E"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBITS AND SCHEDULES</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SCHEDULE 3.18</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;Collateral Locations, Leases, And Storage Agreements</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EXHIBIT A</font><font style="font-family:inherit;font-size:12pt;">&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compliance Certificate</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s73EBEDC2991C5FDDCF05F3B56E042EC2"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">REVOLVING CREDIT LOAN AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS REVOLVING CREDIT LOAN AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Loan Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made and entered into as of the 26th day of June, 2014 by and among CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Borrower</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and SUNTRUST BANK, a Georgia banking corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Lender</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  </font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RECITALS:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;The Borrower has requested that the Lender extend it a revolving credit facility.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;The Lender is willing to extend the revolving credit facility to Borrower pursuant to the terms of this Agreement and the Loan Documents (as such term is defined herein).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Borrower and the Lender agree as follows:</font></div><a name="s7B316A596324D57257FFF3B56E1B88C4"></a><div style="line-height:120%;padding-left:240px;padding-bottom:8px;text-align:center;"><font style="padding-bottom:8px;text-align:center;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:96px;">ARTICLE 1</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LOAN </font></div><a name="sD5901170A318DAA76C0CF3B56E46FF78"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Loan</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Loan</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the Conditions Precedent and the other terms and conditions contained in this Agreement and in the other Loan Documents, and in reliance upon the representations, warranties and covenants in this Agreement and the other Loan Documents, Lender agrees to make Advances to Borrower on a revolving credit basis up to $12,000,000.00 from time to time until the Maturity Date, as evidenced by and pursuant to the Note; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;the principal amount outstanding under the Note shall not at any time exceed the Maximum Revolver Amount. The Loan shall be collateralized dollar for dollar pursuant to documentation acceptable to Lender until such time as the Borrower maintains compliance with the Funded Debt Ratio.  The applicable interest rate and the terms and provisions of repayment shall be as set forth in the Note.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Advances</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower shall comply with the terms of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.3</font><font style="font-family:inherit;font-size:12pt;">&#32;herein and this Agreement concerning the procedure to follow when requesting an Advance under the Note.</font></div><a name="s5DBEB77C2A60D0FD6594F3B56E6329B7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interest</font><font style="font-family:inherit;font-size:12pt;">.  Interest shall accrue on all amounts advanced under the Note at the rate set forth in the Note, except that interest shall accrue at the Default </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rate following the occurrence of an Event of Default (regardless of whether notice thereof has been given to Borrower).</font></div><a name="s9FE8A3EDB575AA3A17EFF3B56E95EC6F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Borrowing Procedures for the Loan</font><font style="font-family:inherit;font-size:12pt;">. The Borrower shall give the Lender written notice requesting an Advance (or telephonic notice promptly confirmed in writing), substantially in the form and substance acceptable to Lender (a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Revolving Borrowing</font><font style="font-family:inherit;font-size:12pt;">&#8221;), prior to 11:00 a.m. (Nashville Time) on the requested date of each Advance.  Each Notice of Revolving Borrowing shall be irrevocable and shall specify (i) the aggregate principal amount of such Advance, and (ii) the date of such Advance (which shall be a Business Day).  If such request is received prior to 11:00 a.m. (Nashville Time), Lender shall use its best efforts to fund an Advance on the same day. Borrower acknowledges that Lender may be delayed in funding an Advance because of the need to confirm the dollar-for-dollar collateralization requirements.</font></div><a name="sBAFC79788C04E3837222F3B56EB6270B"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Use of Proceeds</font><font style="font-family:inherit;font-size:12pt;">.  Proceeds of the Note shall be used for working capital and general corporate purposes.</font></div><a name="s51AAEEBE50FAFE0C1E6FF3B56EE97EA8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payments to Lender&#8217;s Office; Right of Offset</font><font style="font-family:inherit;font-size:12pt;">. Each payment under the Note shall be made to Lender at Lender&#8217;s office for the account of Lender in United States currency on the date such payment is due. Lender may, but shall not be obligated to, debit the amount of any such payment that is not made by such time to any ordinary deposit account of Borrower with Lender (excluding any accounts held in Borrower&#8217;s name as a trustee or fiduciary). Lender shall promptly notify Borrower of any such setoff, but Lender&#8217;s failure to give such notice shall not affect the validity thereof.</font></div><a name="sFF3EC0DC3FC2284522F4F3B56F0A1E69"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fees</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commitment Fee</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower shall pay to the Lender a commitment fee related to the loan evidenced by the Note in the amount equal to $42,000.00.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Use Fee</font><font style="font-family:inherit;font-size:12pt;">. Commencing with the quarter ending on September 30, 2014 and on the last day of each consecutive December, March, June, and September, until and including the Maturity Date, the Borrower shall pay to Lender a fee equal to twenty-five (25) basis points of the average unused availability under the Note during the preceding calendar quarter, such fee to be prorated for any partial quarter; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;if the principal amount of the Note is increased, then the twenty-five  (25) basis points non-use fee shall be calculated to include the unused portion of the increased principal amount. The non-use fee shall be calculated within fifteen (15) days of each quarter end and shall be immediately paid by Borrower upon notice of such amount. </font></div><a name="sCA71B336064D1BEAE68EF3B56F3F3334"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Increase of Availability Under Note</font><font style="font-family:inherit;font-size:12pt;">. Provided that no Default or Event of Default under the Note exists or is threatened, the Borrower, from time </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to time, may request in writing that the Lender increase the principal amount available under the Note by an aggregate principal amount of up to an additional $8,000,000.00; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;the Lender in the exercise of its sole discretion shall determine whether it will or will not fund any requested increase.  In connection with any request by the Borrower for an increase, the following shall apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">each approved increase must be in a minimum amount of no less than $1,000,000.00;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">no request for an increase shall be delivered to Lender less than ninety (90) days prior to the Maturity Date;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Borrower&#8217;s request to the Lender for an increase shall be made in writing at least thirty (30) Business Days prior to the date the Borrower desires the requested increase to be funded and in connection with any such written request the Borrower shall submit:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the purpose for the increase,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower&#8217;s calculations, including pro-forma calculations, establishing to Lender&#8217;s satisfaction that none of the financial covenants set forth in the Loan Documents have been violated, nor will such be violated immediately after any approved funding, and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Borrower&#8217;s certification that all representations and warranties contained in the Loan Documents are true and correct as of the date of the request, and that no Default or Events of Default under the Loan Documents exist or are threatened.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Lender shall review the request by Borrower for an increase in funding, and the Lender, in the exercise of its sole discretion, shall determine whether to approve any request.  In the event the Lender elects to fund any requested increase, Borrower shall:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">cause the Lender to receive, at Borrower&#8217;s expense, satisfactory evidence that the lien and security interest against the Collateral remains a first perfected security interest in favor of Lender, subject to no encumbrance objectionable to Lender;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">cause the Lender to receive all loan documentation required by Lender to evidence the increase, including without limitation, such loan documentation as required to insure that all guaranties and security agreements include the increase;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">pay to Lender all costs and expenses incurred by Lender in connection with the increase, including, without limitation, indebtedness tax, UCC filing costs, and attorney fees; and</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">pay to Lender a loan fee equal to ten (10) basis points of the amount by which the Note is increased.</font></div><a name="sED04935AE3E471958976F3B56F5FDB51"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Usury</font><font style="font-family:inherit;font-size:12pt;">. The parties to this Agreement intend to conform strictly to applicable usury laws as presently in effect. Accordingly, if the transactions contemplated hereby would be usurious under applicable law (including the laws of the United States of America and the State of Tennessee), then, in that event, notwithstanding anything to the contrary in any Loan Document, Borrower and Lender agree as follows:  (a) the aggregate of all consideration that constitutes interest under applicable law which is contracted for, charged or received under any of the Loan Documents or otherwise in connection with the Indebtedness, shall under no circumstance exceed the amount collectible at the maximum lawful rate of interest permitted by applicable law, and any excess shall be credited on the Indebtedness by the holder thereof (or, if the Indebtedness shall have been paid in full, refunded to Borrower); and (b) if the maturity of the Indebtedness is accelerated by reason of an election of the holder resulting from any Event of Default or otherwise, or in the event of any required or permitted prepayment, then such consideration that constitutes interest may never include more than the maximum amount of interest permitted by applicable law, and excess interest, if any, for which this Agreement provides, or otherwise, shall be canceled automatically as of the date of such acceleration or prepayment and, if previously paid, shall be credited against the Indebtedness (or, if the Indebtedness shall have been paid in full, refunded to Borrower).</font></div><a name="s63CD5D2FACC8E4C6CCDBF3B56F9246E5"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">COLLATERAL AND GUARANTIES</font></div><a name="s326C9D01DF21955B5AB8F3B56FBCAFF5"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Collateral</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Indebtedness shall be secured by a first-priority, perfected security interest in all of the presently existing and hereafter acquired assets of the Borrower and all Guarantors, including, without limitation, their respective accounts, accounts receivable, payments, furniture, equipment, inventory, machinery, general intangibles, chattel paper, instruments, documents, contract rights, choses in action, corporate or other business records, marketable securities, stock and other securities, brokerage accounts, depository accounts, cash, cash equivalents, intellectual property rights, trademarks, copyrights, patents, patent applications, trade secrets, goodwill, registrations, licenses, franchises, customer lists, tax refund claims, computer programs, tort claims, and proceeds arising out of or in connection with the foregoing all as evidenced by security agreements, UCC financing statements, and any other documentation, all as evidenced by, and described in more detail in, the Security Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Indebtedness shall be secured by all Property hereafter pledged and delivered to Lender to secure the Indebtedness, and all Property in which any Person has granted or hereafter grants Lender a lien or security interest to secure the Indebtedness.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sCDA2791A803F04EDE6DAF3B56FE35127"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Guaranties</font><font style="font-family:inherit;font-size:12pt;">. The Indebtedness shall be jointly and severally guaranteed by the Guarantors.</font></div><a name="s497BF350E7EC91AE65D8F3B5700843A7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cross&#8209;Collateralization</font><font style="font-family:inherit;font-size:12pt;">.  Any and all Collateral described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2.1</font><font style="font-family:inherit;font-size:12pt;">&#32;above shall stand as security and collateral for all obligations of the Borrower to Lender whether incurred pursuant to the terms of the Loan Documents or otherwise, and whether presently existing or hereafter incurred. This cross-collateralization provision is a material factor in Lender&#8217;s willingness to enter into this Agreement and to extend credit hereunder.</font></div><a name="s711EE05AD6128274A65DF3B5703A9F0C"></a><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To induce Lender to enter this Agreement and extend credit under this Agreement, Borrower covenants, represents, and warrants to Lender that as of the date hereof and as of the Closing Date:</font></div><a name="sC6361C70D7743E67E881F3B57058C0F5"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Existence and Qualification</font><font style="font-family:inherit;font-size:12pt;">.  Borrower is a corporation, legally existing and in good standing under the laws of the State of Tennessee, and is duly qualified to do business in each jurisdiction in which a failure to be so qualified would have a Material Adverse Effect.  All Guarantors are duly existing and validly formed in the state of their formation, and all Guarantors are duly qualified to do business in each jurisdiction in which a failure to be so qualified would have a Material Adverse Effect.</font></div><a name="sBEA536ABFADFD111F006F3B5708869B7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Power and Authorization</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower and the Guarantors are duly authorized and empowered to execute, deliver, and perform under all Loan Documents to which each is a party, in accordance with their respective organizational documents.  </font></div><a name="sAF6EB277A2A247B069CAF3B570A9EF39"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Obligations</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement is, and the Note and other Loan Documents to which each is a party when executed and delivered in accordance with this Agreement will be, legal, valid and binding upon and against the Borrower and the Guarantors, as applicable, and their respective Properties, enforceable in accordance with their respective terms, subject to no defense, counterclaim, set&#8209;off, or objection of any kind.</font></div><a name="sFE81F53D51195EEAFCF3F3B570DC27D4"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Legal Bar or Resultant Lien</font><font style="font-family:inherit;font-size:12pt;">.  The execution, delivery and performance of the Loan Documents by the Borrower and each Guarantor does not constitute a default under, and will not violate any provisions of the organizational documents of the Borrower or any Guarantor or any contract, agreement, law, regulation, order, injunction, judgment, decree, or writ to which the Borrower or any Guarantor is subject, nor result in the creation or imposition </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of any lien upon any Properties of Borrower or any Guarantor, other than those contemplated by the Loan Documents.</font></div><a name="s3AE9ACB23380B7B5237EF3B570FED01F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Consent</font><font style="font-family:inherit;font-size:12pt;">.  The execution, delivery, and performance of the Loan Documents by the Borrower and each Guarantor does not require the consent or approval of any other Person, if the failure to obtain the same would have a Material Adverse Effect.</font></div><a name="s83540114384D24E5FF05F3B57137C880"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Financial Condition</font><font style="font-family:inherit;font-size:12pt;">.  The audited consolidated financial statements of the Borrower and each Guarantor for the fiscal year ended December 31, 2013, were prepared in accordance with GAAP, consistently applied, and such financial statements present fairly the financial condition of the Borrower and each Guarantor, as applicable, as of the date or dates and for the period or periods stated therein, subject to finalizing adjustments determined not to be material. No Material Adverse Change has occurred since the date of such financial statements.</font></div><a name="s28EDEC3CD0CC3E1DB518F3B571737F57"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Litigation</font><font style="font-family:inherit;font-size:12pt;">.  There is no litigation, legal or administrative proceeding, investigation, or other action of any nature pending or, to the knowledge of the Borrower, threatened against or affecting the Borrower or any Guarantor that involves the possibility of any judgment or liability not fully covered by insurance and that may have a Material Adverse Effect on the business or the Properties of the Borrower or any Guarantor or their respective  ability to carry on their respective business as now conducted.</font></div><a name="sA8F0AD40AA551CBB8320F3B5718C5054"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes; Governmental Charges</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower and each Guarantor have filed or caused to be filed all tax returns and reports required to be filed.  The Borrower and each Guarantor have paid all due and payable taxes, assessments, fees, and other governmental charges levied upon them or upon any of their respective Properties or income including interest and penalties. Borrower and each Guarantor have made all required withholding deposits.</font></div><a name="sA511E392F1475FA7AC1DF3B571A65C57"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Title, Etc</font><font style="font-family:inherit;font-size:12pt;">.  Borrower and each Guarantor have good title to the Collateral, free and clear of all liens except those securing the Indebtedness.  Neither the Borrower nor any of the Guarantors own any real property.</font></div><a name="sE82643B5B968E349F319F3B571D67DED"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">.  Except to the extent that a failure to do so will not have a Material Adverse Effect, the Borrower and each Guarantor possess or have the right to use all trademarks, service marks, copyrights, trade names, patents, licenses, and other intellectual property, and rights therein, as are necessary for the conduct of its business as now conducted and presently proposed to be conducted, without conflict with the rights or claimed rights of others.</font></div><a name="s0DCA0ECC30B8E1CC487FF3B571FC52E1"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Default</font><font style="font-family:inherit;font-size:12pt;">.  Except to the extent that the same will not have a Material Adverse Effect, neither the Borrower nor any Guarantor is in default in any respect that affects its business, Properties, operations, or condition, financial or otherwise, under any indenture, mortgage, deed of trust, credit agreement, note, agreement, or other instrument to which the Borrower and any Guarantor is a party or by which it or their Properties are bound. Neither the Borrower nor any Guarantor is in violation of its organizational documents.</font></div><a name="s7BA85682EFA6BC3D42C9F3B5722E4353"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Casualties; Taking of Properties, Etc</font><font style="font-family:inherit;font-size:12pt;">. Neither the business nor the Properties of the Borrower and any Guarantor have been affected as a result of any fire, explosion, earthquake, flood, drought, windstorm, accident, strike or other labor disturbance, embargo, requisition or taking of property, cancellation of contracts, permits, concessions by any domestic or foreign government or any agency thereof, riot, activities of armed forces or acts of God or of any public enemy in such a way as to have a Material Adverse Effect.</font></div><a name="s4A46150E3FA6AF0DAE93F3B5724AF051"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Laws, Etc</font><font style="font-family:inherit;font-size:12pt;">.  Except to the extent the same will not have a Material Adverse Effect, neither the Borrower nor any Guarantor is in violation of any law, judgment, decree, order, ordinance, or governmental rule or regulation to which the Borrower or any Guarantor or any of their respective Properties is subject, including without limitation any Environmental Law. Neither the Borrower nor any Guarantor has failed to obtain any material license, permit, franchise, or other governmental authorization necessary to the ownership of any of their respective Properties or to the conduct of their respective business.</font></div><a name="s72BB5668349E446C19E0F3B5727C8E75"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ERISA</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower and all Guarantors are in compliance in all material respects with the applicable provisions of ERISA. Neither the Borrower nor any Guarantor has incurred any material &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">accumulated funding deficiency</font><font style="font-family:inherit;font-size:12pt;">&#8221; within the meaning of ERISA, and has not incurred any material liability to PBGC in connection with any Plan.</font></div><a name="s281D75E3A914A6681492F3B5729D8CCA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Trade Names</font><font style="font-family:inherit;font-size:12pt;">.  Neither the Borrower nor any Guarantor uses any trade names (and have not used any since the date of their respective formation).</font></div><a name="s25E33FD6F246F09034DEF3B572D0537A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">. The only Subsidiaries of the Borrower is the Guarantor and Cumberland Emerging Technologies, Inc.</font></div><a name="s11626A1E14CDF5712A5FF3B57300528A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Loans to Others</font><font style="font-family:inherit;font-size:12pt;">. Neither the Borrower nor any Guarantor has made a loan to any board member, shareholder, officer, employee, or any other Person.</font></div><a name="s2EFD51A1374917E50C6FF3B573297571"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Leases and/or Warehouse Agreements</font><font style="font-family:inherit;font-size:12pt;">.  The locations at which the Borrower and/or the Guarantor maintain any portion of the Collateral are described on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 3.18</font><font style="font-family:inherit;font-size:12pt;">&#32;herein.  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 3.18</font><font style="font-family:inherit;font-size:12pt;">&#32;also identifies all leases and/or storage agreements related to such locations.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB4C6D409B61929C5A4ADF3B5734574A7"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> </font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONDITIONS PRECEDENT</font></div><a name="s88448B68870601B5B7EDF3B57376E6B7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initial Conditions</font><font style="font-family:inherit;font-size:12pt;">.  Lender&#8217;s obligation to enter into this Agreement is subject to the Conditions Precedent that Lender shall have received (or agreed in writing to waive or defer receipt of) all of the following, each duly executed, dated and delivered as of the Closing Date, in form and substance satisfactory to Lender and its counsel:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Note and Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  The Note, issued by Borrower and payable to the order of Lender, and all other Loan Documents, all duly executed by the Borrower and the Guarantors, as applicable;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolutions</font><font style="font-family:inherit;font-size:12pt;">.  Certified copies of resolution of the applicable governing body of the Borrower and the Guarantors authorizing the execution, delivery, and performance, respectively, of this Agreement and all Loan Documents;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Certificate of Existence</font><font style="font-family:inherit;font-size:12pt;">.  A certificate of existence regarding the Borrower and all Guarantors certified by the Secretary of State of the formation of such Borrower and/or Guarantors, containing no facts objectionable to Lender, together with appropriate certificates of authorization to do business in the State of Tennessee and any other states in which the Borrower or any Guarantor is required to qualify to do business;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Organizational Documents</font><font style="font-family:inherit;font-size:12pt;">.  Copies of the organizational documents of Borrower and the Guarantors, certified by the secretary of each;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UCC-11 Reports</font><font style="font-family:inherit;font-size:12pt;">.  UCC-11 Reports containing no matter objectionable to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Opinion Letter</font><font style="font-family:inherit;font-size:12pt;">.  An opinion letter from counsel to the Borrower and the Guarantors in form and substance acceptable to Lender;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  Evidence that all insurance required by Lender under this Agreement and any other Loan Document is in place and effective (including, without limitation, any required flood insurance);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">W-9, Etc</font><font style="font-family:inherit;font-size:12pt;">.  An executed W-9 form for the Borrower and each Guarantor and all documentation necessary to comply with the Patriot Act, including, without limitation, copies of the driver&#8217;s license of each Individual Guarantor;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Year-End Financials</font><font style="font-family:inherit;font-size:12pt;">.  Delivery to and approval by Lender of the Borrower&#8217;s annual audited consolidated financial statements for the fiscal year ending on December 31, 2013;</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payoff Letters</font><font style="font-family:inherit;font-size:12pt;">.  Payoff letters from Bank of America, N.A. in form and substance satisfactory to Lender; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other</font><font style="font-family:inherit;font-size:12pt;">.  Such other documents as Lender may reasonably request.</font></div><a name="s19028BA45D1A3ABC99D6F3B57397B611"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">All Advances</font><font style="font-family:inherit;font-size:12pt;">.  After the Closing Date, Lender&#8217;s obligation to make Advances under the Note is subject to the following additional Conditions Precedent, which must be satisfied each time an Advance is requested:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Maximum Revolver Availability</font><font style="font-family:inherit;font-size:12pt;">. The amount of any requested Advance is less than the Maximum Revolver Availability;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations</font><font style="font-family:inherit;font-size:12pt;">. The representations of the Borrower contained in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article&#160;3</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be true and correct as of the date of the requested Advance, except as to (i) representations and warranties expressly made as of a specified date, which shall remain true and correct as of such specified date, and (ii) changes occurring after the Closing Date caused by transactions permitted under the Loan Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Material Adverse Event</font><font style="font-family:inherit;font-size:12pt;">.  No Material Adverse Event has occurred and is continuing; and</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Default</font><font style="font-family:inherit;font-size:12pt;">.  No Default or Event of Default has occurred and continues to exist.</font></div><a name="sA89ED30CF7BAC92789D2F3B573CA346D"></a><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AFFIRMATIVE COVENANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower covenants that, during the term of this Agreement (including any extensions hereof) and until all Indebtedness shall have been finally paid in full and all Indebtedness shall have been fully discharged, unless Lender shall otherwise first consent in writing, the Borrower shall:</font></div><a name="sA1BA676F10C04646B24CF3B573F033DA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Financial Statements and Reports</font><font style="font-family:inherit;font-size:12pt;">.  Promptly furnish to Lender: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Annual Reports</font><font style="font-family:inherit;font-size:12pt;">.  As soon as available, and in any event within one hundred fifty (150) days after the close of each fiscal year end of the Borrower, cause the Lender to receive the annual audited consolidated financial statements of the Borrower, certified by KPMG or such other public accountant firm of the Company reasonably acceptable to Lender, which financial statements set forth the balance sheet, related statements of income, and cash flows as at the end of such year, all prepared in accordance with GAAP;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Quarterly Reports</font><font style="font-family:inherit;font-size:12pt;">.  As soon as available and in any event within forty-five (45) days of each quarter end, cause to be delivered to Lender the company prepared consolidated financial statements of the Borrower, setting forth the balance </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">sheet of the Borrower and the related statements of income, and cash flows as of the end of such quarter, all prepared in accordance with GAAP and certified by the Borrower&#8217;s chief financial officer as being true and accurate;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance Certificate</font><font style="font-family:inherit;font-size:12pt;">.  As soon as available, and in any event within forty-five (45) days of the last day of the end of each fiscal quarter, the Borrower shall deliver to Lender a Compliance Certificate evidencing Borrower&#8217;s compliance or noncompliance with the financial covenant(s) set forth herein; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rule 10b5-1 Trading Plan</font><font style="font-family:inherit;font-size:12pt;">. As soon as available and in any event within  fifteen (15) days of each quarter end, cause to be delivered to Lender (i) copies of its Rule 10b5-1 trading plan, and (ii) a summary of any repurchase or redemption during the prior fiscal quarter outside the parameters of any applicable Rule 10b5-1 trading plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Information</font><font style="font-family:inherit;font-size:12pt;">.  Promptly upon its becoming available, deliver such other material information about Borrower, the Guarantors, the Collateral, or the Indebtedness as Lender may reasonably request from time to time.</font></div><a name="sC2454DE23C44A7286F98F3B574221490"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:18px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes and Other Liens</font><font style="font-family:inherit;font-size:12pt;">.  Pay and discharge, and cause each Guarantor to pay and discharge, prior to delinquency, all taxes, assessments, and governmental charges or levies imposed upon it or upon any of its income or Property as well as all claims of any kind (including claims for labor, materials, supplies, and rent) which, if unpaid, might become a Lien upon any or all of its Property; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that neither the Borrower nor any Guarantor shall be required to pay any such tax, assessment, charge, levy, or claim if the amount, applicability, or validity thereof shall currently be contested in good faith by appropriate proceedings diligently conducted, no Lien attaches to any of the Property of Borrower and/or any Guarantor or Borrower or any Guarantor, as applicable, has established reserves therefor adequate under GAAP.</font></div><a name="s2A1EC8BF161B24F0C137F3B5743D80CD"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:18px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Maintenance</font><font style="font-family:inherit;font-size:12pt;">.  Maintain, and cause each Guarantor to maintain, their respective organizational existence, name, rights, and franchises.</font></div><a name="s9E4E398904E79B4D2546F3B574702303"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.  Promptly cure, and cause each Guarantor to cure, any defects in the creation, issuance, and delivery of the Loan Documents to which it is a party. Borrower at its expense promptly will execute and deliver, and cause each Guarantor to execute and deliver, to Lender upon request all other and further documents, agreements, and instruments reasonably required in order to comply with or accomplish the covenants and agreements of the Borrower and all Guarantors in the Loan Documents, or to evidence further and to describe more fully any Collateral intended as security for the Indebtedness or to correct any omissions in the Loan Documents, or to state more fully the Indebtedness and agreements set out in any of the Loan Documents, or to perfect, protect, or preserve any Liens created pursuant to any of the Loan Documents, or to make any recordings, to file any notices or to obtain any consents as may be reasonably necessary or appropriate in connection therewith.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sFFD7DCA5001C1CC43EBEF3B574917491"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accounts and Records</font><font style="font-family:inherit;font-size:12pt;">.  Keep books of record and account, and cause each Guarantor to keep books of record and account, in which full, true, and correct entries will be made of all dealings or transactions in accordance with GAAP, except only for changes in accounting principles or practices with which Borrower&#8217;s certified public accountants concur </font><font style="font-family:inherit;font-size:12pt;">and which changes have been reported to Lender in writing and with an explanation thereof</font><font style="font-family:inherit;font-size:12pt;">.</font></div><a name="sAC54E0BC4804EB75659BF3B574C3CA18"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Certain Events</font><font style="font-family:inherit;font-size:12pt;">.  Promptly give to Lender, if Borrower learns of the occurrence of any of the following events, notice of (a) any event that constitutes a Default or an  Event of Default, together with a detailed statement by a responsible officer of the Borrower of the steps being taken as a result thereof; or (b) the receipt of any notice from, or the taking of any other action by, the holder of any promissory note, debenture, or other evidence of Debt of the Borrower and/or any Guarantor or of any security (as defined under the Securities Act of 1933, as amended) of the Borrower and/or any Guarantor with respect to a claimed default, together with a detailed statement by a responsible officer of the Borrower and/or any Guarantor specifying the notice given or other action taken by such holder and the nature of the claimed default and what action the Borrower and/or any Guarantor is taking or proposes to take with respect thereto; or (c) any legal, judicial, or regulatory proceedings affecting the Borrower or any Guarantor in which the amount involved is material and is not covered by insurance or which, if adversely determined, would have a Material Adverse Effect; or (d) any dispute between the Borrower or any Guarantor and any governmental or regulatory authority or any other person, entity, or agency which, if adversely determined, would have a Material Adverse Effect; or (e) any Material Adverse Change, either individually or in the aggregate, in the assets, liabilities, financial condition, business, operations, affairs, or circumstances of the Borrower from those reflected in the financial statements of the Borrower delivered to Lender pursuant to this Agreement or from the facts warranted or represented in any Loan Document.</font></div><a name="sB2E3AB5D291D919013B0F3B574EA94E7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Laws</font><font style="font-family:inherit;font-size:12pt;">.  Observe and comply, and cause each Guarantor to observe and comply, (to the extent necessary so that any failure will not have a Material Adverse Effect) with all applicable laws, statutes, codes, acts, ordinances, orders, judgments, decrees, injunctions, rules, regulations, certificates, franchises, permits, licenses, authorizations, and requirements of all federal, state, county, municipal, and other governments, including without limitation all Environmental Laws.</font></div><a name="s2245C27542A821B32C44F3B5751CDBCB"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ERISA Information and Compliance</font><font style="font-family:inherit;font-size:12pt;">.  Except to the extent that a failure to do so will not have a Material Adverse Effect, comply, and cause each Guarantor to comply, with ERISA and all other applicable laws governing any pension or profit sharing plan or arrangement to which the Borrower or any Guarantor is a party or is otherwise subject. The Borrower and any Guarantor shall provide Lender with notice of any &#8220;reportable event&#8221; or &#8220;prohibited transaction&#8221; or the imposition of a &#8220;withdrawal liability&#8221; within the meaning of ERISA.</font></div><a name="sA048408FC5C4D7300CB7F3B575397216"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  Obtain and maintain in full force and effective the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Hazard insurance, including, without limitation, coverage for fire, vandalism, malicious mischief, earthquake, and windstorm damage, which insurance: (i) must be issued by an insurance company reasonably acceptable to Lender and licensed to transact business in Tennessee, (ii) must contain a standard mortgagee clause designating the Lender, its successors and assigns, as additional insured, and (iii) must contain provisions for written notice to Lender at least thirty (30) days prior to any cancellation, termination, or modification thereof or of any coverage, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;if such cancellation or termination is due to non-payment of premiums, the time period for such notice may not be less than ten (10) days;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Public liability insurance issued by an insurance company acceptable to Lender in such amounts and containing such terms as acceptable to Lender, naming Lender as an additional insured; and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All such other insurance as required by the provisions of any other Loan Documents.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s82D50DC59F8B881C4F4CF3B5756D934C"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NEGATIVE COVENANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Borrower covenants and agrees that, during the term of this Agreement and until all Indebtedness shall have been finally paid in full and all Indebtedness shall have been fully discharged, unless Lender shall otherwise first consent in writing, Borrower will not, nor will Borrower permit any Guarantor, either directly or indirectly:</font></div><a name="sA142819463BFC7FE9313F3B575974E72"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Nature of Business</font><font style="font-family:inherit;font-size:12pt;">.  Suffer or permit any Material Adverse Change to be made in the character of the business it or any Guarantor engages in as of the Closing Date.</font></div><a name="s1EE8C03B32171F91FEB1F3B575BCB719"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Mergers, Etc</font><font style="font-family:inherit;font-size:12pt;">.  Merge or consolidate, or allow any Guarantor to merge or consolidate, with or into any other Person except through a permitted Acquisition and unless the Borrower or such Guarantor is the surviving entity.</font></div><a name="s70F87C4B0AD64E94574AF3B575DFD88A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proceeds of Loan</font><font style="font-family:inherit;font-size:12pt;">.  Permit the proceeds of the Loan to be used for any purpose other than those permitted under this Agreement.</font></div><a name="sAE4BA81F403A92BF0F08F3B57616EFC5"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">.  Permit any Change in Control of Borrower or any Guarantor. </font></div><a name="s9F9B02D0C014490A2031F3B57635622E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice of Additional Debt</font><font style="font-family:inherit;font-size:12pt;">.  Incur or permit any of the Guarantors to incur any additional Debt without Lender&#8217;s prior written consent with the exception of unsecured borrowings, purchase money loans, and capital lease obligations less than $2,000,000 </font><font style="font-family:inherit;font-size:12pt;">in the aggregate for the Borrower and the Guarantors combined</font><font style="font-family:inherit;font-size:12pt;">&#32;in any fiscal year; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">, prior to any such additional Debt, Borrower shall provide evidence satisfactory to Lender, in form and substance, that no Event of Default will occur or shall be threatened as a result of the incurrence of such additional Debt. </font></div><a name="s1BA90175D94B2EDC4DABF3B576630D28"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Liens</font><font style="font-family:inherit;font-size:12pt;">.  Voluntarily or involuntarily permit, or allow any Guarantor to permit, any lien or encumbrance to attach to its assets excluding liens in favor of Lender and Liens securing any purchase money Debt permitted under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.5</font><font style="font-family:inherit;font-size:12pt;">&#32;above. </font></div><a name="s091AED722A2FE6496430F3B57684028F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EBIT to Interest Expense Ratio</font><font style="font-family:inherit;font-size:12pt;">.  Permit the EBIT to Interest Expense Ratio of Borrower and its Subsidiaries to be less than the following for the following time periods:</font></div><div style="line-height:120%;padding-left:126px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.16666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="37%"></td><td width="63%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RATIO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TIME PERIOD</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.00 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of June 30, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.50 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of September 30, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.00 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of December 31, 2014 and each fiscal quarter thereafter</font></div></td></tr></table></div></div><a name="s0D1A93F5588EFD1C538DF3B576BC59D9"></a><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Funded Debt Ratio</font><font style="font-family:inherit;font-size:12pt;">.  Permit the Funded Debt Ratio of the Borrower as calculated for the Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quarter basis to exceed 2.00 to 1.00; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;in the event that all outstanding amounts evidenced by the Note are secured by cash pursuant to such documentation as required by Lender, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">then</font><font style="font-family:inherit;font-size:12pt;">&#32;this financial covenant shall not be applicable.</font></div><a name="s6C619D74A03A392B6BE6F3B576E2EC1A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">.  Create or acquire any Subsidiary except through a permitted Acquisition; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided that</font><font style="font-family:inherit;font-size:12pt;">&#32;if the Lender, in its discretion, consents to the creation or acquisition of any Subsidiary, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">then</font><font style="font-family:inherit;font-size:12pt;">&#32;such approved Subsidiary shall be required to execute and provide such documentation as required by Lender to become a Guarantor hereunder and to grant a first perfected security interest in favor of Lender in all of its assets to secure repayment by Borrower of all Indebtedness.</font></div><a name="s0B1C0BAFAC55EE7DE9ADF3B57714F824"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Dividends, Loans, Advances to Others, Etc</font><font style="font-family:inherit;font-size:12pt;">.  Take, or permit any Guarantor to take, any of the following actions: (a) pay any dividends, (b) make any distribution of cash or assets to its directors, shareholders, or officers, (c) extend a loan to any Person, or (d) make an investment in any Person other than in a Subsidiary that becomes a Guarantor and that grants a first perfected security interest in its assets in favor of Lender; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided, however, that</font><font style="font-family:inherit;font-size:12pt;">&#32;Cumberland Emerging Technologies Inc. is not required to become a Guarantor or grant any such security interest in favor of Lender. </font></div><a name="s7E22B1AAC64B802E4E52F3B5773A8F8F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sale of Assets</font><font style="font-family:inherit;font-size:12pt;">.  Sell or transfer any assets to any Person (i) outside the ordinary course of business or (ii) in excess of $100,000 in the aggregate in any fiscal year.</font></div><a name="s47FDC311E380747374E4F3B5775DDCE8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Repurchase or Redemption of Stock</font><font style="font-family:inherit;font-size:12pt;">. Borrower shall not be permitted to repurchase or redeem shares of its stock or that of any Subsidiary except that Borrower may repurchase or redeem such stock in an aggregate amount of no more than $12,000,000 during the term of the Note; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;the Borrower at all times shall maintain cash liquidity in an amount equal to the aggregate amount used by Borrower to repurchase or redeem shares of its stock or that of any Subsidiary; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided further that</font><font style="font-family:inherit;font-size:12pt;">&#32;this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6.12</font><font style="font-family:inherit;font-size:12pt;">&#32;shall not apply to the stock of Cumberland Emerging Technologies Inc. </font></div><a name="s0675F5F05207AAC05C6AF3B5777F5F80"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Acquisition</font><font style="font-family:inherit;font-size:12pt;">.  Borrower may not make any Acquisition, unless: (a) no Default or Event of Default under the Note has occurred or is threatened, and (b) prior to any such Acquisition, Borrower delivers to Lender a pro forma &#8220;Post-Acquisition&#8221; calculation of the financial covenants, which pro-forma calculation shall establish to Lender&#8217;s satisfaction that the Acquisition shall not cause the required financial covenants to be violated.  </font></div><a name="sD24A71A85DB85E5B83BEF3B577B28596"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Business.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Engage in any business in which Borrower and any Guarantor is not currently engaged, except for complimentary lines of business approved in writing by Lender.</font></div><a name="sABC4CFA9B8F89DB3638BF3B577D8AF9D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CEO</font><font style="font-family:inherit;font-size:12pt;">.  Permit a change to the position of Chief Executive Officer of the Borrower.  </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sDA2754592D57773F332AF3B5780A0B1A"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cumberland Emerging Technologies, Inc</font><font style="font-family:inherit;font-size:12pt;">. Extend a loan or downstream monies in excess of $100,000.00 in the aggregate to Cumberland Emerging Technologies, Inc. without the express prior written consent of Lender. </font></div><a name="sEDDB98C01DF8884F04D5F3B57827EFEA"></a><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EVENTS OF DEFAULT</font></div><a name="sCBC93853F97192110402F3B57858DF4A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Events of Default</font><font style="font-family:inherit;font-size:12pt;">. Any of the following events shall be considered an Event of Default (and shall be considered a Default pending the passage of time, giving of notice or other condition specified below):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Principal and Interest Payments</font><font style="font-family:inherit;font-size:12pt;">.  Borrower fails to pay any amount due hereunder, under the Note (including without limitation principal and interest payments) or any other Loan Document within ten (10) days of the applicable due date; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, no grace period shall be permitted for the final payment of principal and interest due on any applicable maturity date; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">.  Any representation, warranty, statement (including financial statements), certification or data made or furnished by or on behalf of the Borrower or any Guarantor in connection with this Agreement or any other Loan Document is incorrect in any material respect as of the date as of which the facts therein set forth were stated or certified; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Obligations</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower or any Guarantor fails to perform any of the promises, covenants or obligations contained in or required by this Agreement, the Note, or any other Loan Document within ten (10) days of Borrower&#8217;s or Guarantor&#8217;s, as applicable, receipt of written notice of such failure; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;no notice and cure period shall be applicable to a violation of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.6</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.9</font><font style="font-family:inherit;font-size:12pt;">, and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article 6</font><font style="font-family:inherit;font-size:12pt;">; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Involuntary Bankruptcy or Receivership Proceedings</font><font style="font-family:inherit;font-size:12pt;">.  Any of the following events or conditions occurs with respect to the Borrower or any Guarantor and is not dismissed within sixty (60) days:  (i) a receiver, custodian, liquidator, or trustee of itself or of any of its respective Property is appointed by the order or decree of any court or agency or supervisory authority having jurisdiction; or (ii) any of its Property is sequestered by court order; or  (iii) a petition is filed against it under any state or federal bankruptcy, reorganization, debt arrangement, insolvency, readjustment of debt, dissolution, liquidation or receivership law of any jurisdiction, whether now or hereafter in effect; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Voluntary Petitions</font><font style="font-family:inherit;font-size:12pt;">.  Borrower or any Guarantor files (or takes formal company action authorizing the filing of) a voluntary bankruptcy petition or other petition to seek relief under any provision of any bankruptcy, reorganization, debt arrangement, insolvency, readjustment of debt, dissolution or liquidation law of any </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">jurisdiction or consents to the filing of any such petition against it under any such law; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignments for Benefit of Creditors, Etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Borrower or any Guarantor makes an assignment for the benefit of its creditors, or admits in writing its inability to pay its debts generally as they become due, or consents to the appointment of a receiver, trustee, or liquidator of itself or of all or any part of its Property; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cross-Default on Other Debt or Security</font><font style="font-family:inherit;font-size:12pt;">.  Subject to any applicable grace period or waiver prior to any due date, (i) Borrower or any Guarantor fails to make any payment due on any of its Debt, in excess of $250,000.00, and (ii) any trustee or any holder of such Debt accelerates all of such debt so as to become due prior to its stated maturity or its regularly scheduled dates of payment; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Undischarged Judgments</font><font style="font-family:inherit;font-size:12pt;">.  Any court or other governmental authority renders judgment against the Borrower or any Guarantor for the payment of money in excess of $250,000, payment of which is not fully covered by valid collectible insurance or for which execution is not stayed by bond or otherwise; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Default Under Loan Documents</font><font style="font-family:inherit;font-size:12pt;">.  A default shall occur under any other Loan Document; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">.  A Change in Control of the Borrower or any Guarantor occurs; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Material Adverse Change</font><font style="font-family:inherit;font-size:12pt;">.  A reasonable determination by Lender that a Material Adverse Change in the business or financial condition of the Borrower or any Guarantor has occurred, or that a Material Adverse Change has occurred in the value of the Collateral, or that any other circumstance or event has created a Material Adverse Change; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cessation of Business, Etc</font><font style="font-family:inherit;font-size:12pt;">.  The liquidation of the Borrower or any Guarantor, or the termination or suspension of business of the Borrower or any Guarantor; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sale of Assets</font><font style="font-family:inherit;font-size:12pt;">.  The sale of all or substantially all of the assets of the Borrower or any Guarantor other than in the ordinary course of business; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Defaults to Lender</font><font style="font-family:inherit;font-size:12pt;">.  Borrower or any Guarantor defaults to Lender in the performance under any indebtedness or Debt owed to Lender; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fraud</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower or any Guarantor commits fraud.</font></div><a name="s779F7913642C814DFC65F3B578839992"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">.  Upon the occurrence of an Event of Default, Lender may declare the entire principal amount of all Indebtedness then outstanding, including interest accrued thereon, to be immediately due and payable without </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">presentment, demand, protest, notice of protest, or dishonor or other notice of default of any kind, all of which the Borrower hereby expressly waives, and, at Lender&#8217;s sole discretion and option, all obligations of Lender under this Agreement shall immediately cease and terminate unless and until Lender shall reinstate such obligations in writing. Such acceleration and cessation of Lender&#8217;s obligations shall occur automatically, without any declaration by Lender or any notice, upon the occurrence of an Event of Default under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.1(d)</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(e)</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(f)</font><font style="font-family:inherit;font-size:12pt;">. Upon the occurrence of any Event of Default, Lender may also exercise all rights against any of the Collateral described in the Security Documents or afforded a creditor under applicable law, and/or bring an action to protect or enforce its rights under the Loan Documents or seek to collect the Indebtedness by any lawful means. All remedies provided in this Agreement or in any other Loan Documents shall be cumulative, in addition to all other remedies available to Lender under the principles of law and equity or pursuant to any other body of law, statutory or otherwise, and the exercise or partial exercise of any such right or remedy shall not preclude the exercise of any other right or remedy.</font></div><a name="sFD99E11506FEE820DC2FF3B578AA84C8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Right of Set&#8209;off</font><font style="font-family:inherit;font-size:12pt;">.  Upon the occurrence and during the continuance of any Event of Default, Lender is authorized, at any time and from time to time, without notice to the Borrower (any such notice being expressly waived by the Borrower), to set&#8209;off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by Lender to or for the credit or the account of the Borrower against any and all of the Indebtedness, irrespective of whether or not Lender shall have accelerated the Indebtedness or made any demand under this Agreement or the Note and although such obligations may be unmatured. </font></div><a name="s30149093909CC9B3193DF3B578D201B5"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Default</font><font style="font-family:inherit;font-size:12pt;">.  Upon the occurrence of a Default, the Lender, at its option and without liability to the Borrower or to any other Person, may cease funding Advances under the Note until such time as the Default is cured.</font></div><a name="s7D1F550515679E348A84F3B57904BF6D"></a><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GENERAL PROVISIONS</font></div><a name="sDDAF069B7D44644FBD71F3B579210667"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:18px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices, requests, demands, directions and other communications (collectively &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">&#8221;) required under this Agreement shall be in writing and shall be sent by hand, by registered or certified mail return receipt requested or by overnight courier service maintaining records of receipt, in all cases with charges prepaid.  Any such properly given notice shall be effective upon the earlier of receipt or (a) the date delivered by hand, or (b) the third Business Day after being mailed, or (c) the following Business Day if sent by overnight courier service.  All notices shall be sent to the applicable party at its address (or facsimile number) set forth below or in accordance with the last written direction from such party to the other party hereto:</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Borrower</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Chief Financial Officer</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2525 West End Avenue</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 950</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nashville, TN 37203</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Lender</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SunTrust Bank</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">401 Commerce St., Suite 4400</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nashville, Tennessee 37219</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn:  Tim Bewley, First Vice President</font></div><a name="s8652ADB46C1C3ED78EC5F3B57952FDFD"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Invalidity</font><font style="font-family:inherit;font-size:12pt;">.  If any one or more of the provisions contained in any Loan Document for any reason shall be held invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of any Loan Document.</font></div><a name="s3B381A47AE68F88F29C3F3B579721A40"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term of This Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be binding on the Borrower as long as any portion of the Indebtedness remains outstanding or Lender has any obligations to make Advances hereunder, except that each Borrower&#8217;s representations, warranties, and indemnity agreements shall survive the payment in full of the Indebtedness and the termination of this Agreement.</font></div><a name="sE64324E3408F009884FEF3B579A8BF5C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  No Borrower shall assign its rights or delegate its duties under this Agreement or any other Loan Document. All covenants and agreements made by or on behalf of the Borrower in any Loan Document shall bind such Borrower&#8217;s successors and assigns and shall inure to the benefit of Lender and its successors and permitted assigns.</font></div><a name="sE33793B0A2F87D4A1031F3B579CF0015"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Participation</font><font style="font-family:inherit;font-size:12pt;">.  Lender shall have the right to enter into one or more participation or syndication agreements with one or more participating lenders approved by Lender on such terms and conditions as Lender shall deem advisable. </font></div><a name="sD6ABF178F2821C7604AEF3B579FDB119"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waivers</font><font style="font-family:inherit;font-size:12pt;">. As provided in T.C.A. Section 47&#8209;50&#8209;112, no custom, conduct, action or course of dealing on the part of Lender, its officers, employees, consultants, or agents, nor any failure or delay by Lender with respect to exercising any right, power, or privilege of Lender under the Note, this Agreement, or any other Loan Document shall operate as a waiver thereof, except as otherwise provided in this Agreement. Lender may from time to time waive any requirement hereof, including any of the Conditions Precedent, but no waiver shall be effective unless in writing and signed by Lender. The execution by Lender of any waiver shall not obligate Lender to grant any further, similar, or other waivers.  </font></div><a name="s9AA7E0F934CE797611EFF3B57A1AF65C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amendments</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may not be modified or amended except in writing signed by the Borrower and Lender.</font></div><a name="s638F548B914FCA40FB25F3B57A4CB3CF"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement, the Note, and the other Loan Documents constitute a contract made under, and shall be construed in accordance with and governed by, the laws of the State of Tennessee.</font></div><a name="s55B757BBAD50DC90BEFDF3B57A6E2076"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Fiduciary Relationship</font><font style="font-family:inherit;font-size:12pt;">.  Nothing contained herein or in any related document shall be deemed to create any partnership, joint venture or other fiduciary relationship between Lender and the Borrower for any purpose. </font></div><a name="s7ECE0813E7CDC92F867DF3B57A9F592E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Nature of Commitment</font><font style="font-family:inherit;font-size:12pt;">.  Lender&#8217;s obligation to make Advances shall be deemed to be pursuant to a contract to make a loan or to extend debt financing or financial accommodations to or for the benefit of the Borrower within the meaning of Sections 365(c)(2) and 365(e)(2)(B) of the United States Bankruptcy Code, 11 U.S.C. &#167; 101 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq</font><font style="font-family:inherit;font-size:12pt;">.</font></div><a name="s0E05E4678D2CF58CBB81F3B57AC6EC72"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governance; Exhibits</font><font style="font-family:inherit;font-size:12pt;">. The terms of this Agreement shall govern if determined to be in conflict with the terms or provisions in any other Loan Document. The exhibits attached to this Agreement are incorporated in this Agreement and shall be considered a part of this Agreement except that in the event of any conflict between an exhibit and this Agreement or another Loan Document, the provisions of this Agreement or the Loan Document, as the case may be, shall prevail over the exhibit.</font></div><a name="sF7AFC7099471F5F0D4EAF3B57AF8486F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Time of Essence</font><font style="font-family:inherit;font-size:12pt;">.  Time is of the essence with regard to each and every provision of this Agreement.</font></div><a name="sC62AF05A24CAA88BCD0DF3B57B14CB07"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Costs, Expenses, and Taxes</font><font style="font-family:inherit;font-size:12pt;">. The Borrower agrees to pay on demand all out&#8209;of&#8209;pocket costs and expenses of Lender (including the reasonable fees and out&#8209;of&#8209;pocket expenses of Lender&#8217;s attorneys, paralegals, accountants, auditors, and consultants) incurred by Lender in connection with the preparation, execution, delivery, administration, interpretation, amendment, waiver or enforcement of this Agreement or the other Loan Documents, or in the protection of Lender&#8217;s rights under the Loan Documents (including any suit for declaratory judgment or interpretation of the provisions hereof and any bankruptcy, insolvency or condemnation proceedings involving the Borrower, its Property, and/or any Collateral); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;with regard to litigation costs, the Lender shall be entitled to recover such costs only in the event that it is the prevailing party. In addition, the Borrower agrees to pay, and to hold Lender harmless from all liability for, any stamp, recording, intangibles or other taxes (including taxes under Tennessee Code Annotated Section 67&#8209;4&#8209;409 due upon the recordation of financing statements) payable in connection with the execution or delivery of this Agreement, the Advances, the Collateral, or the issuance or delivery of the Note or any other Loan Documents, excluding, however, taxes based upon the income or assets of Lender. Upon Lender&#8217;s request, the Borrower shall promptly reimburse Lender for all amounts expended, advanced, or incurred by Lender in endeavoring to satisfy any obligation of any Borrower under this Agreement or any other Loan Documents, or to perfect a Lien in favor of Lender, or to protect the Properties or business of any Borrower or to collect the Indebtedness, or to enforce or protect the rights of Lender under this Agreement or any other Loan Document, including all court costs, attorney&#8217;s and paralegal&#8217;s fees, fees of auditors and accountants, and investigation expenses reasonably incurred by Lender in connection with any such matters, and all such amounts shall bear interest at the Default Rate until paid in full. All obligations under this Section shall be part of the Indebtedness and shall survive any termination of this Agreement.</font></div><a name="s37D4E42499F54B3208FFF3B57B462090"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in any number of counterparts or counterpart signature pages (by facsimile transmission or otherwise), each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same instrument.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s77AE7A10C6CA7DAF4519F3B57B709D46"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution of Information</font><font style="font-family:inherit;font-size:12pt;">.  The Borrower hereby authorizes Lender, as Lender may elect in its sole discretion, to discuss with and furnish to any affiliate of Lender, to any government or self&#8209;regulatory agency with jurisdiction over Lender, or to any participant or prospective participant, all financial statements, audit reports and other information pertaining to the Borrower whether such information was provided by the Borrower or prepared or obtained by Lender or third parties. Neither Lender nor any of its employees, officers, directors or agents make any representation or warranty regarding any audit reports or other analyses of the Borrower which Lender may elect to distribute, whether such information was provided by the Borrower or prepared or obtained by Lender or third parties, nor shall Lender or any of its employees, officers, directors or agents be liable to any Person receiving a copy of such reports or analyses for any inaccuracy or omission contained in such reports or analyses or relating thereto.</font></div><a name="s9DB2F8AAA062ED19E0CDF3B57B988041"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jurisdiction; Venue; Service of Process</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">THE BORROWER HEREBY IRREVOCABLY CONSENTS TO THE JURISDICTION OF THE COURTS LOCATED IN DAVIDSON COUNTY, TENNESSEE, INCLUDING WITHOUT LIMITATION FEDERAL COURTS SITTING IN THE MIDDLE DISTRICT OF TENNESSEE AND THE CHANCERY COURT FOR DAVIDSON COUNTY, TENNESSEE, FOR ANY SUIT BROUGHT OR ACTION COMMENCED IN CONNECTION WITH THIS AGREEMENT, ANY OF THE INDEBTEDNESS OR OBLIGATIONS, ANY COLLATERAL, OR ANY RELATIONSHIP BETWEEN LENDER AND THE BORROWER, AND AGREES NOT TO CONTEST OR CHALLENGE VENUE IN ANY SUCH COURTS.</font></div><a name="s89697D0AA2F716E232ECF3B57BBFC161"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jury Waiver</font><font style="font-family:inherit;font-size:12pt;">.  THE BORROWER HEREBY KNOWINGLY, WILLINGLY AND IRREVOCABLY WAIVES ITS RIGHTS TO DEMAND A JURY TRIAL IN ANY ACTION OR PROCEEDING INVOLVING THIS AGREEMENT, ANY OF THE INDEBTEDNESS OR OBLIGATIONS, ANY COLLATERAL, OR ANY RELATIONSHIP BETWEEN LENDER AND THE BORROWER. THE BORROWER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THE FOREGOING WAIVERS WITH ITS LEGAL COUNSEL AND HAS KNOWINGLY AND VOLUNTARILY WAIVED ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN THE EVENT OF LITIGATION, THIS SECTION MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><a name="s4BDEF8EA421B114375FAF3B57BF2D3AA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Certain Damages</font><font style="font-family:inherit;font-size:12pt;">.  IN ANY ACTION TO ENFORCE THIS AGREEMENT, THE BORROWER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY AND ALL RIGHTS UNDER THE LAWS OF ANY STATE TO CLAIM OR RECOVER ANY SPECIAL, EXEMPLARY, PUNITIVE, CONSEQUENTIAL OR OTHER DAMAGES OTHER THAN ACTUAL DIRECT DAMAGES.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s1DAF6C75655E8FEE01A2F3B57C0E5AA1"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement represents the entire agreement between the parties hereto except for such other agreements set forth in the Loan Documents, superseding any and all other agreements, promises or representations existing prior to or made simultaneously with this Agreement.  Any oral statements regarding the subject matter of this Agreement are merged herein.</font></div><a name="s5056C7C2B34837AC92BBF3B57C433D85"></a><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS AND USAGE</font></div><a name="sC7BA0F8A2FD8B6D2CECAF3B57C647496"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Defined Terms</font><font style="font-family:inherit;font-size:12pt;">.  In addition to other words and terms defined in the preamble hereof or elsewhere in this Agreement, the following terms shall have the following meanings herein, unless the context expressly requires otherwise:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Acquisition</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a stock purchase transaction and/or an asset purchase transaction of an entity engaged in the same or substantially the same business as the Borrower or which is engaged in a complimentary business to that of Borrower. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Advance</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any advance or other extension of credit made by Lender to Borrower under the Note.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Person that directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with Borrower. The term &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">control</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, firm or corporation whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Base Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the rate of interest established from time to time and announced by Lender as its &#8220;prime rate,&#8221; such rate being an interest rate used as an index for establishing rates on loans. The Base Rate shall be determined daily to reflect changes in the Base Rate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any day other than a Saturday, Sunday or day on which commercial banks are authorized to close under the laws of the State of Tennessee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act of 1934, but excluding any employee benefit plan of such Person or its Subsidiaries (excluding Cumberland Emerging Technologies Inc.), and any Person acting in its capacity as trustee, agent or other fiduciary or </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">administrator of any such plan) becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act of 1934, except that a person or group shall be deemed to have &#8220;beneficial ownership&#8221; of all securities that such Person or group has the right to acquire (such right, an &#8220;option right&#8221;), whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of 50% or more of the stock of the Borrower entitled to vote for members of the board of directors or equivalent governing body of the Borrower on a fully diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right); or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;during any period of twenty-four (24) consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Borrower cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body (excluding, in the case of both clause (ii) and clause (iii), any individual whose initial nomination for, or assumption of office as, a member of that board or equivalent governing body occurs as a result of an actual or threatened solicitation of proxies or consents for the election or removal of one or more directors by any person or group other than a solicitation for the election of one or more directors by or on behalf of the board of directors).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Closing Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means June 26, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Collateral</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all collateral securing or intended to secure the Indebtedness, as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article 2</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance Certificate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a certificate substantially in the form of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conditions Precedent</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those matters or events that by the terms of the Loan Documents must be completed or must occur or exist before Lender would become obligated to fund any Advance, including, without limitation, those matters described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Debt</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all of a Person&#8217;s obligations, contingent or otherwise, that would be classified on its balance sheet as its liabilities in accordance with GAAP, including, in any event and without limitation, (a) liabilities secured by any </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">mortgage, pledge or lien existing on Property owned by such Person, whether or not the liability secured thereby has assumed by such Person; (b) all indebtedness and other similar monetary obligations of such Person; (c) all guaranties, obligations in respect of letters of credit, endorsements (other than endorsements of negotiable instruments for purposes of collection in the ordinary course of business), obligations to purchase goods or services for the purpose of supplying funds for the purchase or payment of Debt of others and other contingent obligations in respect of, or to purchase, or otherwise acquire, or advance funds for the purchase of, Debt of others; (d) all obligations of such Person to indemnify another Person to the extent of the amount of indemnity, if any, that would be payable by such Person at the time of determination; (e) the principal portion of all obligations of such Person under capital leases (specifically excluding obligations under operating leases), (f) all obligations of such Person to purchase or repurchase any accounts, instruments, chattel paper or general intangibles, and (g) all obligations under Hedging Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Default</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of any of the events specified in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof, even though any requirement for notice or lapse of time or other condition precedent has not been satisfied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Default Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Lender&#8217;s Base Rate </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">plus</font><font style="font-family:inherit;font-size:12pt;">&#32;400 basis points per annum. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Depository Pledge Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain Depository Pledge Agreement dated of even by Borrower in favor of Lender, as such may be amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EBIT</font><font style="font-family:inherit;font-size:12pt;">&#8221; means for any period, the Net Income for such period, plus, without duplication and to the extent deducted in computing Net Income for such period, the sum of (a) Interest Expense, and (b) taxes, all as calculated in accordance with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EBIT to Interest Expense Ratio</font><font style="font-family:inherit;font-size:12pt;">&#8221; means: (a) EBIT </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">divided by</font><font style="font-family:inherit;font-size:12pt;">&#32;(b) Interest Expense, all as calculated in accordance with GAAP as follows: (i) calculation made as of June 30, 2014 shall be made for the quarter ending June 30, 2014 only; (ii) calculation made as of September 30, 2014, shall be made for the combined quarters ending June 30, 2014 and September 30, 2014; (iii) calculation made as of December 31, 2014 shall be made for the combined quarters ending June 30, 2014, September 30, 2014, and December 31, 2014; and (iv) calculation made as of March 31, 2015 and as of each successive quarter end thereafter, shall be made on a trailing four (4) quarter basis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EBITDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Net Income, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">plus</font><font style="font-family:inherit;font-size:12pt;">&#32;to the extent deducted in determining Net Income, and without duplication, the sum of (A) Interest Expense, (B) income tax expense, (C) depreciation expense, (D) amortization expense, and (E) Non-Cash Compensation Expense, determined at each fiscal quarter end on a rolling four (4) quarter basis.  </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Environmental Laws</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by or with any governmental authority, relating in any way to the environment, preservation or reclamation of natural resources, or the management, release or threatened release of any hazardous material.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">ERISA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended from time to time, including (unless the context otherwise requires) any rules or regulations promulgated thereunder.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Event of Default</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the occurrence of any of the events specified in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof, provided that any requirement in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:12pt;">&#32;for notice or lapse of time or other condition precedent has been satisfied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Funded Debt</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (1) all obligations for money borrowed, (2) all obligations evidenced by a bond, indenture, note, letter of credit or similar instrument, (3) all obligations under capital leases (excluding lease of office space), and (4) all other obligations upon which interest charges are customarily paid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Funded Debt Ratio</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the ratio of Funded Debt </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">divided by</font><font style="font-family:inherit;font-size:12pt;">&#32;EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means generally accepted accounting principles as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Guarantors</font><font style="font-family:inherit;font-size:12pt;">&#8221; means each of Cumberland Pharma Sales Corp., and any permitted future Subsidiary of the Borrower and/or any Guarantor and shall exclude Cumberland Emerging Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Guaranty</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a guaranty agreement executed by each Guarantor in form and substance acceptable to Lender whereby each Guarantor agrees, among other things, to guarantee repayment of the Indebtedness to Lender.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Hedging Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean and include any interest rate swap, cap, or collar agreements, interest rate future or option contracts, currency swap agreements, currency future or option contracts, commodity agreements, or arrangements designed to protect against fluctuations in interest rates, currency values or commodity values.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all amounts and liabilities of any nature owing or to be owing by Borrower to Lender from time to time in respect of the Loan, whether now existing or hereafter incurred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Interest Expense</font><font style="font-family:inherit;font-size:12pt;">&#8221; means interest expense (including without limitation the interest component of any payments in respect of capital leases capitalized or expensed during such period) determined for such fiscal quarter and the prior three fiscal quarters.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lender&#8217;s Office</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the office of Lender located at the address set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;8.1</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof, as modified from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lien</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any interest in Property securing an obligation owed to, or a claim by, a Person other than the owner of the Property, whether such interest is based on the common law, statute, or contract, and including, without limitation, the lien or security interest arising from a mortgage, encumbrance, pledge, security agreement, conditional sale, trust receipt or a lease, consignment, or bailment for </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">security purposes.  The term &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lien</font><font style="font-family:inherit;font-size:12pt;">&#8221; includes reservations, exceptions, encroachments, easements, rights&#8209;of&#8209;way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting any Property. For the purposes of this Agreement, the Borrower shall be deemed to be the owner of any Property that it has acquired or holds subject to a conditional sale agreement, financing lease, or other arrangement pursuant to which title to the Property has been retained by or vested in some other Person for security purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Loan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the revolving credit facility described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.1</font><font style="font-family:inherit;font-size:12pt;">&#32;hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Loan Documents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, all of the agreements, documents, papers and certificates executed, furnished or delivered in connection with this Agreement (whether before, at, or after the Closing Date) or at any time evidencing or securing any of the Indebtedness, including, without limitation, this Agreement, the Note, the Security Documents, the Guaranties, and all other documents, certificates, reports, and instruments that this Agreement requires or that were executed or delivered (or both) at Lender&#8217;s request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Material Adverse Effect</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Material Adverse Change</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applicable, a material adverse effect on, or material adverse change in, (a) the business, operations or financial condition of the Borrower and/or the Guarantors, (b) the value of the Collateral, (c) the ability of the Borrower or any Guarantor to perform its obligations, as applicable, under any of the Loan Documents, or (D) Lender&#8217;s ability to enforce the rights and remedies granted under this Agreement or any of the other Loan Documents, in all cases whether attributable to a single circumstance or event or an aggregation of circumstances or events.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Maturity Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means June 26, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Maximum Revolver Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the greater of: (1) the amount of cash against which Lender holds a first perfected security interest on terms and conditions acceptable to Lender and pursuant to documentation acceptable to Lender, or (2) an amount which does not cause the most recent calculation of the Funded Debt Ratio to exceed 2.00 to 1.00.  If all Advances under the Loan are secured with cash, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">then</font><font style="font-family:inherit;font-size:12pt;">&#32;the Funded Debt Ratio limitation shall not apply.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Maximum Revolver Availability</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the amount, if any, by which the Maximum Revolver Amount exceeds the amount of all outstanding and unpaid Advances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Net Income</font><font style="font-family:inherit;font-size:12pt;">&#8221; means for any period, the net income (or loss) of a Person for such period determined in accordance with GAAP, but excluding therefrom (to the extent otherwise included therein) (i) any extraordinary gains or losses, (ii) any gains attributable to write-ups of assets, and (iii) any income (or loss) of any Person accrued prior to the date it becomes a subsidiary or is merged into or consolidated with such Person on the date that such Person&#8217;s assets are acquired.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Cash Compensation Expense</font><font style="font-family:inherit;font-size:12pt;">&#8221; means non-cash compensation applicable to employees and non-employees of Borrower, as reflected in a line item depicted on Borrower&#8217;s financial statements and calculated in substantially the same manner as calculated historically, provided, that, in no event shall the amount of Non-Cash Compensation Expense used in the calculation of EBITDA exceed in any period of determination an amount equal to $800,000.00.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain Revolving Credit Note issued by Borrower to the order of Lender in the principal amount of up to $12,000,000.00 dated June 26, 2014, together with Addendum A attached thereto, as such may be amended and/or restated from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Notice of Revolving Borrowing</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a notice provided by Borrower to Lender pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 1.3</font><font style="font-family:inherit;font-size:12pt;">&#32;herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PBGC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Pension Benefit Guaranty Corporation and any entity succeeding to any or all of its functions under ERISA.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint stock company, trust, unincorporated organization, government, or any agency or political subdivision thereof, or any other form of entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any employee benefit or other plan established or maintained, or to which contributions have been made, by Borrower and covered by Title IV of ERISA or to which Section 412 of the Code applies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Properties</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any interest in any kind of property or asset, whether real, personal, or mixed, or tangible or intangible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Security Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means each Assignment and Security Agreement executed by the Borrower and the Guarantors in favor of Lender dated June 26, 2014, as such may be amended and/or restated from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Security Documents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all instruments creating, evidencing or providing security at any time for the Indebtedness, including, without limitation, the Security Agreements, Stock Pledge Agreement, Depository Pledge Agreement, and all UCC financing statements filed in conjunction therewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Stock Pledge Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain Stock Pledge Agreement entered into by the Borrower in favor of Lender dated June 26, 2014, as such may be amended, together with all stock powers and Regulation U forms, as may be applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Subsidiary</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, at the time as of which any determination is being made, any corporation, partnership, or other entity of which more than fifty percent </font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(50%) of the issued and outstanding voting securities is owned or controlled, directly or indirectly, by any Person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:60px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">UCC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Uniform Commercial Code as adopted in the State of Tennessee.</font></div><a name="s8F01A7D32A339B628BD3F3B57C97020A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Computations; Accounting Principles</font><font style="font-family:inherit;font-size:12pt;">.  Where the character or amount of any asset or liability or item of income or expense is required to be determined, or any consolidation or other accounting computation is required to be made for the purposes of this Agreement, such determination or calculation, to the extent applicable and except as otherwise specified in this Agreement, shall be made in accordance with GAAP consistent with those in effect at the Closing Date.</font></div><a name="sD8AA0F0CDCA60179AA9FF3B57CBC3BC6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Construction; Captions</font><font style="font-family:inherit;font-size:12pt;">.  All definitions and other terms used in this Agreement are equally applicable to the singular and plural forms thereof, and all references to any gender include all other genders. The captions in this Agreement are for convenience only, and in no way limit or amplify the provisions hereof.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s5DF520DB659FA4350AD8F3B57CEFDA0F"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UCC Terms</font><font style="font-family:inherit;font-size:12pt;">.  Terms used in this Agreement that are defined in the UCC shall have the same meanings herein, except as otherwise expressly provided or amplified (but not limited) herein.</font></div><a name="sCB8E306C099C536F0396F3B57D165AA8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:66px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">References to Documents and Laws</font><font style="font-family:inherit;font-size:12pt;">.  All defined terms and references in this Agreement with respect to any agreements, notes, instruments, certificates or other documents shall be deemed to refer to such documents and to any amendments, modifications, renewals, extensions, replacements, restatements, substitutions and supplements of and to such documents. Unless otherwise provided, all references to statutes and related regulations shall include any amendments thereof and any successor statutes and regulations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ENTERED INTO as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">BORROWER:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CUMBERLAND PHARMACEUTICALS </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INC.</font></div><div style="line-height:120%;text-align:center;padding-left:288px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:288px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="288px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: /s/ A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chairman and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LENDER:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SUNTRUST BANK</font></div><div style="line-height:120%;text-align:center;padding-left:288px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:288px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="288px"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: /s/ Tim Bewley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tim Bewley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">First Vice President</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s56DF369BFA5944D48D18F3B57D3BC397"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SCHEDULE 3.18</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">COLLATERAL LOCATIONS,</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">LEASES, AND</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">STORAGE AGREEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cardinal Health SPD</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">305 Tech Park Dr. Suite 113</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LaVergne , TN 37086</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s753E048A88749450D30BF3B57D5C5E66"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">COMPLIANCE CERTIFICATE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY COMPLIANCE CERTIFICATE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: As of the Quarter End: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To: &#160;&#160;&#160;&#160;SunTrust Bank (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SunTrust</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This certificate, which is duly signed by a senior officer of the Borrower certifies that:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Borrower is/is not in full compliance with all loan agreements, promissory notes and other loan documents between Borrower and SunTrust.  </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">If not in compliance, summarize below or on a separate attached page.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The attached covenant calculations are/are not accurate and are/are not calculated in accordance with the loan agreements.  If the response is negative, the following financial covenant violation(s) exist(s).  </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">If not in compliance, summarize below or on a separate attached page.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Summarization of violations or other:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___</font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">signed</font><font style="font-family:inherit;font-size:12pt;">________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Printed Name</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Printed Title</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44%"></td><td width="11%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">i</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s753E048A88749450D30BF3B57D5C5E66"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FORM OF COVENANT COMPLIANCE CERTIFICATE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">FINANCIAL COVENANT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Calculated in accordance with GAAP)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Calculation Date:  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EBIT to Interest Expense Ratio</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Net Income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Plus</font><font style="font-family:inherit;font-size:12pt;">&#32;Interest Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Plus</font><font style="font-family:inherit;font-size:12pt;">&#32;Taxes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Equal:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EBIT (Numerator)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">Divided by</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interest Expense (Denominator)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Ratio of Numerator to Denominator</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(EBIT to Interest Expense Ratio):&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Calculation shall not exceed the following ratios as of the quarters ending below, all as calculated on a rolling four quarter basis:</font></div><div style="line-height:120%;padding-left:126px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:73.07692307692307%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="37%"></td><td width="63%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RATIO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TIME PERIOD</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.00 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of June 30, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.50 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of September 30, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.00 to 1.00</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarter ending as of December 31, 2014 and each fiscal quarter thereafter</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s753E048A88749450D30BF3B57D5C5E66"></a><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Funded Debt Ratio</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#183;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Funded Debt&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(Numerator)</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Divided By</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#183;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EBITDA</font></div></td></tr></table><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Net Income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$_________________</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Plus:  Interest Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$_________________</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Plus:  Income Tax Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$_________________</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Plus:  Depreciation Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$_________________</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Plus:  Amortization Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$_________________</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Plus:  Non-Cash Compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Expense&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:12pt;">Equals: EBITDA (Denominator)&#160;&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ratio of Numerator to Denominator <br>(Funded Debt Ratio):&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Calculation shall not exceed 2.00 to 1.00, all as calculated on a rolling four quarter basis</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>q22014-exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Q2 2014 -Exhibit 31.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s3AAAD6AB2F37FBA941676883836DC658"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, A.J. Kazimi, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="3%"></td><td width="41%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;8, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>q22014-exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Q2 2014 -Exhibit 31.2</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6E13A631D0EF5B253C5E68837862F8EE"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Rick S. Greene, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="52%"></td><td width="4%"></td><td width="3%"></td><td width="41%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;8, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>q22014-exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Q2 2014 -Exhibit 32.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s54D4B92D8ACAB53967366883850D4208"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Rick S. Greene, Vice President and Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="40px"></td><td width="642px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;" align="right"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:267px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="266px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ A. J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A.J. Kazimi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;8, 2014</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;" align="right"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:267px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="266px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;8, 2014</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>cpix-20140630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!--p:f1be721effc54ff09be8f00121ca7898,x:3f976b0886734ddd88e5e6932f1f0be9-->
<xbrli:xbrl xmlns:cpix="http://www.cumberlandpharma.com/20140630" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="cpix-20140630.xsd" xlink:type="simple" />
  <xbrli:context id="D2010Q2May13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-12</xbrli:startDate>
      <xbrli:endDate>2010-05-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1Jan">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2April">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-04-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q1Jan">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1Jan">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2April">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:SunTrustBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-26</xbrli:startDate>
      <xbrli:endDate>2014-06-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:ProductAcetadoteGenericMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:ProductAcetadoteGenericMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2013Q2YTD_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VaprisolMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:ProductAcetadoteGenericMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_TitleOfIndividualAxis_cpix_EmployeeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VaprisolMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">cpix:CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cpix:ProductAcetadoteGenericMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2012Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q2_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">cpix:CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2013Q4_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:LoanPoolsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3Aug31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">cpix:CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VaprisolMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2April">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:SunTrustBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q3SharesOutstanding">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="agreement">
    <xbrli:measure>cpix:agreement</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="number">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="product_line">
    <xbrli:measure>cpix:product_line</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usdPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:AccountsPayableCurrent contextRef="FI2014Q2" decimals="0" id="Fact-71011DD16D5F4DA24124688376BD78A9" unitRef="usd">4220194</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="FI2013Q4" decimals="0" id="Fact-F17FBC3CC593AE1FC5F9688376C094F5" unitRef="usd">2035853</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q2" decimals="0" id="Fact-1F105B044A8DE5F18564688376BCE5AF" unitRef="usd">6014477</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="FI2013Q4" decimals="0" id="Fact-3B7D829250451E190646688376C0D5D3" unitRef="usd">4530424</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AmortizationOfFinancingCosts contextRef="FD2013Q2YTD" decimals="0" id="Fact-4D2D8016086731F7A18C688376D79AEA" unitRef="usd">12038</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="FD2014Q2YTD" decimals="0" id="Fact-37202785ECA11BCADB55688376D8116A" unitRef="usd">12038</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q2QTD" decimals="0" id="Fact-B8BCA00169896A35CCD2688376C9AE84" unitRef="usd">304258</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q2YTD" decimals="0" id="Fact-8CE667D9E88DC2989C22688376CE5771" unitRef="usd">598213</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="FD2013Q2QTD" decimals="0" id="Fact-5F76A01FB888BF390681688376CA3395" unitRef="usd">282645</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="FD2013Q2YTD" decimals="0" id="Fact-3F8811BF3E4547A65D51688376CEE8EB" unitRef="usd">407695</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q2YTD" decimals="INF" id="Fact-C0E01ED6DDF07C3536B5688376FD2523" unitRef="shares">554279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q2YTD" decimals="INF" id="Fact-44C8C92D4DB06E614B5C688376FDD39C" unitRef="shares">188814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="FI2013Q4" decimals="0" id="Fact-F649B99E0932ED0D5468688376BE2B26" unitRef="usd">87613738</us-gaap:Assets>
  <us-gaap:Assets contextRef="FI2014Q2" decimals="0" id="Fact-E5EE4EF1B08BAF5D877E688376BF1962" unitRef="usd">93468664</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="FI2013Q4" decimals="0" id="Fact-01CB1A1898B5A15DCFC1688376BC14F5" unitRef="usd">68679715</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="FI2014Q2" decimals="0" id="Fact-8FB52D3A800C52915E6C688376BD6FCB" unitRef="usd">70632037</us-gaap:AssetsCurrent>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-2FDF2C1FF0865459515168837745857F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NEW PRODUCTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Omeclamox-Pak&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 28, 2013, the Company entered into an agreement with Pernix to distribute and promote Omeclamox-Pak. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;H. pylori&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) infection and duodenal ulcer disease. Under the terms of the agreement, the Company promotes the product to gastroenterologists across the United States and Pernix promotes the product through its specialty sales force focusing on select primary care physicians. The companies cooperate in the marketing and other activities needed to support the commercialization of the brand. The Company paid an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Pernix on October 29, 2013.  There are additional milestones at the first and second anniversary dates of the execution of the agreement totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the aggregate. Royalty payments ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on tiered levels of gross profits are paid by Cumberland to Pernix.  The Company also makes royalty payments to Pernix to reflect their ongoing sales promotional efforts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment that the Company paid to Pernix on October 29, 2013 is included in product and license rights and will be amortized over the remaining expected useful life of the acquired asset, currently the life of the agreement, which ends in June 2032.  Omeclamox-Pak contributed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net revenues during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Vaprisol&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 28, 2014, the Company acquired certain product rights, intellectual property and related assets of Vaprisol&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;  &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;from Astellas. Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia.  The Company provided an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Astellas at closing. There is an additional milestone payment due forty-five days after the first anniversary date of the closing of the transaction of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, dependent upon Cumberland achieving certain first year sales levels for the product.  Cumberland's acquisition of Vaprisol is accounted for as a business combination and the product is included in the results of operations since the acquisition date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the preliminary allocation of the fair values of the assets acquired and liabilities assumed as of the acquisition date for Vaprisol:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="569px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="95px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intellectual property intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,990,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,410,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired contingent liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(400,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration obligation represents the additional milestone payment discussed above.  Cumberland prepared the valuations of the contingent consideration obligation and the intangible assets utilizing significant unobservable inputs. As a result, the valuations are classified as Level 3 fair value measurements.  Vaprisol contributed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net revenues during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The pro-forma effects of the acquisition on the condensed consolidated financial statements were not material for disclosure.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-D442262842CED9BDFD4268837748F850" unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-052902F64CD9FFDCE7F468837748641C" unitRef="usd">2990000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-60E2038737E5080A1C4E68837748B403" unitRef="usd">1410000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-7527CEF26429802B00F568837748ECE0" unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="0" id="Fact-664BC7027CD8BD9EEA16688376C08182" unitRef="usd">40869457</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q2" decimals="0" id="Fact-69EBDB4B3BBDAD88E016688376C0F910" unitRef="usd">39050841</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="0" id="Fact-F0A083D6307182973B74688376DA3E37" unitRef="usd">54349381</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q2" decimals="0" id="Fact-05AF36690FE8F4CA39E1688376D94E17" unitRef="usd">49664762</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q2YTD" decimals="0" id="Fact-74930F47C5F564F9AEB9688376D722AD" unitRef="usd">-4684619</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q2YTD" decimals="0" id="Fact-428AE210079B5AA3EE08688376DAF029" unitRef="usd">-1818616</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-498A9274937B2C7DC1DD6883773EF6A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COLLABORATIVE AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The agreements do not specifically designate each party&amp;#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies contextRef="FI2014Q2" id="Fact-8445CB79D63AF2AFF804688376BC3C9A" unitRef="usd" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies contextRef="FI2013Q4" id="Fact-082E471CDB4974FB5631688376BDF0D7" unitRef="usd" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-677307E727E83D74B12B6883773F74F8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company received notices during 2012 and 2013, that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&amp;#160; The Company is continuing to seek additional claims to protect its intellectual property associated with Acetadote and have additional pending patent applications relating to Acetadote.  The Company continues to consider its legal options and intends to continue to vigorously defend and protect its Acetadote product and related intellectual property rights.&amp;#160; Also see the discussion of the Company's Acetadote patent defense legal proceedings contained in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Part 1, Item 1, Business -Trademarks and Patents&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the Company's Form 10-K for the year ended December&amp;#160;31, 2013, which is incorporated by reference herein.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the Company is unable to successfully defend the Acetadote patents and related intellectual property rights associated with its Acetadote product, its financial condition and results of operations could be adversely affected in the event of a loss of patent rights and lower sales volumes due to competition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockNoParValue contextRef="FI2013Q4" decimals="INF" id="Fact-219182085FD1211CEFBA688376C3A6C8" unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockNoParValue contextRef="FI2014Q2" decimals="INF" id="Fact-11FC8234209E2A3D008D688376C470C7" unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q2" decimals="INF" id="Fact-7423D8B992837B1FBCE4688376C30A2F" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="FI2013Q4" decimals="INF" id="Fact-D60CB19AD7468DC6CFE2688376C3D7E1" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="FI2013Q4" decimals="INF" id="Fact-93042A437AFC2EE5CC6E688376C3E4CC" unitRef="shares">17985503</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="FI2014Q2" decimals="INF" id="Fact-7284517F229E68F7FA77688376C38263" unitRef="shares">17660367</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4" decimals="INF" id="Fact-B7902ADFDFBA2E47617E688376C33348" unitRef="shares">17985503</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q2" decimals="INF" id="Fact-BA02A58C04613884574C688376C39EF6" unitRef="shares">17660367</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1936F0FF819AF0089130688376E11477" unitRef="shares">17985503</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7292F51D3E0504A02ADC688376E186B9" unitRef="shares">17660367</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="FI2013Q4" decimals="0" id="Fact-0B881E4878FEE33A2E69688376BC88EA" unitRef="usd">63073941</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="FI2014Q2" decimals="0" id="Fact-FF1843768D443921D1B2688376BE176A" unitRef="usd">63529644</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q2YTD" decimals="0" id="Fact-A71856DBA1E0D416A265688376CF3223" unitRef="usd">192472</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q2QTD" decimals="0" id="Fact-13D0895899B2231D58DA688376C90925" unitRef="usd">709536</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q2YTD" decimals="0" id="Fact-A19AC96F414D8D100BF2688376D0E173" unitRef="usd">984718</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q2QTD" decimals="0" id="Fact-3B4F2E2509F2FE306459688376CACB9B" unitRef="usd">-648854</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CostOfGoodsSold contextRef="FD2013Q2YTD" decimals="0" id="Fact-71FD336AFB1962C8C91C688376CF0116" unitRef="usd">2263468</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="FD2014Q2YTD" decimals="0" id="Fact-19746E7970E0382719B4688376D07A33" unitRef="usd">2352533</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="FD2014Q2QTD" decimals="0" id="Fact-A8BFF1FB690FDD5F2845688376C9AD18" unitRef="usd">1298816</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="FD2013Q2QTD" decimals="0" id="Fact-624740406557C6701EED688376CB9B7B" unitRef="usd">1154833</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="FD2013Q2QTD" decimals="0" id="Fact-EC7779B127979822427B688376CBF6D6" unitRef="usd">8221632</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="FD2014Q2QTD" decimals="0" id="Fact-51AB5CFC013A4AD98B00688376C8FF7A" unitRef="usd">8534559</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="FD2014Q2YTD" decimals="0" id="Fact-42E41AC76E08EC8AA7C4688376CE6639" unitRef="usd">16219752</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="FD2013Q2YTD" decimals="0" id="Fact-F534D2E151954BB4AA0A688376CF13B4" unitRef="usd">17153713</us-gaap:CostsAndExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum contextRef="D2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" decimals="INF" id="Fact-48F75EF06488F138FA4EA239DDB665A9" unitRef="number">0.0285</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum contextRef="D2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" decimals="INF" id="Fact-4A7D61555B39EE671DD0A23979242B1E" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q2YTD" decimals="0" id="Fact-1055532250A6DEEBB9C7688376DA3E34" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2013Q2YTD" decimals="0" id="Fact-10DAF558C51ED9ADC0E4688376D98825" unitRef="usd">65413</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="FD2014Q2YTD" decimals="-5" id="Fact-708BA547AF92DADECA126883773DB3F0" unitRef="usd">42700000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="FD2013Q2YTD" decimals="0" id="Fact-15BC53A4FEBC6657B7F9688376DA134A" unitRef="usd">610052</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q2YTD" decimals="0" id="Fact-EE64C83E60731C289A2A688376D8B83F" unitRef="usd">800231</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasic contextRef="FD2013Q2YTD" decimals="2" id="Fact-6A015C8F8329C830B438688376CE44C6" unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="FD2013Q2QTD" decimals="2" id="Fact-2055CAAB97B201F86C2C688376CAB9BC" unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="FD2014Q2QTD" decimals="2" id="Fact-B7905F200E1830995291688376CBFFDC" unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="FD2014Q2YTD" decimals="2" id="Fact-10EF30D46A29BE5D0A6C688376CE6859" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="FD2014Q2QTD" decimals="2" id="Fact-3D13784F44BAD03D94D3688376C92ADD" unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="FD2014Q2YTD" decimals="2" id="Fact-E32BD7BF91924224B0BF688376CC9E52" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="FD2013Q2YTD" decimals="2" id="Fact-759638D941B17C34BEBE688376CE963C" unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="FD2013Q2QTD" decimals="2" id="Fact-126EBE13D8360CF5E944688376C9F1DD" unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="FD2014Q2YTD" id="Fact-60D18F642AD5D20AC1B0688376FD90D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;EARNINGS (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings per share for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) attributable to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;722,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(639,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,743,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,405,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of other securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;282,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,025,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,405,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="441px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="102px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="103px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) attributable to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,008,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;215,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,825,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,580,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of other securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;268,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,093,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,756,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, restricted stock awards and options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;188,814&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;554,279&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, respectively, were outstanding but were not included in the computation of diluted EPS because the effect would be antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2014Q2YTD" decimals="0" id="Fact-CDF86A6D2B3873F89AC5688376DB0141" unitRef="usd">711348</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2013Q2YTD" decimals="0" id="Fact-8F66F33D96C7077FD104688376D97A6D" unitRef="usd">15288</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="FD2014Q2YTD" decimals="0" id="Fact-798E1A12A8B66AD1E967688376D8FF9F" unitRef="usd">711348</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="FD2013Q2YTD" decimals="0" id="Fact-10E0BF2447EA628F50F2688376D6DBD2" unitRef="usd">15288</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2014Q2YTD" id="Fact-DD20C530CDA4D9EDB3B1688376E5CE76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the fair value of these marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="200px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,857,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,857,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Agency issued mortgage-backed securities &amp;#8211; variable rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,896,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,896,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,049,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,049,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Agency notes and bonds &amp;#8211; fixed rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,747,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,747,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,496,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,496,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;SBA loan pools &amp;#8211; variable rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,748,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,748,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds &amp;#8211; VRDN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,895,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,895,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total fair value of marketable  securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,692,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,133,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,825,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,724,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,294,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,019,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2013Q4" decimals="0" id="Fact-90977668743DEF77F79B688376BD7C0B" unitRef="usd">15498819</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q2" decimals="0" id="Fact-57AB1B285248BECE928B688376BFEBA5" unitRef="usd">19073458</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q2QTD" decimals="0" id="Fact-E6D7BD299E071E608F6A688376CBE16F" unitRef="usd">1855201</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q2QTD" decimals="0" id="Fact-455C8F2AEA7DABBA76A5688376CCD1C6" unitRef="usd">2140249</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q2YTD" decimals="0" id="Fact-27B43BE2A6AC77F642CA688376CF6F19" unitRef="usd">4430940</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q2YTD" decimals="0" id="Fact-99299A02FA354469A000688376D04D45" unitRef="usd">4037466</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2013Q2YTD" decimals="0" id="Fact-F0CCCFAA4CAC5A15C8CC688376CDE3DD" unitRef="usd">288431</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2013Q2QTD" decimals="0" id="Fact-A27FC1A7F5E797C4F8EF688376CB3665" unitRef="usd">-1112262</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q2YTD" decimals="0" id="Fact-3233784D1DFFE6A969D0688376CEAA0F" unitRef="usd">1696066</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q2QTD" decimals="0" id="Fact-92E589F48A62CE8CFCC1688376C8BF25" unitRef="usd">1232875</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-E105EC2A4E511474E3E46883773D0A86">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has unrecognized net operating loss carryforwards generated from the exercise of nonqualified options of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$42.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. These benefits occurred as a result of the actual tax benefit realized upon an employee's exercise exceeding the cumulative book compensation charge associated with the awards and will be recognized in the year in which they are able to reduce current income taxes payable.  Accordingly, deferred tax assets are not recognized for these net operating loss carryforwards or credit carryforwards resulting from the exercise of nonqualified options.  The Company's utilization of these net operating loss carryforwards and a net operating loss in 2013 resulted in it paying minimal income taxes in each of the years 2009 through 2013.  The Company expects to pay minimal income taxes in 2014 through utilization of these net operating loss carryforwards.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q2QTD" decimals="0" id="Fact-9F37DD9420694436508B688376CA44BE" unitRef="usd">523339</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q2QTD" decimals="0" id="Fact-9EEF1F2C2D0A30E6F969688376C99F9A" unitRef="usd">-463408</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q2YTD" decimals="0" id="Fact-E62148337E45AE250368688376CD797D" unitRef="usd">95959</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q2YTD" decimals="0" id="Fact-F238E53C370DBBA256E9688376D0C8D5" unitRef="usd">711348</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2013Q2YTD" decimals="0" id="Fact-EE07E6EAA0066CBE2CF6688376D8F7B6" unitRef="usd">-2046259</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q2YTD" decimals="0" id="Fact-489D91C11D064365E41B688376D84376" unitRef="usd">1484052</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories contextRef="FD2013Q2YTD" decimals="0" id="Fact-7BCFD12F835B1AC4F044688376D72D81" unitRef="usd">-124061</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q2YTD" decimals="0" id="Fact-038F4E435972A6306E85688376D7F94E" unitRef="usd">-136039</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2013Q2YTD" decimals="0" id="Fact-61B68C734DB2D2E5E34D688376D67C5F" unitRef="usd">37479</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2014Q2YTD" decimals="0" id="Fact-853C495671865D73968C688376DA5FBB" unitRef="usd">109244</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2014Q2YTD" decimals="0" id="Fact-FC64544894FF33F22EC6688376D9416C" unitRef="usd">701604</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2013Q2YTD" decimals="0" id="Fact-ABB235F8AE47FBB1DB05688376D7D6C8" unitRef="usd">-59877</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:InterestExpense contextRef="FD2014Q2QTD" decimals="0" id="Fact-8F4D4B0D8FB4EC729BF9688376CA190A" unitRef="usd">12278</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2013Q2YTD" decimals="0" id="Fact-8915A6C64BF792BA2CBB688376CC7BEC" unitRef="usd">38435</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2013Q2QTD" decimals="0" id="Fact-83D4FFFA588DD4EE186D688376C8D723" unitRef="usd">20700</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="FD2014Q2YTD" decimals="0" id="Fact-69B29225E46126A8834B688376CDD566" unitRef="usd">24481</us-gaap:InterestExpense>
  <us-gaap:InventoryDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-724370B67CB78F043BC86883772F4EC0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INVENTORIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Caldolor inventory on hand at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had varying original expiration dates that began in the second quarter of 2014 and extend through January 2016. During 2013, the Company provided stability data to the Food and Drug Administration ("FDA") supporting that the Caldolor product expiration dates may be extended by up to a year.  In January 2014, the FDA notified the Company that it had approved its request to extend the original shelf life of the Caldolor 800mg vials from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has recognized cumulative charges for potential obsolescence and discontinuance losses, primarily for Caldolor, of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. If actual sales in future periods are less than projected sales, the Company may incur additional obsolescence losses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient for Kristalose and maintains the inventory at the third-party manufacturer. As the ingredients are consumed in production, the value of the ingredients is transferred from raw materials to finished goods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inventory was comprised of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,768,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,228,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,697,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,996,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,722,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2013Q4" decimals="0" id="Fact-9E6EC75F4716F5150DA968837730488E" unitRef="usd">3697862</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2014Q2" decimals="0" id="Fact-404638B123E63E4C2D2968837731D950" unitRef="usd">4228148</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="FI2013Q4" decimals="0" id="Fact-FF05DE9932CF50251219688376BDDC26" unitRef="usd">5722882</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="FI2014Q2" decimals="0" id="Fact-E0DF3B882D64D88389E7688376C07B5F" unitRef="usd">6996843</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2014Q2" decimals="0" id="Fact-40EBE19CE876355269C468837730E211" unitRef="usd">2768695</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2013Q4" decimals="0" id="Fact-C5EE8D050ED4D6539A51688377314F35" unitRef="usd">2025020</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryValuationReserves contextRef="FI2014Q2" decimals="-5" id="Fact-A348890A9E98AC2E76616883772FAD4D" unitRef="usd">3400000</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryValuationReserves contextRef="FI2013Q4" decimals="-5" id="Fact-9BA3747F0F2E31D427446883772E663B" unitRef="usd">3500000</us-gaap:InventoryValuationReserves>
  <us-gaap:InvestmentIncomeInterest contextRef="FD2013Q2YTD" decimals="0" id="Fact-AC684E803480BA152AC0688376CE2A64" unitRef="usd">141359</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="FD2013Q2QTD" decimals="0" id="Fact-FFC44DAC4B9E66A5B004688376C8B5BD" unitRef="usd">48982</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="FD2014Q2YTD" decimals="0" id="Fact-AAA7B2CEDE49914F4AD9688376CD5A2B" unitRef="usd">96887</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="FD2014Q2QTD" decimals="0" id="Fact-D6940C6A311E3C111FB4688376CB3C4D" unitRef="usd">29544</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-42034EABE7BB4B3D27E2688376E5636E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;MARKETABLE SECURITIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of U.S. Treasury notes and bonds, U.S. Government Agency notes and bonds and bank-guaranteed, variable rate demand notes ("VRDN").  At the time of purchase,  the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 -&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quoted prices for identical instruments in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 -&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 -&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant inputs to the valuation model are unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:11pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the fair value of these marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="200px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="62px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury notes and bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,857,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,857,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Agency issued mortgage-backed securities &amp;#8211; variable rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,896,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,896,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,049,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,049,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Agency notes and bonds &amp;#8211; fixed rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,747,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,747,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,496,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,496,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;SBA loan pools &amp;#8211; variable rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,748,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,748,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds &amp;#8211; VRDN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,895,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,895,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total fair value of marketable  securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,692,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,133,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,825,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,724,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,294,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,019,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:Liabilities contextRef="FI2013Q4" decimals="0" id="Fact-C501AB28A50477DCE75B688376BDC0AA" unitRef="usd">8321895</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="FI2014Q2" decimals="0" id="Fact-C30C1D5D5F2E6B34FF8C688376BF0E5B" unitRef="usd">12736400</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q2" decimals="0" id="Fact-D2EE30F686C4AD916F47688376BCDFDA" unitRef="usd">93468664</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2013Q4" decimals="0" id="Fact-7CF28C96ABB3264EC651688376BE649F" unitRef="usd">87613738</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="FI2013Q4" decimals="0" id="Fact-73CF2D99CC60F1CAE008688376BC3954" unitRef="usd">7545770</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="FI2014Q2" decimals="0" id="Fact-EE9261D9EAA217E3294B688376C05C56" unitRef="usd">11863154</us-gaap:LiabilitiesCurrent>
  <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="D2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" id="Fact-12B340CB5E4DA43BADCDA1F1C910FB8C">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="FI2013Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" decimals="INF" id="Fact-5D2F6B483985D2F221E8A1F0F0A24664" unitRef="number">0.0217</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2011Q3Aug31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" decimals="INF" id="Fact-80967EBDDEA01A5B6337A1F006C2C33D" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" decimals="INF" id="Fact-EF3B5882C1A49B67CC2EA23570F7A3EC" unitRef="usd">12000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="FD2014Q2YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" decimals="INF" id="Fact-69A7164D2573E38C8BEFA1F116865CBF" unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
  <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="D2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" decimals="INF" id="Fact-C51E586BEFA5F9E2974CA23B53D01C89" unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
  <us-gaap:LongTermLineOfCredit contextRef="FI2014Q2" decimals="0" id="Fact-8FD2E77508038EB3F722688376BFC5E5" unitRef="usd">0</us-gaap:LongTermLineOfCredit>
  <us-gaap:LongTermLineOfCredit contextRef="FI2013Q4" decimals="0" id="Fact-6D80FEC4DE45DC792A7E688376C0D115" unitRef="usd">0</us-gaap:LongTermLineOfCredit>
  <us-gaap:MarketableSecurities contextRef="FI2014Q2" decimals="0" id="Fact-D03BFE69B070760F80E1688376BFF658" unitRef="usd">14825632</us-gaap:MarketableSecurities>
  <us-gaap:MarketableSecurities contextRef="FI2013Q4" decimals="0" id="Fact-9F889842E309BEDA4F63688376C04EDB" unitRef="usd">14019761</us-gaap:MarketableSecurities>
  <us-gaap:MinorityInterest contextRef="FI2013Q4" decimals="0" id="Fact-2BE0C78BBE4C413259BC688376BD953A" unitRef="usd">-176638</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest contextRef="FI2014Q2" decimals="0" id="Fact-0E3EBE8F26DD704D91F2688376BE840D" unitRef="usd">-200810</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="I2014Q2April" decimals="2" id="Fact-D3FBAD2F97DE41F3F136A1E14C9BC603" unitRef="number">0.80</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="FI2014Q1" decimals="2" id="Fact-6140013459FBB814E6D1A1E14C99A064" unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q2YTD" decimals="0" id="Fact-C7B3CEBE52B7D7E80241688376D76393" unitRef="usd">131128</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q2YTD" decimals="0" id="Fact-B6FDB3027E18DEE32D50688376D72159" unitRef="usd">-1688306</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q2YTD" decimals="0" id="Fact-6FD8DBE92F1B28246BBA688376D7A5C5" unitRef="usd">-3768132</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q2YTD" decimals="0" id="Fact-80DDCD1F0DE67F8938F1688376D938F4" unitRef="usd">-4788638</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q2YTD" decimals="0" id="Fact-0CFEC81F0D240606CD5B688376D767EE" unitRef="usd">1818388</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q2YTD" decimals="0" id="Fact-32E0A79038FAC82C3012688376D9C6EF" unitRef="usd">1792325</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="FD2014Q2YTD" decimals="0" id="Fact-D2AF3876F4698802502D688376CD804F" unitRef="usd">1008890</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2013Q2YTD" decimals="0" id="Fact-1DD338E06065A111E694688376CCAEA5" unitRef="usd">215691</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2013Q2QTD" decimals="0" id="Fact-927320C66670770000F4688376C949E1" unitRef="usd">-639018</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="0" id="Fact-5700DEC3DF7C182DECE7688376C89C37" unitRef="usd">722570</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2013Q2YTD" decimals="0" id="Fact-ED97E473850898AD23FB688376CFF3CA" unitRef="usd">-23219</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q2QTD" decimals="0" id="Fact-64F4CE8820C5DEBAF24D688376CA7FB3" unitRef="usd">-13034</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2013Q2QTD" decimals="0" id="Fact-332C186E28E9DFD4A5EE688376C96952" unitRef="usd">-9836</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q2YTD" decimals="0" id="Fact-2B4BABAC31B716E0D294688376D0660D" unitRef="usd">-24172</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2014Q2YTD" id="Fact-26F3E35739F5A16026D1A1B49FE2E2F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Guidance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Financial Accounting Standards Board (the "FASB") issued amended guidance in the form of a FASB Accounting Standards Update on "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity".  The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomes effective on January 1, 2015. Adoption is on a prospective basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued amended guidance in the form of a FASB Accounting Standards Update on, "Revenue from Contracts with Customers".  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process.  The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method by which we will adopt the standard in 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2013Q2YTD" decimals="0" id="Fact-BDE7E9534F2E0AB9BE65688376D93936" unitRef="usd">249633</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2014Q2YTD" decimals="0" id="Fact-F3A26FEB4F4D5ABA637B688376D85EA0" unitRef="usd">450781</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="FD2014Q2YTD" decimals="0" id="Fact-0984F005FB97D4D1EA09A1AF17A3CF20" unitRef="usd">1000005</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
  <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-C7948F65107AD8F484D4A1AF17AA599D" unitRef="usd">1000005</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
  <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="D2014Q2April" decimals="-5" id="Fact-34449D2FBBCFAEBD234EA1DEC1604D6C" unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
  <us-gaap:OperatingIncomeLoss contextRef="FD2014Q2QTD" decimals="0" id="Fact-0A3591D0C146A75AB4E6688376C916D0" unitRef="usd">1215609</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2013Q2QTD" decimals="0" id="Fact-EC41FA5E3B9B52B617B6688376CCBC07" unitRef="usd">-1140544</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2014Q2YTD" decimals="0" id="Fact-F5F3B89365C31DCB1AAE688376CCC949" unitRef="usd">1623660</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="FD2013Q2YTD" decimals="0" id="Fact-5C9F8EB7FAB8F0772BB8688376CDD338" unitRef="usd">185507</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-29124FF74045B7D76910688376E43103">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;ORGANIZATION AND BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cumberland Pharmaceuticals Inc. and its subsidiaries (the&amp;#160;"Company" or "Cumberland") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cumberland has both internal product development and commercial capabilities. The Company is focused on maximizing the commercial potential of its current brands, as well as expanding its product portfolio through select acquisitions and development of new product candidates.  Cumberland&amp;#8217;s products are manufactured by third parties, which are overseen by the Company&amp;#8217;s quality assurance professionals. The Company works closely with its distribution partners to ensure the delivery and availability of the Company's products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission, or the SEC, and omit certain information and footnote disclosure necessary to present the statements in accordance with U.S. generally accepted accounting principles. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total comprehensive income (loss) was comprised solely of net income (loss) for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Guidance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Financial Accounting Standards Board (the "FASB") issued amended guidance in the form of a FASB Accounting Standards Update on "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity".  The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomes effective on January 1, 2015. Adoption is on a prospective basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued amended guidance in the form of a FASB Accounting Standards Update on, "Revenue from Contracts with Customers".  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process.  The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method by which we will adopt the standard in 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Policies:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In preparing the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual amounts could differ from those estimated at the time the condensed consolidated financial statements are prepared.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the  allowances for obsolescent or unmarketable inventory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Operating Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in one segment, specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold.  Substantially all of the Company&amp;#8217;s assets are located in the United States, and total revenues are primarily attributable to U.S.&amp;#160;customers.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAssetsCurrent contextRef="FI2013Q4" decimals="0" id="Fact-8CBAD2D50C19791B41E0688376BECAD4" unitRef="usd">3537191</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="FI2014Q2" decimals="0" id="Fact-5AE31E1A7A94E59439EB688376BE95D0" unitRef="usd">3744244</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="FI2014Q2" decimals="0" id="Fact-A964DB5A431E3407BE80688376BC3098" unitRef="usd">3036301</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="FI2013Q4" decimals="0" id="Fact-DB23AE4D450213661F89688376BEAC94" unitRef="usd">2554557</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="FI2013Q4" decimals="0" id="Fact-D1C30FD7DD1093386BAB688376BFC61F" unitRef="usd">5509917</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="FI2014Q2" decimals="0" id="Fact-DD812B6BB5A389222141688376C0AF6D" unitRef="usd">7642960</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:PaymentsForPreviousAcquisition contextRef="FD2014Q2YTD" decimals="0" id="Fact-81B393E7F5DE2A8B179F688376D99EFD" unitRef="usd">2000000</us-gaap:PaymentsForPreviousAcquisition>
  <us-gaap:PaymentsForPreviousAcquisition contextRef="FD2013Q2YTD" decimals="0" id="Fact-4D2D8AA9E6263D5C8907688376D765CF" unitRef="usd">0</us-gaap:PaymentsForPreviousAcquisition>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2013Q2YTD" decimals="0" id="Fact-C2F2491B2464750294C8688376D6A258" unitRef="usd">3162302</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2014Q2YTD" decimals="0" id="Fact-99744A33038B5A0849CB688376D8A7E6" unitRef="usd">1580225</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2013Q2YTD" decimals="0" id="Fact-857B351A5A90F5914CD3688376D7B528" unitRef="usd">1829693</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2014Q2YTD" decimals="0" id="Fact-328180D77D396F69E74F688376D9B3A9" unitRef="usd">732072</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="D2014Q2April" decimals="-5" id="Fact-696A717E2893B3A9DF76A1E780E8F223" unitRef="usd">1000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2013Q2YTD" decimals="0" id="Fact-3282280C5F92A6641751688376DBCEF0" unitRef="usd">4371508</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2014Q2YTD" decimals="0" id="Fact-8930E3D89DFE374F93A9688376D60920" unitRef="usd">3254903</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2013Q2YTD" decimals="0" id="Fact-717EF32CCBE9B62CC769688376DB0745" unitRef="usd">69119</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q2YTD" decimals="0" id="Fact-DEA629392D170435B33B688376D67ED3" unitRef="usd">48239</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="FD2014Q2YTD" decimals="0" id="Fact-D8C1F18B42DBBCCF146D688376DC42E3" unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="FD2013Q2YTD" decimals="0" id="Fact-4B8431DD27CFEB039DF9688376DBA31C" unitRef="usd">1500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2014Q2YTD" decimals="0" id="Fact-608E03E3823D4CB00431688376DA9A54" unitRef="usd">2267082</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2013Q2YTD" decimals="0" id="Fact-E309619A46D2E00A0AC9688376D67D8A" unitRef="usd">1481682</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2013Q2YTD_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" decimals="-5" id="Fact-432256AC703FFDB769DFA1CA884CD224" unitRef="usd">600000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
  <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit contextRef="FD2013Q2YTD" decimals="0" id="Fact-FA4E8ABE94D2346CF33CA19DB64F4428" unitRef="usd">0</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
  <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit contextRef="FD2014Q2YTD" decimals="0" id="Fact-239EE7371C950DB161C1A19DB641229E" unitRef="usd">1000005</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q2YTD" decimals="0" id="Fact-94E6DDD3FFCE5B2DDA0E688376DB4F29" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2013Q2YTD" decimals="0" id="Fact-2170D112ECDA34E15A35688376D6CFDD" unitRef="usd">-41292</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProfitLoss contextRef="FD2014Q2QTD" decimals="0" id="Fact-0A0582B31CCBC26F1194688376CA53DC" unitRef="usd">709536</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="FD2014Q2YTD" decimals="0" id="Fact-3A2DBC39C49E88C2BC37688376CF409D" unitRef="usd">984718</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="FD2013Q2QTD" decimals="0" id="Fact-15CA850D765A17728C89688376CB3F4A" unitRef="usd">-648854</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="FD2013Q2YTD" decimals="0" id="Fact-8B86F318B68FBBF5EFDC688376CDAD65" unitRef="usd">192472</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-041DF5BE8F9612198AD3688376E241B5" unitRef="usd">-24172</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-0E6A722A1BD8015438BB688376E09B52" unitRef="usd">1008890</us-gaap:ProfitLoss>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2013Q4" decimals="0" id="Fact-27B1DAE2B1105E38D086688376BDC6F1" unitRef="usd">880647</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q2" decimals="0" id="Fact-1FCCB6F1293A9504E5FC688376BE6F74" unitRef="usd">726868</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q2QTD" decimals="0" id="Fact-B7BCA8E80CF6B5415023688376C8F930" unitRef="usd">861154</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q2QTD" decimals="0" id="Fact-AA0D4EC060D877D420B6688376CB889E" unitRef="usd">1386904</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q2YTD" decimals="0" id="Fact-26767880BDBA452889FB688376CD52A5" unitRef="usd">2835622</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q2YTD" decimals="0" id="Fact-F96AE4C4738E5AA4E330688376CC9BED" unitRef="usd">1687527</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q2" decimals="0" id="Fact-2A1BF7F8BAAF1D6C4FB9688376BF4371" unitRef="usd">17403430</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2013Q4" decimals="0" id="Fact-84408143AD087B89545A688376C0EF58" unitRef="usd">16394540</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember" decimals="-5" id="Fact-3E9214A45B2406F0CDE8A17A75A8ADAF" unitRef="usd">3200000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember" decimals="-5" id="Fact-5113656E75CDD7EDC4EFA17A86BBCB3B" unitRef="usd">5000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember" decimals="-5" id="Fact-D1B96C9CCB268B708A32A17A14DA37DC" unitRef="usd">1800000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_ProductAcetadoteGenericMember" decimals="-5" id="Fact-C01016C29C65E47D5AB2A179EF004D19" unitRef="usd">2100000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD" decimals="0" id="Fact-9E34EA7775FF8C920C61688376C8A64B" unitRef="usd">9750168</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2QTD" decimals="0" id="Fact-E2EA21A09FC4AD54530A688376CBCBD1" unitRef="usd">7081088</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2YTD" decimals="0" id="Fact-CAD4DF12DFEE11C93ADA688376CF6A1E" unitRef="usd">17339220</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD" decimals="0" id="Fact-4AAFB865F0DD0AC00BB9688376D05B24" unitRef="usd">17843412</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember" decimals="0" id="Fact-015167C0B8A7508583796883772C2978" unitRef="usd">6935370</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember" decimals="0" id="Fact-5FDB48E814636B61E52B6883772B9A50" unitRef="usd">4146974</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember" decimals="0" id="Fact-070F8C251506F6DD41876883772A178D" unitRef="usd">2041043</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-62CEC0BB1FBA78301F71A176E82E9939" unitRef="usd">1369765</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember" decimals="0" id="Fact-5068772BFC434EEC71166883772B791E" unitRef="usd">277524</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember" decimals="0" id="Fact-73C3C3AD4DA1538705C26883772C13C3" unitRef="usd">755988</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-1135970E6A85A32F4A366883772950A7" unitRef="usd">1071433</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember" decimals="0" id="Fact-D1C35FB90F890A2D05D16883772B01DE" unitRef="usd">4158293</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember" decimals="0" id="Fact-2844C36B580F567E678E6883772BD593" unitRef="usd">1025971</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember" decimals="0" id="Fact-FA544F5EFB1502C4E5A26883772B0872" unitRef="usd">1344869</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember" decimals="0" id="Fact-377FA3AC6A4C38661DCB6883772BA095" unitRef="usd">1129082</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_KristaloseMember" decimals="0" id="Fact-F3AE03BF4F377C997E386883772AEB9D" unitRef="usd">3559313</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2QTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember" decimals="0" id="Fact-F55704C5257F0705EC406883772A4FE9" unitRef="usd">615547</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember" decimals="0" id="Fact-3E68D41A58AF4EF17A7FA176C9F3856E" unitRef="usd">2484290</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember" decimals="0" id="Fact-0012ED9BD47AC02A74D56883772CCBFC" unitRef="usd">5784905</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember" decimals="0" id="Fact-BACE2C4556465D7BEE086883772AE4DA" unitRef="usd">3063819</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember" decimals="0" id="Fact-313AE2F656D5589B16E76883772A2833" unitRef="usd">84050</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD_us-gaap_ProductOrServiceAxis_cpix_CaldolorMember" decimals="0" id="Fact-FDB4A77C060C5D21CC346883772A6852" unitRef="usd">626684</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2013Q2YTD_us-gaap_ProductOrServiceAxis_cpix_AcetadoteMember" decimals="0" id="Fact-4A75E3EEC2EE1B55AE626883772CA4F6" unitRef="usd">11398968</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD_us-gaap_ProductOrServiceAxis_cpix_OtherProductsMember" decimals="0" id="Fact-C5FF9870ABA9860626036883772B6CD5" unitRef="usd">140000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2014Q2YTD" id="Fact-8AD2110A95FDA778272468837745BEF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the preliminary allocation of the fair values of the assets acquired and liabilities assumed as of the acquisition date for Vaprisol:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="569px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="95px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intellectual property intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,990,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,410,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired contingent liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(400,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2014Q2YTD" id="Fact-5F1F5125AC4AA531CEF1688376FD3593">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings per share for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) attributable to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;722,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(639,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,743,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,405,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of other securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;282,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,025,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,405,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="441px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="102px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="103px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) attributable to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,008,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;215,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,825,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,580,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive effect of other securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;268,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares outstanding &amp;#8211; diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,093,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,756,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="FD2014Q2YTD" id="Fact-413CC4D52FC88504D4396883770275C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s net revenues consisted of the following for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="39%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Products:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acetadote&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,063,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,784,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,398,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Omeclamox-Pak&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,344,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,484,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Kristalose&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,559,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,041,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,935,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,158,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vaprisol&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,071,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,369,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Caldolor&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;626,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,129,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,025,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277,524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;755,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total net revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,750,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,081,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,843,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,339,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2014Q2YTD" id="Fact-1A748EB5A50A83000D086883772FAB3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inventory was comprised of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,768,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,228,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,697,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,996,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,722,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-22C90668249BD5CE5684688377025372">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;REVENUES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s net revenues consisted of the following for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="39%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Products:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acetadote&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,063,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,784,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,398,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Omeclamox-Pak&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,344,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,484,290&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Kristalose&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,559,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,041,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,935,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,158,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vaprisol&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,071,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,369,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Caldolor&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;626,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,129,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,025,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277,524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;755,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total net revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,750,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,081,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,843,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,339,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As discussed in Note 10, the Company acquired rights to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new products and both Omeclamox-Pak and Vaprisol contributed to Cumberland's net revenue during 2014. On October 28, 2013, Cumberland entered into an agreement with Pernix Therapeutics ("Pernix") to distribute and promote Omeclamox-Pak. Under the terms of the agreement, effective October 1, 2013, the Company began to record the revenue of this product and effective January 2014 Cumberland began distributing Omeclamox-Pak and promoting it to gastroenterologists across the United States.  On February 28, 2014, Cumberland entered into an agreement with Astellas Pharma US, Inc. ("Astellas") to acquire certain product rights, intellectual property and related assets of Vaprisol. The Company began selling Vaprisol in March 2014 and launched promotional efforts for the brand in May 2014.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2012, the Company entered into a settlement agreement with Paddock Laboratories, LLC ("Paddock") and Perrigo Company ("Perrigo") involving an Acetadote patent.  As part of the agreement, Cumberland supplies Perrigo with an Authorized Generic version of the Company's Acetadote product.  The Company's revenue generated by sales of it's Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;second quarter of 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;second quarter of 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; agreements for the registration and commercialization of Caldolor outside the United States and amended its agreement with Harbin Gloria Pharmaceuticals Co., Ltd ("Gloria") to extend Gloria's territory.  Earlier in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; agreements with international partners for commercialization of certain of its products into additional international territories. As a result of these agreements, Cumberland recognized approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of non-refundable up-front payments as other revenue in the consolidated statement of operations during the first half of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the full year of 2013, the Company entered into a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new agreements and amended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; agreement with international partners.  The agreements entered into during 2013 provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, will handle ongoing distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulation.  Under the licensing agreements, Cumberland is entitled to receive additional milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company will recognize revenue for these substantive milestones using the milestone method. The 2013 agreements provide for up to  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in milestone payments related to regulatory approvals and up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in milestone payments related to total and annual product sales. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Cumberland has not recognized any revenues related to milestones associated with the new agreements.  The Company is also entitled to receive royalties on future sales of the products under the agreements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2014Q2YTD" id="Fact-3753F9A2B6B99B90B300688376E4E4F3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Operating Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in one segment, specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold.  Substantially all of the Company&amp;#8217;s assets are located in the United States, and total revenues are primarily attributable to U.S.&amp;#160;customers.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:SellingAndMarketingExpense contextRef="FD2013Q2QTD" decimals="0" id="Fact-9354976F64D673325094688376C97825" unitRef="usd">3542049</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense contextRef="FD2014Q2YTD" decimals="0" id="Fact-1BA2E32BD02395C7E72A688376CDB287" unitRef="usd">7544013</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense contextRef="FD2014Q2QTD" decimals="0" id="Fact-582FD920D3978ACB4D6A688376CA62E3" unitRef="usd">3930082</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense contextRef="FD2013Q2YTD" decimals="0" id="Fact-B83111AF342146C5B4F2688376CE3628" unitRef="usd">7215988</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="FD2014Q2YTD" decimals="0" id="Fact-BDB5F7461101EAC586C2688376D9398D" unitRef="usd">325344</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="FD2013Q2YTD" decimals="0" id="Fact-D17430AFA4BC96E28526688376D82696" unitRef="usd">305199</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" id="Fact-15604B92F9751B7D7C0D68837739EB17">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_TitleOfIndividualAxis_cpix_EmployeeMember" id="Fact-6852D935194899974EDC6883773CE81B">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="0" id="Fact-4F063F7BFC9BFC0CE5F968837739A151" unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DD998C042662A0D68E90688376E2E06A" unitRef="shares">15300</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q2YTD" decimals="0" id="Fact-5D225AD7FFCF45D27B0C688376E140AE" unitRef="usd">324576</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-DFDBB02B34F6B32C50DD688376E2FC47" unitRef="usd">324576</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q2YTD" decimals="0" id="Fact-6137A0E3336FFE15DA56688376E02346" unitRef="usd">711347</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-6A41874C4CC2AD66B3A5688376E1DB7F" unitRef="usd">711347</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount contextRef="D2013Q1Jan" decimals="INF" id="Fact-844607C8BBEAC0AD8A1368837739A957" unitRef="usd">10000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount contextRef="D2010Q2May13" decimals="INF" id="Fact-E23B1E3AAF289C22EA9B6883773977DF" unitRef="usd">10000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount contextRef="D2012Q2April" decimals="INF" id="Fact-DF0AA3195306E55F6CA06883773C70AF" unitRef="usd">10000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount contextRef="D2011Q1Jan" decimals="INF" id="Fact-C84E016A8A6245E35ADA6883773CE5B5" unitRef="usd">10000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C672E9C1D58201261BAA688376E1AE18" unitRef="shares">340436</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="FD2013Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-491C012E7F311C4F6AD568837738F17F" unitRef="shares">676551</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="FD2014Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-09203F8410D70144FE07688376E09D10" unitRef="usd">1580225</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="FD2014Q2YTD" decimals="0" id="Fact-EBD263AD4277A6F9BF0B688376E098D2" unitRef="usd">1580225</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="FD2013Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-52B8BC4D1275C75FB5FD6883773907AB" unitRef="usd">3200000</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockholdersEquity contextRef="FI2014Q2" decimals="0" id="Fact-AE757B52036F618A66A9688376BC571A" unitRef="usd">80933074</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="0" id="Fact-9494ACB952573FA6C306688376BFE812" unitRef="usd">79468481</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q2" decimals="0" id="Fact-6D3ECB9C98255BDB3D3C688376BCB314" unitRef="usd">80732264</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4" decimals="0" id="Fact-730642B70C797520737C688376BE5EE1" unitRef="usd">79291843</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-860C784D67FDEE678144688376E25707" unitRef="usd">17403430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-0E2690B2282D70F6547A688376E15E58" unitRef="usd">16394540</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-D02936CE9474C60330C2688376E110FE" unitRef="usd">-200810</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-4C4F295E75B3E6527903688376E17B4B" unitRef="usd">63073941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-888575343110851643E4688376E0FF03" unitRef="usd">-176638</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-86869B78D87CB3F08ADB688376E0B617" unitRef="usd">63529644</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2014Q2YTD" id="Fact-44855A5734313C44DF13688377391AA3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SHAREHOLDERS&amp;#8217; EQUITY AND DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May&amp;#160;13, 2010, the Company announced a share repurchase program to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2011, April 2012 and January 2013, the Company's Board of Directors replaced the prior authorizations with new &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; authorizations for repurchases of the Company's outstanding common stock.  During the first six months of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company repurchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;340,436&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;676,551&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Share Grants &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the first half of 2014, the Company issued approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;175,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cumberland Emerging Technologies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Company received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Gloria for its participation in Cumberland Emerging Technologies ("CET"). As a result, Gloria received shares in CET and will have the first right to negotiate a license to CET developed products for the Chinese market. Prior to April 2014, Cumberland owned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of CET, with the balance of the enterprise being owned by Vanderbilt University and the Tennessee Technology Development Corporation.  In connection with Gloria&amp;#8217;s investment in CET, the Company also provided an additional investment in CET.  Cumberland contributed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and provided &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in loan foregiveness to CET in exchange for newly issued shares.   Upon completion of the additional investment by Gloria and Cumberland in April 2014, the Company&amp;#8217;s ownership in CET is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;New Debt Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 26, 2014, Cumberland entered into a Revolving Credit Loan Agreement (&amp;#8220;Loan Agreement&amp;#8221;) with SunTrust Bank. The new agreement replaced the August 2011 Fifth Amended and Restated Loan Agreement (the "Agreement") with its previous primary lender which was to expire on December 31, 2014.   There are no borrowings under the Loan Agreement at June 30, 2014 and it has a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year term expiring on June 26, 2017.  The Loan Agreement provides for an aggregate principal amount up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The initial revolving line of credit is up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an increase from the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the previous Agreement.  Similar to the previous Agreement, Cumberland has the ability to increase the borrowing amount up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, upon the satisfaction of certain conditions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The interest rate on the Loan Agreement is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  In addition, a fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of the Company&amp;#8217;s assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Loan Agreement, Cumberland is subject to certain financial covenants, including, but not limited to, maintaining an EBIT to Interest Expense Ratio and a Funded Debt Ratio, as such terms are defined in the Loan Agreement and that are determined on a quarterly basis.  The Company is in compliance with all covenants at June 30, 2014. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company incurred no early termination penalties upon termination of the previous Agreement and incurred less than $0.1 million in deferred financing costs related to the new Loan Agreement, which will be amortized to interest expense using the effective interest method over the term of the Loan Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Previous Debt Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The August 2011 Fifth Amended and Restated Loan Agreement carried an interest rate of the LIBOR Daily Floating Rate plus an applicable margin, as defined by the agreement (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.17%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at December&amp;#160;31, 2013). Interest and an unused line of credit fee (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per annum) were payable quarterly. There were no borrowings outstanding on the credit facility at December 31, 2013 or at any time during 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the previous Agreement, the Company was subject to certain financial covenants including, but not limited to, maintaining a leverage ratio and interest coverage ratio, as defined in the Agreement.  In March&amp;#160;2014 and May 2014, the previous Agreement was amended for certain provisions related to the aggregate ownership of the Company's common stock over 30% and certain other financial covenants.  As of March&amp;#160;31, 2014 and December 31, 2013, the Company was in compliance with all covenants.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-0D94F08AB10AB76CAEDC688376F56C9E" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-A30B8672049691978CEE688376F5D153" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-AE817BF1E77692D24241688376F6673E" unitRef="usd">1857533</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2" decimals="0" id="Fact-E781FD9AAAFADED0B898688376F68E14" unitRef="usd">14825632</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-C20DB315D84E93CD5B96688376F6BDEF" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-E32DBB3B65697B2F2007688376F61DBB" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4" decimals="0" id="Fact-081D22721F5B7D490259688376F66CC4" unitRef="usd">14019761</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-61412BBB35F4EF384397688376F67F4E" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-FB7AD7445808F7AD3C1B688376F6BD61" unitRef="usd">3896871</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member" decimals="0" id="Fact-81FD601E2A93B50C5E94688376F622E0" unitRef="usd">6692533</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-242CE004F7F67B27727D688376F64899" unitRef="usd">4835000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member" decimals="0" id="Fact-C2B4202BC03ACA80F947688376F63520" unitRef="usd">6294952</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-A2CF791FD86A30F56D80688376F65A44" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-AD8FD6627A861D6264B8688376F77293" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-A9412D13937C78E21761688376F74014" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-2E38015825AAB034873F688376F7F01F" unitRef="usd">3049754</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-CC3F05B981244A510C0B688376F75A26" unitRef="usd">2747151</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-8016AC02EC9F71C2BCDC688376F7E0BD" unitRef="usd">1489077</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-56731977F99CE22A879F688376F7E50F" unitRef="usd">1489077</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-2F120265C8F425D6CA11688376F76BC0" unitRef="usd">1748498</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member" decimals="0" id="Fact-F137F6352978B284F5B9688376F7199F" unitRef="usd">7724809</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-3CE0EF899C52281937EA688376F7F637" unitRef="usd">1496700</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-2D3DD34E168123B5F85F688376F80FD9" unitRef="usd">2829809</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-FFE4ABB89A4BC1B70623688376F842BA" unitRef="usd">3049754</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-D7E18FD9F2AFBA346E24688376F837EB" unitRef="usd">1857533</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-77ED24F30FA09BC2C206688376F8D831" unitRef="usd">1748498</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-403D42BD4CD7E3FCBA15688376F83394" unitRef="usd">4835000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-D40C370E9C3DAC91E846688376F821D6" unitRef="usd">4895000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_LoanPoolsMember" decimals="0" id="Fact-022A5EF800A4DF5024D5688376F8CE3C" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-02068386DC00CB3F0DB1688376F8193F" unitRef="usd">3896871</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" decimals="0" id="Fact-BEEA23020C2D5047B6B3688376F88272" unitRef="usd">0</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member" decimals="0" id="Fact-3009BA6C81408AF8DF56688376F9889A" unitRef="usd">8133099</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-133DAAF3ABE6E93D3A46688376F941E0" unitRef="usd">1496700</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cpix_UsTreasuryNotesAndBondsSecuritiesMember" decimals="0" id="Fact-0C33FA45713D9F3181D2688376F9E227" unitRef="usd">2829809</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MunicipalBondsMember" decimals="0" id="Fact-33F3F7B32E7198F58D04688376F92CFE" unitRef="usd">4895000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="FI2014Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AgencySecuritiesMember" decimals="0" id="Fact-8CE36A7E75A7A8A6C608688376F9A3D5" unitRef="usd">2747151</us-gaap:TradingSecurities>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2013Q2YTD" decimals="0" id="Fact-BBE265DB56A2126B4CD9688376DA15CF" unitRef="usd">-62323</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2014Q2YTD" decimals="0" id="Fact-392AF2F1B7BA59DDE8BF688376DB0251" unitRef="usd">-181950</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UseOfEstimates contextRef="FD2014Q2YTD" id="Fact-541F5E2AB480FECEE2B9688376E4DF7A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In preparing the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual amounts could differ from those estimated at the time the condensed consolidated financial statements are prepared.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the  allowances for obsolescent or unmarketable inventory.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2013Q2YTD" decimals="0" id="Fact-6502125E4134824598FCA17549304B83" unitRef="shares">175800</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q2YTD" decimals="0" id="Fact-9220FD50B44EC6936257A1754818641A" unitRef="shares">268217</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q2QTD" decimals="0" id="Fact-021F99852FEE37399419688376FB11CA" unitRef="shares">282518</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2013Q2QTD" decimals="0" id="Fact-220D91496843C9CF1491688376FB7B19" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q2YTD" decimals="0" id="Fact-30EA1C653406A11FC212688376CE3464" unitRef="shares">18093391</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2013Q2YTD" decimals="0" id="Fact-F95B3CDF1D41476DB079688376CF2A8D" unitRef="shares">18756691</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q2QTD" decimals="0" id="Fact-AC3E3F00107FDA91F65D688376C990C5" unitRef="shares">18025913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2013Q2QTD" decimals="0" id="Fact-050074C5A706254ADEFE688376C82FAF" unitRef="shares">18405522</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q2YTD" decimals="0" id="Fact-491AE821A8F2CADB9687688376CF17AE" unitRef="shares">17825174</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q2QTD" decimals="0" id="Fact-D10953F1FED348EC812B688376C884EA" unitRef="shares">17743395</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2013Q2YTD" decimals="0" id="Fact-39EA829E2EA2EE5FA0FB688376CD31B3" unitRef="shares">18580891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2013Q2QTD" decimals="0" id="Fact-4A0F8EBE662BD2B4DA4A688376CC3672" unitRef="shares">18405522</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <cpix:BusinessCombinationAggregateUpfrontPayments contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="-5" id="Fact-F25D93FAEDB813CDB460688377462CAC" unitRef="usd">2000000</cpix:BusinessCombinationAggregateUpfrontPayments>
  <cpix:BusinessCombinationAggregateUpfrontPayments contextRef="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember" decimals="-5" id="Fact-99CA09A4CF15C08F8070688377455352" unitRef="usd">4000000</cpix:BusinessCombinationAggregateUpfrontPayments>
  <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="0" id="Fact-D777841A82928DFD63E468837748649F" unitRef="usd">2000000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations>
  <cpix:BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage contextRef="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-429FC76AB23B78778FC768837746C0FB" unitRef="number">0.2</cpix:BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage>
  <cpix:BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage contextRef="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-BC99E26A46809E1A490668837746C065" unitRef="number">0.15</cpix:BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage>
  <cpix:BusinessCombinationUpfrontPayment contextRef="I2013Q3SharesOutstanding_us-gaap_BusinessAcquisitionAxis_cpix_OmeclamoxPakMember" decimals="-5" id="Fact-AC40D4EE1C15ED4DD36D688377455424" unitRef="usd">4000000</cpix:BusinessCombinationUpfrontPayment>
  <cpix:BusinessCombinationUpfrontPayment contextRef="I2014Q1Feb28_us-gaap_BusinessAcquisitionAxis_cpix_VaprisolMember" decimals="-5" id="Fact-F607170975029264CDAC6883774616DE" unitRef="usd">2000000</cpix:BusinessCombinationUpfrontPayment>
  <cpix:IncreaseDecreaseInCurrentOperatingLiabilities contextRef="FD2013Q2YTD" decimals="0" id="Fact-364F4B1411EB709AC790688376D724ED" unitRef="usd">-1707560</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
  <cpix:IncreaseDecreaseInCurrentOperatingLiabilities contextRef="FD2014Q2YTD" decimals="0" id="Fact-27D0386ABC2F3E6EC9D9688376D6ACF3" unitRef="usd">2165828</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
  <cpix:InventoryExtendedShelfLife contextRef="D2014Q1Jan" id="Fact-7A98C189B5634D3A88316883772EA367">P6Y</cpix:InventoryExtendedShelfLife>
  <cpix:InventoryShelfLife contextRef="D2014Q1Jan" id="Fact-CADC05AE040D123798196883772FED39">P5Y</cpix:InventoryShelfLife>
  <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions contextRef="I2014Q2June26_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember_us-gaap_LineOfCreditFacilityAxis_cpix_SunTrustBankMember" decimals="INF" id="Fact-BA04A46CD7109F1A8979A1F0625586B6" unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
  <cpix:LoansForgiveninExchangeForShareIssuedAmount contextRef="D2014Q2April" decimals="-5" id="Fact-281B5B72D5D11D5E06BBA1EB14FC9BF4" unitRef="usd">2400000</cpix:LoansForgiveninExchangeForShareIssuedAmount>
  <cpix:NumberofProductLinesAcquired contextRef="FD2014Q2YTD" decimals="INF" id="Fact-5947A27B7ACF8BF0FADAA1C7C1D4D097" unitRef="product_line">2</cpix:NumberofProductLinesAcquired>
  <cpix:OtherLongTermObligationsExcludingCurrentPortion contextRef="FI2014Q2" decimals="0" id="Fact-6959DB2F0FEFB2FD92BC688376BD3B34" unitRef="usd">873246</cpix:OtherLongTermObligationsExcludingCurrentPortion>
  <cpix:OtherLongTermObligationsExcludingCurrentPortion contextRef="FI2013Q4" decimals="0" id="Fact-41A157077692858BD0DB688376BF65F6" unitRef="usd">776125</cpix:OtherLongTermObligationsExcludingCurrentPortion>
  <cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets contextRef="FI2013Q2" decimals="INF" id="Fact-71419F213E9693C1B5B6A1C9CAFB7C36" unitRef="agreement">2</cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets>
  <cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets contextRef="FI2013Q2_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" decimals="INF" id="Fact-91F8C47BF1E11B9B0F4068837702504D" unitRef="agreement">3</cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets>
  <cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets contextRef="FI2013Q4_us-gaap_TypeOfArrangementAxis_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" decimals="INF" id="Fact-7559236B8A33B641D97968837702D00A" unitRef="agreement">6</cpix:RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets>
  <cpix:RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone contextRef="FI2013Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" decimals="-5" id="Fact-420ED47E8C23183B27CA6883770286B0" unitRef="usd">600000</cpix:RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone>
  <cpix:RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone contextRef="FI2013Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" decimals="-5" id="Fact-944ABB126F9D6FAFFA6F68837702EDC9" unitRef="usd">4000000</cpix:RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone>
  <dei:AmendmentFlag contextRef="FD2014Q2YTD" id="Fact-C14E3E96B08CD4130DF9688376B65A0A">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="FD2014Q2YTD" id="Fact-032F524422273D5B91CE688376B548BC">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="FD2014Q2YTD" id="Fact-8AD706CFF17025C039DA688376B6CE8A">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="FD2014Q2YTD" id="Fact-2A8E4FE91DC7B414937B688376B63E56">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="FD2014Q2YTD" id="Fact-109F28C667FC3D5F4A38688376B67CAD">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="FD2014Q2YTD" id="Fact-3F451CCA80AAEA15C53F688376B651C4">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="FD2014Q2YTD" id="Fact-597142740FE47E28C018688376B6F3AC">0001087294</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="I2014Q3SharesOutstanding" decimals="INF" id="Fact-B628AC73D073AA2BB415688376B6835D" unitRef="shares">17577699</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="FD2014Q2YTD" id="Fact-5DBC77D6B51D9E197BBF688376B5D0C9">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="FD2014Q2YTD" id="Fact-441D1DBB2D4BD2841098688376B61864">CUMBERLAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cpix-20140630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20140630" xmlns:cpix="http://www.cumberlandpharma.com/20140630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20140630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20140630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20140630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20140630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2108100 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityUnaudited" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2103100 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2403402 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2403403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2303301 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2107100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2407401 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2105100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesDetails">
        <link:definition>2405402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual">
        <link:definition>2405403 - Disclosure - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2305301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities">
        <link:definition>2102100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails">
        <link:definition>2402402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables">
        <link:definition>2302301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewProducts" roleURI="http://www.cumberlandpharma.com/role/NewProducts">
        <link:definition>2111100 - Disclosure - New Products</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewProductsAssetsAndLiabilitiesAssumedDetails" roleURI="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails">
        <link:definition>2411402 - Disclosure - New Products Assets and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewProductsNewProductsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails">
        <link:definition>2411403 - Disclosure - New Products New Products - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewProductsTables" roleURI="http://www.cumberlandpharma.com/role/NewProductsTables">
        <link:definition>2311301 - Disclosure - New Products (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBasisOfPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBasisOfPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2104100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2404402 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual">
        <link:definition>2404403 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2304301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityAndDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt">
        <link:definition>2106100 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityAndDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails">
        <link:definition>2406402 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityAndDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails">
        <link:definition>2406401 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="cpix_AcetadoteMember" name="AcetadoteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_BusinessCombinationAggregateUpfrontPayments" name="BusinessCombinationAggregateUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage" name="BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="cpix_BusinessCombinationUpfrontPayment" name="BusinessCombinationUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cpix_CaldolorMember" name="CaldolorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" name="CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_EmployeeMember" name="EmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_EquityAndDebtAbstract" name="EquityAndDebtAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_InventoriesTextualAbstract" name="InventoriesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_InventoryExtendedShelfLife" name="InventoryExtendedShelfLife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_InventoryShelfLife" name="InventoryShelfLife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_KristaloseMember" name="KristaloseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cpix_LoanPoolsMember" name="LoanPoolsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_LoansForgiveninExchangeForShareIssuedAmount" name="LoansForgiveninExchangeForShareIssuedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" name="MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" name="MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" name="NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_NumberofProductLinesAcquired" name="NumberofProductLinesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_OmeclamoxPakMember" name="OmeclamoxPakMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cpix_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_ProductAcetadoteGenericMember" name="ProductAcetadoteGenericMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_ProductsAbstract" name="ProductsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_ReconciliationOfNumeratorAndDenominatorAbstract" name="ReconciliationOfNumeratorAndDenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets" name="RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone" name="RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cpix_RevenuesTextualAbstract" name="RevenuesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_ShareholdersEquityTextualAbstract" name="ShareholdersEquityTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_SunTrustBankMember" name="SunTrustBankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_UsTreasuryNotesAndBondsSecuritiesMember" name="UsTreasuryNotesAndBondsSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cpix_VaprisolMember" name="VaprisolMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cpix-20140630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:href="cpix-20140630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:href="cpix-20140630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:href="cpix-20140630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:href="cpix-20140630.xsd#EarningsLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:href="cpix-20140630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:href="cpix-20140630.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:href="cpix-20140630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:href="cpix-20140630.xsd#Inventories" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:href="cpix-20140630.xsd#InventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:href="cpix-20140630.xsd#InventoriesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:href="cpix-20140630.xsd#InventoriesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:href="cpix-20140630.xsd#MarketableSecurities" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:href="cpix-20140630.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:href="cpix-20140630.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProducts" xlink:href="cpix-20140630.xsd#NewProducts" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:href="cpix-20140630.xsd#NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:href="cpix-20140630.xsd#NewProductsNewProductsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:href="cpix-20140630.xsd#NewProductsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:href="cpix-20140630.xsd#Revenues" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:href="cpix-20140630.xsd#RevenuesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:href="cpix-20140630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:href="cpix-20140630.xsd#RevenuesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="simple" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0ce13e30-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ce13e30-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18320242-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18320242-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_78bdb110-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_MarketableSecurities_78bdb110-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_05404162-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_05404162-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6952f2e4-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_InventoryNet_6952f2e4-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_83b7103e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d216a96-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_OtherAssetsCurrent_83b7103e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_940b342e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ce13e30-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_940b342e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_54e9c33c-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ce13e30-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_54e9c33c-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_837d6190-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ce13e30-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_837d6190-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1ed1d0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6e59ec02-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1ed1d0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_Liabilities_6e59ec02-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6e17fb62-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e59ec02-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_LiabilitiesCurrent_6e17fb62-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_05630b34-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e17fb62-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_AccountsPayableCurrent_05630b34-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_85404948-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e17fb62-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_85404948-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit_761d7602-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e59ec02-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_LongTermLineOfCredit_761d7602-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_f48c087f-2811-56aa-4a78-22db9ddbdd45" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e59ec02-9656-11e2-88e7-12313d1a0274" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_f48c087f-2811-56aa-4a78-22db9ddbdd45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_adca42f6-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1ed1d0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_adca42f6-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_adc32df4-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_adca42f6-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_StockholdersEquity_adc32df4-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1e2a510e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_adc32df4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_CommonStockValue_1e2a510e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a33a731a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_adc32df4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a33a731a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7a4f00ec-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_adca42f6-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_MinorityInterest_7a4f00ec-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1e12e4ba-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e1ed1d0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1e12e4ba-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_181e990a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_181e990a-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_328d60be-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_328d60be-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a198e26-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2a198e26-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_ab78f61e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ShareBasedCompensation_ab78f61e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_43ed111a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_43ed111a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0c1127ae-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0c1127ae-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b2ec077e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b2ec077e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_62c142a0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_62c142a0-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_63654850-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_63654850-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_63a56200-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_63a56200-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_761f989b-5331-c55d-055b-22dba313e3b9" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_761f989b-5331-c55d-055b-22dba313e3b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6310926a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb5e5da-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6310926a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_181e990a-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8b21b464-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8b21b464-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8ac0ed78-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8ac0ed78-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_931f38d0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_931f38d0-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_8b982568-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_8b982568-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8b6ec042-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8e1730-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8b6ec042-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_181e990a-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_92a8373a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_92a8373a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9308e58a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9308e58a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_43eda0b2-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_43eda0b2-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_93194042-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_93194042-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8932a1c2-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ca2b500-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8932a1c2-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7cc2c354-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cc2c354-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6058d0a0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6058d0a0-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8028df7e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6058d0a0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_OperatingIncomeLoss_8028df7e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_a7332b38-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8028df7e-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_SalesRevenueNet_a7332b38-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8028df7e-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_22d5e98e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_CostOfGoodsSold_22d5e98e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_aacb810a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_SellingAndMarketingExpense_aacb810a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a17a5cf2-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a17a5cf2-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5b9b5a38-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5b9b5a38-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0c1661b0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_23967884-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0c1661b0-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6a12f3d2-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6058d0a0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6a12f3d2-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_678fa826-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6058d0a0-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_InterestExpense_678fa826-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_610ca94a-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_93e5ee3a-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_610ca94a-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ccc070c-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7cc2c354-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ccc070c-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b93d27d4-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b91dcd62-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b93d27d4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b91dcd62-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b8c2d1f0-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b93d27d4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b8c2d1f0-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6952f2e4-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_69867b82-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6952f2e4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_69867b82-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_698b130e-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6952f2e4-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_698b130e-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/NewProducts" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13b6e3b8-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1088a3e8-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13b6e3b8-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1088a3e8-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_11427534-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13b6e3b8-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_11427534-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_11b78bc6-9656-11e2-88e7-12313d1a0274" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13b6e3b8-9656-11e2-88e7-12313d1a0274" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_11b78bc6-9656-11e2-88e7-12313d1a0274" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_469b8396-d78d-11e3-b035-22000a1e8102" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_13b6e3b8-9656-11e2-88e7-12313d1a0274" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_469b8396-d78d-11e3-b035-22000a1e8102" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cpix-20140630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:href="cpix-20140630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:href="cpix-20140630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:href="cpix-20140630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:href="cpix-20140630.xsd#EarningsLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:href="cpix-20140630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:href="cpix-20140630.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:href="cpix-20140630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:href="cpix-20140630.xsd#Inventories" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:href="cpix-20140630.xsd#InventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:href="cpix-20140630.xsd#InventoriesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:href="cpix-20140630.xsd#InventoriesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:href="cpix-20140630.xsd#MarketableSecurities" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:href="cpix-20140630.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:href="cpix-20140630.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProducts" xlink:href="cpix-20140630.xsd#NewProducts" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:href="cpix-20140630.xsd#NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:href="cpix-20140630.xsd#NewProductsNewProductsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:href="cpix-20140630.xsd#NewProductsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:href="cpix-20140630.xsd#Revenues" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:href="cpix-20140630.xsd#RevenuesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:href="cpix-20140630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:href="cpix-20140630.xsd#RevenuesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:to="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:to="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:to="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:to="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E84A69EFD175C225DEE2A17EB60EC561" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_CommonStockMember_E84A69EFD175C225DEE2A17EB60EC561" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_F6EDE716FEA15F8004B3A1AF1B69D703" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_F6EDE716FEA15F8004B3A1AF1B69D703" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMember" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:label="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LoanPoolsMember" xlink:label="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:to="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/NewProducts" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_97BEED678BEA522E189D6883766B750E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:to="loc_cpix_VaprisolMember_97BEED678BEA522E189D6883766B750E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:to="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:to="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:to="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D736F770BF506D6F4B1BA24207BF13D6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:to="loc_us-gaap_MaximumMember_D736F770BF506D6F4B1BA24207BF13D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OmeclamoxPakMember" xlink:label="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:to="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:to="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationUpfrontPayment" xlink:label="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationAggregateUpfrontPayments" xlink:label="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage" xlink:label="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_29F6AA7A999E4B56CCF8A24207C07A19" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_us-gaap_SalesRevenueNet_29F6AA7A999E4B56CCF8A24207C07A19" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:to="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_AcetadoteMember" xlink:label="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OmeclamoxPakMember" xlink:label="loc_cpix_OmeclamoxPakMember_965D3A3C4F83F9E43298A176D095F29E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_OmeclamoxPakMember_965D3A3C4F83F9E43298A176D095F29E" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_KristaloseMember" xlink:label="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_B05E5CE24842B629A936A176D0954636" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_VaprisolMember_B05E5CE24842B629A936A176D0954636" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_CaldolorMember" xlink:label="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OtherProductsMember" xlink:label="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:to="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ProductsAbstract" xlink:label="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:to="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_44BE227E660D193437BCA176D097FEF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:to="loc_us-gaap_SalesRevenueNet_44BE227E660D193437BCA176D097FEF1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:to="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:to="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:to="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" xlink:label="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ProductAcetadoteGenericMember" xlink:label="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:to="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenuesTextualAbstract" xlink:label="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:to="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_NumberofProductLinesAcquired" xlink:label="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets" xlink:label="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone" xlink:label="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:type="extended" />
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" xlink:label="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:to="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_SunTrustBankMember" xlink:label="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:to="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:to="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:to="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:to="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:to="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:to="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:to="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_EmployeeMember" xlink:label="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:to="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:to="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:to="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ShareholdersEquityTextualAbstract" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="arc" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cpix-20140630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value assets and liabilities assumed in acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="lab_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:to="lab_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22_label_en-US" xlink:label="lab_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:to="lab_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:to="lab_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:to="lab_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92_label_en-US" xlink:label="lab_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:to="lab_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:to="lab_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:to="lab_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:to="lab_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:type="arc" />
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long Term Obligations Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other long-term obligations, excluding current portion.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE_label_en-US" xlink:label="lab_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:to="lab_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:to="lab_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:to="lab_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 17,660,367 and 17,985,503 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:to="lab_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:to="lab_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:to="lab_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:to="lab_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="lab_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:to="lab_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:to="lab_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:to="lab_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:to="lab_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:to="lab_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:to="lab_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E_label_en-US" xlink:label="lab_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:to="lab_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:to="lab_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:to="lab_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:to="lab_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">- basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:to="lab_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">- diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:to="lab_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:type="arc" />
    <link:label id="lab_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_EquityAndDebtAbstract" xlink:label="loc_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:to="lab_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7_label_en-US" xlink:label="lab_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:to="lab_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669_label_en-US" xlink:label="lab_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:to="lab_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900_label_en-US" xlink:label="lab_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:to="lab_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:to="lab_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="arc" />
    <link:label id="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383_terseLabel_en-US" xlink:label="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners</link:label>
    <link:label id="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383_label_en-US" xlink:label="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners [Member]</link:label>
    <link:label id="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383_documentation_en-US" xlink:label="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" xlink:label="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:to="lab_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="arc" />
    <link:label id="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F_terseLabel_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of regulatory notice on approval</link:label>
    <link:label id="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F_label_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval [Member]</link:label>
    <link:label id="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F_documentation_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:to="lab_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="arc" />
    <link:label id="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8_terseLabel_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments based on total and annual product sales</link:label>
    <link:label id="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8_label_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Method Future Revenue, Payments Based on Total and Annual Product Sales [Member]</link:label>
    <link:label id="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8_documentation_en-US" xlink:label="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Method Future Revenue, Payments Based on Total and Annual Product Sales [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:to="lab_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:to="lab_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:to="lab_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="arc" />
    <link:label id="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048_terseLabel_en-US" xlink:label="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acetadote, Generic</link:label>
    <link:label id="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048_label_en-US" xlink:label="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Acetadote, Generic [Member]</link:label>
    <link:label id="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048_documentation_en-US" xlink:label="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Acetadote, Generic [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_ProductAcetadoteGenericMember" xlink:label="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:to="lab_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:type="arc" />
    <link:label id="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D_verboseLabel_en-US" xlink:label="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D_label_en-US" xlink:label="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D_documentation_en-US" xlink:label="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_RevenuesTextualAbstract" xlink:label="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="lab_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="arc" />
    <link:label id="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A_terseLabel_en-US" xlink:label="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product lines acquired</link:label>
    <link:label id="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A_label_en-US" xlink:label="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Product Lines Acquired</link:label>
    <link:label id="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A_documentation_en-US" xlink:label="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Product Lines Acquired</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_NumberofProductLinesAcquired" xlink:label="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:to="lab_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of product revenue from generic sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="arc" />
    <link:label id="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590_terseLabel_en-US" xlink:label="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements with international partners for commercialization in international markets</link:label>
    <link:label id="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590_label_en-US" xlink:label="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Number of Agreements with International Partners for Commercialization in International Markets</link:label>
    <link:label id="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590_documentation_en-US" xlink:label="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Number of Agreements with International Partners for Commercialization in International Markets</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets" xlink:label="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:to="lab_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from license agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="arc" />
    <link:label id="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues, milestone method, future revenue upon achieving milestones</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB_label_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Future Revenue Earned Upon Achieving MIlestone</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Future Revenue Earned Upon Achieving MIlestone</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone" xlink:label="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:to="lab_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="arc" />
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887_verboseLabel_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury notes and bonds</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887_label_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Us Treasury Notes and Bonds Securities [Member]</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887_documentation_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Us Treasury Notes And Bonds Securities [Member].</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMember" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:to="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="arc" />
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840_verboseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Agency issued mortgage-backed securities &#8211; variable rate</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage-backed Securities, Issued by Private Enterprises [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="arc" />
    <link:label id="lab_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785_verboseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Agency notes and bonds &#8211; fixed rate</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:label="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:to="lab_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="arc" />
    <link:label id="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE_verboseLabel_en-US" xlink:label="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SBA loan pools &#8211; variable rate</link:label>
    <link:label id="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE_label_en-US" xlink:label="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Pools [Member]</link:label>
    <link:label id="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE_documentation_en-US" xlink:label="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan pools.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_LoanPoolsMember" xlink:label="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:to="lab_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds &#8211; VRDN</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:to="lab_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01_verboseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01_label_en-US" xlink:label="lab_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:to="lab_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="arc" />
    <link:label id="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172_verboseLabel_en-US" xlink:label="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172_label_en-US" xlink:label="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172_documentation_en-US" xlink:label="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_EarningsPerShareTextualAbstract" xlink:label="loc_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:to="lab_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:type="arc" />
    <link:label id="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA_verboseLabel_en-US" xlink:label="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA_label_en-US" xlink:label="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA_documentation_en-US" xlink:label="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_IncomeTaxesTextualAbstract" xlink:label="loc_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:to="lab_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss carryforwards generated from the exercise of nonqualified options</link:label>
    <link:label id="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711_label_en-US" xlink:label="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Expense from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:label="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:to="lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:to="lab_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:to="lab_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:to="lab_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="arc" />
    <link:label id="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0_terseLabel_en-US" xlink:label="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0_label_en-US" xlink:label="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0_documentation_en-US" xlink:label="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_EmployeeMember" xlink:label="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:to="lab_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF_label_en-US" xlink:label="lab_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:to="lab_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:to="lab_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:to="lab_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:type="arc" />
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_ShareholdersEquityTextualAbstract" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of subsidiary shares to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash contributed to noncontrolling interest in exchange for newly issued shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="arc" />
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9_terseLabel_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans forgiven in exchange for newly issued shares</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9_label_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9_documentation_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:to="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8_label_en-US" xlink:label="lab_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:to="lab_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:to="lab_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="lab_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:to="lab_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:to="lab_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:to="lab_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:to="lab_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, Beginning of Period, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and related tax benefit</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of shares, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:to="lab_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, End of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, End of Period, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="lab_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="arc" />
    <link:label id="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD_terseLabel_en-US" xlink:label="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011</link:label>
    <link:label id="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD_label_en-US" xlink:label="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011 [Member]</link:label>
    <link:label id="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD_documentation_en-US" xlink:label="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011 [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" xlink:label="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:to="lab_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="arc" />
    <link:label id="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20_terseLabel_en-US" xlink:label="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SunTrust Bank</link:label>
    <link:label id="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20_label_en-US" xlink:label="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SunTrust Bank [Member]</link:label>
    <link:label id="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20_documentation_en-US" xlink:label="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SunTrust Bank [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_SunTrustBankMember" xlink:label="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:to="lab_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:to="lab_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:to="lab_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:to="lab_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:to="lab_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="arc" />
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate spread, minimum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate spread, maximum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate of line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:to="lab_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F_label_en-US" xlink:label="lab_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:to="lab_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="arc" />
    <link:label id="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_OmeclamoxPakMember" xlink:label="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:to="lab_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="arc" />
    <link:label id="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31_label_en-US" xlink:label="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31_documentation_en-US" xlink:label="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:to="lab_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:type="arc" />
    <link:label id="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9_label_en-US" xlink:label="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Upfront Payment</link:label>
    <link:label id="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Upfront Payment</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationUpfrontPayment" xlink:label="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:to="lab_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="arc" />
    <link:label id="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional upfront payments</link:label>
    <link:label id="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED_label_en-US" xlink:label="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Aggregate Upfront Payments</link:label>
    <link:label id="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Aggregate Upfront Payments</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationAggregateUpfrontPayments" xlink:label="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:to="lab_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="arc" />
    <link:label id="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments based on percentage over gross profits</link:label>
    <link:label id="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722_label_en-US" xlink:label="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage</link:label>
    <link:label id="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage" xlink:label="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:to="lab_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:type="arc" />
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE_label_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE_documentation_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_DocumentAndEntityInformationAbstract" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="lab_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525_label_en-US" xlink:label="lab_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:to="lab_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:to="lab_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_5D37DE5394A4EA49759E688376742E38_terseLabel_en-US" xlink:label="lab_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_5D37DE5394A4EA49759E688376742E38_label_en-US" xlink:label="lab_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:to="lab_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:to="lab_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143_label_en-US" xlink:label="lab_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:to="lab_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:to="lab_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:to="lab_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8_label_en-US" xlink:label="lab_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:to="lab_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired contingent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="arc" />
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35_negatedTerseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligation</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Consideration Obligations</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Consideration Obligations</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:type="arc" />
    <link:label id="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1_verboseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1_label_en-US" xlink:label="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acetadote.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_AcetadoteMember" xlink:label="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:to="lab_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="arc" />
    <link:label id="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55_verboseLabel_en-US" xlink:label="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55_label_en-US" xlink:label="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55_documentation_en-US" xlink:label="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_KristaloseMember" xlink:label="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:to="lab_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="arc" />
    <link:label id="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0_verboseLabel_en-US" xlink:label="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0_label_en-US" xlink:label="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0_documentation_en-US" xlink:label="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_CaldolorMember" xlink:label="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:to="lab_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="arc" />
    <link:label id="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9_verboseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9_label_en-US" xlink:label="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_OtherProductsMember" xlink:label="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:to="lab_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:to="lab_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="arc" />
    <link:label id="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939_label_en-US" xlink:label="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_ProductsAbstract" xlink:label="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:to="lab_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:type="arc" />
    <link:label id="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9_verboseLabel_en-US" xlink:label="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9_label_en-US" xlink:label="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Numerator and Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9_documentation_en-US" xlink:label="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of numerator and denominator.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_ReconciliationOfNumeratorAndDenominatorAbstract" xlink:label="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:to="lab_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:type="arc" />
    <link:label id="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF_label_en-US" xlink:label="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_NumeratorAbstract" xlink:label="loc_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:to="lab_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:to="lab_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:type="arc" />
    <link:label id="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F_label_en-US" xlink:label="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_DenominatorAbstract" xlink:label="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:to="lab_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:to="lab_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:to="lab_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:to="lab_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit derived from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncash investment losses</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities, net of effect of business combination:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:type="arc" />
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Current Operating Liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Current Operating Liabilities</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E_label_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Previous Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:to="lab_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investment activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34_verboseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit derived from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Interest in Corporate Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in unpaid additions to intangibles, property and equipment</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:type="arc" />
    <link:label id="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE_verboseLabel_en-US" xlink:label="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE_label_en-US" xlink:label="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE_documentation_en-US" xlink:label="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventories.</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_InventoriesTextualAbstract" xlink:label="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:to="lab_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:type="arc" />
    <link:label id="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83_terseLabel_en-US" xlink:label="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf life</link:label>
    <link:label id="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83_label_en-US" xlink:label="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Shelf Life</link:label>
    <link:label id="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83_documentation_en-US" xlink:label="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Shelf Life</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_InventoryShelfLife" xlink:label="loc_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:to="lab_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:type="arc" />
    <link:label id="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A_terseLabel_en-US" xlink:label="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended shelf life</link:label>
    <link:label id="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A_label_en-US" xlink:label="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Extended Shelf Life</link:label>
    <link:label id="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A_documentation_en-US" xlink:label="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Extended Shelf Life</link:label>
    <link:loc xlink:href="cpix-20140630.xsd#cpix_InventoryExtendedShelfLife" xlink:label="loc_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:to="lab_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserve for potential obsolescence of products</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:to="lab_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NEW PRODUCTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cpix-20140630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:href="cpix-20140630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:href="cpix-20140630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cpix-20140630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cpix-20140630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:href="cpix-20140630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:href="cpix-20140630.xsd#EarningsLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:href="cpix-20140630.xsd#EarningsLossPerShareDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:href="cpix-20140630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:href="cpix-20140630.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:href="cpix-20140630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:href="cpix-20140630.xsd#Inventories" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:href="cpix-20140630.xsd#InventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:href="cpix-20140630.xsd#InventoriesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:href="cpix-20140630.xsd#InventoriesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:href="cpix-20140630.xsd#MarketableSecurities" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:href="cpix-20140630.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:href="cpix-20140630.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProducts" xlink:href="cpix-20140630.xsd#NewProducts" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:href="cpix-20140630.xsd#NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:href="cpix-20140630.xsd#NewProductsNewProductsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:href="cpix-20140630.xsd#NewProductsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:href="cpix-20140630.xsd#OrganizationAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:href="cpix-20140630.xsd#Revenues" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:href="cpix-20140630.xsd#RevenuesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:href="cpix-20140630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:href="cpix-20140630.xsd#RevenuesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:href="cpix-20140630.xsd#ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860A6E70A1DD788B623C6883763F4E45" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69E25FA8FFE74DDFEDA16883763F3163" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73D9AE64D5DDF84ECD9D6883763B84CA" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_047C0F316CF9707BC7B96883763B7A41" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:to="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A5D438F8501C2644F1C0A17EB657E7B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_MarketableSecurities_ECBBF84E0CC87FA1AD4EA17EB6573A23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_EE52B2EB2E93236874BAA17EB6570736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_InventoryNet_F398E07AF71C8F04F40FA17EB657CC22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_OtherAssetsCurrent_409F6C45F978CFCDFDBEA17EB6573634" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9A9424ECBC008CD71377A17EB657AC63" xlink:to="loc_us-gaap_AssetsCurrent_93E384BC1DB95229C769A17EB65C2E1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_275BAB025FDC035571BDA17EB65D580B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38C32596223983E26CD3A17EB65DBE5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D8671C4D1202F4C8A04AA17EB65D4039" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1B643CDA04E48BE97D73A17EB657D60F" xlink:to="loc_us-gaap_Assets_FE5C76930A68018E1B01A17EB65DAA92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84D96CC2AF2154D92729A17EB6578617" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:to="loc_us-gaap_AccountsPayableCurrent_39A000A2058B3C28304BA17EB65DE3A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9EBF88B7F233F93455B9A17EB65D5D2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0FE274E09FA80CDD30B4A17EB65D11EB" xlink:to="loc_us-gaap_LiabilitiesCurrent_E8C176F9BBE97D48D026A17EB65DDA6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_LongTermLineOfCredit_B58BA250D3C37AFF9A38A17EB65D80DF" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_52C65ED0DD5B8BE7409FA17EB65D6DB2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_Liabilities_122D21C4A5DCFA023F8CA17EB65E00BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_CommitmentsAndContingencies_E146CD929DCA9612F587A17EB65E4FC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:to="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:to="loc_us-gaap_CommonStockValue_F9A3BDB2D1BAC75A2C21A17EB65E07E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_104C855CD49DC703745EA17EB65E7F81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F28558B909A26F1E2A76A17EB65E0E54" xlink:to="loc_us-gaap_StockholdersEquity_4130433B4606A12EDA61A17EB65EEF4A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:to="loc_us-gaap_MinorityInterest_B1887C2260E037F61668A17EB65E95ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301BAC038C7813AD8819A17EB65EB01B" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73AFB5AD28DAF04B1486A17EB65E7F35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BEC1FE8E650CED6D60CBA17EB65D7B22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2190AA75888654F37193A17EB65E416D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D8559137BAE2DF9B912D688376B25DE2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D8559137BAE2DF9B912D688376B25DE2" xlink:to="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:to="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_529E88F508B68BBD050D688376B23088" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3FF8476A1DFC9E429740688376B22FAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_279F77E0DA1E3A416944688376B2FDC8" xlink:to="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockNoParValue_AA2AEAB6E107AF7BFEEE688376B2464E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_83785D721F170B97D405688376B3A86C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesIssued_8EF8A051CF4004AD3D57688376B3E14A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276A759D2AB9A7E967D6688376B213EC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4605C660E1135297D17F688376B3E715" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_778850D8753EF3659978A17EB60EE66F" xlink:to="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4F09EC86639E015BBC59A17EB60E90D8" xlink:to="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E84A69EFD175C225DEE2A17EB60EC561" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_CommonStockMember_E84A69EFD175C225DEE2A17EB60EC561" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_RetainedEarningsMember_7AA05A6DFC5B4B941FEBA17EB60EF7B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3988A03FA62A088B3323A17EB60ED1C3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_12D8D5C8E927A99C5270A17EB60E35DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02DD032CC948B1AD1329A17EB60E36C2" xlink:to="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C183F6AFB0BECDC2897EA17EB60E1DCC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_413614AE5AD0B4DA4C79A17EB60E76CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_AA109977E67B036778E3A17EB60FB785" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9E29C3DC660816C33C54A17EB60F7C63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E073805D42802BBCFEAA17EB60F6849" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58BFDBCA3602256A68C8A17EB60FE18B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_F6EDE716FEA15F8004B3A1AF1B69D703" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_F6EDE716FEA15F8004B3A1AF1B69D703" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_D3E9FA013BC848A4C225A17EB60F43BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2030328325899E7B6A92A17EB60FC708" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_ProfitLoss_7D79C22E8346BA2220D6A17EB60F5350" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2475EE52FD5C0476F54DA17EB60FB8DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26A829ECD2B2F7510B64A17EB60E421F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B3DA7E8BBD5874A66D7EA17EB60F0832" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:to="loc_us-gaap_ProfitLoss_9FD250F47495BDC6EFF7A324128E62EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_F855DF6F5EA5872F670AA324128EEEA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8B4591A37BC6269D4C96A324128FB25C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_ShareBasedCompensation_2D585CECD68E22353859A324128FEACB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_65C361A3679BE596B573A324128F71A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_43E9F64474D7511E247CA324128FC950" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_D174E8FA6F9A1D7018FBA324128F2B01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B1863902B7EEFBFF3E01A324128F6BB6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9CE2A68AB21D569D2877A324128F7EF1" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4B2EAEC7CAE4D6BDC8E0A324128F2F8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F9053509C4D1FF651954A324128FF415" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_AA40FCC8252056296ED4A324128FD4E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BD976A85CFF7881CFD92A324128E6524" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0E8E9E71E9E2815AB5B9A324128F9B19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91B264EB2C43E954CC69A324128DA9FF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C0FA79B94535DFD9A07AA3241290C7B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3D7C072BAB7BA8AA2CD6A32412906BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3C5BB948D873D88A909BA3241290856D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_CB3BD56AE758A1540542A32412903CE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_1A749094CBC6CA8F5B99A3241290E42E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_C245E1D62D3719960774A32412900827" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EB28B459C387C7BD5058A32412908648" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D50E339715FC5F014E57A32412907438" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_821B28AC68356FAB8123A3241290F6D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_A90423EFB30D9A45A3ABA3241290FFF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_865BF2DC96ACF0EBA08FA32412906C34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_E547DA46F6B63D2FB463A3241488BF50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DDF5C9501AB2D75D36D6A3241291F1C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2074764399327E682F4EA324129089F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB86FFA7CFF0FF81BDB6A3241291FD71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D9D68D198255B9FCE1ADA3241291E563" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_333A2DBB136C5B3C82ABA3241291CA57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_550D11A59B7CE00C4B8DA3241291CA20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0C500FCA3041886BDB78A324128CB782" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_39808FFB987BA32AEC99A3241291FE30" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86C0BAADC8E851D0ACFDA3241291DFC9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_93E45AEF2DF62DC41761A32412919D73" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_SalesRevenueNet_6E4CA2C2CCA3CE4596BDA17EB6370342" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_CostOfGoodsSold_601F014230CC504F3550A17EB637C464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_SellingAndMarketingExpense_070789932D08861F7410A17EB638B608" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58480DD0F80A6D180914A17EB6381A34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3A982DA388421842F449A17EB638D1DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_264560D7F902DD6452CFA17EB6385B02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_CostsAndExpenses_0CD25FD003453B3B4930A17EB6385198" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ADE18C2D0B06C7F320AEA17EB637AC3E" xlink:to="loc_us-gaap_OperatingIncomeLoss_F05F58DFD21B6824C5E8A17EB638C72B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_FFEB7C1F4F45C9C656EBA17EB6389C4C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_InterestExpense_AEE85EC09A5321BBEBBCA17EB638D79E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3B1DE03FA2F59E380CC8A17EB6381646" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B232EAE7F379406D03CFA17EB63D2B11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_ProfitLoss_413F38CA7CC356136265A17EB63D716C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9956418EF2943B36C1D1A17EB63EE5C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_NetIncomeLoss_52C55A16F16ADD6CB6A9A17EB63E08FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:to="loc_us-gaap_EarningsPerShareBasic_37E151A46588DDE5CAEFA17EB63EE3A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4FA9A4576C296FF7CFB1A17EB63E74B9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_D87B2B4860335B1911BDA17EB63EC91F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7C87ED65F47FD1D3A5C4A17EB63E4857" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5A3896AC3FFB3776AC2BA17EB63E8BD3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A3D9FAAC40E35DD15705A17EB63EBAFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F4017A212391B6113AE2A17EB637B2B8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_94DDC3405E6453E595A8A17EB63EF19C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="cpix-20140630.xsd#cpix_DocumentAndEntityInformationAbstract" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_EntityRegistrantName_BB7E8A659A6E183A6600688376747525" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_EntityCentralIndexKey_9604BB7ABDF5A565B786688376747C41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_DocumentType_5D37DE5394A4EA49759E688376742E38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_DocumentPeriodEndDate_026ECCCA14097FB8B3CF688376741283" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_AmendmentFlag_0AEB2C0919E37607730D68837674F143" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_DocumentFiscalYearFocus_9539F11AAD8BC139AAF76883767466CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A7222CF53DA3361ADDFA68837674F1AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_CurrentFiscalYearEndDate_9DC9F9419EBCAB9924366883767427CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_EntityFilerCategory_508E29678B0EFE4CED2A68837674E1C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_125E0B9404D34547FF4F68837674C1FE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_CB1C7C9CB2E97A734CC968837674176F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37C6B52C347DDEE6289DA17EB5E9541B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37C6B52C347DDEE6289DA17EB5E9541B" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8B272AF9140412391272A17EB5EABE6F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3062849D695428A9935DA17EB5E63A2F" xlink:type="locator" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ReconciliationOfNumeratorAndDenominatorAbstract" xlink:label="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3062849D695428A9935DA17EB5E63A2F" xlink:to="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_NumeratorAbstract" xlink:label="loc_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:to="loc_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_6913BD46F16311FA6959A17EB5E618CF" xlink:to="loc_us-gaap_NetIncomeLoss_D42DACE64EEDFF5328CAA17EB5E689FC" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_DenominatorAbstract" xlink:label="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ReconciliationOfNumeratorAndDenominatorAbstract_B68C31F62F5383C82E3FA17EB5E6F1E9" xlink:to="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FCE48AC7C769D28B387BA17EB5E64605" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9B4D9147876F29D4CE91A17EB5E6EDB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_B5D4F28CE009F6A47648A17EB5E6367F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37D1BC342578CBD77B82A17EB5E6D301" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_19FE21D1787726B19983A17EB5E3806A" xlink:type="locator" />
    <loc xlink:href="cpix-20140630.xsd#cpix_EarningsPerShareTextualAbstract" xlink:label="loc_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_19FE21D1787726B19983A17EB5E3806A" xlink:to="loc_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EarningsPerShareTextualAbstract_7ADF3F3410C8E1EF7236A17EB5E39172" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9986F04FEDBC41094B51A17EB5E39245" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_227379CC7B17D045A49FA17EB5E83125" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_227379CC7B17D045A49FA17EB5E83125" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0851D1280B25E7FFE9A9A17EB5E895F3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_BCE6721D637EC97907A668837695EDBE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BCE6721D637EC97907A668837695EDBE" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_86E805D0CD588FEAF29B68837695C79C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:type="locator" />
    <loc xlink:href="cpix-20140630.xsd#cpix_IncomeTaxesTextualAbstract" xlink:label="loc_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B7C4D4A94AE5290C9F2A68837671AAA8" xlink:to="loc_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:label="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_IncomeTaxesTextualAbstract_B74657DF8CF848A300966883767154EA" xlink:to="loc_us-gaap_DeferredTaxExpenseFromStockOptionsExercised_DD508ACEE23272924F4C688376716711" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B9449DA303FA3FFE718B6883766190B6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B9449DA303FA3FFE718B6883766190B6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_0455A4CFD86D27CF4F9D68837661716B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C0EB3AD3EBDF36652D6DA1CC3E0827D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C0EB3AD3EBDF36652D6DA1CC3E0827D2" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_CB4FFF4BAA62401D36F6A1CC3E0834A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D02A5806DA90C9E7DF77A1CC3E08880E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_0815249158A4F64B6B9EA1CC3E089135" xlink:to="loc_us-gaap_InventoryNet_9D308D856D478F3AF330A1CC3E0802F3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_E1D7EE064148596462B66883766E2AC8" xlink:type="locator" />
    <loc xlink:href="cpix-20140630.xsd#cpix_InventoriesTextualAbstract" xlink:label="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_E1D7EE064148596462B66883766E2AC8" xlink:to="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_InventoryShelfLife" xlink:label="loc_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:to="loc_cpix_InventoryShelfLife_6FE38CB25891CD56E13E6883766E7C83" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_InventoryExtendedShelfLife" xlink:label="loc_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:to="loc_cpix_InventoryExtendedShelfLife_295CAC7C7410178FF1B36883766E410A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoriesTextualAbstract_2A8FE3B6E9A74FE76C516883766EB2CE" xlink:to="loc_us-gaap_InventoryValuationReserves_E6F7160B6B0CEF98FF526883766E7D27" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_82E7EA2D9E74792936736883767BD9CE" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9272E11054D5C322FDED6883767B3687" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BD3A7035BEE9C953D6506883769632D8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BD3A7035BEE9C953D6506883769632D8" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_213179AE0C74FDC3A27E68837696FF9E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B1AC71C3CDA3F05554C688376857B8B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E3B825723E6A0AF7640E68837685D5BE" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F4CA4ED3B17FEF57D2C2688376856B93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_042295632C78CC3F0A6668837685D92B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CD68A11E9CA9FA6C761968837685645A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_EF60F620FE10F5E94434688376855899" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMember" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMember_6AD0CA1F33807532B007688376858887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember_B6D604D4AAB8C5F3D1BC688376854840" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:label="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_AgencySecuritiesMember_D6448BE8F8887C2E3004688376868785" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LoanPoolsMember" xlink:label="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_cpix_LoanPoolsMember_1EB9E86874876B06C5A2688376868EDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_EBAC94C1C62D9773B25E688376850491" xlink:to="loc_us-gaap_MunicipalBondsMember_A2DCB2E9C6A0960410E468837686C2D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F173536DE5C8CAE3B5D5688376855B76" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_312D6E5E55FED44D296668837686D1C0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B877F77EF1619AA971C5688376860766" xlink:to="loc_us-gaap_TradingSecurities_03886DD39480ABF49135688376866A01" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_80B1AD6F251F4B37E7996883768A6491" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_80B1AD6F251F4B37E7996883768A6491" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B382FE519B253E19C83D6883768ACCF5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/NewProducts" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C16AFBB7E9695AFF50F8688376777BDD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C16AFBB7E9695AFF50F8688376777BDD" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3152C49DC1D8487CDA99688376775FE5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8016F967F10C3640C2C76883766B4FC1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8016F967F10C3640C2C76883766B4FC1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF1D042C7E19EFFF88B86883766B074F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_97BEED678BEA522E189D6883766B750E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EBB7A7646D935ACEC006883766B9E69" xlink:to="loc_cpix_VaprisolMember_97BEED678BEA522E189D6883766B750E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ABD0220A8EC00BC1DE566883766BCFD9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CDE7F119F187BE8FAFB56883766B1A98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78FEAC0B8FB4522358656883766C0A95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_16E2D835D0870783F2036883766C43B2" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations_17AE33510D54EB3140E66883766C2B35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_553E7EA4DC074E1F547B6883766BBF55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6E58762502DC50105CCF6883766CE3E8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2F109028FA6D7ADFB50EA24207BEFD72" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2F109028FA6D7ADFB50EA24207BEFD72" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_633AAE0DDB1992CE6557A24207BFF750" xlink:to="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:to="loc_us-gaap_MinimumMember_B52BF5B3D7023B304AE0A24207BF7C4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D736F770BF506D6F4B1BA24207BF13D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8B9AC0B12731AC8053ACA24207BF0F76" xlink:to="loc_us-gaap_MaximumMember_D736F770BF506D6F4B1BA24207BF13D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BF258184904F947E49CFA24207BF59F1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OmeclamoxPakMember" xlink:label="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:to="loc_cpix_OmeclamoxPakMember_652B75AD154788CD1DF0A24207BF92F3" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58031AEDC45FE4CE77D0A24207BFE753" xlink:to="loc_cpix_VaprisolMember_8F1B883B36704C9B4644A24207C04A31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C7D3ABC820E3B9AD2138A24207BF5F08" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationUpfrontPayment" xlink:label="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationUpfrontPayment_B50BBB1E083C0DA6ADC5A24207C099C9" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationAggregateUpfrontPayments" xlink:label="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationAggregateUpfrontPayments_C35153A1AAD3E2E95620A24207C0BFED" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage" xlink:label="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage_2261A7FD19C8639DEF75A24207C0B722" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_29F6AA7A999E4B56CCF8A24207C07A19" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_68CC78878CA548353247A24207C06068" xlink:to="loc_us-gaap_SalesRevenueNet_29F6AA7A999E4B56CCF8A24207C07A19" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/NewProductsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_78F08E6459F5CCD19D71688376884A08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_106C9AC8B37BCC7746A8688376898EF9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5AA67E3164D72B9DF8A968837667D765" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5AA67E3164D72B9DF8A968837667D765" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3BD9E85098F45BA3FD0D68837668D506" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D85C1EE76E4FB9BC6F7EA17EB602A10D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D85C1EE76E4FB9BC6F7EA17EB602A10D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99F11DDAC4855E4830B1A1B49FB151DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D85C1EE76E4FB9BC6F7EA17EB602A10D" xlink:to="loc_us-gaap_UseOfEstimates_0C7BFC2F8ADBB6AFE943A17EB602F5B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D85C1EE76E4FB9BC6F7EA17EB602A10D" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_31294C7B743AEB6F26B2A17EB60261B7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_52FE4B3F0948ABA878A76883763D969A" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_A0EE082CE024D7933FBA6883763D2BD2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_AD4F2D6D7597CCFE8C3DA176D08E0378" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_AD4F2D6D7597CCFE8C3DA176D08E0378" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:to="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_3BB61821B1421F560AE3A176D08F9882" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_AcetadoteMember" xlink:label="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_AcetadoteMember_BE0176B76C759B131644A176D08F6CB1" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OmeclamoxPakMember" xlink:label="loc_cpix_OmeclamoxPakMember_965D3A3C4F83F9E43298A176D095F29E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_OmeclamoxPakMember_965D3A3C4F83F9E43298A176D095F29E" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_KristaloseMember" xlink:label="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_KristaloseMember_EC5008141400C2FB4EFAA176D0952F55" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_VaprisolMember" xlink:label="loc_cpix_VaprisolMember_B05E5CE24842B629A936A176D0954636" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_VaprisolMember_B05E5CE24842B629A936A176D0954636" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_CaldolorMember" xlink:label="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_CaldolorMember_67E84D029B579FF55AA6A176D09562A0" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_OtherProductsMember" xlink:label="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9E9F72CFAC328EC6ADEBA176D08F1804" xlink:to="loc_cpix_OtherProductsMember_7706698E5850B25F134FA176D09532E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8CADD56DF64817AC653BA176D08E53F8" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_D00185170A72C56AD3EBA176D095D68D" xlink:to="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ProductsAbstract" xlink:label="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_7122E6514870BEBACFA9A176D096E2B9" xlink:to="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_44BE227E660D193437BCA176D097FEF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_B2D23DC9A9638A42016AA176D0961939" xlink:to="loc_us-gaap_SalesRevenueNet_44BE227E660D193437BCA176D097FEF1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_86254E079A758C4D42D6A17EB5D837E4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_86254E079A758C4D42D6A17EB5D837E4" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_93BFA952F8FAB0F93A9DA17EB5D875D7" xlink:to="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_76CB95DCB3F5D92E8A42A17EB5D8E669" xlink:to="loc_us-gaap_MaximumMember_04E836700128537D47E2A17EB5D87900" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_976E0902657415F277C8A17EB5D88853" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember" xlink:label="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_NonCollaborativeArrangement2013CommercializationAgreementWithThreeInternationalPartnersMember_2669F2E6158C1C0C88E7A17EB5D85383" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalMember_BB7715D7A9507E4216FAA17EB5D9C43F" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember" xlink:label="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_154F6859755E0D9B72AFA17EB5D8ED17" xlink:to="loc_cpix_MilestoneMethodFutureRevenuePaymentsBasedOnTotalAndAnnualProductSalesMember_7812DD2CC4E3C23631DBA17EB5D9C4B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_95694D97F3B9DF80C0F2A17EB5D99D16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ProductAcetadoteGenericMember" xlink:label="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8C6CA198FD46ABE4311BA17EB5D9C986" xlink:to="loc_cpix_ProductAcetadoteGenericMember_51B9E3540F9FBD326D21A17EB5D97048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2BD6ADBE41CB925FC351A17EB5D86841" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenuesTextualAbstract" xlink:label="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C8A997B4544B9A3DEE4BA17EB5D90F95" xlink:to="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_NumberofProductLinesAcquired" xlink:label="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_NumberofProductLinesAcquired_B4A74FD340E31AB1C2BDA1C7C158818A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_AC410742E1962908C15EA17EB5D9C9B0" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets" xlink:label="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets_41EE631B0024376CF9EFA17EB5D94590" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_CA8114B9487631FECF52A17EB5DA5D7D" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone" xlink:label="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_RevenuesTextualAbstract_A33D132C37C7C56C39BEA17EB5D95E1D" xlink:to="loc_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone_E9ADF3AD01DADF7C21FFA17EB5DA1FFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_509CD7521D329EFC9E276883766F8620" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_509CD7521D329EFC9E276883766F8620" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4BFFC7D8B9364CE692D96883766F25FC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt" xlink:type="extended">
    <loc xlink:href="cpix-20140630.xsd#cpix_EquityAndDebtAbstract" xlink:label="loc_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_F0147A0471634910692A688376877F8E" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A7070C9F048C9C5317E6883768764C7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails" xlink:type="extended">
    <loc xlink:href="cpix-20140630.xsd#cpix_EquityAndDebtAbstract" xlink:label="loc_cpix_EquityAndDebtAbstract_346AA6905C31021A0115A2E385086843" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_346AA6905C31021A0115A2E385086843" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1ABCA86DFA144B0183FEA2E3850E4335" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member" xlink:label="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D750136418247009EA11A2E3850FC7BE" xlink:to="loc_cpix_CreditFacilityFifthAmendedAndRestatedLoanAgreementAgreementAugust2011Member_EF3218959D463C12823DA2E3850F2BCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7FB7E1B8340DE9D60CB0A2E3850F5320" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_SunTrustBankMember" xlink:label="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_AF1293E516956C5E1ADFA2E3850FC1D3" xlink:to="loc_cpix_SunTrustBankMember_EE5C9447C62CCD042FA4A2E3850F5B20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_407F3C78CF4423279309A2E3850F6AC1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_176FAD87525ACB3F97D6A2E3850FD371" xlink:to="loc_us-gaap_LineOfCreditMember_D2B8D69DBD0152D8A40CA2E3850F36F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9B770A51EA1C5DB1D79DA2E3850FA50A" xlink:to="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7097AFA4DBFA71EB4505A2E3850F1FCB" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_508589E54C04FDEC3688A2E38510FE40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_E729A76887152507191CA2E3850E3800" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_5C4D9B667640A61D03DDA2E385100AB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8B33E53D34EC30E61819A2E385101327" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_A5742D5FCB6C36B7EA07A2E385106D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_255CB1CD77145EB2F78BA2E385102126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_288F4B2731F4DEF3A101A2E38510ADC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_918F03D37733559FA08DA2E38510C887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0F002C935CACE583E215A2E3851033A5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36158EC9BE698B6044FBA2E385104172" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:href="cpix-20140630.xsd#cpix_EquityAndDebtAbstract" xlink:label="loc_cpix_EquityAndDebtAbstract_98563FC1EA25A64CF7CEA1CC3DFE0E94" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_98563FC1EA25A64CF7CEA1CC3DFE0E94" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423BC63063340097E9F3A1CC3DFF83A8" xlink:to="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04DEC6E6AF64E8EAE92BA1CC3DFF633C" xlink:to="loc_us-gaap_CommonStockMember_9763ECBEA327B8061674A1CC3DFF2FA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_39BD81D38B1D47D916BFA1CC3DFFA92E" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_EmployeeMember" xlink:label="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:to="loc_cpix_EmployeeMember_EAB4E38734B24ABE71E1A1CC3DFF3DB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_EC7479F72CA7FDCEA056A1CC3DFFEAC4" xlink:to="loc_us-gaap_DirectorMember_A84EA3072AE002349DFFA1CC3DFFBBFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5F5BC49AB3FE1943CFE3A1CC3DFF0DB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3C9104EF30C15E252BAA1CC3DFFAB8B" xlink:to="loc_us-gaap_RestrictedStockMember_8A2CB607D9F324BCD052A1CC3DFF6454" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7CBC8D7AD05079C92687A1CC3DFF75E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_ShareholdersEquityTextualAbstract" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE214F2172E79D4AA844A1CC3DFFD857" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount_372EFB3AF64679C68EFDA1CC3E0071FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_DAFF29BB5D261497CAD6A1CC3E00C9AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_AFBC7AB90FAF0C4EABABA1CC3E0074D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_FE4AECC62B9544673199A1CC3E00CC99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60C96A4D5D1DEB20C7B5A1CC3E002268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_8F93A94F3B8B46E29C4BA1DF001897C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_31055112026A2B33C627A1E14C88C34B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_D91B7EBAEFD08A68202AA1E780D583D5" xlink:type="arc" />
    <loc xlink:href="cpix-20140630.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_84DB7ECBB456E441BCF5A1CC3DFFC022" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_2D44631C47F56D416779A1EB14E737F9" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/&
MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ,
MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N
M);GWYIY2E^50"1=K`RK<F6I;"1^^VADU(IN+&5#>[?9HII4'Y3N^GD&&@T>8
MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@
MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A
M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD
M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E
M6,S*L9B58S$KQV)6CL6L'(M9.1:S<BQFY5C,RK&8-<%BU@2+61,L9DVPF#7Y
M+[/Z4,@!;3[__G0T8WYIA)Q?E^#._!:W&?I;<BXLR#=O0W5Y=H#OLX]QA&)O
M;+5QH>*T</HI[#K,>G?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[
M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N
M<F5L<R"B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````",DL].PS`,QN](O$/D^^IN
M2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#
MNBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\
M(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FR
MMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<
M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````
M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````O)C-;L(P$(3OE?H.D>_%[)K?BL"EJL2UI0]@)88@((EL]X>W
MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/
M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M:
M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+->
M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA
MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$#
M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T
MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B<TL<'
MAL<'TVD$AGC<I^/AM8!/8U2Y)`U+@K`D:5@2A*611H*!2)`F`@2"])>"'XJD
MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8Z<PS,'-,I+V-JO+FK,Z>A/EWA
MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`#H7\N$,#
M``"W"@``#P```'AL+W=O<FMB;V]K+GAM;)266T_;0!"%WROU/UA^+XXOH8!(
M$)14C40I*BD\6AM[$J]8[Z:[:Q+ZZSMVB!E?0,E3LG;F^.S9;R8^O]CDPGD&
M;;B2(]<_&K@.R$2E7"Y'[I_9]R\GKF,LDRD32L+(?0'C7HP_?SI?*_TT5^K)
M00%I1FYF[>K,\TR20<[,D5J!Q#L+I7-F<:F7GEEI8*G)`&PNO&`P./9RQJ6[
M53C3^VBHQ8(G<*V2(@=IMR(:!+-HWV1\9=SQ^8(+>-CNR&&KU2W+T?=&N(Y@
MQDY2;B$=N4-<JC4T+NAB=55P@7=/PT'H>N-ZDW?:26'!"F%GN+V=.N851$%P
M7/ZRC.*!P]J\%95+9_/(9:K6Y4\QVI=Z%:*!=77KD:<VP_N#P:"^]@/X,K.[
MBRCO$?TJ07Q.]>G(:GN[1&(\J7@B+;<O\51NT^<*C[!,?8H[\UU'GW'\HJ>I
M7QJG*M^43$$:2&/\9I3@*<.PXBLFF$R`J`1$)3A,!0W49D(B4^6]AYE[BYYR
M:B8B*M&>9EY5J!D,OTYF>)@,QE'OZ9C(5&30/?W22R;YOPK7ZJBNF.$F5HOX
M3F-CO:F4>-1NOK;=_&3Z"2R;"XCO(2DTM[Q934V<M*LG3$ML;Q/?*&/B.]#Q
M?<8T333\2IY^VJ[_#<\@B^8#<4K4=OU!NV(JL<(JW7)Y2HLZ,%:F,B52;.5X
M\K<HD2[IOH:Y)4E%V%9OC^[`.,5AED,\8YN&X:C1!SWL"<'F2N-!/4-\N=2`
MR$E+3RBB/>#W<)?GW%9%E6ML*(NAXVQMAA#1'O`[W-W"&M%0:9$T'TZ9]P_$
MC$(?4<[\_4##,)&\1A:4-W]?X'IT*'?^N^#U%%+^<-"VYAKAKZ>68AAT,*0G
MT"T>4OJ"#GV]C8H$6\8%#3"@%."BY?^=CGT5(LT04"YP<9`.Y2*@7."B);0;
M`7U;H2QL_QOI!&Q7QC/8V(+AOW,]08>T-X,.D_0P>Y)LD-!!L:>XQT'00*+#
MX4>3*;ZF.Z$S(NQ@^;$./8XAY2/L,$J'W.Y(>K85-NQT8&V0?FD,6%.-KAO.
MYIP>4-APTZ&UH=-<,*UI/)36L*+5JRC`EYN$B03?NLJ/\K6ERL[;O7.._P,`
M`/__`P!02P,$%``&``@````A`,A+?.UN!@``_1<``!@```!X;"]W;W)K<VAE
M971S+W-H965T-"YX;6R,F&UOHS@0Q]^?=-\!\3Z-GP!3-5TM#WNWTIYT.MW#
M:YJ0!FT2(J#;W6]_8TS`,R')JE+;F!]C_V?&,XZ?/GP_[+UO9=-6]7'E\P?F
M>^5Q76^JX^O*_^?O3POM>VU7'#?%OCZ6*_]'V?H?GG_]Y>F];KZVN[+L/+!P
M;%?^KNM.C\MEN]Z5AZ)]J$_E$9YLZ^90=/"Q>5VVIZ8L-OU+A_U2,!8N#T5U
M]*V%Q^9G;-3;;;4NLWK]=BB/G372E/NB@_6WN^K4GJT=UC]C[E`T7]].BW5]
M.(&)EVI?=3]ZH[YW6#]^?CW63?&R!]W?N2K69]O]APOSAVK=U&V][1[`W-(N
M]%)SO(R78.GY:5.!`N-VKRFW*_\C?\Q%Z"^?GWH'_5N5[ZWSO]?NZO??FFKS
MI3J6X&V(DXG`2UU_->CGC1F"EY<7;W_J(_!GXVW*;?&V[_ZJWW\OJ]==!^$.
MS"OK>@\SP6_O4)D<`.G%]_[O>[7I=BM?A@]!Q"07@>^]E&WWJ3+O^M[ZK>WJ
MPW\6XH,I:T0,1N"-P0B'H=LO+^U">@%9T17/3TW][D%6P%3MJ3`YQA_!H%FY
M!/UV^E$+N'1MZ(\&7_F1[P'7PNBWYT`_+;^!;]8#DLP@,4;2,V(<9,QFYX')
M+,>OY&?"A`&6/JX?E#OK/R_3C)IEGB=([``8&=<M\`3I)1$RC&27"#&27Q*.
M$;1N.;MN,PH!<)89$D<D%E$.$N!EIG>)["Z1WR*0#EC(C/_-Z,H';XSN#HFK
M$HOH/H?B*&`\)(F4ND3$-&>:$)E+\$@KJ3B9)L>(E+$04UB1$LC^&25FE$1$
M8G\G%H&)1K$T(G>)["Z1WR*0CG!6AQDE$5%$AT7"/B)<Q%KS$!,I(GB@M"2^
MR%Q"R$`$E,@1(4*IG+@C'5!D9N)A1HD.XNW$(E:'C"5CFB1%BHA`":9(A<I<
M(@J48IPHS1$A>`#^&KV%=)@F/U78<X4RHT0'\79B$:M#AQS\/4[05\W4!;C4
M8<P(D2$BU%$@(FPC=PFA91"*R5E(1CPKPXP2&62&Q")6AN"*">KLU"6X#@+!
M2-'+7$(Q&:F0."M'A)(L5E>V.8?N-A./?I@HF0+:^SL9F"&SF!*T]Z6($%J$
MBB1GA@A(&G&16(A0+`KCR0:*"#<]\3*S^F&BA*1W,C!#;@52!0%!4HP(P4,Y
M9<;0M6U3ME9X*#C4<<+DR`R/>"`C1S'68[KGC![;5-UF$DVQ'2)CF6$EL!M#
M=J''118<$A&V-=X,F3E'03J/@F3HM.]^IAPCD*QLRG>LQK30&36VLR(U)-L3
M;AF[#!%?K#-%@-*0152(:R$.M9X6.<AP`:ZX=.*/99@&.B/#]E4D@RPBX9:Q
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M=>"_CV3WD?PF@M).S!\%^F%\%(BF6/?^3P8F[H_][($>(5/T?`$`*8X9`N`Y
MR>></K\6&,@C)]G..T:882Q!D^`G`W-=@K5AG\]*<($Y">3Y-0FFJ4[[991@
M>RW\'K\@TBZ6",O<S*F[2';?2GX3P3EEVO>,&MO5P2.3FJD8#CEEF:&$19&"
M#D,J=RH0H^$X%CA?/7H[&68B+0(>D6J88T8'FNFK>W_^!&"NWFB*D21/!F90
MI)D(8N<8:RL98>85H9.$9C%X9LJFWDY.[$1!>+V:S9\"X*[S0A'Q6S(P]@(F
MFNN<B)COG`B9[9R(F.V<]E;57DH>RN:U3,O]OO76]=L1,DQ"71I'Q]O<C\)<
M[9'QA#_"S>+E>`:WO_WX<GP![F1/Q6OY1]&\5L?6VY=;F(H]1!"=QE[?V@]=
M?>JO2%_J#FYC^W]W<,U>PITE>P!X6]?=^8.YF1PO[I__!P``__\#`%!+`P04
M``8`"````"$`?.VBI0H&```1'P``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6R<F=N.HDH4AN]WLM^!<#]R$K6-.FGE?$AV=O;AFD94TB(&Z.F9MY]5
M%"!5,*SNZ0MIEQ\_Q?KK7)NOW[.K\"TIRC2_;45E)HM"<HOS8WH[;\5__[&^
MK$2AK*+;,;KFMV0K_DA*\>ONSS\V[WGQ6EZ2I!)`X59NQ4M5W=>25,:7)(O*
M67Y/;O#+*2^RJ(*OQ5DJ[T42'>N;LJNDRO)"RJ+T)E*%=?$1C?QT2N/$R..W
M++E55*1(KE$%Y2\OZ;ULU;+X(W)95+R^W;_$>78'B9?TFE8_:E%1R.*U>[[E
M1?1RA??^KLRCN-6NOPSDLS0N\C(_53.0DVA!A^_\)#U)H+3;'%-X`Y)VH4A.
M6_%968?*7)1VFSI!_Z7)>]G[7R@O^;M=I,<@O260;?")./"2YZ\$=8\D!#=+
M@[NMVH&_"N&8G**W:_5W_NXDZ?E2@=TZN27.K_`D^!2RE-0!>/7H>WU]3X_5
M92MJBYF^E#5%U47A)2DK*R7WBD+\5E9Y]C^%E$:*BJB-"%P;$46?S55]N?J,
MBM:HP+5546?*7%Y\HB3S1@.NK88R6^GZ?+%:?OQ]@*R3`M=6Y=,E630:<&TU
M?J,DRT8%KJW*;V066G7]/G!M5=1/F_S4B"A0%UH5?::N=$7_C$-*6UF4GL_S
M#_HLT=I;UWHCJJ+=ILC?!>A*H$SE/2(=D[(FPDU];RIMUP*@(<8$?R;\5H2L
M0MTN(?IMIRG+C?0-FE3<,'O*P&>/6;',841'?F(9HV5(XR,/-_F`Q0=L&H#/
M[M$**^JT1"OJMAJ_O,5KB?86GP\$?"#L!23(=)=N\+"?[C:K)$RRVCYAWP06
M=8;GT*EPKW%H[WB46E/X_(TPJLRFPQQCN&=98XS*ZMA#AB.<(:&I&JOB4@:2
MU]G'J7@HX:-$@!+AD%@\$L<8"DUFS%`29@QM`HO.X@./&'S`Y`,6'[#Y@,,'
M7!KH9U13YVS6O3%&9QE_C%FP3#!D%)6K2^$TPZ06AJ*QU)(PD]HFT$LMCQA\
MP.0#%A^P^8##!UP:H`,ZZ9Z\-O"HO8-<^Q]@@I9I>X.P%V`R!,-L/T-UYZW)
M75]-?H9I2:\U:2K?5U,&'M"U.,[Y`TH8*&&BA(42-DHX*.&BA(<2/DH$*!%.
M$8S#,`F:<IC\O!6AM^K<TU1NI-U39E6/)(I,_]B&>Z#(1"4P<!$31RP<L=&B
M."CAHH2'$CY*!"@13A&,RS"=ZKO<S@I(F'574;DQ?D^9">L.*&&@A(D2%DK8
M*.&@A(L2'DKX*!%0@LZ]M+D\U[B!+NP#B^5"UQ^C'.,KV13H3:Y;7TF8]54;
M^$J9*5]1PD`)$R4LE+`I0;.EZ"M95;D1Q$$U7)3P4,)'B8`2$R4-^X0&.R_P
MUW65C+.PINL[RX^\Y&?.8>VA5"]F]I29<A@E#)0P4<)""1LE')1P*='D?JGW
M$UNGPT,E?)0(4"*<(AB#%=@YZCO<MMTZSEO[:/[4V@::\A9'#!PQ<<3"$1M'
M'!QQ<<0;032-6^'YHQ"W4`Q&(*[7"2<1UFNR6N_UTWQK)ALW7'-6!A/I!IKT
MG.HTC:#N7;A.P<!53!RQ<,1ND'Y9N`0ZN(J+(QZ.^#@2-,A$<<-)%=9OLKR?
M\ILN_YEIM<8MFO=D.PXJQ:3?%(']4[)/)L^XF;F!2Y@X8N&(C2-.@SS*RM4&
M%]?P<,3'D0!'PDF$M9KL-_!6SXDA=4_]3+8\N::M:=RK[QMHTFJJTZ^?@Z9-
MD0D5$W^0A2,VCC@XXN*(AR,^C@0X$DXBK-^0WH'?O2T1.#H:^LU-[_<--.'4
MH4'HJEJ=UWUY-U.LJY:!JY@X8N&(C2,.CK@XXN&(CR,!CI`#OE_WK=1O>H!'
MCS*RI#@GA^1Z+84X?[O!7@B,_;M-%^Y.#I_K@T,N?E#6<(X`>VU<W"4GC2/Q
MO;K>C^JHZ\-8W%#7L/\XU#?5-6Q##N.6NH;=R&'<5M>P*3F,.^H:]B8A+G4O
M`.>4]^B<A%%Q3F^E<$U.D!-Y1@[R"GJD2;]4^;T^`7K)*SBAK/^]P-%S`IN9
M\@S@4YY7[1?R@.XP>_<3``#__P,`4$L#!!0`!@`(````(0`(0`KRJ@(``&4'
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)15VV[B,!!]7VG_P?)[
MXUP(!42H6J+N5MJ55JN]/!O'(19)'-FFM'^_XQA2DJ"6?<%X?.;XS(QGLKQ[
MJ4KTS)46LDYPX/D8\9K)3-3;!/_^]7@SPT@;6F>TE#5/\"O7^&[U^=/R(-5.
M%YP;!`RU3G!A3+,@1+."5U1[LN$UG.125=3`5FV);A2G6>M4E23T_2FIJ*BQ
M8UBH:SADG@O&4\GV%:^-(U&\I`;TZT(T^L16L6OH*JIV^^:&R:H!BHTHA7EM
M23&JV.)I6TM%-R7$_1),*#MQMYL1?268DEKFQ@,ZXH2.8YZ3.0&FU3(3$(%-
M.U(\3_!]L$BGF*R6;7[^"'[09_^1+N3ABQ+9-U%S2#:4R19@(^7.0I\R:P)G
M,O)^;`OP0Z&,YW1?FI_R\)6+;6&@VK%U8;*$F^`75<(^`8B<OK3K062F2'`T
M]>);/PK"&*,-U^916%^,V%X;6?UUH.!(Y4C"(PFL1Y(@]B9A?#O['Y;HR`+K
MB04(KY0P.3K#VCE[X2P.XNG'@1"7E#:9*35TM53R@."!0MBZH?:Y!XL)%)%9
MX[VUMF>0&`W6YU7DSY;D&>K!CIB'2YAY'[,^86Q5+'%Z9B"@H),!:;@@PUK[
M,L)YU+_B88R)`K^/68\Q81^17D#$':2G%&IW0:FUPL/"Z"UA0=`1M+$_.`R4
MK\.\7=$BUA\BTO<0/9EPS069UII@"+:3`%TPD.DPYS*C8)#T]1@S""5]#]$3
M"CUX0:BU#H5.!D(=IB]T(&,]Q@P0Z7N(GM!I3RBR\R;RNXZQIT/!TX%@ASD7
M/!"S=HBYZSAO$#!,4WO'Z?3-U\ETD](U=T.W_#M56U%K5/(<I/K>+42JW)QT
M&R.;MKDVTL#8:_\6\#GCT*>^!^!<2G/:V$G<?2!7_P```/__`P!02P,$%``&
M``@````A`$3F+]-U`@``YP4``!D```!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&ULC%3;;J,P$'U?:?_!\GLQD$`@"JEZ47<K;:75:B_/CC'!*L;(=IKV[W=L
M)S0W[?8%\'#FS)GCL1?7K[)#+UP;H?H*)U&,$>^9JD6_KO"OGP]7!4;&TKZF
MG>IYA=^XP=?+SY\66Z6?3<NY1<#0FPJWU@YS0@QKN:0F4@/OX4^CM*06EGI-
MS*`YK7V2[$@:QSF15/0X,,SU1SA4TPC&[Q7;2-[;0*)Y1RWH-ZT8S)Y-LH_0
M2:J?-\,54W(`BI7HA'WSI!A)-G]<]TK350=]OR93RO;<?G%&+P73RJC&1D!'
M@M#SGDM2$F!:+FH!'3C;D>9-A6^2^5V&R7+A_?DM^-8<?"/3JNT7+>IOHN=@
M-FR3VX"54L\.^EB[$"23L^P'OP'?-:IY0S>=_:&V7[E8MQ9VV]=CJH-*\$12
MN!&`SNFK?V]%;=L*IWDT2^)R,LLP6G%C'X3+Q8AMC%7R3P`EKOI(DNY(X+TC
M2>#S@\F373*\Q^0H+;(DR]/_2B"A'6_#/;5TN=!JBV"T0+`9J!O49#X!^YD+
MWKBH_P<M&8B^+"?Q;$%>P$FVP]R>8])CQ-T%1#9""`@858`+%U2X:(6AWU%%
M>2HB0*8'D/<*OI6[?R&.-$"="QI<%/;ZH$":)&,3OL1MP!3>IW26%WEY*N((
M$:=9G,8CQY$(Z.2""!<]%7%B]FW`Y%[$-$V+9%J,)8(3AXA)7LZ*_)WC2`1,
MTP41+GHL(CGH(C@1,,&)O"SS8CHY$7&(R&:@LS@5$<YJ&-*!KOD3U6O1&]3Q
M!N8@CMQYT^&DAH55@Y_5E;)P\/QG"Q<JAT&.(P`W2MG]PMT%XQ6]_`L``/__
M`P!02P,$%``&``@````A`)2Y8NMF!```8!,``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C<N>&ULE)C;CJ,X$(;O5]IW0-P/AY"SDHPFX<RNM%KMX9H0)T$-
M.`+2Z7G[*6.<8)/&Z9M.4_6YL.LO%^#5]X\\4]Y16:6X6*NF9J@**A)\2(O3
M6OWW'_?;7%6J.BX.<88+M%9_HDK]OOG]M]4-EV_5&:%:@0A%M5;/=7U9ZGJ5
MG%$>5QJ^H`(\1USF<0V7Y4FO+B6*#\V@/--'AC'5\S@M5!IA6;X2`Q^/:8)L
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M<Q+6I@9(T#WL9,&/<1C"QKC,\!@CW,9C!!OBBX9`-(2B(>H8=,C9/7$@?S=Q
M+#_$+.;'XE>R?<+PQ*Y/3`T>L?N(((/3)\0@;A\1@GA]0@SBRY&@CXPF_'I"
M.1(-(IPXL$V[XC15/9[<BYBXB4BL+K;,\"BET6+,3W#WC!$683]CIGP<YP7&
M?8'Q7F#\9\R,GT_P`A,^8^9\G&B8X>2!AMB3QS+N\A`W)X]HV(D&6S0XHL$5
M#9YH\)FA6P2"P,$+3/B,$9I9U&<LX['#N63!HZZ;+-9HB!D>B)V.:1E"_]M2
M!N[UZ*J\:#LI84L)1TJX4L*3$KZ4"*1$*"6B(8)39?I<%6)>J]"H[AFW#*&E
M;BDSI@]/00_F>XP7*M"6$HZ4<*6$)R5\*1%(B5!*1$,$IP>\.G1W2=/Q.RV%
MN$5=Q,<R989VBY2P*;%HM#4UH44Z7>]($W:KV_5:FE`U'O7.F\A"3?C4-S#S
M0$J$4B(:(C@MR(>:^$XY?;1WXA:U$!ZV6\H,K&C'B.85E-]%-O-]NHL<*>%*
M"4]*^(P@<Q2J+>CZA%>$D/D^G7\T1'!:+)YHT=D7Q"UJ(537EC)#6D@)6THX
M4L*5$IZ4\!E!%#$T(>\!\WZ:]U!*1$,$IPQ\8O>W2><EM?&+V@@SWK;0D#AR
MQ)8CCAQQY8@G1WPY$LB1L$5H(^X)38XW2-W3;OKH/50?>G!!OY)S5)[0#F59
MI23X6L!3W8(.?+?2`Q/;7,+7*7Q,"';77,(79]\>D`,68M?O`^#8XQ*?T)]Q
M>4J+2LG0$6YE:#-X'RGI"0F]J/&E^;K<XQH./)I_SW"2A>`;VM``/F)<LPMR
M@_O9V.87````__\#`%!+`P04``8`"````"$`YNS2'TD$```+$```&0```'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6R,EUV/FSH0AN\KG?^`N&_`?#M*4FUB
M]IQ*K50=G8]K0IP$+>`(D\WVWW>,@6!`N'NQ&V8?C^?U3#S,YLM'D1OOM.(9
M*[<F6MFF0<N4G;+RLC7__>?U<V0:O$[*4Y*SDF[-GY2;7W9_?-H\6/7&KY36
M!G@H^=:\UO5M;5D\O=(BX2MVHR7\Y\RJ(JGAL;I8_%;1Y-0L*G++L>W`*I*L
M-*6'=?4[/MCYG*64L/1>T+*63BJ:)S7$SZ_9C7?>BO1WW!5)]7:_?4Y9<0,7
MQRS/ZI^-4],HTO772\FJY)B#[@_D)6GGNWF8N"^RM&*<G>L5N+-DH%/-V,(6
M>-IM3ADH$,=N5/2\-5_0.D:!:>TVS0']E]$''WPV^)4]_JRRT[>LI'#:D">1
M@2-C;P+]>A(F6&Q-5K\V&?A1&2=Z3NYY_3=[_$6SR[6&=/MB2<IRV`E^&T4F
M:@"D)Q_-WT=VJJ];T_%7R+,#QS>-(^7U:R:6FD9ZYS4K_I<,:CU)'T[K`U:T
M/A"8EA=;,HXF?I+4R6Y3L8<!10%;\5LB2@RMP6$;>+M]+P5.-!7TB\"W9F@:
M$"4'Z_O.P6ACO</9I"VSGS(^5I%#AX@#$GY)9WCZ'7F-.T*D`6+O!8#T@8`N
M3F$5<78;[*4!G#P#'\4T)0);1<@4<50BGA(#)TK<[FS<PKHUX7<?)L*C*/:2
M\0:,KT9QT!)$2\1+A"($`IE)@+!"<0^"#$9GM9=(U%01#GT;!=%(QY`([0C9
MT8@@0P*%D>=Z:+1-K"*NBQWG>:**$JC_&27"JBI!DY*7#.S4IVV<$BU!M$2\
M1"A"@EDAPJJK+<DL"=$21$O$2X0B!"Z:F8P(JYJ126U))&AJR[4#-T+C*VA(
M>,@+<.BIU4>&A`^UA>U14N,A@9"+(SPH846(:/3/:[:[I815%8*PJT:QE\Q2
M1K0$T1+Q$J$(P;-"A%576I)9$J(EB):(EPA%"((F/Y.2QJSF9%)<+=-6E^]C
M%XVR=E`0Q_:0[8T0HB`!=GTW?-Y+35>,%<1#?N0,RD-5(]KCM,"0[)K#:QCA
M417O6V@I,WJ$Z)%X$5'EB#XZ(T>V5VA-_3T[;8_B90B*<5&.%B%Z+_$BHLH1
MS71&CNRQ$$PO9UIKDI&U%CA!$(VNJ0-2".3[7JA>(40A$'*P'8V;I(K8CH_#
MYPN8J@4.=DZ+,*O?&X0#-9`]DM!B:K0(T7N)%Q%5CFBJ,ZF1O1:.MD_-3*4M
M->3F&WR`(4!3C$2/Q(N(*D>TUADYLN,N5YIDY/M8Y-G^Z#8ZP``EM$C`"4/?
M&94B40B8:N!'K0`QA#U]A'!U#M[HI!`Y8\D9I:#5A1YHGG,C9?<24N%"1^^M
M_6SWXH@7_9%]C]8P9TSM1,R"PF[U"V!"NR47^CVI+EG)C9R>82M[%4+R*CG,
MR8>:W9J)Z<AJ&,Z:CU<8NBE,,/8*X#-C=?<@-NC'^-TO````__\#`%!+`P04
M``8`"````"$`P`DV!FP"``!K!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6R,5-N.VC`0?:_4?[#\OCC)$@B(L`)6M"NU4E7U\FP<)[&([<@VE_W[
MCF,(L%2K?4GB\?&9<V;&F3T=98/VW%BA58[C08015TP70E4Y_OUK_9!A9!U5
M!6VTXCE^Y18_S3]_FAVTV=J:<X>`0=D<U\ZU4T(LJ[FD=J!;KF"GU$92!TM3
M$=L:3HOND&Q($D4C(JE0.#!,S4<X=%D*QI\UVTFN7"`QO*$.]-M:M/;,)ME'
MZ"0UVUW[P+1L@6(C&N%>.U*,))N^5$H;NFG`]S$>4G;F[A9W]%(PHZTNW0#H
M2!!Z[WE")@28YK-"@`-?=F1XF>-%/%T-,9G/NOK\$?Q@K[Z1K?7ABQ'%-Z$X
M%!O:Y!NPT7KKH2^%#\%A<G=ZW37@AT$%+^FN<3_UX2L75>V@VZD_PG0#F>")
MI/`C`,[IL7L?1.'J'#^.!NDX>HR3%*,-MVXM_%F,V,XZ+?\&4'RB"B3)B>01
M9)[V(?3^81*$=`:>J:/SF=$'!$,!J6Q+_8C%4R`\*3^E[[U`19E'+SP\QV.,
M0*6%Z'Z>9-F,[*$X[(19WF/B6\3JC/`U!1V]&+!Q)>:<TT=]3E].+V(9`D!R
M$?$FP3UB%/60FY3@^3\I?11Z<YTAF_0$047`#*\PZ2UB]1[B1@207(GHFC!,
M^YK[W1R#I8O=R<5-$!,PHZXC<99E\?"-EFM`F@Z3\<5.D!*&.\R&Y*;B*]XT
M%C&]4Y`W`>8^VM^I1>*;\B:^A+O6#2SI-^`*M+3BWZFIA+*HX2501H,QS+P)
MMR4LG&Z[B=QH!\/??=;P4^/0]&@`X%)K=U[XV>E_D_-_````__\#`%!+`P04
M``8`"````"$`](P4!V,#``"^"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6R,EM^/VC@0Q]]/NO\A\ON2."&_$%`MA+VKU$JG4]M[-L&`M4D<V6;9
M_O<WCDF(G>UN7X!,/OYZQC/C8?GIM:Z\%RHDX\T*X5F`/-J4_,":TPI]__;T
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M^C=EI[.";,=Z2<DKV`D^O9KI$H#(R6OW?64'=5ZA*)G%:1#A,$;>GDKUQ/1:
MY)47J7C]GX'P3<J(A#<16'$3P6!Z?[%O'.D"*(@BZZ7@5P^*`K:2+=$EAA<@
M>//\MOT0"YQHJ>E'C:]0BCSP4H+U91UF\Z7_`H=3WIC-E(ES&]GVB#XAK5OT
MAKLNMI?L>D+G`7P?`H#01P'T?FJK]K/?8&,,(')WW-Y@.R62P$:**1+:Q&Y*
MC$0LOZ,W_=96*(J1FSA-[#TVAIF/F-@FMA\2Q8?$[CW""@0<&26@JZ`H&`I&
MOUTA.);AW-/4]G9CD*RKIC0,H1UL8#L&'I(H#W!F$\68P$&09;FCL1L3(8Z3
M_%Y?5C30`Z-H^G+25C<M3DUO#`/[#)&Z:?F0*#XD=N\15B")%8B;%OW63DN8
M.>YN#)-T><%I.H^BW$&V%I+-@S@.G8XH+"3-PABGSH6QLY`LSH+L5]F!BV>4
M'3<H_=8-RFT>PYB@0NV-4TI;`\R[J)TB*JS%219BIY1W8P"G$,E=P4J.GOO.
MK3OJ&?W6C</9:6.86W*R((QS'-E-L;61-Y-C(T$.*;[W17<SP]C4SO0;I7$R
M;1TS%\U8J:DXT2VM*NF5_-)`+T1PE(-U&,>/H;Z;'?L&+V`T3.T%C._.[@\+
M8*JVY$2_$G%BC?0J>H2M@ED*_2',`#8/BK?=D-MS!?.T^WF&_TD4ADXP`_C(
MN>H?]&@9_GFM_P<``/__`P!02P,$%``&``@````A`&W%9VC0`P``,`X``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULE)?;CJ,X$(;O1]IW0+YO#@$Z
MZ2C)J#GMCC0CC59[N";$25`#1K;3Z7G[*6-.=B)(YP*"^?S;?Y4QQ>;K1UD8
M[YBRG%1;Y)@V,G"5D4->G;;HWW^2IQ4R&$^K0UJ0"F_1+\S0U]T?7S970M_8
M&6-N@$+%MNC,>;VV+):=<9DRD]2X@CM'0LN4PR4]6:RF.#TTG<K"6MCVLU6F
M>86DPIH^HD&.QSS#$<DN):ZX%*&X2#G,GYWSFG5J9?:(7)G2MTO]E)&R!HE]
M7N3\5R.*C#);?SM5A*;[`GQ_.%Z:==K-Q8U\F6>4,'+D)LA9<J*WGE^L%PN4
M=IM##@Y$V`V*CUOTZJP3QT'6;M,$Z+\<7]GHO\'.Y/HGS0_?\PI#M"%/(@-[
M0MX$^NT@FJ"S==,[:3+PDQH'?$PO!?^;7/_"^>G,(=V^Z)*1`D:"HU'F8@V`
M]?2C.5_S`S]OD?ML^DO;=18^,O:8\207?9&171@GY?\2:J;>BRQ:$3BW(HYO
M>@M_N?J,BMNJP+E3<3\]%:\5>>Y%'O=CR=@T,8U2GNXVE%P-6*C@GM6I6/;.
M&H3;8+81Z<,+6<X$_2KP+5HB`P+'H/5]Y[K+C?4.^<I:)I`,'`?&6:E,V#$B
M:T(XZAJ&3H[:)>Z(KDLR:K#`36\)4C6RU,U<M(J9=]T#V0`BPS1=?9H/,-$M
ML]!F?H?P522Y15QO"(!B#];0R%Z3,<_O$R3N*C9E@VKS11T]?(")[C">K>K$
M#S#)-*,XA04_<MHE4K3"HSS.FZ=%/)`,'/O<:@$/9XEHEHAGB62*4*S"AG3'
MJFC=(E@;O0W7<]68!Y*!@4:,IS+A+:.%(YHEXEDBF2(4L[#/C,PV*]BU^Q4L
M[NJFM>D&DAF;UHA0$JMFBW+@#2U^:E2B69%XEDB48>0HPS"*:=@S==.CQU;<
MU4T_J_,-)#-E6A+2=.MYF(W<9V=%XEDBF2(4SZ+D&EXNW0,L6G6O^CM$,DNQ
MK[WO;-,>]L+&1BCO3\0BFB7B62*9(A2C+W>-BE;=J/:&"233&EV8*[]=1/+D
MQ$_:UA;*#E/.9XEXEDBF",6Y`_7;G1PWS;IW[;43M-"$EW`>B>:1N$7Z*#O+
MF2@GDZ)J`$09,BQR?3>#2OAF$?C:0QFT4#\_=1'8L`JT73]L>TR$+OJT:#PO
M*@I[8>?^N#(NLG"716:)Z0F'N"B8D9%+!:\H!Y[HOK7_8'AUFY*_OP%E?)V>
M\(^4GO**&04^0E?;A``95%;\\H*3NBEA]X1#`=_\/<.7&8:*TC8!/A+"NPLH
M_*S^6V_W&P``__\#`%!+`P04``8`"````"$`$47X#","``"B!```&0```'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6R,5-N.FS`0?:_4?[#\OIA+V&PB8+71
M*NU*K515O3P[QH`5C)'MA-V_[Q@G-+>'O``>GSEGSLR([/E=MFC/M1&JRW$4
MA!CQCJE2='6.?_]:/SQA9"SM2MJJCN?X@QO\7'S^E`U*;TW#N47`T)D<-];V
M2T(,:[BD)E`][^"F4EI2"T==$]-K3LLQ2;8D#L-'(JGHL&=8ZGLX5%4)QE\5
MVTG>64^B>4LMU&\:T9LCFV3WT$FJM[O^@2G9`\5&M,)^C*082;9\JSNEZ:8%
MW^_1C+(C]WBXHI>":65490.@([[0:\\+LB#`5&2E``>N[4CS*L<OT7(UPZ3(
MQO[\$7PP)]_(-&KXHD7Y370<F@UC<@/8*+5UT+?2A2"97&6OQP'\T*CD%=VU
M]J<:OG)1-Q:FG;H4IEI0@B>2PJT`.*?OXWL0I6URG#P&Z3Q,HCC%:,.-70N7
MBQ';&:OD7P^*#E2>)#Z0P/M`$J7!+$[G3W>P$%_1Z.256EID6@T(M@,T34_=
MKD7+&#K(7/#%1<<[J,I`=%\D:921/32#'3"K:\Q_!`'V20(*OB'AHN<2\2*Y
MD+B!F1!G$LE-"1>%5F-TXB*>"$:G*X^9G6#2"7$F`9`3%\C-.@FGAKG;'$.]
M)U*7;CQF,;9S%@?S"QV_9GXX/:WY=ZIKT1G4\@I(PV`.JZ+]DOF#5?W8P(VR
ML#/C9P/_`@X##`,`5TK9X\&M\?1W*?X!``#__P,`4$L#!!0`!@`(````(0!A
MI?4O>`(``#,&```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(R46V_;
M(!3'WR?M.R#>:WR)<U.<JE'5K=(F3=,NSP3C&,48"TB3?OL=('$N=;7FP3''
M?_X_SN'`XOX@&_3"M1&J+7`2Q1CQEJE2M)L"__[U=#?%R%C:EK11+2_P*S?X
M?OGYTV*O]-;4G%L$#JTI<&UM-R?$L)I+:B+5\1:^5$I+:F&H-\1TFM/23Y(-
M2>-X3"05+0X.<_T1#U55@O%'Q7:2MS:8:-Y0"^LWM>C,R4VRC]A)JK>[[HXI
MV8'%6C3"OGI3C"2;/V]:I>FZ@;P/R8BRD[<?O+&7@FEE5&4CL"-AH6]SGI$9
M`:?EHA20@2L[TKPJ\$,R7TTQ62Y\??X(OC<7[\C4:O]%B_*;:#D4&[;);<!:
MJ:V3/I<N!)/)F]E/?@-^:%3RBNX:^U/MOW*QJ2WL=NZF,-4`"9Y("M<"D#D]
M^/^]*&U=X&P<Y9,X2](<HS4W]DFXN1BQG;%*_@VBY&@53-*C"?P?39(T2J=Y
MDH__[T+"BGPFC]32Y4*K/8+N`*;IJ.NU9`[.+H4LADHR]_'!??4:"!N(OBRS
M?+0@+U`4=M2LAC1YKR'`Z6$`N("=("Y:8'CVD&1V"PF:T87F'40VB'!12.QB
M>I:/^S7Z7%=!\P$$2`:R<-'K+-(\N4$$S=07,IW-8OCUBJM"05<,(%ST&I&=
MYX<D@F3L"<DH>9\P'B2XZ#4AS=-^B0$1-`%Q-W*$\R*NDI@,(EST%G&[VT%S
M1,"=]C[#W:3G]CUUE(O>,FZW.VB.>S&(".<^G):.;OAWJC>B-:CA%71J'$V@
MV#J<^C"PJO.'9:TL'&+_6L/ES.$DQ1&(*Z7L:>#NE?ZZ7_X#``#__P,`4$L#
M!!0`!@`(````(0`1KE`/%04``)P1```8````>&PO=V]R:W-H965T<R]S:&5E
M=#(N>&ULC%C;CJLV%'VOU']`O$_PW3!*<C1P-.V16JFJ>GEF"$G0!(B`F9SS
M]]W&3HP-F<Y+@,WR]O*^+..LOWRO3\%[V?55VVQ"O$)A4#9%NZN:PR;\^Z_G
MAS@,^B%O=OFI;<I-^*/LPR_;GW]:7]KNM3^6Y1"`AZ;?A,=A.#]&45\<RSKO
M5^VY;.#-ONWJ?(#'[A#UYZ[,=^.@^A01A$14YU43:@^/W6=\M/M]591?V^*M
M+IM!.^G*4SX`__Y8G?NKM[KXC+LZ[U[?S@]%6Y_!Q4MUJH8?H],PJ(O';X>F
M[?*7$ZS[.V9Y<?4]/LS<UU71M7V['U;@+M)$YVM.HB0"3]OUKH(5J+`'7;G?
MA$_X,2,RC+;K,4#_5.6EG]P'_;&]_-)5N]^JIH1H0YY4!E[:]E5!O^V4"09'
ML]'/8P;^Z()=N<_?3L.?[>77LCH<!T@W5T.*]@0SP6]05ZH&8.GY]_%ZJ7;#
M<1-2L>(244QX&+R4_?!<J;%A4+SU0UO_JT'8N-).B'$"5^,$P^TG!U,S&*ZW
MP2L2<\S%_U.(]'+&,'S-AWR[[MI+`+4%A/MSKBH5/X)GM7Z*(`^%>OFDWHX8
M,/=@?=\2MH[>(:"%@:0+$!>1+2#X#1(!CQL9",:$S)6$L@*K,+`DQ&W\R#/5
M$#:!V!E&1/81PN$`\RQP4-9-"$XL!^EQT)!XC!)-$$<QPRXDFT(8BD7"N/7B
ML("E++!05H]%[$Z1:H@866`6$RXH<2&9"T$XD<(2=5A`92^P4%:/1>).D6J(
M9B$09DS:=>I\3!&,4\0FA>5P$(L<E-7E0)''04,,AR01,:,N(ILBN"0DCFVH
M'`YRD8.R>AQL''5=:HCF0"6#17KMDSD(3B5.K`^'@]IQ;*->>T-9/0YV#9J#
MAF@.$D$Y(.HG8PH1L9")Q+9_'!;)(@ME]5AXL4XUQ+`@,(E7N-D4$,=(,$O2
M88!!XQ<",9H]#EZL4X/1)'"")&7<I^%B.$OB&-OJ=IFXVGE-"=9Z-]4*:J.I
M<V(PIC`0%139M.L&<2"$<\;O:87:0Y8BHB7/X>'KYCAT$VH>"660%^%%+7,P
M,6@%E=1&S8W(LGABK7OP>U-/OP13@P%MNF&\H&4?0EP>2N+FS8*U\CD1L2LQ
MF9FJ(R,$Y'$6D"D$NHG'W%:[RV-90.$#8]8OML8,CZE`2L%((CR!RXP;G3S.
M49+@>SVS+*)XKJ+,FR0U&-,S.!84\UE`ID(JH5*EM&[<@"PK*9Y+J;]WI@;#
MQIW-NC?-HAWX+]VYEQ44SR64^1)J,#H(L:2$>8V4.0@)34)L];HLEA44SR74
MWZY2@S&I()(*AF:!<&24$APG=XB091T=S:Z.^GM6:C#0!K=>9786G9&/,4Y(
MR+*.CF;WN\\/>VHP4R8S(EJ.ER$N#U='QV]AR:'>QA4]D;F>3O8HW;4&HU,D
M*(>N]:.7>1C8A9))L;N,EO64:#V=ZACS=<Q@3+%(ABCSOY`R%R.`!Y_TO\M$
M:=Y<48DR>]7B*YG!F.9!":5(^@KB8&0"^Q"+[8;H,EG65'4$\IAPKSE2@]%,
M'N"D'6,/DKD0+(6XM]>194T=S6Y$N%V)J9*I7L90`(3,=EWC1W.5"4GP]/O5
MC<BRJ,*Q>1817]@,1A]:[NS_#N;._J_/U_I@><X/Y>]Y=ZB:/CB5>Y`(M((V
M"CI]NM8/0WL>SY4O[0"'Y?'V"/^"E'#H1"L`[]MVN#ZH\_OM?Y7M?P```/__
M`P!02P,$%``&``@````A`!L0DR->`@``YP4``!@```!X;"]W;W)K<VAE971S
M+W-H965T,RYX;6R,5-N.VR`0?:_4?T"\K[&3V+DHSFJ35=J56JFJ>GDF&,<H
MQEA`DMV_[P"YK)-H&S\8&,Z<.3,,3!]?98UV7!NAFAPG48P1;Y@J1+/.\>]?
MRX<11L;2IJ"U:GB.W[C!C[//GZ9[I3>FXMPB8&A,CBMKVPDAAE5<4A.IEC>P
M4RHMJ86E7A/3:DX+[R1KTHOCC$@J&AP8)OH>#E66@O%GQ;:2-S:0:%Y3"_I-
M)5IS9)/L'CI)]6;;/C`E6Z!8B5K8-T^*D623EW6C-%W5D/=K,J#LR.T75_12
M,*V,*FT$="0(O<YY3,8$F&;30D`&KNQ(\S+'3\EDD6(RF_KZ_!%\;][-D:G4
M_HL6Q3?1<"@V'),[@)52&P=]*9P)G,F5]](?P`^-"E[2;6U_JOU7+M:5A=/V
M\9BJ(1+\D12N!2!S^NK'O2ALE>-^%J7#N)_T4HQ6W-BE<+X8L:VQ2OX-H,1%
M/Y'T#B0P'D@2F-[IW#\XPWARCGJC-$FS_TL@(1U?AF=JZ6RJU1Y!:X%@TU+7
MJ,D$F%W^@Q2.@;G-)[?K,6`V8-W-TOZ4[*"@[`"97T-Z7<3B!B(]00CH.(F!
M8KP3<Q3AK#F&_UG$X.3O=<X#9.05QMV]Q>V]3EQ(_$9<9[V(>]8=X@9(YN,F
M\>&[B/\QIJ-C<%.'LU[HR+HQY@%RT#',LKB?#;N011<R'J5I?#[*C@KHYQO5
M<-8+%1<AY@'RH8HNY*:*<%=#D[9TS;]3O1:-034OH0'B:`@<.MS4L+"J]3VZ
M4A8NGI]6\*!R:.`X`G"IE#TNW%MP>J)G_P```/__`P!02P,$%``&``@````A
M`.+`ETS`.0``@,4``!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=ZVY<UY7G
MOP\P[W!`.!`-D#0IR;*2V&Q0%.6PHPM#4NGI:30:Q:I#LN*ZI4Z5)!K](1C,
M&\Q\&6`:,/KS/(7G3?PD\_NOM?<^UR)+%W=G&FYT$JK..?NR[K>]]M=_\VX\
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MXA^;P]YK_A`V<9I?#?4)6WO9&^?-M^X=OG[QY.CT^<'+I]G)[PY.7QP<'KT^
M/SX\>'Z6';\\;+X>!CT$4O/>"`@-\G?9[_.;YGOW=G=W]W8??W7_UZW]IRV>
MW\S:R]G;W?Y#<[#TQ4D^'TZ%GD'VM+=H?7P``@>&Q&>CWE5SE'N7O5'1^B:-
M_6Q8]-G1W^>]>?8,8BA:WW<AL_EY6&'W`'^XWQSS<#F?`\JL.OFJW=W;WMZ[
MO_U@KSE&0,FSX2B?9X>`Y6HZ;^/CH-_/>8''`V;CKQ7#'$['X^DD.UM,^]]M
M96?7O7E>9*^6"V-0.+;YV>$4$I@4C,I?Q70T'-@43WJCWJ2?,P#\6&2;KR>]
MY6#(Y)_S]]G3[+//FP,]S?OPS)ZQQ8/FPPBG7E$PW&]:CWO%M3%N7W_D?UX.
MW_1&P+6%PQ>]^7?YHG<QRK,B[R_GP\4P;[T$J"0?BFR>]W-&XNVM;)(OLNEE
MUAN-IF^UL]97QY,WS#B==PSX:G$-:IC.<.U[:&[A?+J`^FY_YV2.W)LCF"2C
MM,N9B-W6UASN>()`O1IJHSY?YUN^L-L6U/TLHF,T[%T,1P;$%DX2%&>]&X&P
MN<(Z4"HC-5^L0^:6%T_S-]/1&V@T&PTGN;#5G^<077-`GQE=<[6]R.=CWDZ[
M:+[J<]_R@MAEN!`:"B=`M`(K0+]UT,&]'W_X\8?F%,9BU]/1``7Y?__UI__V
M?W[Z[_]JR%W<M&`:F+,0<_J[?_F7R32;(;(@^&7^VVQO=W<+T:O_9(4S;V^Y
MN(8LO\\'//YJZ]&CW:T'C[ZRU?+/7S_^<NO+W0?QY6%1+.%E$=BT9'IH2.!$
MK>5)K=D[,&T^OH"X(^-NP33%+.\OAF_R44L*G<)[H`;B[<TG@*G%1`YO6W@W
M2)K0>SG%DD`734?@_"H;3L!H7K09WP<6SRQ:JVHAV;;6_>X'B+L31"BF0KX8
MHE]6BK\J:K=*C#;W6W^MA>&U7G<<K_5JA0;:[W<*_K,%\M_Y`8IYA;SJ+;"?
MG#M8/5;:-?H"\L!XZ$_'>;;Y?%H4@LN=*N+!VD;7@^9JPUQI=;<84B^1]/,<
M8;YL"_G#*;3EY/$.$[3(.W01KXA99O/I8-GG;91BRT`\RYU>Q6=CTTE0;W/-
MIWD!G_1=LPU8T6AJ`K_YWK?Y!"B/;%F]P7@X,7M/'-A\\V`\G2^&WQM&FL^<
M"_JM#3;?"R@U9G/\C82_YFLH(.-$6%)OK7R<.QS;SRMC9Q<YAG@>ALH6O7=M
MS`0$\RS;#&-^SG>3_+*M`(1A7U:VV;EXO:`'66^1%<N+8C@8]N:HW<5B/KQ8
MNOVPF&:3-85/:[[62&Q65E=5\#4A<A1$9EAR!F?Y^Q\RV'9VT2N&_6QS.,ED
MCJ7!6GC<S@;#T5)6X]WO_ET^O+KFU>T>WE[O"AO+-=`M4J2Z$'_[CA6L>.FP
M)EEN1>X*$9Y$@ZFZ0QF2S[#UUK)=[>U+>_MR/AUG,M-@,G@$3VWXIMM`*JFB
MB>J#P9^613`J(#/,4`@-F]V,T+`WD1]4:@8OHN;-<`"*+F[6F_IICACN#TT.
MN-BH"(9L!4L^S2]S+-B!^&_5.V="^#:TQ6O0M$1DI[`Y>H<%7=A(@4<S[!\D
MUB`S`.;O\GE_6)@19]8.^S(UT@25]+]0%17_JH65[[W!/#`?40S>EB/"2O\:
MVQFW!^9P^]=@5+$"L][EI6P<$-R%ZN0MY/::M,'%LL#P8<M`Y6(X,:"TS+MD
M,I>.1W._T<MH&3'IVV!NVY*G-<>CLH'FL'5CO+)I'Z';"S!0"?AWT5]SMB:[
M#'&=BKO8Y6"`*6^6!*3/C+!8TQ-JSG.R1'M"B\;1KF;O</U.YM-^G@\*I\("
M)U+(6^M3V]2L-X2"IW/X'E.S\`4WEU7;"81;=]2:;R<H+\54D*1#RTBXE"[-
MKYH@OH3FD"%W2Z2+Z7P^?<N+`&URAR-UM"Z7G@5`5G2IR_%LM19M[N@TGP5T
M"B55A=GR(A+(JH2Y&>#W>=8%B^9L&F*0XS]"/@*Z"1E9:_;'+1$&`WS7B[(E
M+HC%3>3XF(%HP:SFQ+=^3WAK]9>(N&U;786=>+]KMRW)8Q`SJ:?-+B=&Q[TJ
MQY5T6N">K,5^=RE:;>7(/+)UC'^S3UO0"G:3'.+FLQ""VLJ>5*%^XB%$D'%K
MP.FVC[>B77/7(-BD3D";S&5_?2[P6FPMN+?W(@3^X107EL#C_&UO/F@%=U?I
MU;B4YMZKG!DTIRF$>3ZR\)Q4^`KC^$-XM<6!=69U7F^NL>N=5?M)Z%!P%+(I
ML7AKJ+W[LSB)./+6SU_-KWJ3X"X9^)Y@-)LR.2'(@%/?:=M4O]JJ1$71739(
M]5OMY9F+9ARXB@FZ.L[_ZO3;@Y?'__7@_/C5RTQ1^R<'9\=GV:MGV<GIT=G1
MRW-[T@3VX5)A&F*R@^P$&VW<Z^=+"T@4<L-W;&%#.:O1VR%\E6UB/OSXPX9L
MZ][D9B-#KVV4`VU`S'A(F<(]P]X(93RKC6P&(-^A#XFFH[O8/P-65>,6,C:Y
MM;8&R769?KU1A#L0NB![(?,6H[7HSX=F"4H&F7^]DYTS:%CCO8+?A^CK&VS+
M^15"W'4WZ\1_O)X6LZ'"K+T^'@VBG-\$D:L>"9(I^,R)(TVO;FQ(Y/Z8Z"$Q
MF[1#P43?8%0H!8,D(:@FH]O8RB)>;)K@L)(C<IG"@A4@DTV,P7L-S0D(8;TP
MX6@("+`+>Q/^@2,VR</';CSZJ,Q1C(D];X5M,;:,$^R4Z1Q+>B<KT2*D`"P6
MKA6XK81W(*6#[IF^@6:)O43H^8J&A&6F_/KG)7`'D<#<@"-+9L8';(B=`RE4
M`C@HT!!C8*NGT^E\=`.D@'2`UD0&U,XM!(A)EEU@6+(>8#@!P&$UMU`#ZYFE
M*&T-Y=IOA<+&O7?#\?![;5=P+NF)I2[8!Y2E[8G68[#=R*O84I#S+7$9_2\N
M$-LUF/%B7-Z,Z,DE*8XI0\^GRZMKD@@C_(`J23N<JF3-;)/\;1H$1`\L25+#
MVD]_^5]I'B>R<6^RO(3*EG*YP/_B>CB'HGH$<'(6^_9ZJ,@0U`CBYD6>0SYZ
M*9&6C1@1B@&_A(E(R+"72S"(,"(;5@?DV^G\.Z""7T3H-GL[%(;8_4#A)(4]
M),`T/]$F*'F:X=RQ.)MS`!FS#,],]-[TAB-'EI%295'&GX%OZQ0R)PFK9.]O
MBAFRZ9L-L4X^?Y-O[!^[V)C."&RQ`L`):(@NR`*&']AQCX2-B2@A;!G#B&+%
MD)KBKS(U%0PBZ*"HQ2HKR\RNB6#`C@"5=;!G4"#I;5$3^7`$,`M1DT-)7_IN
MV(7^_X3_*KY73)Z\\^[&%_M?]Q$L\VQ^=?'-QK-G!.?Y/_T\?T;PVM\[GI`D
M&B[TZQ<V`#GI$%W_\8<87E]K%I8S!H)[=T[0#>\L9.ILFRFAUPDUB03B$:/E
M`"2(<\K`Q5:$DG`"SJ83:&JB?/T(<2G6TX/:!Q.V6Q0FNZ?996\HP6)D`(@$
MXF&9CH?Q%I)]D"A0RX>DVP^8OQA>38:7B#Z^,.$2Z,(H9!F%F)+AA5PGA:5+
M3$/"Q$Y-:LK@3R3#:\XG'T99Y02)E!A>)#L?&$<:HVE_\_QJ.3*3PFP,_726
MDI0F?@F;N)&.^A@3QF=I6Y+"]NK1(2(,A$Q)2&5]O&-2+368Z>'E=+J8(`C%
MU>)T,7`-[E6`5_BC8\FO=\YV,C)=BCV#*7:4SZ1RM#5@+?2BBW$Z9R@J@R`J
M]<-@6%Q/ER.DH&#4,R<8]/QI.3$<ECSX?H0K,"C&8^1K@TZ7\^Q@,D$)9ABG
M4)>8'I-\3%IM^_>B-X/TC4H$<,78ZUK\^/\%USN)(W27(V2^&-9CF.*1N/&?
M8[=HTMRML&+X;JT)(/:/$F\$VE6X\_,A4&E21':M_.<.Q?"Q>Y(=`#TG5A["
MD$/L#(Q`67N@4R(B8A?=#2LIS(L1Z_$J/4:?#1GGT@MAC,JA>+/@ES)#E"6@
M_":8=NPHU4/Q]PKE';-*U;P?+&=Y/P5@/\_>8FY)3,\)]V+53D<R/E@P=K"8
ML_+F+V3X7M;#OP<9HF'6XN'W%(E47H6,[J?BH_T.*E[LGV*!8#H<E!KLVR6V
M.G:S[RK5_W5;3L>3[``Z'EG9GYNFI7-?&10_GV+'^:#(GDSY'_.SLXUG!V=/
MS*?V"@S,6VF8J[``>,%X&"8@OT0A4J;WJTLM1WT]4Q&6E->&ZS'IXJ>PM16G
MJ+[C52G<917HF1L#)OKYYVR*?VG_P-28498IXTG33D)QY(8K#'DV:8G(%SP%
MY;PE3H(E80:-/I7%D190T2Z21BD[,IQ3AHG=H0HK?!P,<`W%I[8@#9/>K0R!
MC2YWP0P\K'HYWU=D-XOKX:5,1WQN^9P(L[=#K$2SR'IX$7_BEYBB46S&).#B
M!B>E,K9932E$$T2H;SYM_((,W9@%)Y==L/];'#@9LU[2]B46ZL!#<?)8S9O`
M%XNU,NY9[`3N270FY^=%[Z9*4,)ZK-+Y%#2R)2*Q:@=/>AR"(T4W`+\\P$,R
MD>QM7@2$8[8*M<&N$T*$H!H9L#UPBI$_Q1K_7FK'BRD<GVP:TU64/9W"`:!`
M?MY0^)86,^,\)AJG^.AA>M$_&.J-95LZ3N?YI;QOIS9(BS2]I5V!+?,'!SDB
M-:@[6]J%Z[K%B%6X4L'E;:^G@\('E!.0QH/[+J57\0%G`(.<D9*94TS?:T5S
M6!XP:$`*.MK2)@93<6,QQ5@/\77,S3\M!U?R9SUZH&08=<W,,P;WK':NA(.<
M4*$D"((`U0AG]\Y]*>7"Q4F2-$[XL,D(YSH;AQ(54_KO\&2UHJ[QXN>6"C5[
M_]N#@Q/'(T[&&F3_U4Y&X8+<@PKQRU)!`.&G8'YT+#;$PGJS&<&Q`2LC.A<9
MA:$`=`ZD1850#YM248N\#0_MSUP4\*$]K7^;G"W$C#E;8"N*`"?EX&$E\L6A
M<??39:J_1"C"(DFV1!E9T4>4M)3%!/Z5-,5%8V$F#5/TB6`;[%7EG`AF2872
MSRXW)A$D`2:XW6`6>=2)#?:<72S-J!C<-<711(&<]-_FCG6#O*TAS0,)H5*_
M"CJPE#85'76"YZ\:QE:JZ#6L`M<?11IM:$9)+#!`S"3N',Y<.PS#PGA=.DYA
M2$/6>[F96Y784#9&=O#O[]`?1*CE+$M4@,V``:'%@2Q0FF!Q_O,'(PL%2&L%
MU;B3G2TANW*PX#LZ;"T2R!P1L9`&6;(Y118>H$)L&9%&T1DE4:1R(5D3*U0W
M]F('T8/C$I)7`+GJ6R<AL4,$GWU(]DBPU)98@X?/5%2$C1=J,(OB?$O0-#<2
MT3A:#F&VT4W(>`28Y&\46^E7U?16AK13X;-"Y7(J*(%&?8=@!-_A0WA$D&QZ
M)8:#0B2ZR3<1](0-</('0XHFYJZ+(&@V'7>:.!'IZ&'']R$M*1<GS"AS`J^B
M[DT@5H-'<<H4'_A-MKE'OD,".E6`F^Y0+N`JO^CU"9T:S/K].9MRIWG.`XEQ
M/8`:E*\`4_A2H1YR\_[GCO/ZF-,+N4&%V:+(,(+M9=FZDKLJ,[]I,6^PZ<#=
M6>[*I,F:YY!7%%!NX;`V6`[S#IEBWY`;6Y7."1L@E/,BQ5]-+/6%)=.YG,-1
MPLR1$V=*1"826G#F0QP2![/J2#$6QUJ@+*+STA48:<&P"(-8,-NK4,Q*&$T]
MO<'B->IKQ#$\?*9X;N&$M[!Z^F1Z./:5&9)KW"SDDXSY\8=D:[1`^Z*$?QF1
M:T+WV*I83(MOD5R^6!C:0X*[_.R6RM,7!Z>_/SH_>/+\*#L[.GQ]>GQ^?'16
MG^863[N"7*\`,-Q62&>@-97''@SS<WA>"C6D36!02-Q)5-)']03"=\>I"8N0
MPOC"E,GH<V6XEQB\$PNLB>8O$/W@PRT'Y2E(&\F_4GU\ZST#UT5O\MWV%78S
MQ$`>:8O8.")4QQADU"-[B?T/P@R;&W\\??IRXW,$B6MHDPLBKE`HXBY8I,/^
M"`(B.FQF5=>&E/?!OA)`YKV!"=,R_`H?)BFVC8+:5OZM`DVE,F>X;/H,P(DJ
M%8%FMV8^Z+^06BP5D_?RXYWD<P8KLI=X7Z=30*)0_V5O+-KVI$,UC?#O%`AH
M9R\<'Q6*K!"C&+3?$09JHP*#L8T>^[Q'4D&JG-0`V0-!8BD;""]F.8$X22GS
M](JPN$MDQ9\`8M72XX&MPAQ>(<JR"&@#_F!UPJFA=H7B0895BM\;3J3M+A6_
M^WA=48CNV,)YA;W)ILN2(517;A/'8ZYB<>4``8#9QMB%WX<W*WHWXW-,C2D$
M:[EW&VELO.N%^Q@44*T9W^Z#\]X\\TK`Y/(&EX0B`3C#C7F">4%$\U.EV%!S
MX<2$*9KX$3]?X4SYCJZI(!:XP_K-V"=G8'DE5OWG);)%NM3\19"A-`XFO-.4
M*UV\0!2)C)'NU6P^U[ZSO;@@D]@LG74(IE3QMA>`1L9)-3DTG,PX&,.I!1OE
M07V4M@-_@$4V9GDI$[H>SBH3:F'+2>6'L(*(Q@#7*C%`M9:C)K)^,9^2,1EI
ML>@#E0:HA.("(%)Z,'W;,N\C<+;K>F>Q_X<:Z.4VEX"&HQ;SI3NP+:2TM*E/
M<3];8XJ"E-R(;,NM$_RV01;UM;'0%:-$HC&&D0!!<06"^JV1PWA*7GL;#0F)
M#4R<A.S<6[-+`Q[T904[S.>/J_:DBZ*!!B)W7O]B!7P>M.%S5DMO&AD:GO-R
M;9BRK-EFJ-),8PY9$?L5B8()7)*E*:C50GJ0+^2ZZQ17LNRTO0`:#+M4BXY[
MJJ*%;9Q!50?!M*Y4+=R#F29JK!1]F^L2@T'WTONVHV#5F9@/D1X6$-1UI%E`
M'VFK*L\Z5#-I7B4T$/!B>3>71+X>C(@6@_O<0;@T*H>E"8)O5A?$QF-M$/G"
M'O@$(Y,=S%Y6,B2O#'T4@CW,@+MED,6H*!%D?D?<<[EV8V^=_B'%CD7MG#.Z
M,:7+7ED7M3W$O%3C]2?B9CJ7@%2:=\PL#HJ0K$Y@9(PTLJA&0KK37/"MA2%S
M(A5UZO4)W+A@)QNU1$A@>R/.G$$@"PZD`RI@:<2L;X.$;TL1O-PJQ3M5`$`E
MNBR%NT5H&/YE#/&QDOE2%0L";<G)ES$A!X'C!52`&48O*-C6DGK%=T&M,,Y\
M^ET^_V*`R<#BM"(G;A6^FN(!/#?#?#0P5JD8,69K1&E35HD1*NDS*P67_6LQ
MEBJ/I/`8IJJ7T:+*V8M'`EM;G'=NG!(KDVIPU,$0HJE]Z`3BQ3-[0I"`N%>T
M/\$C<40%)9+M6K>)4_F9R4#Q0L*JE2,E5M:C3\K,H`FT>*B.):+#88<`7EO,
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MK.8QVP?R;9OC>C:]CN!.U#8_)`9OYZWC8=L3Y-H9D:O6RM.+Z8U;XA5'!Z<O
MCU]^>\:HK\[./L].CDZS,WJ('-6GOSUFT:1FN6-VVLWUQ@2S$A`C*B6E,>V1
M=VAO_AWM7RS]OD+Y2A/Z2<4\[A:)&LY(2J.)FWUEXMHFXWYXF=XO)2RJ;?Q8
M:2?T_AS8^1EJ!X+<:TIF%3+5BHL4>%&_A#H[+/9?1IIN"=#-1P]^O;6[][CY
M1>M0[-.2$5J#K'$,UR0,YONPWYSIJ7A(ZKC,BKGG7TK.YB?KSA?8L_GYV?#=
M.F!;+44^44BMHP#WWRERYA#ZM$+JT[-!=YS*&H!8%8BTK<YE93T=:?*06SR+
MA'T;@[0_"]/O/7Z\]3BVWKH#D'^M@NO++Q]NW?_JUVL1P\?NH9`M8/8P44KK
M1.#]G_@Q-7/AS($,Z,IA?G.X@E5M$5(5@@_D&4O5*MZ)DV7N![9C5,Y')V<J
M'.BAONVU(&>2N:\LD+V+$"KM[(H)?"IGIZ,W1\AZ9:>I(&#U(:K3HS\>O7S=
M3*XL]D]"DJY[CM4BZ)S]AJB!I:I4O)AR3]@S=EP`Q\SC#:7)\XM9\DM)XZ<2
M3_N=9DF@Z'8=QT&?9DP#W)JF/GXUSDF5C:?OMD]ZK4.UOZ=,EQ-T)'R;G_VQ
MA[M-WKKY^V%O--#AE^;OKY`1K1_=P:ER3^.S;J6#!:`ZC27Y'!,_+]D6-?OU
M6(<=R5<1U5Q=2O`N")&_51>-=#;+=90=3:L!P5R/N#_E/?T\%$,QQF$Z64D4
MM;+R;+"T$A@4[\.=[-4D>]5?3'42\/YC[W''V=#TJ2H/$:Y:/$/B./:NL"8M
M66HQ);RQ"6828F;>F]G)33(0&_XK-:-\P_[#JFRUA&''`D)M'SLDRHFXFMA5
MA-($OD1UFHW0F'>VP`",ZPTM^>K`Y"0[JV1>N6M$^C1*$'@NY0@WL@:K>)!E
M7PX;RR(%ERH$?,2T#84W:HNO;$O/".\P>^/D)C``AV70L5878$AXEE]0GD$8
M,F#AX?M@X8!ZOQ%9Y'"$ELXY6T0E^SN@(CYR9`122Z=P(B2<\E0&J(&(P:K\
MA8?XJ81B!2<[20H=Q-3591;IKAZ:=F@I'"9@Q'>D>E]8RRB#K@8<]3@F<\V(
M3A'$`ID2;!`7\729,&<G(/UCKS5MY;&Z^>YXDKTDK6\=X)CQ?IU&ZC1-Z$71
M9Z/I1&^>G3VA$E*&XO,>W2?DV]L)Q^?/#T7C_@RX:C=0/#"$Z4*9G?&`?N$Y
M@>K0_@_*3-)-YU<ML(^,4!XBZN"TA!H!%,N0]HP3&?=IO-1$+[-V6\1<E<JI
MU'N%)2$$*G,[!]10QPN14?SPE*+4!.)43V`,.5QHC/9\B37\_;A"&"T$P)/E
MU5I`FG&6:B,!-?95X^RTF8&"4,?T<=$ZK_'9WL[CC,P<1V$15>#EL_L[Y%/#
M#]&HP6.D_H/X.6!'ZC!LHDK^>%!O%4B(4>,\V+F?QK$?OMS933^D@5=YC+=-
MT"+I?=-`F(M=YN1J4P^:%\MT;HX]Z5FDSAH#2-<DHBM9CT-_DMPA2@\(^ETG
MX*,2->N;O*M-4Y-N!C[2*79HP.K4ZAKD=[WY!=+A6S3QL-?J`7`XW=G*GB\X
MBK#A;[@<R]_!.X/P$50)&CFBJN(SJ^JEY$!"PY&Y<N.NP>^P<M[S0(B%W-8:
MF&5]5!"^@C*3!580XOV;)+OC<6B19B?FXD%,J%]8"9I`/"M%7U:`U\>-@$80
M6LE0#P[6R;P@O50)&M%;U`18M9AEQF0<AD?^41;TV>[.H\1(+(;>==L4T"\I
M#U=UU7*V3>,MJI5H'R41C1I%&`$\%5@;@PC3PK&\F70J.!6\:&&5>I=@^^C]
MRR%%I=0)CGC!),"#R(F01'+K5O/;4S>C;*@EV1\_E^8CW<)NY)ZM`I`Y.5AH
M5EX)LAJSJ/HQ/7*%5$=&1+)+R_2JCA"")Z2QX;(T]QX(R\J<`2]*<2QIPC*T
M@SA4AKLME,[D&@K^HA\.\7\G;8Y(4#P;-E,5#D/%<E(;P54*6)=X+#W)]"9N
MNA]RF0P8ER:W=MX@*8\HL5W=!)R6;K[VHIX,\MJA[QH=GE=$FUJK*UDI919V
MH4;`:O;A]J7&Z39Q`@OH32_!5^U\:9A2=J[^H,"AA'2-Q%%X`'YHIS?<`%5Z
ML,I+*")*>(371,U+(%W#P#WL1#NL808)Z/&C';+`.J`O6#O$TM@P9A4@!O3$
M?8SB3!/``<.JLXJ5N++6<I"02Q=FTX^D,U7)[^-+N%8@D4A+`R]GLH'7$H/O
M*5^KTF*M\=G`1XE9"+'<?\):M(8-S2O0\C,"X6%I>_QU`,%%FHBQY\?4(R\9
M;7ZRXM)_XTCX?HV]XT&7Q$O:K%KLN)G&'\A&A"XTD2A&VJJ8JJ$E#TQ-BZ'D
MV9<RI,ZN"!&DJGJ8M"7)?'I#.R/5"2,S+OWHLS-_E.)!!ON1"1,KE7D2J23E
MMN!0#*LWB?XTG2>Y);%Z_)+PY/FKTU;Y=ZUJ*^MHV&(U&J9FM'[!J&PC8QIC
M1AZ<?+C.&0VY+",>PY,XT1X;)20&;%0!)REG)6`K8V+6JT60C4FABL`>K5^3
MB+&@6J=P#-):D]YJS*_Z:'Z-%=R:SP4S>=_Z(Q7YHA'C`1'5-J1&.?,ZDAF1
M(BU4+>TC5#)K!69^['`)WD=ET*2J%76>QK$E$$I1FY4#&?I"5"!JWHQZ)6O[
MGH%W\-AOE1(Y+Y7R#6,';0\G6VX1;1-'CX+>*:8\AG5>@:*B34.UI,"&"]5@
MK$I%64Y/0ES9V2B4-`^H>P;.N759I4.(G2<A&B0DL_SM,>:)8BAI%/Q/K%>L
M$_WLM.Z'>CPJX;\@;*QN#'*(6"Q'@%5H38+2^CL!/9?YHW9#H0F!:)%-T51J
M?J,I5&4DS-DA`!4'B]MQJ&6+8ME8ARV(%"Y=0#DAT$0P22:5U^OY[MFDK&JU
MDP$>(?QFO<-D5-DL(8<0H;O:T#P,@<H*6,*FA/G$U7)D:A4_'UXX\!\HO=@N
M]E\+8&#SH\R&:VJ;J>$QFL*QI;LFDH$S:,/@4*L83*0'`CUB%@S>3N_]H0G(
MX//&#E^5<.6CG2PX(VV/5V8Z)*^49^Q\Q=QR0HQBGW'6V49_.E]><1!<99K)
MZ]_<>/;T`(=;P:=PE#65XR6BC)J^M;EP1-B7S0)@93>)>N8JV>G`RB8(>(J%
MF%%EDCH.@RJMR!N;F>"J(.L^!2_XH2`N3D+@F5RQL(`^2T!'E^#AC8:7_.:^
M3EKZX]W=,2S/V2["'FJ/;6>G&4>.F=PY3.E$+4EIKF;4@U^X\:^R<5A=_<N.
MJ]AP_?*\M0ICU5Z[KKI<2>G0(U)>)BXN:U1^^LE5FY7@HG!UTDG?1R)#R=&<
MHA[Q>+#S4"9B"E(F&ON$(IR`Y9=QDK7&7UOB8167;OF(B-LQ&_2,06&A8D19
M,$Y)']"7QVT5/%\3>#J%;>I:,DGOU[$3ZJ:7F%=E#*J&`H=W9P;^V$YITS;,
M<OO)WJ[TO!8V8N0K2BY/?E3M=PF0,J'H68CZ,C$`4GPA1$GT4:H=":(FG`*:
M05AE9U/T.#&R@9I7&JE49A)YE1$,C5@:,L'*JQ8[URU,$@G^11S=`:^XV)(>
MF`PET"OSA57IVW%S)RRV7)95[!/[G127!%;YU*3CO/>6Q1%Y,8&)F*R;RFO;
M,ZR3&=<BRO>,#OQBMT``'V.W*`,8#?AZ_ZM`(RFN]YL2@4DSTJ>H2B*.X6C?
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MLF9*`C3978=9M?!.J2:<4ZNO3%Z)7O=LBPSK4(D,C"%]=VW:;DLYX<]3?/W@
MX>[6PP>/UD+81\K4U)0?6;;6?.^I]!Y]]6CKRR_#[9MWT-XGV@JXJR+:K)BZ
MC?O1&WV?/@)D_5,*<:V)/Q8,TCMK3?2>J*Q6&:PU_D=NI&G)ISE+E=Y=7W.*
MP\V)0T6U36]GWZHO1A&`$E7^:@58S9TVT[`A$!!D,J$V;SM8<Z'20C^AH-W[
MZDO=3KG6T!\)]R@2X".\B`A)$YH6QAC/1M.;'$]4A#:(FF@'4Z/Q<@`.>C%/
MWY2=C_M$/2ZW.=`)9A#*+!I.7:HW-5D:4I-SZVG-(O3$CB?R-]:%CAO?,E5:
M$)5&E:'7`MQ[,H12I0K$K#7VQR+E;J"<V;$!1-\LWA]F?:6X;E$1X1FXQ*>3
MW0;F+&Z=VG4$I!A"ZU<AEB.D,@8BU*H7[2YH,`5<J6@0B6A%Y?65H8-'*:%*
M;MZO5'8><7Z-N.15=I[WKR>Z7X*T@@,Z,O"*WKFXV<FD:G`K1I.?B:VK`R1T
MI5I*H;90[R/CPLI/J%>QDX;FN>.IWK50"H(.C\ZMQXZ`#>BI0MF*PZ9EF/VL
MM$3&VP;]LM.F\8-)'XL`B/,FW%%-KR<R$CU"ALKW6[Y"WX:F).`E.-%EJ=0A
M#<Y`?<BW[&0G9B0R7!5*E0U-WZI)P>,O?R4+EK%5&0%3:CT7X7KJP)0BI[G*
ME]7T7[CR3PFE_A&\YU1.47I#N965_(5*30USGD]TJ1OGOA)R;W"DRBM-#J=S
M0KIFOYK!#*W5PB:.'CLR((\PW$SG8*S9S)ZM!"0>9>Y1=E?&;5J?[E3QJB":
MW=\`,&H$PC1V7Y1(.XU,)5\9->,-.\8*^5"FAL=JP27*+T$4S\@O>3MZD1>&
M.3&Y("F='BCK4-F%V&;$];?\&>#=O7;`'<A5*ZH@DJFJ*!;D@]HRR`E9<\M0
M\J(MK<@>[_XJ%$[5V3M>;^-M$>(PT+4B[Q[8"4P/%3BUFR30L%J5NK^I]9B_
M2A&509<#V:(:JYTQ60U1:I4JLK(VLZJ,B;4_,=B=N'__)3Z--0P[B$5=:\F'
M5_28U0G#^X_,O45$5&!F)`W&61-U9NB96!Q[J)C8(GNNX\EIOFSSI[_\[_I/
M/_WE7VC.+88Y6T[.YTM"_T]HSN49UEIJ7=`;)=?M8'FE=_$U]KC:Z)+O#T)5
MHN`G?0?X!JWY!:Z-M!ZR(3:UR2Q2_T,2N-"H^K?IR+I5L8<NER@!=FAI$5(/
M$P!9OY+ZH:V8`$*/_W!9=N6".XK?R.1JYOK6E>\SR,8>[H9Z2XI("/IY7ZM#
M0VR,?6Z3&G6$?.6P:HP=.,W%FOCX"J1?`1/M3[<ED,$*76X]X/#9_233?4#B
M.]9\%+ATWG<N)1D^W4O5M*H7@QC\&K(R>8[;&\/7E6J&601Y0DAJ*")@"V+M
M5VKDI^B_7HO),+Y*D^OWA(65>]UB#Z!3+Q<(T$)WX001$B/+\!ZDS(]%FZ?.
M^2[RH_>."X,UT`&L4AN;Y\=/7IUFLQ&T9L`"NY"K?UVPX1[I;<:%CO@*4O+W
MK>7*<FPTHM6&44*WFR:ZZVOR4246T=R_$FSO[Z"P3%=$(:E\^"4JAI=V=^ZC
MS0CW>Q4DJT``DTOA9)E#:CFAT(&B?Q2EW@?;`$BCA:V(!;7&ZGL:6[P1+PX-
M]=I*.3PI+X,L>:4^N'U*OXL1%,Q%(-9B#4&>JMWN;NC8"&BO,(;*`L$Z`FM4
M!T!"<QN!,I()\7/ZB1--1Q.AP^1!*0"KIC%P+5TPJ,28-%K&Q.R`V!I:.'IR
M?*XA$R"/_-KJ[%2ZW5!/0W;!R`.I_CN8"T4GDA,0%5".98:H*B.6NAAV_"!^
M_%5]9IV60&\O%M*C975R&YJ'%I,&8^L,::IV6%XKHTZ::=,ML=;BFFXOM#;-
MQ&HMU(*1PE8U=O8UFHD#99)_M\HIYUU;OC\*FK\M-@QX8$,E'&I4%M-7E""6
M1PK8&H`+21)')XCQR\HK!6&"J%13DT2"JE!=[`7$[I<=,YM))38@+D>#F!U:
M5NR49Y82TX8>RRI5,?1I\]&HJ4_:@BUG2X,>NU75[PO:'Z9#55UC_0\EZ,.N
ML#U-$@@R+IB><CG7C:ZV!B_`$`*&]8/(PYO`'+>"<#0M7HM1<"19V%K#]**1
MDFURZN.K7XFLHM(M;ZJBZTYB%C.<=*UHAW`RT;9I@NW''R395-DX1OU+S':(
M),##@W#HN%0C&&ETY5.W\Z"(M5(7?W3PX?)L66"5A6;Q1BTJ&/2[2@RM^*PL
MXW[8%$S[I0QJDW'=6E=29SU)]%Z"R+KUV,WJYE,$U@FH]@(JJJ;L60US0=A4
MM/EQ."CVXP\I.DRJQ$+%OI/V#NVFEGC"1!9_E*^FXKR]=H,72]NFM-&#(`@&
M/+D`9%:*9=ME=K3,@*C05'$"/X?0(<;-Q&?`%SKSEFCOH7T<23)ANHVANP1F
MBP".O0GH>>]=RX6GQ).-X`ARL^J:-9Z'KUX<9><'_Z5Y#'UU/._@/TKE2QT7
M,A;5H35<&(%RX?A\Z8:I$L%+!Z$Z[R51GIRSE+F8O7IE/'Z7W7QHU4VQYP1T
M4H^6K!7M>L](VF</[^]\%2WJM29@[>NEDO=-X5N(8L(U%`HV]H/6!'XQ-A.U
M42@5J5STFZ46N*:<L6IB,!,F3-!3S2A&(YK!)&A9M7,QG=*XKAJ3<]NSL_2Z
MTO+#`D%HW0IZ@S@R#XJ_4QM%)#2RW=0/FAES0`6?L;83$T'\Q89POH-B@/^Y
MJF>NY:K183(1M.O8(8X19=Q5II?L8G-`\DXZDY1S?]E*5Q/]>61`4%J;_FKF
M&A"GRT[UCMLU%V2JM&O=P%'I/?:I"!VV#3_@L0(HK=)\%`S@&A!YHWHVR2KQ
M&&3WUT#'KS?5B+5UFY5D5ZZ0%T=?K!K7E$H<Y8-V&F0OLK`:5I6?86>$=>(G
MJ;-F.'7_\-7SYP?X<ER%_,>C[.#;TZ.C%Q34K]U+O1)'P:[NL56=SX8F"V)[
M>#GP074AV%V]B5](&K+447.!#:QD+HU0`]OA`DB$XFF51U-]Z>75EGC'VB%@
MRS45H&LVS[?)*M`4CKD:54V\9:?JJ_?(GB/_#F%-63$2II4"]%A)"K4W%AW-
M.%XG(@N+C'/$KG$]ASQ5?N0)1SALJ1IT7:TZP$"K7!)R%JZ7*9B=>QM8KKGH
MCW=I<=`2?D-ZE'==BLJ,:PK`PQK4F^A7CNJ6>H#UIW&*3V9N@H_=C*!-JA:?
M/J)TXY7Q[$T112$6C0QE;F+4Z<5H2&0GXMR9C77H2@=!TF!=VU.5DCACBRR>
M>?':C)FHS)"$4[#</!_U,36?1:Y?T`38Z'[NS1H*)-D7.LI"P2:)A^,+:CT0
M$L&D=P/+J-PWKW.A)MV2J(3L5!!C)6MEZLM,/SF]D=>)87'#M!V/IJJ#=<6@
M-MJ*2SURM@U)G^DNZ^R)7"WY>\UZZ+,GQZ=?G)V?GW[N:3)QADTND#1WG$!Y
M&X5+KP"CU)\H\:705+VL.4%4#R(44IK#A/TM6]1'EMAS7U\ZAPL6B!K7.H.8
MI^ZXAPP^10XJ\5I-5G)%["*<Y65=AW:0!-3I5A__H(Q`(SQ6O[R>/8LU^^+X
MW,2L%7X=OGIY3G/(HY>'':>8GA/Q'&&V<P'4O+&8U=;O>47*)91,2"3UL0A*
MO\VKCZ2Z9&7BV\E4JK1$,$YR!'FR!SN&DZH(\!1&L_B*+"GHEY@6,31KE*QP
M/@U[=4@&D04[BMO$SP6WAS2C,4H,<'!'7&2*(Z<16IFRH</.$&;B";2]H`3*
M5BFWO>/0;.-L6[D7T9O?9E>.#'\8ZP:)$5QZ%T)^G,M7E$:I*_BP;"#*VOB'
M7:IFBQL9SJ(UK:FU7"[X"&]JMY;&>T,_#NR'PJ0D\@KZYS_5?::Y]:MI,[T1
MG<=N*+A<%:`/='!/23?QD*K$EW83<K1\@R+$Q*I,4Q>?OA7F#K:NG%`[S@P)
M8!4E=HKZY.-5UPGZ03<!'G,_A/XWR;YM76;!K2:Z>EU`.''R;"WAXS2GE<<+
M7"5PGNDBR57W&D?G.?G4\)*;Z19G1*Q96A-PP0*T$2`FHQI]Q6:XBSLMOB*.
MJ%ZOS&\IBDFT]#F7!PL7EQSOEV(UDM'+3?PYA-8ADY93TI`!3G5$@1$-U;A"
MR"<8)MR2MNQ?I0[`+ZE"B_8&F((TX,&$LY9)3CI:MDZJXK_B;MJA!?T5F+%B
M&_@I0J_D)XVSU'4NX=A>7TX6UB)V0RL"H53AB:^^(3<7^XFF0#*]/H+AL;H)
MWLNCO\M.3E\]?7W891GOO^IJ657%(;L$WR8&%`*O!`8M=T>#&O6L0HS`HVOT
MIJIW>S*[V_H2,0/VL&ZMF)EU&46&R79@Q5:!';[A;-[[GGNSB'S1O(PJ!R5E
M#9,(6RQ:?)KQ39^?@O]''_"\9PI2&/H=U[_WIW2)9D_9[$9M4K+-1,B?3A#\
M;B>,WAK[XSA<_8\NPXD,R9'!DHL@=!IN.<(9$0JXX87CO:^3Y<E&.SN`55$,
MK-5&S'-Y"?#OUW?+Q9H30_=XP=L4,Y:WCSEK@"ODRN44&2]-2A[$+S^$)#P9
MC%^.YW3--75D>)0(/(<#Q4%<1,:Z^U/G79E_)H`D:6$NQA*4W/!59I'+$/3^
MA.`'!">-[:?Q["/&HXI'*:3A]^[B0#&"DQ%H78'.>G:C`-E+K$7D`&ZRGV2^
MS#ZK-!30%(%#V%3LM7;_U]X;SH9D8Q8/*75[]<"[NVI>[ZNMA".-U>HJ/_T8
MENIW'B!3HIY,#@Y+H:6?0%);8`!8BN%2K&8'XU7)$'K$R.W5=V87[Y&:9%/W
M=W]59E2!J6=U[/H95G)E%T)`!A;`,MP)7FB1BL^=0%.'K!W8UWV.%(LW5Y(^
MT1+"Q;#"$-=`Q18H3E!.@8`!U@AMT#KTU>U&:`U,33Q'ASNJ6J#%!LOU=6!;
MVK#JG;#&9!3%\JB*ZH@1M3*/E?)1<RP)P@:@1(Z,%8Z2<T&QUDYFIDZ(%B/;
MBB$V5)EHNGJ&,]%(5/]F[T$97GBR^^`^7?6J_2+-D*I4&W$_4N4$'L5%Z;2<
M&++2+C%9\%K"6K+Q/2.SR'\ENL4IPW=K3<!*U@M,=*=-8P4^($.BK#7C>V[I
MYSR'U75!NKA"9D%'$T5A#;,#J8L]U`_AAA@%B_3L-*S<>Z>;`VJB;==N?[@2
M?E_IJCM"6QZI^"B$K9QCKW+&_R.IPD1E[!:Y4^G<B'$;S$1=>UBS>&)[QH$"
M;*Z=YCT5*Q8YMVYQA>9@R/^$JTM@*VZGF@TETG7?'::GCD"&P&2^Q-C,=66,
M..&:VSCG\0?^@53$*!H/>RYX(]Z4S2SK,O6AR@%IABG9CNB.V[$Q@0]5@['K
M)*LAHLS)^6,\7*PTKTM1+[S;;#N)P[C93FNMO=9(?*PYE4@V13/Z!PE4%CPA
ME,NE+S+=\XOHC+I7%BCV8X?VC0K0#';6M[C9MB/M@]X-WUS*@A0_1-U<UH#'
MXF\]#;-%;6S'0,L2IUCZ5:XVWF(EW\(2.!6%Z:VL)/8CR_G<EF%QO1>H(T(S
MH+9:*(K#W#C!6[85U2,+`X-P#6$)IXL8O\,\BOY&)('DV#=4FW;>[5@!>BP]
M/:^N0A"+I12(GXI#>2X($SR]Y28<F$C70$U4-$B(1X6;%?NGO$;%?#R;F5I>
M."4),)%Z]2)#Q!*.FL7S@E757*M!)\*M=3/#<:?@0QS*CE+'$I=[+H?*Z-Q!
M$J@QAK>H+JOY^N;#W=WRB$4YS&'Y=0SL!("D.'5KJ/L:J&NP<^NN)P4>9'4$
M6GV(VPTI15V@6I'TJA5!+:!1!?_NA-S.CZD)=&AO6N$11B'`#?*$:!W(MKTG
MU*^S%)&#OFXA+"3SQ(#56_^J-_#QD:XO"T7)S@*>!:^L1?9PNJ;6R,RO3GI0
MO86J<MD5PT5::QI>9>V45DW==ZVJ^Q?#ZYN-JE+_JS*\S(5%0.N:X7$OM,Y.
MA%J5./@2HD=HMRN/4`:VK.;:4P'INH;88L`DEJ*H:+_EO/O*A5=^K[=+"]'3
M$Q4@2G6=.&_ZD\T3&H,JO="ZKH8"';QNB_=5CA%OGNN7]MO/RFMMF<(]=OL6
M'Y=NH'+4[>XR729>%S>+_:-X]]/F<\I&N),*97QFI[M7S7:J-L6J$`O"D-ZH
M"'F*J*3GV"N@C7=.-2<[C4WI5HU]5M[]6F&YYC#'H1F``A"K1JH&_E:^=*9.
MWSJY#=A*]98D-)OITF;8:!6B:BYN!>J>@L[A"`!OOCY[FGW6PO@:.&S.]'[7
MMUW\T[M=<CS_I/Y/Y0WAMXTYL4B64.JWK*41UK[(+7UQZYS-V]S25UU7NKF`
MW\O^^?9+U)O[:GRV]J5W:2VW[J![]`^`7SE0XTJ\]UW'!\#T_H?!-'WVL\"T
M.?H'PU0#?01,]?E[P?06N7J7*%CG?K!$#TJ]]K--9%(AJ=U6#D_OOJ#LML_?
M:S%V#Q$FXRW+N1LNV3F]V6C@V!*1Z=.JC@KOWM)J!4^WK)?MO4$*FVZ46Y9:
ME<1R#`!8/_9<*<P+F=RF9"EUVEUX;;V9=KI**1Q3=>SA0!3X<F+%_A:"?VO1
M#"*6UI"NN:3@K/Z33IXTGZ4(9?-!2AYR6I6#BQS':;[QDG1^O2;J8)X*N3P.
MKYA6(_)_$.NF_(3:N845Y=B57;.5[-61Q.:$+WJT8U^.FS]C@.3DMJ2TB:O$
MUM\3*VQ0QL.J5O$2FM^=Q#`\/`.1RA@TITP:3E7T1+@#Y+P#6//[$G^10F^A
M.NXLU.4UK#&.*6R4OG)S<+>Y*J_/W5;R7(%5$,'G%IMH?EI.E9`;HE<X7A4P
MX\X9F,V")0;10!0BI/Z^&Y(MK`0P`/M4?VQ!NAAY3XMHKO,5MG=JCP]!I^Q,
MZ.M*IU=O'ARW[G6W?;4=EZN8WF\MJ680WL6&72_?R8E[V0M\[^LB.U)TNKDS
M6O?LQ+KYA\V'M?G6H)RSU!FR.=*]+[W]8_/W([MV`I(NFTHV7[GWJ/O34T(%
MW*UM)%&VQ:TUMBMIL@5W(]I5S;&RS;LPL7LK4#G"#%!I0J7BV.9^JA!_T'QH
M7X;4X/WFP^J7H3M-&?+!>%^-2&`5E8-U7&B.?!1Z731_CSV;FK]W0F]S#0HY
M+?MN54_QB*41:FX'-">K?L,5#V8K;'G'W_:K:9_>^\-*]"`O)`3Q;UHG;JV<
MI/&EJT_F`71B8?^\.>&]A]W$>6_/?F^^CAY2]&E.,%-CFM!B?&IVTL%VYJ%+
MPD*-NXFW*XXU632'.>P5U[4H$.%M*M:ZAM;.[SJ\WQQ>Q]OLT+(U`OB0$3KI
M0\K*#L3!71<+W,F2R9ZC8*1P#HG:#0$'@CJ<=_9?LF?A8-<6-W%U^:#DQW;2
MZ?CF?FJGVIL/6Q.L?9+=8WK)2*`K6GD>OCD+CQ)WMEBWOONTU^P?[('JR(I_
M;`Y(=6SL?+R",A]T4V:<S`\[H,K<4BG/UW'^9@:T%S?-*=?_TK,6=Y_E;LY@
MMA7\4#V'+64[Z;*E5KS<;7C57X;21H'B'`S-A32W&LXS1LB01T=@><FMG6HL
MF;8YTG$Z*Z:(3Z#X.W5V_:LUY*HB8!]_<*JY^%HDZB!D3.#BYT1A=,Y242Q^
MMD1)W!M\'0/5JYB5I#+,ZG<CMM1C*FVS5$AAM7&W<D)MD;5_;&<O565O=UQ7
MEM<M0:C+85&A**<)B!?=)/BZ7OC3_.J@3"@V\I,M<Z15;Y,,_9*T_,1DK:RF
MG/&+HECL_S\!````__\#`%!+`P04``8`"````"$`]F+.Y7@,``!L=```#0``
M`'AL+W-T>6QE<RYX;6S47?MOV\@1_KU`_P>":8L[H(XDBK*DG.5#))N]`&EZ
MN+AH@5Y14!)EL^%#I:B<?47_]\XL7[.B2"ZE%3>)X5BBM#/??//8%Q\WWS_[
MGO;9B79N&,STP>N^KCG!*ER[P>-,_^N#=371M5UL!VO;"P-GIK\X._W[V]_^
MYF87OWC.QR?'B340$>QF^E,<;]_T>KO5D^/;N]?AU@G@DTT8^78,;Z/'WFX;
M.?9ZAXU\KV?T^]<]WW8#/9'PQE^)"/'MZ--^>[4*_:T=NTO7<^,7)DO7_-6;
M=X]!&-E+#Z`^#TQ[E<EF;TKB?7<5A;MP$[\&<;UPLW%73AGEM#?M@:3;FV#O
M6WZ\TU;A/HAGNI$?TI)/WJUG^K6N)28OPC6`^,-_]F'\W>^2/Z_^^.I5_U_?
M?O>/GYSU/W_^IOS9S]_JO4P-D0D^J)?YNE\K%CY.)/=2"VYO-F%0&#(<@"5X
MY/9F]ZOVV?8@$@:(9!5Z8:3%X%`PA1T);-])OK&P/7<9N?BUC>V[WDMRV,`#
M+`;2[_DN>`0/]A(-W>I9(IK,I@G"X&P:XA%JDP\FV7BPWB;[WT=LXG2-FG6=
MPQ^GBUE1;Y<T7>6X*'%XCJ[<5T1/]+B<Z98%Y6+0[R.MU&$74C9=]$%?9\JN
M1YU9-K2&UEBJ95PLEOV&"H>63"H;%%IOQW>=T2E?695U:1GN*@,PX>2RZ$+J
MUN3WV,*?+N*DXP[M,AYC4KFBSU*OJ(T/KN_LM`_.+]I/H6\'2"SMU-BWN3Z9
M"[Q&\>^")R=R8Q3+2<D]+%5"W@>4@[(*")K#A=S)@%#*'GX[-ZVU"W.$I`P?
MC_8ZUC(IY?'208A5"<D$3#$ZZF*T2<#)".0X/K-CW-X.EA,[2#G7\_(9P]#$
M@38<N;V!R4OL1($%;[3T]</+%H;9`<RSDJ1BWVOX]F-DOPP,-MCL)5]M:+`+
M/7>-*!X7;'"?)M;B^MY:W#.]!!FFM@B*"J&6M1A?0.C]?+J0CW0Q9=':DVB^
M8<&/9*1O1_@C6:@%_Q;2.$T+CBD+9"Y/BUV<=_=?CZ?3Z61P/9E,IN9P8)J,
MY&4:T6ZP=IX=G(I+HZF,8`0(IL/)]-H`('USPE1UBF`(`,:CT60TF!HF_++2
M?'D$LCD=Z:J]2A`H\BI!H,BK;#XHH_2EF0*K8(ISE2!0Y%6"0)%7V;!%HE?'
MRKU*$"CR*D&@R*ML3"S1J["ZK#A7"0)%7B4(%'E5VN`SK<!3Y5XE"!1YE2#H
MVJO9M&IQ?V^Q-:WRR*QZ?,PF73!W7(;1&K;FLOVF`<X>DV.W-YZSB6%R';F/
M3_@W#K?P_S*,8]C(NKU9N_9C&-@>O.QE+;*_-2UAJP]V]69Z_.2N/H$R;NJ>
MX$U47$I#7HE,'.&;8[,_-D?&=3*)DJ3:=];NWB];E^L^&BM`(W+;;#CA,,B5
MI.%0+''VT`NI^P1;,%<S3PLV@)C(0D*PA0P;B^5^41M)"S$;20-!&TD+41LA
M=8XE5\;D.MS#+O.A@RUKTN\G*ZNB>NH%$N!'(N8X"-*FS&=CDR.,-K9I:RO4
MEU)NS`W\86L&1RQM:%&VLZ'!$2L;6HC:R,=-YEU.>+Z<@.7Y")(#OKFOGP8#
M%"4-,SP'13"M3[BXGNSY")>[X^8VBB=6@X0SNZL#OE0:(X7?M,N&$<#*\;R/
MV"?_?9,/`V"UZ_;F>4/.#X&3=O"L"CS]!%_"BFWZ,NGRDS=`<U4CH[*19F^W
MWLN'O;]T(HN=R<-4L*,6Z"G>S=E8I7C_UG,?`]]AZW5Z(N;'*(R=5<S.-&)[
M,55XAA5X!JD@$3SGZ#<K]`-/PGR<HQ_6@XXZ$7A1JA^"2UB_S'C`<ZK2H`87
MT*"NPR,3`<SZ,P3@!!4(\!RPE`,(3Q4(8#:5(8``+1``G)JH."</!J2:00P4
M*D'_I51"C<FLY%1>T,JJ\@OZ:ZRTN/)[%LVDWD*@%S3#FQH`9ZFL*K&J2@QQ
M.V1:00&\J:'`@EY73I<WJ*KYR@@A11<P%(Q`&:AC1%Y4DIH+.@L`]8S,)8Y#
M2%!@*5(-`>`H@4`<,5#4_PXH!D4],(T&15TPA<#UP1WF!/4$UT,JP@!XE&1%
M,4X8<#U&AS00"*HJ)(D&0U6)I!A4U<C"%8:J$DD@J*J0U!.J2B3%H*I&$E>H
M*I$$`C"BI$)23Z@JD12#JAI9N&*HJD02"*HJ)/'$\,(ELD>739-%5+)^.AZ?
MM'ZJ/6\:%U('59,F\'O6/)D])3-'\`6;2Y&I-%Z*9V=KI]I3&+F_PB03+\E;
MP6*J$^EXM6;LKNB17R)[^^`\PU0TV7IZWE2O]0*2;'WC,!AYA)68"OVPB*]K
M;91+Y^<,+.<3T6@YF]0W+LP?1`:_N-T8(8T@<'%'-0;D.L4@/00DI0AFKFJ:
MH)-4CH&Z"CI,L5IA`7-8?!JJ66.L$N4XFY"JG,8);C"WJUPXJI<*IQ479($6
M:.$&<WS1_AH<T<9RX2"X2&^%^9CNN7S]M)?COZ;SU/`B"LSIY'3_N@%%!XE:
M`Q1VM7NBZ(:'T^*ZW+'80G9C26O%ZI<'MDTN4D=?@LHV6'#)K=O4I&,YHVJ8
MC[L$?%`='\WQ97J>;EFT"K9L-M"&M1:XOSB$D+L\LZH0DB[I$EG044&!^[O4
M\LF7OY,B](1!EAQN+XF6S*:JZV&97)$R((%R=AJDP,!6R(J3:EF'1F"PI#.V
M-J[@Z\:)>%M5W8ZC6@&VRM&W'"SE?)+B1%IJ13-'*.A*F?.EP06`YT\B*7U)
MK9<T3I>.[DSG2L'3F`D5-;E>N4B_4IF<U(%G4G3ID9`HO`H2&^")L,AW%%(Y
M%0)]VM2"1WW2P$B4>@A4@>X8OE4WC#\1;V-RJ00G,<WJBP'?RPB%:&/=SA>"
MFG>6Z"#L0D!/]3,'IVDT<5*6G#?9X?'!4G-=CEP27T4IXO&5IHXB]?,DU**U
M1PAVB5;EL('68R6S@6T^S85YE9,[)1([0(,T"2W#5Y:\-K8/E.YZR5[7I)V/
MQ!H%+JDK496.*,.IF3/D?0^[PZSP,C^?/@U(A=.GC+PQJ(2J4@G?UU&52K`[
MJ`.5`XSRV/A$--3)HGT/,+%I7(9JH(L?]G:?/>3<+$"Z9/L1Z26D)Z5Y8VI0
MTE36V\IB?Y&0.FG/!JD2ZOWXF)<<1`+[P)W[D6[)M7#DQ0KLN>YM6*7@_7MR
MR6B5FR3X>'1X(5!=:>#A*>AEF^"*1($$(Z3V(A<BO55$R,YRVN5*'*!>I'Z?
M@.\+H`NIR$8H))_A94U'?SP]*CN5QA#B:G75Z1,`B:\IQU'PA;`2$XVLK#07
MLXWLR#'D[/QQ.&.<W'^#O_M&?GZYAK=;AR?!]'^O76EO5R@T7QW!+FFY=SVX
MN1Z.I?#<_]5^!_>0FB<'T[.UZV3E1=:`N025!1?7M)4%$A)R#1CM45DPY6PK
M"]0GLN#),506W)JDM2RX1B>5A5?K%'R9$"5M<4&35!;/_4B0>_.8'W':07"A
MR2*XJ*S"CWA55&'C$$QN*ZOP(SB.R@*3V\HJ_`@(B2P3E+255?@1O$!E0;BU
ME97[T>2Y'PER?WW4CWRLXD4H(KBHK,*/?*P.!6.5RBK\R,<JFMP65^%'D$JY
MAP_:RBK\R-<)4[!.4!L+/_+<CP2Y/ZRH?,0;@A&?2"E\!Z\(1SA0%.$HD5)X
MC8_RH6"4)U(*?_'Q;0K&=R*E\!3((Q:9\(&X1;F/ACR[IB"[<WN=55T^8+"?
M$8$!#Q);[3UXEEN(3X)C%UGA%@TQ"$^^%Y+TY*P^:0NX9U8NB,\'[$9%!-T_
M;ST[L.,P>M'PPJI<'._TD:"X/X5ASA$O`<_(%`'T`SPW#Q[)IP$O"4-\#.-%
M-6W$Y+G`TX-W66@C!EHG:/CXPY-SVXB!UHD8OJCB^$E$S+M@N\\]Q-=2[+I%
M1+QW@T_.FH\<GF$#0(I(^N#LX\C.XX]/*4.0F`]XI[5<!E\BDH?89+>%2\>?
M'^#&:AF).-(FN8.C?Q'@?]G'A$9L1808@G7IP8WAGIA9$G,B$)8(CH<0+G;,
M11Q4%$$9?[.C`+.%2]V#&*VPJ+AT%$;_Z^?BKGN,]QB?+,GNQY?/!X"HM;.Q
M]U[\D'\XTXO7?V9WFX5@2K_UH_LYC)F(F5Z\?H^W\84LABL$H-R\W\&M8>&O
MMH_<F?[?^_EX>G=O&5>3_GQR90Z=T=5T-+^[&IF+^=V=->T;_<7_@#)\#.<;
M>-#E&8^Y9(_CA(M'!^:;G0</PXQ28U/P'XMC,YV\2>"S>W<";+@D(S.BM\L?
M$WK[?P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T
M:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z'
M'FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+
MT@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2
M"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VX
MB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?
MB8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7
M,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-
MK2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F
M?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPX
MVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"
M8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT
M_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R
M:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#
M$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X
M9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<
M*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,
MKG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX
M15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DW
MQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(
MGIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q
M7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9
M>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"
MG$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY
M&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HP
MF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%
MRI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8G
MB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<)
M:G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])
M`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^
M@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJ
MF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"
M5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)
MLI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI
M9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*
M6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_
M@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"V
MENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]
M</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"```
M`"$`N5B/$+H$``!A%```&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R4
MF%N/LC@<QN\WV>]`N'_E#$+4-Z.()TPVFSU<(U8E`]0`,\[[[?=?*D@+:YVY
M<.3QUZ>'IX72R<^O+)4^45$F.)_*VDB5)93'^)CDYZG\]U_!C[$LE564'Z,4
MYV@J_T*E_'/V^V^3&R[>RPM"E00.>3F5+U5U]12EC"\HB\H1OJ(<?CGA(HLJ
MN"S.2GDM4'2L"V6IHJNJK611DLO4P2M>\<"G4Q(C'\<?&<HK:E*@-*J@_>4E
MN9:-6Q:_8I=%Q?O']4>,LRM8')(TJ7[5IK*4Q=[FG.,B.J30[R_-C.+&N[[H
MV6=)7.`2GZH1V"FTH?T^NXJK@--L<DR@!V38I0*=IO*;YNU=69E-ZO'Y)T&W
MLO-=*B_XMBJ28YCD"`8;8B(!'#!^)^CF2"0HK/1*!W4`?Q32$9VBC[3Z$]_6
M*#E?*DC;(D5BG$)-\"EE"9D"T//HJ_Y_2X[592H;]LAR5$/3+5DZH+(*$E)6
MEN*/LL+9OQ32[E;41+^;0(F[B0;2BX7M>V&8>4UAZ]LM<)MND)&Z-]$:F;KE
MC+_3$:T=#OC2^.@C?6QIEOV-`2'=I\-J/'Q>[I5",ZJS]:,JFDT*?)-@O4"C
MRFM$5I_F:>!\3_4>39LSS+:8X&^$G\J.+$&"):B?,\-R)LHG3)SXSLS[C.6R
MR*)!R.PAOGXC/'PUMLBR(9HB`17@LVT*7\VJCW"NZX9H7#>-\/^NVS["N>X:
MHG$-J>#44YST=]\1%(BBS0-2[N;1##N1R;`WAO-&>#139\=KT2=LE47\/L*9
M+/L$;Q)0!/K3QL"9K(3$ND\8UIAM[*;/</5LA<2N3QB6Q=83#C%<6_;/&290
M6%-#@1*9"907%KS@\\*2%P(J=*/07&Z05B\PZQ>8S1!CLD.Y?8'9O<"$?<;@
ME_J^S^CN(S8F$G,X$B(SD?#"@A=\7ECR0D`%^FPC"W_%"VM>V/#"EA=VO!`V
MPF,-]H+?/V>8`8*'[M"<)3(\S#LKW;!L-O(Y9:"N]F[`K:^%D/"%Q%)(!$)B
M)2360F(C)+9"8B<D0B&Q?T8PR<+.:"A9(D]EN*NUJ1G\?7Y.F6?)"@E?2"R%
M1"`D5D)B38EQO7\QU?J/G<<;H<=62.RZM<"["OEC:PF%'OMG!),L;,F&DB4R
MGRRW6YE3YEFR0L(7$DLA$0B)E9!84\)^DJS08RLD=MU:AI,5>NR?$4RRY/V9
MWZ(;:KLC)S_S"7,/_3EEGB4L)'PAL102@9!8"8FUD-@(B:V0V`F)D!*.54\U
M=:1QS[D]]_LC$B9<>,OLAMOL]XG,AFH_#.HWICE%Z#W,=2Q5LQ_;G9I8=`E'
M'6OJF"/\+J$Y8],P-:Z:)8L8AJOKW%TL8!##-,<V][JWZA*Z.39UE_-84^+)
M#-UT/335T4S#8.^F6X8P;->QN4QVPEI"(0%'+"2:X9;2:.D1"GW-SE!Q1@N4
MIJ44XX\<GJ\DL59M3V[>3/)NQ^ESS8,WY;[N:QZ\#O?U$$Z`AO2Y[LV'_!>Z
M!WO:OH^O>["U[>M+W8,=+NA*VU`X^+E&9[2/BG.2EU**3M!%=03+0BKH&1&]
MJ/"U/FPXX`J.?.JO%SC*0[`E5D<`GS"NF@M207LX./L/``#__P,`4$L#!!0`
M!@`(````(0".T$+-;0,``'D*```8````>&PO=V]R:W-H965T<R]S:&5E=#$N
M>&ULC%9=;YLP%'V?M/^`_-Z`R0=-%%(U5-TJ;=*TSV>'.(E5P,QVFO;?[UY,
M"!@R]26!R_&YQ]?'OE[>O>:9]\*5%K*("1T%Q.-%*K>BV,?DU\_'FUOB:<.*
M+<MDP6/RQC6Y6WW\L#Q)]:P/G!L/&`H=DX,QY<+W=7K@.=,C6?("ONRDRIF!
M5[7W=:DXVU:#\LP/@V#FYTP4Q#(LU'LXY&XG4OX@TV/."V-)%,^8`?WZ($I]
M9LO3]]#E3#T?RYM4YB50;$0FS%M%2KP\73SM"ZG8)H-YO]()2\_<U4N//A>I
MDEKNS`CH?"NT/^>Y/_>!:;7<"I@!EMU3?!>3>[I(Z)CXJV55H-^"GW3KV=,'
M>?JDQ/:+*#A4&];)L,T/GO'4\"VL'/%P1392/N/0)P@%D$17`$RB_Y[3W(>8
MQ6_2M)_/*1^K9?NFO"W?L6-FOLO39R[V!P.9IC@\E1E@X=?+!1H'ZL5>K0RQ
M-8>8C&>C:12,:3@EWH9K\RAP+/'2HS8R_V-!M*:R)&%-`O^GFF0ZBF@P'T?O
M)QG7)/!?D]!P-`FGT>T[I/AV6E5I'IAAJZ62)P^,"<)UR=#F=#&&NJ88O,=H
M3")8BIAHB+ZL@J7_`O5,:\3:(N"W0=`N(CDC<$D@69,1BC"0$:.8$5<`):QM
MH)T@=!+T$>,&T<D(%6ME]'"MQ^@A.U?\"H'63"8-C95B$9,68MI%)/]#=*0`
M24O*60)&8P+S:8HYZR986T1;0M1%)'W$161'`CAN0`)&NQ)NNPG6%M&6,.\B
MDC[BBH39H`2,=B50UW46TM9`7=OU(5=$@+L'ZH!11X3CN[6%3*MM,:&WH2,R
ML=_;(J\HP`[4WWL8=11<?&T-:2'M#-3Q;-*'7!$Q'Q2!44?$9;P582$=$8YK
MDS[D0M+Q)(53?Z`45=B1X?A^76,Z.ASK)@.8:T+PU.JO";6'67N'4L?]ZQK3
M%M*SQ@#FFA`\W0:$V$.O+21T=L":6DQ'B./A9`!S30B>;1<A[ND)G=UU2NC:
MM<:T!5V256;""P+2S*I-1:-I%,WFEP);K]C&;KM7SM6>)SS+M)?*8P'G)H6A
M3;2Y>=17@N8#M/:2[?E7IO:BT%[&=S`T&&$;5O868%^,+*O>N)$&FGKU>(`K
M'H?.%(P`O)/2G%^PP367QM4_````__\#`%!+`P04``8`"````"$`(0GT!)(&
M``"H(```&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R,6MMNXS80?2_0
M?Q#TOM;]%L19K+)(NT`7*(I>GA59CH58EB$IR>[?=\BA+D,QH[S$-GDX/)Q#
M'E)B;C__:,[6:]7U=7O9V][.M:WJ4K:'^O*TM__Y^^%3:EO]4%P.Q;F]5'O[
M9]7;G^]^_>7VK>V>^U-5#19$N/1[^S0,UQO'Z<M3U13]KKU6%Z@YMEU3#/"S
M>W+Z:U<5!]FH.3N^Z\9.4]07&R/<=!^)T1Z/=5E];<N7IKH,&*2KSL4`_/M3
M?>W':$WYD7!-T3V_7#^5;7.%$(_UN1Y^RJ"VU90WWYXN;5<\GF'</[RP*,?8
M\L<J?%.77=NWQV$'X1PDNAYSYF0.1+J[/=0P`I%VJZN.>_N+=W,?A;9S=RL3
M]&]=O?6+[U9_:M]^Z^K#'_6E@FR#3D*!Q[9]%M!O!U$$C9U5ZP>IP)^==:B.
MQ<MY^*M]^[VJGTX#R!V))F5[AI[@K]748@[`T(L?\O.M/@RGO1W$NRAQ`\^/
M;.NQZH>'6K2UK?*E']KF/P1Y*A0&\540^%1!//CZP<:!:@R?4^.=GT9>%&]3
M<'`X,@U?BZ&XN^W:-POF%A#NKX68J=Y-`/DO1>$742KK8$@]E+[>^7%ZZ[Q"
M)DN%R0T8BK@W(*()X@"!B05D8<'"$BH$[L1&U$*!;2W8N%,@R3A'3+C`S%U)
MQ#V'(&2@HP69,26B=&]#D`6)3".!F%0FS`M3/XH#GT+N*<3ULB3V)@BA`6,Q
MT!"EE(87!U,`S`5BN%QP"$("YO:"A"Z,J-T2!C$<&0Y!R,2$S"B,**49\6-=
M&,3$*$P:)5&@Y>Q^B?!3/TO=.08AD1`2>D9$K48FT:<J8KB,<`A"1FQ#\^K5
MR8C:+7D0PY'A$(1,1LB,\HA2+2,K>1"#\@1I%J?)O"9P\1*$&V9)%$Z3GI#P
M8`M@4B*K-3IZ9[D"<4EA(900=5A=(P]-$FQAX2OZC%$@EA#&,4,H(6&$\Z09
M=1([T:90"H1*^4F8>)&N%(%X818G[CP<2D1XH8$(6B1QVD2ST=Q#D'FX.&58
M""4"819$5A*)ZJUUY"&()<1!*"%JNY-$Z)0D,ZNU!*<7P59Y79AF;I),2T5E
MAD"2,`VS>7.G1,R6ZQD\-]$<-5<@-B,8QPRA1'C;]=`Q-U819ZLJ,QR$$J+6
M.TF$;KDA$8)0HC`-(G>Q1!01"LD(A!(QVZZW]EUO<=*0O>0*9,Z_(H)QS!!"
MQ.>=5U9OK2(%,O>&A%@()42==Y3(1Z?D)5(@E"B.,W]]8B"0)/'#=X\,/O2U
M\)>)B"C6]Z)Y6T.)9-N]S68$XY@A-"/4<76C\]%4^56D0.;>E$08QPRAA`!C
MRHPHUC*S,CH?0<KHC(<Z`F%/=>():D%DE1F#\R;:`T8N8VQ(A7$^DAGJO"M"
MZ)P;4G'VJJ3B(%0JZL#3)$;'W%A-HZV*)\GY-*`HF"MIY]1M5]DPN&X2TUTO
M]Q%DSKVBPD$H(>JZ*T+HFAOR<-:J"'$00@@>EY<3>)1'%F^M)`4*Y>.1+L\[
ME;1SZK1Z-@*#X^J'DER!.'E8""5$'7=%"!V3ER?@;!7E82&4D+#$]5DW$,6;
M\B#H'7G,E;1SX92&SD6QUGDR'P3E$/,`0:PL'(02X5TV0'>$$3'/0@K$$OJP
MRP;49:=5@Z[(FYIL.QZTS:<X#<*<X@*SN\IB*I$7Z\]""L1F9/38.;/S[D4E
MXITV0(?<D(BS4;5R.`@E1)UVD@B=<4,B!.$1(?6"P,WFMSJ*R!(2^UF817-^
M"9'0[+"RF$KD)UHON0)Q$K$02H1WVQ#=EI=(@5A"&,<,H82$4Z[])40#Y252
M(+.YO5-).Q<&.'>N6WTHJC5Y4FV/RQ7(/%2<)RR$$H(P'"%1O?4<%"*()<1!
M*"'JNN,*"M$E-^1!$*X@\ZLY%4=!N'=S(77;E50&UTVUUTNYC,$?LED(S0QU
MW14A=,V-E<19JYH['(02HNX[285NN2$5@E`'\[NY<`EAW\V%U'57F3&X;SK[
MIAQV+F-L2(5QS/.<9":B[JL3DM5;JTJ!S+VA5"R$$J(N/$H5H6OR4BD02@47
M189W=!3"O:.+H*^%WTQ$1+%N?/H[.MF6EXB%T(SP3ARA$_.K28%8B3".&4()
M`<:4&5&L96;U=@$NG04([_*T_4+<2)LJL7.\:\9+UFOQ5'TONJ?ZTEOGZ@C'
M6G>7@*5V>-.,/X;V*N]:']L!+H[EUQ/\1T`%%['N#L#'MAW&'^(N>_H?@[O_
M`0``__\#`%!+`P04``8`"````"$`@W/6\Z4%```Q%```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6R4F%V/JS80AN\K]3\@[D\(A!!`FSU:PJ?42E5U
MVEZSA"1H`T3`?IQ_W]?8!HQINGNSV3P>C^>=L?&0A^\?Y55YRYNVJ*N]JJ_6
MJI)767TLJO->_>M'^,U6E;9+JV-ZK:M\K_[,6_7[XZ^_/+S7S4M[R?-.@8>J
MW:N7KKNYFM9FE[Q,VU5]RRN,G.JF3#M\;<Y:>VOR]-A/*J^:L5Y;6ID6E4H]
MN,UG?-2G4Y'E?IV]EGG542=-?DT[Q-]>BEO+O9799]R5:?/R>ON6U>4-+IZ+
M:]'][)VJ2IFYR;FJF_3Y"MT?NIEFW'?_17)?%EE3M_6I6\&=1@.5-3N:H\'3
MX\.Q@`*2=J7)3WOU27<3?:MJCP]]@OXN\O=V\K_27NKWJ"F.OQ55CFRC3J0"
MSW7]0DR3(T&8K$FSP[X"?S3*,3^EK]?NS_H]SHOSI4.Y^_6R^HJ5\%<I"[('
M(#W]Z#_?BV-WV:N&O;*W6].R=UM5><[;+BS(9%7)7MNN+O^A5CI9?O!B,"_X
M9%YTZ^Z$#9N`3[[LRK"W^M8RL.J=E4PV$>[Y2NO53E\[&Q+NG8D[-A&?7UL1
M1Z+/D#-,U.^NJ-$,]Y7QTRY]?&CJ=P7;'2EL;RDY/+H+9ZPD+.:A2-@K&;%^
M(N9[%>$B^RWHVZ-A;1^T-U0]8S:>;*.+%@=N0:I%W/IS$,Q!.`?1',1SD$R`
M!K6#9.R'KT@FYD0R#];C8)*#F3YNP:?X<Q#,03@'T1S$<Y!,@*`/V_<K^HCY
M7L7?L:3KC2C(HS;;J=&LZH?!9!`MD4`BH40BB<022:9$D(Z#^!7IQ!P;'V=T
MT.[L9M*IS5WI@\D@72*!1$*)1!*))9),B2`=(B;2^7DEM%?(0_,H,?&H&C0;
M^EH4?1B,^#1?(H%$0HE$$HDEDDR)H`@A+B@B5%1$B6$,)_0@$5\B@41"B402
MB2623(D0/AZ2"^$3*H;/B#6&+Q%?(H%$0HE$$HDEDDR)$#YINJ2+847NL^Y2
M9"]>C>VC#_<"L19E,6*.LBBQ=OVU8>JV,=MU_F#`=UT@D5!R&PTVY#8R=6OC
MB)LY'@RXVV1*!-&X`2>B^2$B5!1'B8':3P[1_)9C1LCP8*1;IAB<SXP<>I?N
M+-MR9D_6@)IL:'-#KLN0D<V0V^@S:\7B6FMCNYZ7()FN)61&1[>WD)H>B[EA
M",GA^3XP9-D#\ADR1U4!0YM15BBC2/85R[X28:(HA+0%X\;F-=9IM\#:49)E
MCZ&-6&5#+."!6]$*FH9AZZ8MVOBC#4])P-&8DE!&$4?4^<9R=K8U"R`>;;CS
MA*/>N:B>-`VC>M;O_>>QUFF/(62%(F2%+W=@5MM1BR^C@"-GF!@RM!DG1MQJ
M1+&,$HYZ7Z)`TAN,`H?RTI9!$$*1A<*/YW-^(`XZM3+NGV)N1>MD.8YEF[,>
M*F`VTW/,T;CC(^[I[GHQMZ+K;7?8=?9L7R3<>7_"Q!R1)F+,T?]N`MIS"+FC
M"+D;-P%#8WE]G:)=_U;8-_H!1^/$D*')L8\8LD9?,9\X^DHX6A!(>HH[`G_4
M-W)Y(7;ZKDK?B,J\.>>'_'IME:Q^K;`I-@8>RP.F+\G(O4NBP>39"#*.]^>E
M$;Q8/_7MR6R&1UZX%SQYAHON7E[!PP+]7IGY>3+=I\6%/=-%Q[C@:.NB[UK@
MD.`M>L)!<`^+(SY&2*EE;]CR+JFX/!)BA!1>'L$!<$G]Y9'$0;+Z\L_4XT&-
MH)?RA8<S0EL:P?,7H2V-X#&,T)9&\#1&Y9=&\,!%;$LCGN6B0Y3%'&P7S8W,
M(]M%=R)SSX'$)?$'!V59&O`=2%\:"!PH7QH('0A?&H@<E&1I(':0D'Y`&VJ"
MWW%NZ3G_/6W.1=4JU_R$@X3?)G`D&_J3#_W2T3.H/-<=?L`AQU&YX*>Y'#?O
M>@7C4UUW_`ORH0T_]CW^"P``__\#`%!+`P04``8`"````"$`EMKD*K8&``!W
M&@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6R4F=MNHT@0AN]7VG=`
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MCVZN<+,@PCO];$8'^/Q,/[`=ANQLA=MR/P;+ZC`;Q[S/#[NV>=-@B4/:NGM.
M-PSQ(<@X#>-(Q<3`^BBH]0,UW^LP2,AX!_3U8*UWQBM,=#&:!-B$R!8AMZ"3
M3:,>51"I(%9!HH)4!=D,&"!6*(8E\!G%U)PJYH,-.)A28"KZN`5W.:H@4D&L
M@D0%J0JR&9#TP3K[C#YJOM?AKYA1<VW)@@)FX\R-'-DD%"9"-"(1(C$B"2(I
M(MF<2-)AUWU&.C6'=0\'P$R[+0L+F-&[VH6)T(Y(A$B,2()(BD@V)Y)V4#'3
MSO<KI8-$/K2`$0?B_%QT*(RXVQ&1")$8D021%)%L3B1%<';.%`U'D^FLP)P=
MH_APH@ZR6$9L^)B)59>N,!)B$8D0B1%)$$D1R>9$$@M'ZN?$4@=9+".*6%=>
MSJ$P$F(1B1")$4D021')YD022XLXY=*QO-5TI>*II1ZR6D84M1M%K3`2:A&)
M$(D121!)$<GF1%(+UZJJ]OUU3!UDL8PH8CU%K#`28A&)$(D121!)$<GF1!)+
MH!+\G-K!0Y8[(D7O5M$[60G!&$48Q1@E&*4891*29=-J8UK2_/@EK`@9"UM:
MZP0CDK41I8@*)ZM)&XL%CAQ%V"K&*,$HQ2B3D*R-5AH+VE@!(FECR#3%$$."
MT!&C"*,8HP2C%*-,0K(06C@L"&'UA"1D1%.N0X+0$:,(HQBC!*,4HTQ"LA!:
M!4Q"QJI]19^'^DM5/`<-7'=D*MI9T2`)')$]FRF&W,U0UMO$,Y5%>23"8EJ!
M",6C%7QPJV1RI$\,-G$M92^GDP5WRB0DRZ<EPR1?;#9624@R&3+AVIT*`(*>
M1T8KN*^$%7&50O`(<>FQ;&Z'_)@;UW.W2BD1C386>_BD^SWFR)JEXR/]I4I_
M:]-9JS.2\>!#?W*.:*6QD"-6@(`?SW-`&((<<12.R/4$.H[(GI1%(X('3NX8
M8Y3@6"F.E4F.LA!:12P(8<6%)(0A2YYL]>&,C%9L&FW3](BMW*3'R88KBSB:
M4A)CE'#$@EON=N.YR@#2R88'SS@:@LOJ:54QJ?_E3F=%B)05AB`KO+N0,.1,
M6HX811QMA6,\(FMR3+C5A%*,,HZ&6+)`6DE,`L5>9@6&)(0A%Z[!:9>J.R(D
MS,J$69ZL\%X>K=@\N=NMZ]G*0V\T1I+V,G.;K?CD0_VEW(KUYVQ@U7G*NLBD
M_J0<F0LU%7%^>MP/YG)!-2+(G5@$'$W3>QS19GAS-[R9B3B:'.,1S9.`8Z7<
M<8J5<80/*U.NGM`J_];<Z7T&8V?O$]D;K+ILG\JPO%X[K6A>;C#=L#`/.X'9
MB\Q@X\.#"+BJW/.A9%_@6Q^JVP5.UCXM`)=:X%TIE$^X!>;=IYG`+3#;\'YU
MJ05>O#X,]9,Z7MK)0J3`A$!+W/+A10GN^<&&^$L=![8/;Q>P0^#X\(R^P%T?
M'F<7.$@+%GN`S>F'BRU':*'+#T>#;>C358A;8FBABQ&WP*;TD\46N#`AB\NC
MWO@!'%,X6D@V/CT?<0M<"CX])G$+W`T^/2UQ"UP1/CTA<0O<`C"VI9:`P!Q#
M68M]0F+#")9F#6HN\%EJ"2`']-)?BN;X].['+5#\0`Z66J#D@1$LM4#E`SE8
M:DF@A=8%N!\H>B`[0XLAUC_\&G#/G\H_\_:ING7:M3S#5E\/QU_+?CA@7WIV
M2FB/30\_`]`#0[O`#SPE5&%K^MKHW#0]_P)=&^(GH\/_````__\#`%!+`P04
M``8`"````"$`6;`7.#X.```\0@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6R4G-MRVS@2AN^W:M_!I?NU19W%BC,5G2@>16[-[EXKMARK8ELN29G,
MO/W^(-@"@1_QV',1VU\W&D`W"*(!<#[]]N?ST]4?N^-I?WBY[037W<[5[N7N
M<+]_^7;;^<_OJW]-.E>G\_;E?OMT>-G==O[:G3J_??[G/S[]/!R_GQYWN_,5
M++R<;CN/Y_-K>'-SNGO</6]/UX?7W0LD#X?C\_:,/X_?;DZOQ]WVOB[T_'33
MZW9'-\_;_4M'6PB/[[%Q>'C8W^T6A[L?S[N7LS9RW#UMSVC_Z7'_>A)KSW?O
M,?>\/7[_\?JON\/S*TQ\W3_MSW_51CM7SW=A_.WE<-Q^?4*__PP&VSNQ7?]!
MYI_W=\?#Z?!POH:Y&]U0[O/T9GH#2Y\_W>_1`^7VJ^/NX;;S)0BK?J]S\_E3
M[:#_[G<_3ZW?KTZ/AY_1<7^?[5]V\#;BI"+P]7#XKE3C>X50^(9*K^H(E,>K
M^]W#]L?3^=^'G^O=_MOC&>$>JB)WAR?4A'^OGO=J#*#KVS_KGS_W]^?'VTYO
M?#T.NM/^>-BY^KH[G5=[5;9S=??C=#X\_T\K!8TI;:37&,'/QDA_=#T<=_M!
M#T;>*-AO"N)G4W!D*G^CW*`I-[J4ZW>O)\/A8#11S7ZCY+@IB9\?JA$/AO:3
M"H7VP7NK#"X^QB\?JC00QZI?I-;!=6\R#(:COW%M(+X-X"PI^TXG8:0TO<4O
M'VLQ(J+]U`K->ULLL0E,</[&QS=Z--=/P6)[WG[^=#S\O,+4`D^?7K=JH@I"
M9:X9_\W(N#P1>##OE/H7I7_;@2+&^@GTC\_!9/CIY@\\8G>-SLRC8VO,14,]
M9LKLP@5+%ZQ<$+E@[8+8!8D+4A=D+LA=4+A@XX+2!54+W,#M%]]CK'[(]TI?
M^5Z\-A-@@M%S'"T:4F3A@J4+5BZ(7+!V0>R"Q`6I"S(7Y"XH7+!Q0>F"J@4L
M1^,)_Y"CE?YM!_^V!OG(]NQ,ZPS;2LYS,+^H7+Q/9$ED120BLB82$TF(I$0R
M(CF1@LB&2$FD:A,K%IAD/Q0+I8_)"?-K*QAC)QA:Z<U@7%0NP2"R)+(B$A%9
M$XF))$12(AF1G$A!9$.D)%*UB14,>+4=#)GD%:Y]+KZ::3*$H5]'87Y1DF(+
M(DLB*R(1D361F$A")"62$<F)%$0V1$HB59M8+L;KW>=BA6T7:S+"CY:+)_9`
MGU^4+BXFLB2R(A(161.)B21$4B(9D9Q(061#I"12M8GE8JQ&?"Y6V':Q)GTL
M45LNGCHNOBA=7$QD261%)"*R)A(328BD1#(B.9&"R(9(2:1J$\O%*MUM+1-E
MHE#8=K$FHSICJY=V<R(+(DLB*R(1D361F$A")"62$<F)%$0V1$HB59M8_ISZ
M_:FP[4]->BU_$ED061)9$8F(K(G$1!(B*9&,2$ZD(+(A4A*IVL3R9X!LTS=`
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MCOJ3P%EX+M7^(^*.Y:D,GA6CJ$%OU[>6@KJ^03`83<=.FV+1,?4EC-)WU9=)
M05W?<#P93+O.+)Z+CJFO8+1Y5WVE%-3U!4%_.IF.G&2I$J6Z0GL4J'3--PIT
M&F>-@B:S:R\7-$(()%`+E*AC-[V@I2#3W16CJ$$M6VO1,K9B0<96PBAE6YEH
M&5NY(&.K8+1A6Z5H&5N5((^'5;;F\[#.XE!0?#<+-!IA==!ZSMR=S$9KH%88
MV'3N#P:3D?,$+8R.&%\VJ-^_U+=B%$E!K")-$T;.`%X;+3$?LZV$42H%==M[
M@\F@YT[>F=$1XSE;*AAM&)6,*@O9SX)*^GR1TLF@%2F-$"EIXUR=&6#20E@$
M+1@M&V1%01=LH4@*UB=V=?*X9A2SK811*@5-NS)&.1<L&&T8E8PJ"]D>5FF@
MS\,Z/;0\K)'SSG&61O-`:\G;9#B<]@-'9V%T)#!+0>;)7S&*!.FIM=<=!-V!
M8WQM=,1X+,@83QBE@K3QT;0_[(^=94QF=,1X+L@8+QAM!&GC@V`XZ4V=EI=&
M1XQ7@CR3F,HW?8'3>:@5.(T0.+$[#S1"E`0M&"T%F:ZM&$6"C*TUHUB0L94P
M2@496QFC7)"Q53#:"#*V2D:5(/9P[Q=Y>\WMO+U!SFO"6=3,&RUY373'P:#O
MC(&%T9'`+!O4FHU6C"(I^/9KPFB)^9AM)8Q2*2BO.*S9W'=09G3$>,Z6"D8;
M1B6CRD+6)(;DP/LLU-R)E,[SVZ^)1JO]FF"T;)`5!6VKA2(IV'I-,(K95L(H
ME8*MUP2CG`L6C#:,2D:5A6P/JU3:,]M@\\_-!QODO":<]<J\T6I>$Z/>:#1Q
M'I>%49'AM!1D'OP5HTA0,Y$'N%+B',JMC8K8C@49VPFC5)"V'018+$V<Y6!F
M=,1X+L@8+QAM!#7&N[WA=.SD=*71$>.5(,\4]HLTOL=I?(/:+XD&M5\2C):"
M3-=6C")!9C)>,XH%&5L)HU20L94QR@496P6CC2!CJV14"?)X6"7&O@=#)\SM
MUW!/HYZ5C4^=L_MYH]6\)":#[M!9@RR,AHR`98-:,]&*460*UEM$X_&PYSQS
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M>:^L"NUA`.L?>@"5OK..TVAD]FKF/8T&9L)?-&AHEF-+068(KQIDQ9ELK:6@
ML14+,K82MI4VJ-6N3`H:6[D@8ZM@6QNV54I!8ZL25-NR/>^D^_74UQM>XRG3
M]VW-K4I]<O;[X;5]<M;C;8$&V9N^4V>"GALMF3`7C):,5HPB1FM&,:.$4<HH
M8Y0S*AAM&)6,*@O9P7%2^C>"(^<Q/<[V&^3$P]F.G!LM$P]MJ[7=NV2M%:.(
MT9I1S"AAE#+*&.6,"D8;1B6CRD)6//J_V`"HN3T=-<BZ(86O)>P5T-QH79S.
M:,EHQ2ABM&84,TH8I8PR1CFC@M&&4<FHLI#M=">7?\=#@!-$]_70(.LAP`FQ
M&P]=L#7B%Z:@A&C):,4H8K1F%#-*&*6,,D8YHX+1AE')J+*0'0\G\Z_CT9]<
MJT6>^\J060D?Q5!`-'("XJQ1YDU!*R"7@B8@A%9<,&*T9A0S2ABEC#)&.:."
MT891R4A]5Z1<J#VA`Z*_$])?2#SOCM]V\]W3T^GJ[O#C!6O?`*<HGS]=N/Y"
M:=;OXA.E>F5`$O7Q4KW8)4E//FMR)<.PJM=;+A^%59T(N7P<5O47`2Z?A%6]
M2'-Y#P*\'A%HDDPAJ7-T1X(U;*@62EP&2]E0K9=8@N5KJ)9-+,&:%?7X)/C6
MZTN]G'+JG\&-7B_"B5[]/ISKJ?G+(/R"F'.39H.PJF_Z.!4CR0C5FI1+(+4(
MU=*4)<@P0K5"90D2C5`M5%F"Y")4ZU66(*,(U;*5)3-(9EX)$K90+=2YS`(2
MM5YG"5*S4"W;68(,+52K=Y8@40LCKP2;%_"!;QAC#P,]]4FP3X&>^B38KL#P
M\TFP:X%!YI-@9P)CPR?!-B'J\0T/[!:B'I\$FX:HQR?!OB#J\4EF:,',VP)L
M/R$*OK9ACPE1\$FPU80H^"38<<(8]4FPJX0QZI/@?``]]3U2."9`?WR2&7HZ
M\_84^\SHC\\'V$M&?WP2;"FC/SX)=I;1'Y\$N\?HCT^"362,-Y\$>\D8;SX)
MCOTPJ_BFNQE\,//Z`*=+Z*G/.SA`0D]]$IPCH:<^"8Z3T%.?!.=%Z*E/@F,C
M]-0GP>D1>NJ3X(`((]XGP:%MJ`X-^=G&V6VHS@Y9@B/<4)T7L@2GM*$Z-F0)
M#FM#=7K($IS9ANK$D"6X1X$6^.8=7*=`"WP2W)A`"WP27)Q`"WP2W)_`./!)
M9FC;S-LV',"'ZBR76XTS]E`=Z;($1^VA.MEE"4[<0W6:RQ+<CT*K?4\PKDF%
MZHX.E\'5*'C4)\%]*/34)\$5'/34YX,Y).I"!]>#FS7HJ4^""S;HJ4^">S;H
MJ4^"BS08B3X)KK*AC*_5N,"&,CX)[K%A[/@DN,X6JGM2W!]<8<.H\DEP<0VC
MRB?!C4OXP#>[X/XDVN:3X#8DK/DDN-N(^/@D,[1@]HL6#,*Y5[)`&74MC7N*
MBX9HM4^"^X:(G$^":X>ANJO&UF98-?K&+JYVPP.^60<WJ=%/GV0>X'V!"[-<
M"ZX+PYI/@NN^\*=/@NNZJ*>6W%P6=OBD_W7[;9=OC]_V+Z>KI]T#UO7=^A;[
M47_]K_\XZSVYJZ^',S[F5]MS5X_XOS3L<&F]JW;R'@Z'L_R!YMY<_K\/G_\/
M``#__P,`4$L#!!0`!@`(````(0`G0<[YJPH``.<L```8````>&PO=V]R:W-H
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M_7ZX_K=[K=O]T_,5PSU7)KON@"?AW]%QKW(`H6]_]K^O^X?K\]TX7HY'7]O+
MM=PKF_%H]_UR[8[_T\+(N-#&L3'&KS%.%C?SY32)XODO.TF,$_P:)_.;931=
M)TOX>.?A,V.W&.Q4R]\Q@+0/%;^?>A#F1&^'7V,7X]GO/&AM#/!K#&:V5Z3=
M1`])/Y3Y]KJ]OSUWKR/,#W3^Y66K9EN4PI<90_/D85217#NE_46IWXT1'<;M
M`OKC/EI&MY,?2).=T=D$=+A&1AHJ593;W`>%#TH?5#ZH?=`X8()HAY"129\)
M6:FKD*FQ&P*V#V(O/M(@D]P'A0]*'U0^J'W0.(#%AR3_3'Q*_6Z,?YTA]0+:
M:)VYJS3W8AY4AJ`%*00I!:D$J05I7,)"QYSY3.A*'8F/-<")/>&!;;32N[$/
M*D/L@A2"E()4@M2"-"YAL2,*)W::L(KV(5+3-IK,X>?MH+-!B<QR00I!2D$J
M06I!&I>PB+#J!B)2E$>D28*UTXEHQH<Q&Y2&B`0I!"D%J02I!6E<PB+"PAF(
M2%$>D2:+>%AT,D%R00I!2D$J06I!&I>PYJO*S6X6E&**\N9K$CO-%R07I!"D
M%*02I!:D<0EK/O:W0/,5Y<TWI"^=^OTI$R07I!"D%*02I!:D<0EK?H0*S6F_
MV:MO5`ES?=[OOFTZI']DMVJES@/K/=R-Y[I(4SMO9I"J-IS)XRWNN=6BV5-(
M5$I4251+U##$8U:;N$VY#V/6>[ZI0E6`FT@C%K-&J!]5`1-/(V^MR(T-%&RX
M@PVATFA%LT&KLH;&L[>9U%:!W#0,\>#5#F^#I_D6Z8V?!6D0<L<9Q86W!!K#
M1!?8NO#2A@XJI%9I4&P-*ZE52]0PQ&-3>W@@-KVUL]C,;H]%=8AMN?1#TTHS
M5RE:B''56LFZ'_AE'.,<P1T5D5%9#8-:2E09]/[C:C+$>CJT//*;W@1]+5=#
MNWBWJ>W?=MN'\T%7"ZP[-9H[JQLR6*T4<UOCYH1L-Q2$UD[/:$/LO)3-%6E9
M7[5!B_XTV:^G#=/B`:IJP`8XY+PN$E@@!O&<7P_]IE=N6*C8G`3/)2HD*@UB
M.2]\U=*P88C'INJ"0&RZ7(`=]>(FT@B#Y&3.RLO5S&B9=$9FS9)D+99N[0I*
MY+T@.SMLI405(3U9HM5L.I_'WL&@MDKDO2'4>^?QJ\(B$+^N-UC\&K$DU<B)
M(X\$*@BYH1DMBRK2LGU22]00"@2B2HQ`(+KR8(%HM,#N89>`E7=BSB*M-5.;
M-S:D53R/[/PW)^1!A3JZ,%9),HQL*5%%OE$-V!8LO"RIK1:Y;Y@O/HZJ1+'A
M?[@(F8K&S6^-T"WTN"S2:&:+QERB@I`;LS9TNJ$B+;LSUQ(UA'I?+,"85UJT
M"/685U0&>1/5FR69T9K15)K&\W7DE0:Y5:(^*<B[[:;2('?)M8;]^YCP1+5*
MY+UAWGG\JMCY]0'&&NE7F@:Y$YB0W09RB0I"-@U*@UC(^HESZZLF0XL:0KTO
M'B"OK$0&_]&]N*4T3C(B0(W<,X[1<E`N42%1*5$E42U1PQ`/4)4Q=@2'#-;5
MC;M"Q08Y]8!$N42%1*5$E42U1`U#/!!58MA`Q$AYAQYUCO$./0:Y!P"#^*%G
M)2:D]@4MFC*%-2142E1)5$O4,,1C5G7&)V(VA9"SOJI7XZJBLR@SZ.U#CU6@
MV`J)2H-0P)%69;7>./18!;)I&.+!JWK%!C]DKBYC6.8:A/7?[FQ+_]`3F_K'
MKJ&Y1(5$I4%81*C5E=2J)6H8XK&I4B00FZY06&P:L7W%/SEDZBX"H_S^*20W
M6E0E3J>KU=JK)`O2L352*5'U2\^KR5!O=G$T7ZR]>J<A%5E9Q:K,L3WTX737
M51'K.8W8SF.0/9/D_7,P06S`!2%;%)8&L9U'^*K)T/IJ"/6^>`JH:L4&.*2W
M+F)8(`;Q]/;/-['6<L\W$A42E0:Q]!:^:FG8,,1B2\)E4X]YV6002^](G&^,
M%F7N4M7%2_],;Y5HFA:$[("4$E6$J"B;KZ8K/U-KJT3>&T(R>3$(H;'ML1>_
MJ5^<3==HN><;B0I";FC:EYNDI&53N9:H(10(A)='E*2)+(,,^N!\8[3H?+-8
MQ9'W`B>W*M31A4%.85]*5%G#OOI=8AB]U:VV*N2[88YX$O/*Z:,5"*WS"PZ#
MW,.-0>[A1J*"D'.X,0@_U/2*M&R%7$O4$)*'FX175,/@RLJIU\0BB1W4;K`K
M_W!CM.SA9HVW$-Z*GULEBJ,@[W9_+0UBJ:R;-7A?SA=B/ZFE]X9YYP/\N>HJ
MD=650>X60\B>/G*)"D)VZ$J#6,BF>+.^:C*TJ"$D#S?XYL-=AOH,CN<W\*J_
M"["W^OK>P#OL].;><J5K*%YHK+R5.#.&T*(QSB4J)"HEJB2J)5)?MY@""$_4
M@ZR_5M&?.!S;\U.;M8?#9;3KOI^0P\L5WK`,>/A,YDO?B1[?X/.9/C=]'J>X
M>L<#?9[@<YL`_S)+OZ"A`8-9BMO<`)^GN!,-\$6*F\4`7Z:XL@OP!`;A)R>S
M=(,$DC89)"ISI03S-54)+"68MJG*8RFI(%&Y*R68GVA;2+))8K0MU)$9)'E0
M@JT";0O98,=`VT(2;!QH6TB"S0%M"TE0VZ:JW`O$`XFJ^J0DB]>IJK^DI()$
M55-2LDFFZ(-0\F60Y$$)JA[T0<@&Q0_Z("1!#80^"$E0Y:`/0I(-(MV\$>DR
MS8(2G$%257++2''R0.^$)#B`I*H`ES8XAZ154+*)U=P,3<XL1K[AQ"V]X6",
M%H0R$0=;V(0D6;R`36@NXH@(FY!D$V-,=;7M+1QX/8C>"?4U7@#B.2$)W@.B
M=T*2"A+U,DQ&BA=^:%M(LHE6Z0:O0Z4-7DVGZCVLE.#U<ZI>QTH)WD*G95""
ME]&I>A,K;?"V&:MM2();--B$1@XW9[`)2;((8ZK/4EY?5Y"H&QK9`MRYH`]"
MZRCN6=`'(0EN4O"<D`07*NB#D`3W*H@G),'-"=H6DFP0Z>:-2),T"TIRV*AK
M/!DI[CC1ZI`$5YUH=4B"&\]4W>U);QL,7&B6XLL"1-,7+-X89%&$YX?R$/?G
ML`E)L@@K/&Z3Y?-Q$PV;7C(9'H2O3U^V3^V_M^>G_>DR.K2/V/RG_:<29_VA
MJO[CJM_SCKYV5WQ_JE[YCI[Q07&+#P>FJF!Z[+HK_8%'3X9/E.__#P``__\#
M`%!+`P04``8`"````"$`=EGM'9\0``"*40``&````'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;)2<27,;.1*%[Q,Q_X&A^TC<EPI;'>:^[^N1EFB+84E4D+3=
M_>_GH:J26<"#V/*E6_XR\5!`9J&P29_^^OOE.?5K=SSM#Z^?;S*WZ9O4[O7A
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MGXZ'WRD,9\BHT]O6#(Z9P*C&[US\`ES>0@P&#\;]B_'_?(/<Q_MU`OUUG\F7
M/MW]PFO]$/M4/3ZV1TT\S*MM9.LN:+B@Z8*6"]HNZ+B@ZX*>"_HN&+A@Z(*1
M"\8NF+A@ZH*9"^8N6+A@Z8*5"]8NV"3`'<)_R0$D_1_E@/$W.2#1JPK0I,@Z
M`1</*5)W0<,%31>T7-!V0<<%71?T7-!WP<`%0Q>,7#!VP<0%4Q?,7#!WP<(%
M2Q>L7+!VP28!K(!CK**`Y]*7=]R8PX]KXATOVP&M1CX%_._B5+!=:A>72]")
M-(@TB;2(M(ETB'2)](CTB0R(#(F,B(R)3(A,B<R(S(DLB"R)K(BLB6R2Q$H%
M?'LH%<SG.YH`\?AO_/&M@,<E[IE\Q8Y\-7*ZFAP7ETMR$&D0:1)I$6D3Z1#I
M$ND1Z1,9$!D2&1$9$YD0F1*9$9D361!9$ED161/9)(F5'(AR,CED#F!PF`,2
MNVI$"A!Z/RMJ%R<I5B?2(-(DTB+2)M(ATB72(](G,B`R)#(B,B8R(3(E,B,R
M)[(@LB2R(K(FLDD2*^28?OM";K`=\HC@'9=HUHC4B32(-(FTB+2)=(ATB?2(
M](D,B`R)C(B,B4R(3(G,B,R)+(@LB:R(K(ELDL2*+V;NR?B&\_ULX1;Y\-Z(
M;TK8H8](#@LT?=L+:?L;4+LX27[4B32(-(FTB+2)=(ATB?2(](D,B`R)C(B,
MB4R(3(G,B,R)+(@LB:R(K(ELDL3*!K-SEEC]R0!OL!WRB.215HF09YR07YPN
M(2?2(-(DTB+2)M(ATB72(](G,B`R)#(B,B8R(3(E,B,R)[(@LB2R(K(FLDD2
M*^38'/&%W&`[Y!%Q0NZNZRY.EY`3:1!I$FD1:1/I$.D2Z1'I$QD0&1(9$1D3
MF1"9$ID1F1-9$%D261%9$]DDB15RL^'HBWG([:`+*NIGW4*VKME02`P?^C&1
M@<1L6#II)0AC4F(HR3E#B7@AC1->^8N7_1QFG9MXCDOMT?H7BQ7)SJK9#S4/
ME&Q?$MFZ9M64T`W;5\).\V6E;+9(W?;%R&Z?NS:6@G;[BN^TSTS0$\]Q:5\T
M<;?:%Z-D^Y+(;I^9!29T/?&+YHE6#3&RV^=L`=90(NP8NWVZB6`_AYFMN,^1
M*]^:_<CW9B6((/5\A)P1RUF;UN*"\)*DJ#-J,&HR:C%J,^HPZC+J,>HS&C`:
M,AHQ&C.:,)HRFC&:,UHP6C):,5HSVEC(3A0SD4DDRN5%,-P9R")D)T/1G:1F
M+EZ:#(0:[-5DU&+49M1AU&748]1G-&`T9#1B-&8T831E-&,T9[1@M&2T8K1F
MM+&0G0QFBN-+!L.=9(@03G<DS+4,H3JC!J,FHQ:C-J,.HRZC'J,^HP&C(:,1
MHS&C":,IHQFC.:,%HR6C%:,UHXV%[,B;F8XO\M$,R/I:Q4A'^UJ&4)U1@U&3
M48M1FU&'49=1CU&?T8#1D-&(T9C1A-&4T8S1G-&"T9+1BM&:T<9"5N3-06TR
M\N&,)5.X-2?9YZ?]PX_J`=/%S&5^%OK;8X&@\!Y#>/A8BQ&.<,UY9CY3SCK?
MB;IZR`#28-1DU&+49M1AU&748]1G-&`TC%%&FSQ2KZC)Q9PS3QJKAS1YPFC*
M:,9HSFC!:,EHQ6C-:&,A.U]\*Y1K^<+KE6R,M/-J,3+34UV<%)W=D+IZ20<V
M&#59OJ5>27EGY=U6+Y'O,.JR?$^]$O)NQO?52^0'C(8L/U*OA+S;.6/U$OD)
MHRG+S]0K*>]TSER]1'[!:,GR*_5*R+N=LU8OD=]8R,[!=U:GYJZ),T^)4=;:
M9BNZ:V/QPD0UD7ZZ-HYN5(A7)1S4,N5"J9!SE!JQ3RZZ&&4N8C0%Z;Y^2Y2N
MUM>6@EAM)I[*6?=VQ$MK[`K2&GL?JK$O7E=:.!!QK6\H2.L;B=+5%H[%*ZHO
M6\Y6RFEGU)R(N-8W%:3US43I:GUS*7BU1Q?BI34N!6F-JP_5N!:O*RW<B'A8
MGYWHSG:)K,[,U2@WT2.$1)<7J!9[9<L75(\1;B:(5T.0SN2;@K2U+=9JBY?N
M!74$J597D&KU6*LO7OI<`T&J-12D6B/6&HN7:DT$J=94D&K-6&LN7MK&A2#5
M6@I2K15KK<5+GVLC*-2R(V^VF#P3<G.SS8U\A'+V$*<;7_&,+/:R7Q!G,*G'
M\CF]B=00I%G49-02%.5YKES!74CG\]U6'TF^CB`5[S+J";HBWE<?$1\(4O$A
MHY&@JQTS5B^1GPA2^2FCF:#XV=/Y2JG@?%CFZB/B"T$JOF2T$G1%?*T^(KX1
M%(K;:6<V&7UI9[@SZX\0TDYT:V;Z!J]$]M09-01ITYJ,6H(J%_DVHXX@U>HR
MZ@E2K3ZC@2#5&C(:"=(W9,QH(DBUIHQF@O2YYHP6@E1KR6@E2+76C#:"0BT[
M\F:KUQ?Y:`LXN0-@)E,(LS.G<O>K8Z\\UI?OSU[JZB59U(A13D?3)J.6%#0K
MTU_WV5*^E"G0@!,]:%X_Y!U6ZC+J?4"\KS[RY`-6&C(:2<&K'3-6+Y&?L-:4
MT4P*1AV#FV3%4MI9?,_51\07K+1DM-*"T3UEC_A:?41\8RG9:8=AUYMVACL#
M3H2@);JU;(208X+JC!HQLA(J*IA`+2FHR=)FU&&M+J,>%^PS&G#!(:.1%-0V
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M7NV8N7J)_(*UEHQ64E`ZQO/L:_41\8VE9*?='VZ88^O0_?[%*#GSB5%>=R'J
MC!J"$E/I&"6RKR5>NA_?9M01I%I=UNJ)ESY7G]%`D&H-66LD7JHU9C01I%I3
MUIJ)E[9QSF@A2+66K+42+WVN-:.-H%#+SHAWMJ]SO'T=HSP6UCH0E9SI?$V\
M[`^\L\M0%Z_H4UHL5K*\?1W[%'2"V(Q18G;4$J6K];7%*ZJOG,GETA5G".UP
M?5VNKR=*5^OKBU<\5<B7LX5BSCG&&'"%0ZYP)%)7*QR+5U1AJ93-\^XUUS?E
M^F:B=+6^N7C%`<Q6\I6"T[X%U[?D^E:B=+6^M7A)AZ8SE9)[[+2Q*K33W-F\
M_K>390Q)-/!%".DO`VTM]LKK7*$>HX*ND!J"]!5MQLC*XUA>M=I24+4Z@E2K
MRUJ]&"6>JR\%56L@2+6&K#5BK;$45*V)(-6:LM:,M>924+46@E1KR5HKUEI+
M0=7:"`JU[(QP-K4I(^:'-TS$3+"COV@0_5[UR^[X?5?;/3^?4@^'GZ\8"#/X
M[MU_NO#H;RE4*P$N[**LRS/%P-R`\UE*L(3S7*<,_B[#E_#Y'5[%WVL(G\_E
MV0"_&NJI(8>_[^#A7_+!%_23IT`^P"^/>7@AP&\8>3C:YFT:6N9K6+4<X"([
MZV!P"4QBL`5#2F#R@RT860*3)FS!`!.8;&$+!I7`)`U;,)*@KWP6C-"!>4VX
M#`;JP+PM;,'@')B7ABT36,R[PQ:,S(%YA=B"`3HP;Q);\)4+S*#!%GS;`C-V
ML`6?N,`,(6S!ERXP(PE;\'4+S(#"%GS2`C.NL*4*2]5KP8PA,",IE\$L(3`#
M*EL:L)AQE2V8(@1F>&4+9@I!RVO!S!Y][7N5,,%')OHLF,$C$WT63.21B3X+
MYO/(-Y\%4W;DF\^"]1+BX[-@V80H^"Q8&2$*/@L62,A>GP7K).2HSX*E$'+4
M9ZG"4O5:L!Q%Y'QEL.)$Y'P6+#P1.9\%ZT_DM<^"!2;RVF?!YE!@-@$X#[!'
M%)B%/UNP#128]3];L!L4F&T`MF!3*#!+?[9@WP?CL,^"3;?`;)QP&>R]!6:S
MA"W87@O,G@E;L,L6F*T3MF"S+1A[+=A-"\RN"9>IPE+U6FJPU+T6;%H&9I^)
MU;!W&9CM)K9@"S,P6TQLP2YE8'::V((3!L34]R7!00-BZK/@+`$Q]5EPI("8
M^BPX64!,?18<'B"F/@M.;A!3GP4'.(BISX(S&L349\%1#6+JL^#$!C'U67`D
M@YCZ+%58JEY+#19S2L%]C9,OQ-1GP0$88NJSX!P,,?59<-2%F/HL.*9&3'VS
M"9Q6(Z8^"PZD$5.?!>?2B*G/@N-IQ-1GP0DT8NJSX/@?,?59<`L`,?59<-"/
MF/HL..]'3'T6'/LCICX+SO414Y^E"DO5:ZG!8HZZ?3'-(Z8^"VY1(*8^"RY3
M(*8^"^Y+(*8^"ZXV(7*^;S"N,R%R/@MN-2%R/@LN-P7F"@NW!Q>:$%.?!=>8
M$%.?!??#$`6?!=?$`G.%A^O!U3#$QV?!A3#$QV?!O3#DM<^"ZV&!N=[#]>"2
M'?K:9^G`TO%:<+\..>HK@VMV@;G>Q/7@:AVRUV?!A3IDK\]2A:7JM=1@,=>[
MN)XZ+.:6%UMP-1&9Z+/@AB(RT6?!1<7`7/UBM6H&7UK\/@%;</<;[0G7@\XB
M"5>DD2$^"^[_XME\<PI<W444?!;<ND4]/@LNS")#?!;<=<6[X+/@FBJ>+;3<
M71X;?R#O;?M]-]@>O^]?3ZGGW3>L/=/AU?AC]+?THG^<HV5KZNOAC#^-9U:P
MJ2?\S<,=;G^FS=\!^'8XG.4?Z+"[RU]1O/^_`````/__`P!02P,$%``&``@`
M```A`!5#.<!"`P``70D``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6R,
MEFUOVR`0Q]]/VG=`O&]L;">IHR15NZI;I4V:ICV\)C9.4&UC`6G:;[\#'&SR
M(/5-%!_GWQW_NP,O[]Z:&KTRJ;AH5YA,8HQ86XB2M]L5_O/[Z>86(Z5I6]):
MM&R%WYG"=^O/GY8'(5_4CC&-@-"J%=YIW2VB2!4[UE`U$1UK8:42LJ$:'N4V
M4IUDM+0O-764Q/$L:BAOL2,LY$<8HJIXP1Y%L6]8JQU$LIIJR%_M>*>.M*;X
M"*ZA\F7?W12BZ0"QX377[Q:*45,LGK>MD'13P[[?2$:+(]L^G.$;7DBA1*4G
M@(M<HN=[SJ,\`M)Z67+8@9$=25:M\#U9/)`YCM9+*]!?S@YJ]!^IG3A\E;S\
MSEL&:D.=3`4V0KP8U^?2F.#EZ.SM)UN!GQ*5K*+[6O\2AV^,;W<:RCTUKQ2B
MADCPBQIN>@"V3M]6.($(O-2[%4YGD^D\3DDRQ6C#E'[BYEV,BKW2HOGGG(B-
M[E@VAT>JZ7HIQ0%!8<%;==2T"5DDL/G"&.^-=87G&`%/@?5U3=)D&;W"-HK>
MY\'YP._@XSTBH/L0D.^%$,9J0IA]FI@/SC#F#1$#7AKPD-$KF_K4S2HH,TXK
M37UB+I3SR48^4^\1A`*7"ZD;*^@%H@];3S-/<#&<TP=B`&84PVXGF4V@I,=B
M&`<;SDO56Z#5+B80;&%V`4_FDP%O'$)\;QF7@J17%((>.<V>S/-Q^L8CY/>6
MD#_S^@7IFU-NZ$^K3IK/O#9F.83WEA`^OPS/S^%3,ID/VAB'$-];0OSM93R!
M`HV2/];3FD/JT00S,*IH?@4+P4=8JPG)1\-KUD_XO2E(.XNO\,.!=9K/XU'+
MD'Y6W2EEI_=H"B.0*Q'"$?;"N+GL#S^'[4V!,-F5@X%<'E=K/M&C'V&@#WIG
MPS$1M*`9]%.]DSSS/6C73_C]A(['GV3#$1'RPQ'U:IP/)NE-8=I7)A/NK+.T
M29R,V]NZG&3>#V>8^>EPNLO,720-DUOVA=6U0H78MZ"G:45O]9?H?6+.^E-[
MMKAWEVOD5^#.Z^B6_:!RRUN%:E8!,S9Y(^FN1_>@10>YP\TG--QV]N\./F,8
M7":F65$EA#X^0.3(?QBM_P,``/__`P!02P,$%``&``@````A`.`@-'T*!```
M90X``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R4EUMOHS@4Q]]7VN^`
M>$^P,=<HR6BX='>D66FUVLLS(4Z""AB!VW2^_1YC$F*GX[1]*`'_^/O\SS&^
MK+^\-;7U2ONA8NW&QDMD6[0MV;YJCQO[G[^?%I%M#;QH]T7-6KJQ?]#!_K+]
M]9?UF?7/PXE2;H%".VSL$^?=RG&&\D2;8EBRCK;0<F!]4W"X[8_.T/6TV(\O
M-;7C(A0X35&UME18]1_18(=#5=*,E2\-;;D4Z6E=<(A_.%7=<%%KRH_(-47_
M_-(M2M9T(+&KZHK_&$5MJRE7WXXMZXM=#;[?L%>4%^WQYDZ^J<J>#>S`ER#G
MR$#O/<=.[(#2=KVOP(%(N]73P\;^BE<Y)K:S78\)^K>BY^'FMS6<V/FWOMI_
MKUH*V88ZB0KL&'L6Z+>]>`0O.W=O/XT5^+.W]O10O-3\+W;^G5;'$X=R^^*5
MDM70$_RWFDJ,`;!>O(W7<[7GIXU-@J4?(H)=W[9V=.!/E7C7MLJ7@;/F/PGA
M24J*N),(7"<1C#\M0B81N%Y$O"7V4/")0+Q)`ZX7C7#I1C[V/Z,"QL><P'52
M<2$H<RX<F=>Q'EG!B^VZ9V<+!CED;N@*\<G@%0B*0A`$`Z(4C5]%Z\C`XP&>
MOFXQCM?.*Y2VG)CD'<9%*I.^QV"5R>X9+U*1_![QYYX<<'2U!:4VV!*M&QO^
MS[9<5^TKD4PTF@YC-\:11U0DO44"@D(2>[JI6P0'`/C>'/&8X_P66>`P",AL
M6_$$139X$JVZ)RW@1#*!+&081[Z/-"1]C&02@3%\S9ZO)B8W$8HE$#%8$JTP
M'&\ZPJZG=I5(QA!,^I#('A*YB5`,P2=T8^CR&8FG:FUB;:`D$I&E(:[GAX%J
M-'T$9!(P9"(W$8J+X%T7XJGJ`B9A-<I$,H8@4DE,8]`G2/L<LH<*N8E0;(2*
M#7UN$ZVZ'2WIB61DL"'&Q`M5O^DC().`(2&YB5#LB,W/SZ=JT:K;T:)-)#/E
M'HD_K7[I0R*3A,F0B5`,Q8JAR\<BGNI&YAEQG#,3R4@C"^Q'R-5'8OH8R21B
MLF(B%"L8MD`WQ;EX&1_K9NX64/'NQC;$D4XZDV'B(8]H0S6;$(-*;D14.V*E
MG<?:U8Y<@&'%ND[]H3:"$BP9&6H<>2'6BI=.A"'23!'!"$51K,T3N8(L7`^'
M\PJN>A$+[#M>Y+I[ZP43K9,$2TCN`B)8X5TWT%:@5&$"XKMQX&E,IC`X]!#Q
M]+YRA5G`@23"<SBJ([&^SH[TB0TV[G=?$-'7FPF:Y@+8=2`2:--%^@$FFQA#
M,<5!XN?C6QJ3!P6Y,>V*(_VCZ(]5.U@U/<!(0\L0EJY>'A/D#6?=N"_=,0Z[
M_O'G"8YS%#:M:`GP@3%^N1$'D>L!<?L_````__\#`%!+`P04``8`"````"$`
MT:DVND8&```U%P``&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(Q8VV[C
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M7/<WD&5UC3U]6(1OFZKOANXPWF&XK2:Z7'.VS;88Z?%AW^`*E.Q!7Q]VX1/<
M%R()MX\/DT#_-/7;X/P?#,?N[9>^V?_6G&M4&_.D,O#<=5\4]/->#>'+V\7;
MGZ8,_-$'^_I0OI[&/[NW7^OFY3ABNB/U2M6=<";\';2-J@%<>OEM^OO6[,?C
M+A3Q790P`3P*@^=Z&#\UZMTPJ%Z'L6O_U2`PH700;H((I&F>X]#ME[>:R+2`
MC^58/C[TW5N`58%3#9=2U1C<8T##W$P_KP4EK13Z2<%W81(&R'+`T:^/:?2P
M_8K:5`:2+R%`$<45H21%&C,77(7#Y3JE&E53*C45AUP/8)"9`_<F6")B-D/(
ME+CDE2G5**;&F2&-Y_<U"0V1#L33H;B%(!PPR`H'-;H+<27S*M/$XZ`AZ92&
M+)4)I!10N`#(N$RL4(0!UI[#8"H"&<TY5T\]-;R)<@W!Z6:ROAJW$(1+O.0B
MV,Q%/?54R>BB<PV)=7$RQH5??BX@!L:B=U3!*G=4N9:C&J4,,EM;NC8T1$X,
MO&>%?J;9Q9$$,;,G*JB=P;;E=6XUZLWM+2[7$!U?\$A(.4\PD2L(@$606?T(
M@XPPF&K"R8-ZZC&Q*FH5-$0SV20`0GI54Q`$1#RU`$(%T)!7U)B&/1)63DW"
M8#0+X$S8*;0<-P"4@S*M949`>YG;IIFG>&XPAD,*6>07!4'$7'"[#$I"&9LE
MX3<J:-]S?2OS^C`WF%NM>A-"^2B/LWRN90K:^H@HOG\:C"D/D*ET^]#D1L?1
M&,YDS*-WBA64TZT0T09(B/@F.KVZ"TUV1,R$G</0T%$,@DL6VZ:C<JSXJ-,S
M>")8-(U7CKG!F"5#'*7<@Q0$LH&$)=%[NQM0,YWSLW11Z7?O].HL"\/-PROK
M@B!$(A.K&U5EW4=AQ4AM!-.]KEMN$@8Q6[!P(5&6)C:_E`5U5-_/8&FMN#-0
MZ\P-R!1""JEP',O4BFNOD&38R[8#*2%JL'-NM"FZ/0S,UIO118-N-O$M""'"
MU]UU&J;N"LRO$@/2BFQDRA?-0Q%Q!F"33&FL&RQ?&BPP:X]:#P,R-%!RF?F8
M@F*D2"!BMK4HE16;=?J8:YMU707\NLP-R#0RCQ.6>N(5!((."+$#H836?98O
M?1:8+3>CC6NB&_QBJ'YH81<FD']BH1S6+98O+1:8;_8&9/*3",Z<DZAN'`J!
ME&=Q9M-,F5";O7:.^@;EG4F`63<P:FC0M5*2.`6QR`O!R"1-8^?80*FL&RS7
M!DN;V!:;H:)!MYK8Q%F'4"+K)LN7)@O,-J`AHD%^]DU>7'_%EB'50RE0AYW3
MLN*LX!5@SC7H'0JNIVXD\,QFC#*@ENI[/->6Z/:M$\EHH3&Z/E8/K2:*1MPX
MM*)AN$<2G\STV+-7\'W>@,Q<D_9>>Q<&XBM'=!'KUCH-^Q2LM%H0`S(-`U'*
MN+.CZ1JA&`%X@G5V"DKEMK6*%6MUOB(92AID5!$`BR.2"7,E':>I<#R)$J+6
MNDC3BL6"=P;)!;%8P(-!#)X%%A0CXU3&[^V$@CKM@M**XX)7%OD4XWI\DRR-
M,QEY7E@03"2%S$1J*Y"J1"UW06G%>GT%<N':JL@8;K_23F<JR<7(+(YE$MN*
MI)2H]2XHK5@P>`KDXO\M^":$$J(6O""T8L7^A4V.EY1J#]-7.C)BB9,0HY"+
MX"B1\'=)?4NI+_G:NG^IB_IT&H*J>SWC[0S'6XEY=+X=?>+J>LT;S_'6=+IY
MW,X/\"[S4K[4OY?]2W,>@E-]P)#L+L&T]?K:4W\8N\MTM?C<C7B+.?U[Q.OI
M&J_OV!V"#UTW7C^H6\#YPOOQ/P```/__`P!02P,$%``&``@````A`)=J>X^S
M!```9@\``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULE%?;CJ-&$'V/
ME']`O*\Q5]O(]LI<)EDID:)HDSPSN&VC`=H"/)[]^U3US31-)C/[L(P/IZI/
M7;JZV7Y]:VKKE71]1=N=[2Z6MD7:DAZK]KRS__K^]&5M6_U0M,>BIBW9V3](
M;W_=__S3]DZ[E_Y"R&"!A[;?V9=AN,:.TY<7TA3]@EY)"V].M&N*`7YV9Z>_
M=J0X,J.F=KSE,G*:HFIM[B'N/N*#GDY523):WAK2#MQ)1^IB`/W]I;KVTEM3
M?L1=4W0OM^N7DC97</%<U=7P@SFUK::,OYU;VA7/-<3]Y@9%*7VS'X;[IBH[
MVM/3L`!W#A=JQKQQ-@YXVF^/%42`:;<Z<MK9!S?.W<AV]EN6H+\K<N]'?UO]
MA=Y_Z:KC;U5+(-M0)ZS`,Z4O2/UV1`B,'</ZB57@C\XZDE-QJX<_Z?U74ITO
M`Y0[1).2UK`2_&\U%?8`A%Z\L>>].@Z7G>U'BW"U]%TOM*UGT@]/%=K:5GGK
M!]K\PTFN<,6=>,()/&><O&/H"T-X"L-@$7CA:LU6?\<P$(;P%(;>\F.6$!4+
M&)Y2Z[N&#D\82W16#,5^V]&[!=T+*>FO!>X%-P9G(L,B32KG4/H2V0>D[^R5
M;4$V>T!?]UX4;9U7*&(I.(G)<75&*AE82'2;38%\!#B@5,F%VGQ&+M)1KEPH
MD<!(_T2;9$B3;`KD(T#3!N7_C#:D0Y^.4QF$NIB$<\(Q:4))%44)-I!\C&B2
MH?$^(QGIT"C0)Z/RKR::.>E=S8JB-!M(/D8TS;#Z5+._7N`^YSO-;%JT8++E
M<@E'@F@<2+C4`TD529IE!I*/$4TEN!ZIE-L'45T)1SQ/M6AJ()F!Y&-$6Q9V
MYLRRB.K+"H3-;K8%4P/)#"0?(]JR>.`^IHB,%E%]68Y$\'@T4#B=#C,D-PKT
MXF2<%+A\!FTV2_BG4W).\7U,K:9V,ZL645TM1T"M;(#40#*.@`[)R3DRLZP+
MY]],EABL+RP@'\JL\N1/PDLE:<-2X`:NF8+LP5'R),2BTM+BXM`UJ\C@B3X^
MGD&?=)L*EK]14&9"N81F%L>I.K,X'[;BT,>S(G$%!'E6R?%"3R]^*E@!Y'S$
M\G56]F#)0'(!>6-#=[56AGK*<+(^5(OC<[&"L3!<JO(EH;`X]J@X/?D@UJ(1
MD+XE)MV>NIP5C45YX>0HR!ZL1S3<<`4/E8;_C@9G[B,:I9J/8DTUAR+H`^76
M"R<7@=3E+`_&AF*9.UFR>!_##=OLXUQP?+;-]`K@!'YH_M\*\(&MQ<(AB$5F
M+877.`NB<3-S:,4NK*R:N6"M9D3A?'Y'U'=ZQ;:`]?C5E]_(&M*=24KJNK=*
M>FLA91ZVCH+5G?O`3HL)GN!='%U.<2^&&\L,[L=P+S#Q0Q`?>'JFCH(8#F73
M(`EC.`9-'+9@C!ML[HT/;^863]P@3F97AV:*L2ZFMPS>9+-OH&T@)W,V213#
M&6KZ2M9QPHH^B3U=QS#[37ZVCN$$,/%\'<,Y8.*)NX3XYLH$XQRBF'N3PQL<
MG.#-4;+@X^=:G,GO17>NVMZJR0G:9<D&3\>_D_B/@7>:]4P'^.S!IK,N\#U+
M8)`N%]#2)TH'^0,74%_(^W\!``#__P,`4$L#!!0`!@`(````(0",6`\Y9`,`
M`$D*```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;(Q676^;,!1]G[3_
M8/F](28A7PJITE7=)FW2-.WCV0$3K`)&MM.T_W[7-B$8B-:7$`[7YQY?WV-[
M>_]:%NB%2<5%%6,RF6+$JD2DO#K&^/>OI[L51DK3*J6%J%B,WYC"][N/'[9G
M(9]5SIA&P%"I&.=:UYL@4$G.2JHFHF85?,F$+*F&5WD,5"T93>V@L@C"Z701
ME)17V#%LY'LX1);QA#V*Y%2R2CL2R0JJ0;_*>:TN;&7R'KJ2RN=3?9>(L@:*
M`R^X?K.D&)7)YNNQ$I(>"ICW*YG3Y,)M7P;T)4^D4"+3$Z`+G-#AG-?!.@"F
MW3;E,`-3=B19%N,]V3R0-0YV6UN@/YR=5><_4KDX?Y8\_<8K!M6&=3(K<!#B
MV81^30T$@X/!Z">[`C\D2EE&3X7^*<Y?&#_F&I8[,D,244`F^$4E-ST`4Z>O
M]GGFJ<YC/".3513-%ZMEA-&!*?W$S6",DI/2HOSKHDC#Y5C"A@6>%Y;%)%I.
M9R3\+TG@%-F9/%)-=ULIS@C:`U*JFIIF(YL02I@8<&_0&"\Q`E$*T)==2&;;
MX`6*D30Q#RX&?ML8TD8$P-ZF`+TC*0QJ4IAJF9P/#NCRA>-\LU$^@T)=.W)"
M,F\)7`H7,^_$1&V$)QE"1B0;%.H$Q6ZG')(K@\OA@MZ1`VA&<AC4YFCKTB#0
MG9VLBW'=BU%.@_J<#EGXU5J.<T(7='0BV^3K:ZN8SSYY@W1+$)+5.+G9"H?M
M9U"?TR$]P>MQSK7'Z00OP"EM=YL`G[Y!/,GA=)R>P$J,:+:PS]I`2^CLZ]*%
M-UQ"C)^NI;"R9[-P`MYN7=E8SFTQUC1V%&3U;!/>,`X9=Z*%>\J=&?UZA]<=
MP#,+,;;J*0^C:`);6ZO<.:_9')WR!O*57QWKIS"NZJ4@<W+E-]][4V@@G__J
M5I_?-Z/K&1)U>L:XOI^A@?P,-YQ)?&N.91C:U`X:K.X-GQ+?J&WIAP:UD3'N
MK>X-AQ+?HDYXM_1#L]HA`]DWW`H']'!I/;O:B-[B-H;U2C_K&]8=W.ZX*YD\
MLD^L*!1*Q*D"/YHMK$7;"\,^-"=2'Y]O]NXB$;1?X'ROZ9%]I_+(*X4*E@'G
MU#0]DNXJX%ZTJ$$['/)"P\%N_^9P96-PY$VAOU`FA+Z\0.:@O03N_@$``/__
M`P!02P,$%``&``@````A`,KS8Q)>`@``5`4``!D```!X;"]W;W)K<VAE971S
M+W-H965T,30N>&ULC%3+CML@%-U7ZC\@]F-B.X].9'N4=)1VI(Y457VL"<8V
MB@$+R&/^OA>3>)))%ME8YG`XY]S+M;.G@VS1CALKM,IQ'(TPXHKI4J@ZQW]^
MKQZ^8&0=525MM>(Y?N,6/Q6?/V5[;3:VX=PA4%`VQXUSW9P0RQHNJ8UTQQ7L
M5-I(ZF!I:F([PVG9'Y(M24:C*9%4*!P4YN8>#5U5@O%GS;:2*Q=$#&^I@_RV
M$9T]J4EVCYRD9K/M'IB6'4BL12O<6R^*D63SEUII0]<MU'V(QY2=M/O%E;P4
MS&BK*Q>!'`E!KVM^)(\$E(JL%%"!;SLRO,KQ(IXOIY@46=^?OX+O[=D[LHW>
M?S.B_"$4AV;#-?D+6&N]\=27TD-PF%R=7O47\-.@DE=TV[I?>O^=B[IQ<-L3
M?X3I%IS@B:3P(P"5TT..$W`0I6MRG$ZCR6R4QLD$HS6W;B7\68S8UCHM_P52
MW+L'K3[#,W6TR(S>([A78-N.^BF)YPG4SCRX\&B.9QB!G@5T5R3I)",[*(,=
M.<O`@>?`B0<&`?7!`O+>L/"HM_!U>L]E`,[UDMMZZ84>\OT:3X;H?A<Z<QXK
M30>A8!4XXS/.>W$7T8%R([I'H5_0]*'T))U^\`BD.SQ`YH:'1WN/H3]'!.;K
MINM%[NF%9M^B=#*+9N]M\HQ+_2-RGCA)9T-503],<9@@R4W-O_*VM8CIK8)4
M?H`&=/AX%HF_Y(_X>+[H/RHR;,"L=[3FK]340EG4\@HD1SXT,N&S"`NG.T@.
M$Z\=3'G_VL#?B\,0C2(@5UJ[TP*,R?`_+/X#``#__P,`4$L#!!0`!@`(````
M(0"`>@]]8PP``!\V```9````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)2;
MVW+;.!*&[[=JWT&E^[%$ZLR*/14=2%%'<FMV]UJ195L52W))2IQY^_U!L`4"
M/S9QYF)B?]UH`(T&B`;@3W_^.+S6ON_.E_WI>%\/[IKUVNZX/3WNC\_W]7__
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M8K@[JLCV](J:\/_:8:]B`%W?_"C^?=\_7E_NZV'OKA<T!ZU>IU[[LKM<X[TJ
M6Z]MOUVNI\-_M5)0FM)&PM((_A4CX5V_TVEW^[]AI55:P;]BY:>U]DI]_/LA
M_>#65_SPL1+2L<#T+&C>!>UF-_RX=^#WTL?XX6/U=J4$?BA+?+C>AA[A(C+&
MF^OFX=/Y]%[#=$.O+V\;-7F#*(#3RI@H!_86)0C6K5+_K/3OZU#$^%]`OS^$
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MR(+(DLB*R)I(1B2O$LN?`]N?Y8;Z3J4\UY?]]NOPA!4TN.VGE;KM9TTZ.B]3
MF^.1)EVLXF;Q[3F;C?%-21;?"9&82$)D2B0E,M,D:-^6JOE-I]+$OI,7+&Y*
MTL0ED161-9&,2%XEUF@$2)*KX?VKX2CT[?$H475`2H1TKTB`FH&S'QD;!>GJ
MA%%<HHH?$Z-56G9\.#4*8CEE-&/+<Z/E;_/"*(CE):,56UX;+7^;,Z,@EG,+
MV2.FLB7/@J02=6>F",+HFXDQ:#J[DE*KI4\G=+:I;570A+7B$H6F8,):4T8I
MHQG;FK/6@M&2T8IMK5DK8Y1;R':ZRIQ\3M<957E(I'PW5*<>&(<./M`5IU."
MK[7:EI:[;1^7MEJ#8AZUFMU6/W`VE1/1Z=\6FYA14J*?US>5@KJ^=M#N#GK.
MU$U%Q]0W8S3_4'T+*:CKZ_3Z[4'36;>7HF/J6S%:?ZB^3`KJ^H*@->@/NGU[
M/N2B5%1H1X%*VGQ1H),Y*PK*_*ZR&P@TPA#(+!^7".,K:"+(=#=FE+"MJ6@9
M6ZD@8VO&:,ZV%J)E;"T%&5LK1FNVE8F6L94+\GA896(^#^L,S?*P1ETL595Y
M%MJ#.<*W0\W&MMI0?'\(6NUVO^O,H+'1,:.@B[5:MX&)2ZT*2J0@OJ&F"5TG
M@*=&2\RG;&O&:"X%==O#=K\=NHOWPNB(\25;6C%:,\H8Y1:RYX)*Z'PCI1,]
M:Z0TPDA)&T<0E\,B:,QH4J**RV-&B10LSO:+C?>44<H%9XSF4M`T=<%HR057
MC-:,,D:YA6P/JQ3/YV&=^J&@^&X8:.1\<YRMT:C4DJ])IS-H!8[.V.B(\8D@
M,_-C1HD@O;2&S7;0;#O&IT9'C*>"C/$9H[D@;;P[:'5:/6<;LS`Z8GPIR!A?
M,5H+TL;;0:<?#IR69T9'C.>"/(N8RB5]`Z=S3&O@-,+`B=V1NF3`BE7Y)HP9
M3029KL6,$D%F[9TR2@496S-&<T'&UH+14I"QM6*T%F1L98QR01X/J^S2Y^$R
MZZQ.#8V<SX2SJ1D%6DL^$\U>T&XY,3`V.C)6DQ)9"Y2V5$&)%/S%9Z)L@EG&
M4C8_8S07\_*)PY[-_08MC(ZT?<F65HS6C#)&N87L14QEGKZ1TAFI-1?*)-6L
MO:-`(PR+-'O,:%*BBLMC1HD4-/Z=,DJYX(S17`J:=BT8+;G@BM&:4<8HMY#E
MX=#)X.6`JN!VIEXBYS/A[%=&I5;YF>B&W6[?F2YCHR+C,A%D)G[,*!%4+N0!
M;KM[]HYM:E3$=BK(V)XQF@O2MH,`FZ6^LQU<&!TQOA1DC*\8K065QIMA9]!S
M<KK,Z(CQ7!`O8<B:O1.CX,ZPZ6R\^I$HM:H?"4830:9K,:-$D%F,IXQ20<;6
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MI_4M1*O\;N"$J]4.G*_2DBM<<85K,?73"C/1D@I;K4$8.O,]MRJTPT`EYI4P
M^.4$U(F\%1X:(3QD;$;JW9<ZA3'#-2Y1QVS')H),",<ELL:9;$VEH+&5"C*V
M9FQK7J)*NQ92T-A:"C*V5FQKS;8R*6ALY8(*6[;GG72?//_7Z0U?+>54_8!1
M/U,[[,[/N]'N]?52VYZ^'3'5\`P1AUTWKI].#CM17@R(R[M17B2?#D<`1JJ7
MJ,V1(`XCU5F6(/8BU6>6(.#P<M,GP9/.SX4OG%J&>.I9]-7E(0QY:ABVHKQ8
MU!S]SVW8]U4\1(N*^SFG`%:(2`44=P+K0J3BBB58'B(57BS!*A&I*&,)5H9(
M!1M+L!Q$*N98,H1DZ)5@M8W4+.,R8TC49&,)UM5(S3F68'F-U-1C"5;9*/%*
ML/.`#WQ#@`T(>NJ38).!GOHDV&L@_'P2;#D09#X)MA6(#9\$>WS4XPLG;/51
MCT^"'3_J\4FPJ4<]/LD0+1AZ6X"](T;!US9L$#$*/DD,2>R58+N(&/65P980
M,>J3(+F/5/K)8XH<'W/-)QFBIT-O3Y$DHC\^'R`11']\$N2#Z(]/@K00_?%)
MD/JA/SX),D#$FT^"1!#QYI/@S`X]+=Z'.K-^"!\,O3[`T5"D#AW8;SC]B=39
M`TMB2-01!$MP%A2I8P>6X+`G4J</+,&93Z0.(5B"HY]('3RP!*<[D3I_8`E.
M7%&/SP<X>$4]/@G.7U&/3X(C5M3CD^"D%?'FD^#`-5+'?=PV7(*@!;YU!W<A
M:(%/@NL.M,`GP:T'6N"3X/(#<>"3X"0=<>!K&T[/$0<^"0[($0<^"<[)$0<^
M"8[+$0<^"2XWT6K?#,8=9Z0NV-AON->$1WT27&:BIS[)$#X8>GV`.S/TU.>=
M"23J4H9;@-LQ]-0GP249>NJ3X!8,D>B3X!X:97RM3B%1UYK<`EQ"(W9\$MQ%
M1^J2D\O@_AE1Y9/@UAE1Y9.,@@`^\*TN>/R`MODD>,H`:SX)'B9@?'P2O"/`
M^/A;$$8CKP3O!3!ROC)X)8!6^R1X+("1\TGP9B!2%\WLMV$ORGVQ.QI$>`S%
M^O-!E/OX*,"W`B]=N`3>^<"7/@G>Z<"7/@G>V<"7A:1Q6][Q5SMOF^?=<G-^
MWA\OM=?=$W;(S>*UV5G_@8_^Y:HWU[4OIRO^7D?MLVLO^$.L'5YT-.^0<3R=
M3E?Y!<UMW/ZTZ^%_````__\#`%!+`P04``8`"````"$`8@I/P"D*``#T*@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R4FMMNXS@2AN\7V'<P?#^Q
M)5L^"$D&L<[`+K!8S,Q>.XZ2&&U;@>T^S-OO3Y$ELECLI',S/?GJ(/X\%B7?
M_O[C>!A]:\^7?7>Z&T<WT_&H/>VZI_WIY6[\YQ_E;ZOQZ'+=GIZVA^[4WHW_
M;B_CW^__^8_;[]WYR^6U;:\C9#A=[L:OU^M;.IE<=J_M<7NYZ=[:$RS/W?FX
MO>+/\\OD\G9NMT]]T/$PB:?3Q>2XW9_&.D-Z_I4<W?/S?M?FW>[KL3U==9)S
M>]A>T?[+Z_[M0MF.NU])=]R>OWQ]^VW7'=^0XG%_V%__[I..1\==VKR<NO/V
M\0#=/Z+Y=D>Y^S]$^N-^=^XNW?/U!NDFNJ%2\WJRGB#3_>W3'@I4MX_.[?/=
M^"%*FUDRGMS?]AWTU[[]?G'^?W1Y[;Y7Y_W3O_:G%KV-<5(C\-AU7Y1K\Z00
M@B<BNNQ'X#_GT5/[O/UZN/ZW^UZW^Y?7*X:[?]ZN.^!)^._HN%=S`-*W/^[&
M,9ZP?[J^WHUGBYMD.9U%<3(>/;:7:[E7L>/1[NOEVAW_IYTB]?0AR<PDP;^4
MQ.9X)VYNXA9#7+2X64;3]6R)A[\3N#2!^/=3#\3T[M7B7Q,7S6]623)?K#YX
MXMI$XE\3&;\;.-']W(]/OKUN[V_/W?<1)CUZ\O*V54LH2I',#(P1.PP59LQ.
M>3\H][LQ=&(0+J#?[N-%=#OYAK'?&9^-]/$\,O)0@Z;2YCXH?%#ZH/)![8/&
M`1.H'21C;GU&LG)7DJFQ&P).'_`>R,B#0G(?%#XH?5#YH/9!XP"F#]/^,_J4
M.Y:9,Z31,N:"-MHG<9T2[I(-+H-H00I!2D$J06I!&I<PZ5C!GY&NW#'QL;B=
MZ>QKUT[O:A]<!NV"%(*4@E2"U((T+F':H<+7'B<WP\8EU[(*Z-53JS>:S+`=
M#?T1+>?>0`].%)8+4@A2"E()4@O2N(2)Q1;MB*7=25&N2)-%/*S>3)!<D$*0
M4I!*D%J0QB6L^=A``\U7E#=?D]AIOB"Y((4@I2"5(+4@C4M8\U599@\-ZGU%
M>?,-6=C>%R07I!"D%*02I!:D<0EK/LXYI_GFS+M1)^[U=;_[LNGZ"H-D*6\N
M2Y-$UR_J_,HTB;$VG87C[9#YX$0+IQ"D%*02I!:D<0E3&J%2^X34WIUK-<@5
M:Q`*LO[\GT;>#I%;AT&I1*5!T7R8'97U,IEG?.^IK0-E;ACBXE4!(*=II.L"
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M,YTQL^:SV=K?M*T3C5%!R`Y;*5%%2"^6:#6?)DGLU9:U=:+L#:$^.]>ORHF`
M?EUE((YR;"*-H)]09A#$$LHE*@BYTG0N-DD-LKEJ"K2H(100H@J+@!!=;S`A
M&BVPS=HM8"6ND]IK'ND#:14GD5W_YH(YN)#\(M)H-AMZI)2H,FB.@]2V8.'-
MDMIZ4?J&Y>+CJ`H3*__#3<C4,>[X:H1NH<=ED49S6RKF$A6$7,TZT.F&BKSL
MR5Q+U!#J<W&!JAZQ`H=-2)<I;'PU\A:JMTJR2'O-:2E-XV0=>:5!;IVH3PJ#
M$MM-I4%L-GO9PPMU<*+L#<O.],>?J[IZ=UYU&>0N8$+V&,@E*@C9:5`:Y$HF
M+YNKEJ@AU.?B`GEE)6;P']T;]&`U]HOO`8>`?_H8Y-YL),HE*B0J):HDJB5J
M&.("51DC9S":*X08Y&RUY&51+E$A42E1)5$M4<,0%_*Y@B>6!8]![@7`('[=
M6?D+TGK1DBDD*B6J)*HE:ACBFGD-)&:G=[]3,KP+GD%,L_;Z^:7'Q,#!RAUB
M")7T,+NU5C;P)Y<>ZT!I&H:X^'"1A&8)D09A9[,GV]*_])A`IVC+)2HD*@W"
M&J-65]*KEJAAB&M3=4=@5>IRQ#U78HW8N>+?'#+C]/XM)#=>5"5.IZO5VJLD
M"_)QRB:)JE]Z7DV!^K"+HV2Q]NJ=AEQD916KFL;VT(=37Y=`K.<T8B>/0?9.
MDO?/N1LG5G!!R%:`I4'LY!&Y:@JTN1I"?2X^!52U8@4.)XPN8I@0@_CT]N\W
ML:E^["S-)2HD*@UBTUODJF5@PQ#7IFJ,@#9=>C!M&K'I+>\WL?:BF;M4=;'_
M-C>W3K1,"T)V0$J)*D)4E"6KZ<J?J;5UHNP-(3EY9[QLHK'M,2^/#'(GJ4'N
M_4:B@I`C3:**D)W*M40-H8`07AX-0F09A&U5;<L?W&^,%]UO%JLX\E[@Y-:%
M.KHPR"GL2XDJ&ZA.GVB)8?1VM]JZ4.Z&)6*3>,8KIX]VH-[=&UQ=4;F7&^/E
M7FXD*@@YEQN#G#ZHR,M6R+5$#2%YN4&NT"KML2=$%U/>*O4O-R;07F[6>`OA
M[?BY=:(A*`QR+S<&N?NM#>R'%Y^5%^(\J:T396]8=C[`GZNN9K*Z,HBM7NV5
MV`M)3EX6%83LT)4&,<DB5TV!-E=#2%YN\#L(=X#%##:7&W25_KF#_IQ^;,\O
M;=8>#I?1KOMZ0D6U7.`"-.#A=Q8/_1,]OL'O+_HCR.=QBL^\>)3/9_B]1H`_
MS-,'*`L$S%-\.0SP),5'M@!?I/AZ%>"S6;H)/B&#10V:C,%43=7824L)BQI"
M::E@4<,F+9B:T!ZR;&81VA;JK@R6/&C!+HFVA6*P6:)M(0OV3+0M9,&^B+:%
M+"CK4E7I!/3`H@H>:<GB5:I*#VFI8%&%A+1LXC7ZH)_GWI3)8,F#%ASXZ(-0
M#,Y]]$'(@N,??1"RX(!''X0L&RC=_$3I(LV"%I3?J:HVI5(4W>B=D*6$1=6>
M,@8E>%H%+9L8(Z>+.=%OF&^X;,IL63Q'"T(S$7<ZQ(0L69P@)K3B<#M"3,BR
MB3"F>!D3:`$LZBV0M.#=%YX3LN`5&'HG9*E@4>^!9#:\ZT+;0I9-M$PW>!,H
M8S)8U"M(:<&;UU2]B906O(!-RZ`%[V%3]1)2QN!%*_;.D`4?D!`3&CE\-$),
MR((/'FA;:.0J6-3'"=F"392@#T*[)3XQH`]"%GQ$P'-"%GQ+0!^$+/BD`#TA
M"SX:H&TARP9*-S]1&J=9T)(C1GW!DDKQ>0^M#EGPE0^M#EGPL2]5G[5DM@T&
M+K1*,TRVOO3V5V(TQ=-#LQ`?CJ$_9,%'6\2$CE9\@D5,;YD,#\)/$=^V+^V_
MM^>7_>DR.K3/.,BG_4\#SOI7B_J/JW[!.7KLKO@1HGK7.7K%KTM;?$R>JI_<
M/'?=E?Z`\,GP>]7[_P,``/__`P!02P,$%``&``@````A`,,D(I=I`@``CP4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULC)1+C]HP$,?OE?H=+-\W
MSH/'@A)6T!7M2EVIJOHX&\=)+&([L@WL?ON.8\A"X<`EB<?CWW\>GN1/;[)%
M>VZLT*K`211CQ!73I5!U@7__6C\\8F0=525MM>(%?N<6/RT^?\H/VFQMP[E#
M0%"VP(USW9P0RQHNJ8UTQQ7L5-I(ZF!I:F([PVG9'Y(M2>-X0B05"@?"W-S#
MT%4E&'_6;">Y<@%B>$L=Q&\;T=D33;)[<)*:[:Y[8%IV@-B(5KCW'HJ19/.7
M6FE#-RWD_9:,*#NQ^\457@IFM-65BP!'0J#7.<_(C`!ID9<",O!E1X97!5XF
M\]4$DT7>U^>/X`=[]HULHP]?C2B_"\6AV-`FWX"-UEOO^E)Z$QPF5Z?7?0-^
M&%3RBNY:]U,?OG%1-PZZ/?9'F&Y!"9Y("G\%('/ZUK\/HG1-@;,X&J7CZ6.2
MCC':<.O6PA_&B.VLT_)O\$J.K$!)CQ1XGRB3:#R-LSL@)$349_),'5WD1A\0
MW`Z0M!WU=RV9IU!!YHU+;RWP%",(RH)UOTBS)"=[*`8[^JR"#SP'GP\/`O1!
M`N*](>&M7L)7RVNN@N&<EPZ*%[SL)L];H:YGX:39!R!(!)_1F<_XM@2XW`C9
M6Z%.T+$AY33+!D+0"$YW:`#FAH:W]AI#78X6N)TW52]*,[E@(G\AT]EH:*O?
MOH0?+>?AIMEH2"G`PP"$:R.YJ?D7WK86,;U37@#P@W68NV7J._N_?31?]O-(
MA@T8DX[6_)6:6BB+6EX!,HZFD+4)$Q463G<0.<R*=C`?_6<#/SX.-R>.P+G2
MVIT6($R&7^GB'P```/__`P!02P,$%``&``@````A`,9(&[P-#@``D$```!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULE)Q)<]M($H7O$S'_@<%[6P17
M$6&YP]SW?3W2%&4Q+(D*DK:[__V\`I!(H%XU1WUI2U]FO0*0B5H2I?[\YU^O
M+YE?A_/E>'I[R'J?<MG,X6U_>CR^?7_(+A>M/^ZSF<MU]_:X>SF]'1ZR?Q\N
MV3^__/<_GW^?SC\NSX?#-0.%M\M#]OEZ???O[B[[Y\/K[O+I]'YX@^7I='[=
M7?'K^?O=Y?U\V#T&C5Y?[O*Y7/GN=7=\RX8*_ODC&J>GI^/^T#CM?[X>WJZA
MR/GPLKOB^B_/Q_>+J+WN/R+WNCO_^/G^Q_[T^@Z);\>7X_7O0#2;>=W[W>]O
MI_/NVPON^R^ON-N+=O`+R;\>]^?3Y?1T_02YN_!"^9ZK=]4[*'WY_'C$'9C'
MGCD?GAZR7SU_F\]G[[Y\#A[0ZGCX?4G\G+D\GWZWS\?'P?'M@*>-.)D(?#N=
M?AC7[J-!:'Q'K5M!!";GS./A:??SY3H[_>X<CM^?KPAWR339GU[0$_Z;>3V:
M',"M[_YZR.;1P_'Q^OR0+90_E2JY@I<O93/?#I=KZVC:9C/[GY?KZ74=.GF1
M5"A2B$3P;R0"N1O^E<@?_W[(WY.K-#]\K`4N(+@O3V_,RWWRBKGRO[@O/+%(
M!3]\K-^JM,`/'VJ1EX=G?OA8BV+41QX_1"T^?&]W8?R#O&GLKKLOG\^GWQF\
MC'BRE_>=>;4]WSRB*&.B,,8YA%3>&_>OQO\ABP@B.RZ@O[[D2]7/=[^0E/O(
MI\8^7MJC+AXF,8ULPP9-&[1LT+9!QP9=&_1LT+?!P`9#&XQL,+;!Q`93&\QL
M,+?!P@9+&ZQLL+;!Q@;;!+A#^.,<P+ORKW+`^)L<D.C5!"22P@JX>$B3A@V:
M-FC9H&V#C@VZ-NC9H&^#@0V&-AC98&R#B0VF-IC98&Z#A0V6-EC98&V#C0VV
M"9`*.(8<"G@A%[_CQHP)(?&.>\7[=$!KH4\IZ51*N]1CESCH1)I$6D3:1#I$
MND1Z1/I$!D2&1$9$QD0F1*9$9D3F1!9$ED161-9$-D2V29)*!<PEE`IF_@NG
M<1[_C3_F"GCH!%#.I2-?"YUN)D?L$B<'D2:1%I$VD0Z1+I$>D3Z1`9$AD1&1
M,9$)D2F1&9$YD061)9$5D361#9%MDJ22`U%.)H>L`0P.<D!B5PM)L9S("L_.
MBGKL),T:1)I$6D3:1#I$ND1Z1/I$!D2&1$9$QD0F1*9$9D3F1!9$ED161-9$
M-D2V29(*.4+H"KG!Z9"')-S,!&NX.I$&D2:1%I$VD0Z1+I$>D3Z1`9$AD1&1
M,9$)D2F1&9$YD061)9$5D361#9%MDJ3BBY6[*[X&I^,;D7*\RJL3:1!I$FD1
M:1/I$.D2Z1'I$QD0&1(9$1D3F1"9$ID1F1-9$%D261%9$]D0V29)*KZFDL/[
MN4\5O/#7Y^/^1^T4;.ME*#?NZ;A'I*AQ#PGVJ6:W5_3N\]9TWX@=9&!O$FD1
M:1/I$.D2Z1'I$QD0&1(9A<33VQS'/N%ME@O6MG82.\AM3HG,B,R)+(@LB:R(
MK(ELB&R3))45J$K\FZPP[NFLB(@^KGI(3,D@7@AZ96N?WXB=Y)$UB;1(NAW[
M)*7SZ35F)W82Z2Z1'DGW8Y^$M)W/@]A)I(=$1B0]CGT2TO8#F<1.(CTE,B/I
M>>R3E+8>R")V$NDED15)KV.?A+3]0#:QDTAODR25:1YJELE4DX$FX.F<BE`>
M<U4BA0KI.-?%"R->PJN8]FJ(5S48I+S[4J54L)2:D4\A+&*:LE-+4"$>[=JB
M=+._CC3$TCEQ5=8.N"M>VF-/D/;8_U"/`_&Z<8=#$=?^1H*TO[$HW;S#B7B%
M_>7O\]7[G#4B3D5<^YL)TO[FHG2SOX4TO/E$E^*E/:X$:8_K#_6X$:\;=[@5
M\:"_=**;:EIBIHT3/:RR88<L+TO-E*\QGB+1!=4%W<>H$2'48<2K*2CX8A`L
MLEN"]&[;K-41+[V(KB#5Z@E2K3YK#<1+KVLH2+5&@E1KS%H3\5*MJ2#5F@E2
MK3EK+<1+[W$I2+56@E1KS5H;\=+KV@H*M-*1-V4U5^3#<ELJ\B$JI(>X<GKP
MJIN/%<B/0OH%L0:3AGII?D0--8M:XJ6H+2C,\\)]M7Q?L2;JCOJ(>%>0*O48
M]07=$!^HCX@/!:GXB-%8T,T',U$OD9\*4OD9H[F@Z-ISQ6JE9$TL"_41\:4@
M%5\Q6@NZ(;Y1'Q'?"@K$TVEG:GBNM`MK>ZFT"Q'23G3K7H2T:M]@U!2DM]9B
MU!94C>4[C+J"5*O'J"](M0:,AH)4:\1H+$CO<<)H*DBU9HSF@O2Z%HR6@E1K
MQ6@M2+4VC+:"`JUTY$V!SA7YL'"7BGR(K#55Q1YP0J\BUFK_O'II8'-DAB5X
M218U(U30T;3%J"T-O?#[8*58\4HTX$3B.I%W6:G'J/\!\8'ZR)4/66G$:"P-
M;SZ8B7J)_)2U9HSFTC!\,%ZQ6J[DK,WT0GU$?,E**T9K;6@VL$[QC?J(^#:E
ME$X[4R1TI5U8/$RE78A2*YP0);*G@1:44"%*)12AMC349.DPZD8HH=5CU.>&
M`T9#;CAB-):&^H9,&$VYX8S17!KJ/2X8+;GABM&:&VX8;5,-TY$WY4-7Y,.R
M(AI*^M2\$%DK'.MK85V\;D[D#?42^:8@'6!;C-J"PKD6'RNKN8HUYG741\2[
M@E2\QZ@OZ(;X0'U$?"A(Q4>,QH)N/IB)>HG\5)#*SQC-!4777BG>%ZM6;!;J
M(^)+02J^8K06=$-\HSXBOA44B*?3#D_!F7:&6[6#$*56.!'2V;_A$6H*TEMK
M,6H+TAF[PZ@K2+5ZC/J"5&O`:"A(M4:,QH+T'B>,IH)4:\9H+DBO:\%H*4BU
M5HS6@E1KPV@K*-!*1]Y4+ET#3EC13`TX49$SO:6R*A-U+_0JAC-M\;Y0RMDS
M;4-])#>;$4I,(2U&;6EX<Y7042^1[[)6CU%?&MZX]H'ZB/B0E4:,QMHP*'/?
M5_G!3-1'Q*>L-&,TEX8W'\Q"O41^R5HK1FMI*`_&<>T;]1'Q;4HIG7:FC)E(
MN^CTVS]^+?'"LF<J':-*:'*K%:*B5B$:4<,$:@I*+J7#AHGL:XN7%MX[C+J"
M5*L7H8167[STN@:,AH)4:\1:8_%2K0FCJ2#5FK'67+ST'A>,EH)4:\5::_'2
MZ]HPV@H*M%(9D4?J)C-"JGH!3T]!$2IBN:J;J(JUG*^+%V8B]2I;58:&>(53
M:;E<S7/Y.O(IZ0*Q%:&"#LYM4;K97T>\PO[NO4(A5[6&T"[WU^/^^J)TL[^!
M>$5+A>)]OE0N6!\PAMSAB#L<B]3-#B?B%798J>2+7+WF_F;<WUR4;O:W$*\H
M@/EJL5JR[F_)_:VXO[4HW>QO(U[R0'->M6)_;-JF.DRGN56\_G\#7YZ+VA%"
M^LM`6Q>DZ=B(4$EW2$U!^HJV(I3*X[#'HFIUI*%J=06I5H^U^A%*:`VDH6H-
M!:G6B+7&K#61AJHU%:1:,]::L]9"&JK64I!JK5AKS5H;::A:6T&!5CHC3"GY
MUE2X.+UC_#/!#O_Z(#Q%_GHX?S_4#R\OE\S^]/,-0YR'-?F7SS&/_^[A:]"G
MQ6OX>XA`T^9Y_)V$Z<OF!1]'&9E_+?I?<6]LJ!5]'&]S\)*/,U#,\2+[)@AL
MP>OKFUBP!6^Q;T+"%KS,OHD,6_`"^R9`;,%;BWMW63`:^B8EN0T&1=]D)ELP
M$/HF0=DRA<7D*5LP"OHF7=F"P=`W6<L6S"B^>4'9@GG$-^\I6S"=^.9U90MF
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ME+(04Y<%%2W$U&5!80LQ=5E0N4),71;4$A%3EP7U0\3494&!$#%U65`G1$Q=
M%I0+$5.7!15!Q-1E034?,77-&"CJ(Z8N"^KVB*G+@O(]8NJRH(J/F+HL*-0C
MIBX+OI(@IBX+/I8@IBX+OH<@IBX+/HL@IBX+OHX@IBX+/G\@IBY+#9::TU*'
MQ7P1X/<'7YD04Y<%'YL04Y<%WYP04Y<%GY404Y<%GX014]=R`E^&$5.7!1]_
M$5.7!=^`$5.7!9^"$5.7!5][$5.7!9_:$5.7!5_<$5.7!1_5$5.7!=_6$5.7
M!9_8$5.7!=_0$5.7I09+S6G!20;$U-6F"8OYNLS1QHD%Q-1EP<$%Q-1EP=D$
MQ-1EP3$B1,XU!^/H$"+GLN`$$2+GLN`@D6^.B_!5X_`08NJRX,@08NJRX"P6
MHN"RX$B6;X[+<#\XAH7XN"PX?(7XN"PS6,P9&E;#42S?'*5A"PZTX5F[+#C$
MAF?MLN`L&W+49<&1-M\<)>)^<(P-V>NRX/`:LM=EJ<%BSE"Q&@X'^N8H%5MP
M(!"9Z++@&"`RT67!:4!DHLN"0X&^.6;%_=0PT0:E/VNFKV,9%&Q=+3[&8LO%
MZU4?1V-9OUWU<:Z5>;_JXU`J\W'5G[KXO.KC."C[KZL^SG*"W\47BC\3?]]]
M/PQWY^_'MTOFY?"$75TNJ(F>P[\H#W^YAAO"S+?3%7\@;O:&F6?\Y?\!YRIS
MGU`4>SJ=KO*+Z2#^?PE\^1\```#__P,`4$L#!!0`!@`(````(0!+OX/#N@4`
M`%<4```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)18VXZC1A!]CY1_
M0+RO<6/`!HUG-5PF66DC1=$F>68PMM$8L("Y[-^GBK[0MYG,[,,R/GVJ^G1U
M=57#S=?7]N(\U\/8]-W>):NUZ]1=U1^:[K1W__YQ_V7G.N-4=H?RTG?UWOU9
MC^[7VU]_N7GIA\?Q7->3`QZZ<>^>I^F:>-Y8G>NV'%?]M>Y@Y-@/;3G!S^'D
MC=>A+@^S47OQ_/4Z\MJRZ5SJ(1D^XJ,_'INJSOOJJ:V[B3H9ZDLY@?[QW%Q'
M[JVM/N*N+8?'I^N7JF^OX.*AN333S]FIZ[15\NW4]4/Y<(%UOY*@K+CO^8?A
MOFVJH1_[X[0"=QX5:JXY]F(//-W>'!I8`8;=&>KCWKTC2>'[KG=[,P?HGZ9^
M&:6_G?'<O_PV-(?O35=#M&&?<`<>^OX1J=\."(&Q9UC?SSOPY^`<ZF/Y=)G^
MZE]^KYO3>8+M#M&DZB\P$_SOM`WF`"R]?)V?+\UA.N_=#5GYNY"$D1^ZSD,]
M3O<-&KM.]31.??LO91'FBWKQF1=X<B_1*MRN-P2=O&.X88;P9(;AA^P"9@=/
M9N='J\`/M[O_FQ'TS`N&)[,,WC7T:,#F0.?E5-[>#/V+`]D+$1FO)9X%DH`S
M%F&V6!%SV/H*V7=(W[M;UX%@CH`^W_I!<.,]PR96C).:'*(R,L[`C42WN0X4
M$N"!4B$7MN8S<I&.<OE$*0<D_9HVSN`FN0X4$J!H@]W_C#:D0YXJH0Q5,2GE
MA#))HV2"(@0;2"$CBF1(O,](1CHD"N2)M/V1IIF2WM4L*$*S@10RHFB&V27-
M/#$1G:5QERE%0O#SMMA,D+A9;B"%C"A*(JL21%4E%(G@(920V%?#E@F24&(@
MA8PH2N!`2C&AIWB[6X%R6K7,@XP6JDJ*!+)*/]AJ*@5)J#200D84E=B6M5H3
M;5;;=U2BA:J2(IK*G:92D(1*`RED1%$9*RIY?B&J*J'(5LXO$FNU,!,DH<1`
M"AE1E!!HF'K`"!ZLMS9U-E!5,D@+6*P%;&$)G294*)"J%.NUMK4^],!WI-(*
MS[HY-H&44$B5&JYUJ8*U2#6@8O$%+%4JEN]%*M]?0JNZHH="]((S]ZF,L20H
M-Z%"@=3)L1);)J<%6IF<09'H71DQH-R$"@52)\>2:IF<5EIE<@I%<$9$Q?)#
MHXM;6"323D!.*"L@]+80QVOXI^YIP3B;#2Y6U8S%UZ(982W1*02:>5YDL"1D
M25#.(%##606#;)-CO;5,3LNP$C`*;>3BN=%6F1%&BN=(D("8D<@7SJ*/F<T+
M4X.#E=:BCQ9@11^%0!]WFQ$&Q0+*3:C@D&5R+*"6R6E=529G$-0Y*9OT_D<H
M*X":)[$V:J;D"XLOI&"0+QN2[=(2U)!AL5U4L_ONW(.F<U,]ICU,CJG*KKNT
M-BNK81#(E71J69\1RHID47ZHW=WRA;6LAAINX:P+]V^N!M<LK8:KGF'U=#`H
M@DHIW/JA=G7+&,N'U!`L\T1S%LUC>"4V\[A@G,U\SI0=\+%8?WP'9KJV%EKN
M82T\:AEC15(R,V@[OV'.NUEPR")*;0IS6NSBU?+:MUR@G#E/?O17.4^@(>CU
MB$%:-]/O4PN+KR4W(7S'1O?@"U@TFO2=F;[*M?5PJK/Z<AF=JG_J8.O\':2P
M@.G+>AHG<-4`!SI.U@FV=ML(O-]#)[6,^#Y_\]>\P2>!N_F+@(:GZ,KJ"1S9
M\$T"KRWFS'<!^+<:!`F\,Y@&:9C`#=Z"1PG<IRWX-H$;K`7?)7!G-/&,[!(L
M2[:1&$:L(??720K9:+&!$<QF<R2'D=PZ`H<-8FBS20EL$]Q&3&\I"9*4EC5M
MHS(8P<YIVD`KA_781J"!PSRVD91$,(\MGM`.P9MMI(`1;#R@P!/BX&O/M3S5
M?Y3#J>E&YU(?(<W7<^$>Z(<A^F.B!]-YZ"?XS(-GU#G#![P:+IAKO(\>^W[B
M/W`"\4GP]C\```#__P,`4$L#!!0`!@`(````(0`5;(Z3A0(```@&```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(Q46V_;(!A]G[3_@'AO\#5-HSA5
MNJI;I4V:IEV>"<8VJ@$+2-/^^WV8E-EK*O7%,H?#.=\--M=/LD>/W%BA5873
M18(15TS70K45_O7S[F*%D754U;37BE?XF5M\O?WX87/4YL%VG#L$"LI6N'-N
M6!-B6<<EM0L]<`4[C3:2.EB:EMC!<%J/AV1/LB19$DF%PD%A;=ZCH9M&,'ZK
MV4%RY8*(X3UU$+_MQ&!?U"1[CYRDYN$P7#`M!Y#8BUZXYU$4(\G6]ZW2ANY[
MR/LI+2A[T1X7K^2E8$9;W;@%R)$0Z.N<K\@5`:7MIA:0@2\[,KRI\"Y=WZPP
MV6[&^OP6_&@G_\AV^OC9B/JK4!R*#6WR#=AK_>"I][6'X#!Y=?IN;,!W@VK>
MT$/O?NCC%R[:SD&W2W^$Z1Z<X(ND\",`F=.G"F?@(&K753A?+LK+)$^S$J,]
MM^Y.^+,8L8-U6OX)I'1T#UIC#+?4T>W&Z"."O@+;#M1/2;K.('?FP9U'*WR)
M$>A90!^W6;[:D$=(@YTX-X$#W\A)(X.`>K2`>,]8>-1;^#R]YTT`IGK9>;U\
MIH=\O?(DANYW`9B$E>5742A8!4XQX921,0L=*&="]RC4"XH>4\^*)"H$CT!Z
MAP?(G/'PZ.@1ZW-"8+[.NL[B7I[5].A<,R#+6;6*-]H(TS")<RQ[5I:+RS*6
MWC/F^B=DUM3BC;;ZY^S?)([Z:9)-]3UCKG]"IE7.BCQV(M0DW+PP]9*;EG_B
M?6\1TP<%E?1#']%XX7>9'\S_\6*]&Q\"$C?@?@ZTY=^H:86RJ.<-2"8^:&3"
M50X+IP>('&ZI=G`SQ]\.7EP.@Y\L@-QH[5X68$SB&[[]"P``__\#`%!+`P04
M``8`"````"$`$>7F9`4#```V"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6R,55UOHS`0?#_I_H/E]P8,)&VBD"J]JG>5[J33Z3Z>'3#!*F!D.TW[
M[V]M@P,)E?(2A6$]LSN[7M;W;W6%7IE47#0I)K,0(]9D(N?-/L5_?C_=W&&D
M-&UR6HF&I?B=*7R_^?QI?13R196,:00,C4IQJ76["@*5E:RF:B9:UL";0LB:
M:GB4^T"UDM'<'JJK(`K#15!3WF#'L)+7<(BBX!E[%-FA9HUV)))55$/^JN2M
MZMGJ[!JZFLJ70WN3B;H%BAVON'ZWI!C5V>IYWPA)=Q74_482FO7<]N&"ON:9
M%$H4>@9T@4OTLN9EL`R`:;/..51@;$>2%2G>DM4#B7&P65N#_G)V5(/_2)7B
M^%7R_#MO&+@-?3(=V`GQ8D*?<P/!X>#B])/MP$^)<E;00Z5_B>,WQO>EAG;/
MS9%,5*`$OZCF9@:@=/J6X@@4>*[+%,>+V?PVC$DTQVC'E'[BYBQ&V4%I4?]S
M0<2J.RZ;PR/5=+.6XHB@L1"M6FK&A*R`N!/O&'PZX$IFHK<F/,6W&(&0`O1U
M$\WOUL$KU)=U,0\N!GY]#/$1`<AZ;=`;:/<2!C42Q@"C^>"`(5\TS1>/^&PM
MR=RG;MZ"9<.TXM@3.2D7DPQBYCYBE#J$3*1N4#`2NG$J/5YZ!J?A@J[0`)H)
M#8-:#>]/AX!-DZJCO!<C3M?N9>0],J_'Y!TR=)\DH2]I1`YC,4C8DL>WX>S4
M`A,PIN^0,?T'XV(6WFE4^W$QZ+GGR7E?7=`5GB\G-0PZSKM#1M,T4!W90F`E
M#!*WOD3+Q)MNWX_I>VB8,4F2:=L)N#?@[XVQ\(4SIWEVT]A%#85.(>,RIJ\K
MZ:ZGVUCVPO;0V)V/:,V=.[75C608S6Y/8P/;]]S_'AKF39+%F4%NY[I]5S.Y
M9U]852F4B4,#5\5TP*-^UV\CLWG.\62UM1OI'+];;:%7$P<(@3?VJQ'X,[#,
M6[IG/ZC<\T:ABA6016@J1=+M??>@10M]@Y4N-*QQ^[>$[S.#96AN$RJ$T/T#
M2`?^B[_Y#P``__\#`%!+`P04``8`"````"$`^S(L,#(!``!``@``$0`(`61O
M8U!R;W!S+V-O<F4N>&UL(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````G)%12\,P%(7?!?]#R7N;9AMCA#8#E3TY$)PHOL7DK@TV:4BB
M[?Z]6=?5B3X)>0GGW"_GGA3K7C?))SBO6E,BDN4H`2-:J4Q5HJ?=)EVAQ`=N
M)&]:`R4Z@$=K=GU5"$M%Z^#!M19<4."32#*>"ENB.@1+,?:B!LU]%ATFBOO6
M:1[BU578<O'.*\"S/%]B#8%+'C@^`E,[$=&(E&)"V@_7#``I,#2@P02/24;P
MMS>`T_[/@4&Y<&H5#C;N-,:]9$MQ$B=W[]5D[+HNZ^9#C)B?X)?M_>.P:JK,
ML2L!B!W[:;@/VUCE7H&\.;#^S36)]W6!?VN%%$,Z*ASP`#*)[]%3NK/R/+^]
MVVT0F^5DD>:K>'8S0O,E)8O7`I]=XSR;@'H,\&_B&<"&W#__G'T!``#__P,`
M4$L#!!0`!@`(````(0"I@6=`S0(``/X(```0``@!9&]C4')O<',O87!P+GAM
M;""B!`$HH``!````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````)Q6WT_;
M,!!^G[3_(<H[I$`U3<@-@K832#"JM;!'RTTNK85C9SXW*_SUNR0T35@:J;S9
MOE_??7?VF5UM4^7E8%$:/?+/3@>^!SHRL=2KD?^T^''RW??0"1T+932,_%=`
M_RK\^H7-K,G`.@GHD0N-(W_M7'89!!BM(15X2F)-DL385#C:VE5@DD1&,#'1
M)@7M@O/!X%L`6P<ZAO@DJQWZE<?+W'W6:6RB`A\^+UXS`ARRZRQ3,A*.L@P?
M9&0-FL1YTVT$B@5-(2-T<X@V5KK7<,""YI;-(Z%@3([#1"@$%NP/V"V(@K29
MD!9#EKO+'")GK(?RC6@[][VE0"C@C/Q<6"FT(UB%6K4IURI#9\/?QK[@&L`A
M"TBA.BR73=WF6@[#BV&I0:NV9N&A0D*"-L:%=`KP,9D)ZSH@7PR;F$L4%>(*
MT*Z*G'J#3[4COOB=KJHM31-YG</84*$U0LQIA4;)6#C:W`@E=$1LUHH%+U64
M?I.S8VSFCJ*E1X5Y-_E,F/-.:(]V);1\*_NP).Y&H$1N$CZST"IWS<"#L"_@
MQ%(!?^]+NG*=SJ?":NI`Y/<&D<_`\OE:V.Z$?T$.>G/`T9TF(?7NH4"EV[51
M,3T;?/IG4Y2^Z(()+%TGLCMZ45+@"[$]$'%LE!)+8XF8'/CUR@)52K<O0,W(
MV*2I=*6\#$L]XBAO>K8.`?X)?XE@$V^B`R[[Z])=_\["4(Y4J:/JTV>R*U.?
M3J-:?6I-#OKTNM.:4`M*=5Q>E4UG0QQH5>J@(DPWWS47?5@^*O$%S9>-H$>^
M;I_]X])DKL]IAUZOW[[[P2>=4/I-N@EIWJIWYK`75ZL%KA%IPI07Z%Z*I>RF
MJ&72W@AKFZFT!LV'T7(O]0L^90LSH2=X-SO;AZQD(*:ILI/O#]@MC4VK"B?C
MM:";'N]T_A<4D_ZY^LZ$9\/3P<6`AGCCC`7[CTOX#P``__\#`%!+`0(M`!0`
M!@`(````(0`:,QE5V@$``#$6```3``````````````````````!;0V]N=&5N
M=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````
M````````````$P0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`/Y[WY32
M`0``'!4``!H`````````````````.0<``'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L!`BT`%``&``@````A``Z%_+A#`P``MPH```\`````````````
M````2PH``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#(2WSM;@8`
M`/T7```8`````````````````+L-``!X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"+0`4``8`"````"$`?.VBI0H&```1'P``&0````````````````!?
M%```>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M`!0`!@`(````(0`(
M0`KRJ@(``&4'```9`````````````````*`:``!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L!`BT`%``&``@````A`$3F+]-U`@``YP4``!D`````````
M````````@1T``'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4``8`
M"````"$`E+EBZV8$``!@$P``&0`````````````````M(```>&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0#F[-(?200```L0```9
M`````````````````,HD``!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M`BT`%``&``@````A`,`)-@9L`@``:P4``!D`````````````````2BD``'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`](P4!V,#
M``"^"0``&0````````````````#M*P``>&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;%!+`0(M`!0`!@`(````(0!MQ6=HT`,``#`.```9````````````````
M`(<O``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`BT`%``&``@````A
M`!%%^`PC`@``H@0``!D`````````````````CC,``'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`8:7U+W@"```S!@``&0``````
M``````````#H-0``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(M`!0`
M!@`(````(0`1KE`/%04``)P1```8`````````````````)<X``!X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`&Q"3(UX"``#G!0``
M&`````````````````#B/0``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M`BT`%``&``@````A`.+`ETS`.0``@,4``!0`````````````````=D```'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A`/9BSN5X#```;'0`
M``T`````````````````:'H``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"```
M`"$`^V*E;90&``"G&P``$P`````````````````+AP``>&PO=&AE;64O=&AE
M;64Q+GAM;%!+`0(M`!0`!@`(````(0"Y6(\0N@0``&$4```9````````````
M`````-"-``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@`
M```A`([00LUM`P``>0H``!@`````````````````P9(``'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0`A"?0$D@8``*@@```9````
M`````````````&26``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`
M%``&``@````A`(-SUO.E!0``,10``!D`````````````````+9T``'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`EMKD*K8&``!W
M&@``&0`````````````````)HP``>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;%!+`0(M`!0`!@`(````(0!9L!<X/@X``#Q"```9`````````````````/:I
M``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`"=!
MSOFK"@``YRP``!@`````````````````:[@``'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+`0(M`!0`!@`(````(0!V6>T=GQ```(I1```8````````````
M`````$S#``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`"```
M`"$`%4,YP$(#``!="0``&``````````````````AU```>&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`.`@-'T*!```90X``!@`````
M````````````F=<``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`
M!@`(````(0#1J3:Z1@8``#47```8`````````````````-G;``!X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`EVI[C[,$``!F#P``
M&0````````````````!5X@``>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M`0(M`!0`!@`(````(0",6`\Y9`,``$D*```9`````````````````#_G``!X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`,KS8Q)>
M`@``5`4``!D`````````````````VNH``'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"+0`4``8`"````"$`@'H/?6,,```?-@``&0``````````````
M``!O[0``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(````
M(0!B"D_`*0H``/0J```9``````````````````GZ``!X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`,,D(I=I`@``CP4``!D`````
M````````````:00!`'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4
M``8`"````"$`QD@;O`T.``"00```&0`````````````````)!P$`>&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0!+OX/#N@4``%<4
M```9`````````````````$T5`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`!5LCI.%`@``"`8``!D`````````````````/AL!
M`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"````"$`$>7F
M9`4#```V"```&0````````````````#Z'0$`>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+`0(M`!0`!@`(````(0#[,BPP,@$``$`"```1````````````
M`````#8A`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0"I@6=`
MS0(``/X(```0`````````````````)\C`0!D;V-0<F]P<R]A<'`N>&UL4$L%
3!@`````K`"L`GPL``*(G`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>New Products Assets and Liabilities Assumed (Details) (Vaprisol, USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vaprisol</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intellectual property intangible assets</a></td>
        <td class="nump">$ 2,990,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
        <td class="nump">1,410,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Acquired contingent liabilities</a></td>
        <td class="num">(400,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations', window );">Contingent consideration obligation</a></td>
        <td class="num">(2,000,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
        <td class="nump">$ 2,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Consideration Obligations</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedContingentConsiderationObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of inventory recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EarningsPerShareTextualAbstract', window );"><strong>Earnings Per Share (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options</a></td>
        <td class="nump">188,814<span></span></td>
        <td class="nump">554,279<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EarningsPerShareTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_EarningsPerShareTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EARNINGS (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles the numerator and denominator used to calculate diluted earnings per share for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">722,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(639,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,743,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,025,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="441px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="102px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="103px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,825,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,580,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,093,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,756,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, restricted stock awards and options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">188,814</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">554,279</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, were outstanding but were not included in the computation of diluted EPS because the effect would be antidilutive.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P
M-#-F.#(P.&8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C
M,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C`S
M,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYD
M96YS961?0V]N<V]L:61A=&5D7U-T871E;64R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]"87-I<U]O
M9E]0<F5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M36%R:V5T86)L95]396-U<FET:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^16%R;FEN9W-?3&]S<U]097)?4VAA<F4\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2979E;G5E<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5N=&]R:65S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5H
M;VQD97)S7T5Q=6ET>5]A;F1?1&5B=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;&QA8F]R871I=F5?06=R965M96YT
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI
M=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3F5W7U!R;V1U8W1S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]"87-I
M<U]O9E]0<F5S,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DUA<FME=&%B;&5?4V5C=7)I=&EE<U]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%87)N:6YG<U],;W-S7U!E<E]3
M:&%R95]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y2979E;G5E<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y);G9E;G1O<FEE<U]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.97=?4')O9'5C='-?5&%B;&5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%R:V5T
M86)L95]396-U<FET:65S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y%87)N:6YG<U],;W-S7U!E<E]3:&%R95]$971A
M:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%87)N
M:6YG<U],;W-S7U!E<E]3:&%R95]$971A:6PQ/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4F5V96YU97-?1&5T86EL<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E=F5N=65S7T1E=&%I
M;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DEN=F5N=&]R:65S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y);G9E;G1O<FEE<U]$971A:6QS7U1E>'1U86P\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R96AO
M;&1E<G-?17%U:71Y7V%N9%]$96)T7T0\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3:&%R96AO;&1E<G-?17%U:71Y7V%N9%]$96)T
M7T0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC
M;VUE7U1A>&5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DYE=U]0<F]D=6-T<U]!<W-E='-?86YD7TQI
M86)I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE
M=U]0<F]D=6-T<U].97=?4')O9'5C='-?3F%R<CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O
M<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S
M+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53
M:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T
M4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T
M96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N
M9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S
M:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE
M=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?
M.65B95]C,#<P-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,4%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A
M;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^075G+B`P-"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN
M9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG0U5-0D523$%.1"!02$%2
M34%#155424-!3%,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,#`P,3`X-S(Y-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O
M8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q
M,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y*=6X@,S`L#0H)"3(P,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@
M1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)V9A;'-E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&
M;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R
M<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)RTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!8V-E;&5R871E9"!&
M:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#4W-RPV.3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T
M,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P
M-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44%!
M1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A
M=&5D($)A;&%N8V4@4VAE971S("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SDL,#4P+#@T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#`L.#8Y+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PX,C4L-C,R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,#$Y+#<V,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C;W5N=',@<F5C96EV86)L92P@;F5T(&]F(&%L;&]W86YC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#$T+#0W-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3,P+#0R-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV96YT;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M.3DV+#@T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L-S(R+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S0T+#(T-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3,W+#$Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,"PV,S(L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C@L-C<Y+#<Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q
M=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M,C8L.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#@P+#8T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!A<W-E=',L(&YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,#<S+#0U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#0Y."PX,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPP,S8L,S`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPU-30L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,RPT-C@L-C8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L-C$S+#<S.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C(P+#$Y-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#,U+#@U
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPV-#(L.38P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU,#DL.3$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R
M<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L.#8S+#$U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L-30U+#<W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V;VQV:6YG(&QI;F4@;V8@8W)E
M9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX-S,L,C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S<V+#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW,S8L-#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS,C$L
M.#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F5H;VQD97)SXH"9(&5Q=6ET>3H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VOB@)1N;R!P87(@=F%L=64[(#$P,"PP,#`L,#`P('-H87)E<R!A=71H;W)I
M>F5D.R`Q-RPV-C`L,S8W(&%N9"`Q-RPY.#4L-3`S('-H87)E<R!I<W-U960@
M86YD(&]U='-T86YD:6YG(&%S(&]F($IU;F4@,S`L(#(P,30@86YD($1E8V5M
M8F5R(#,Q+"`R,#$S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8S+#4R.2PV-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPP-S,L.30Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2971A:6YE9"!E
M87)N:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-#`S
M+#0S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V+#,Y-"PU-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R96AO;&1E<G/B@)D@97%U:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PY,S,L,#<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL
M-#8X+#0X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N8V]N=')O;&QI;F<@:6YT97)E<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R,#`L.#$P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W-BPV,S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PW,S(L
M,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-SDL,CDQ+#@T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S(&%N9"!E<75I='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3,L-#8X+#8V-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M.#<L-C$S+#<S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B
M9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5#14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E
M9"!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%5N875D:71E9"D@*%!A
M<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+#8V,"PS-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPY.#4L-3`S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<L-C8P+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W+#DX-2PU,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E
M7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F
M,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8O5V]R:W-H965T
M<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%6#%!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@
M3W!E<F%T:6]N<R!A;F0@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I("A5
M;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!3
M=&%T96UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(')E=F5N=65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL-S4P+#$V.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPP.#$L,#@X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-RPX-#,L-#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-RPS,SDL,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W1S(&%N9"!E>'!E
M;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O<W0@;V8@<')O9'5C=',@<V]L9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PR.3@L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-30L.#,S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-3(L-3,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR
M-C,L-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y396QL:6YG(&%N9"!M87)K971I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.3,P+#`X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-30R+#`T.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-30T+#`Q,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M,C$U+#DX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX-C$L,34T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS.#8L.3`T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV.#<L-3(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPX,S4L-C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-#`L,C0Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-34L,C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP
M,S<L-#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PT,S`L.30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P-"PR-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#(L-C0U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DX+#(Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-RPV.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L-3,T+#4U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C(Q+#8S,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#(Q.2PW-3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ
M-3,L-S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!E<F%T:6YG(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C$U+#8P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,30P+#4T-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8R,RPV
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.#4L-3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y+#4T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0X+#DX,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV+#@X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,2PS-3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R
M+#(W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R,"PW,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C0L-#@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,X+#0S-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@*&QO<W,I(&)E
M9F]R92!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C,R+#@W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L,3$R+#(V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8Y-BPP-C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#@L-#,Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O
M;64@=&%X("AE>'!E;G-E*2!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U,C,L,S,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0V,RPT,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,3$L,S0X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DU+#DU.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S`Y+#4S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8T."PX-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3@T+#<Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,BPT-S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S(&%T
M('-U8G-I9&EA<GD@871T<FEB=71A8FQE('1O(&YO;F-O;G1R;VQL:6YG(&EN
M=&5R97-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,#,T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PX,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-"PQ-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,RPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*2!A='1R:6)U
M=&%B;&4@=&\@8V]M;6]N('-H87)E:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S(R+#4W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8S.2PP,3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#@L.#DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$U+#8Y
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%87)N:6YG<R`H;&]S<RD@<&5R('-H87)E(&%T=')I8G5T
M86)L92!T;R!C;VUM;VX@<VAA<F5H;VQD97)S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XM(&)A<VEC("AI;B!54T0@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^+2!D:6QU=&5D("AI;B!54T0@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"UA=F5R86=E
M('-H87)E<R!O=71S=&%N9&EN9SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^+2!B87-I8R`H:6X@<VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-S0S+#,Y-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#0P-2PU
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RPX,C4L,3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@L-3@P+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^+2!D:6QU=&5D("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PP,C4L.3$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L
M-#`U+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X+#`Y,RPS.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ."PW-38L-CDQ/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&EN
M8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S`Y+#4S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-C0X+#@U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#DX-"PW,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y,BPT-S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T,#(R7S)C,6)?
M-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8O
M5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05)!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E
M;65N=',@;V8@0V%S:"!&;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y.#0L-S$X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M.3(L-#<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@
M:6YC;VUE('1O(&YE="!C87-H('!R;W9I9&5D(&)Y(&]P97)A=&EN9R!A8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,"PR,S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3`L,#4R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$969E<G)E9"!T87@@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8U+#0Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C4L,S0T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`U+#$Y.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AC97-S('1A>"!B96YE9FET(&1E<FEV960@9G)O;2!E>&5R8VES92!O9B!S
M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M,3$L,S0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$U+#(X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO;F-A<V@@:6YT97)E<W0@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,#,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,#,X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYC
M87-H(&EN=F5S=&UE;G0@;&]S<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.#$L.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C(L,S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!C:&%N9V5S(&EN
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@869F96-T:6YG(&]P97)A=&EN9R!A
M8W1I=FET:65S+"!N970@;V8@969F96-T(&]F(&)U<VEN97-S(&-O;6)I;F%T
M:6]N.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L-#@T+#`U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T-BPR-3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,V+#`S.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PP-C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S('!A>6%B;&4@86YD(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,38U+#@R.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S`W
M+#4V,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`Y+#(T-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#0W.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8W5R
M<F5N="!A<W-E=',@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-S`Q+#8P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.2PX-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V
M:61E9"!B>2!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PX,3@L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.3(L,S(U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A
M<V@@9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;G,@
M=&\@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#@L,C,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#8Y+#$Q.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E<R!O9B!M87)K
M971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,L,C4T+#DP,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T+#,W,2PU,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@
M;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#(V-RPP.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0X,2PV.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@
M86-Q=6ES:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#`P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061D:71I;VYS('1O(&EN=&%N9VEB;&4@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,S(L,#<R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#(Y+#8Y
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!U<V5D(&EN(&EN=F5S=&UE;G0@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW-C@L,3,R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-S@X
M+#8S."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN9R!A8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!B;W)R;W=I;F=S(&]N(&QI;F4@;V8@8W)E9&ET/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#$L,CDR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC97-S('1A>"!B96YE9FET(&1E<FEV960@9G)O
M;2!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,3$L,S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,C@X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F('-U8G-I9&EA
M<GD@<VAA<F5S('1O(&YO;F-O;G1R;VQL:6YG(&EN=&5R97-T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!U<F-H87-E
M(&]F(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-3@P+#(R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#$V,BPS,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@
M8GD@*'5S960@:6XI(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S$L,3(X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV.#@L,S`V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D
M96-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Q."PV,38I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV.#0L-C$Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PX-CDL-#4W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-30L,S0Y+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PP
M-3`L.#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#DL-C8T+#<V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;VXM8V%S:"!I;G9E<W1I;F<@
M86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C:&%N9V4@:6X@=6YP86ED
M(&%D9&ET:6]N<R!T;R!I;G1A;F=I8FQE<RP@<')O<&5R='D@86YD(&5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-3`L-S@Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-#DL-C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F
M7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Q,04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!3=&%T96UE;G0@;V8@17%U:71Y("A5;F%U9&ET960I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^5&]T86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M0V]M;6]N('-T;V-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E)E=&%I;F5D(&5A<FYI;F=S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DYO;F-O;G1R;VQL:6YG(&EN=&5R97-T<SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@0F5G:6YN:6YG(&]F
M(%!E<FEO9"!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<Y+#(Y,2PX-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8S+#`W,RPY-#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#,Y-"PU
M-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#$W-BPV,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!"96=I;FYI;F<@;V8@4&5R:6]D+"!S
M:&%R97,@870@1&5C+B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3<L.3@U+#4P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W+#DX-2PU,#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-R
M96%S92`H1&5C<F5A<V4I(&EN(%-T;V-K:&]L9&5R<R<@17%U:71Y(%M2;VQL
M($9O<G=A<F1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,R-"PU-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C0L-3<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;BP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@
M86YD(')E;&%T960@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<Q,2PS-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW,3$L,S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@<W5B<VED:6%R
M>2!S:&%R97,@=&\@;F]N8V]N=')O;&QI;F<@:6YT97)E<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5P=7)C:&%S92!O9B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-3@P+#(R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#4X,"PR,C4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<'5R8VAA<V4@;V8@
M<VAA<F5S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S-#`L-#,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3@T+#<Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P."PX.3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-"PQ-S(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M86QA;F-E+"!%;F0@;V8@4&5R:6]D(&%T($IU;BX@,S`L(#(P,30\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`L-S,R+#(V-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C,L-3(Y
M+#8T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3<L-#`S+#0S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,C`P+#@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4L($5N9"!O9B!0
M97)I;V0L('-H87)E<R!A="!*=6XN(#,P+"`R,#$T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-RPV-C`L,S8W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-C8P+#,V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R
M8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R
M,#AF+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@0F%S:7,@;V8@
M4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N
M9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3U)'04Y)6D%424].($%.1"!"05-)4R!/1B!04D5314Y4051)3TX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$V<'@[
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M;W`Z,3!P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
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M9&EN9RUT;W`Z-G!X.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
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M=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E;6)E
M<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
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M1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXN(%1H92!R97-U;'1S(&]F(&]P97)A=&EO
M;G,@9F]R('1H92`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
M<F%T:6]N.FYO;F4[/G1H<F5E(&%N9"!S:7@\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;6]N=&AS
M(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%R92!N
M;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!T;R!B
M92!E>'!E8W1E9"!F;W(@=&AE(&5N=&ER92!F:7-C86P@>65A<B!O<B!A;GD@
M9G5T=7)E('!E<FEO9"X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M
M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&]T86P@8V]M<')E:&5N<VEV92!I;F-O
M;64@*&QO<W,I('=A<R!C;VUP<FES960@<V]L96QY(&]F(&YE="!I;F-O;64@
M*&QO<W,I(&9O<B!T:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SYT:')E92!A;F0@<VEX/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&UO
M;G1H<R!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
M<F%T:6]N.FYO;F4[/DIU;F4F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A
M;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
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M>F4Z,3!P=#L^26X@07!R:6P@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT
M:6YG(%-T86YD87)D<R!";V%R9"`H=&AE(")&05-"(BD@:7-S=65D(&%M96YD
M960@9W5I9&%N8V4@:6X@=&AE(&9O<FT@;V8@82!&05-"($%C8V]U;G1I;F<@
M4W1A;F1A<F1S(%5P9&%T92!O;B`B4F5P;W)T:6YG($1I<V-O;G1I;G5E9"!/
M<&5R871I;VYS(&%N9"!$:7-C;&]S=7)E<R!O9B!$:7-P;W-A;',@;V8@0V]M
M<&]N96YT<R!O9B!A;B!%;G1I='DB+B`@5&AE(&YE=R!G=6ED86YC92!R97-T
M<FEC=',@=&AE('!R97-E;G1A=&EO;B!O9B!D:7-C;VYT:6YU960@;W!E<F%T
M:6]N<R!T;R!B=7-I;F5S<R!C:7)C=6US=&%N8V5S('=H96X@=&AE(&1I<W!O
M<V%L(&]F(&)U<VEN97-S(&]P97)A=&EO;G,@<F5P<F5S96YT<R!A('-T<F%T
M96=I8R!S:&EF="!T:&%T(&AA<R!O<B!W:6QL(&AA=F4@82!M86IO<B!E9F9E
M8W0@;VX@86X@96YT:71Y)W,@;W!E<F%T:6]N<R!A;F0@9FEN86YC:6%L(')E
M<W5L=',N(%1H92!G=6ED86YC92!B96-O;65S(&5F9F5C=&EV92!O;B!*86YU
M87)Y(#$L(#(P,34N($%D;W!T:6]N(&ES(&]N(&$@<')O<W!E8W1I=F4@8F%S
M:7,N(#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P
M)3MP861D:6YG+6)O='1O;3HU<'@[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!-87D@,C`Q-"P@=&AE
M($9!4T(@:7-S=65D(&%M96YD960@9W5I9&%N8V4@:6X@=&AE(&9O<FT@;V8@
M82!&05-"($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92!O;BP@(E)E=F5N
M=64@9G)O;2!#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,B+B`@5&AE(&-O<F4@
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M($IA;G5A<GD@,2P@,C`Q-RX@16%R;'D@861O<'1I;VX@:7,@;F]T('!E<FUI
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M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$X<'@[9F]N="US
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M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M8F]T=&]M.C5P
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M('1H92`@86QL;W=A;F-E<R!F;W(@;V)S;VQE<V-E;G0@;W(@=6YM87)K971A
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?
M,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X
M,C`X9B]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY-87)K971A8FQE(%-E8W5R:71I97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M;G9E<W1M96YT<RP@1&5B="!A;F0@17%U:71Y(%-E8W5R:71I97,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^34%22T5404),12!314-54DE42453/"]T9#X-"B`@("`@("`@/'1D(&-L
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M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M
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M<FEA8FQE(')A=&4@9&5M86YD(&YO=&5S("@B5E)$3B(I+B`@070@=&AE('1I
M;64@;V8@<'5R8VAA<V4L("!T:&4@0V]M<&%N>2!C;&%S<VEF:65S(&UA<FME
M=&%B;&4@<V5C=7)I=&EE<R!A<R!E:71H97(@=')A9&EN9R!S96-U<FET:65S
M(&]R(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S+"!D97!E;F1I;F<@
M;VX@=&AE(&EN=&5N="!A="!T:&%T('1I;64N("!!<R!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M)SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL('1H92!M
M87)K971A8FQE('-E8W5R:71I97,@87)E(&-O;7!R:7-E9"!S;VQE;'D@;V8@
M=')A9&EN9R!S96-U<FET:65S+B`@5')A9&EN9R!S96-U<FET:65S(&%R92!C
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M9&EN9RUT;W`Z,3!P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
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M87-S971S(&]R(&QI86)I;&ET:65S("A,979E;"`Q(&UE87-U<F5M96YT<RD@
M86YD('1H92!L;W=E<W0@<')I;W)I='D@=&\@=6YO8G-E<G9A8FQE(&EN<'5T
M<R`H3&5V96P@,R!M96%S=7)E;65N=',I+B`\+V9O;G0^/"]D:78^/&1I=B!S
M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3!P>#MT97AT
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M)SX\='(^/'1D('-T>6QE/3-$=VED=&@Z,3`X<'@[(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.W!A9&1I;F<M;&5F=#HT.'!X.SX\9F]N
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M8VEN9STS1#`@<W1Y;&4],T0G<&%D9&EN9RUT;W`Z,3!P>#MF;VYT+69A;6EL
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M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY,979E;"`R("T\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT
M;W`[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
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M/"]T<CX\+W1A8FQE/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)W!A9&1I;F<M=&]P.C$P<'@[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P=#LG/CQT<CX\=&0@<W1Y
M;&4],T1W:61T:#HQ,#AP>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US
M:7IE.C$P<'0[<&%D9&EN9RUL969T.C0X<'@[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3&5V96P@,R`M/"]F
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M;&4^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M96YT+B`@5&AE($-O;7!A;GD@:&%S(&YO(&UA<FME=&%B;&4@<V5C=7)I=&EE
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M<'0[/B`\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R
M,"4[<&%D9&EN9RUT;W`Z,3!P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0Q,2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M
M=V5I9VAT.F)O;&0[/DIU;F4@,S`L(#(P,30\+V9O;G0^/"]D:78^/"]T9#X\
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M;&ED(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SY$96-E;6)E
M<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O
M=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
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M:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/DQE=F5L(#$\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C
M;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/E1O=&%L/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^52Y3+B!4<F5A
M<W5R>2!N;W1E<R!A;F0@8F]N9',\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
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M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$L.#4W+#4S,SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O
M/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I
M;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^,2PX-3<L-3,S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXR+#@R.2PX,#D\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
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M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q
M,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(L.#(Y+#@P.3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<R`F(S@R,3$[(&9I>&5D(')A=&4\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
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M;G0M<VEZ93HQ,'!T.SXQ+#0Y-BPW,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@
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M-BPW,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I
M;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C$L-#@Y+#`W-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
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M/C$L-#@Y+#`W-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^-"PX,S4L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
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M>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R
M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXT+#@S-2PP,#`\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C0L.#DU+#`P,#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C
M;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-"PX.34L,#`P/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HQ
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&]T
M86P@9F%I<B!V86QU92!O9B!M87)K971A8FQE("!S96-U<FET:65S/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXV+#8Y,BPU,S,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
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M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^."PQ
M,S,L,#DY/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P
M,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$
M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$T+#@R-2PV
M,S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-RPW,C0L.#`Y/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P
M,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C8L,CDT+#DU,CPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
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M97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q
M8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X
M9B]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY%87)N:6YG<R`H3&]S<RD@4&5R(%-H87)E/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5!4DY)3D=3("A,3U-3*2!0
M15(@4TA!4D4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I
M;F<M=&]P.C$V<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB
M;VQD.SY%05).24Y'4R`H3$]34RD@4$52(%-(05)%/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SY4:&4@9F]L;&]W:6YG('1A8FQE(')E8V]N
M8VEL97,@=&AE(&YU;65R871O<B!A;F0@9&5N;VUI;F%T;W(@=7-E9"!T;R!C
M86QC=6QA=&4@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@9F]R('1H92`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/G1H<F5E(&%N9"!S:7@\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;6]N=&AS(&5N9&5D(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^2G5N
M928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O
M;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C(P,3,\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXZ/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I
M=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[/CQD
M:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML
M:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W=I9'1H.CDY
M+C@P-3`V.#(R-C$R,#@U)3MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[
M9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.CAP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$S/"]F;VYT/CPO9&EV/CPO=&0^
M/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3G5M97)A=&]R.CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$
M;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.G1O<#MP861D:6YG+6QE9G0Z,CAP>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DYE="!I;F-O;64@*&QO<W,I
M(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<VAA<F5H;VQD97)S/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-S(R
M+#4W,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N
M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M9"`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH-C,Y+#`Q.#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+7)I
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SY$:6QU=&EV92!E9F9E8W0@;V8@;W1H97(@<V5C=7)I
M=&EE<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^,C@R+#4Q.#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS
M1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.G1O<#MP861D:6YG+6QE9G0Z,CAP>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E=E:6=H=&5D+6%V97)A
M9V4@<VAA<F5S(&]U='-T86YD:6YG("8C.#(Q,3L@9&EL=71E9#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXQ."PP,C4L.3$S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXQ."PT,#4L-3(R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O
M;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/&1I=B!S
M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT
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M=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3`R<'@@
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M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
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M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X
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M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C(V."PR,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C$W-2PX,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D
M:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT
M;W`[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SY796EG:'1E9"UA=F5R86=E('-H87)E<R!O=71S=&%N
M9&EN9R`F(S@R,3$[(&1I;'5T960\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3@L,#DS
M+#,Y,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3@L-S4V+#8Y,3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT
M/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
M=&]P.C$R<'@[=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/D%S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/C(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXL(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&%N
M9"!O<'1I;VYS('1O('!U<F-H87-E(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#MT97AT+61E8V]R871I;VXZ;F]N93L^,3@X+#@Q-#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A
M;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
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M;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R
M,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C
M,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,3`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2979E
M;G5E<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-E9VUE;G0@4F5P;W)T:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%5D5.5453/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F
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M<&%D9&EN9RUT;W`Z-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93II=&%L:6,[/E!R;V1U8W0@4F5V96YU97,\+V9O;G0^/"]D:78^/&1I=B!S
M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/E1H92!#;VUP86YY)B,X,C$W.W,@;F5T(')E=F5N
M=65S(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&9O<B!T:&4@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SYT:')E
M92!A;F0@<VEX/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&UO;G1H<R!E;F1E9"`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/DIU;F4F(S$V
M,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M.CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF
M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T
M>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH
M96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT+6%L:6=N.FQE9G0[)SX\='(^
M/'1D(&-O;'-P86X],T0Q-B!R;W=S<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT
M9"!W:61T:#TS1#,Y)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,3,E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@
M=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I
M9'1H/3-$,3,E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I
M9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T
M:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H
M/3-$,3(E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H
M/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS
M1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$
M,3(E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$
M,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#<@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M8F]L9#L^5&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D
M9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z
M8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH
M:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O
M;G0M=V5I9VAT.F)O;&0[/C(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG
M:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX
M<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO
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M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXS+#`V,RPX,3D\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N
M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M.3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR+#`T,2PP-#,\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N
M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV+#DS-2PS-S`\+V9O;G0^/"]D
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#`R-2PY-S$\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT
M/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ=&]P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W1H
M97(\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/C@T+#`U,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R
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M:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^,30P+#`P,#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
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M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^.2PW-3`L,38X/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C-P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C<L,#@Q+#`X.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
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M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP
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M;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C$W+#,S.2PR,C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
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M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3!P>#MT97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^07,@9&ES8W5S<V5D
M(&EN($YO=&4@,3`L('1H92!#;VUP86YY(&%C<75I<F5D(')I9VAT<R!T;R`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SYT=V\\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;F5W('!R;V1U8W1S(&%N9"!B
M;W1H($]M96-L86UO>"U086L@86YD(%9A<')I<V]L(&-O;G1R:6)U=&5D('1O
M($-U;6)E<FQA;F0G<R!N970@<F5V96YU92!D=7)I;F<@,C`Q-"X@3VX@3V-T
M;V)E<B`R."P@,C`Q,RP@0W5M8F5R;&%N9"!E;G1E<F5D(&EN=&\@86X@86=R
M965M96YT('=I=&@@4&5R;FEX(%1H97)A<&5U=&EC<R`H(E!E<FYI>"(I('1O
M(&1I<W1R:6)U=&4@86YD('!R;VUO=&4@3VUE8VQA;6]X+5!A:RX@56YD97(@
M=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L(&5F9F5C=&EV92!/8W1O8F5R
M(#$L(#(P,3,L('1H92!#;VUP86YY(&)E9V%N('1O(')E8V]R9"!T:&4@<F5V
M96YU92!O9B!T:&ES('!R;V1U8W0@86YD(&5F9F5C=&EV92!*86YU87)Y(#(P
M,30@0W5M8F5R;&%N9"!B96=A;B!D:7-T<FEB=71I;F<@3VUE8VQA;6]X+5!A
M:R!A;F0@<')O;6]T:6YG(&ET('1O(&=A<W1R;V5N=&5R;VQO9VES=',@86-R
M;W-S('1H92!5;FET960@4W1A=&5S+B`@3VX@1F5B<G5A<GD@,C@L(#(P,30L
M($-U;6)E<FQA;F0@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H($%S
M=&5L;&%S(%!H87)M82!54RP@26YC+B`H(D%S=&5L;&%S(BD@=&\@86-Q=6ER
M92!C97)T86EN('!R;V1U8W0@<FEG:'1S+"!I;G1E;&QE8W1U86P@<')O<&5R
M='D@86YD(')E;&%T960@87-S971S(&]F(%9A<')I<V]L+B!4:&4@0V]M<&%N
M>2!B96=A;B!S96QL:6YG(%9A<')I<V]L(&EN($UA<F-H(#(P,30@86YD(&QA
M=6YC:&5D('!R;VUO=&EO;F%L(&5F9F]R=',@9F]R('1H92!B<F%N9"!I;B!-
M87D@,C`Q-"X@(#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG
M:'0Z,3(P)3MP861D:6YG+71O<#HQ,G!X.W1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SY);B!.;W9E;6)E<B`R,#$R+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!S971T;&5M96YT(&%G<F5E;65N="!W:71H(%!A
M9&1O8VL@3&%B;W)A=&]R:65S+"!,3$,@*")0861D;V-K(BD@86YD(%!E<G)I
M9V\@0V]M<&%N>2`H(E!E<G)I9V\B*2!I;G9O;'9I;F<@86X@06-E=&%D;W1E
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M87)T97(@;V8@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q
M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/BP@<F5S<&5C=&EV96QY+"!A;F0@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#,N,B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD-2XP
M(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@9F]R('1H92`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SYS:7@@
M;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(')E<W!E8W1I=F5L>2X@/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I
M;F<M=&]P.C$R<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET
M86QI8SL^3W1H97(@4F5V96YU97,\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N
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M86YY(&5N=&5R960@:6YT;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
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M;F0@1VQO<FEA)W,@=&5R<FET;W)Y+B`@16%R;&EE<B!I;B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
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M<VEZ93HQ,'!T.SY$=7)I;F<@=&AE(&9U;&P@>65A<B!O9B`R,#$S+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!T;W1A;"!O9B`\+V9O;G0^/&9O;G0@
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M<B!U<"!T;R`@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A
M=&EO;CIN;VYE.SXD,"XV(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@:6X@;6EL97-T
M;VYE('!A>6UE;G1S(')E;&%T960@=&\@<F5G=6QA=&]R>2!A<'!R;W9A;',@
M86YD('5P('1O(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^)#0N,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&UI;&5S
M=&]N92!P87EM96YT<R!R96QA=&5D('1O('1O=&%L(&%N9"!A;FYU86P@<')O
M9'5C="!S86QE<RX@07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXL($-U;6)E<FQA;F0@:&%S(&YO="!R96-O9VYI>F5D(&%N>2!R979E
M;G5E<R!R96QA=&5D('1O(&UI;&5S=&]N97,@87-S;V-I871E9"!W:71H('1H
M92!N97<@86=R965M96YT<RX@(%1H92!#;VUP86YY(&ES(&%L<V\@96YT:71L
M960@=&\@<F5C96EV92!R;WEA;'1I97,@;VX@9G5T=7)E('-A;&5S(&]F('1H
M92!P<F]D=6-T<R!U;F1E<B!T:&4@86=R965M96YT<RX\+V9O;G0^/"]D:78^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE
M8F5?8S`W,#0S9C@R,#AF+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=F5N=&]R:65S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M26YV96YT;W)Y($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y614Y43U))15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$V<'@[
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M(&=O;V1S(&9O<B!S86QE+B`@0F%S960@;VX@=&AE(')E;&%T:6]N<VAI<"!W
M:71H('1H92!M86YU9F%C='5R97(@;W(@<&%C:V%G97(L('1H92!#;VUP86YY
M('=I;&P@96ET:&5R('1A:V4@=&ET;&4@=&\@=&AE(&9I;FES:&5D(&=O;V1S
M(&%T('1H92!T:6UE(&]F('-H:7!M96YT(&]R(&%T('1H92!T:6UE(&]F(&%R
M<FEV86P@9G)O;2!T:&4@;6%N=69A8W1U<F5R+B`@5&AE($-O;7!A;GD@=&AE
M;B!W87)E:&]U<V5S('-U8V@@9V]O9',@=6YT:6P@9&ES=')I8G5T:6]N(&%N
M9"!S86QE+B!);G9E;G1O<FEE<R!A<F4@<W1A=&5D(&%T('1H92!L;W=E<B!O
M9B!C;W-T(&]R(&UA<FME="!W:71H(&-O<W0@9&5T97)M:6YE9"!U<VEN9R!T
M:&4@9FER<W0M:6XL(&9I<G-T+6]U="!M971H;V0N/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$R<'@[
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M9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^0V%L9&]L;W(@:6YV96YT;W)Y(&]N(&AA;F0@
M870@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C
M96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!H860@=F%R>6EN9R!O
M<FEG:6YA;"!E>'!I<F%T:6]N(&1A=&5S('1H870@8F5G86X@:6X@=&AE('-E
M8V]N9"!Q=6%R=&5R(&]F(#(P,30@86YD(&5X=&5N9"!T:')O=6=H($IA;G5A
M<GD@,C`Q-BX@1'5R:6YG(#(P,3,L('1H92!#;VUP86YY('!R;W9I9&5D('-T
M86)I;&ET>2!D871A('1O('1H92!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T
M:6]N("@B1D1!(BD@<W5P<&]R=&EN9R!T:&%T('1H92!#86QD;VQO<B!P<F]D
M=6-T(&5X<&ER871I;VX@9&%T97,@;6%Y(&)E(&5X=&5N9&5D(&)Y('5P('1O
M(&$@>65A<BX@($EN($IA;G5A<GD@,C`Q-"P@=&AE($9$02!N;W1I9FEE9"!T
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M<'0[/B!T;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
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M,'!T.SY!="`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T
M:6]N.FYO;F4[/DIU;F4F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M
M<&%N>2!H87,@<F5C;V=N:7IE9"!C=6UU;&%T:79E(&-H87)G97,@9F]R('!O
M=&5N=&EA;"!O8G-O;&5S8V5N8V4@86YD(&1I<V-O;G1I;G5A;F-E(&QO<W-E
M<RP@<')I;6%R:6QY(&9O<B!#86QD;VQO<BP@;V8@87!P<F]X:6UA=&5L>2`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD,RXT(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,N
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M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N
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M<VEZ93HQ,'!T.SY!<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
M="UD96-O<F%T:6]N.FYO;F4[/DIU;F4F(S$V,#LS,"P@,C`Q-#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A
M=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M+"!I;G9E;G1O<GD@=V%S(&-O;7!R:7-E9"!O9B!T:&4@9F]L;&]W:6YG.B`\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N
M="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E
M>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z
M,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W=I9'1H.CDY+C@P-3`V.#(R-C$R,#@U)3MB;W)D97(M8V]L;&%P
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IB;VQD.SY*=6YE(#,P+"`R,#$T/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
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M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,BPW-C@L-CDU/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CL@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M.SXR+#`R-2PP,C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
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M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
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M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
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M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
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M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV+#DY-BPX-#,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
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M;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C4L-S(R+#@X
M,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?
M.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMS
M:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-H87)E:&]L9&5R<R<@17%U:71Y(&%N9"!$96)T/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U
M:71Y(&%N9"!$96)T(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%2$],1$524R<@15%52519($%.
M1"!$14)4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
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M;W`Z-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[
M/E-H87)E(%)E<'5R8VAA<V5S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SY/;B!-87DF(S$V,#LQ,RP@,C`Q,"P@=&AE($-O;7!A;GD@86YN
M;W5N8V5D(&$@<VAA<F4@<F5P=7)C:&%S92!P<F]G<F%M('1O('!U<F-H87-E
M('5P('1O(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^)#$P+C`@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!I=',@8V]M
M;6]N('-T;V-K('!U<G-U86YT('1O(%)U;&4@,3!B+3$X(&]F('1H92!396-U
M<FET:65S($%C="X@26X@2F%N=6%R>2`R,#$Q+"!!<')I;"`R,#$R(&%N9"!*
M86YU87)Y(#(P,3,L('1H92!#;VUP86YY)W,@0F]A<F0@;V8@1&ER96-T;W)S
M(')E<&QA8V5D('1H92!P<FEO<B!A=71H;W)I>F%T:6]N<R!W:71H(&YE=R`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/B0Q,"XP(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@875T:&]R:7IA=&EO;G,@9F]R
M(')E<'5R8VAA<V5S(&]F('1H92!#;VUP86YY)W,@;W5T<W1A;F1I;F<@8V]M
M;6]N('-T;V-K+B`@1'5R:6YG('1H92!F:7)S="!S:7@@;6]N=&AS(&]F(#PO
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M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,S0P
M+#0S-CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!S:&%R97,@86YD(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^-C<V+#4U,3PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&9O<B!A<'!R;WAI;6%T96QY
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93LG/B0Q+C8@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD
M,RXR(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(')E<W!E8W1I=F5L>2X@/"]F;VYT
M/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
M=&]P.C9P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z:71A;&EC
M.SY297-T<FEC=&5D(%-H87)E($=R86YT<R`\+V9O;G0^/"]D:78^/&1I=B!S
M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/D1U<FEN9R!T:&4@9FER<W0@:&%L9B!O9B`R,#$T
M+"!T:&4@0V]M<&%N>2!I<W-U960@87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C$W-2PP,#`\
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M8W1E9"!S=&]C:R!I<W-U960@=&\@9&ER96-T;W)S('9E<W1S(&]N('1H92`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/F]N92!Y96%R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N;FEV97)S87)Y(&]F('1H92!D871E
M(&]F(&=R86YT+B`@4W1O8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:7,@<')E
M<V5N=&5D(&%S(&$@8V]M<&]N96YT(&]F(&=E;F5R86P@86YD(&%D;6EN:7-T
M<F%T:79E(&5X<&5N<V4@:6X@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@
M<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&%N9"!C;VUP<F5H96YS:79E(&EN
M8V]M92X@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W!A9&1I;F<M=&]P.C9P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^0W5M8F5R;&%N9"!%;65R
M9VEN9R!496-H;F]L;V=I97,\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.W1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!!<')I;"`R,#$T+"!T:&4@0V]M
M<&%N>2!R96-E:79E9"!A<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0Q+C`@
M;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!F<F]M($=L;W)I82!F;W(@:71S('!A<G1I
M8VEP871I;VX@:6X@0W5M8F5R;&%N9"!%;65R9VEN9R!496-H;F]L;V=I97,@
M*")#150B*2X@07,@82!R97-U;'0L($=L;W)I82!R96-E:79E9"!S:&%R97,@
M:6X@0T54(&%N9"!W:6QL(&AA=F4@=&AE(&9I<G-T(')I9VAT('1O(&YE9V]T
M:6%T92!A(&QI8V5N<V4@=&\@0T54(&1E=F5L;W!E9"!P<F]D=6-T<R!F;W(@
M=&AE($-H:6YE<V4@;6%R:V5T+B!0<FEO<B!T;R!!<')I;"`R,#$T+"!#=6UB
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M(&YE=VQY(&ES<W5E9"!S:&%R97,N("`@57!O;B!C;VUP;&5T:6]N(&]F('1H
M92!A9&1I=&EO;F%L(&EN=F5S=&UE;G0@8GD@1VQO<FEA(&%N9"!#=6UB97)L
M86YD(&EN($%P<FEL(#(P,30L('1H92!#;VUP86YY)B,X,C$W.W,@;W=N97)S
M:&EP(&EN($-%5"!I<R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
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M92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HV<'@[<&%D9&EN9RUT;W`Z
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M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY/;B!*=6YE(#(V+"`R,#$T+"!#
M=6UB97)L86YD(&5N=&5R960@:6YT;R!A(%)E=F]L=FEN9R!#<F5D:70@3&]A
M;B!!9W)E96UE;G0@*"8C.#(R,#M,;V%N($%G<F5E;65N="8C.#(R,3LI('=I
M=&@@4W5N5')U<W0@0F%N:RX@5&AE(&YE=R!A9W)E96UE;G0@<F5P;&%C960@
M=&AE($%U9W5S="`R,#$Q($9I9G1H($%M96YD960@86YD(%)E<W1A=&5D($QO
M86X@06=R965M96YT("AT:&4@(D%G<F5E;65N="(I('=I=&@@:71S('!R979I
M;W5S('!R:6UA<GD@;&5N9&5R('=H:6-H('=A<R!T;R!E>'!I<F4@;VX@1&5C
M96UB97(@,S$L(#(P,30N("`@5&AE<F4@87)E(&YO(&)O<G)O=VEN9W,@=6YD
M97(@=&AE($QO86X@06=R965M96YT(&%T($IU;F4@,S`L(#(P,30@86YD(&ET
M(&AA<R!A(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/G1H<F5E/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('EE87(@=&5R
M;2!E>'!I<FEN9R!O;B!*=6YE(#(V+"`R,#$W+B`@5&AE($QO86X@06=R965M
M96YT('!R;W9I9&5S(&9O<B!A;B!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N
M="!U<"!T;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD,C`@;6EL;&EO;CPO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@
M(%1H92!I;FET:6%L(')E=F]L=FEN9R!L:6YE(&]F(&-R961I="!I<R!U<"!T
M;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
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M(&%B:6QI='D@=&\@:6YC<F5A<V4@=&AE(&)O<G)O=VEN9R!A;6]U;G0@=7`@
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M9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXQ+C`E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('1O(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C(N.#4E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^+B`@26X@861D:71I;VXL(&$@9F5E(&]F(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C`N,C4E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('!E<B!Y96%R(&ES(&-H87)G
M960@;VX@=&AE('5N=7-E9"!L:6YE(&]F(&-R961I="X@26YT97)E<W0@86YD
M('1H92!U;G5S960@;&EN92!F964@87)E('!A>6%B;&4@<75A<G1E<FQY+B`@
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M971E<FUI;F5D(&]N(&$@<75A<G1E<FQY(&)A<VES+B`@5&AE($-O;7!A;GD@
M:7,@:6X@8V]M<&QI86YC92!W:71H(&%L;"!C;W9E;F%N=',@870@2G5N92`S
M,"P@,C`Q-"X@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.W!A9&1I;F<M8F]T=&]M.C$S<'@[=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/E1H92!#;VUP86YY(&EN8W5R<F5D(&YO(&5A
M<FQY('1E<FUI;F%T:6]N('!E;F%L=&EE<R!U<&]N('1E<FUI;F%T:6]N(&]F
M('1H92!P<F5V:6]U<R!!9W)E96UE;G0@86YD(&EN8W5R<F5D(&QE<W,@=&AA
M;B`D,"XQ(&UI;&QI;VX@:6X@9&5F97)R960@9FEN86YC:6YG(&-O<W1S(')E
M;&%T960@=&\@=&AE(&YE=R!,;V%N($%G<F5E;65N="P@=VAI8V@@=VEL;"!B
M92!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92!U<VEN9R!T:&4@969F
M96-T:79E(&EN=&5R97-T(&UE=&AO9"!O=F5R('1H92!T97)M(&]F('1H92!,
M;V%N($%G<F5E;65N="X@/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W!A9&1I;F<M8F]T=&]M.C9P>#MP861D:6YG+71O<#HV
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE($%U9W5S="`R,#$Q
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M,3!P=#L^(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,I+B!);G1E<F5S="!A
M;F0@86X@=6YU<V5D(&QI;F4@;V8@8W)E9&ET(&9E92`H/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M,"XR-24\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#MP97(@86YN=6TI('=E<F4@<&%Y86)L
M92!Q=6%R=&5R;'DN(%1H97)E('=E<F4@;F\@8F]R<F]W:6YG<R!O=71S=&%N
M9&EN9R!O;B!T:&4@8W)E9&ET(&9A8VEL:71Y(&%T($1E8V5M8F5R(#,Q+"`R
M,#$S(&]R(&%T(&%N>2!T:6UE(&1U<FEN9R`R,#$T+CPO9F]N=#X\+V1I=CX\
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M>2`R,#$T+"!T:&4@<')E=FEO=7,@06=R965M96YT('=A<R!A;65N9&5D(&9O
M<B!C97)T86EN('!R;W9I<VEO;G,@<F5L871E9"!T;R!T:&4@86=G<F5G871E
M(&]W;F5R<VAI<"!O9B!T:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C:R!O=F5R
M(#,P)2!A;F0@8V5R=&%I;B!O=&AE<B!F:6YA;F-I86P@8V]V96YA;G1S+B`@
M07,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P
M,3,L('1H92!#;VUP86YY('=A<R!I;B!C;VUP;&EA;F-E('=I=&@@86QL(&-O
M=F5N86YT<RX\+V9O;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B
M95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)3D-/344@5$%815,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.W!A9&1I;F<M=&]P.C$V<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.SY)3D-/344@5$%815,\+V9O;G0^/"]D:78^/&1I
M=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/D%T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#MT97AT+61E8V]R871I;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F
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M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
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M(&5A8V@@;V8@=&AE('EE87)S(#(P,#D@=&AR;W5G:"`R,#$S+B`@5&AE($-O
M;7!A;GD@97AP96-T<R!T;R!P87D@;6EN:6UA;"!I;F-O;64@=&%X97,@:6X@
M,C`Q-"!T:')O=6=H('5T:6QI>F%T:6]N(&]F('1H97-E(&YE="!O<&5R871I
M;F<@;&]S<R!C87)R>69O<G=A<F1S+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T,#(R
M7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F
M.#(P.&8O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0V]L;&%B;W)A=&EV92!!9W)E96UE;G1S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I
M;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T],3$%"3U)!
M5$E612!!1U)%14U%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P
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M=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VX@.#`X+"`\+V9O;G0^/&9O
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E
M7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S
M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4345.5%,@04Y$($-/3E1)3D=%
M3D-)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
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M+B`@5&AE($-O;7!A;GD@8V]N=&EN=65S('1O(&-O;G-I9&5R(&ET<R!L96=A
M;"!O<'1I;VYS(&%N9"!I;G1E;F1S('1O(&-O;G1I;G5E('1O('9I9V]R;W5S
M;'D@9&5F96YD(&%N9"!P<F]T96-T(&ET<R!!8V5T861O=&4@<')O9'5C="!A
M;F0@<F5L871E9"!I;G1E;&QE8W1U86P@<')O<&5R='D@<FEG:'1S+B8C,38P
M.R!!;'-O('-E92!T:&4@9&ES8W5S<VEO;B!O9B!T:&4@0V]M<&%N>2=S($%C
M971A9&]T92!P871E;G0@9&5F96YS92!L96=A;"!P<F]C965D:6YG<R!C;VYT
M86EN960@:6X@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^4&%R="`Q
M+"!)=&5M(#$L($)U<VEN97-S("U4<F%D96UA<FMS(&%N9"!0871E;G1S/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^+"!O9B!T:&4@0V]M<&%N>2=S($9O<FT@,3`M2R!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,RP@=VAI8V@@:7,@
M:6YC;W)P;W)A=&5D(&)Y(')E9F5R96YC92!H97)E:6XN/"]F;VYT/CPO9&EV
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T,#(R7S)C
M,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P
M.&8O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3F5W(%!R;V1U8W1S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@0V]M
M8FEN871I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DY%5R!04D]$54-44SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,39P>#MF;VYT+7-I>F4Z
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M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY/;B!/8W1O8F5R(#(X+"`R,#$S+"!T
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M=&5R('!Y;&]R:2`H/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
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M(#(Y+"`R,#$S+B`@5&AE<F4@87)E(&%D9&ET:6]N86P@;6EL97-T;VYE<R!A
M="!T:&4@9FER<W0@86YD('-E8V]N9"!A;FYI=F5R<V%R>2!D871E<R!O9B!T
M:&4@97AE8W5T:6]N(&]F('1H92!A9W)E96UE;G0@=&]T86QI;F<@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)#0N,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN('1H92!A9V=R96=A
M=&4N(%)O>6%L='D@<&%Y;65N=',@<F%N9VEN9R!F<F]M(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C$U)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!T;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,"4\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX@8F%S960@;VX@=&EE<F5D(&QE=F5L<R!O9B!G<F]S<R!P<F]F:71S(&%R
M92!P86ED(&)Y($-U;6)E<FQA;F0@=&\@4&5R;FEX+B`@5&AE($-O;7!A;GD@
M86QS;R!M86ME<R!R;WEA;'1Y('!A>6UE;G1S('1O(%!E<FYI>"!T;R!R969L
M96-T('1H96ER(&]N9V]I;F<@<V%L97,@<')O;6]T:6]N86P@969F;W)T<RX\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D
M9&EN9RUT;W`Z,3!P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^5&AE(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B0T+C`@;6EL;&EO;CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!U<&9R;VYT('!A>6UE;G0@=&AA="!T:&4@0V]M<&%N>2!P86ED('1O(%!E
M<FYI>"!O;B!/8W1O8F5R(#(Y+"`R,#$S(&ES(&EN8VQU9&5D(&EN('!R;V1U
M8W0@86YD(&QI8V5N<V4@<FEG:'1S(&%N9"!W:6QL(&)E(&%M;W)T:7IE9"!O
M=F5R('1H92!R96UA:6YI;F<@97AP96-T960@=7-E9G5L(&QI9F4@;V8@=&AE
M(&%C<75I<F5D(&%S<V5T+"!C=7)R96YT;'D@=&AE(&QI9F4@;V8@=&AE(&%G
M<F5E;65N="P@=VAI8V@@96YD<R!I;B!*=6YE(#(P,S(N("!/;65C;&%M;W@M
M4&%K(&-O;G1R:6)U=&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0Q+C,@;6EL;&EO;CPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B`@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0R+C4@;6EL;&EO;CPO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B!I;B!N970@<F5V96YU97,@9'5R:6YG('1H92`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O
M;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/G1H<F5E(&%N9"!S
M:7@\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@;6]N=&AS(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^2G5N928C,38P.S,P+"`R
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M<VEZ93HQ,'!T.SY/;B!&96)R=6%R>2`R."P@,C`Q-"P@=&AE($-O;7!A;GD@
M86-Q=6ER960@8V5R=&%I;B!P<F]D=6-T(')I9VAT<RP@:6YT96QL96-T=6%L
M('!R;W!E<G1Y(&%N9"!R96QA=&5D(&%S<V5T<R!O9B!687!R:7-O;#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/CQS=7`@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[;&EN92UH
M96EG:'0Z,3(P)3MF;VYT+7-I>F4Z-W!T/B`@/"]S=7`^/"]F;VYT/CQF;VYT
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M=&AE;B!L875N8VAE9"!I;B`R,#`V+B!)="!I<R!O;F4@;V8@='=O(&)R86YD
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M9B!T:&4@8VQO<VEN9R!O9B!T:&4@=')A;G-A8W1I;VX@;V8@=7`@=&\@/"]F
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M<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BPY.3`L,#`P/"]F;VYT/CPO9&EV
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M/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,2PT,3`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M*#0P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#(L,#`P+#`P
M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
M;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BPP,#`L,#`P/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
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M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^=&AR964@86YD('-I>#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!M;VYT:',@96YD960@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN("!4:&4@<')O+69O
M<FUA(&5F9F5C=',@;V8@=&AE(&%C<75I<VET:6]N(&]N('1H92!C;VYD96YS
M960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E<F4@;F]T
M(&UA=&5R:6%L(&9O<B!D:7-C;&]S=7)E+CPO9F]N=#X\+V1I=CX\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T
M,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P
M-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T@^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!"87-I
M<R!O9B!0<F5S96YT871I;VX@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@
M0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3
M=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N="!!8V-O=6YT:6YG($=U:61A;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@07!R:6P@,C`Q-"P@=&AE($9I;F%N
M8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H=&AE(")&05-"(BD@
M:7-S=65D(&%M96YD960@9W5I9&%N8V4@:6X@=&AE(&9O<FT@;V8@82!&05-"
M($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92!O;B`B4F5P;W)T:6YG($1I
M<V-O;G1I;G5E9"!/<&5R871I;VYS(&%N9"!$:7-C;&]S=7)E<R!O9B!$:7-P
M;W-A;',@;V8@0V]M<&]N96YT<R!O9B!A;B!%;G1I='DB+B`@5&AE(&YE=R!G
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M92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HU<'@[<&%D9&EN9RUT;W`Z
M-G!X.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!-
M87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D(&%M96YD960@9W5I9&%N8V4@:6X@
M=&AE(&9O<FT@;V8@82!&05-"($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T
M92!O;BP@(E)E=F5N=64@9G)O;2!#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,B
M+B`@5&AE(&-O<F4@<')I;F-I<&QE(&]F('1H92!N97<@9W5I9&%N8V4@:7,@
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M969F96-T:79E(&]N($IA;G5A<GD@,2P@,C`Q-RX@16%R;'D@861O<'1I;VX@
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M9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93II=&%L:6,[=&5X="UD96-O<F%T:6]N.G5N9&5R
M;&EN93L^57-E(&]F($5S=&EM871E<SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE
M/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O;3HU<'@[<&%D9&EN
M9RUT;W`Z-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(%-E9VUE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+6)O='1O
M;3HU<'@[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N
M="US='EL93II=&%L:6,[=&5X="UD96-O<F%T:6]N.G5N9&5R;&EN93L^3W!E
M<F%T:6YG(%-E9VUE;G1S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MF;VYT+7-I>F4Z,3!P=#L^
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M;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P
M.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q
M8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMS:&5E=',O4VAE970Q."YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA<FME
M=&%B;&4@4V5C=7)I=&EE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&UE;G1S+"!$96)T
M(&%N9"!%<75I='D@4V5C=7)I=&EE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F
M(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@8GD@='EP93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z,3!P>#MT97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&9O;&QO=VEN9R!T86)L
M92!S=6UM87)I>F5S('1H92!F86ER('9A;'5E(&]F('1H97-E(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<RP@8GD@;&5V96P@=VET:&EN('1H92!F86ER('9A;'5E
M(&AI97)A<F-H>2P@87,@;V8@96%C:"!P97)I;V0@96YD.CPO9F]N=#X\+V1I
M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+7-I>F4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'@[=&5X="UI;F1E;G0Z,'!X.VQI;F4M:&5I9VAT.FYO<FUA;#MP861D
M:6YG+71O<#HQ,'!X.SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[;6%R9VEN+6QE9G0Z875T;SMM87)G:6XM<FEG:'0Z
M875T;SMW:61T:#HV-S5P>#MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X
M="UA;&EG;CIL969T.R<^/'1R/CQT9"!C;VQS<&%N/3-$,C0@<F]W<W!A;CTS
M1#$^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0R,#!P>"!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#EP>"!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#8R<'@@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0T<'@@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0U<'@@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Y<'@@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0V,G!X(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-'!X(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-7!X(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$.7!X(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-C)P>"!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#1P>"!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#5P>"!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#EP>"!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#8R<'@@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0T<'@@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0U<'@@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Y<'@@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0V,G!X(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-'!X(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-7!X(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$.7!X(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$-C)P>"!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#1P>"!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q,2!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ
M93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/DIU;F4@,S`L(#(P,30\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS
M<&%N/3-$,3$@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#MF;VYT+7=E:6=H
M=#IB;VQD.SY$96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^5&]T86P\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/E1O
M=&%L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ=&]P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^52Y3+B!4<F5A<W5R>2!N;W1E<R!A;F0@8F]N9',\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
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M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$L.#4W
M+#4S,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PX-3<L-3,S/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
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M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXR+#@R.2PX,#D\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE
M+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
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M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
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M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C(L.#(Y+#@P.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M(&YO=&5S(&%N9"!B;VYD<R`F(S@R,3$[(&9I>&5D(')A=&4\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#0Y-BPW,#`\+V9O;G0^
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M<VEZ93HQ,'!T.SXQ+#0Y-BPW,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M:70[9F]N="US:7IE.C$P<'0[/C$L-#@Y+#`W-SPO9F]N=#X\+V1I=CX\+W1D
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M9F]N="US:7IE.C$P<'0[/C$L-#@Y+#`W-SPO9F]N=#X\+V1I=CX\+W1D/CQT
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXQ+#<T."PT.3@\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^375N:6-I<&%L(&)O;F1S("8C
M.#(Q,3L@5E)$3CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-"PX,S4L,#`P/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
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M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXT+#@S-2PP,#`\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0L.#DU+#`P
M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M-"PX.34L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O
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M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
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M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
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M;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O
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M>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X
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M=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL
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M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^-RPW,C0L.#`Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L
M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C8L
M,CDT+#DU,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS
M1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D
M96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ-"PP,3DL
M-S8Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N
M92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y
M96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%87)N:6YG<R`H3&]S
M<RD@4&5R(%-H87)E("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8V]N8VEL:6%T:6]N(&]F(&YU;65R871O<B!A;F0@9&5N;VUI
M;F%T;W(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M
M=&]P.C9P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY4:&4@9F]L;&]W:6YG('1A
M8FQE(')E8V]N8VEL97,@=&AE(&YU;65R871O<B!A;F0@9&5N;VUI;F%T;W(@
M=7-E9"!T;R!C86QC=6QA=&4@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@
M9F]R('1H92`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T
M:6]N.FYO;F4[/G1H<F5E(&%N9"!S:7@\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@;6]N=&AS(&5N
M9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C(P
M,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXZ/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE
M.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD
M96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W=I9'1H.CDY+C@P-3`V.#(R-C$R,#@U)3MB;W)D97(M8V]L;&%P<V4Z8V]L
M;&%P<V4[=&5X="UA;&EG;CIL969T.R<^/'1R/CQT9"!C;VQS<&%N/3-$."!R
M;W=S<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT9"!W:61T:#TS1#8U)2!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,34E(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,34E(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HX<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@8V]L<W!A;CTS1#<@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
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M:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE
M.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^-S(R+#4W,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L
M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH-C,Y
M+#`Q.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+7)I9VAT.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT
M/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ=&]P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^1&5N
M;VUI;F%T;W(Z/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY$:6QU=&EV92!E9F9E8W0@;V8@;W1H
M97(@<V5C=7)I=&EE<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXQ."PP,C4L.3$S/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXQ."PT,#4L-3(R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N
M;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D
M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z
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M/3-$,3`R<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0T<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0U<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0Y<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0Q,#-P>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#1P>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CPO='(^
M/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.CAP=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$-R!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N="UW96EG:'0Z8F]L9#L^
M,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
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M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
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M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/C(Q-2PV.3$\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
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M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C(V."PR,3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C$W-2PX,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\
M+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY796EG:'1E9"UA=F5R86=E('-H87)E
M<R!O=71S=&%N9&EN9R`F(S@R,3$[(&1I;'5T960\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,3@L,#DS+#,Y,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3@L-S4V
M+#8Y,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q
M8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X
M9B]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY2979E;G5E<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E9VUE;G0@
M4F5P;W)T:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@;F5T(')E=F5N=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C9P>#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SY4:&4@0V]M<&%N>28C.#(Q-SMS(&YE="!R
M979E;G5E<R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R!F;W(@=&AE(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^
M=&AR964@86YD('-I>#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!M;VYT:',@96YD960@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE
M)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L
M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\
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M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=VED=&@Z,3`P
M)3MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG;CIL969T.R<^
M/'1R/CQT9"!C;VQS<&%N/3-$,38@<F]W<W!A;CTS1#$^/"]T9#X\+W1R/CQT
M<CX\=&0@=VED=&@],T0S.24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#$S)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$S)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@
M=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#$R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W
M:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I
M9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
M=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T
M:#TS1#$R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T
M:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[/E-I>"!M;VYT:',@96YD960@2G5N92`S
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CAP=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HX<'0[9F]N
M="UW96EG:'0Z8F]L9#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H
M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O
M=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HX
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/C(P,3,\+V9O;G0^/"]D:78^/"]T
M9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C(X
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
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M;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#`W,2PT
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI
M9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV,34L-30W/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO
M;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PQ,CDL,#@R/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O
M/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXX-"PP-3`\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C(W-RPU,C0\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$T,"PP,#`\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C<U-2PY.#@\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@
M8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C4R<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY4;W1A;"!N
M970@<F5V96YU97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CDL-S4P+#$V.#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P
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M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXW+#`X,2PP.#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ
M,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D
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M;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR
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M9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXQ-RPS,SDL,C(P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE
M/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S
M9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R
M7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T
M,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)
M;G9E;G1O<FEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5N=&]R>2!$:7-C;&]S=7)E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R
M,"4[<&%D9&EN9RUT;W`Z,3)P>#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/BP@:6YV96YT;W)Y('=A<R!C;VUP<FES960@;V8@=&AE(&9O;&QO=VEN9SH@
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
M;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT
M97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P
M.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MW:61T:#HY.2XX,#4P-C@R,C8Q,C`X-24[8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.W1E>'0M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A
M;CTS1#@@<F]W<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0V
M-24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q
M)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$U
M)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$U)2!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z8F]L9#L^2G5N92`S,"P@,C`Q-#PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[/D1E8V5M8F5R
M(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
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M:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
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M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0L,C(X+#$T.#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,RPV.3<L.#8R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
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M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
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M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F
M7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K
M<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.97<@4')O9'5C=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"=7-I;F5S<R!#
M;VUB:6YA=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@9F%I<B!V86QU92!A
M<W-E=',@86YD(&QI86)I;&ET:65S(&%S<W5M960@:6X@86-Q=6ES:71I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$P
M<'@[=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E1H92!F
M;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T:&4@<')E;&EM:6YA<GD@86QL
M;V-A=&EO;B!O9B!T:&4@9F%I<B!V86QU97,@;V8@=&AE(&%S<V5T<R!A8W%U
M:7)E9"!A;F0@;&EA8FEL:71I97,@87-S=6UE9"!A<R!O9B!T:&4@86-Q=6ES
M:71I;VX@9&%T92!F;W(@5F%P<FES;VPZ/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M=&]P.C$P<'@[=&5X="UA
M;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M
M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA
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M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#0Q,"PP,#`\+V9O;G0^
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M.V9O;G0M<VEZ93HQ,'!T.SXH-#`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXH,BPP,#`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/BD\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXR+#`P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L
M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT
M/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P
M,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T
M,V8X,C`X9B]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$501T))
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DUA<FME=&%B;&4@4V5C=7)I=&EE
M<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O
M9B!M87)K971A8FQE('-E8W5R:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F
M(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-"PX,C4L-C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"PP,3DL-S8Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5+E,N(%1R96%S
M=7)Y(&YO=&5S(&%N9"!B;VYD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E
M8W5R:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-3<L
M-3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPX,CDL.#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5+E,N($%G96YC>2!I<W-U960@;6]R=&=A9V4M8F%C
M:V5D('-E8W5R:71I97,@XH"3('9A<FEA8FQE(')A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;V8@
M;6%R:V5T86)L92!S96-U<FET:65S+"!B>2!T>7!E/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!M
M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L.#DV+#@W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,#0Y+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3+B!!9V5N8WD@;F]T97,@
M86YD(&)O;F1S(.*`DR!F:7AE9"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER('9A;'5E(&]F(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<RP@8GD@='EP93PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L
M92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#<T-RPQ-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0Y-BPW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-"02!L;V%N('!O;VQS(.*`DR!V87)I86)L
M92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@8GD@
M='EP93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0X.2PP-S<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<T."PT.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUU;FEC:7!A;"!B;VYD<R#B@),@5E)$3CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!M87)K971A
M8FQE('-E8W5R:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PX,S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PX.34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`Q/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER('9A;'5E(&]F(&UA<FME
M=&%B;&4@<V5C=7)I=&EE<RP@8GD@='EP93PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@;6%R:V5T
M86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#8Y,BPU,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#<R-"PX,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#$@?"!5+E,N(%1R96%S=7)Y
M(&YO=&5S(&%N9"!B;VYD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R
M:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-3<L-3,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPX,CDL.#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,979E;"`Q('P@52Y3+B!!9V5N8WD@:7-S=65D(&UO<G1G
M86=E+6)A8VME9"!S96-U<FET:65S(.*`DR!V87)I86)L92!R871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER('9A
M;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@8GD@='EP93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5V96P@,2!\(%4N4RX@06=E;F-Y(&YO=&5S
M(&%N9"!B;VYD<R#B@),@9FEX960@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!M87)K971A
M8FQE('-E8W5R:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQE=F5L(#$@?"!30D$@;&]A;B!P;V]L<R#B@),@=F%R:6%B;&4@<F%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I97,L(&)Y('1Y<&4\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#$@?"!-=6YI8VEP86P@
M8F]N9',@XH"3(%921$X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET
M:65S+"!B>2!T>7!E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#,U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M.#DU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5V96P@,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R
M:71I97,L(&)Y('1Y<&4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ,S,L,#DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPR.30L.34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,979E;"`R('P@52Y3+B!4<F5A<W5R>2!N;W1E<R!A;F0@
M8F]N9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S+"!B>2!T
M>7!E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`R('P@52Y3+B!!
M9V5N8WD@:7-S=65D(&UO<G1G86=E+6)A8VME9"!S96-U<FET:65S(.*`DR!V
M87)I86)L92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE
M<RP@8GD@='EP93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@Y-BPX-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`T
M.2PW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQE=F5L(#(@?"!5+E,N($%G96YC>2!N;W1E<R!A;F0@8F]N9',@
MXH"3(&9I>&5D(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET
M:65S+"!B>2!T>7!E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!M87)K971A8FQE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S0W+#$U,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#DV+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5V96P@,B!\(%-"02!L;V%N('!O;VQS(.*`DR!V87)I86)L
M92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&86ER('9A;'5E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@8GD@
M='EP93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@=F%L=64@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0X.2PP-S<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<T."PT.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQE=F5L(#(@?"!-=6YI8VEP86P@8F]N9',@XH"3(%921$X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@
M;V8@;6%R:V5T86)L92!S96-U<FET:65S+"!B>2!T>7!E/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O
M9B!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R
M,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C
M,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,C0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$580D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5A
M<FYI;F=S("A,;W-S*2!097(@4VAA<F4@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYU;65R871O<CH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I
M(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<VAA<F5H;VQD97)S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<R,BPU-S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8S.2PP,3@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#`P."PX.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(Q-2PV.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5N;VUI;F%T;W(Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"UA=F5R86=E('-H87)E<R!O=71S=&%N9&EN9R#B@),@8F%S:6,@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#<T
M,RPS.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ."PT,#4L-3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<L.#(U+#$W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#4X,"PX.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T:79E
M(&5F9F5C="!O9B!O=&AE<B!S96-U<FET:65S("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#(L-3$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V."PR,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S4L
M.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960M879E<F%G92!S:&%R97,@;W5T<W1A;F1I;F<@XH"3
M(&1I;'5T960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X+#`R-2PY,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ."PT,#4L-3(R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,#DS+#,Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#<U-BPV
M.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P
M,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C
M,#<P-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M2$@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^16%R;FEN9W,@*$QO<W,I(%!E
M<B!3:&%R92`H1&5T86EL<R!497AT=6%L*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H
M87)E("A497AT=6%L*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&%V86EL86)L
M92!F;W(@<'5R8VAA<V4@=&AR;W5G:"!R97-T<FEC=&5D('-T;V-K(&%W87)D
M<R!A;F0@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@X+#@Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4U-"PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B
M7S0S8F9?.65B95]C,#<P-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#(V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%1T=!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2979E
M;G5E<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O
M9'5C=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@.2PW-3`L,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W+#`X,2PP.#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W+#@T,RPT,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W
M+#,S.2PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C971A9&]T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY0<F]D=6-T<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!R979E;G5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP-C,L.#$Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ-#8L
M.3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PW.#0L.3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L,SDX+#DV.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2W)I<W1A;&]S93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]D=6-T<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPU-3DL,S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPP-#$L,#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPY,S4L,S<P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ-3@L,CDS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86QD;VQO
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY0<F]D=6-T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C(V+#8X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8Q-2PU-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$R.2PP.#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`R-2PY-S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;V1U8W1S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(')E=F5N=65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#@T+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<W+#4R-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S4U+#DX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y
M96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4U0D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E=F5N=65S("A$
M971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^<')O9'5C
M=%]L:6YE/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3,\8G(^86=R965M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^06-E=&%D;W1E+"!'96YE<FEC
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3,\8G(^06-E=&%D;W1E+"!'96YE<FEC/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^06-E=&%D;W1E+"!'96YE
M<FEC/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3,\8G(^06-E=&%D;W1E+"!'96YE<FEC/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^3F]N+6-O;&QA8F]R
M871I=F4@07)R86YG96UE;G0L(#(P,3,@0V]M;65R8VEA;&EZ871I;VX@06=R
M965M96YT('=I=&@@5&AR964@26YT97)N871I;VYA;"!087)T;F5R<SQB<CYA
M9W)E96UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CY.;VXM8V]L;&%B;W)A=&EV92!!<G)A;F=E;65N="P@
M,C`Q,R!#;VUM97)C:6%L:7IA=&EO;B!!9W)E96UE;G0@=VET:"!4:')E92!)
M;G1E<FYA=&EO;F%L(%!A<G1N97)S/&)R/F%G<F5E;65N=#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/DUA>&EM
M=6T\8G(^4F5C96EP="!O9B!R96=U;&%T;W)Y(&YO=&EC92!O;B!A<'!R;W9A
M;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/DUA>&EM=6T\8G(^4&%Y;65N=',@8F%S960@;VX@=&]T86P@86YD
M(&%N;G5A;"!P<F]D=6-T('-A;&5S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S("A497AT=6%L*2!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<')O9'5C="!L:6YE<R!A8W%U:7)E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4@;V8@<')O9'5C="!R979E;G5E(&9R;VT@9V5N97)I8R!S86QE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@86=R965M96YT<R!W:71H(&EN=&5R;F%T
M:6]N86P@<&%R=&YE<G,@9F]R(&-O;6UE<F-I86QI>F%T:6]N(&EN(&EN=&5R
M;F%T:6]N86P@;6%R:V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V96YU92!R96-O9VYI>F5D(&9R;VT@;&EC96YS
M92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@<F5V96YU97,L(&UI;&5S=&]N92!M971H;V0L
M(&9U='5R92!R979E;G5E('5P;VX@86-H:65V:6YG(&UI;&5S=&]N97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P,S$T
M,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]F,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P
M-#-F.#(P.&8O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%041!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY);G9E;G1O<FEE<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W(&UA=&5R:6%L
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<V."PV.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(L,#(U+#`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1FEN:7-H960@9V]O9',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,C(X+#$T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-CDW+#@V,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L.3DV+#@T,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PW,C(L
M.#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F
M,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?
M8S`W,#0S9C@R,#AF+U=O<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15-'04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV96YT;W)I97,@*$1E
M=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M86XN(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY);G9E;G1O<FEE<R`H5&5X='5A;"D@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&5L9B!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'1E;F1E9"!S:&5L9B!L:69E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E<G9E(&9O<B!P
M;W1E;G1I86P@;V)S;VQE<V-E;F-E(&]F('!R;V1U8W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F
M7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K
M<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$581T)'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-H87)E:&]L9&5R<R<@17%U:71Y(&%N9"!$96)T("`H
M1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$-3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,3,L(#(P
M,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@
M,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CY297-T<FEC=&5D(%-T;V-K/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^16UP
M;&]Y964\8G(^4F5S=')I8W1E9"!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D1I<F5C=&]R/&)R/E)E
M<W1R:6-T960@4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CY#;VUM;VX@<W1O8VL\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CY#;VUM;VX@
M<W1O8VL\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F5H;VQD97)S)R!%<75I='D@*%1E>'1U86PI(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5P=7)C:&%S92!O=71S=&%N9&EN9R!C;VUM;VX@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5P=7)C:&%S92!O9B!S:&%R97,L('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T,"PT,S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-S8L-34Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97!U<F-H87-E(&]F('-H87)E<RP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PU.#`L,C(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3@P+#(R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D(&EN('!E<FEO9"P@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@87=A<F1S+"!V97-T:6YG('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q('EE87(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!S=6)S:61I87)Y('-H87)E<R!T
M;R!N;VYC;VYT<F]L;&EN9R!I;G1E<F5S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L
M,#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N8V]N=')O;&QI;F<@:6YT97)E<W0L(&]W;F5R<VAI<"!P97)C
M96YT86=E(&)Y('!A<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!C;VYT<FEB=71E9"!T
M;R!N;VYC;VYT<F]L;&EN9R!I;G1E<F5S="!I;B!E>&-H86YG92!F;W(@;F5W
M;'D@:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO86YS(&9O<F=I=F5N(&EN(&5X
M8VAA;F=E(&9O<B!N97=L>2!I<W-U960@<VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R
M8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R
M,#AF+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%4044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4VAA<F5H;VQD97)S)R!%<75I='D@86YD
M($1E8G0@*$1E8G0I("A$971A:6QS*2`H3&EN92!O9B!#<F5D:70L(%)E=F]L
M=FEN9R!#<F5D:70@1F%C:6QI='DL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,C8L(#(P,30\8G(^4W5N5')U<W0@
M0F%N:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#(V
M+"`R,#$T/&)R/E-U;E1R=7-T($)A;FL\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY#<F5D:70@1F%C:6QI='DL
M($9I9G1H($%M96YD960@86YD(%)E<W1A=&5D($QO86X@06=R965M96YT+"!T
M:&4@06=R965M96YT+"!!=6=U<W0@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D-R961I="!&86-I;&ET
M>2P@1FEF=&@@06UE;F1E9"!A;F0@4F5S=&%T960@3&]A;B!!9W)E96UE;G0L
M('1H92!!9W)E96UE;G0L($%U9W5S="`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%U9RX@,S$L(#(P,3$\8G(^0W)E9&ET($9A8VEL
M:71Y+"!&:69T:"!!;65N9&5D(&%N9"!297-T871E9"!,;V%N($%G<F5E;65N
M="P@=&AE($%G<F5E;65N="P@075G=7-T(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EN92!O9B!#<F5D:70@
M1F%C:6QI='D@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EN
M92!O9B!C<F5D:70L(&UA>&EM=6T@8F]R<F]W:6YG(&-A<&%C:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQI;F4@;V8@8W)E9&ET+"!M87AI;75M(&)O<G)O=VEN9R!C
M87!A8VET>2!U<&]N('-A=&ES9F%C=&EO;B!O9B!C97)T86EN(&-O;F1I=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&5R97-T(')A=&4@<W!R96%D+"!M:6YI;75M/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A
M=&4@<W!R96%D+"!M87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+C@U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A=&4@;V8@;&EN92!O9B!C<F5D
M:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,3<E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&EN92!O9B!C<F5D:70L('5N=7-E9"!C87!A8VET>2P@8V]M;6ET;65N="!F
M964@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XR-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XR-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?
M-#-B9E\Y96)E7V,P-S`T,V8X,C`X9B]7;W)K<VAE971S+U-H965T,S(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5813X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@
M5&%X97,@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CY);B!-:6QL:6]N
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487AE<R`H5&5X
M='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!C87)R>69O<G=A<F1S(&=E;F5R871E9"!F
M<F]M('1H92!E>&5R8VES92!O9B!N;VYQ=6%L:69I960@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,BXW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S
M8F9?.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O
M<FMS:&5E=',O4VAE970S,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14=(04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^3F5W(%!R;V1U8W1S($%S<V5T<R!A;F0@3&EA8FEL
M:71I97,@07-S=6UE9"`H1&5T86EL<RD@*%9A<')I<V]L+"!54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R
M."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5F%P<FES;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I;VX@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E;&QE
M8W1U86P@<')O<&5R='D@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,BPY.3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W%U
M:7)E9"!C;VYT:6YG96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T,#`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!C;VYS:61E<F%T
M:6]N(&]B;&EG871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,#`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!N970@87-S971S(&%C<75I<F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C`S,30P,C)?,F,Q
M8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V8P,S$T,#(R7S)C,6)?-#-B9E\Y96)E7V,P-S`T,V8X,C`X
M9B]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#1$%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DYE=R!0<F]D=6-T<R!.97<@4')O9'5C=',@
M+2!.87)R871I=F4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY/
M;65C;&%M;W@M4&%K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^3VUE8VQA;6]X+5!A:SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#(Y+"`R,#$S/&)R/D]M96-L86UO
M>"U086L\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q-#QB<CY687!R:7-O;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E9A<')I<V]L/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,30\8G(^5F%P<FES
M;VP\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R.2P@
M,C`Q,SQB<CY-:6YI;75M/&)R/D]M96-L86UO>"U086L\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R.2P@,C`Q,SQB<CY-87AI;75M
M/&)R/D]M96-L86UO>"U086L\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I;VX@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5P9G)O;G0@<&%Y;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%D9&ET:6]N86P@=7!F<F]N="!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F]Y86QT>2!P87EM96YT<R!B87-E9"!O;B!P97)C96YT86=E(&]V
M97(@9W)O<W,@<')O9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(')E=F5N=65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL-S4P+#$V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPP.#$L
M,#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q-RPX-#,L-#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-RPS,SDL,C(P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#,T-"PX-CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-#@T
M+#(Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L,#<Q+#0S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PS-CDL-S8U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,#,Q-#`R,E\R8S%B7S0S8F9?
M.65B95]C,#<P-#-F.#(P.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO9C`S,30P,C)?,F,Q8E\T,V)F7SEE8F5?8S`W,#0S9C@R,#AF+U=O<FMS
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M9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#,T+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]F
G,#,Q-#`R,E\R8S%B7S0S8F9?.65B95]C,#<P-#-F.#(P.&8M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories (Details Textual) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InventoriesTextualAbstract', window );"><strong>Inventories (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InventoryShelfLife', window );">Shelf life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InventoryExtendedShelfLife', window );">Extended shelf life</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for potential obsolescence of products</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.4<span></span></td>
        <td class="nump">$ 3.5<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InventoriesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_InventoriesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InventoryExtendedShelfLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Inventory, Extended Shelf Life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_InventoryExtendedShelfLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InventoryShelfLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Inventory, Shelf Life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_InventoryShelfLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation reserve for inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SX 210.12-09)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryValuationReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EADAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventories (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 2,768,695<span></span></td>
        <td class="nump">$ 2,025,020<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">4,228,148<span></span></td>
        <td class="nump">3,697,862<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
        <td class="nump">$ 6,996,843<span></span></td>
        <td class="nump">$ 5,722,882<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXGBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity and Debt  (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="5">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 13, 2010</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Apr. 29, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Restricted Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Employee

</div>
          <div>Restricted Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Director

</div>
          <div>Restricted Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Common stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount', window );">Repurchase outstanding common shares</a></td>
        <td class="nump">$ 10,000,000.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000.0<span></span></td>
        <td class="nump">$ 10,000,000.0<span></span></td>
        <td class="nump">$ 10,000,000.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">340,436<span></span></td>
        <td class="nump">676,551<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,580,225<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,580,225<span></span></td>
        <td class="nump">3,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of subsidiary shares to noncontrolling interests</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Cash contributed to noncontrolling interest in exchange for newly issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LoansForgiveninExchangeForShareIssuedAmount', window );">Loans forgiven in exchange for newly issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LoansForgiveninExchangeForShareIssuedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loans Forgiven in Exchange For Share Issued, Amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_LoansForgiveninExchangeForShareIssuedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_ShareholdersEquityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestOwnershipPercentageByParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a stock repurchase plan authorized by an entity's Board of Directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchaseProgramAuthorizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EATAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) (Line of Credit, Revolving Credit Facility, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 26, 2014

</div>
          <div>SunTrust Bank</div>
        </th>
        <th class="th">
          <div>Jun. 26, 2014

</div>
          <div>SunTrust Bank</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2011

</div>
          <div>Credit Facility, Fifth Amended and Restated Loan Agreement, the Agreement, August 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Expiration period</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Interest rate spread, minimum</a></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum', window );">Interest rate spread, maximum</a></td>
        <td class="nump">2.85%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate of line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.17%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
        <td class="nump">0.25%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.25%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effective interest rate at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARKETABLE SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of U.S. Treasury notes and bonds, U.S. Government Agency notes and bonds and bank-guaranteed, variable rate demand notes ("VRDN").  At the time of purchase,  the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the marketable securities are comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 1 -</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices for identical instruments in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 2 -</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">Level 3 -</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant inputs to the valuation model are unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</font><font style="font-family:inherit;font-size:11pt;"> </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of these marketable securities, by level within the fair value hierarchy, as of each period end:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="200px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury notes and bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency issued mortgage-backed securities &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency notes and bonds &#8211; fixed rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SBA loan pools &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds &#8211; VRDN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of marketable  securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,692,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,133,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,825,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,724,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for  investments in certain debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Debt Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Equity Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Loss carryforwards generated from the exercise of nonqualified options</a></td>
        <td class="nump">$ 42.7<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncomeTaxesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_IncomeTaxesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11283-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxExpenseFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 39,050,841<span></span></td>
        <td class="nump">$ 40,869,457<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
        <td class="nump">14,825,632<span></span></td>
        <td class="nump">14,019,761<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
        <td class="nump">6,014,477<span></span></td>
        <td class="nump">4,530,424<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">6,996,843<span></span></td>
        <td class="nump">5,722,882<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">3,744,244<span></span></td>
        <td class="nump">3,537,191<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">70,632,037<span></span></td>
        <td class="nump">68,679,715<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">726,868<span></span></td>
        <td class="nump">880,647<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
        <td class="nump">19,073,458<span></span></td>
        <td class="nump">15,498,819<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">3,036,301<span></span></td>
        <td class="nump">2,554,557<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">93,468,664<span></span></td>
        <td class="nump">87,613,738<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">4,220,194<span></span></td>
        <td class="nump">2,035,853<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump">7,642,960<span></span></td>
        <td class="nump">5,509,917<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">11,863,154<span></span></td>
        <td class="nump">7,545,770<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
        <td class="nump">873,246<span></span></td>
        <td class="nump">776,125<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">12,736,400<span></span></td>
        <td class="nump">8,321,895<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#x2014;no par value; 100,000,000 shares authorized; 17,660,367 and 17,985,503 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively</a></td>
        <td class="nump">63,529,644<span></span></td>
        <td class="nump">63,073,941<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
        <td class="nump">17,403,430<span></span></td>
        <td class="nump">16,394,540<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#x2019; equity</a></td>
        <td class="nump">80,933,074<span></span></td>
        <td class="nump">79,468,481<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
        <td class="num">(200,810)<span></span></td>
        <td class="num">(176,638)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
        <td class="nump">80,732,264<span></span></td>
        <td class="nump">79,291,843<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
        <td class="nump">$ 93,468,664<span></span></td>
        <td class="nump">$ 87,613,738<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other long-term obligations, excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_OtherLongTermObligationsExcludingCurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Line-of-Credit Arrangement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6517033<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361426&amp;loc=d3e1314-112600<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361426&amp;loc=d3e1336-112600<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermLineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Retained earnings</div>
        </th>
        <th class="th">
          <div>Noncontrolling interests</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2013</a></td>
        <td class="nump">$ 79,291,843<span></span></td>
        <td class="nump">$ 63,073,941<span></span></td>
        <td class="nump">$ 16,394,540<span></span></td>
        <td class="num">$ (176,638)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period, shares at Dec. 31, 2013</a></td>
        <td class="nump">17,985,503<span></span></td>
        <td class="nump">17,985,503<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">324,576<span></span></td>
        <td class="nump">324,576<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options and related tax benefit</a></td>
        <td class="nump">711,347<span></span></td>
        <td class="nump">711,347<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of subsidiary shares to noncontrolling interests</a></td>
        <td class="nump">1,000,005<span></span></td>
        <td class="nump">1,000,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
        <td class="num">(1,580,225)<span></span></td>
        <td class="num">(1,580,225)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(340,436)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
        <td class="nump">984,718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,008,890<span></span></td>
        <td class="num">(24,172)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2014</a></td>
        <td class="nump">$ 80,732,264<span></span></td>
        <td class="nump">$ 63,529,644<span></span></td>
        <td class="nump">$ 17,403,430<span></span></td>
        <td class="num">$ (200,810)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period, shares at Jun. 30, 2014</a></td>
        <td class="nump">17,660,367<span></span></td>
        <td class="nump">17,660,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchasedDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>New Products (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of fair value assets and liabilities assumed in acquisition</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary allocation of the fair values of the assets acquired and liabilities assumed as of the acquisition date for Vaprisol:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="569px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="95px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,990,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
        <td class="nump">$ 722,570<span></span></td>
        <td class="num">$ (639,018)<span></span></td>
        <td class="nump">$ 1,008,890<span></span></td>
        <td class="nump">$ 215,691<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#x2013; basic (in shares)</a></td>
        <td class="nump">17,743,395<span></span></td>
        <td class="nump">18,405,522<span></span></td>
        <td class="nump">17,825,174<span></span></td>
        <td class="nump">18,580,891<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
        <td class="nump">282,518<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">268,217<span></span></td>
        <td class="nump">175,800<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#x2013; diluted (in shares)</a></td>
        <td class="nump">18,025,913<span></span></td>
        <td class="nump">18,405,522<span></span></td>
        <td class="nump">18,093,391<span></span></td>
        <td class="nump">18,756,691<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_DenominatorAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_NumeratorAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001445305-14-003560-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001445305-14-003560-xbrl.zip
M4$L#!!0````(`'N("$6&++>ODY$``(.<!@`1`!P`8W!I>"TR,#$T,#8S,"YX
M;6Q55`D``SH[Y5,Z.^53=7@+``$$)0X```0Y`0``[%WI<]O(E?^^5?L_8)ED
M-JD2)=P$Y+%3O)!H8ENR)&>23U--H$GV&D0S:$`2YZ_?UXV#IVA)!D6":I?+
M)H$^WO%[K]_KBS__]6$2*G<X9H1&[QO:J=I0<.33@$2C]XVO-\WV3??BHO'7
M#__]7S__3[/YK\[U1Z5'_72"HT3IQA@E.%#N23)6?@TP^Z8,8SI1?J7Q-W*'
M3I0AC2<X#F?*KWC@D1#:9,UFWM3T?*@-<$O7\'#H6^9PJ+H#[`Q55=,U'[4<
MUSEY.#>&;LL>J(YCMPPS"`+'P1:V74,?:D-U@-VLM8=!'))S_J\"W$3LW)^2
MA_>-<9),S\_.[N_O3X'@`1""HF`Z1O$$G?IT<J:KFJG:!G"<U0HP*2OQQDX9
M]D]'].X,7O#"1E/5FH96%">,FKK66NI'5*/Q"(JKQEE>HJ@`_'_;4IJ_'B"&
MB^(I:XX0FI8UAH@-1.G\Q0:2>(/!"A-Y^_99]G*Q*-E&>\02%/DE-0]KU-\;
MHK3FNNZ9>%L6961306A6._O7IX\W_AA/4+/L`#2H*#_S!LZ9>'6-AXIH\'P<
MX^'[!M=FLU#6Z0,+&OGK9#;%[QN,3*8AT'F6-92!P:=1@A\2A03O&SVHJW[1
M/Z&99F2]E<4`Q229Y<_*IR3@SX<$QXJ@""^Q4Z"B>_&/Q@<5F%*=ENZ:/Y^M
M5BZZ.MO05][3%,>$!JO]@V#BI`>F]8%3WE2MIJ87K<S?K53"4;!<Q9AW'"Q4
M*)XN=%T\RH6V38[:%^T7%-5/BAHW%%5[CA2US+9V(47]B]Z>QB2LGQSUIFH^
M4XZBBN[N0HY&3=%H/!^-QN[0:-94BN;SI6CN4HIUM6GS^38MJACJCN3X2QIA
MW?XMCW-^@S`S((F'?(@@DUG[@;#RU36^H^$=Q)7+93YA'NZ5I7IXD%Q`N!&+
ML'6I@8\DPI?#K/9*K<572YWS>.2WFS2ZC5.6=%#T+:NX!\7/]8E'G+7R<?XB
M`#(>IB'Q"^:4@$"Y+-;/^3Q?Y[#QH7BW5;X_GVWLXT5$K*MH3L2ZCJKL^3$U
M-SYP/9^OZ_E[G9=VM*23'[=1NZG;S[31Q2I5V:B7#;SZE]M>_5R=\7Q79W`Q
M5N_J%L18>IRKF`:IGUS&-SB^(SZ>>YNVCQ,4T`37V]5L8C"WLQ4.]V)D=45'
M%X4!#6E\M.!89E!BXQG8^$=,@-:0LN-U':LL2GP\`Q^7R1C'^6MVM!#9P*5$
MR3-0DK\I!^F_X0AZ](\6+UOYE<@1R/EW31.`%\R\[5B,,@$XG`2@ENB0"8#$
MADP`]IX`U!(?,@&0*)$)0"T2@`-&SDT"+7-F^_])@;LNG4QI!%_9TFH;/)[0
MZ":A?LW7S+:R.U^Y6N-7(F<-.;>S*;X<MN,812-<KL\*I_.91ET:AFA`8Y20
M.[Q0B+?#I8MCGZ"0_`[O:=0>Q5B\_94DX]LQ?+F`ON-(O$3A%?`-5ESS06ZC
MO'*OM5.!2>R*S0FU7/=\V1:/'8NQ=`&=E)$(,];VP9LR(I`YCT\GV`_1A#Y<
MH9H/&H^P642H:WSN:Z-!79'R3S2%1)"&QXR291XE0M80(J=0]SN%6E=TR"E4
MB0TYA;K?*=2ZXD-.H4J4R"G4PY]"/3SDU'(/Q<O.W>Q8C*4!MN]1'/!)LI6#
M(BP!\"4X.(+9YR46%P]K;.!Q7X9V'`B9SU*3),27PXLH('<D2%$X]^O]R32D
M,USSV+!*3#UK.GN38/,19%FR$LD[1')Y5([$V$_JG@8?&)C+0VY+PI5X7L.S
M7`@XJ(6`NB)%+@1(A.SKU/ARK6L<X,F4J^Y*,+4PW[S4M4>&R;@--0(<M*.`
M#U0@E^`C1?,U^OF'=)0ROJ"OU1O@;_S@^?>14LS<5P<5Z2?6_(1<,-S[@F$M
MT2$7#"4VY(+AWA<,:XD/N6`H42(7#&NQ8'C`R)%G+@[WS,4Q(.<SC7A#,0WY
MS<WB9``DFV\"1-M8EWAZ(9ZNP:^3"`=]%$?\*O`W@:3-3+]U#%WP>X&_F+78
M^Y)=5)YD5QG#W_GUL<6;2L1A?-'K)HZ5DU95BT,>$91'!/>,P=IY*&.G'LJ4
MJVNU<0)R=>UH5]?V8.\>(O$_49CB#J`$L306`O!B_)\41_ZR`RC+7D33-&$?
M\1T.:VY,3V!_#NPM_$N$?`\A99E/Z/]HS",9=CGDQ@S6F&5:-]A/8Y(0S.;^
MGMOG%:5AS0.WUX+9<VAZHAYR;[JB"(GWW>#]*[N-1:>SSS2!%U'0H5'`YD6E
M'>S7#IZH(&D?E=M'N3=^Q+N1%G$`%E%NR]^H$FD#.[.!3S1.1FB$.\C_AH-Y
MH0O&4AQT9E<QN8/TIL]G=/AV8FDE!V`E+U6:M*/=V5$:@4"G*!2#N+21_=O(
M!H5(_#^*?_V-0U:7"'D:0N3LRRO`3,Z^U!SO<O;EP.U`SK[LRS[D[,O!682<
M?=F3#<C9EQI:B9Q].3P[DK,O!V8C;VOVY2WFPC+OK``+1YXGRIQL-]@YSAQ*
MYBM5X^.MY1<REM\#QHXH]I9Q[G9L7/.#0,O:1P]DDDY6\K<MQ[$^D1"SA$;X
M$T[&-/#2!#*<:\A;HA1?H1DOS#J(X>`RNJ4)"D$%[2A*49B?_;]!8=V]5"G%
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MR7RE:GR\M?Q"QO)[P-@1Q=XRSMV.#7E6\5#/*AX6`N19Q4,YJWA8N)!G%?=Y
M5G%'6.!0T+X8[71D:/)7:&N#7ODKM&_A5VBUINKLX#!D=CS9N!DC&-TNTX2W
M&@!>2D/LI`S4QUC;!]_(B#A&6UK?Y03[(9K0ARM4\PCQ$39SZ*SSN0<$&$U-
M;>KNH2/@J??^2*0\O^\?O0I(HG(3*DDD45DU*A=E>ERH-+]H'A[HSM.0^$_$
M9QMIS:\@VXZN91[WDP_I3=W9C;;U-G`7UO"R"'-'*2*(Y)<TPKJ][QQQ\=52
MY\+R;M+H-H:HO8.BFL>F;SS!>TS-N?=9U_.^9F1T>S?FMAX%U=`;.>"0JA!/
M&I%,-JA(SE>$,<GV6F7@*`L5+19O%WOA36[L(DHWN(VBA9QH^/BBMJ?9%;"_
MA8#N;1PLEGM11TR`9RL369$7M9ZRX)&F(2(P=:UU_O6F]]*6KW`LH+_20T#N
M`)ZK<.,5/X-SBOGMHZN.YLED+0)R<XL+W?5P1"<DVM[A]T2\VN-ZH\7;!;[7
MI5=NI?!]FD8)NT(S-`AQ-XUC@+^26](U'BY<@*4$V"<3%++W#;61+0<@/VFV
M-%73>CW-[EF>V6OKIJ:;MN,8+;O3:SEMMZ'P;D530OVF#NUQU[&=AI?1:7PQ
M'Z/3TUI>IVMTNY9KM/N:U[4\-Z.SJ[JF9ZW2J:N&Y5C&R^@4-]S>\6*?<?(2
MJ6J>IEH=U33;3J]O>9ICV854NWVK[:U2:T-K9JNU3NTF2GZ$YBT2-CJMGJ.[
MNJ6:EM;77!5(+B3<LWK&&A(L0S7U#4AX`LT3&B?Y/7V70P\,(/)Y6$-9PI9I
M[@F:]7_?]AXCV^SI/4?5;-6Q6X;FM=J:T\W([K7<=K^]2K8&R'`6B-Y"RH\0
M;6XEVFCIJMYRK'ZWK6F=;KO7L:R<:$?3[%T1?1'!4#PBH)DV8_@1LK\\3G;'
M`5HA?+!=Q[7;AM7M]O0<(B!JQUPEFP/$>I3N56I^F/(M`G>Z?=MN]=R^X_2Z
M.I#?U0O*^U:KI:U2;KF.KAFO0[FQ5>:6U[+;JN9U',?I>`:8I:/EE+<-PUUW
M?(YNF]:K4;X-Y)X#8`::^Z9EMMJVU;,*ROM]I]]9<RAJRW9?2CE$J@$)4WXS
MZ'S;3__!#],`!UY,)WRA-TWRQHI5W2+H@*[257>YF<&+S]X"BUVUKVK]GMWK
M>6JK:UB&W<GM&*I;^J+/+$(SRS+UEKO`9164OXHPUBUL61BFV76ZKMXS>QW5
M[MN:V;&ZA3!ZAMO=(`P-0*V9NQ7&!NQ^+]:P3;?CNGW5-?1^#P8_&+OST;NO
M=W1[%;A.R]:,UI*#W@311PC9$D;TK7[?['M:1W4Z;<_J.:U6/R?$TUQ;7R7$
M-3BEMOD40EX2(JA:MZ/!`.LZ':NM6;VNU]6*L$;;$(0!,2VWI5FK]&P."K:3
MM45,CM>Q])[1=E2U:^FN9O7M;A'#VEYWS=&T5-N``;7U)+**Z5``WH!DMP?W
M"/-#RH/Z6R"Q$U+_V^/64E*I>SU/[VJ>!Y&*95JNI>7NL&5"I-KR&A]^"I-W
M$/<K+)F%D,`/H<GF$$U(.#N_)1/,E,_X7KFF$Q2]$^\8^1V?:^HT>=?X:92\
M6ZG.D\CF&)/1.#F'^.%/[Z8HX/,)S81.SS5[^O!H(_SY)B)(-(:T/5FM)[[>
M9QT-:!AD#7WN_ZI<75_VOG9O;WBC9[Q8T<,9T/E<DJNF6!0_)PD*B9^U5*Z<
M-*_0MTIHAMX>WG%<-*&7470>XN$:,2]E(B,Y4B[]A/+9--TY4;CYGBC)&"O<
M3Z)HIF"QERU02)10!45*.4FBW)-DK(#GC,B#`N\"PI*8#-($0[%`F8*OI?!Y
M22:GRU\5PA2D#&+$]U5`#<S\F(C]&$H^DP&D(&[+W'0`OW2"IS'ZG8;X1.&-
M$)_P#7>B0V@6F!Q#MS.(994AC04?28Q1(NBE0^7O&'1%!V!-P.]T%M*8*']>
M4U0U8/C[:=[#C[8O6OL+*&"(?2$;SFV0T@!'*%32T!<SH0PCAD^5KR#*G'$<
M3QAGFG\IM;:LW%Q)3#PL14Z5$0)=4J%Z&M(1X1D*\F/*LI)?P1N"PL1..";(
MR6&PN3W023H:*P0:85/,KUA/9@KC/V?$M>1C^-?G3G*D`',,A\`F5`8_'<\4
M'T9E93J>,5`UBMBI<@LM^X)\&-CA$YWR*1<,XA&=0J5O..%M<;(H/(J!<@@'
M1""@1!ASJ`&++)U.(3P4E?S5N]\+L0EH9GV6(D,DX':03H<QU^,T^^DF7J,2
M1?_1/%65"8<UC2IID#.;JX<N&+N;&?NIPKD#&7,Y<\>3W6[/*<A^OP?TFPEI
M2&*6"*DR#(,5%T($45;,N)H"@81<:O@!(J]%,<Y]1L)_V8IKYT!EE:,(C8#B
M$?!T"L/E3.`UUS-3^*\&<`Y`_9-JV-"L/U6FZ4H:@E&H&H(&_/?,..S`^/@@
M$O*3R@(G(^%,P$4,N5L01LX-:S!3NF(>/>1`*Y&;H;2T00C@*%CZ-X!<O*J>
M.=KA4XR'PIN`3DD,=(PHUUSF>C)?E:$=#\$1)>RT'F,V%\6!VL^J5Q3#=[+J
M/K=Z)!X4D"A+V+@]%L,(!P0,KCAB6(FYY+.1YQ[(5P:8AP,\V>=PN\M'P!A/
M$.'Y'7@D&'?XD)4R/$Q#:&>(2^?$MREP<"(>PY\H?A;$AS/Q=JGD?!"]'Q-_
M#+%1P&E5^`HWT&[H@-/E`$<<"A!!45"1RK13HUJ5"2E60YM^:E7NCB.<@"+%
M[\8QB'IBKLZD`@/P(;")S_^@BC^9N4)R*'X;AD;G$8Q\&0T)_^67;-@C#]5P
M-8&'8Z:(W<2OQ@?'Z$]H,GWW!\U6WQFJ,#:S$H8.WVT^$J(7>Y$.GOXB5?/P
M($YYO)7G:N9R.%^Z,D@)^.F3TG=F_O*$)W$XY"-B"H,>O(38&<9.#NX8AWQ'
M>^8$Q0C]J'!>0CNO!Q%W40T\=$)\%.:B`O&]6Y/MO)G6-,E=E:`%VBGU]*-T
MB2"NS;A4$"07!<]98CH%B8#`@I/EU%0D!2#*`#A(LF0B1I!_05P<IQ.%T8#`
M?WFH`TH84S85J..#$[1)1)PBLF><WD$N.R&^T,%X!OHH'L`7"$T@>YT0E&4@
MA3+O$3A"WCJH+\B5QU,T$6%!`%6P(UX!/"(E1&GDC[/A5%=5^U2Y2#B+X!S$
MV'9/MR;A;('9C6GU,JW+Z5),^3KT;E,F?0<ITUR*B<(GZ\#,3_-4B8,CVI@L
ME:P%*<]JP;B:0\B1(#V:09UAD@<F12JUG#\584;>6_$U`<TPY!?Y%!A156%^
MY7([`5Q.^;`&55.`Q&(LC_PQP7SO6>F<,BG,,(KSB#PWF0)B.?H`4/-F_I=E
M3B[;5KKHIH16L@7D'*9(3"[ELZ_Y'!(J)U`69RA6(LXL=F1IF#G";(8!ZC$(
M`2(?SZ/&G(I`)(KU&$2X;0YI&-)[$4CQ17:%I9,)BJ%<,6^#0\(WE<0\TPJI
MOS0E,D202=WQRZ?FDTO9F#$/I$6DC@9\\QV?=('WZ42,+4LQ]X+TA+X*39[O
M1)*^F,UZRKQWT0J7_7G9"A&P%M\7^XUH/$'A>L]EPYF(??`E>1FQ],"_LRGR
MB^_/G[$'C8U(E!&)TH06#\10GSVY)T$R/K=;+:!G0.,`QTV?_P+BE.'SXL,:
MV.:$Q^4G""@H)S=ZWS`;D'+?9Y^ULNQ9$LP_QAM;$,2\;UBV.WU8:F/>]L;V
MYE5?7M%Z:4WS>14?XWUSU#.@24(G[P;(_S:*P6\%S3R6]WV,A\-W2SC408>+
M(%O\GC6T]"A#`7_R7?H7D+]+QW.Q,?0DY:)\[D6VVOZRCK9*]27">U03AR+#
M/U8EG>]B;HN47B@,@<A*I:&?N*YZ`EGOSJ5R*/KG]08Q!(@0,[UO\-R^<;8Q
M%7I$`,_S3SPK.S8?=`=C.(TA*'D&9DIZ]4;U/F?C</I:%J2=F%JE%G0HBGY]
M0WDCHWB[G&&"ET`BS_060OU=6%6EDMVKN?W95%]GO%K'S^[&]<HA]A<YFCU-
M4-VY"8(U,A+DTQ0*'4"'XN-.[#'+)',1:=,'!7)V$BC%$D3]S%+G1EFI83Y1
M1-(^7S2(.G6WW%N^"T:L;*Y,G>T&@`8`,*`I3[)_Q$@//CVJ+CW^GOB.)'_>
MJ=M[CM@.!4$5Y@UG8N)W4_E7(^R@%AT6$H;'HA4EQGSY,=O&-=Z\'7&^PD:8
MGS*^O0P-Z!U>6B7B2QA3Q-,4W@Q?K,C7;XH5MB?04JP1K<U0*FD"V<[O8B,9
M2(L,P1#X>E=$!PS'XM@B5.*_RW&JM/D25+:4=+)*"]_SYH?0)C\X+Q9'Q.]X
M*,;"$HLRF?\6"#0W7^S:Q;XBK=HUU.JV%6FGIMQ6]`:W%2G%MH?FD*^R\5V:
MV$\V+B+2J##L@&\0%/,3(N;.-BUD!US!C[#B\E:FW/.E_(@FR@0>Q?PE7X0,
MRJ,YVW<U%9_G1X">=L[GNV>#KD'*X%5^Q\%%?JL&*H\L%K,O[2CX.)]T:6?+
MJ_-TL'@W6SI4],/743UR>*IGFKINZXZI=_L]M]/S>J:>'TMR/,=2UT]I\C];
MY5:E#'8G\`O`&B"+)/@CN>-?MYQVW97P54MW5=VSS6[/];Q>M]_RS$+XMJEU
MUP[WNN[NI/\=@>Q2$]F\_NL`WE;[_#1]RVCU+=51VUK7[!<R[YCJVCT'FJGM
M4N8YZY5(]V^4!GQ#]<:N/N/D5>3;LO16M^_IMJF[CJIW5-6S"OGVN_TUAZ+_
M/WM7VYM(DJ2_GW3_`;6TNET)]^3[R^S.2EE5F7/6=;MW;-^<[F,UE-MH,/@H
MZ.G^]Q>916$PF#908+#SDVU,P9.1$9$1D?&"FM$H/UK\(H73O+R%=_H?OA$X
MF&NA!_@XS4>C[Z"#PGRVC8ICA6!)*A$L/E-)IJTU>-8_0V&U5*S+D!*:\;DJ
MU&=A:F09:XIIA;9)EK"$)DEF,J4L>EB&TWAI^ZA&($8,O\0RR)H:;F20HIF@
M2`+MM:2)G'9@R0RU5"XU?&"4::I>9!GTZ=U`W#@JA$;.*L=20[6=5EQGFEF\
MM`RF@0VE('M81M5C^WS0\>.^BJRH?F[:%$("E9%C,N6@%9C3QB:Z;M="B,D>
M+^@,=HT)K'^TH-7HFES7^@8CC"AC"9P44B?<`(M9I&I^<X@L]5$ZPZ`3!!:-
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M4NV=7>OJSZ5BE`4A;,VF"2S?J6_G2U_?KJ),J,?VR^OWOP-Q?4#+I^,6.>QL
MX(W*MU<$R[^7\V5W#Y&RL.OA@:K:>C*K0'^:E]ZW[+=.<3\.^U"56<"WWX3:
MOHYO0M4.)7OP9\C,]A5YH;2A"@"&FI6I\^X'Y(:$!`#QV:=M]^X^`]-5;_<@
M*E#AH8H(-Y/0%;-.,R\#>WX9Y7>E%PGP';T<].<J%^KZ]?MJ*IPO?P:#&W!]
M+<IQ14WX\Z;H!@&Z`M7>;]4F:,MT@5M]9X2*@?YZE9Q?_G1U?7WYMQ9\IR^&
MF'ZY)\GC%<](N8['/27FL]=GDAG:!%1U(B%B.J.H_T=-A5'HM>9C)+X29LT2
M_4,!<?6-(Q\,ZE9QRX586F]M)&8N_K*861\Z.("@CXI;W]+U:UC3\&[C*,P&
M1]GC,_#NKE>MU1^B=2"A4W496&7^/K2/88RGB=1@+!I'C',*S9KUT50_;L;6
M^E;V?A[T^K^\&X\FQ;O63SL`">[$@[&GB&42IV!^:\E<P@6MV^MD#F6/C;WM
M@6QG&`BP`)"TDD@+EK5D"2;)U#!P`%>].L/@X\?SZV`+M,Q%UDH_75R?7_QJ
M+])S>W36P1.'TH?B"^BTC_D8CLWUV5V;8-[W75-M,<R4&YP4O<Y#H-][?D'C
MU.UNP)+P;0A,IQCG7=^UICJ3*E7WN0A52[>@UPL0@&X=;/Z<E[V@QD!-PF*Z
M/N`*2G,P')SU!C?^BZJ>%_[<\H=0^?XA4+Y@V/3*Z8W4)-Q">&.L^&/^]JO3
MSWMWX9R%TV+L&QKT0E'>RF+.LAQV>D'9!H/M84VAQ##_NG"OYJNU@EU6G<'Y
MO>^!/57)H21TBFCV*8_*^Z:XBP"NODL+Z/J!<X;W#^K=X_4%\]4[PV/^]Z^]
M+T,X8,M@@(`)T*W;!\T6.K<M<[T`ZHK5U62H3)5YBAO?-`(H&_9N>GLX5]<T
M7=%_+'/!S#*IE@1?T2D*3[5JV\*4-W_L[<DN_!>8+BW<;IW#P>E_SDR+L^M1
MWBU\PYMI#YZ*9QNQ%]O+9''#$7P_.ONO68%>*-VKKIO`KPPQO;FK(%QWDZIZ
M)50U=L/1O3^;*_-L!'0=%;ZBSI=5]@;-U)$W[3*=+Q#"KV,R")>\H8E0!]1*
M>3/I/W"O?_,*1?),CEV2WY4"T`XO/UQK>6NK-[NV7EV["+Y-OQLZ971]U6D!
MB/-PH?90].AMN%"6F[?ZOCT+_#85@3G+OS_\LZ@K-K\.^Y.[H%>+2JSO[HMQ
M`+*YW;:)L;%LJ$PGL5X,05R>%WI=[#U)L,:*(,5=A@G&J76)F48MJ1&I6C2=
M'GJ-H\4E+,'8"NFCZ.HB4HQ=J@AE!&E+#,T04MD4*9,HE8TCK08*F,GX=C@*
M->R;X96,T$PE6A/`F&"7I);5E$6&N%5=/1%Z'--?@V<'X&M9(A,H3;`VF0_\
M9JE(G:U;_H+U:O&^@5?3R#<$K7W+9,.H-"XEUO(T%;8&;5FZLH>JU(IS1-=@
MKJ!LB7<]=Q#%.):.$`TXG71&RAJO(F)5`UPLA4!4R%WQSHW(V)#(X.LA8C*7
M@9+P'I?`<D9D2IG:CLAS>'9!OI;<B0'@7*7@H&*J@/22I35R;9W8CMP-(0>:
M[SQS_&FUJ:EP"'QSD&@'.E-CBJJ56XR9E"^]9_M;N22:.(XS:A%'S#-`EM8K
M5R+1^]OSS>]`4:(4MDQ)Y:RE%*1+Z#J4HM1R,WY_/4?UPN7AHZ_?%-R:FTWG
ML`+-"H<!8U03G.&$U&V=@6(KP'&B!6,;@'N(?YV'\-=%,?YT<YU_V_26S$@_
M,B)+#+8H8U@8(J9]Q5-'"5G.4="$2;(`]"DH.V!>/QP`@RVC-%=:)X`09UQE
MM0FFD29+S:$ETIR*`V!>1V?0)JD6CF&6J0R._\1-62)#P!-+=-:*P<[L&_/Z
M@0`T88Y8PI%VQ%G0@HS7DU!,FNBE;M=G@BG%V5:@2WC9YU645\-^=U,FEMAE
ME`KC$M^KW/>&Q_5AY1#&2VW4"=@+8*K-`UWX_@W!K=]YK,$LM%)+9!%8*A+K
MI,X/0-+0I9TGH`PXI0V"6[/%1B6@K%SB[_VSC#MO9,WF;&18+8D_T:!W15/@
MUO.?`%7#$$."<YD*B;"UM0,#W">7^`]CSM1&E/,NY.PV94-T-I52Z@03V%JM
M"&%$)C4Z)[+EWOV$8$')(KIY`)O"6[^S')N$IRZ%91AF,JT2-#5C4N6<7#J#
M%*>,<]THO+59#)9ADX)I@91-E3$RK9T]*P1=RF+``AQOR1LDWWJ5XH`<&;&8
M8\U9DC!C4'W&.`R*<0F?Q)Q*3)^+;W'PX7GHG5Z.+\&B"V:==\=](Z+\2^%?
M"[-PIS.9%U:2G?3DS*<'?("#QZU#_D`!<BMGF#6$ZBQ+A.`+L\+J:7KH/2)J
M;O[#]@3>?:.J,<5O8J.,S`3FG"?@%5HA<98AOU$2S$228+MZH_!NVU21]_$V
MW13^*KRR,L#`F(I=4@R*F]ZS9LPL'-H(U@3V+P>ISZQ-$IW*N:2^)?%'\RM:
MBV1'V.NU%D:9<1S<=HYM!@=XBNH0&AP`:MDR%IS-JZRMH#^\S4_-"2[+I^HR
MQW[SO?++QZ&>U=0_X_,&G1]#XT<Y.4TRD_GA9=-2`9HEU"V7"A#Y*)JV`;K'
MRP*3U<?5?5E&<=\O0F;RH#L_(VKC;>%)RN$8=C9)07_)1-8C!3.#*5OV!\$_
MF#_JGH.IB56LEPF0;Y8J:@5XTC@E2AMBZE%RB:)+HP850N"=[;**QU.7DKSL
M=9Y#_/FD"S_3C(/-HRC1`!\EC*K:TF`L%4^&P1?TU$HHVZ+][6FT!!1/:DRB
M90+O=4JDI'9EX,4D?0KM&<"E^X"[;&621P%.\!H0^+!`6JW]4*29$>RR)^$"
M6K8GM&M8`2/K*,J8,$0GEL-158]O`J-3<;T&K=@);>8GC3VA!]=0EV:82L4<
M8XG)$,TTRVCMG1&39=M1=PIF>\1K*&PI23*9..WC1.`3)0A\H0IQJBTGVU%X
M-\3KU8/D6E`%I,4)EBEEB4WJ$+V%_ZSCX#7J86?$:[@"CD+`B&FFJ$"IXU:S
MVG72#C_-%3]0$<^"O%$6%\JP<H(!IW)X@TEQ@NHI?1JD\)5E<5ES>7%^\>M5
MZZ\?/EU=_:WU+WO9NOI/<VF/,EEA57M?GZHYZ/@"^G#)/ZB'5$\31&<#I/UP
MC)!'V\G[G8E/56AUIZQ<3/FE=>^O_CW'S))`8L'TT11,-U)R_]QU>'W6".KM
MVST_?)K>3FX>'IMM2`-@3KRQ=-4U6NOW"G%0[(0([/-B_M)8"VFU8PMIP?^R
M73=GO.US!__"U[G`K=IC'U///K6=FE$;JIDG&O/)XV[,M]1@?P=JK3;%KH,)
ML'!JA\E;<(ANT:`ILN#F+$A?@`5_0,F79LJ5UML!F];OQFA^5MX->`L_W_:Z
M8(8TVTPMLEKCK+9L<L<.UIMQY47M_J[W.[;ER@,2\13$^6B(]7KU8.2XYEJ"
MGWQG8=^CJ2J<;OW5E_#\K96/JT:1=<E2)Z2@5D&\6SA:?E37N8>VUUL[(*^O
MM_#31#J%#L*2D#:7!VN;?BR\X)_;I4MP=`.BGHEZ9I,)#8+J-L+JT+2)\QG>
MI(N8/=R)1B?QQ97]\?#<T1$N<EQT$K<@V?^$P&+1/<M]S[\O1>4,EJWA7(GJ
MK.\;_GMH=-/9ABU?W\!$V9:,MJGF3:FW8^&)Z-,<3EN_/K%0;89XFQ,2Q>)`
M-O;)'T(A+]7W>:RF>H1F1:%59UET)J/]31/]@>OW>J:-$D7:_'`^\ZN?[14=
ME0,<?6]'/&<&-CE87/35BVCT[#;T[*;Y_?N7Y*9&D%8?&I*AUU\/O8`)C`AO
MZ^=GZ.P^3?/9Q#AAD8Y^913)H_%*HT@^.F6?'G*[U1Q:LM@;?"FC\L0K:^[R
MT9?>H`*93\;#^H5*#X57JN(;(>6#9+UXO0UCP,O;U8?H;1_$B&S[*-OV0?X"
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M%YU\`IOLWS:-+OTYG/2[\`^@X;C7G8:>WJ_7>M/?GQY;.)M(^&APX;=.49;7
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M,$5[MI]6C00M)W=W^0C>5XT$O0&ZM[YZPGMU#Z^`@H?__U%,WSV[-6BW/G]O
M]0LX4UI_]L:WT^-B[O';'FPQV`%PY.3A4"KRSJV?&MH;=GWEX/;#'F-=N*\+
MYPW6A1.V8V$X0>C@)=/B+=2%QT7&1<9%OM%%GDBE_/&&:S%NJ(+Y5)HSU+T8
M5H>JX@5`Y*A-.2HK.L7=YV+4HCAPU9ZJWR.K+;%:4]T73H73/@1GLK&;I,A*
M;YV5&FOV%UGI[;+2]7"<]R,C14:*QUMDI:-BI7B\158Z[/$62]F?X+G_?G_U
MOG4]"I>4WWT>15'EQ'P>#KJ-M?;9*G7P*?J?1!I=<VTX?L2&C61?OFP;(,5E
MF]/F9@Z<-.?XYV(5TA'VF8A*+"JQ@PY".FG>B6HLJK$C8<6HQJ(M%I585&(G
MS8I1B3V_KT5;$=U6:+DV)2JQJ,2B$HM*[`246'0HHQJ+:NPX63&JL6B+O8P2
MV[6'T:NXK31?BD'G>ZM7EI.BV[H;CL9?\B_%F><,7]T_J_-;:&;T-1_U0N7;
M*!\7&S#CZ^W)N0<+XUC89-^V0C0)7K%<T+;2HJUD;%4;I2)*192**!51*J(-
M%>4BRL4FIP5BNBUYG((1I2)*192*QL-:1Q2M/U2\ZU%N_D)TZZ;WK>CN+;3U
M>GKJ'_)6[5AX:-]'UA&)XNF>9:]'Q$A;,MG&O+F^VE'`HH!%`8L"%@4L"E@T
M$J.(11$[>1'#;:9%6S8XW2P*6!2P*&!1P&)JW9;TNTI,JS_,!ZW[(6"(N7/Q
MWC?><+WT>71R<@''CM)M)!L;*AVE(DI%E(HH%5$J7IU41!LJRD64BU6GA60*
MW'<5I2)*192**!5-QZV.*%2\3\)^G`QZG=Y]WE^1+_?[97:Q#['Z48_EUQ-@
M9FU%>1LU&&#>EG3'PF_[/MZ.2&Q/]]Q[.P*ZCRR&**)11*.(QC,T"F@4T#<B
MH#H*:!30**!'*J#1R(TB&D7TJ$4TGJ$O'_%=8!I\\I'=,/FM=9/W1JVO>7]2
MM(8WK;M\]$<Q#EF*<RT`]\-S%'BN.YSX[WH\/&]KL7P5[4R?2Z7FB=*\WA)M
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MY%UK`M\5/FI2=M_]$W.FE<)Z;GEKP>P&G/U&G@+.I4EP0A0G3"4VM9JH&KBS
MB>%+P#62E'&U'?!?BT$QRONP4:9[!\^5XU$^AB?MM_MB4!:+R+-`<O+;=?84
M>"LRF61$:XLDM@(I)TP%/DTL%FX)O.(</O0!^P_P[`B>K07/.$^5(\8:F9DD
M,5(8/@6?9C@5C\$3S!!A^E#@@?+_^S1X(A-&$TN,,"EPNV`DK2GOA,/Z,7C&
M*-(,'9#R:\!K#2QC$'&&<L8$_(I0!3Y#+&-+/,\0E4R(+<&?#SK#N^+#L"S=
M:'B7`M3>8`+JZ=-]X9\:#LJDN!F.BNI]U_FWHOS8&PQ!$W\'>2I&13F&+UK\
M%/M_$_CWQV)\.X3_?(6WW!6#<;GI+CJ4IJDSAJ4FY08#/Z;I=!<S2[-LB065
M8G1.?`ZXM..BZ1JQ-D2Z%!OIN)5:ILPIZVJ=1(588JXSC#$A@KQUJJX764HH
ME8IE.'/."J.%SJ8BFUICT+*F%UJ@>9%]LT1=PZJ:6*ZT8\H(DEJ5NC3%4Z*J
MQ)'ELY]0HB0_&J+"!V:]LM,?>D-P9N,]S5H/=@-&W*;$,,LQ9I)9:EE8N*09
M,DJ\^^<CTWK>3+[NW15EZZ+XLW4YO,N?=E/G'N_W!L79;1&\XO]G[]IZ&S>2
M]?L!SG\@C!,D`62';-ZSFP"\+IS-S&P\3G;/4T!)+9D9BM3PXLN_WZIN4B9%
M6;9DRB-[&HO-R!+975U=7]W(JE:(_$TGZE$,B'$&\M79GS=\HG&63/E`Y^^]
M#^\"Z=+Y3_!QJ\/^5)('I)C=YY12CZX=QZG?_*O#)A8*@=!G7`Q_Q("%3_5+
ME=+[9(`JCR04D.?.SH8>2>45E;QL`2':G705%0`?"$:R>0K73:44//.,`R.=
M2R"T@-<HS^\`(#=1/BVD.?,J2KAT!CA@@]%;FD_B@KWP!FOX7$%X-XOABFS)
MX(7?1\MEGMT"O$N:W+T8'_]/(V>F!",E\/T@[#N3+J\H+'4,;)C%H,VR"09R
ML%C@9"2!LJB2$A>,C`$4`R^D,KIMKH<+@#G(Z&J9I5*42G2Q3+([2K\M[OE(
M;R>4HARS42;5HDJ8YR:-LPPUQP(=.+96:7(5Y7.8J2BR2<RVY28NK_CL?,/P
M:)8;X`"0(+4V.D[917<0*N/GFZMXPFZ[DZ(<[L7POLS@AFDU01)@B<"LF&DT
M7!`HEV5TAY>=29(S`=XCO<G="+3XC#*&X+(C%F&Q(=.L;,\/`H73P6H?%3FX
M<@(#`O>ZWW-FXTU/%D4@]O)>_('G51G#?G!>\EU["D7(TVC39<!)]+UJTCB;
M@6Y@%5Z"7C@8N"X;X0H:`>]KF<$-*6`0V88_\ZR:7[$1NX3#.I=T`HR%+8*Q
M'QP8M<9JF+V6>K8]=]++?VRS>0]8QSH><6N$[.H>A*KI^[9&9,.&^,W0Y28U
MX#F:Y@;K[H$./IIJ;R"X2\:>M&[WNNT@")60>`3LMRH'1@@>8DVK;8>VT_.Z
M-4/59.N`Q&YQ9@,#8GD+'-I`TYV`Z+)J6$W8!3%#+^RR=?C?H4C=[G>'1+4"
M7?544_9=UR&Z$=A-J.Q9?L]%-!5%U?9@*RCO@OJ4_WN>HMJKP.N[H!,:7S.5
MN2N/`]D,#(P-(`SPW(!XH5$3;H6FV\NNG!)9,\@:FQ^E:HAU;-\`S;)]6_$4
M!>(=Q&"@*6ZS#@W^V_/1-4N3=3+L,M`/3TOPV^G.*0;3]4)?(:&EZJ[B0#@L
M:UI-OTE\2^F'PT23#64;_2UJGD7X=L;+JA5J@:;JMDD<0Y6-P-(;PD-;ZVF_
M4T4U9'6K_.Q`^`>P(?G[+*W=@U_C:`PFIMQC`PR4%\]4-=\E/@1\`7RJUV&8
MGMZ+G%53,[>NXF'2AES4]LVQ0"5IMFZ8BF7HOJF"3JH35[ZCAVX_W2[;1-,.
MN*H/C:'GB>^=U:QG:+H&6-?"4%5#0@*OT5:VIAA>3\W*$+T\OIXUJH99R79Q
M<UR7J'IH.8%FPD8HOBNO8.,;GM6#C6Y;IOG<E?!<PIZ)>,"YK[DRV`57"SR3
MV&[8^`Z.8LL]WT$AQ.R8N,[L.Y*VG9N6K>B.`<+AAJ9-P/YZ;N.">:8;].1"
M!9N@#TC:-JZI/@AKZ.B6Y?M:$``2_29Y!*I=[>6.95.6AR)M.YH,VR4V(6`K
M#848#A"E-5SS?=WH/UD!Y"E/)HWK\+O],D\F`:,MNZ!Y7=,"6ZBZ'G?]3`+6
MQI/?7.;IC^#]Y8>+\P$33P<M-&P%@C=9_@G4'^PQYE7JV#_.IQ`6YLQF080(
MNU#-,!>!@7V*/TT^17,JS?"AT!4$J?,L@Z`6(_(B8@&]"SH-8F:>(LAIPM.D
M5_'R/KO0&C3'"+T>-._FEUCB@<:H'"$J_02A:5SRS`)>M49`5+)O2Q`@#%!Q
M/LRJXNAK/T&$"CYA<A_WMZE9"Y7AYU2"6)9>954!#"DJ"+;YA.!?QHDTQ2=C
M\;AB@3'RAS.A[95A_J(H67JEIB3);G#=,T!3P2CDE9Z</^R[*06`0F".N9ZB
MR>7,XKPH3^-T5'_*JE):L"SR]D#[R6`A+RA[$YY*CQ*0/(HEKU')T@ZU[F$"
MM<Q*^"N&O<+<`OP\K=CV8XJK*$92-BZR!#B%+"R`J:>+[!J9=3_*^(YEO")\
M68)M32%=P8[A3\UF%=(RS_ZB$YYMK(7K?@38UBNX]$SZ-XH"O8ZG-)W@!=-X
MPDAF63;,>N`4O'9W$;&CC9NDV348=@A!1E+49-SB@@ETVLJ2=6>%[S$_V*3.
M,-'"DW\LP&*SO)(]]Z)DB@G7/DL1#6\@)\X$Z:76`3XC78QIWEJ+PM;2+^G=
M:RU7T12/QF&R#-IK'J<`/GJ[C#DETK06^0B%>QZE32:X`&*!#9\K,!Q<M;'L
M(;(&UD+AGR:1^`LH6Y@`?S?.)+]BR,0%='4_8!*AAB^7\3#E#N>.&GR&H(+9
MZ'Y>S:7V*PI`Y'?@F3@GWX.R7BZSO.3JLU:]*W&$"0!W97]Q"-XQK<D&`D"%
M5$N<-V+I53`0YVE[%1HG'*9$S/.$<=DQ(3!U7#+6L@<9UYC9+3$#_;D"'XPK
MM)I'])[K8-N2F93$,]ID=U>T6[*\`%T#BK'@5FR0S9_%U_V3D/:2(EC1(`,5
M\>TP!+&\^%F?J*/4F&_C4>%;4HO]QYZM9U&M)VS<NA=KO@OW4HH)\QN0*^`S
M-MX/?L5]FQ%H)`CT<J"%W=^`?33\`U#^=%,]TP9]N/FB&P[4ZX-2/\*G;OA8
M#/8QN0,'?M8\@.4^(MBY6<6"H"6,P0(.^`R_,&N8-CXDK7W*KL2@28DQ[R:A
M'L&EK(L%EX%7XM*!_0/Y3;G+W'ID//E<Q47</"*<T+R,XG1E:-G+Z@4/"-%$
M<D/^SQSL=H01J#3.08*ZC(O9<]HE..;XQFWSV%=:5CE`K:"M1^4(OR7`;Q%-
M:,5>0P>.S_'!+_K/>&-K)I34!="&]!5KGG<3+&(<?(IQ\-U:?.@T=S2C<U$`
MCA35@C^TK9<,C.#+677T6;\1XP!8=5$_]&:V/(]N)`1ZSLP[L*D;Z+X2&7'8
MBQO"CAV9';N7\YNH8*$QH`*S-5PV9UD"830(R8_[^TI/2-EUZH;D1A(AI`;:
MV-_M0=,,0)UTI1>O60W,.V1-:)+4U[!4*?Y=+*-)\_?NR<:;>%I>_6C;9Y:L
MRX9%B`'KL_1OFI(6V-0D6A;TQ^9##U#W)+9[FJU*7*R-3>R>T!6-4?;3B:%_
M\VCQ3+=2I[Y1V?>^%Y_P;2YPMVYWHEJQAQSUF:TH#\#+#?QKJ0/P\L"B'_9)
M!!I!Z4';)VIDA=0=0NH:ET5ZT%,1ASSM)J07[0#@2^+XZ+O.#E?#_9ADO8;:
M;3(R#6MDV/K!N7(L^X_WB;;@1]@Y0FB;KT#;R$2'_P_7`_W8]_^YVN:9/<Y?
MO5\3=O*8^SC@SSV!X!4>-$"(-5*TP4Z(?8Q#QR(KA[;LPH!_Q:A2P4DV1Y9Q
MH(YJ;Q=5!PO9K==NV]CQ'8<1IX'ZKAV]>_5R#=G>A/]MC&S;&%G:RYWE<?02
M)-(!1YH.$`I-*+1'V:6/3$)&EO5R?6Z/7H(&]-?V;4FYK1CL@;*Q)L[_!X;Y
M[VGY879!"YI?K]?`/M9O,C`"S]1#S52,4%=TV7?LNH.1K%E6KSI9!:?>ZC89
M>Y2@`5:PI?&D)FN&:KD*40-##32/^*19@>+;NMQKP@?!OM)M+;#O"G9M[AF&
MLNX'MJT2+]1EHBM$L9OFGKY'>O6$.F`5H+J!U%Y#S.TT;6%?(/NAZL(LOJ'Y
M0(ME!V9=XRB;;K^LVP"'"/RAG6BZB&[>-8_:GK/1@1LHMA=8IJ'J.C%LKVFV
M)0=$Z74`(+`.P]8W4/H@/<^G?\ON>WH06+ZLRX&O^8:NVHZN-(*JA6JO!08!
M"9&)/`#]?[#"KSA+G\SW4[U=BJV")K!EQPYLR_$(R(>A-+6F#JREIR,TIODW
M$-XC9'^"UQC=(=AV'>P^$,HA"4`):,2L>T68)#`,M5?5K^K/()CWE>/]29J*
MWYV+W3W`5&#)P&C9=12=.-ZJ*R%Q#*W?G$-1NRU&-M/Q#&JW5&R'H:=ION-I
M+E@/P]%=6=96[?YTMR</FF6O*[$AB=U>P^TXCND2+_`#S;8!9YKC-T7YONZ0
MGBS@C^9!B=W"6=^P-=DS'%51`M53%"5T&\ZZJM='&K'U;C>*W8@MSE.?CK%U
MXKO5(:B\;>+'U4&H\*/'WS&_S*/IJG'"?E7K&@$1#QPW,%U7<U6?F`'AZPMT
M0S6"-U:U_LZY^&=PZ;B_!M+'P/O]XOSR.?7K7]SG?2GBV@7,,1-65AG2.JAW
M"E+;.JP7?V5A""^EOXT7,&!=_5=6>8JUL).HN#J3[N6\?3M6%<0%ZPGX^]G'
M,^DR9SWA67DQY:WDQEDZ+4;\YW]@7B!E=>_.G*:3WG7\4Y1^.IU741X!*NAT
MA!6?,9L9>S/"$A9X%;_SNY,_+OSW)]]CH[YN&7U3A#&2.B4;DR0J"JR"+-IL
M:2TI*E8U_1RV[1^Q6O\ZBA.\Z726Y:=83=.Z`#L$+FG*;JL[#,0I%EKQN@W\
M#Y"'Q.Y6?_`(@M]*'<++%<L]L/>L4*8I.L#ZI^2.U1[T)`'[,/3%@]V/_1MX
M+X76<=FL"@F;D=8=,N>LM`=Y5K<.:%7LL6:;2`;L6\JP%3=6L>Z!6%<U8TTS
M]D>9,ASB(QU6NL2:.?!VQ'!OMNH$S*9CRZ-7<!N6)/'Q!JK9655*O$![!M;M
M@I6$W//X*H:5`NCKFF;81>QS#&,T%5$S+-5@]5]5P4N\IO2:)MF2BP0_SH(Q
M#JNH2RQK3'!;;X!=<&$N94POS"M@-%;%885TG*,6PH)*;(A1%M\W;4'AJZ35
M7@LF&Z_F6)<.W)AY?%T3>@7\Q<VN%\"Z+51I-/VK*G![/U<9_@._3K@"K\O+
MN$CSZD[L`L&KS#93\]VON'!)Z2SZ>T9'TP"D1T`V1D>>029.EU6Y&D7MCC)4
M'?.AQ<F1BFJQP"KYIKKH2:+48@.R:Q-?&NFJV=(>&)",A84YQ7K"+`+X(PM9
MI=V4%I,\'F-)/\74^58N[E14U&/K-M,B/<3C38]4>0V2(EM/R=1V<Z.'*D>!
M1>Z2'WW,'^ND_C6K7=BUC]`UN#M]=A89'U\_:Z&'Q-9O'1W5U4A@^,J\XO:I
MI[T>:<G[A-RQ0,9K1@;Y^I!10-"5L$;E6W#QMS6SWX74PZ,T3@$S8TVG<CXT
M=]D7V90F$"WD>'J4=-UD[=#IP5+TVJ+AG2T[!_/QGPO@$013$XC4:@,WQ8'R
M]3L$K+]N6*MO'=8?6T"H,5-WD%A!BD.-`:/M-#X?&D-YU,J``=JW1<OK97'H
MPQ%WJYG@N.G-V%)$JU9;XSN(B]N-+U`7\@@\OP:M.,+(N=%DK%<%:X=8_UI\
MN[J>;40QXB<=U+TQ8`:,R^K43^.F9<U'THEQ-J1YTHAU7UDUT6@RQ6L-&[$Y
M3YH]P(SV416=H*'8R*,:6O4,+)#@C$ZC.:-3^JN:SMF'.E)EW3_J;H;L:(G[
M.6;9_:KOJ6>!27T``\SSD1L9/`D#V<0H@X@2NUX6U9@U*;S&>!'&ZD\]:S&S
M/0.;O^DCN8:6EN$J2MBN*(<=F^19T83T4XB)ZV:)W"*!9$0+9%;;=-6VL^]M
M8K.T-ECK2>N&.$DU!:$:5_>6,P$&\.XPV)`'N[?A'WDTQ=0?O86MY)LZCGG[
MMZCX5%OL$<9[GVC^PY1&"5"')'$!'S4V'?AS%]-DRN#2$@N6.VKL._9P@D50
M[!833W!8FDZN<#W8C?&:#]-.=2SY,PC69:YN'ED4%?8R!5&\`?N)_W88B;WR
MLD4\`4GAN9!.Q]3VV*M<:+<M#L2O,;UN&O%UE&`7SNN=;)X-Z!R3,LN<%D`X
M[WF%F6#.7D;,358ET[KQ)67C`E,*Y`)KU%.?Z%*N)X18[SWI.WH;E_5PWW/8
MP80WE`G'JE,./Q*(CS2FY0VE:1/EXT[6N;M-R8:^*=A!"Z^T]RM)OURV^[E(
MM2YD"9E5QJ[%H]69+ALUYPB%B2O`1UC,1`H&8Z?2\%99$BCR[<F6)SH5CY2S
MO[H&,\#J>9QR(J.JS)HO^"NA[!ON#ANFCB\\#M1VAFC/[#M#9&#/?GU2['UO
M-,B^=VK[WJB+18I%BD6*1;[,(D53J&?6,>)[EH,4,@Y3M]CS5JS]V&.)AD]"
MHEY(HEZHF9,0M9ZH#=5;[+5(6IT*$UI+B-(PHC18V9@0I:]7E`8MXQ>"]/4*
MDC!O0I2$>1.B=%RBM)-Y$_UY'Y"YK84X7Q*F#_*_EF/V9.MHFU,=17O-0W!J
M^%89RLC2S9&N#M?[YU5+#MXG^OX<8=\?H<2$$GM$W"RBD,,#]57(CE!C0HT=
MB2@*-29\,:'$A!)[U:(HE-@.ASE8Q!Y9LBV4F%!B0HD=D2@*)28"2J'&A!I[
MY:(HU)CPQ;Z,$OO:3]UB3ROK9H"L,!5;4N3E/)K34Y0,[&=V7PJ[LJ'*W[I=
M`7<0QB<?++0/H[_HP4$'\#".14P.[2L(E^`-XT(=67@6C3G8^VX"%0(5`A4"
M%0(5;PX5PH<2N!"XV&0M9,T>F?I@A;P"%0(5`A5O%17B[?PGY+O6#[]H9[=F
M\2V='BRU-2BSWYJ_]N;/710/SE[`EKT=B)&1J9DC11\L42``)@`F`"8`)@`F
M`":<1`$Q`;'7#S%EI-G&R)1E`3`!,`$P`;`O#["O_=6ZCZXC)5F42LL,:!#O
MSHGGON()UY>V1Z\.%V!V+'LDFZ9`A4"%0(5`A4"%0(7PH00N!"YVL!:F9D'X
M;@E4"%0(5`A4#)VW.J)4\2$9^ZY*XTF\C)(-[\O]<>&_/P2L'NNQ_'82S-K(
M4O61/&"">5_6'8N\'=J\'1%L7Z_=^WH`>HBW&`1$!40%1(4-%0`5`/U*`&H+
M@`J`"H`>*4"%DRL@*B!ZU!`5-O3+9WP[0J.\^LPN._E-FD5Q+EU'246E;"8M
MHOP3+=E;BJT6@(>1.15D;II5.-?ZX7E[P_)-M#-]*I>&9\KP>LL8&389]"B,
MQ[AS+/)P:`="^`E"V0AET[G/&BFJ.I+MX=HD"V4CE(U0-D+9;+A/@9",Z"-#
M'>P8;J%MA+81VD9HFTWWF2.3:(.>`"&4C5`V0MD(9;,Q:4-L;63KPK,1RD8H
M&Z%L#AU'R8H],HWA.K%]+=JF]0CK!_;09N/U&S[__8>J.)U'T?+'\_2:%N6"
MIF5QGOIT7#KI]-WJ(5#PN8K+NX^K!T'PHP<LC^+T,H]0HIRBH&7AQ\4DR8HJ
MIY?`+3?))I]^_M__D:2_-[/\&D?C..''24U@77#5!9W]=!*>$UE1?]-.I"F=
MQ(LH*7XZD4^D>`H_19/RU--EQ7&)Y>BR9IJ^%YBZ:UB6:AJN[\F.<R)5:<R'
MJHKIR<^62A3+UN^7UYIX!XJTW\B#%*FRI_BZKX<D,%Q5"T/+JRD*Y4!WURE2
MB*D:FBSO1A+P^6,)7+S*$I#D@F_#3G3Z)`A4.30LP],<WU:,4#-K.CT_]'N<
MLU4-KC6TC71N).>YQ&_9=M,+B>79AN.Z*C&TP#-TI28^,#0[[&T[*`_55*T!
MB/>J/`<P[$:N"O3ZMNUYAAPJGA/(LM7P6K5U;9U<4]=TT]PL$O7\N].W11:"
MP":&XMN!XQ#%#%1P[FH4>;+NZ49/9A7+4!5]LRP\0&!*/\R\G$[C$J;$2^^"
MVV6<1V6<I?\"!9A-.R3[G.)?JI02X\]ZF#^[`SBW<;'ZZ8)>9\DU:)SN->_H
M8DSSU56HP,[3HLPKU&B=`=HDKMVUB7IV[V09W_[YL0)E5Q6E&Z6?^(TMUBH$
M=(#LN7J@^8ZFNH[O^8X"0F`K<NA:WLG/_U+_O\W'Q_GT.&?/@8\Y:.V+J*1.
MR>\*TNE&F?W2O.W>=4&G=+&\7^L]E[M3A_&LO'+@CBF=`GXO8+&PUNFO690Z
M\YQ21L'J0S6'[8'E*LWVW,/@_'W8VBW=)Z'A:I9J6_B1$"6P8+?D4':(!LJO
M!82T8D/]+)_)@)GM._C`?CR^D>^BVWA1+=PL!W\$^1\MX9<U98D;J?RFPBI5
M1>QF:S<MV3;,P/7]P`$O`1P#535Q-V7#(YZJ^CVUQKT_>?MF/K0G`^[F*U9\
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MZL1"W.PD[TDHK)GFT()0#2G>24`6956/8K.3`&2))6FDDL2*5%#.0IWT2;[1
M(9\DSV]I).4X_;S_]%-A.\)A8KE-K'),&A,1`:F]Z[7#*D$F4<];\+2*DN?"
M=OFUA*3YMECOU#VYN\HF.6@'=;RNB^48=#863NX@06).1Z`\U'%'N8RII2)%
M^A)^T$:I(Z`?`>X\6'7,H`]A)$$T09)$J%V2*"JL-+3#2,?D@81"A6?`Z$.^
M2;/F]JJNOA3@\).[/\!.OR]=46;E#`MSLTWQY8!J[J*<!RM<4<)3$+&0)9&)
MK"),=";$1))K/M%.3BD;R?[3(3L?1OPH1HET)N&$198J8RUG)B0]1HR&>JK.
M^"N1KX936W1]$9<`)642JYFC"5.0O29)W.,4A^G$#;V%7Q0=&_JGPW8^G([S
M21%C4@,9G+$R<DISY7K)P[\G=;2W(E)JS^Z>&:?+=8Z5F9?PB:00+"C$B0DB
M(34U?04;M"FR=J)-BBJN'D?I`&CG0^DXFSBS)(XT!&<N3B'EXX2RGDVIM)/J
M+(4@B8\#S1>@]+Z<5:O\WZOF9$88%CNN(NF$U`J,6DB8Z8(.B.C$%&IPFTJ3
M/:AW3S\)L./DI,9PB'-1.,*84@K1F^@`2V,;3S09+);4]$QP_<?#<&D6<492
M*26$DA$FZZZ'2PMMZ40;P3D0JLX!F#@*6`C`&)MRXZ*4*@9_VFYK`_*<E$>3
M<CN#W/49C(PWF[JXWOHP\W/UH2H1SKI:+D%$#X=NCS/;&AU9$7$%V8U6$`Q!
M2-3![AQ/IY$E:`[5#\#^%`#/CM]QWDCA1&J5`L$)C4UBQT2O97'DDDGP\)9R
MPL6/A-]QI>"<@<Q)RY35QAD1A[;/_K34(9O@IQ67/Q)ZQXTD2T02)W'*:1)1
M:<%I];;($"D/)1>"1NR,^'V-9[-J6Z(7`/=0PI\S7Z]JKJIE,;MK_QTVF1]&
M;X>1=-SR,.+:@765A/D(/1':66:9(V_^Y=Y^_WCO_G.Q`O<(4`4?JU7V<._,
MZ'9`+G][F_M6'<K(/^VU8E"U_G:N!H+V(U[^6[')@"SM-U_;1U]7RWF[],<<
M\XA@1]?@]VTQA[#U^"LHGH)2UV`A[W7AX.?7[)IX7P8^S0R0WQ?!YC8/ND`\
M6X[Q_+3)RGE6SYL@J>"_X!>\\HV+/R5O?@V*IMGF\R!KZZ7!34>3H"C]@HNJ
M7N%YV"S`ZP^O^L=ZGFWRH"J#-Q_S=57[G[$5HL(K<?4NHJG*]H7#NS:)!M>&
MC^NJ`1W$#VFU6E<E2KI_;!E86&1S]^9=$'P&>$J0P0%&5)RZF,&E".H:/F*F
MB,_!>^=C"*H=!)LJN-XVP$OTN$4]VZZ:#2[7!%]O\Q;K>0<1+C-<.UJBSKN'
M`3[`-7R/R4TQ"R!?76Q@@6P3W&9P0QU\+99+^/M+#M>MLC_AFWRQR&<;)!;@
MEGO<_K*W-A)H,;`1'K-=;IIW'OD!\>L<;4O3+59\\<3_UZS<9O5=0"]0(,)W
M03RO?+D<>.R?!Q2JFG5WPW76%+#LN60__/ZR_]?L;BSY*)[G%.8+E.8O.4A/
ML*BK%0@F&.T,A>UKL;D-TFT#>.=UTTOFK*I1!@O@VWKISY!O[LMKX86O!N;=
ME(`._.77[P0/N+,J&@2[JN9>>IJ\_E*@8&:P-#R\;!9Y7<,5L,JL?SXB!Z*4
MK1"75OCJ?+',>[4`'6@@NVC%"^_\>EO,;G?2%^3?UNW%H!=Y^^42G@'$@ONK
M)I_"\VZJBO-\@5H"I%V@=#6;?(T(S5!Q8.%L=EL`LK!@T=RG%%#^`I&85\B)
MIKH(4(X06I#_/[?SFU6K:*`7F+RN,GQO^0J8?XT4_/NV0(H@3SHN=U3MZ>S1
M[D`9&9&FXWBKHJ#0RPS06%40*W2LR[\5/E<^N&`S"`P\U;]6_?<XOFH966R>
MHJ#1N\!F]?(.L-VI:5EM`C`%JV*SR>?OIL#.@&V`=K9>+PM\0WN^V:DT+`64
MSH'42%Q@5ST8XW7;>-(9+32']>1>+]5>8+:K[3+S0/?&JB7([#8K;_*=_(*B
M;5ISZ36FO:A``@'C/(@S+W0M'FC8L_(.L<R:!IB!@'F[76U0Z.">`J[8/6X/
M<2#/V"CVB*%0H*E%NMWE8$5R%'R$K-67EEFK'`1Y'ES?=;+_-6^Y[BGOGS4\
M![CI>7.\\W#2/7AJP'8OW(.0,&MN+^NKK-YT'^(92'8+ORN^Y?.VP=!_"_).
M3R[]&1M9'7+AL&B1Z,3*<"@I:3YI?6)"2\Y'")X.XBO@>#QH=SR&*-<FD'J9
M$*)WR:.^Q*1"&Y/[.(J01(J>&<=I:`^)0)UG3>[`OG_*EOGEHJUCMPUXS\U0
MB%;"$1*Z1$=&&`KXZ9C&CD8Q=N%-D&V;/L)];)\+[.NC/>P,?\+-^]5PWRX\
MW-M:Q@W9JO3MC=,-XOVBOA;*R9"2*#;*"24@=VW)%H=:/]`K\V.3S3RPY?0V
M'"?L0@AMF$N2U,4V,8P+&U-C4\@%A9'3QI3[?2GG0WRH;SZ_]$5B'FIJ2$J%
MC"-0=F%E7WZ@D*-/VVQH*,FH?G0`AF<`>;Q&8E-!71Q:#N8V9(FD8([Z@F:2
MDDE][BVE@H1"G!O*1ZQFZ'BBP`6$*:<F36@<]Y6<%`N<$U)*QJ4DKT#*(T"&
MJ7;*)I&+$^5(%+$D47W1&JO&T]V#$(S[*3#6-QG$-#Y>@4C?CP#S'^)R?C5*
M+"\70XH]6*9#;?]/J<AHRH1SD2`BQ!U&J6FW&V<%IX1_WXJ,/'-%9E)_N?SX
M>_SA_7_'G]]??@CB#R9(XD_O/P67+KCZ:#_9#Y_]+R_.1STRY)6SS]3O82\Q
M^KRZS>H5I`Y;?_ZF"4#`WOFPM("<I=E>0^Y59#7N+F'997=0[$T7#[_!6/S-
M;D%?DL&J`D3F(&20GZWWG@""U<;1BVJ&+4D8&6,$F^T"E0M0(@CIJS4*IX<%
M[H%4$=?K1-P7-B!`QBP9LX)97:S[1&F^G6WZ3*D#\B\-IA0K3%XV67T#@78[
M'ZW-3"%)7&/I#6#80B(PP^_PJ3=9`^X"$PYP&M7-G<\#()]<Y7./28]BT66X
MD%]@@@U4Q]P"HO4Z;_.0I6\=Q?(=5EH&B(%B6,;(FS;KW8R2C.M\B?EFTR=,
MZ[S,NYN'E`Q6A6<T8&R6%QU:\',#3JS!Y-?GN2-&`U?F'O!-FX"O_:X=)B%%
M659?VH2I)U\+$>0S<%$>_'V;80\9$MT3!U/K-=PPY+4@NS5FRML24A44B'55
M86J(GWIJE7D^;X[G)3^B?F!V=EU!:EF@'&!*W]'HB)`"E=;#.8M)]C@2_!7V
MQ1;_TV>2HQ5V2240'55QUIT7\5+?7$`."FD@YH`-%D#@.\_)33.`ARGF`MQ`
M!4O7U?;FMDLNQYK6<F^,"#P-\]9^D1DNC.DQ*M2.*L.<V>B?FYW,H&B`+=\N
M0`FV=:L"F]L"LM(U)"1`BHN^=@,7XG'6)L_+]J*!0'LK]W('^?:V]F4:>-8"
M4V^LK=RC[->J_AN0"?S84`U`<LR+IMV]\-8!X,"^'%]H*-'AM?D_:!N`<]?*
M\I>L6+;<N^M3^;$9Z>S+603Y.U09$?QJ792=T03^9#?>ZU]T9K>SQR@^VS+;
MS@NT#V"NYD"@]J\NF,C'==UF"![NT:BM%E_GOB"8`\%;2<_:@FU;S6M0MG<%
MFPDI3T2U&VO:G0GU](0HK&HKAK_A:<R6&B:?^=QJY\1X6\J:SC1\#K&#$?$>
M(9FWQ^5LN9T#!WPAY\]M=WCSHB<1,@1(6Y4@S64%'A3K1F@%?-UH?$.98VW0
M.[?*CP&%.[I265?2PL)QZS<A^T?S#90'1/*B?!?$\/P&I*]8@)F&.[R=ZYUT
MUA:%6HA]10ITVQN.'9M!>5:`)");E"/DA\K9\\3J@!QAI1@`JMN2[2`_=7[C
M"WX(5B>,HX96A-Q^ZVI_OO'9VX^+P->'X5*;7OB+JA5V$+>G8O=HYG<TJFI3
M@DWVNS)MK+Q/]S'!1U@<`-E76V_`H=?`>D_B?.U+?KMR_E!<;OJ8XWDT;&ZK
M[7+>%IJSGCU_;DO/PQT!3Q-<)$/3BZ]?M-K605R68*V#=@,--=[A9@4E;_^M
MJ\3GP5V>U4&[L_'_1.5;^>[VN+RV[O;!>JR_%ZK@Y?,V;FV*;^<Q:"OX\K;Y
MSBS#`QTC=A'/+G$F"XU:6VT&S84;0'Y]4.SW.!:=/6GYV6TH^>VE84.IW6'"
M(!@,`0B\%VKXQ:<T6XQ[NMV*,X6Z[)5#A'9X--K[.K\%NX)T*'R1(?@%[%SS
M:_`U:]K?_>8>&`B,KWR<N+EWY4^1_P%%OOQ^>)S/KIY'=WYVZ?SLTOG9I?.S
M2^=GE\[/+IV?73H_NW3^L;IT?N0P9V34?&=0D3>_G:TB^FJXW(]<MV"_:P2G
M?<8?C9<OVZO_:WJM,WNIMD2VVT=X>HFHK0FAST(K?7J!ZF)44@Y6X"[@\]]R
MOPW>M(%0MY.$.M<:3E0K[S]'I47_P]*#N:NP@27]M`5-VBW6%TV]-GDM[,(P
M7\9:@P$&R-!.'(2U<SZ]7>L?C-L+[6`.'\&TVHN79LW>0H-?>!<`R6NT@=Z7
M[(&X1X_V2<W(O^":WL[@WH27/V\4>BL#MR[OL$X^E"*6^1>LRNZ%D!<!.+A-
M5?M]-72L=9'#]UT9$^ZK^UV,Y5[U%X*UV0:K=#WI9[X\."_``-=M_-'ZXA[3
MP?;"Q_QDT<J\`VYKMY/]6.\#QW7GG=?MF/Q;\`O]U=,)Q+#ZV@;/&"_@/NM-
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M'6F:"&I)/S4CC<WD:#D/>43'IVRGSS\=OB-3/<+8<FII',5:V%`+KFT_Z-3J
M<-K8QR,AV%[+W-/APX[&9X`8:RE,$L8"`.6"1(E59)AR2?2D%XT3+CDY3,(=
M",^"\@BC3<)X;(41(6&42TF=TCTAXU1/&,W"4(1A=#J4+YP9:B@0S9G(&$HT
MYTHF<3(,.0*H[\,9AD1K>A_.Q^9R/AG28R.%C*(LD0FPGBO-&*/]/)"4Q$Y.
M6H<C*9C>:Y1\"J17V9TW!*ZJP5A\*:IM,^I!/[6Y4]&$:VXC%QK+8I702+N^
M[5];-X%Y,HWN.#@O`_UXRZ<`,Z7B6%O))#=AJC2)AH$183H1C)<#_3%?;VL(
MCAH<2K5K*#\5\)0Y)L"T,B%%!-JG1=KUJAH9L^GH*8X=M80=!/\!D%Z.PG&Q
MT1K,:LS!<BF0=J*$3H>3%#CF:])N&RK"QI,MGHO"YZH[6O$>G&1Y4X!G;DW0
MR2-4PBCA(8W#6!,7:BI2PWOI24)VH&$8=%7S*08/0O1B!(ZS@#-%%3%19+B6
M3FH;B4%S$QY/VK)Q1D5T0(A>`'_7X/]IU,0*(4R\6(#]\M'CR8<0I)9Q1"/+
ME.:(A'$1#KZ*%,%!7FPZ4NDA<W0*F(\@^O@4MZ=,@E&,*9*&3K-82D&C?DZW
M25+KIB>/(*@*B3J"U^.#W9Z)R"/^0G-BN5'`&0NAE=/`I-YV$3T]5<19*#0Y
MIC;/0.2JQOQD<W>UA)P`6(EG2=KNRA/9@J+F.$M3B!T3"?]'LL<F(9&83)21
MFHYGC#P=L/,A],CL'AM+IKEFAD9$\##AO+?+,K)FHC]",7X.A+`NG\\;/.0#
MYKQ;Y7*!\QN;P\,CGX"+2JFC*A',)$F:.BID-R'%I#@2\9A_?PH\9T'AD1`E
M49`$&,.BU-F$<-":0;YB3J=GJL+[YNQEB."!*_^:B@TJUMWEXAPF0!)E"4ZX
M9=R(-"$@9[TMBW4\'>+/F(R(8H>1>A*$9T?PD=%#D*1)JF.0-V8)B0FD0X,2
M07QS8#0H$.#U$+Q</#78&8X[?KY;PVUQ7>-6SS!GU\_*_8!%A^4RN_;5JB_Y
MZ")<)[U_$F28A/R?Q>;V,S8$O6\;]=NMO:NNXWMZJG+/L0L.X9^,TXAPYTP"
M=M:XF*:Q4A!X,381&GE$$0[3Y`DT[`*!M*K7B'R.]:!3A</%PJH8_(7`$Y(R
M=9RG,=4FP8%.8AHW/H;#(9C.ALHC,XRXMC:"2"/5(3$)E32E'2J4,3V=N'?_
MJ.LY$,)0_[+=&[#?4/"ZTO=)V0B.$S4&)"NU8<*,B8GMS:QP;!(*/\230["\
M&/3CXL3`3QM*F4U-S(6E8<S[8_<@6V8Z1PI8HQ\R-4^"?U%LGG>@EH2*)>"T
MTB1ETD$@U`^YBT-N)JXL(CH<#_3:/?DDB([%U#$$!BG7J=!6J93!W_UT.R?(
M]*2V5B(:3]U[#D3'S_/2$`P:J%*$\PFCB*FT+ZFE"7=B.K-."J7&;X]Y)DC'
MXO5$2<<ABI+*)8D+K3-I?RXV-G(2X5+-1,3.P;83#^@?/CU^_*P^$=2X$&<\
M@[]F%,<$=CF\98(FT]&N]X:P?3?D/N9XYB&?VZPN`;L#SG)_<#4DP8S%-#&*
MT%!PE71!O"5X4/S1`9Q'\#H<S7_(3QS['274Q)8EE)(0(D%#E!S>-@:V8?+:
M*46DB/8`?!"0EX!\I#A+'1@N`(UAQAH284/73RJWTD735T\QJ:1Z#L@?\R;/
MZMDM7&1V!__LMS5NZYYJ=I,H`9MB%4F=3$(!"0+K)\"#U/-)OJTDW7L?U5%@
M7@3W<5,8Q\0(FQ))C(HB(Q@91ALD(*S3V((KJ<GW`OR80Y:1C$!>$\C01,@`
MUF'NJ`G9@2&S"APV8]\#\$?&-&@9XQ3^B"L;QA"E<D[^E[TG[6W<R/+[`OL?
M"&,:.P-4NUE%%@_W9`#JRF:23?=V=S+8CS15MHA0I(>DW'9^_;[BH<.4;1U%
MF9(>@@XLB4>]L]Y[]8ZZ38,<'M!LT^#8G-D[+GQ5GWE!E6TFX-:;,-ARCH54
M=2-[Y/0\;T3![C%'O?HH:B0C8<T^R:9NF(:^O/;7%K0_`"\=FIJF[E#3\$`1
MVCW'Y2;WZI.?X6C-,`G+<$UN[@&`-+>S*K'U1YG8V="':S:KS^6Q^J?T:YD!
MNG`*JU^\`)8Q3G+QHTQ."H-7G#ICZ#)J@ICT9,OND=X?R"EAMNRW`ENQUSB!
M,=@3KVX=%+O`:;0+)Z?4L+@UM'E_,+"'@[XI)_O8GF/U>F#9-<9P\*=1:55P
MEGM%:W`.*,A=WX6-$C:_GJT[GL$DG-0$Y\1NVOC4:8^>;<+9UZE.K3YS^Q8?
MFK;L!2;A=(<C73<'M.$O,KH7G"^0\EF/=BB[+]FVS>785%=V%Z^/DAW/,AL<
MY]H<('+6KW#[Q;W2MDA.+*.>[H[DQ%30=89>:SL0AT%#7=MRK(JC<G$O':YZ
M`W,`9MY@-!Q2V@=K;U`O;B2/DII[B6&XC#U#W)WH^E)`&'8X\,CX2!\,=*^O
MZ[UZIQOH4HLV5^>8!KC\:E>W@6#]G(99[LM>#Z_X*I13R^[K/<>3<Z@X@%("
M9#.0+[NQ\UFN3!A2ANV-%<5<0[P,#A\->B:8V]2T#*MG43G;I0*GYWJ\>4X'
M%[JV>7!P-B:/K8/^8!S\!FMD#08F=>P*'E!XSIKT#I/JIM$2N_6J&JRE7(L%
M2+_[L@`VB5X&R&)]\"IZ/3KJ>;9CZ'1D4X#$&CILZ+I&LQF9`?2Q^,$)5*3R
M5#^_XN[+$3N2OT";@M(?]FU*K9KG;+>IL1CL"DPERVVF$;:`R#;Z\)]4Q![E
MAF/KO,]JI4#AE^:89^ZJVQ^>&$D*F`[,/^[:,BSC<#")1J9GU!1RN>XU^O11
MW09G0)D4;4RB3;6"3*F3?4%!-[BZQV#K&=":XW0Z:'"<2;G#W,/#T_>CL:R,
M?AD:!MY7'[0U=_01M^PAN._#&IH!7S.&2V=`3?H6[/9I*H+(GR8/G_U7VI".
M/&Z:,ES;DR$?<#BXQ^8D<NQF#-`P3<=R#VXG;$8B6/;(,[R^Y0&E',N2;21K
M:,".;$:A*7-7CHR5DFA_`1H9WE#.CS1'`$+?=>VAX=3;ZK#7/'HP0,$95*4`
M;0;/9M09<6[K9I\S;H_`8.##OJG7T)BC86-/M2CGR]'<P]D(F\N/`2H`K!V/
M.]X(O'49E)`N.WBW(\,!5[[9SMHQF:O8"U!GE^HZ9<.!VQN8-G@-S+/-`:]W
MU#Y8#HT(!/@-KJ[,[-E8@#8$I^?UAZ#4.+=,BP_LWG"H+^0'K(9FAKQE.%2E
M=E-NQ8%X>T,VLK@UX-QQ>]0:SBUMYAB-7<@Q=:Z2W90J!'""/%!LNB6'4S':
M[QMF#8OE-`^@+`;FT.$MT@V9#4#A0P,,:S8<TA[GGDP8KV1'3M1M;CZ&*\]M
M#ZX+MN"V/A^-7#"LO9[G.I8.`.E&O:'*@XHU@X&?#6`U(0HF8CR3Z1QKE''6
M>USZM$T[8SG$C5+=<\')!NYRF,TJKC)Y;SAR#]O.N.T.I]^*1A6R!+(H&BY*
MR++95%:6_2GFG4[*SGYI4=.6!/YRL:WL,ZC=^]%,S(M5Z\JV:KA`4<`6+<I%
MRCI;^?WBCJ7RBJ*\7U9BUDZ/FH+RIY@,BGZ^FQ"H?HK$_=7\*:&L?RT_+[^W
M[-#8?//\P26*`Q%%U36%Q,C/F9S)7GW>GK6`8K=A7"[2G^5)_45:+*OXYGLX
MSB=7EFW#>JZ3="S2]X%,L;O+Q%7]1X/9%@M/YW_)]"&YW/B'"_-"2Y/OY=]T
M?NV'?+SX,UW[A&(Q/UQPR[U[6'G&XMEKG[>X=?<;^:YWFMO=^!SL%77O15H4
MI5;H+DN"/\IZYMLTF<7C]U6_K2`0XN;FXPH?LB>%P\N?J]KBY:]*+I#?O+K^
M)<YOMZ5.#CPORCKTNRIK038=K;(E*RWR<LWJ"HU>Q.HNR'N6$EW!X5]48>=5
MGGL!2SLBH^!(I=A@Q'5U`O9#ZUCI"OWE?=>I%D3"3W^XD/WW+C[,X=P``=OI
M)^"!D]-!93^'\)4>+ZL\,U\ONU"O<]9NIX>2($I,JE2"ND+HPPO*F>SB]0`Q
MK>Q]>"MKP99,_3:D2BEFWU3<_@K>[D'VJR;_M+>O*V>QO^%NMN&PDH4(KG9A
M3*[AA<6?K<ACZ4E6**)W#UK1*4:KVP0?GU@R*91*!7-#%*%\[K2).L<NN67O
M==E'_4GHK!T&-(`!Q\E,.MG["&GGW2-U[O%KZ#L1_[E5M;<-VKK"00K]A@]%
MX'?M]2]V8=OEE..Y<Y(Z:_^S2+]._%3T_"P,9!U%&,UR,?XF5[C-40D?T1&G
MC'M]T_.X0?O#497^.QH8,J7ED$<E;?09?'HR(IL1QT$852<C\6PJ;:QBZH<<
MGQ8GQ0`DV38RJ_IF^U%0E$=HXQ+'FJAH(+LD:]FD'J.'XS)P7,;>J][]I&SQ
M-'<WN5G<-B>(@L4<^9E<>>#FNI>.+K-G&;,`/H>_4W;ZYNQY^F;Q=[L=A-%=
M[SOX"T\3P)U.%KL4[G!V4S/.EFKFF9B&W>V81B,W80]L%9\:??N+!CFKN[;<
M33781-MQYY$%G["@\08L^`HFWYHIUUIO!SSOWX_1Y"#C&_`6KB;A&,P0M7XH
MLIIR5FN:W'CXMQU7_EJ[OR_[';MRY0&1>`SBW!EDG:X>1(Y3=YIZ](<ROS;&
MVCZ=LQ$47<#+(-X$MA:1*DM7;-T!.;UCF>>1=`R'+S9CA-L'.W'N"B_(^_8Y
M8$$W`/4,ZIEMDELLPR4Z=0Z-&TQM.4L7<;`X$T4G\<V5?7=XKG.(0XY#)W$'
ME/VK""R*\7L?8/5O1>D,9EHRR^?S7.=3'^E'.48R#'9AR].K-;&);1K$<+DJ
M]=85GD"?YG#:^O3$PB&FS@EG#,7B0#;VT6]"1?IF>"\T@$T$N6RJ4`[_SN:3
M>]J0K==<O],IU&(.(_QP/O/)IT6CHW*`K>]\Q'-N8+.#Q45/7D31L]O2LZOR
M^]N79%756^5#BV3HEX^'WL`$UADG[N89.OL7(FV,C",6:?0K420[XY6B2#[9
M93>K#]RXVQV[PVYWZKO=[5MO8YKTX-WNJ,X.U.YNJ:O?&T!I=+FI7Y=.=;'T
MY@5<M9]Z_C5\P,(;++SI$DMBX0T6WF#AS?'$IK#PYI#BW!EDG:X>1([#R#L6
MWF!"_%N$-HFN.\1QL?0&CQ.P]`8U38M91)03RZ6H9SJ2]W?L=A+6UG1)FW>'
MYSJ'..0X]`-W0!G6UNSLT]C$89Q06UE4ORL\@4Y+=W*@CD\L',(='7Q]93;X
MJ8@%UM9@;<U;><660QBU#^45GWSB/CHJ!T__/67QI#8GSN$F(9V\>*)7AW4U
M;UA7X\J."RV%H,\UB1]]2A3)W472YE9[IT+G*I)*YVYM-37KV=%;<1[FC_\*
MQ^*G^$96S<@90%_$O8AG8I0FT^%#+M+8C_JS#`@GTJSW^#E-QK,@S^!57T5Z
M'P8BVV8XETF-?M\<<#;J.P[7S8%IN,5P+EMG-N\[1S^<JY],@3L?Y\:"_3$K
M9BBF)5:S<@IJ)H=N@=>>KXSSPI%;N\&!([>>K!I';G6K,+"L^J.ZKF[(%K7V
MK/HSW$,/H3*.95H6`OC,?>Q8%MIM`+%6[JR*-?<R+(N/;4Q*ZQZ_=3=`@!R'
M!<)8(-S!JDTL$'Z+A,BS9#5E?;^0U9#54*LAJW6"U;#MP;Y<61^(8+4+5KMT
M%W'(<<AQR'%'@;C.(`LY[APX[NQS/[U`Y/XXR<5;>EU=08:R'@GMP:P^X<T@
MNF40A[JJ@.\*->5]F$3Z=KLU:H(CTP0FH:9%7"Q11DV`FN"L-0$GMF,25\=!
MH*@)4!.<LR:@E!BN0UQ+V:C%KI!S7U6`#1J>P^RGJ0@B?YH\O/_L_[%+".O5
MDK33J>4FAFD2QU+F?)]\M3;&B!7$B,]'P.:E:`H'D:*(H8BAB"W:!1$3G$6F
ML%TW"A@*&)YSXCFG0I3]G(99[D=)MLU!Y^GV730(YRXQU.5U=X7.&.#KCHES
M=%+!B&Y2^(=2@5*!4E'?9Q'7X,2PE=GW*!4H%4<O%2:AW`&O%_>*O5V-<SD7
M^=V_`R\DB3"<],KT-YL2TU`F6!A.PG`2"A@>B:"(H8@=[EC?<HEM*<N?0P%#
M`<,C$3P248FROA^-)1>@.R^#7,PBEH.5#QCBPA#77"8H)]Q4-@<*90)EXNAE
M@A+*7*([#*4"I0*E8A&S99RX-D[QW-O)Z)"CVVJ-B)S8V4H0Z6SF`#HFT3F.
M`<0(U!'M;.<CG<RV"6?*`@HHGBB>*)X*+593)SH.T47Q1/'LHGC:'-Q)1UG/
M@;,7SST/N_C1^YO?DMR/5F91ML-;BN;C=@5MRGJ>;(RE8VB*XA*;ZX2JZXGR
M*G:ZP@\8)6[=&D!E@\IFQ10BND/A'RH;5#:H;%#9M!L6L8EC&L2DRLZW4=N@
MMD%M@]KF&6UC&"YAK*4X[`EKFZ6`SH?<!PC77K_F[[]_F&7O;WW_[NIK,!'C
M620^W0SC/,P?_Q6.Q4_Q39)._3Q,XB]EG&24)M/A0R[2V(_ZLPS0*M*L]U@/
M_O+B\5>1WH>!R+X!NGI1$OSQC__\#TW[>_,U/\7PQ#Q)'_NS-(6_OLEUS^\"
M8L02XU_$S0\7HX&<!/B_[/^^#2ZT<`Q?^$'^GGJVZ0Q[W..ZYQA`SH'N6(YC
MV#8;>3UC=/&/)Q1<IL:W<"HR[5?Q7?N23/WGM>'2[5$8B_>3<G`<9?J[%>&B
M4I1:'<V1:<F-UF"(+1]5Q3,K]B_6.Q9!DA8TOI*,5[Y-3C1>*'5#)]K:68R[
M`*+Y\?A@<`Q$(*;7(EV"A1:P-.M)=X&%:&'-Q=IW/P.FG<JB7C&6M,HG0KM)
M(MAR@4FNFB`OR^-+;+8!:ZYLAGK-B6$,^WSY>?FAL93I:)5[Y37S!Q<:1`M$
M%%77_'"A7Q2?03T&]>?MA>I[.,XG5ZY[Z>A<MQS&+(#/X>]J/0U$C?R[3%S5
M?S0$:K'$Y;#U7&\[:T\I-@A\%RO[X<+B[U[=$5:WG^I&NNM]!W_A:0)X)`/5
M.V>";UXKUOF)L'MAL/C8F`DK-T'MV;T/'3_DNC:XKC99M&<M%<PNWHY)O_C?
M-?!BX'<_4G;0NPN*.I]8H"XP\1IG'4-`@A';<HCE8MW^P=CBC'=%U#;GKFUD
MU92N,/K9=?HKC'KNU+/AV.V:41B'V42,M=LD&6]CV"A+,3VZ3%*3,.80:AXL
ME[0KO-+VSHX;^!E+E0%&LDT<JZ4T@=.5*NR.^F*&=COLI"B9H//FU>&R#$["
M_K:(ZUHRW^GMT=85#L)P0$?#`:C04*%M,K:;,>*H:TZ$"DUIGM7+"5!/TJ;$
M[10N^2+N$J!,?#L(LR!*LEFZ5<848WU7MRR'F6YOP/M#;CEFF3&E,V[8[+`9
M4Q8(2ZLG:5^&OP]__6WX]47J;KI<U:LM+K\*P<H-@_))51*=]F63DL0W6'9I
MET^$UD^F(+Z/\\[A]L=LI992<F(69OF:-"CX*RV^:0"WY6(V30#+)ZD01<I9
M%C[L^](R?VT*7TXR3<1C<;A$ME-)R%.6>G>ULW@LGN;N)@WNEH;=&27W45U7
ME\Y'K3WS^0SWT.ENQK'DY2&`S]S'CF6AW0;P2#(RGW<VG-WV!F<OIW^^6+O;
M1PB'R(/[5EAN*\96G9"IRJ'%,!-RW!+'?0T?]N,W5'IGG@Z\!_[6LR1FGF/F
M^>%83=G1%[(:LAIJ-62U3K`:%M#LRY5U>?_+,5<<0W>`@__N,%SG$(<<AQR'
M''<4B.L,LI#CSH'CSGZXJQ>(W!\GN7A+KZLKR%"61GA,R8`&T2V#.-15!7Q7
MJ"GOP\*FM]NM41,<F28P"34MXMHXW1HU`6J"<]8$G-B.25Q=67^3KE`3-0%J
M`M0$6P!-*3%<A[CJ9MATA9S[J@*LT'YV9O-4!)$_31[>?_;_V"6$]6J;A).9
M7P?299K$L90YWR=?:(<Q8@4QXO,1L'DI&FN?PU#$4,3.4,08,<%99"ZVIT,!
MPW/.;B+N[,\Y?T[#+/>C)-OFH'-C97YT.ML@G+O$4)?7W14Z8X"O.R;.T4D%
M([I)X1]*!4H%2D5]GT5<@Q/#5F;?HU2@5!R]5)B$<@>\7MPK]G8USN5<Y'=?
MC@!,MFE>>X;A)##`;$I,0UVW50PG83@)!0R/1%#$4,0.=JQON<2V<#X8"A@>
MB703<6=_)-+WH['D`G3G99"+6<1RL/(!0UP8XIK+!.6$FS;*!,H$RL3<LJ?,
M);JZT1DH%2@5)R`5<D*M:U.4BGV=C`XYNJW6B.3P6RM!I%<ZV9U.D,DQB<[5
M)=WNBK>N<!1&H(Y@9SL?Z62V33A3%E!`\43Q1/%4:+&:.@&(4#Q1/%$\NR>>
M-@=WTE'6<^#LQ7//PRY^]/YF,35^919E.[RE:.)R5]!VN,'*[2%%O79RB<UU
M0M7U1'D5.UWA!XP2MVX-H+)!9;-B"A'=H?`/E0TJ&U0VJ&S:#8O8Q#$-8E)E
MY]NH;5#;H+9!;?.,MC$,ES#64ASVA+7-4D#G0^X#A.NN/]C"EI`6A;%X/RF'
MK5&FOUMA2'C-P\=6QUEDVCC,@EF6B;$6QMJO22XTJA,MGPBMGTR!V(^:'_Q[
M%J9P0<'1F98G6@.Z75Z>?T^4/$>+Q7?MKIJLIOGQ6`-^GF@K;36+K^N"4N#C
M.$_#ZUD.0`$T_=GT6J017/)?V7+,2QO/4B"%)J<L7FJ?8NU3D"=PI<8<(K\T
MR-*M6C&!KT`C/-*/-?\V%6(*WVK?0UC.9Y'&X8/V#>#P[\0,A#'3_GI1?GOQ
M-[D,H$2UJF*U`-%4DF,%CDOMMQ@DMJ`/O&Z::<E-\6'^-J*)FQL1Y.&]F*^7
MULM=)NNUN(55PGM3$8`:*'ZK`2\>&F8U5HOU+![[3S^>^>EC@9=E#)1/G(,A
M4=<D0@F6_"W,Y=MO?;@\*9"71,DMW`PT#-(DRXH5_1:'DDI?<S\7V:4FJ3`2
MUVGY_I(,YC9D\+)<1)&?:9\G?CKUM=^^$NVG.+@$6M0_E=2HN%X+0''Z(!HU
M*DHA(/+Y<#5@9.9'\L<[N.ZQ@#`5D2_7[(-4Y06!:L:[E.1_0H`,GB*Q,6=.
M>-?_^&DP*=$K'QCYLSB8B#GNDAA>">1(4G@\_+]`U'4J+RUN?JPXMBFF.RDA
MUK(2^DGJG7LQ+21+IVR535?I">C*\ZBDYU,!@S4GP1_:+S[L:GZ>I*$`,OWR
M2U^*6?D;4%8B"80.J)C,7U&(H?P&?@_C^R2ZEP0!VLRG_6AW0-$X!Y2"QKSS
MTWR-V"WQ8#:[NXO@]?,W%0N4#YSE$UC8GP#/CR(&C`0:;,P94+1^8+4F4$1+
M+R]9#][^;>6*6EIOY:,*EKM^U#(_$@73A;E\2/.%"S537%\O$:0]C(-H-BYW
M`KF6Q@KF;[Q+128)`TQ^#:2[?+*P#&2K4")K7E\_XCO(H!+U_Q=ZZ6AP5018
M5+.?2!*J61J[I&J75DN[DJ=EH/@!U'^#,@49D_1:.T_X;7&X=N[L+@\BP'K9
M7;F%18]$(96-2]95!N27>I<9$`RB*7P_R4#-2\7SSUDL-$,G9\2(EPIW:46[
M<OE17GX5YK#I!TLYR-J73<Z#NV1;M*LN5;'$LR9/MURMN;VS,#Q3(8UVL#^D
M%2.E+4BF4Y$&(9#TS_);0%5=/:LELSP+QZ)IW!?W^M-2$832"UBU[_[;3Z_!
M,/D1'A+ZE?D>%(Z4'V6`NTLP]O(Q&'/E%:45#ZP%#ZQN`LLDE]8.V(8@=MK0
M3\%(2Z6UTS4%T1HW5.DZ572GD+RQ=/\*.EW)\$7%,!/`O7*6*>@H':<T]BLW
M1AK38!B6[+26<VH'K#!ILX6C7SH$H$NJ)ZT^MR9T*+U&,-I]J71G46VX9TNF
M>[9BNTMO^#8N3%;_#E[V$$Z!.Z-'11NR?FFIW9`!'B#;^U3<S.*QC&QIL[OW
M-ZE\U)W_6.(=3.VD4-ZU\5T9^*#/BL2NPG?(I!06X@:/E.YL@<JL#H+(ZV_"
M-,NUB1_=R&NZ)30J]]$V=Z3!$CIG4:0]"G^^E[SH^>9%2I8JO(/II2[XMB3B
MRTI<R0M`)2G60R^IH<K'7@)HA0J+@*`A%=%]N9'YN2;\8%*[\'.5)IU@:>J!
M%(52,*6*RX3X0SX"=LU9)*,4CZ6:N9>;6+VEUCJN=%)NDBA*OA<AB?I*`C``
M[TS@9WAN$M\F\N=%Y*W:B<M80"7L"Z/S)56Y$J&:@MZ5NC=;@!%&8?XX7^CS
M0;`Z8@!73B6@\"IX^")X"5:E@.=)H-;KX;!`?9A'98P6U++X?^ZN];=MY-I_
MO\#]'X2@1;M`DCOO1[==8(8<MK[8;%Y.@7XJ:(FVN:N'*TK)^K_OF1F2HD3Y
M(9MRG'S88"V1U)PSYSWG_.B7WC'XL.5%M0+YV!BZ-2QR:P_^-(*-*<'J-89M
M4IR#^D_V\W_#L_;9U7;-+K"]=1&M/:WY`5ZE6I^!(9T'-F\>,EI7C=)O5CTK
M5I>+27Q^D*B.U#7"Y1^\OO(,>#+7/[R+`@'<LU=-F31L[@V;$4E_,LK9T-GR
MG91'HQZ,YGQ>*U'0FR"&(7(9P.+?EP$^_=Z<5`^:AV_I]B4$)//%:BO6`N5J
M6HV[#.KH4%Y5"X@-_1?!@GMMVO8^.^8+3`@(TF*O'5DNKO/IRM=HP6*<KU=K
ML-5MZ;1K@T?KUF9U?NCV<\?Z___Z?^OJU46>7_WE8W'A[_M07"V6_NPC+:OQ
M=%'!CY["9MCI8OS;3__[/Z/17V^ZX1V$:>/K^&][2SC'@C\^%.=_>Y&E?J_>
MDW^=IB]&Y00^R,>K5U1RFFE#K+!:6XTL14@H1:5PS+&,OOAI)SCJ[N=I.0-^
M_`(L_K"8Y3<W1-PGMJJ/F/E.'X(X9M5B5]##3OH5UO6,&.."7:ZY/4Q-8T"2
M8BM^1Z)C6!Y]NC<I55SXRY%W[9`V@?.]VDJ,6S%^/7J3S_.+Z`>]_HTO%U41
MSO\6RXL\>+.MT\'<'PG7WG1U?17*^:U.0-8`CFOTL7%V^102)/AGYQ2CA<Z4
M/U;-<9@/BD!X@QK7D<E6&2#&/-$NM@;!WW2UA$QL6?H?6L4P)V0[0,"GUQ]?
M;\S6>`WV8N9CN4<JZ5Z=VU73<'AGYI,W^?*WPM_E?K^"P*;HZR9]3]Y[W02!
M!$*FU=]>H(ZB:LJ9EB(3+!624L*19E%1$RT5X2_`#I7Q:>MJ\N(GN)P@IKNK
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M!@/[<07VZTTX9V^_/?6!T=OSDSE8PW("`>C6O6D)X1*$Y?&FKNIS@9C5)-.2
M8RM3F:`T\$Y2[2R6+WYZA_]U%ZL>QH;O@L'CJ_+W?[O9U71Q710][@H01=`6
M$#>FM-:2N32IN9LXA2UPESUO[KK_K,O5]<D<.+,.D54X.SJ]S.=OKT)5\>_P
MB%5U,H\_.R3G;U)WEB%!,VFS1,-_*'$\TXW(&LQQ1]U#^T+UXB<L.>1+`S#Z
M0';L;(*G[:2JUL4DU@[C1>&7JL.,=LNYCTVM-Z[,WPOA)"QAB[_P\6PQOX&W
M)[]D76.::JT2Q,"$$N-M@=--GD$<$F8?=SG=8N[A9-Z+3__,I^MB&-_&4T*X
M2666)1F#/Z1%24TD9LBXOF]C7(H[2;QEA<>B<$A!V/*I66HM(I:R3%A*$H[2
MM!&#+&&]D/!).>2_J_7-_>Z/F7R&<Z`("$RE08Y2*K+,89X:7@<-#J)@U@L:
M),:4R7L2N&^!1Z+O6`(@#,-*LH0E"3&I`"$`!M4JDEJ9/05_((%;+\>0XQ;O
MEHN+93[;=*&9V6(-^6^7*3%0Q/^?SV^V;HHQ@62BK(60%IE4&4Q;WZ%Y3ZQQ
MK+2AU[OV[<ZE#4(.>D_>Y->8WDR0(]1B1XW)B-()(<YHVQ`D9=K;IJ],$'E/
M#*3_TUO\3X:,H5B#3Q&.\PSR.=2$3!*"_&=&$+Y#X!+%',+"*,A*&7<4O(YI
M(T!N>]6`(Y&SQQ,_?6B1"$F<3G`*R3N(@L#6F,:D&(?5GM"",L3HKENYE:S'
MLX$>F0U,XP3(=S*C&"?@7TW*:Y%0&=ZRK`T;A!2<X^.P(5CDI_8N2!-$,\4P
M2B7\%LL<DHWWU2E&/;7@"D'(=C\.!(H&8L!-!#B;$D%-RHB41F20B2#;$J!2
M\@P(&%Z.7_%N#$VLL@E+,9$\D3RS/&LK!T@:VX\0@V%['`<N%]-)L:PB"=LD
MG\0]NVG#C)-<6@YB)S*!P1P+$[-&81,NL=E=KD*:4B39SGJW%G#X`NE[=F/=
MF&EF$JLYX9)F1B3@`.L%9D[AGD1)7U9F:M<J'+3`DS`G$"KDRY`!=^KQIXM?
M%O,P7[4(9<>3T#Y1K0[BNDBI`YH2K0CG-K4TI4G#=4LQZW-=4D+$K5Q_R**?
MAA&W[*Z$W63$2I1(+4$*)94-(QQW#O=WEVBL&/TV&0$2<:#=^5#X]I1BXO+E
M'!Y=W>X^E``^*G_`DJ7.":G`A339*9>H'\9+ABBCN\;G&^$FB-51N8D<$1I9
M0A0!;YP)SF0;EW''>P<36%#-./M&N7FX;.Y_\AWU$T0T%8G3#')H@<"5-*<G
M#F.4]2I,K\`[*OR-LO1P`;UWH,@@0"::@_.VU`E.I$:TX:.TK!=E"/#9()VW
M>L7OB9$/D4VE%)<<["%(HN)8,.H:ZXFR#/7.3E]A*015WR9+#U?W>\NF$DIH
M*U6J)`0S&5(F;7,`*W#/"PG*B1;LR8,;CP6PIT_I'DU'C"G.#<2C("LT82S-
M-N4R;,S3-1V%ANZA6XR^Q!\Z`U[%!WW\A_G@_O'VY]1]^-CI>!FY]Y].3O\U
M,K^DH]39T^?67'3#E%<H!(PV"=;S;(IZ&^;<-TT_OG?>5SYWD"OF\\5Z/O;M
MA?5,\K*ERS<S^8*8;R!J/WOB?E.,AFXXK8=DQL$8P=U>88&Z:IW/`]K"A_74
M`WR<O<*JZ=7Z6(PAA0ZMD,8/F9_,NP`/^.4HE%[#9'YHS>I\N3VP\*=J9!?Y
M<N(?W'0.^%[.JVGNMR`V59:+Y2BO:Y#U@$EHYO2-G-\PWW=(\FW;&U&K^L/]
M?@IN!=STW8?=S7H]&J6[\S:=*=D!IVZ^X_':K@G8[,+CUWE?^:(,O614#,/@
M6,P=A,_W7;^0XB7G_9=3/6;]?I"O:Y2\ACQPONZ.".'^5F#H.8>GW*/!00>.
M,I5^_'!ETP,TBI%+;*5Y=LOOS?YMC5)&%*/5UNR"/P,?>`3UOL*%)=_[MH]'
M&H#E9J^B$?`#VG437+1PDR9L>#WZL'MQS9&M>R+RC6\^'T_+\_-7GPL/'U5W
MK9\OULL`NS,O/<B.CUEJ/^P'7OW_7WA9N?6GV@6-MA[]5!OA>_S]@.A0]NDN
M3HQ"&N@M]::%J*C[E@,<6`O[XR>JQTTF')X0MR+.,DUFY;P&!?A<;)[03AU/
M_-^3&^:/JYT!Y!I3`'[\TH\,AOE%^+L8T$8=:>#W!IO5F81RLV)YX6W":3&^
MG`<`M`$SKB,C:[2)`=N-N<*,U7$&Z/'@B#;+Q:Q!E?!120`9R#U:9GD5-0#D
M]JXM&_WY1>).7_RPA37PLGELRY#:%OH'NM,@V/4<[^>BXQ4"Q)RW/O/B8K'R
M$V_PR#@P&^9=_+V3`MPT*,ED,Y33#.4FER`7<.4LM/N_'KT+21?<U]VO#D&+
M+_.AAK45_^-@>2Q0^7(SZ'>6PUK'16.WPE2V!\R#;PJ_&9&(L^O1/W,_Y756
M3E=^KBB@J]4CR?Z^TV(.O*F*8K-[UZ,T\C*,1B6+Y55MA\$<GH0.RKF/BD`.
MPF+BEFY--I5S[QS"[7%G=ZH0?@:Q'NB=!$C"+FC%SJWPHYVMZ0)5/E/U@66/
M\^JR&?J.1`ZS5O*:#;[6Z0(V`#2EN`#9\*+0*%3I/1TDBO.+.'4]+[Y,VS`L
MZBWLS>C35>BJA0BD:`!*PFCHWBT%<:PM@.=.=[C]1N.Y)5A>J)?597G56(QR
M(,P\A8;1T]K<;?OQ]5E53DH(,GJ9>`"L])\MVM'+:"FK6N%C]#"-\X'QTOE6
M\3I"%X10S$]/Q^]?S?)?@<M^^'$#X_!H)UI/K(JGG%@-3_*9;5J<K4:FF3<>
MBA9,CQP4O)U'"#<B[D1F]4!B-=)F`I^6J]'/7C5;FD=_;E2!H!^WOVJ_P#_^
M$(WRQ_7\=+D&UVGS^6\146%K,GR["FG6%_Y:7]T<9>6Y1X6M$4O\,GTV$`1Y
M=SW^UA?MWR_JGXZ81,7G<K&NZAG5Z]&T"$/C7R[+\65`N@Q05%<>3Q9L1@KA
M0$`[I1&8UT.U!F#@(@RZSA>CL\5R&2`_NN/G.^O)5]MP>6'Q91SNS0>"#1L.
M!2K`W'C$XLB'X+*WA476T_L[9-8^)88W`<\7OKK(`R@IY`$0HT'.$;MLAZG>
MU[YG6#=9TP99D1^6]H/-M>Q[E0W%L:@#934H%7CH&E'NHV%8JS\L"8'S8.AZ
M?\`#!R8;Q6G5LY4JG^F6\(A\V;B1_C4]Q(K@YVL`'+BKY4,(3QN%_09D\>4&
M)L>G^-5Y/M[%6O,I>HAGJ@&2[*=R/J<U(%$XT5^&PL9\G^$$'6O1#7X^L6\_
MC*ZFZRJ*=O?N"F0BG[QN3'/I,4OJ&WQY8[:>M6E%_9@EY(P@`KLF:]]C!SO*
M@8!^H)QK*'DEKX=*`V,&UL368'U&YT4Q&.?0:S)4N@KA;/1PI0?6R)<7&^R,
M]7SM96W;SOM3UEHF&A'J7N>I#)`7^77`N*@A1WU9?F3WA08[7L3?.X:`&<1M
MZ;$4:V3PP]$Z;H?0>$[*_^F&,&D74PR8\"ND\U[8&V-W7L[SN4=/`9Y!3IC/
M([Q_W5'S<@3I=T`KFH+'B*A$+UMDM!HHWMF34__(=E<;L(</OI(0LYI1M@XQ
M9@CMP^<O?1FU6D.(&%_EX+>MP2<K]YJN*"SYJK[4WQ:N]GAO&RGQYJW<`X94
MUIEK&2HI$9-^VJ&Z%U)^8\:_)74^7B]]I@'V&I02&!(9%:MYL#$U\E-T@YVO
M6NBGW5@@QM;-8Z>A;'`)._,'M`%X]^R%W2O");5,A=/]:@?RJTY.=N6T3A9\
M/?"L\&'$<A4T-X0:M5@UE?0-G-SFK1SM11%7;N1?9]6^)Z0A;?M'A]O?I\^2
MWS6;](VFRJ</3D3'^7)9QDKB3KASW@E&TMQ#)6731:RS?`@94QWGY/[U%./@
M6B!=O2CGP1(UI@=<Q1;:&63BPX0%6`[D;L%.-3ET!ZZN?LO-#SO.%>C=ZX.#
MEQV&M.$BB0TY/J3PF("S'T9?BOVQ0(Q+P[?;-8-N=U$=AC0TY^.8P'18V)0A
MZ,B'JZL`Q;<J9]NO/_IF].K3+6G?=D'R2W[?<."@:`#<`UC>_*(8+5OG7VX:
MC;O?;:E=\]*53HYZ4K\*:",5;:&G><O/RYL\EJ>N`>(-V-J;]QA]+JMPL+KC
ME#:5E4W=N=>XMM7$$UP,17^,1[0-3G=`FM[#Q?CV''CB#DU-%2P\I2>4_3V[
M*XPY&/?MOJW/VQW3I\O<2T2G??+6QOPL+Y=A/M%>ORER_UR_3=FR^,^ZF(^O
MMWK)VVM/YE>@RC_[\RFR`RSTQM>\/21.]?;<NT`SKV%F-@O:>N:;]3R<:$XM
MY/9WC?:DFOG&=(N1L1X;K0$@$AD7B>Z-H70&4'I<.9AIW=;[K\6T@,_TJ3I=
MAA\-\E#!M8%UFTMO9Z*AR"HA/4J?T%A+E3C7,#'%O#<O<30F/BG13F%I,^RD
M%)JDA!&&:Z*%D+0G.3C,E-"!2;]Q_%HJG*7:&).9U*6P/UHUJU.N/U>*F2)<
M4#+D\H:T"?@QXNVCRG>+Q?2.'4T(2BW%/%7,:9JDW&K1\,RFKH>L,:@8/P=F
MM==#0G8!KMOFX]^*R>:BB%9CK]\MR\_@/%W;F7`'8QTEJ;74"BZTM"0CJ`$S
MR`2&;X[-V!N-O\(I(9+@C%N9,HT(UZT*)\D>)4%@W01^KC[@L?MN+OS/W-<`
M"LPPL;"O/&,NHXI1W>ZJA(^^>]=Y+'7)K#2I9(PKI#+X7YI@N[%#HC<*3Q5(
MK7SN4GGCD"#X*8&P(T93RU'"70,'G`E"7`_I1("W'=Z//AL=/"1XA9@C<0BQ
M3(+&62(ED6G#.H^GN<LZIN@VS./S<EOD+O=L&4'$)HB:Q"B4:=;:&\I)7U"(
M9II_=Q'-PXRU(4DF-:B:$A"M0VZ3*M0PCQO6<W7?K[$^0+],JL`V"2*-@CA%
M$,%L$T2#KNGCYC7/(:,>)$_2$":DF&HJ$ZD<P1!`-4R$>.JXDM=EXM=VZ\11
MA3"'/,L8BRA3DF8-(S*$>^D%A71:<O:U<^6'V9LDH1F"!$IAPICA&"4-_%<F
MN2$]]%`BF<3\V<8PCU*@>Z:?RL,@)HBX1&<2@[=+VE*4=,CV\.0A9==(RJ\M
M'X>0R(6DD$')3.O$$6*4U*T*.([ZV)7#D_@0BW`(B23#$*0(GJB,$9Z*Q.#6
MW`F(7?8@+RFFU7/U''<$[QFF,D1?6BI+%,M\S:2F%FO=!\&5A"FDO_:&/LRF
M40BV709Q=<()41@<FC.M`1>T#ZK%M)#/-]Q^5$GMD4$!26F:4N9`-3"!M"]3
MO#$$$-BGO<R%***/*#=?/2@=NH*0.6:L5=J_\0-;B02A#7L9L3TLQR.'&M^R
MI*;28<@"=$9,9@UEPI&F/`'_N%[M\@AE_N<@J8>X0"E=2E@&::9!VB8D(0U0
M9Z9217OUJR.XP,<$NH=DB`S1%!0J90G("<T2:S!OI8/J7G)SY`K,,4E-&4JH
M1$XG-#6)QDZQ=E<)9,=]4O70I#X;FW)/14`0XG*(&!`R+,TX(BQMI2-Q-'EV
MYZ+'\D<(+("B2J0)0@$)+K5-4.SCJ'[J^TU4M)\->ZUSAE!@<D)2CIBTPK;N
M7A'90T9^MDIY1P68(O`G1B0*,Z0,.).L>25)IA4$.SVP9$PITM]MU'A8]@*\
M2(W)J+%..$U3:EK[K1GNG[,<.7MYRA@.'!?-#.,24PCD*/;'O@WICI!>XO;,
MLXVG/&("QOE7B5'B()]7&5<I:L)?39(^3.\S]_I/JW+>R0LCG>1&^A><)`(U
MYP?:T+3W;I-#BZ"?YJ`58>CE[WDY_WE156_G)^U,_HUO[KC1C5A'!$\M%X9@
M(BP$M74Q)X6P-NEYZ5>059).IG/'<AZY]MM?-T$UY&<D@US7&J[3U"E;%Q12
MBPCOY1ROP`B`I#YT\57Q]MQ5JX#W<LM:-X5/AC/NB+%,H<PESI&F3N8@,I3F
M27%BO^:;J(%SOB^VY=U0S=9'?-MV@P%TM2RN\A;5[`9HITTS<`?D*8Z9GB^6
M,]^/'MIX_8N<.YA>^7A<7`6TJ?'8#]7&V<HP]#WU+XJ>;=YH/?-S%+/\MR)H
M0FQO#H-2Y>PJ]_W=ET4-0.$?%T9TJW;TKNF#GK0MO]7KT4<_E[5Y6.P`C\.^
M53$MQEOH'Q[G"%86D'KVK=6W6)\5<>ZBGNX(]T%H.XLO-/-]^G$"R%_JQXH[
M#RH:P0CHK*"2XTO_<;6UQ"U^Q%^J1K^N)_'5YIN1U[)YIWT[(A"G)/+I=56V
M4*7`D^*S!XT=E\OQ>N:O'7N>7Y;5:K$,KQ;WPTC+$DQ_$=_9'1N_\\]Y.0V3
M"F78W!I*QXQ7ZW92WQN']=0S_/S<]XK'0?(%$-U0.O&#"&%XR0\B'"I:\77A
M7C"+R?88W)^JT6P1,%4OYN4YD`$4MMQM-ODOHS_C'P*?/!3)ET!Y[*$/HYUG
MD*!$X8$M6@)5#=[KV7^[N[+FMI$C_%=<>DH>9,U]J#:JFC-1HLNRG:U]2D$4
M)#-+`PY)K:7\^O3@(`D!XA%+MLHO.D`0T\=,3W=/X^OJ(0T03L)D@FOSNVD#
M8?8G\N>*D<</+:^`FWPVJG#4IJ":&K>I$>$?<+F</NQ:T]ZUQ5T[_6ME,/)K
M4[^*<%:]'^G'DX0R5+>!.E^^/V*N_WW7H-GLN'$*".TQX8%ARA1A'!PE9[#D
M3%/$K%JM$UAIN*I6W:3_D](78G?]7JL)01$"3<M8<$)30;BLV%58"8:'.J""
MNTVP?,7LKNFD#KJ-6BM.8@A44@W14GO&93%V@^PJ<#G4:V67KF47E.MU"OX4
MHTZ["'^VN1IPKK`>8/>[S&-PT)]XS,Z^(@H&.\$I0\)@'%WR=ML^\TRPH>5:
M=;O2>`.C3]/XS`RNMT=1<TN=C]@SS"H/6#8SUD5B.IWIEPQ*+L3K87#]DC2.
M!AH1PDA&;S2.$+8T#&J-'!_6(.$:T]?"X/I%B""(ELQ!W(C`NC+C0VS>J'&*
M1#/4`A$KAC@GY&49['W+9K/Q:-<5"";%!-@1C(K$&9]B(=E.4"P[[:67&V:R
MJ:OMYG:B\+F96Z,[CY'F-.(8/+@#P2E,;*L[Q<)@@W`I&9@7_AJ86V]:J`Y&
M$1U(,"0$'@V*+7.>8COHZJA4R+Z%:?D^S*W1'`-N5+!!"&(]L<P;UA1X.$=%
M)X^^\ZI;QUS*<1[:A'20SV;@OE\U*`VF?4WUXQ<('(KY1?;03X[4*3(<\RNB
M%GFJ]F%F])\[B)FJARVRJ?_,TJ%".=G0OS(2[C6-)GBK,&PGEHFFT3`3L&I[
MIU=U^TKP!79EYYF$0-_1GI"W$\CYYWPT@7CM_B+;U-13:V>0-@SL%'=(185D
M*Q3.*>\=M;"7$<IE/BHAK/MO?GT,H>(<XKL41)D*R:9B$<)!D,#)N$;Q2FG,
M%("GAO)5G`W?@;]FX^L&>OK\:C*^;4"H7VIR=:LJI%00*H`I(<I'+]H.6Y)!
M"-&O&]LXMUY0(!LT43[4&"N7"4^UO&GT=PZK_Z_3<C:[F)8W$%]?Y-,4]J;W
MX5]RWBX;'"9JNEG_[#X!>6ULODQT=%(82ZB5"K24_FM6O0-COZ*9HC)MX/Z_
M)6L4LZM\?A9QU[AIF\1MP6$-1!B8_4@';)AN:F4J<0L^*&[,OYN\NU;IQ]A<
MXQCR+`3L,`^>>4^%7]A<1OI%-IN,19>I;Q+`R^R\`DDLD98<@7T4S'GCVDF!
MA>\=NFVTCD\R?-P@._J\_GU<N`3\!/.EA2U>L9@[^XJ"168QPSA8X,8XJ9MW
MCKPD+/0*VO>!9XA"6SYVHNWY>%H?N1#I$55@'AV)-(C@].*,3!@7>Z\$$2RX
M(NJ;66J2H^%^7N&<O/^43VY.QC==\U:3C_^>%:O5>$8KAY6V7%#FJ0%BZWR.
M!!\>O-J]HPOQVX*^I\89(F8'(B#(<XB;@&`E8T*E5DT.39(4)FD@@O>(&!K\
M!*;V^4T-HQP;A)]F9UO`!;KL"WPR?T@`YN]78#_A>S5PBUM@?@ZL9Y)PX8A8
M=KOLC/6HBW"#;?N(GN[>D,Z5CXO9?'J7%E_G`:O<//K6$*-+0]*B0"<0Z(U;
MC$$,]A?G)02F$7PN+;7!,246N!*V_RH.ZIB39Y;XJB[+K)C%<EKATX^+T&#2
MPY5J3ZFKH4P-,MN?8:2"E7_2AA*%+;>2>.XQ]CP@8:T!0X19=-K&WJ9!6(?I
M[4E;8:B.]6#/K<]$DN06SN<VAJ:K-ZZ9-$1:"79%V8BB\<9@)QV&/1`VAQ4.
MFD.8?Z534F"E86(=.2M4GZ?#K).RN/V03S^O^+W`=(T$U=BHIN'J;NWM-=?>
M$B`^1/CE-;%M5W=/+>VWMY>4,-'0OR-AS\G2&M`(B%IP:J&>4%\45]:CMJFM
MC8+'WG*"&S'AW\P2V)J\N%ND$Q;H5[-?Q_-/%0I<O=5GDXNF,P!,UM2I%QR]
M<2ILJ#X]+CJWGE;G;X/E2N3IB2EA2]>18!JTT`F<@%L!$Q,BXVBEHZL26"#K
M+6?E2S+R(^6UL-RIG`@&G$Z3Q5B8_,ILGY5@"2>3[*JL^T6MW)0>TAM^074B
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MQX<5^&U5NCK)UIQ?+^,GS$+:;BU2SC-,D8]-V&D%-V`0CFZ`[?R7@][#EV,V
MKD4<ST;9Y+<\FX;BVJ<ZKLW#(THB)XP10B1-N&C8-<>1EC-E'<3N^YCL4UP3
M\-1(2UI\.:JBH?J6BWPZ!C'"M6UJ*97Q$@D7(T[;ET-4>]/*P@4%LGA':CJ>
M'.4I0A*MVY)!C`HL!HV]DY9AIJEL_4!!`Q<ID,)LB)#%*'TR:AJW5TR*Z(AR
M0LCH0#&1&:I:(L`*^9J(?23V*>J2TAFI3TA:L5N,3R/CV"4T'F-"*A+F+:8%
MS$OLV-X11OOONB.G1R\'#,4<`D<'UZ?9Y+BXSN__D3]L4U&KP0TEDD%D`:87
M9(#P@O-(#4Q)E.H#E"2Z4<+@2#U"*M#7"B=U_2%^'?CTLY]KXG!!E'&P?I"D
MQA`+DX:W%"O*!ZLR)$]QANXPL(;"Q]Q$L#Q3!PJ^A5UM&Z%ZZZ3TL*K!Y0A8
M2]M645ON$1C*(S,:Y9.4JX*(MGKZ*FF=X1[3`MMKU2>UF)]EG[>96PS\GH0.
M2#RSGB@&<WVAX51HMG?D/I[:<'EBSOR;B[^9RU/CPL</Q\Z<O']S?.96*>L.
M7I,&P?+OAS=E.2_*>0[!\>]O[JM+TS(5!G^:S[\<'AQ\_?KU[?W5=/*VG-X>
M$(3H0?KX(-VXU]P_A_G\E[V\R9CMO3F`Q_]RD+XT/DP_X=__`5!+`P04````
M"`![B`A%,Q\_QR`/``#ER```%0`<`&-P:7@M,C`Q-#`V,S!?8V%L+GAM;%54
M"0`#.COE4SH[Y5-U>`L``00E#@``!#D!``#M7=MRVS@2?=^J_0>MYW45\R+>
M4LE.^9),N<J)5+:S,V\LD&Q*W%"D%J1\F:_?!D7;LDR1E`B`EG<>$LLR&FB<
M/@`:0`/X].O]/![<`LVB-/E\I'Y0C@:0^&D0)=//1S^NAR?79Q<71[_^Z^]_
M^_2/X?"/TZO+P7GJ+^>0Y(,S"B2'8'`7Y;/![P%D/P<A3>>#WU/Z,[HE_QR$
M*9T#C1\&OX/W-8HQSVPX++,:K#[AES\]DL'@/HL^9OX,YN0R]4E>J#/+\\7'
MX^.[N[L/]QZ-/Z1T>JPIBG[\)+4U!?MM^)ALR+X:JMI05S_<9\'1`"N=9"WR
M+U-^O&=?O$A_IQ>I5<=QCHN_/B7-HJJ$F*UZ_,>WR^NBBL,HR7*2^'"$&`P&
MGV@:PQ6$`_;SQ]7%BPP0;`]!)$FPF!$Z)Q_\='[,$AZ?I7%,O)0B6K=P,J4`
MS"P9:L(4^CBC$'X^\A?1/=9?'2FFKK#:_](@EC\LX/-1%LT7,=;_N)N"\WF4
M%[F?),%9FN1(`:17!"V4;!3EJF@20)(!*RA+XRA@O#XE,3/1]0P@SWXD9!E$
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M4,P0+R/B17$!`'Z'OE+0TM1[92:F,NL?"5W-SW>O18M<Q*C?CK);!3@J-:93
MDD1_%MXQFO.49!'Z_Q,*&?:'K?SM]CE(57N"\YHVJR>[Y\2Q&E>`P\ZR6<G-
M=`)4:-EZMB07IU!+[Z)>2H!Z[9IP=6J.ZA13AUD:!T"SU?H+DO@<O+Q)LT9!
M&4JN_K4BWBYYR%#]]1^Z5J0QQ\IJ^23VEW'145UBHC(ITYW/TOBJ4&Q.D`1L
MK8=?L2U7K444O>>Z\Y,JA2*H2ISZ+ZQ=%E_LD(0D\XK]C&4VG!*R.$86Z,<0
MY]GC-XP7^E!1R[V67\JOW95S]5@T&@?BST=8E/LR@:OXH.J@*T/'-,RAJH(V
MM&VPAJJFJWJ@$D6S1B\K$+/]HI0^0BFX!F=+RM:W&RM2IG.50%--XIA=ZK-&
MCA/J#U**K>GSD7HTN(-H.LN+CZL<"/5?<>;EUE:9XAC=VM7RX1`I,7^49_MW
MW<V2\@4$519N7+8@SIHL_F#=U"V)BT:<GZ$+_8"-^-\D7D*-T5O)NZJM:XHV
MT@Z;#'M9,I6#EPRNU*U?5%"C*KEKV5[@J6JG;JZ:"=J!,8$3/#(,?^+[Z1)I
M>@4^(&51Y>^0MQ@0:L1<Q1@I(]44T"7H!T8$SC#)(,3C"NL#:EI#@/5DKND8
M6JC!B+_!1P=F\(ZPR##P.)\!;>OXO4[LVKIGJ8H._(UM')BQN8`CP^03FBZ`
MY@\3G#H5^^WHGBS8E*Z^C=>)N<Y(\?21)H`&,D?[3I,`SOC(8,+7*$%8+J-;
M""Z2G"33",>D%13U7*@7=(T1.+ZN^X<]Y'=B`W>$)`\&W]/$WV4\>$Z/O9X5
MF*HCP/.7.?YWLCXO8&08?7TO,`FN\]3_^6(YL\;^3:*N"2H$:O`&U[K65&]7
M0:R+X8"O'.S2!E]CI3R!DDSS9D?W=6*&CA5Z(J:QTLV_FX6V6WI_:&2N94S(
M`YMJMU_%>"F`$W-39\[;.S#\7@;;LHC1&25I#LU.+7^+A&NSY1EG9!_J!(<S
M"_C!)*7O3Y/I#=#Y993`.#RC$$2UO7]%<M<RU<`R10S_T@G0K?_G`TZ]V5_O
MO[-O2M:5"HR].)JNCCM\N??C)3O15])PDM+U"*8U$^^3C1N.;%^QK7"HV:HZ
M-$Q"AB-BV4--"SPG"+P@&!EO>3K;U?220)/1$[QV>R^24O]2\9,\IY&W+/9K
M;E(V>TN3'.%&5:8XDP<*65W?P:<`EP0^&6FA@$UUZ;T-_\E&;QCWP]"=V,9J
MI6M!>+#N:A_&;>37'JA*B>E(Y_,T*=1M#-_82.IB%8BA*@)6[/OBR6Y&V@S7
MZ(Z/#(M?L=C"!(+'HV@X&UO.F0E8!'\8^;5^;;.P2W2=6+I*#G7<X<P*(8A)
MB>")DI06?6>CQ[*9U+7(*%04$+![TQ<'I(\@'#"5-7XT1/-N&4JV2&&OJ6HP
M\@3T']*G2OS]5K[`K1'DT_%&=+7\D.N:2S$DA8*WO=)"MCHM+J.0%*%>'9(Z
M`1JE`7:1%$@&Y[#ZN7,D<'4VKFJKX#A*IPY!#!HL]@ZK,*'I;838GS[\R-A>
M?7F)1C(]\?/HMFF#L'TFKN5[!AB!@*Y1CL,MSNRI1$PE!5B%4<YNB:@/IRH3
MN8X.!H!^L,P09;#7`5;[(R;#[N>PH.!'!63X.8;R=.K)G+F=?[XX55O!B#;B
MKJ[9@:EX!QMH)XDK@K"4PZ(0*&6@E->G?+E?,._B%!*<<M;-Y!HD78VHC@V:
M@$5E.<ZY-.[PAE'*NC$[AWI*"B]TSO1MZFZJ!5SB679HJ@(Z&#G1>Y)(P@T]
M&=SX<N]#EB&32PI_1=2J*[";]]LI7W>DXTQ:%;'6N'9T8'CX5).-LI3@K+5Q
M>!Q^C1*2^&P/.<WJCU#7B+F*KZJ:103T7.9[ZKDX8RB#+3\2G%7&T9\0_$:B
MA,T`Q@D[6Y7E+RX]J"!,@Z3K:>`KEB6`,]:[ZH/XXRCG].++98F+Y/41S!KR
MM!%W3<U71QH1<-K!?E<,$@1F/S2JN$.R%7_6Y%Q3-XV1;0@@CO/.B=,-Q7X8
M4X3//4/3=%=,NPRP]L0PT7@"5@Z5=TXB3GCN%<?Z6ILR>/))G_KC2;MGPB)T
M0\=VO*&AZ^K0-XQ@J!B&5X1C$IT==/.</9GR+A:9I4#:8]?S?`RQW<FW7;+!
M9J,JCF:*V,!X5ZO2@D&50:\M2*WF`AUW32LR0;AM4*UNMZ7UN=_1]ZXI'TRE
M[)J2AV(N>9.>^(@4A:T7*M3MJK;.Q+4]3?5&IMA`Z1Y<I\X6W]QV%0EI+\3:
M\7JS5O*N37P%`DOL`<'W2"=.:$H*[/`!@JQ8@<>>',G_C>1,YX=QN"NK=LW+
M=70UU.UNERF\P>U;[@23`*S,;NMK2B<4;J-TF14M)HL:-G;K!;&3=FS-,`5T
M5*-WV5%Q@[&7L6[S\J%=QKE-6:RS";XBXG;7?G=LA8]Q')#L<7+WM$?897)7
MD0EB3#3/$+%\*6=$ZWMRQP=3V9[3%2S*]C$.+Z,$LA97,K22=QV-V+KU[@)I
M.YNYQD/B":9T%YP=SQDORFL(@/I1]GRRHLGEKI)%3U"QP;`/]OAC#P3B!>3;
MBH/;;<CKE&\1H444[V`OR)9$.MD@][&@,`X?3XQ>)&<I7;#W7>!'TGIHK,V#
MS7.=D1#WO=?07J&]&V=`)2\<X.B^I/X,&P@.Z\\W'+1;/-@B[-J.KA'5?W>S
M0.X\$@%E7Z=^.;TS+NFD*UKX697ZN>IS.C2VK_FZT6E'Z*\3A9Q:Z+YV.;1#
M@\_U9./-ZE*`)79"SXWL%,*4PMIKVINW2V`K?)G+ZOS[-\AG;!VB39RT1"U<
M4S'L0!$1,2N'G/M2ZG4PR!N&7`;UG\)K6O75%:E=6]'L(!01OB^'2F^6`YO7
MO7+!7LHQ2'38L_+]UOHW+#92NL32=<W3!>R+R>%29QMMGG#LC(^<*XRRXC:=
M\HQN_;U%+Y.ZFNZ8EFT+B`"2%++!V^0<$))E\W'X6YH&V74:UZWX;J1T-2TP
MP+$/=KSH9J`*:W<#1TJ'#L6U;$44!XO=P,]E[>OZ]JU"+B&^9ZO=+B3J-:"4
M)P6XXB2##5>0`98S*Q[?OH4X+0(/FPE1*^<2U2*&'Q[L"CQ73O"&2@8M?H,$
M1\*87?`2S*,DRO+5P^C-Q&B0=`W/\0PBPBN4LV;.E1K\P9)_U\`.`5'U@NRL
MO&FJGH!U##E/7W*E!G>LY*R]/4Z/5PYTB]MRMXFX)E&U4`\.]GV00UF*X&@`
M.11;J=<\$FVD=+$IAL06?%N7R-GIX3"J*_#R]@EVN0YNV_UEIJKXQ!F)G0&)
M)!;7!7@>^$B*S7UN"AT?J=DY+[8%YRN6(O9.>,%[_IQV%&6`)V&7_SS%O\'J
M`!_VS*S/Q<YX_N+60%$79C\^I\`0G``MHKCZ*/.</>\09UN*%MN>?R](#\')
M+8Z&4_A>*#X.SZ-XR<(MF'K9>)EGZ$BSEPMJ6O...;F>@UZ2%;S!,(<M-7E5
MA5.21?[NB%3G@WBH@1\<[LNN0NV?RD56QDA:68=M:)T$_UFNG,Q=^=:<H^O9
MOA:HX<%>;M`[\X1@+&'PK1F,;G#\68I_0J-*@QOFQ6P;#;F5O#;=DUB47'0K
M[H>34%2?[LRC&@_U01?KR5S3,;10@S?HB#RI^96M<L\@*'9)4>=QR+9'Z&W#
MW4F-TEAWV[0\^V"=COT-6;&>QQ\L6:O'A>97Y.X;P;E>1.+=.;)5F-7:4W41
M+S3*6E'F31&>6$D8Y5]WS?*''SEC>MW=)S++K!\!A18M!^CO<#>A:;#T<YE%
MK3;Q3I)@_7F\#/L!]@QF?S['Z3)C)Y:SLW3N14E1U2OPTVG"[JF^"+`)1&%$
MGC8AR[L8B@'F+HKCROK4NR^"2G15W3-!]SI%&;PIC"MK>H&<"'&4S^$RNF6_
MMMZ)EZB%JRJV370XV#C@-\'1])#L)\-9Y(M`Z0]):S%E>:ZJCC3+T,5&3/_5
M-GJQU*&U@J?W<Y]NS975'BI*1KP]R_;\PXW6>.]-@X_1ZAO)ENO>]ZP&J:\&
M.YT=!64HS=B+H^DJJ*:B$?2@A3LR'<_6'7,86';`L-6'GJ(;0PW9J1`5;%71
M.@?._K\TB,,PH(0EE;5)Z?I'0E>!R)+F_VM%RYGVC^F4)&5T+1*+[:YFXW!"
M(4,+2@G9:-9@DL:1+V'=ISR2**T<29S:*$[22N%CJ7)H7.PRSM(8NYML%<E9
M'#+Q\MX*7OV38N"M.KS^0PN-/AVS/WDD`_SE?U!+`P04````"`![B`A%[>B$
MOP<@``#'<`$`%0`<`&-P:7@M,C`Q-#`V,S!?9&5F+GAM;%54"0`#.COE4SH[
MY5-U>`L``00E#@``!#D!``#L75ESVTB2?M^(_0]:S^NJ5??1T=Z).B<4XVXI
M?$S/&P(B(0G;%*$!2=N:7[\%DJ`EF21`$(`@]SYTFR+KR/PRJRHK,ZOJE[]^
MO9N<?$[R69I-W[Z!/X$W)\ETE(W3Z<W;-Y\^G*H/YOS\S5__YS__XY?_.CW]
MIW[_[L1FH\5=,IV?F#R)Y\GXY$LZOSWY?9S,_CBYSK.[D]^S_(_T<_S?)]=9
M?I?DDX>3WY,KGTY"F[/3TW53)ZM/X<L_KN)9<O)UEOX\&]TF=_&[;!3/E^3<
MSN?W/Y^=??GRY:>O5_GDIRR_.4,`X+--K9TEBK].RV*GQ5>G$)UB^-/7V?C-
M26!Z.JO1_KKDS\6OX_FFPN/"]&SUXZ9H4?=)TU_PLBR44IXM?]T4G:7;"H9&
MX=D_?WWW88G&:3J=S>/I*'D3X#HY^27/)LG[Y/JD^/?3^_,G#02Y7`6\X^GX
M_C;.[^*?1MG=65'PS&2327R5Y0'8SXFZR9.DD.`L4%(0]/-MGER_?3.Z3[\&
MJ"`!#(,"J+]45)L_W"=OW\S2N_M)@.KL.`+O[M+YLG4U'9ML.@_:$C0Q36H0
M65FU54*GXV0Z2XJ.9MDD'1=#0,>30D0?;I-D/OLTC1?C-'Q;3?C!3;T,(Y=Q
M'M"]3>;I*)ZTR-76=KMF\<,\_+_0EHMK]Z]%.G\X3E[5S?7&T.SBVL2S6S_)
MOARIA/6:[).QB_LD7ZX*JS%^=Y\GMZ%"F);.PW)UE[S+9BWRW*BW%N$HE]C0
MNPO3V?SA?%JLI4N2JIBK4[=%4EV<3XN%O8#D,LD_A)^3*A+WU>F8-)O,XW12
MN:;4J-H/H1^3K_-%]:1;OX6.R?X87TVJE^SJFBV2N1JR'^.OU71M*=H-(8=)
MM[)BJT1^#I-'EM<PO+84[8:0FH-V=XU.R:HMQ(J*W1!9;T#NK-`B4;_&^1^!
M\=#ZAV2TR--Y#17;5Z=CTFHJ78VJ'1-:3\+5-5LD\[?DRV6>C1>CZBWFEJ+=
M$*)FLV2Y0WR7QE?I9`E`^"[82N.:HF[46#?,//X8YZO]^>%<U&BE&_+KJ>S.
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M:2O!04G2:5HL\^]"F77)@J9V`DNK/L-BE$S'A:>TM5YKAGPZZ+EAS.8E*=D3
M9]F0M20JD#7)1MLT;ZEUU_'L:JEZB]GI31S?!Q6$^"R9S&?E-\54CT\!7$=:
M_[+^.MHXUP.OR7GXN)%3T)YD\O9-Z#;:73A"G"E.I45*2\6=9-PR)@3F3".(
MG7G*U*2((&=Y"77W7"W-FSH<+0L&;J3GW`&KH,.*0"8)*;GQUH@J;KZICLI'
M)UD>5LRW;V!9:SVI'+0&%G'[]H20M<A](#9\L9SE?AY-LJ#O;]_,\T7R[<LP
M^H,6N\FRBS#!)3?%A_Z$_V&43.,\S=37M)96/RX?422=$)X"H9G0V@(*;`D&
M!J(O5=BS;.Q1C0/EN4LMC@!DJ1U="WI-WJ?I[#X9I==I,K9/S)5MPMY5)\+>
M"Q(&$K3>2$>0Y,$T7O.'O#+15K.M,\'O-!?WB+V9O)Y+OV6$?CQ-Z%\#GO`R
M7`7H7_"%O9E-/\RST1^_9<&:^D<\6>Q;[[>6CY1"RBG-'`1<>:Z]<Z[DBS#B
M^A+XMMU,IP9`&W#T+.:E,V*F%O/;+$___<V8WR_LY[6BP(V@EB/H(0=:<DL`
M7?.(E6#-QCAZ72(_$I07$?SY;+8X3.BK&I%P7BA`H?$$`*(LMI27O#E(5".!
MX]<H\$:`O(BP+Q;S(L6VR'D^1.*/JD6$`6H8`PY"'!9$;B'W&RXYI(W$3EZC
MV)NC\DCVOYP]]8YTZ#&IF[_Y2APE!@KLF?(::&>L04)RIR!WNI""-:_,40*0
MM0`C8R01&BH+,9(E-Y@9U)/%=*BCI+80]CM*#N-^^(Z2U?@JTFFSZ=)U6]-A
MLJU>1#R0S@C&L'0`4JT-W8`C@7T-CI/:\MVE)BT`T\>"^XS,RBWSUO(1EB(8
M$M@KAE385FJ,$2[YLM#@5^`X.4Y>67<H_3A:,%RGR0"$_Z*V]J]/C-+]!O:J
M;.0$44PZ'^Q&:A"BUCE4\F,H@WT)NYY5?:1,=AO6C=#H0[KOB_R,:3(NT_DK
M1;R]0L15V"$J9KVAFFA)H'>ZY,QSS8?E)6E7SJU`TH>P?\NFA049D`I-WYP'
M6S+L]N:5(M]7+8+("DN-<!)Q):6AB(.-!42M'I:WI%W!MPA,'^(_GX[R))XE
M-EG]>[Z:FY[D:[T/O/@L_Q+G^UQG![84(:8$"JND11IY3B'0C)18$`3]L%:!
M%K>#W0+52\#L.WH#3Y-%X1RZS/*E2.;S/+U:+`\F?,RVCXF]>\0V.H@(Q`P2
MY:BR0!.KB.$;,XRS:J])ORK6F5Y\M\]\`7!?JP=8*0BDY-PQK@%FG`M7+@->
M<]',`]R9#=.7"K4(66_SU2IP81=YH>=)GF;C9;QR2;^.E^[CN_NP^WMRMF/7
MW'108Y%T2!IL"Y^Y@,Q@;&@)L^>&-=O==F8/]3H/=0GD"ZK6:E2TI5O[6HN(
M`QP+0"U!`B"MC7>JQ(0)(H<5HWIAY6H1R1>?N(K?+NZ7UUFXKTD^2F=[0]L'
MMQ51H;W51F$&$*),,6%$B8>#HMDVCOZ@FM4:CB^WZ2\1]`';#_$DN;A>99B7
M1F*EV7Y,LY%GSCH.61ATD'H!`-'!;%`>:B8M!\T62?;:M:U'2'N;T-XG]XM\
M=%O,O]^-H*H);%_=R&(GO0H]:R.("#N2,-S*@4:P;C9A\=>N0FWC]M)ZLEK#
M&RK*JG*$``88"8RHD-)QS90LG>[><-`LS"Q^9$UI!%P?JG*99]?IO+AR:(]*
M?"L4<<ME4'`G,&%:(82`924'%%/02/3RM8N^,4`OG-Y5XR:[?H[HM73/7.O$
MUK\WKO6NJ^^#ZZ7+K<?-^^QYZZT-O1"P[7Z&UCO>>;M:ESWU"NW.&]&Z[*D?
MM:UY?5F7_?:BI-4WCO72Y7ZA=FLH^3A='='9=LO5K\&X6.3)^&+ZOB"VL/M"
M@;#[S,L_EU<(O:N1OMQJ/Q&&R#)'':7>64(LDFR=P2Z8A:;27!LNEE5)TZWU
M$7G(,<7,.FJ$40YK:M<G<P2EFK-&)F_+^=8OI#79,#`?;);W!A#]L&:_Z-;G
MR;\6R73T4)'K7:-V%*`1B'*$'5-`><X(<"50ENJ^CD\>E/']`FJR2U%;0[:/
MO?J&ZFTT5Z8.UZ@=`8*0I`PCPX4QV`.U&?C42J2'FT[>JD1W:4OKR/TYM&9P
MZ>=#5Y875)+SZ?UB/GN7?$XFL#*-=4^MR!.CB+-80^Z=I]PB@TH>F9:]G4FH
MYRAL56J[-.)HE%Y*$U`C35C7BHQE0D'HI%'2*V8X@W+#(Z'-3G]WE@36MR8T
M0ZD/3?@U_M\L_QBZFUU<%U=1%C[0I<?\VX:\PH"MV4+D?)$C@HIX/O#424(P
MV9AQ0C9+PCE<0UZ9$=L-N@/1K$K#I'8;D=/*2&*@8<A*SK%&=+.2`R+A<(W:
MUB5\N`8=A>&?3Y<&9^J^'A4Z1'6^OT"Y^";Z-/N8+V?>A]^R>5+,R3J;CF??
M2-EIQQQ2/6+*`J.@QU@`3C'2`/"2$R%$LY-YG9FV'4@HZQRT7F:.+)_?Q#>)
MCD=_).-O!*^R$_7#99Y^CN>)*_+![O-TMD=]CFTRTLPR0"Q12@M#/;90FQ(=
M(DBSM(K.;.3N5*IG(/M0,U7<P?Q08P[:7R&RC!"AG?#%:#'(80#*&9J)IF=I
M.CL&T;V*M`)3HV7F719/+[-L4K&</"L60:>E*X@@@C,-F*$*;2ASMIFKOK.C
M!ATO&\>!T\ORL)BFH_0^GBS7L^JI?TOQ2"%K-`I[>J:`#/,2!&ZCC":@U4CD
MG9T!Z&%:/QZD7J;LY99^L\.WZ:R(*H8-O;J:S?-XM"^+O[)NI`7GQ=W0'C(H
ME9(<FG*_SX)-U%<\^5!_V(M&EMM&M0\M^IC'Q8G.[S-FMFC-=V4C@$6`Q&))
M!%#:AT&%-_R$@3*P:UY:E$_6+C*=9]C6?4.P]0RIG8\$=MG3H6_\]92=I1>S
M,,?,9FH4%JQ9R6IELM6^:A&EV'&GB#6`$P<])5RO](QI[6FEP=W1V8[1;3)>
M%(>6MA`_TP^/_JJ\5_+`IB*E+4`(*.$,`-I`ZR@K$3&^H3G3<B94.R+][EKV
M3I$:;/[2%FXK0CX[:D1AWK>`(,,=E,[[L#O3H@0DR**O^VH.NYFR,ZEG78#6
MATVSC=+B8YXDE5[VRKH1<%ISQ1EA5F*J3`%CR:]T3`XW4G.T!&MH1!M8_?@Z
M,K@(S/!4HP47V#_BPNN:3?9[P)Z6BB37SEG&A7:*(N2@D+:DBU,PL*<^6L0Y
M:PN3/H>OR>ZNTNGRI%O8W&<WT^*9BO-Q,#O2Z[18[M9;@14FXZU;@O/I6F;)
MN_1S\><\GMZDF[HU)H(>J(B,==Q#*#T4O/`<*Z]I*0.H9%^W9C?7R^,-W.'"
M_?I4?G4TZZ$WY5[W%W'AG3)`"Z])F$HP%:S$U0`E!W;9VBM0XV;`OC:%W3P4
M.R]_ZTMUM_0<0>:0%9A:(#C@`GL$<(DUP;K9XQ:=13D'K\3'0]S(/&S(0KR?
MA>+"@'2\OAS@XFJ2WJRN"=AE?O9+102Y<AA3""PE3F-8'!@H<44:#^RYHU95
M=_AP#WA6_EN6C;^DD\G6`?Q;LB_8V%&/$7-4<(8H0-90``$UQI?8.NR:6<2=
MQ:V'-`NW#&WGT:M'H9W''^-\]7C]CQ;38<(8+@071E$2UD","%>((,`-8&'S
M_N>+Z1ANL=)&(."PELHBB,4*D3`Z?,.[O/J,Z=06Z;$QG<.0&FQ,YWW8C2<5
M49Q-F8AAK)0#UFHH)3*.4<I+ICUO>-_7T.(VM27[_)F2AC#U88PL::M^>^9;
MJ4@$UL,N%R*.H3("4*Q,R0/PG`TW^M)`#MLD>10.KU.F@XN6]"O*%\@J#7#>
M+>ZJTTD?EXLT16$FTMAR@+#&@`1@2CZXZ2UZ7M,>;R2!YYFB1_#?S[&SK_7D
M^+A<9#EFGG,0F`',,D\TU"4?$-MFP[$S%VTK<CR"_Y<*5C?+<-$>40$%D8!X
M2;@CTOB-$2%]LX3-C@\Q]V8IM0/:Z\]>H`*$\>.L(=0[8ASG=C.1.4X'_%[K
MT1(\.(VA&58_OHX,SF8;GFJT$,*XN$M&D_@N^WH9[WZE=4?)B`5[A5-E(25<
M"&.A]1OZ)/(#N_RF1;RS-G'I+S-)>*B%")8EXX`8J0DCI/0A$87[6KM?5EY'
M8=)6F/#3?>!W.K^,'U;.L-J1O:<5PXX!:*VA`P(;8!53MCA1N*)>2M-;FF`+
M$8Q#'9R=(-26?-7-39[<Q//D*36'Q'!W-1$93"$MGFA1%COD)&4(E!P%O;>#
M'\7MR[PEK%I+`L@>XDD1$%MN+;/K-3D7GY/\;WEQ\_KR'87B`O91^#J^V1;I
M:*WM""$&%?<62B,8EM9YOAD!FJ/7E&O2EKYT#6(?UGGQI-/L??(YF2Z2_>'S
M9R4C)#U3JGA;6CJB*3/&BY(7KN#`'@/L)BIV%"1]AJM[.6-YD=_$T_3?J[ET
M.EZ>9KZXOLR36:'^\[3S5T"J";C,)NFH^_OXUSK15S<OF7BP>NGE]W2</'KM
M94U8\6:<"V3DTWAB%K-Y=I?DFU&W9ZIIW&9D`8""0@X41X:R8KW6"G)F@:26
MB4JKINN4A4,YFQ6W]ZP/$T_''Y+\<SI**J_S[Z2_*,R.UE)F/2,"<F48Q6ML
MA:/8#R+YH0?-V9D9\7)8#S9]8LW?1;[FKB):L*UXA+5F4""H8?&H&&5`+=_X
M+J#P4HAFAF=O214OHA3?/[AV+*Q]F*);^*YT$.^L$TDG?1C)7AF,A#-A0)?C
M67@H`!EN\.`X<6V7?6L`_7B*,+@(P4#DWX)30XV"83K.YKO3<+85B[0#@0[-
MF>%4:HAAX4Q=4\:,'MAM/BT@G+4&1O_1&\FHQ0H;X@7V8=N+D12EW>21;'9.
MN3,_8LO".AJ/1O+Z>Y[.YG%AY^V7UO-RD3,4``%):!`8Y#5Q7I6TH1J7]/3K
MPVM95D>BT5]\30/JJ'&("((T0U))S$JZ",/-\IXZ<ZRU+*6CL&@D(Q-/QMDD
MR_?+Z&FIB'$GB`5(:LJE#\JBU(8NAE2S3._.SORT+*.CL&BV0LUOD[SDHF*)
M^KYHQ#E@3(9-DJ!`(^HA)KZD$"/7S%7-7HFTC@?D!>(0->X.W5$CXA`AQR@D
M@@-=W+WJE5SSQAS2`PMFOX##JA7<&@WCC6;OEN[6<I%&%F%KPO3/L%`DM,S*
MI9I!B0<FTZ,1SMK#8M@Q1$*T0X@[QH`-M!/,M5GS4CSQ-9"=WI%RJ`@:'H9!
MYT'#9S&E_4]T_YE"2T8H*;DF-`A,*FR=(\5\ZS2U$OCJ&V/^/[2TV[.-M`T+
MF'8$&BV#/5(DW*RQ%4R0ON:!CD)+M36GE]#285@/-K1TV,E<B758;,.V7GBE
M`^9825LRS:GMZQ6B`021:HM_Y_'=P[`<YE%/S@+WU!J-??$(I2L6\)*'L!(/
M^/+4!G+8<^:S&0ZO4Z:#"_3T*\K^1=CLV"<@3A1I]``B03&WA+L-'UR"OBY1
M:'#LL[8$]A[[/(S_/N18O')S<:WRO."U6-PKEMVMY2/)F0,2($8Y@=0CSHTH
M^1*BX4FMWHY\#F$);@/7/O3E$86SU0LW\;=O/H9/L[!_+L[,5K_N=EA+$:3$
M,T$EI]0!*S5'RF]&H(5\N,OZD;)]_@)0+[C]N75I<.;$L%6H!?=QH,%DDR#:
M;'7?VB,2"^TQV5V8>$=I/"E3P&_R9/GK[^G\]F-H.LS=RUFZ^#&>7,;Y?!IF
MZOWQI$X[C5`P"SQR#%)AH`%&",?_K[TKZVTC1\(_:7D?P+[P'`3(C`/;,Z^$
M8K7M!NQN0T<RV5^_;,DM;6Q)+?5)9_8A@9WP:'[UD:PBBU4U:A2+Q-Z^#L:)
M,E'`6]'T]_PIBTI`$=7"U6,Y]^O5>I&]J@K7V5V6OZRN[J^SA_53)<PJ$W!4
M#:X*]?*R*+_-&GP%>FD\:,TYC'9%M#D`=P1!MG%]V)Q(&8+;A<@9S&EG%-I-
M`6SO]*I?+.K9LLHS>%NN9E5P3544ZS@3MOKHYOZA/<DN[")P`9&UR!CBL$&8
M86CU'A'=[M7`8#Y'DU-M6'A']-[MY/,O*9/$2NZQEM8+8("O;6`I+6SG`G4Y
M:3ZPK=@#K!_/U5L89A24PEO"5,0,0[B?#%(D')2QF[C.]OEN!]"O1X3D;+=$
MY-^?C\_.C?VW+&K?^=UIA>-DI4"AE@Y3`KSTVF+$+*K70,D!22SE4`_H'_#_
MZ06:5@*M'4)>/4&:?+>.%`\*8PLQ,I@;;B@S6&I7?REUL%V\D03=\BZ][.\1
MM':'*AM/H/+^E6?50';Q^8^>B9RH$S11G'B+"7`8*@U-5&$4C-\?36X!A4I#
MT/W`7@X#RMA.>U4>AN7YGGMU\:`,@8`3Y*!D2`(11^/V"YIN=U77^S%"KZ+N
M$8\NJ_&6;%?WN\.O977Z=?#@RY>+=V=FGXJ?BFZSLA\-*S5DGX%`YZ+5J@%`
M!'-FO'2U!2T)E>TXU/OY0/_+14*@CJ3?WV79?%EMGM7<N;J_(+]E<^5@E(`P
M[KA$\#AP[XRGM:ZLJ.7MU(O>'TT-LA3UCDZ7A>DU[4\%Y*EC+C=;%-G\SY<J
M&.-CGGW+BX==\89EJ(<>@I/*>JPL@#;^P`V"OIX?*OZH6[&E]^=;@RTZXT,X
MFMOZ*(&N;N+OV6/Y%,6^=%'#6_V(QI[-OJZFZG?[9[H@4)6R>W5OHJ:;K_SL
M;I,Z\?,9WO@GZP7@X_YE)*9&&4<%=@A2A1P6%`*,U40>]X>^N<EK_FB=X#B2
MBC,A.*2(`@XE--LQ1DM!C.;M=M+SO2<IE<-@DJR'>C4I/Q5QN5Y7W5UG\^SY
M91.#+EODY;SA6J2Y<HAV9-S7F8W++B$:0(&]JV$BN&4*S8%]VGL0>CDP4&-H
MPZ<_NO'@^YSJP7(:.V<$"D0X`#)J!_!UU-YP[=*]#.E3I!>QI1-R_Q3>)'=W
MDCI=>C"N?EXP?7Z_>E3/&\4N*H#742.?K;+YYW*V=X;:_[!^6"\KSRG8$."B
MORZ"\QA!(:FTA&$#D4#8UH@@;1([Z^]7R&42F(ZQ&!W:RQNTFF-5`O>:.Z@%
M)L`Z:1DP&M2CHQB-=9(\L2[3$SQ3"?]S1>U%XR[45#4H#Y'$CD(F*3/40147
M[GJN09MPWJ?N`CR#$3U@]:LS)#D=)3UB]*"5W*R+VT7<I?2L:(@;^+YD<(X:
M20@W#!EC`4%>D=W`=<L5?S`=H3^XRSYA&=_FN.C88L-P`KC'A@OC"4$8<8F!
MK$?$E&D7VV%@7\ZACRE:`#.^J/^8/3=GZ#M6)4#.O*I>+R.JJA>QDEM6C\YB
M#M/=Q+N(ZJ34.Z/SJW$@N6TZ!=%/JZDU/J-\7SA8I(5ETFH+XJ)HA2*@7A,]
M9CZQZ&S=!7-"%6N%R!@ROLA,/Z"G2LTY4!0Z!0VU&EHN=\</BH)V7GV7^U=,
MO(MW!F9\43>NWH>*!PXD5U'UM-HK#ITF%-!Z5-`;G>[NW45$)Z7="9E?1>[)
M[=A3BWM\,5]GW\JGRA?GY^]M#I5TJEZ@0%`A'24&$&^=P7%QK&_QO2.)F>/=
M1/4VB%*/P$QUL.;^?LD7L_VMQ86':V^K!VJ(E9HQS@A0#%J`K:U'#51J*3@.
MGLX,XJ#2$:BIZ/$:84J7BT7YO6+Z["7^S^K'A30YUDP0&F-'L<4D3A#@&!10
MUBC`:#2-='V3'%UZ`JS5Z>PEWU/Y>-Y$6B_OM\_;8[ULL8I8FK*8;^1R]'%`
MS]T$13E!EL;UFL6U5G.G`*^189:9D8X+)Z%2`H".?\2T><"0+5?7LU5VL[D1
MWR=,KOYM&V$ORC0"</8AU"6-!D2IT=!8SB&A3B//A:X10A`EEG!EF-5K-/A2
M)=AVAO5,L&VC`0GAB48<0T^L\UC%1;Y&2%G3CF"#98M)AV"MX)M*Q_K?(:G5
M5CUTQ:6:^)%6@H3"1]T2<XXQI=(K('9ZIA&BG88U6`J;\32L?O":BC-_%NME
M-J]W\^IU7[ZJIH?/LOU\N)!!9[49<!4!S1FI'9-",T"(WRW:!/)V677YQ^?3
M$.@-_OCIZ+N@]_\QY2NAS==L`EM%7%^R8KF-W[</L*5_[(N\!L)2WV>+^4[4
M)Z9"]\:#BL0A'D7Y.2XM44I4J3:-P=9[*VCC&CL0:KNX4HU#7!X;X_E9/3KV
M$;C11EBN+*"`2R,1$[S&D-.6J=9Z?L\T)E6.IO08%^AD'TEME+^JI^WR5&%1
M%IOH>Z>O*$_6"P1A;1@&#&,"@.1.5EKC%AR!U5@1@UK&CQN-&F_)V2.F8VA4
M;SZS\<;K8/D`HDUAF&/*,^*$4TXB78\KCM6D>]79D[S*X5#Z=5B0W,5G2L*?
MX*X[*N9E<;,J[XY['A\M6\5$Q\YHIS#B6@`&&=_MWLBKT<(#GAF+K)M,WMYR
M=T1C#.G>YJMM&)-Y_BV?5U$O&A*.'"H?L-160(N%AI9P*R'3OAZ7DFBLS/0?
M3`GH`\M).%+%3;K.GC8P+1_SE]MR&\2O<4.XL*7@#"=\DXA9<6^-4X"R&@NG
M#$E78>@HVR:F#(+;/YM+R:D=:5.HAVMS]_SR5/[(CJ>>.U`J.*6)PX)CHA%1
MVG'H8/U=V+8,A#B80C$8ZF5?"(UR29@OLKLHAD;]\>>"00D2527`D7(`($QD
MQ?'7D6CM$\N=,;2L>P%I#'%O5:/878,N^5.Y0#W5ADBEL7=0$FR\V]E1P.IV
MZ_-HB0BFTB&[8#@&%]KCLA]9,?_R-"O.>A\U1'?!8B,A(,YC4(69132:?[LM
M5XN$/?1;LN/M864ZH/Z?LOV@FYRR^X&9.CY#JW@VB_QNE<W/.Y8[6#X(A8QF
M(-H0'B.B3=QZT.Y8B]#1#*+SM*MI1?ON'4-W0-O%@7CG97!FKHC&BD$0J[DS
M6A/*'"%0&T_KKS<`M7-3F8X._5\L#X+C*!M:Q='K[&6]N'N,<'Q9E`^+V;-:
MKQ[+1?Z?;*Z>RW5Q,B/!60T$')'T&E?'Y"SJL$PX;S<CCX8)ASZE=!0]BO'=
MS>X`6$W`DKE=+_+B8>OFMX'KM(]`4^5@E?=(:DTM8I!(;I1E]8A-W.K3,.;'
M94=WG*9FQE^SI_5)=Z>FND%Y;;C2$GCE@2%.::5W,X'8L>S^='G1!J8D[*1C
M6_`6NKV'^O)J]9@M;A]GQ=4F&N3RM]C$:OFI^8'E6)\0O"/*&<.0EI3$%1M#
M*7>3TLAVOG;#Y+P8D*1IHITTUS=__17-A=UTAD/P^4`W@<7M@BEBJ876:00,
MU[1&$2'6SC-OF,P;"7*V.Z)C\/*/LJC<22/0L>F'^H7&I^)ND<4![=/4?(E#
MK/V7ZE(G>-BEV2"\Q$H2CZ,!39A#57)D!:T'`(JHSK1S^>G]_<S`O!L1P3%X
M]GM>1/-E_XE7WZLT68_YR_ZEAOZQ'<L)6EW02L`04`HA`H@II#&.NP%7T$%B
MA#"8M#,7>G\U,S"+A@-L#-+4"=9OR]?DC/MI<+/^NLSG^6R19U7V5G5_GS_E
ML]5)&[--<\%*&)'7*IK70"@F(CPJHL(%L%1@VRYSA_A@-!H!N79Q$\I94>7:
M>\B_945>N+^C\1.WY?@O&RP^+9?K$Z=3ES81D(W*)(:&<$^9)9!Q'M5*IR%Q
M'/.6P?/D!^'"P&B=?GCW[W]51;_&G2_^\E]02P,$%`````@`>X@(1>O*>;=(
M:```04(%`!4`'`!C<&EX+3(P,30P-C,P7VQA8BYX;6Q55`D``SH[Y5,Z.^53
M=7@+``$$)0X```0Y`0``U)UK;]PXEH:_+[#_@9L&=C.`W:9$7:B^S$"BI($7
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ME!)3_$^S,5T492YX=/KULI90?-1CC'<0*UZZG/`TWB3+\DDEQ.4/\%+OGVM9
M:%\7^J-6]G^_G.TJ]-S)>/G:S5$(N@[2JT)557FA3B%G?)VE]2>G^2>G6*F>
MN#^T<>G0W'C9K[FE5^N\=Q$G]2WY[,:QDR6*DQ5/1'>H_E=!LCQR5:IOG"UC
M\2R_STZ?7:"\5S1$7>(![K[2(%&=5\UYT:KR7LQJL^8?K^OH]O+_-V$:%M&=
MI[T_?1&MU1$F?%LHV&"6S:A#3(<QT]0,FU9:+.KYUB+;/F:.-KE!!$":8O;&
M([&A/=::47R-KH,P00_!>L-1D*8\2U$0K=`Z#*Y$ASD+>9I_+/K;*Q1&*-A5
MYNTV.^)U:D?%R2\1C);[5V=+SGW%)^CJ:?\#],>7X$I\/Q>/"O5C$U7&X0;2
M#GK!9D+@8>L8C]@"H,3.1%\M'[]_O/;%4R):AL'Z4UP&WSXMJ.9:!F.J[:N*
M+GY63=6R%=-S#-VDAF*V;?E]Q!JPI=?R\J:^%8AJA=/UD-KXUM1^^[1]+NVU
MUSH=ML_^#6O='NWBJ;^-HCB&1IAK8\W3J.-9IFN2.HIK8'_QP).KN&WO"%@X
MI*GMZVC=XNS+2^_+);#O`G6H'9L&M`9&H5+(=+!Y;D0#5B0=FPE`9-7'O=PV
M4E!@FR014-H&LVQ+4S6/.0QCRL0`CIAF'<QF!I%A`S3&X(BH!%6CH9^D6`$V
M#H*,(1V3(<<)JBV;&"$'QAPEB:R1LP**="5>Y4HW2UKCA07IK1VM\M\\,?)X
M"-8B:&IG+$B2IS"Z^5N>CUC8NJL1ZE,=*TPU-,U7&*Z#>Z8#Q$T_,8?'C]!7
MI&"6^0]\IQ0(HIXL;@>F\;V%@6IK:O'#GL03%&2H5HD*F2.CJY5U#2CKU_J9
MH*WG2L5#WJU`]/T6)-]XEN?K+OERDQ0IUH4`K.-3S<.,4=.W%=O5O#H6L54@
MZ:1"#`ZVG2J4;F4!H29G7CN&#>X:#%E[=EVVL&L0-KUF20.*.CDX$_)TJT/<
MXRT%';$ME_%&8.PS7W*!-!'S`\^J[MS"\W3543WQGT548E!3<^PZ)C:)`1RX
M=0DU?(JG4H>2K;P3%/$BQQJLU_'W?+43%#S=W&TYNAO+5N`@K_;S\YZ?0MEV
MV#?V6*_!IJ8A7Q_NS@12_=3E<`#8GT&MH74>/8C2X^1)A%KXQ*(>-FW?5!CU
ML>9KV*]C,*:J,$B!BAX<2K4:>)<'9E$[T@SF#8PL6QD%3T;&R+X'#=B0LFHF
MF)#3'O=PKP`Q\#&[Y<FS!-1"PY9O,$WW+9,RG[F^Z^QZ20;18#"0"#`X$@I-
M:/DLVPQD@XQO[0@QL&$P3I1.'22;1\;%2T,:H-'!O9F@HTL-XMYNI2Z35@N+
M>(1J#E-<Q])5U6*F44^7,]53O$6V72X,FW@Y6C)H]=X;:Y8;FD.QS+D;.(!.
M2<Q.]6I2IUFI*:>BVDY!M79K)GB0%-\TY02TH#44/B7Q/4^RIT_B'LGL:)5G
M?._SI39Y?T8U=<=VL*K[+L-$UTW%<:N8KDZQ`^ME=`HU>'^C5E?,@_!:6I$:
M`=*CFZ7M8#*:ES"VU+).4"&L\-+;>3G^,*;)IP;Z]&+O3&#43UWB`>X_(*K\
M,`HS?A$^\-5YE(G;+KQ:\Q*2>51"&5%URU!5,0HCGFHPMU[J(_I/.H/!JF.P
M$3(FM:BJBR-#JJZ.MF/5B%;":%4*.RV4H3U#ZQ[2^+AJMJH!6#UY/!-D]56;
M>)`;43Y[\T%4O^K.N=0P%::YBHI57V/4QEJ=,78U3"SI!`X@QD@YG*ZY&XAK
MX/3-0'9UR>#L)$V7Q-EI:)?'D;!Q)JSI6(FWLSG2E@`3.@M?L$D,!@FV#8H5
MZBD.5NK2;=M2X9F<HT6.DL+ID+HY[@DD9].K'3+)FDER-$>3,ZUMF4E+AZI^
M-1T#K'3KMGRQ>Z-8#*<NLWCY[39>"T?2?&B5/6V7'#L>4WR/>H:.F><:KH&9
M4\<W'>@T<&]A!^]+7)S;SOG%^9=S[Q+9'USD_<_7\R__"Z1#?RZWX\<D]L((
M<['_*GN5KLF>IGM7H:UE#7CJW?69`*S_>L4#WZ[R$#Q\TP+[GFIJ'K9\FV+F
MN@0[6AU143Q@*KI#H,%!5[\MM+?'!/0MJRX^@L$VI('2*)O!2U=O6]0.7;*^
MS@]6TC5Y&T_=S`&O&OX4/.4K_NJY.&+9&&-;Q3IU"%,IP=H6?QZQ@<D;R2"#
M@VB[LO6^%":Y)ACJ7<N1V?"F`4=JM5N5HJG7_SXWIFDPU\W)F>"F:RW>6.W;
MR118BO@EW1:6Y_B4.J:O$N);1--UIY[S=W57]222Q!)11E[JM]?OD<D9R]@(
MR!H/[)],WOBU;L\4F>.7UAS+'7<P<R;8Z5R-U_+'G6WI,.!:>)0IIN%;3K%;
MAD9=K!IU)-<V0.L")8H?=7&@/&IDC),=6?7J6?<1U>3#*-#PJ;5Y,P%*EQH<
M'2X!S6B/D3BZ^<*3NXLPXA^O6<)78;9P1!_)5G7L$D9,V_<MF]`Z%L4N<*<L
MJ1"#]UP^\X=X_9#OC2"^7^Q(N2R406DBY5]+G@QM')`H0LYI)O2@B\JQ4M*$
MT]ZO.=3$F"Z&SH4RG>IPR)GNAAPES?(^?*PZ1U6TCU?K\*;<1-E[7*XW^9$8
M%>8^Q4G^^4)7F:%[+G9=W:&.9^;O5=0:#-=I.54V2.B1QE3K;6N#=W6&L;P9
M6I-[+37^$E)1KA7MB45;M=M,=*5W4OM7U>$P13'SO0S/9$K?\_%.]`GBV^M1
M]_[O2^$_MG[<Y+;D#Q$-&P07CQ`9HUYYM`SJ]\2/G&'K%H]PP\J/J1>*JKJJ
MPC1;=YEO8Y7XE%4A/(P=V<'TT7)'&47W,GH^;A%XV-RK.]+CY>F&R>W&QZU=
MFDN754;ZVR-B8/7;;]T8W]V%V5VQ8UJT8G&4"?#P:%EL;:1H!G,MU7*9;1F*
MZNNTWBW2TWRF0L[5Z!('1`?X\1E[TLJ=&O?%0;=I[&)G.W*,Y22,)(<FLG8F
M#K,'X]L.-;"F#U]GPIY>JG*XRV)O]@".ECA<T'4>55VCJD]D9UD27FV*/=F^
MQ'E&1N@23HE";\XCP0*>[M9<$*PX-L.$,I,JQ'8I5>HY"<\1?P=+\(TL;O`!
M>%D'Z,JML2]1.T3.^-K`J+I?D?^JEKJ>H&UEZB$ZVJ\.RF+TO$*HKM&4)Y#T
M>44:*#[1I9\)^*>J_8OS3R:\"!T>+]N(ODIUG3H6MFS5\!5/M4UCV]GV=.!V
M51T"#8[]R]L@X96V__R!JHKY<[&;1!^/@O9VRF)]$!^[(_H%CS\%TZ[ME7HM
MH0>[9XM%>$V.(D[2'-!(/8Z*N.6.YOD<E>,ZJIO3T=1ME:G*-H[IZ<#S%*#%
M#XZF4A%*<TD%FM2?HQC=!]7YEC\C!>,37/Y":<XQ,?3<9+=Q$OZ#K\1?FR>&
M@4^(818C4O%'B^HG.B;UE\,TW?!5\9?Q)LO/32\Z54&:3_/^]R;BB.`3E"?0
MB^^X?,GOKGB"B%)\2DZ0*.6>+[/P@:^?)#(%L,O9/CTPV'6$YP3$!2RTG)2G
M,8C.:V'Z!!F!?5..I`&D_)L)Z^3UOS+@[V!$:ZY]YED01GSE!4DDFE]J+Y>;
MN\TZ/P'<Y=?A,LP6"M:88"IS-<ME)B:FIM<;#'JF3Q48Z7H(.,)"G5(CXI5(
M(%WZ,+4=;T9V$T:@K8VU.O1^3Q^J!/YI9!H=MZR!3SWZ/1-B]5FC>+";L_/@
M<J$I!&N$.)J!17]0]5S;V/+3\S4;,KDJ4?PH<ZSIF\/)SJ/)X_[)CB)[M6ZP
MT>/D0T;04+&UIS.!4)<:'!T:`LUH?_A4&(G!3IY=*S-F"T>AU&2J:F!/D,PW
M%,.H5S%ZENZYD!E;<.$#3],>Y+3#2A;XS"FP9^VP,JA=`T#EC2F"L8^D.G"M
M@3'2!L^$,/+Z#X^AZF;$R-.O"Y/8OJ/;KDI=V\>:HVC4V'6PB-ZMVS.(I%&Z
M2CUUBX:Y)F/.L_9Z.2:=7YV\BR9C_^"3J:VO[TQ`/7:M!YD\!9K>V[YO"U6Q
ML&V;.J74T#6?F(I5[TKK:8KA2BXAE@LV]KKB[6;\8+!W][4=LD>U%`;CUW=V
MF]EV;NT6*W>S=B8<[*\^P&W;@$:U[]#RFWS]XF=>O$D3W6QG;'75]S2'^-C2
MJ.W8U*2V:5!*3(.XEF&USBS)EC]@!Z>4A+::)ER#\(8[3?V/KH;.I"5UK\=A
M'Z$?8Z1;CANFRW6<;A+^A3]FCJCKMX6-/0]3E7E8U5S3(L1W[#JTZKC`C5[[
MB#C\+)WW-^_#5^\2.HCKPTTY)`UM8U<Z[?2A/W*%J)`X-:I><0U`K2Z>SQ1@
MG:ITA&7=[0*<5[R,[_AE%F3\;G]W1E_#BFFKBDHLQ3$4A=B>6O8_B.FH#FU]
M+J]<\<,UN%(1VDJ:KC?PAC<-S:JKFS-I2IVK\>)`WSYL:=\3"-8\_<P?>+3)
M#Q1?&)[&\I5`C-F$>9IN&?796<3$1(,^]8&E#_Z$%R)04NJ!3C2!G6KY1!_0
M(AA,*A%3G#MU8$+3PUC2KIG00EK^X4.VDPV`-<II\7J@]WC/HU0,[VL:V:ZG
M4*:ZV,$&,WVB8MNKX]F,`'<&E0XS."\*9646L-(&?8U"WL)V_!C%.QA(=J;5
MHJ;KE[QE3P-B.CLZ$]9TK\>+%<2]&`.BS\?KO\;Q*KV,UZN%@14?*YI*,&,Z
MUGRBZ[@.PS0#^!87M/116)._J7"?Q*O-4K2@5,B2H`W(LO:0&<HK.%MRDPHM
MZ++1H<&`LF?%$8[(F#8C?$C)?X4:\C8`4IK%?*G`TV]!\HWGF8>*4PML8I-:
M%A&`HM10?%-3ZHC4,3"%9C*E`PV.D$I;\>R]J]6!LYGR1K9-8H[B(#1WN;-N
M*ZONP(R>KWS+H,8T96=79T*>/FKR(BG9DSF`UZ!2+KY\*T*Z8IRVCHOCR>N@
M.M4H=EWL4VP;KD*QI6AU4,4FP*Y,MUC#3ZM4\HJVM=H)!+\#U<G1=FP:STIH
M<F;/PSUE$Q&JT:8&2/5C[TPXU5-E7KSCU)]%K6GU5Q[Q)%B+F/;J+HS"?&"7
MOP9=AR6V1577)I1JJB)^^9IFU6%=Q;5AO.H:;7!B50*+QA8\DPAD5F=?VU%K
M3$-AW-IW\KFVB<AUQ*H&=O5E\DSHU5MUXF'N1>A1>7?Y=/,_BBUW/UZ?1YFX
M"\.K-:^.358-33>P:_H65EU7_$%E?AU5=S!P7JMCL,'YM:\/>FQ>1Q_;`6M$
M`V&\VA>6YYEVTM`T9Z$W&M5`JYX<G@FL^JK-X3%[?9HD/:NVP,Q5==\5OF@Z
M<8BCY<>[UW$4BT+6V(,+A[0E^1.O7LRC=9Q&.^Z9W/19KW9UG3:;>*X,,$?6
MVK:9\$1>_Y$Y,:`1[8_HO.=Y-RI_(2A?'W01I^G"Q[JO4]=W5<4QJ*HQW:-U
M*&:J#@0;,N4/3(ZM)!26R]S>KX6JALU=^C.N'3N&]@R&CYU=U:K`]Q?-=@US
M$N=+3QHPTL7!F9"D4Q4.3]_L;`=@J>P#3XOMO\M8V_<,?=]S3*;XFJ_IS&*&
M;GA.'<]B&H,-E*3###Y$VNZA7,(%2!5Y^]JA913?8'S92:H`<S+5>])OF=,`
MFLY^SH0VW>OQ8KEQ+\8`N%.67V>#;,^CNL>P9>M$$,[Q'(=MLT&FY2TB?I-O
M[]46-[#26[46JVPM^T+@E.''DIW]N-66+@/8)`F5RI]IDL$'1C0"1,ZRV7!#
M4OX+7'2Q`?@B3][_\455RL-)-J)?5'60XBAU^'6<\/)[7X)'GA[NHB/&9,]+
M*=]%_HUGM_%J1[UT01S%]3#Q;=77+8]0S-BV@Z48F@$91<U)]\"CL_/],1FZ
M*JI5#]2RO&)@U,W'.M#[8/.0/"2B]T:3*$<+VE45[>I:WP/5_F1E%=!>'4[J
M@6GAQ(E`?I8$@GQA%"1/Z#SC=^G)3';B&?'*-CYSYG=_S>9Y-D-K7GV3;V8:
M99[#0EKUO'=XQ*_ST[55HGIVON^0:6G8<#'93HRXJJ,HT%Z[7)01>N_UXPR]
MKSKP^:.N4"?U>)-P$O(H&LC"+H\-(:GNVZ/WE:JQ<Y)OF'.4O/)VSHJ2':KQ
M*M&ZVM*:/I^26)1>9$$UA?B$,MMDC.B&0@S5T.L(IF(P2"<=4.S`?>C\;>0N
M<QL0@]IQ9"!O8.C(;7G6Z_S7V<)QYU\#721,G@E09)3'G>\P(#;$[;/K-+7:
M6]&R=$-3J.>KED8<8C#%K;;S)IZG,QW6G>D__N`=G;S%Y0!"08;2S54:KL)\
M3!8<M+&HGRV[![A`[>@VT97I!X(S)1[8TP8P#G=]9L+/`2L8CW6K=Z'Q0E>9
M+AAO^(IANZ[!',.N%_]ZF/J@,U-@)8_=E7L!SV5U_-W>B2I=N'G<2@DF]NIB
MW[R;Y-B49_:T15=K&^>(I?;BFY`#M*`U3NJ3GS[QI#CJ=KL'A>:+\C7=-)AJ
M&;YO,M_9XLO4'`NV;D4ZS.#K5G8GGY68N>=)R90!@"-O=COVC.(R#$-;>X4F
M5(B:;N^:M^QIP%!G1V="I.[UB'N^U3IRR@G2<+D@IJ?HBJT9.J6N*WI5MN=O
M^UC$!AY\*1=C<$*=HJM<"'H?1NCKI;LC%#2])>FA''OZ-Z\K>$Y0H6EBZ!0:
M`,2!^3A3W``K<80U,I9(@\8-UYN,KQ8NS;<%U:B!"=$=Q5*4[8Z`'K,4OQMJ
MVD89`3:K4DK_N&GMI!QPAK"P.W(J51-#IU(!P`[4S9F"!UR-(^B1LZ4U?'[G
MX<VM*-\6;3>XX1\V=U<\^7A=A$X_;K(T"Z+5L_,,;$(MPV;$]QUBFN(GM5Y5
M[%'')3`J]1Y^<%S5BD^#4G))JA3%.[%`:O5_"=KA;%+O89RKI:)**RK%YJ]W
MEW+1GMXM`J<;]T&M;<#D8%=I)OP<KG[Q2+?[0,0M^YPFHZ;G&KJOF;ZKN,36
M6;U;D*=1W1P&M^UBCSH.+3$+[1'V;':_8.W?Y4&I.L58%F1E#Q2%79)_,80"
M*R?)3QD+N\*S>N"_T+*PB6OYMLTT[!'==17=Q/4"%<^Q?>"N9WU''WELW2M"
MY2WO!-%1O!ZC<SH/D+YE)QREG2_,O&':O7KM<-J3C8"=C.[N$W[+HS1\J-YC
M^,"SC]=?@L>%I;DN(QK6/4/3B:=;NEV_DN#YBL46&4_:[]4O'P>T\&,KJ77[
M?2:MTVK>3F:VP^)8/L(0^-S"@Y6_^;H0P4*A\&0>*T(:/&S@7A_.SX1QO53E
MQ39*?=ESE%W+^_!Q4;Y'56RQ>[5WQAI6--/&_Z3N6GOCQI7L7Q&PP,XNX`ST
MEHC]1%+47`-)G$V<&2SN!Z/3+=O::4L>J3L3WU]_2;VZW7;+)$5*#!`$>;2[
M3IV2#JOX*C]R0L\'CAT"MVM+&$=1&K]UO'["-VN<Y&^/8[;71G_CZQ"HC*]-
MN=ZS`VK-<;>E>7L&1BM_)[K#_&-JXMNA9S=:<M[C5R1$`3T+*X<*#TIESXIH
M8Y$7_<P_EKOLM:ZF`$9V9&.0VGZ,`0X\*E(]@-#'@K-MZNQJ+Q2__`-^)O^X
M>I^0SU]^L<C_?KV\_C\+?DRLA*!KT?8CZNCFRXF6X5E,Q(\Q_M*?L&<P36FP
MS,OA2(:D/@Z&Y$L:'#OM;J*).GZ-7-]GF_TVN[HEQ8Z:_R/?T"SNMJP>FL&V
M:U39'&#_06NL8K7%^WI'D[RJ1D^?NGYG5,^_9-7W?)W5URS#OW%1$L($$=_!
M"+A!BKV@W9H7)'$8^XY(!;D,0LVU9X>ZO92CQVT-P*UO3U8/O4E@>O!4*AA\
MW@QPX2ASRKCQ`1:3?'VQU3,"Z*!_;+18--RFC"S+DG`Z"AD0$O[V7/1=R^"/
MO+X!'DHA"-PT3B&R4^!!D/0&HB")1$89_F_5/3(P(+16I5!$55Z`&3YEUD.*
MH)IR\:&G55;O_HB:B5-DB`))`#]M=R7INMB;_B%C"R0W44A%)$@P\M(@`2Z)
MH>_V)D@8`N%WG?-[YWG;D_)AE1=2[SLO/P)OO`9JI-[Y-UG1]]:W%+SUW@L2
M9=*;+PK]M7=?RGWNM__#ZD?^L'_HC-@^B;TPLFW'C0,O2OR(#$8B8-LB[[_8
M-VM6@`Z,X*LO2`[?RZ^/%['7O\-A_;-%,K<`/*-A1`+DZ#)$!"3!ERJ>&$$A
MN*8?O[J%5<4TART#M3E'%!(;V&X81+X3I&X4=?<F4F,Q-2\B"'(6M&]/V%*,
M9==R\0A<.VOPL2S>K<]_1*J`D&2:3UWTDRRF,@P/VY]PA&@@=G7T;]?TC_5J
MW=Z4NT@=\BIS(\(TC6E#!&JB$Z7*AT^TH>71BPB+#7V@CIZGX\>ITTTG\-,P
M#D`4!,1.`(I<F`X)5.((S6.HMFVPR)V\F7(UE/)8\8GADF$2D\E78W)>'Y>I
MV03I'-%.78$Q1%6UN7?:GE,KC7P[Q:C19_)RA(D]1KA\>,BJ=;[:=FU$X5V5
M-?_[1[Z[OZ:/9]M2IVC^<[7]M*IV!56X#K%+*]O4):$3Q-C!-HYC$O6(`R_F
MRC\-@*E9WT<%_,)B#EHO/+0&%ZV_J8]6XZ3US$NK=U-D*]S"#\3XR&``0GV#
MB/;'@&.NP+CG06"+Y<_S7,AMU33A^>#;^JDU$N>VD)H1?A.VHAK"1&G<NRF2
M&'W(MUF]*XNL[4:2[G?[*NL6^3]GZRQ_W%W=?L[N]EL6:;8C+5]G5P5\?*S*
M[ZMMAPRA*'*")((@L"/BNTZ8P@X9P+Z7<B=`\\#1OJ&K`<HFE*H!JE4T6"VJ
M5:L.K<CX-%.<./(2\T(DN*+0X^^;6[4>6)T+%]91^`YN6!^'\/6>2.49,\51
M()\P+YYR><.<<>7+#Y0P>RX/F#=L)HSW,WM<+O:.J!J_/ZV>FDD7M*JSS55Q
MS>Y#A\4&%L6>YA;M5KTO*_KS_>)][+A)XF+L$P^[7N@Y"3K@0[&245PU*,UC
M>0^7W4*3;9A,--?*-[.?JP:S]=B"MFJ&6M58H#QV$T?V)<.F>'P?0HKZD%X/
M(6W]Z?=D6XU'RL=YY;%5--HO&6--8[Z&6$\?^P5YELD`=(72]#Q`F]^\V8!>
MXD6:[C%+5U6W#;]=X@Y"X"<@2CT$DC2VL9WV>W(`2)Q09&U9RH#NL?KUDS0R
MNU_D^.-;[]5.G=AX*<>:KKY[+Y@969^=1*0AB[#3?'C9E6\J(:(*<WS4IUWO
MOXEQB*$#XC3Q0XB([SG.0=)`+",S$E:6T1JYC2<3N!22',TT*M&=93:-G"7H
M;?F90*I9&C3%D=>%:#(U?',@G36XSG:K3;G+?LN*K,K77885.`@0+_#M%*0H
M\=PP<?NCAR"R??Y9C6EF-.O1@.K"ZG")5*L3&>286YB//"D5NK!>$BA5]T]D
M4J"2GX]1N=I\&K-\5?8H!^?J9C7$F5`)*_*D5/Y4B7:_$3QI_CXOLLM=]E#?
MX!@"$"$_\'T$H)<0X@_#"049B.2:^E!H7V\>NV3"^B<#:C5(11-3C8'A2US-
MB(G8D*(D''H:],BR.9(%ZX^0(5GR#(Z>M@&:B5J^++LS7+-KJ/:K[7!A'_2\
MQ/%<[$4XPD&(/8!(;RL@3L)W7]XD$R+OLM35>#TPZ[\Z:/\M>0.G-(D<*?8<
M[$DIX8*T">33<]`GETF_>\<.VF2_TM^M9]]@93_R>E=;5!RLW7U>6]FVV4WX
MJ_7NW=34^@P=YY+JJ>R9D$Y/]J%4^#@)G6YI+HXO;[ODG8T#-5S_M<^K;'.#
M?!CY:>*Q2^,=B!SLLJ9QU+@3Q+$30_[#*5.L:$Z!#^T6^MT86P;/6G7XA(X"
M3&*30ZAG(U),K0\<]DOB#3(+SLZAR&F(N;B4/,P@S2GG$801]\])M1+*3-!K
M-8Z4JI\FT5M7V6Z`;K3XK2PW]<>,CA+8=^S(=XD#0A?8,;5!#M/D2.B*&RD#
MFO6ZZ6UR+-?5<=%\UTT3BNRHFT8GWVR$=B;%!+O=L33L=6H0-:TVYKXU]!5:
M1F8,)K%HR&3`-!].K]R<3HA0"=_W&1I.']7L^-&K)X_2LGIQ:.FR>/;1#ZOJ
MSVQ7W_@.(:'G(-MV?2\*<0I(?VP;^`'@DJSE4<Z6IZX&M]H3B_FSLXJ/_5E%
M5MJM7YQVS(N3SS^T[DG4U`L]#/SS&>8_!U*3(A='+>+@R;-PYMPJ>Q9>GGRE
MS\+SSW_XV9X%\4D:\Y\)N7)A^6=#:')(2QC>F&%:-O0FE#UF$/'*7)<)H1'9
MO[C.LDW-%E)8`G9U2ZW3=S'_MLU@73/+&,:.XR/@QQ$%D!*<!OW.21@D$>?*
MAD*#<ZUST&IL7=X5^;^R35N0;?-U5M39(6D1W^`XF6R^$FUFEH4W&S7@6E(9
M/*;P!X!6BW#^O8]O4#:^"5(5WX:4=BH]>KDM4BU90F7?Y_:E9NHZ=H*%K*HB
MVWQ]+`NXOL^S[WEQ-WS\A@"8I!Y,;">A?XBPZZ2]&$/Z1R1:Y,V!27-)=[6[
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MN2H^,T`5%9/V]MVJ_RM:U7G7GRUU(B_PPH0$.,:0>%14@AY@@"*A,YOSH=*<
MV3-'K,83JX/=Z<$`O;\$>P`OV9-SQD#R:;29,123<"WATZ+ERM@>D?KY(VK(
M2+"`X^72+Y/L.(*>CMZ4M,K^VF?%^JFY1H`:B]T@<CT20ANF4>C;?<]I"@(1
MJ1%B@CW-VG^$RQJ`R=TEHH1=0=F>B5@Q09;C5*_BGB>*1TL5T&R:2JIPZ9S^
M*:-+7-E>,]Q=26#[K@N"T'-Q%&-,TW,8AH-IX'+-::NT-UM6>V&=>2/E;C%1
MPK6@SLU$LVSB*<^P7M4[3QN/ZBD@W3354^'2.=531I>XZET6C_M=_3[[GFV=
M[@A_ZF/HD\1#3I22-(@2%[N]R1`!3VQ3PQ1+VG<S-&@L1U;&9,@3E"_-K,G+
M5@OLPNHH7*K]Z@A1/$(U@5[3!&J**^>$:3(]DP3)[4SB)(RAXQ"`(4AAB*/0
M`8-)/X#3!8G7TDR"Y"H0)&[RY`5)!VNJ!,DU29!<*4$2I==@01)VA4.0Y.@1
M:"C__V7%&L'65[?G%F^:LC0-[31T[90X=AH0X/N>/TRXQ0"(M9I78U/WS!>#
M:34XV>[$T;5/B=DP9<SS*=L2I`O.BBGC6XOB<1(XHGZJ0V"($BIWJ]3[Y*I7
MR*Z()0ABX&,'AVX"HLA#;C!,W=D^<!1K)*=5<U12;C9-(?_*E%(#]=JT<ID9
M-FX2I^FE8"!^'L44=4Q<,Z6HX]MG_[6^KIJY/M8`*F/KO*@L-O7!=I?3AC"Q
M,712SXOM*/!<9-M1;SN.XTC@QC15)K67OE]__?*KU6-EO1"S]N+O;PRNR!YI
M922/J^)B[(H)XM?Z0.K'@=0&Y3,UE+C)6!G1`CO-ER!<;AOY2^+A&/&_3MTA
MSLG,N>W?JHDU86^W<I]*C4^B:/9=5KN[U5V&5NL_L\W!ZF5=[[,->OI4Y=]7
MNXRP`[./55X/>%"8A+:?^!"B&`>IESAHV&GJQ[XM-INJ#<8\XPV\:U9;\P:M
M]=`Y\^Y;XXU5'U[3__R/V'6<_[&^KZJ<;;2R*NJ5:,*N+62<^;L)L1),YT\B
M<@!]8;6PK6]/5@?<.D*^U/2O+,=CV;[NL)F2_&OW\[06F(=8;DEOQ>C%`)*$
MOA\C$J=LM,`N\6R[G[X)XR@.Q`1;TLBL<GR2_`_B>YO_H"^\A/+*,LNGJS-0
M*J::'8U"Z;T6-7R=F1&MFTBE(4HVU8M2Z?,E,D'QOEP5G\IRV]MP"`*$?1V[
M;0#9(0Z@.]@@"1&8B!#]:NV*\P5!:TM!68\,U:0,3XX[COD%G:2):0I#8C50
MI.8*A,D1F!/029)<[?]^>*PFE_4GSITKWV4Y,*%,E\9>*G@(1,ON?9&O\\?5
MMBGV.UO033!R"<`AM`'-#!V;#$J,W00(EM0R)K2KY8#J)"?[_7/R4;0.EN*0
ML\;539Y@_3JPUD[\+565OL+*6,4YA41#<K!I/IQ6BM,)F?7(]ONASX_GN$E(
M`A($*4E\/W'!L'\\3!PL=$WXO,@T+\\?;QUL_6D*SB./^I,9&ZLLQDX$-WY-
MZ:$V<\3YA-3<8(LI\#)Q-O80^'N.AFW+A-Z0<6,AYS4<")<-`?]\98-M@)KD
M]7I;,F3#K28HCJ(TBDCJA`Z`$$0.[D^CAW84AH)3EY/M:<^2&[7YWMPH4=YV
M=ZXWDPF'I:0+MF+!ODAT#G,ZVYS3F;/2+#BSV6"[L(YN[CC@6^ZJI3<I&YOR
M5$:W(0JJT*'3B5#%5'$KW76UVE!9/4S!WMA>3+4S\8`?VQ"E/G"\P1"M!QPQ
M91/_?A.43%#`)$CD$RR][(D)5(?E:.UE9BEZ0<:(],@39XC43'"@5/4,B2RO
ML.L;J97Z4U8U_:U.6S]&[`+'U/,=&\?$(6GD>F%[@R/Q@!.Y`LLM4TUI%Y@>
MH$416FVWKZE-8"?3R[$B,R>O8M)C(J$"JSAS$BNWJC,0_$@)KAG&R:L[;SA]
M;K5'%5<FK/XH\Z74\#")5L3%+M_DV_TN_YX=AA+R8[W=;[(-N]0?EP^/^_:Y
MN[H]10D?RGVQNP$@#E/;I[4Z8BW>@(\"9P#G^J(;?F;!I'VX8,U@RL*J=^7Z
M3VOU?95OFVR4=35ZI#]ROZHS:W=?E?N[>XM^S:[*USNVA;/]_-^K:M-._)6/
MS$_1W'6FP'(6Z,9%5+"(/\)_O$FI]Z!M?G+D`ZM`7HYN%U;KR=RUO@KVQ^8#
M9HVN(8G\S$Z?SBLL0+G`]>OK\B&[7OUX;;HCPFP;*O`A"5Q@8Y"ZL*U1(@="
M&'/?MRYO0I],M*@L"LN(.;X1DD;>9A74&O*.*G'EQ0WIJNCA*\`'>UE]FA*B
MR`^#*$ECG,9^##W;!F%O+O`)YRU#4ZUHSZ,.;Q4=<:?6AU/HY*BU9^)15I86
M)E"@MIZ)2+FRNB-TQ]!-+JC/>WJNEE;`C0EEM`HW2K6/C&"BDV2W655E&VJ3
M_'ADW22;+GBL@+MJBS;R@[4#K;/-39($=@PQ(:[G1B[-KM*^74;DT%^"RR\J
M+6L7\/=E75OK554]T=JWK6OOLB)CN]6[RFEWGUE9!YB53D59_$7CE]_FF6S]
MJS0V?$GI4D$1&PUZE$V:VN'LFG<V,P\=5&O`.G/6*L#B2!:K(Q:&9+5:7"OU
M/\J"XOIE?9]M]JRA:%.RHA6UQ8I:"J89K6%5T<>Z[7^"G@Z?^;1Z8O\&F="T
M'28BC'"<1#"Q`SL"&+AA'$$'8R])TR@@0A?>S8=*\V[2WA$FMPW,=]\83NO8
M&>O8&[8)Z/B#G4=6XY)DCZ`98\PGX6:&5TS@YXZLEE%`62!&QHCY@VW("+*`
MX^72[YGHZ$-+PL9\>]<6PU86#$US/Z'O>@C3*B[T/)_6$A$!J=<;C3T8"XTH
MDRQI'B6Z2^@.H.0N2)W()J=VST:DX"X'80[U*.H8/6,JJ8164Y1/C3.G:J:0
M(FZ%.K$U=-]("`Y)"-/0)S&!!+BH-T8!8!%EDK,PLR+)WD4J21^?%.EG;IH$
M+765Z*N\C&C/-!X-T9R)3I0J'RU!C6FWL#1E?W>$%$2A1S`BD-;Z*+9#6N'[
MO2$WA8+G8\2_?]9=.X*2(L$6GYSHI4E,2CI^VKG"A0Z'O^!C1$+DN3-$/B8X
M4*IZC$0/G^0[5MI=%IO\>[YA"S$L#_(`2F(G\6+D)'Z4`"=$:6\,`E>HVZJ<
M!<VI20.*S;H<8,F52Y+\\8F)?NK$!$6&-3WG4%XC9D19IA%IB+I,=.+T3(H"
M2N15YH]\=_\YVS832/5]_GA=DF)'DZ7^>G0<^1%((Q?#*$TP@780]C`(Q/XD
M_9EH>P%E^ILBMHXA6[O2:D'+UE3*(R*I:#,&0TSKI.F>1_#&>1.10D41,%4D
M5;GWEGPJI9'SP-_#X[9\RK(N0R00^<2+(\]'K@\1B1SB]":\!''=QB/SO;IG
MD3HT0D?+!)D9%R_=I`A.$'5`I&Y*%"5&Y(B=/H(D3]3Q$\5YGNZ9A^>V_$GR
M8,(V/UGHY?3'0'0[7UYE:TI4?UM:[-/"V(Y<2&S;]7S`TM7."D)I*I(O"GZU
M9O7KT8ANJ1/DAR][TTB-F`;V0)::U7I.Q-C>-CG&#$FF9-&?[E";0@+_\=AF
MHP']F::0#=(`81]`Y*7$`;Z'4S*LY-D)$JH@Q;Y9LR"T.WT8&KD)*T&:^(1!
M'T-BNB!`CI[CF\<\C,B"'%^&J((D^--CD1,HX-\:)+UCZ0"OV'RBS]C'U4/6
ME7*)AX%C^R3U;.P$Q`U<!(<Y,A0CH1U%2P"<4:'D)J>6"1N?U!D?,<%JLMUN
MT.T?769R2P>E8[NDEHR@(1J^+`>G>[*6#PCWB/)YN/WC>'$VABY&H1TE(/5<
M'^'$#MQA3X<?"&6;<A8T:_H!5+N=0%#0)5GC4V3]A(FN'#SG:JDB]55>1G1Q
M&H^&"-M$)TJ5CY;J9/6<"KX?[F*&Q'7\U'4BET2`M9"+_6&32!('D=+4=#H<
MS:+%<Z+FC0,U[Z7OW9\CFHHRUGD#*2:F<\5PF<3V3>:GI+'JPFJ(ML_IL6B*
MJIILOA7@QN9]N:7$UVTE=WJ=0NPG*"(8(3\(B>\["*=!;Q7;KLBEK].-B<B$
M7->](XB_6%UM._4:%04D<ZPOS\NNA`AWV`QB56!Q>EYVY=:K7V%Y\HTU;_I]
M;A5;'6$F+&PK]*;4\E0)'WFEU<CGK+^;]%-5WE6K![C?W9=5_J]LTUT:Z-&Q
M)D4>.VD21@"',4F3QCJQ[<A).6\=4VQ4^R!P@&B5^UV]6Q7-I?GK[K0(BYGH
M#36J^.9,V.<G6G`\:*8UCGCN(%Y8!Y#+W)_*1]U85JV6>U,R9\5>O3A4JX$T
M63'<)'O6I>I35N7EIE'H^B:!:>H"A(+$#1T?1!@F86\9`RBV9#?=G/;)VH,`
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M^DF0.`E!KHTC%/0873<4NTQQ3F!SCYIM3S!:F;0PNZ%SKB%3*G2:AT7=49M]
MZ&MWEW0>_63CVBO!T#%V38GYSSX^3?)=U1@T/0#<X\Q'RF=9["BW]$-WE[1F
M8(T2+XMUE:VZ*^E7[,:$3Q1G?_MF_ZF;.`4>!'[JH1CY(7$!]FFEF:2V[<0@
MPJ'(N*(5B.X=BZOV[I=Z_ZW.-_FJ>NJ*+78#2?',,9I,MYA%"S&]@>(;18R)
MD=BH\1RVU2.ZL'KD77..+HHM^D.-U'YZYC%B"M4C8\(L$31D#)C'UW*!5T10
MXS_D15D=V;GZNZ`:=Y\_TK%ES?8[W67HJ05TXSGVO]D[M]ZV<3>-?Q5=S@!>
M0!))D;KD2;/%=MH@Z>PN,!>&ZRBM,(F5]:'_]MNOCH[3Q`Y?BI34Q=ZT2=KX
M?=Z'TH]GDI`HBL,XX;%`J.K84![I"$O&),*@*5>7<3T3_,/KD%X$9:^Y[@MT
MHNL6YF,C&\APIP5AANRIRL`1H8]R@ZMG]E^]8;\7)@.\O(!@'R4R$^)Z2:WT
M_T`#>=HUU7>?2KZN`+[-GS!_T[<`BWS'-[?\[JZX+U;[>J(YC035@NM,A8PG
MK!+%*RV4A8HPI`@$K%X$>":L7.V^!LU+7GP^U",NYYO&]8!S_GW]M>XF-9>Y
M;_)_W?\(BMWN4(_4V$QC^"DR,P1/7EHP%O=RZP+J!!^!7)?,J>9@M;D-GE2/
MS&,;8R^`V6LYS830?G,L1WSP(?MMWI>KS2ZK/"N^Y9MBHSNV5#]IQE_>-6#I
M5CO&"N,$11+3C"0*1PFE:15?1%A31#.CV6?G03VSN9%:D[;1ZA"_[MV_C-Q)
MC8=AMO4\._&\%UK_L!W!#EJMBS<797LV';!C9RKS[?;N."T$LZT]`(->J:N\
M>3R'[3Y>\BH]/YS`OL.[316ZLOB'*G;K^W)WV.9/NXYB336/5:KK0X?C%"44
M==>\"I5*T^L'AH3PQ[NCJN!)EM$>1"]-QPL>76@ANG!V)@U!)ZF4[A\\ZRN,
MC\'E85MW_IN[*^M]?:)*^Y]E&M-81U%(L"(2Q7&FM.KC5T(H<$^=J["0]\UJ
M5]U1G_6]P4.--5R@,(6CP,4')[?^'D4N@DYF=XMO4"L-&JG37>A[V<)+2P9<
ME\),:.<^K[.W[3HU#GZ9;GME;US?64!UJ*H6"^)5XR6M&C--%%%%E':WYYI]
MM.^I]EZ-[7WH0*,,Z>7/(R"CS.WQ>P7NFS>#VSDV%YY8JC]WJZV-"7`VW*SS
MS6I;E.W1O7&J&<M(R$3"A*@O]U9],!0R.T2`(O@F1:=EX'W:,-.`N/#F%[1E
M8VB57V:<NF&"#BOWYD80NR3.@62`)8`^5QOCK\WN,5\7=T5^VQW>BK*,89K4
M2U9DJG&<4ASV`>.,@Z[&MH\R$E<6P8DTZR.S[;TT[5>-8:,=;J`.>NHUG3'H
M8C=IJ*ESH=#P1%YTA-Q8`V_=O#\>V1=742A)5<Q%RJE.$ZJ2/E*$-`Q#\(\?
MKP?TWOZ84PO7@&T;/X99=X>,O/+;OGEO<CRHO7US8<J`#,XU:VS-,*;(R<7=
M'\JKU;;;2<]CKKE(=!12GE&1::W[8#C!&C9H;!?#^PAQ=]U\LP%N4:]KM3J7
MP])`,Z;X=PZ&E<ZRF]:R#V6]''62,S=>->8"7889.1/`#$RB=/ELV6.F/7_H
MZ;"U9?7AC"@:1UE$0Y%2A4/2A42<)=(:-N!((R.GVRJU.@JT1P_<5#"`O+HY
M!$.ML).C'*=CT<\>F1')VMGY<<D^E?-T&FB//:/:93%+IC/&0Q+)#(<AY@HI
M0OMP.L+`4VEMHTS#IG;MXU`NF1IIR20/#@[GT:);/C<UC%H5$!`![9PKA*!I
MO`4@*UOLX?/QZ2CH)4Y"(I,DU%&$2%P!+Z+9,2:-R$`"04)-@Z&3<[&'L@CD
MJR60?!GJ@DH?3:P<!TTG4B!\LG%WKI"RRN4M4MD;9+'\4&_VQ?['?Q6W^;O-
M7;E]:-:A7^??\LVAV?6MO^_S[69U+P_5*_V0;W?BQ]6VO#VL]_7^EYM\^ZU8
MY[NG=4)89)FDBHD4)5CJ)(U5V@I.LIADP-[@=#J]@_+F\/!0'[A1W@6;?!]L
MVU2L5SN.7HZFTWB_0@'"P-R);@_?Z&4'1]W--N].>;//L-<^IY66CDO#:&GF
M5$_`3"J/&1AQ=O'GM$4#VH2RVS=[,]]M5/YY7P7_<[7])]_7+U9[*,E-OCYL
MBWV[/U/FV_VJV'S:KNK:E.]V^7[WM,C_26\<H8BF7(>2XDQ)Q&/:#9NF29:E
MP`F3R61ZK[3^Y-?_H3]Q\5X'-UK^=?WNTSM]`ZRSIBM$LRKKER@]6(UUDE*]
M5[!.JJF9GM+J3XUZ2BSXK?X?76Y!EUS09O?[L[U0T]5GOHKJ0G4V^=,QD]IL
M>A]>V<0U@X*!K__Y>-?T_9[=ZW;<?D8I8R14C!*D,Y20-*6,1U2+JDNHJ\H4
MNKAE4+`QUKM4W:%3A<=;-2?;<6EDG<G"&"?6S^3M=YS4N>4S#BTS?B^O\YH*
M^:U>;3<5%W;=)>R4\Y#P1&62""Q2'&5:]-$R*H#[,"V#>&_?];J"O!,&;-O9
MFF=&L1%<@XX$=';UBH*_6TUC0^IU9RY0::"5,\'0T"Q*I\^7DQ.,NYA1K)@B
MDNDTICQ-)8EIV,=$1`D8;@:%\@Z=,V=8NCEHV-1/,P*-9B2,0V>.H9R*1I=<
MNL`D)^;.A$QN<C$ZH]?*(,"06WL"L,K;O]]M7C;)KBM!6;FM#W]?Q@EG<:JE
MBD6<41*%(L&]#!Q'&60/@^O8D!?08H/#\53NWWK!OS?G#K[:G:EU!YUPZ"8(
MYV5B.C`V77%`Q[O<EX2G`2R0I1?'I?P4SDQXZBV]%Z-(/FV$7</Z+&@E[/Y0
M#U1=E=OF-HY]>R!M<TI'^7K-L,012B+,->$J%%AQ+.NSP%IU-)%RV=X35/6W
MMWO#"?EQA$'0\',.QI00J^K;=;X(1/ZEV-0M_N86A4ENUG%BZ\51J%'+;2;4
M&#OKUZX\'=MT-TL6.8_"-*54)U2$**&4:=3%S`1E!$Z.0>$FY\';MY#^,FON
M3+V>R3OL)A?(FCN80;`ZO5V%_.+NX]=OW%JF]54J2-4+`%F42(0DZ5L7&94)
M`BZF<R_`_RJYDPOQUB?*;&Y?=^R]Z<S;I*9#I^'JRR1;M:]>S;YX=D/AJ>I%
M\"%O9N^JEO%=7NP/X\,2;O5;#28_Y383L/K,\+6&D$\SAT*XK03.2,$ZI(B%
M1.&8A;$0,M.\EY(P#+O7W4-\S\-:YQ!L>S&[CQ(8Q.+1S'<'XWXWR*]'XTMF
MPW'LI.CFS6,W*9H!V:&=;IK%];]UUY?K[_EV752BEH2)3`G)41+&,4EXPF2_
M\"/3$0/.C;J/[[U1W$NI7_"R5=<LY]SF]ZOFAJK5]^!SOLGO"NA%?QX*PT$S
MV7LIN&\E-_^ETQP<1<\#P>=-M6T/#RJ@>>/718*0UK`#*V'HO<X?J^?\:XW[
M%VJ6"NDTX]73)23#C&-9A>\#8R3$<I-_J9$#0.V@>$8O==J^U*?2`"NZ>G7-
MO=A3C/F]Z=);;ZD3A^?T5KI)Z+6WT*%53MZZM@&VC$,4HIBAF+`TU50D/(W[
MR)*&S-UK9QAPDO=NHC'WM^VR?`&!7O\";R`T(\`K:&66^4VXV[)J'+\O=[LE
M532MWFS-$$X$C^,X5$D?@2`2@NZW-?]8SX,V=?>_V*S+ASSX[;[2\_O85YP>
MG;CPLEC8-9.7PD;YSY>,VB8_]B*2&%.B-8DS162(:9(1K([384SQ;BI8;R#5
MD7]9\"GC/@/XA''UF_^_=,11><WD#1\[:S]+1V"FNUDZ(I#B5-?W-A!&,4\2
M174?,ZQJ<B@O!@6;C`+_AQ:,F'H\DS?732Z0!2,P@XS?LGX;4O5`-3&?MB0S
M$=.89VF$0QS%*(WJ;^N`1'.ADPPV`FX?Q_](-[_^\.[#'S?!;^\_WMS\'ESI
MZ^#FW_FU!HYK#[#2;/QZ'`]AX]3'38F5J.Y*Z`G/:CCKT`4L#7=U)DQRD$CI
M^H$#TNA]L<D_WLEM?EOLL]6ZN*_:).WU;YK&*:\/T:01B4E(HS22/-:(D;#Z
M(P3UH.VC>.Y0U\+JVKV5%O3:+&]S'&"F&8_&\1'&(VL+O?#HK$,7>#3<U9GP
MR$$BI>L'#LBC^HB7=YO=?GNH3XJXSF_SAV;:K&U^-_?(15Q(SA*5\0AC$48,
M9;J/C!$B$#`Y".>94,VI3D\2%\&3R$77*;&[4M*%TV;4&MED&+Y<^.N%9&^[
M=@%I#BV?"=M<9E1Z>SZ=TJZ[J4Y14CTA"8Y8C&D8IE4G-.IB9Y(*[8YWA@'G
M0#R[^RW=^.V">AZL]L"]:>[`-''.FGU`XW\)^D%S`O'/RK`W";A^++XOG[<K
ML^)N_Y57$F[S6[ZYO<YW^V;%0;G:\"_;O#DZ[.F+PY?#;E\]0%%W4(;.4!RQ
ME*0*)TA&,8N1ZO7%0BH32HXNRC-)?^J2+8(FFZ!+IUE<VB<4U!D%QTP6P?YK
M?OIMFUI0YV;(W/%+^#*79UVX,';[*5>#<X4F+N#;<MT@JEVY_DL6]+,4YE_@
M/]7OM;5UK8W#!(5-G>W:[%?J]<G*<^*Z?[J\RXE?)`=CV$VOC6:"ZD@PA$.E
M4Y6$4H1]/(+BP4/81D%\CV#79;$-/JP><KMQ('OW[,>LG1L''+(&>#;:*/4;
M(SJ#;9Q)3V9X'@9#U!;&#*)-^T!U/26>17&*-(F2E"22Z(BK[-A3BA0:2AU0
ML&GFSQ9!]XI9CM,,]]B>3=[L=3*M!G!V-'*=.@8DF)79,R:973X&1!M@E-E8
MS,UA\VE;-=?$:O-/WUS31*884YG$4JH0QQG'1X`*L^:3[6=[YE:O**@E0?J[
M-C89C$MX=@B&GF?F6(T*V+@$Z-Q[=LNNCPYUS:QK_3+5<SWD`:;,H:,[1'[I
MYMD8-'G7-#EQ2#,D*9,9QC&*:8K"M(^4<!G93]49??RX$W,NEAV8N68SX>;<
ML$'3:W-80@!:,@"R;R8-LB$97)P2LS##DB+UD$37R(MHDO'Z'IR8<"E0EE*5
M]/$4H@-8`@@R]E1_.R3C8G(?XJ0-7SR9.'`2W]"_$6CSY(\Q<RPLG25Y;/*X
MR!]K8ZP&M;I6DXH%4TFJA`HC$BO&<=@O\,Q0DH'.Q[/X^%$'K@8,3YFZ!1^0
M\F#4H"&HB:Z=>6F)X1@3T+^9H&1(!A?&D:S,,-\Y^G+T/164AIQ$FD>2*!$I
MFA[G^C@).00?%A\_[LH:NZZ0C6MF&/%L&`PC4*_\[*"%S+4-L&\F%!F2P<][
M9(>:84F1KL%#PY3RC&,E,DXC+3`)21\KRJ2PYXAA@+%)8M?YL?/.AB8>;!O(
MDVFZ.Z^Y8LP4H(FSI`HTAXM<L3($</OOM_+^6['Y\CQHUR@B(2,LU03+$&=*
M2Y0PU@:-PDQCT#*A89$\L^8H[N=99?!]P(/L-*/.>$["\'/6Q.EN";Y@U`4B
MN3%X)FARE,R+JX/=631L@5'ULW?[_&&W#+,PC&6*B.12$X9T')$^*$(<M/MU
M6*1IEA8%?S?_T$ATLJS(W%GX$(Y?4P>-Y@#]'&\Q46\5="41V.*9D,M1,B9K
MB"PM&D0N_?VQV*Z>MI,MB<0J%4E"$QSR)%(A4JJ/'7(!FM=R$M`SQY[T!(]O
MG"3HT51[=GGUTPG"%L&)QY.<UFCB&Y!GUK;/&&OV.1G0;:!A@R#WY^I[\7!X
M$.5V6_ZK;BZN'JM_V?]8,H&0)D@A7#4/0YU$+$I[#1&*Z5#860<>J?&V;M0N
M@H=69_"Y%QJL.Z4.:&COOCT51S'>$1T[K<%1;"#?-'\T3)XS$HC+P>4Q8VP.
MS\T`GXX,-%ML#A'PUV.YN:FXOKM;K6NZ5[^7;_>K8B/+3?7K]94J2TXHCA7)
MI$BJ7KB@FH>TUYBH1!JO5!];V&PP'!RJ;(+=23K-[[4)!>MC1I!5X*.7\F6<
MS[Z`O>,^J#,*;GXJY"ZI0/X:A0S8)S#GPK;;9#!)H9OM5'!L]BOU_Z1E.H<]
M$I/E7L[@I1JTKKH_.O]ZM<]OFB,+JD[BNG[]ON3USZZKERS_L]C462QC0J2(
MI*(TPD2+.*-,](KB*$[L5UX[E>&Y[=!K#:I.=1[L'K?YZK9J0;3B!BW-=EL8
M9GVXF90#K(I_L;S[6":UR/H^RN;$ER?MS<^#1GU5);Q55".L`H<8?:''-T+I
MS:3_-T:F%]>:>S37*[O;&F@9,Y9A$5,495CI#/&JD]HKXDIZ9[>AC&G8W8H;
M@=VFA>&/W1[*851VOU54LV%W*]0QNX&E]PNS&YJI`W9;F3MH>N14%]]?]1<R
M+=.(92%2B%*$"*EO967'&1K)V.#9$=NXH]*YZHS?/QNF<S`C8FVX_83(&%X[
M&B![1N)@M>^/.Z[DSF!"Y(R1P/F0H<4Q$Z1Z2<U@-L2-?8.@^=?FL,MO^Y&4
M^J:R8E]#/LOS)ZHO41(1IF4J=)(RD8089\<6.(YH/!2A;E2,/,UQ:$0?YS86
MP?JH.[C+\WH=3J?<`6L=E9,]><<O(D<<;H4?!ZH7P9/VH!)_TC:>`9:-7`9"
MVFW)S1C9CA,U`+@/:XUQ_F[SK0I0;G]\R/?-@LOJ[X]WU_DNWW[+^7U%N,UJ
M7U1??JY:[JOU?AFRB,0XK<1PG"58)*(^7U]*I$.61HC`;GYT'A["!JL+(8^*
M@3QV;[09AB=U&$;?H]1%4(E<M`N]ZR]K)'>*@Q/)P=^]Z+%7@T--O0!;;^4S
M$\;ZRZ\<Z4&W)>KUZE]_5FWR;;&Z?Z9EMY0"9UF&!>=)C,-(H21+^L@(\\B2
MH?8!O5.SDA8\]-ILR3G`4"`KQW'2FHZUFT=]BY\(.?:%WV^;9D*_X8[/C7<.
M,CI'.%=FP9F6%9MB]S6__:,L;W\*K<*8$Q8FBJ>A3#55&:5]:,9";0FU`1&]
M4ZW7%GRIQ=EB;8BG0*Z-9*8UV(Z&-@)G0[;SMIF@S8'I<V.;BY3.P<V9759]
MX&6J4,@4(XG"E&6(9PB%?8PPSM!R7^Y7]_#>[9L?#!IX/&HP?LL^U;\R83?)
ML`MD;-/<7@F0]@M=%Z`!@(=\73[DGU;?5;%;WY>[PS;_E'_?BRJ9?Y8LT2PD
M*I2*,)9IGL6I2!A#-$F)I*F$UMT#0OD?P/D@/_ZI@T_\O_4-N,H>XJ%I73V2
M>=!*NI855+J")V'!W[6TH-$V_A#,>9\NLL:!O;-ACXM<7K#(F4'&;+I95_7]
MX3[_>*=7VTVQ^;*[RK<W7U?;7*QVQ9IO;E5Q?]CGMY]6G^]/Y(2,1"J*62AB
MHFF6Z92G/*):$,U24M75(&SY4N%_<"6O'YCBOECU6R8VAX=\6S^<S7V+M_FF
M?"@V]?=`X'DK&#,6SJ%$8)CL%=>%T&NN)P>#1O4B:'0WA=(IKQ!::P^F`ZFE
MR1<8Z[O89H)?[VF6X[X-UM`6AUVQR7<[OOZ?0[%K]\J('R??-8*6DBK$A61Q
MJ)%(N8HCQ'B,XY"*C&0A@ZS_<![<\[*/4R[TBH-3R8O@\X_3'W1<@!X;Y;Y0
MH*2>H#SL$>VH*#QSV<Q2(R`[+IW9D=AU?F<1[,5(8_9VFUJZP_T$B:M/$TC1
M,$8"A9CKL`]")<X@8(5]LF=JOKDMS(4Y9H#SYPN,7IV.J0[P?&;#!>+8V343
MG%B*+UT\,4`0O(*AYMASD<6$10RG(<Y23#5.97;D3IJ!3JZSC>$9#J_5W7:7
M&UB;:(:.,?R#0<3*.B\\.>/-!;(,=7,FC!F<1NGV(7/`G?K+;=[?_D18B"*N
ME<0DTUAJ2M41>)H2T-7BPZ--P*)%T&NTO2C!@<GVA/+G[W!6@:P=C5O/'`,2
MS,[M&;/,,B$#J@VQRNS(MX\/^?I^]5!^OUKU]_(F5?.-$JXB@BEC4D4J.X9)
MFU4!AJ>V67RV9W8=%?U;)0ERG):-39=Y-(9#,/H\,\?J?G$;EP#GAGEVR^[H
M+ZAK9J=VO4SU%<@.-64.9V<-D5^Z>38@N/S/U>.VV)7W70B618*QJH^;T!#+
M5.`$XS:$K'J]R*CK:?.YGC'9JX&\^U!G#.CHT108&7LA5E"$&@,`HD>#[&`(
M,,J,@\\S/,=`2Q_FP#];Z>7PQV!X-_C]\>:*A$E9098RR0EFB*`8TSYF$B:@
M^<Y!@289B'MO??7-,%.M>[Q^_'0Q,&=DY5C=W*--L!XNW-WY=FXM<GF[7VMK
MD%D;K0\HRX?/]4JP*N!?CU6RF_W5ZD==IRT%"8404;U/2(:*)UQ)TD=-4VET
MA[JC4)YYU:D)'ELYD':+`QL-VGCC.FA)J!-QBZ"W]&H22P&MPW&MM6LP#K38
MK!'YIA'GVI7N')Q#4]-A-J67QVP@Y/F7+]O\RVJ?/P^_6TI$(H)XQ+E".M8I
M2>*PCR\RK8;@WCJH9_#SV_8@[]5]<'A>!X"N$7!JLUUU,(K#+BJ&H]"?^36=
MX\-JBU&<=UEOV)2`=15RSAU`93+8X)E6*\/S>J."<62<=55S7?Y8W>^+?-<<
MW5K>=?$_?LNW?VS+W>YJ6]X5^]W)D59QG$2<9BI*)4O0_W)WK<UMXUCVK[!J
MJ[:ZJ]RS?(+D[B<`!%*N2>Q4XIFMW?F@HB7:X;8L>B4Y'?>O'X`OR;8DXX(`
MQ<R7Z<2>\)Y[+G!P\;I(,\;C?@PDL:]4$'`\-)8'IP;P<S\B.;>YK#C7/,79
MU5VN!'SG7N)W'AL'!LJHA:#IC6CGC9>)H:[WX**IC"W/E[=>.-(-I_;#:1VY
M4"H9>*X8#ALCSQM+DX.GC9AJ#ZY@6@&CKKV0370XMNCP.^.T;:J5-R]X7J[_
MGB^?"KS9%-O-IR*7EWT7UZLOQ?QIO2Y7]WBUN*I6Z^ZO\IK9YM7E,A(D/F>1
MEQ(_"IA$&&3-C>`$4\J!Y2!'@001$[VR0,(+Y[MT0^K%0[[^O=C6ESPW$G;9
MZ,GMLR,_!-P;&2=F:GLHDPL6;!2OHU3C%Y.DV@.G<T%F7;T3]6W=?3?J2[R;
M\U_<-<'_B4V<4<,[D<V><7VNSMB?().]K,VHA'FVVM8EY^^J]4,SZ^RJ:7I^
MQ%R2AFZ8!6$4QIR'O#$<A]3C[Y4J,V?(GF)T\&I%:``Z>PB5RM':8A>0L8_.
MLEY&_H+MHF&[W"']R]`,6X6&8QFT40JGD"&;=:BRU=H456M1E+/&V)?BOI0V
M5MNK_*&8$1*S!*,HQ8AY28`1<MW.3ASYD<J*D_;'+2\@M8*T`^5(5(I*I,_8
M:5D?A2R8BD-Y.I&[B7S^+_?5]_\07C9IF_C#ZVSM&`,'I&4P66=6DN'X*T.M
M!JP35"C4.E]>KA;%C[\6S[,4N:$PADG&(QRAB,0)Z@W14.D0L_[7QU&*%I53
MPW($+K!6@%E3%0N;A&FI!8`K8WKQBH23@J%+V&040]N!-Y(QC`HES>ARFAOQ
M3V91%L09BX(TQ"'#81I'*>N^+]]G494*T$<M*T2?>]^H+U'!B7E?#:QQHCGQ
M.TV'@9Z_[_"1#J_%R03ZN1[N:F!CT.C5_1-Z6;XM9JZ/&*44B^EC&G.2D(#V
M4Q//3Y1N?NI_?:Q^OGM6TI&X-+H\D#7UOF^/,$T14.;*H!Z\(.$=8=`C;$(*
MH>G``:D80H629F!A95$_UK;,[V<N9L2G;NJE3'S4C>/`S3H#W`N5M0+V5=NG
M)CLPCD0#4`8@-^\K@CU:8$J@RHB!_O_"Y2/]7H^6"?1W3>#5T!:AD1/P<C//
ME_]3Y&LN?K*9I2+SX)X\4I<0Z@4IQCSN3"%$E8Y/#_G^6'E!@\N1P)P:F49F
M`.9./3>P29MF=@!@S&!^\(J(=S($7=HFH!F#73B0)0RC0T-'FK2D,89CW_<I
MCX(,!P'R<)9QO!,M3/64!&)A9"UIT^=A:@)B$*HGML@;IBAJO!G7E#TRE%1%
MA[S)Z8J6$T>519\2)6VA3^OU"Q7KYCMI1E.>AB(=(A23-/7#H%_Y]&/*5*5%
MVX!E96EQO1AR-58P]/E[7UA&H0ZF*WJL&="58UP<D97!U$U`58;[4!EL2^!=
M45XNBS45)NZK]?,L<A/FIRA.B,OJ6GN9WTL7\ZCR1H?.M\?9$:TQ.1TH\'8H
MD"[5S5![3&EMA:J29&P?](7_)W=!]9B:@$X,@O]F!W0(#9`S$]7#0[7ZNJWF
MO]>OT&RNG[:;;;Y:E*O[&24>C6E*B<_2&,=!2&G:K[7&2.E-`D.F1CI-44-T
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M)DG-D=J!D\)XSA&X?3M]%LL7B:E+$D["R/>#*$$=6.KB5.ERQWD16A]5&R`"
MVEE'3N6`G6.,M!&KB8R&K6L_]:#7^C#:\`9M#O^2`QF8!*M#EEY(SC(XT4K\
MOU?WXM]TOWN>>8CY61)$F9O$;IP$W'>##G88$'^VJJMX+6[.,UKI0%;2PK31
MPC?>J1^[ZR1NWD-TECO\9QS2M,(\_N!F+;13&N9V3O:__YE'O`,Q&VGL&]):
M_@5'P4%T6!P/AX=)O^*C`N;\-&;QITTI6D']O>O;97E?_VDS\V+,@B#RW"P*
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M)2CS8\I#GK8W?I$7>XC`JD\/,@51(ZVJTI=7?V=7-]=?+ME7X/@QC$*U06`T
M[F!*WL-R=KB<?YRO9O,IFDY(J1%V)Z*'9GRI+#0_R'(HGA?;?%%MB_:!8<)<
M+T8D1C2.4N(%GGQ@6/PD<Q..*/'4E$CKT]:5IP<$6>D!$Z2PFF>3&9BN]$BT
MGC\'<P-8IK+)D=XZ4H]H<,GF5[X=6W?1I6`*"R/:V"L#;0`B@']=EQLQO15B
MTAIA(NMS$R\407.ISTG(.&Z,I)'/(\670/2^;5T"=X@@_1S.D8((6B4'IH([
M*%HR"*<'H(-6:=(3PAVDP4KXVKMC4JC-PA2T4!]\9:(A0-20YLM%M:S6K0D4
MLR3,7#\E49QR\4V,46<"^=@%:"'PR]:5L,,#Z>A0=A14T"(M,`WL@&@I()08
M@/Y9)$A/_3I`@[7OI6?'E$_3_RGHGB[T:GCX(9IWO?U6K#^OJ\737+Y65-N)
M8Q>A-&%1$KG$C[@7A+RS$_@L!0B?SN>MJU\-"M+#M4A2T#_;[,!$L$;C='"T
MI%"+*(`>VB9,3Q0;XAY;6(.E\8"3Q_1Q"!]3$,E!^"M##0.XE_$U7Q:;+\7W
M8O547!7;_OFCV/-]AB(O3&*7,((IQVEK#C&?**KF4"O6Q5.`<5I<T-/ZVLRI
M[5Z,01E,45LP]4ZQTL-R5K8KCO!R8J=B*),3V:08[$9EMH%!\K).RWHCQ,_\
M(*,I3E&0X%#$&G437N2E`20I`W_;NJATB/X3DFS`*5)(R:QR`U./72:F]20E
MG!Y`(F:5)KTL[+.I_.NU;\>2+VT.II!YZ8.O3#0#8,YUO;[/5^6?=8.09R^K
M9;EH'I]<+3Z+-M$UENL[7J[RU;S,EU_%3PK9BG;@$N1BQ&(7>UD6)PE!?D";
M+>2`ARQ4O:H^#AB+\[P]_/5)[IT']5FW?1_DV^>]%\[.C?-E,T;8/Y'[C!O=
MB61*(SM=G;-#`:6'5DOQUTH>]?Y>X/5:]*3:\*$S*BAE8IZ)$\Y9'&899QGV
M.@B!AP+8%-"D9?L["M<?/V)R_07?7/Z=.?C#%\8^L:L;Z"DWHVRKR?FY:`;N
M4.RC=/9@3N1,'(#%$^)K(Q83D5@KKE7VFS)DTBJ/(`MY7I:M7%^)-'XM:1="
MGA6KZD$>519_Z[-%E-#`X\CG49`$-/%9(%?H&(D8XAYHH\&T:>N"^1*PS+-6
M'>0Z"UOL0$-F?<9#H#!G/B?WT`6YUZ1?O2!]#ZWFK-LX_X!)^3GCH#=G!W2"
MP=-Z(#O'9OVV2)["HH`UWZH16BEDH-K9[*R@U`M(%HHOHL#S.$9IE'96O(1R
MP%`$_[C]39L.$FB!58,EA='"+CVP\6"G_GIJK\$00,_M,J6GV#VFP7K\QKMC
MBJM/PQ0T=0#ZRDA;`*YW7!7;R]6\>B@^5IO-+`O]#%.&0L8R+@383RCNC"0I
M5WK83N_+D*:L4495[LB6-1KG%S$UVOSJY-OMNKQ]VM;7@;>5,V^>+=C(BO;?
MJJ5H(V-7FGY!V(E9LQZQ$YD7:X*O3+0M2,IP,#6)LI"+CS/733G"88S"I+,3
MH!B2-.A\WGK:L`<*E#AH<:60.M@F"98\#)\L:O$$2"!L\Z670F0&)W6`B=L0
M,J:02`S"7QEJ%<!DXK^+\O[;MEA@(3_Y?2&2F-MB?7WWYI48DF_*^8Q3)JS2
MF,8HS?R$!$E,.A`A<D&UW\U:MIR,=&!_RQNT3=*Q<:H=3N??_RWQ/>^_G%L)
MV/FE;#.3S:\C)R4@8D\D+78"-)&DQI)SU1AMW$07S\KED_C9&R1X\7]/FZT<
M,F8I";/4"^,D1MQ/LY"RU.O@L(RX@SN[`0R6NWV-4&[G%7=WQ7PKES^K^BCY
MII@_K9MB0TH=?=S`J&VK3B$FL'RN0^RTD)T&L]."/O!RG;/#/045?I]=J!X;
MC->4E=FDFRH:;9S6H0G9,4"S(,X\0H/0C^*$DBR.2>)W,++`]2`%`DW;!JDS
MO/`?)"E;M!(QN;3L&+GPQ&QPF*8L`";<4TO.#-$(6,[]`\_GU5-=N?3SNEJ)
M/\Z;DW.?JV4Y?V[^=W<N)$VYYV49IF$212)C#%PBA(>$*2=>)'X!6_$U;-QR
M0O:EF,L353O,SH>G<I$+S,#<RSSK:DG760D';KT5?^P3_1+LA=,`=?[1_O=\
M!]N@E)Y<I[<4G8E(JSW_WJSV6R5265S_MBFN[]AF6S[DVV(S<VE,./5Y@C-"
M$.8L#8-:PI'K\XCXL.._P(];WPP0>.0,M4<$E$0H5VJ"9Y$DF)R]9F=""O:2
MHQ/ZI$GF1-1'%WUEI$5!+Y$7]U*NOA2/U;H6L8.R%7A^&@H`L;`I+'(?$;\S
MCCP2`Z^4&[%I76>N'^NZ^B(G:`&#KYF;X59-@,8G%:9++3ZG!S@A85+B[H1>
MF>5^(C)FV*G75]@M4`:X2O7P4&Z;6UNKW6L:\[+8[&XH[&[5!UF*&0JS*,MX
M$C*:=05_`Y*$%"M?[S%IU%Y'W<-9'WU^@?3%)9]SW;P$,7FBV]J)R$2ZKR7G
MWESTL4>AV>Z\7\`[IJZ\6D1Y&KLQ$?J2=BAB''J0A27#IBTO*]'K3Y\N;^KK
MD`Z^RAQZ?75S>?6!75'X,P"F23<HHG;XMJ6BY[PJ"2%SJ)#"H_(S*:F&=SI2
MJDOB.`4N#N$,2):R)'+3A(<1P0'/W.ZYA"2+7`2;.HX.S_XL\\L'?'7YO_CF
M\OJJ%F6"OUY^=:ZY\_D+^RJDNOX-4)S'CZ*:?$\Z?#"!-U*\9!KC@.FHG!@I
MSM8`)C*6G,]_DZ5.A@="?7VR,WI]1_/--[ZL_MA56G%E[75.<>"&7I(@DI$X
MP8$?>GY"Q1]5U^X'V;"X8M;!DO(A@3DULC/6;SS!TZG5,1/T3J3_FO'E]5J8
M.8(@M^NDK<_KZGNY*!;D^6^;8G&YZM>\\7Q;?F\>Y>N0I![Q4<B(3\.`I5%(
M*4I;)!E.N>(E(XL`K.=J=2>\JSNA;!I.U>\0Y#U:U?M)-@.A>D;CK!&`GM+8
M-AK8P75NGYU?)&*G7/WJ[/9J=JC/)Y1P9D\>UK`6IHF(JDT/WU[/M$NFL@`+
M"'?EMKXEFO+,CUP>QF$:D8PBQGG<6F#(9PPFK(`/6Q?,W>7FD7O@CH03/4N#
MJ8GT&!WDU>!F`FSANT/DFYNJ*[92O+@@?5-!>Z.89<0()Q$5&)/$HSQ+_1YK
MY(>POG(6B-9[W9Y7LG[`NO.K?CR^K34@?B[_-I=#ZN/>D&HBI3E/X-62GLE'
M')86O0IU[U!=Z/^R+2OQL2XK(7[]TR10-J)T8B`X:Z.8R)!R7@ZJ"?52X#"7
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MH83Y?A`%2=0M]G&&*0%>=-`S8CTSJW']=BN!R>J"/3+H_09-#A5W9>V3!]R/
MW6.-*K%F9Q?V("^G]E^'$3D1_1GJQ>L]5Q.D**L-^S$OQ)0U_]&J&A?N'49P
M8`([0Q$-D)!`%*>$12DB41QTH&(/>[-5<9]OBX6:*-G%HM3]TJ;[[<-6[H4-
M_#K-NFT<<$3+*[^+3EGOR18_BO6\;"Y!;K;5_'>G>I3.0"]O60Z9F@9.(%9:
M4MD&229P+?(F.,<D].+@^N/(PCJ([!/Z.TX0)R+3(SE;G:.?0/>_]F;@_3&Z
MU3VM-MO-3.XE<Q2&<9C%D><Q/XQI9Y.FD0O<QQIBROXNL&@Z<N>A7(F)=;'9
M:LZ/A_&IN#TT%I'`;9[]E=/=86*AEC6RL7=G3I!T:I?%!+<3D3DSOKS>]3!'
MD'KED-6ZR)?EG\7B0UZNY,;*]>IR];UH=U]FF1>'+.$8\11[6>QZ8M;=F?6)
M"\P]AUJSGEWNI*H#Y<BB_/`B(T-I59.K4?C4*T/2(W,DM&X36LC7'KZQZX^<
M9NN$=)GB>2+J9<R=UR5+C-*DK&&7J[FPNRFRHOGOWC8PS1_+;;[L]X!YZD9!
MY*8TS#S.4>2E4=@AX*$7P=(N@X9'.8HW_R8?8MP(=7-R(6KMU=1EF=^6R^;$
M1UX7`):)Q:&#0!?UF2&1?^SJ!-\^;<J5G.O-JX=;6<M=C%W0\T(FXZ>FFV<*
M'$Q".Y#.+QW,7V7D=C/E%NKYCNFHTWA"6RW$8B(R:\.SRGI#'BR^;46\C2QB
M67Z7KQC-B)>@('5]$C/&"><!<[W.-B($P;)((R:MIY(=)GG^L@4U6!=UJ-55
M1%N<FM3"GN,O"AR/)(%O>0.)WP#:)RM[0WQZ5_`&$S9`ZF1RNQ)DRU7$E#(?
MHP03W\NB^F6+..Y7$1D'SI2'V;(N;AV8Y\&2!J)05\N,<V=2Q/;`G5V\]K"`
M5$N'X,G*E98S[^J4/D5J[P*^M4B?UFMYJ[C+"#_N)GJSD/@,,QI3S,(,D8PF
MS.VGXCQ1/.ABP;#UB7"?,SSFS_43FW(.W#QW,V]P[\^((:_H&8[`:;$[,_5&
ME*\%NS>E_3@)Y@$O&YXO`GIO'IJ-A-K;B"".#@P[%HF>PGN*ECRKK+?2X<NT
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M+&>1&R4=D@2%B9&"CT,`6%\K?EWPL>S`FB_X."@0@]1TK`@85=4>]"3J%<&9
MA0NMB3!-6W"->*@FO.;(5"_XF#^W!8WP_/^?RG4A,`GYWSY_%NU^BU<+)G[Z
M6+^Y'F0Q=6.?8!(3G&#LTPQU"!"A%#:5-VC8_J&IQ:*L;VO*<F6/+<YZ/E]T
M((%R:Y)V-9D=FV\M>>U`2IY;F$Z'\\*ID5[4O+/W>;=3P5.9Q1-2:B$4$Y%0
M&YZ]KA!JBSQ]R?R4KW\OMG+7_FLQ?UHW"7-`(R+2Y21+XB!+$IRZ*>GU.D+9
M0+74LFE=*#^+GW_+-R+IJ>Z<AQZBL^DQ#M5)/:XU)=(>R<;4<0?1^:I`\CBB
M>(@WB!X.XGVJ4CC,J?=4T`!ED"+A\Z)8;.K[[/FR$*+[*=]*H\_7=P>!4!*(
MC!5A%HNDU8M"-PK]#DA`F0_9-S=OW?+F>0>XF:QO!&1CZF@^$(I*>=88`%7S
M!?T2;9U!=GAE+"8AHE!*3PFJM?!,15SM.?BV(+U5*L%9)Z_6G]?%][)ZVM32
MOZEGIC,/QZ&0]Y`2BBA.>$32M+/*0I]UZ>8-0&B'6=1(-F\T'H^M=Y3R<N'<
M56LGW^'3S31U^86EF#8Y'99;2AH[:,X>MC/EE(>)4D@F!S(\%:$SY,V1]-$(
M2?H3Y\O55K3!4NAGNS=/_3!B7H;\+(B]-$5N'(>=83?QXX&39K"]?W9W=3UN
MXE#TK_#82K,K#-B81_"'5&FD5#/M[F.4F9!MI!0BDK2=?[\V`9*9,@G^(NR^
MM&FDSCT^%Y\Q/M>^X^XLKCMX>A5"%OC5?%%V0ZRUE^03O-O4`UWE2^7E6)OK
MB4F:A0%=>RDVI,J!BSVGT&=AF,0`<@*Y#R(&XQ9!'(780NV/3MBQ:G\.1Z?T
M_"8CVX4_6JS;MJJM$N[<HIZL+VW%CQZ<BXD(I(N1:?O/BN292F9WO5R/`QZ(
M>#&*PB0)@Y@A'/"(=;N9"0^M%/Z8`!B]\&?57;AHO?#'*!%&:CI6!JRJZNGJ
MRPD7_EQ@5EUH;:1IVH)K983#A-<>F5HFSD.^;9;.L]6]O#AMMB)5OI1]+@*0
M!3@E"(<0\33#(`C;X!S16->XT8_HV*R1\_RIK*KRI\C&3MX,*?Y?;=@\U_@,
M'!H#EM5=F7$(-G%B/IP@"GH_>C5*232Y0K1S^^5=[@9:+N;<3T08+0_J@K5B
MBS(]#ULV9)@=^S&PIE'#<IXF?A2$C&>A3Y,T@FF8=N8YYQPH][\VC.=\=<DL
M]:BP0*V&"^V<4R/7N::S@>=U^&YI,??Q-=12-N)Z@MIF.*!+EK$%JAST\^E9
M;\XQ@AD/J&QD1KC/LM3'O*N6)*%B#W.W6$;0PJGU\]%*V3`=G4ZNU#16O9]/
MWVOZ9/OY])!]0:#'2>)$Q'NDP6KW\S&G6+L8<[;ZU#2T^520LMJ6U6*??RW$
M2IK!**9IA#C*4$@#GD7HN)*.,,XX]$V*,/6C.GZ??VS*+7>'I]UZN5Y4+]Y.
MIJSVAPOQM)7%7OSLC=2$MA.0816F008TUKVCD6^T_FVRT.*L+W=KD7H2ZHVK
M+=^E4*'*TCP-$U%7!P.[4E5IBSJ=:LJ'?-N<6IFMA(9_+XMZT3ZGE$/9P@BD
M64!C2$/4G1X"'!#-6B2#@,Z+D4[`ZOW.&EJCEOK%E-KTJI4BN>;5O*CR-;M'
M@,>-@=N55KY#V;#R2E.^IZ)V%D?T?IFE';(<V.MSFF'$>1H3SGW.,<AH=D)`
M8V"A(DDG[%@52>>W$7TXM'YNG[/NS%B_G@+;AKI5]IT;Z9-USZVXYH-S,1&]
M=#$R;9=<D;S!^BG#I\52_B7/D_\0:U2AXY_S:ETNW]XS-Z<)19B"!`<09@DG
M#*2TQ<`@"E44U&K@$31TV6"1;W2UGLJS=?6'_`1?43GMDC],.V_&NYIZDI;B
M^L,9TCOOB-7KN1=S9/U4H?*"@CK)R$0TU,W8RA$>:2LZF@IYKZH7H>1_+3:'
M?!Z&81K0+`,A(C`+"0XZ/PR0%,;S;0WZ<;^H]B8RJAI791Z_A:@^I=^JIK?8
M>T_Y/^NBJ#M?KKQCB$G,YC=,*D]CW4Q,>OYJ#VK0Q#6CS/*,A="G`*0PR6+"
M?)]$&::GX('?S%A6#-P>LQ-5?;ZV`.W,UES>\/V_GJ=#,_"?FJ>#!Z4U3]4H
M&SQ/'P_;[2:O6^UL)`*^*7]^*E9E];UV(+ORX3#!/N8\2W`LY2%EI#O+"S@+
M?;6R#EM1G1=PG`/UENO=\Z;<':KCQG9[BD*\LW3(58]-6*-_V.O)+7A7>S-Y
M17BMDA*C=P;R=N<A!K)W01UM\S\1?;0^K-+M8ZNQEI$A96,4\?%TO*U8]NPE
MT4XE.EP8$3]+4]EK"D-`_93P3KLI)XF:>#J'XUQ5!?(_:OD\NW):K'ELG$-S
MGZOA&T&329+&YI#$?N<UZ,].^\H\]9Y2.PWA=@)M2OJ5=>TH^9R(I(\WWI[5
M\(A$#[="CWAFU>=%M6_^<7;9#5__RI?'ZR&:6R.68)Z$+((IXP'E**`D`C$"
M+92$QJ%*J9R+^(Z+YFIS])OXIM[6/Q3U_5J+_JMJ=G=V;L1VDJ:!ONF-,Z1H
MH#;2+N_I$G@[J3]#+`N=!>;FLIOV&IRQ=R0T:+UDJ#I,TD2DV^D0WUJLSND<
MVA^\ZS_^)?^U/RPVIX//*19K_PRQ)(TCSF)$($`8AS%"+`L(4VH&KAW%^9KZ
M#)OWH4'W<=!2S"Z;E[5R3!K5]'`J_"FUYQZ%1]U>W!VX/\U[;+\WT!ZEMT7-
M-+IGFP^CM/O$Z*CRR^.W?+.Z7Z_R.1)!,,D"B!-`*$0,A*P-$Q,\:$FL^[,=
M+W=K(-Y&(-'1"A6.%#36$3UZVOIRYQU)NA^!)`TA=426F8`.)$U-24\CO::@
M&IQ,23EUX/<IIC8-BDK)?NWS8IDO3^&"!)*4Q"2.@`]BS#G(PC:<^"I55TSU
M&(Z5LP7D[<PD5(,\%2EURYNVI';L&6JK!GLZ&NN616.M56)3471_&_I5\=4G
M:U(B;#",7C$VI67PKF\7419AU,_40[[+JQ_Y;LX0CP'R,Y3YA/%$A(1!]VN`
M!K&:J6<0R/G60H.D/GZV+07S^_5BXY5/._$3=\^Y>`[J<J6J7!Z>E:NT31@>
MMB\[$K6:^NUUJ+P6UL@;K._S<V$?U0*I$]DNM3&2TOH3IZA3V6$GKSO;D?+[
MT[JH0YZL,?FJGVWD,<$0P(!$"26`X@C'A*9)<HP>QY`SJ&)(60KIVH-B?WN?
M'V;T*_GRJ*A,MC@=IE(WH%--L5J`WAG"5ZZ_!.G5*,?V_8=Q=T'-+),_$66S
M/:K2Z1/[F^*=/T3WXI/XLOU*_"'O91+?_`M02P,$%`````@`>X@(12B7=O<?
M/0``Z]D"`!4`'`!C<&EX+3(P,30P-C,P7W!R92YX;6Q55`D``SH[Y5,Z.^53
M=7@+``$$)0X```0Y`0``[%U;<]M&EG[?JOT/6L_K*NK[)97L5%^G5.5$*LO>
MS!L*HB`):PK0@)0LY]=O@R1H6:(($`1`FIFJV%:H[N8YW_GZ].G3MU_^_G0W
M/GI,BDF:9[^^@S^!=T=)-LJOTNSFUW>?+H[5A3D]???W__G/__CEOXZ/_ZD_
MO#^R^>CA+LFF1Z9(XFER=?0EG=X>_7&53#X?71?YW=$?>?$Y?8S_^^@Z+^Z2
M8OSUZ(_DTJ?CT.;D^'C1U-'\I_#AY\MXDAP]3=*?)Z/;Y"Y^GX_BZ4R<V^GT
M_N>3DR]?OOST=%F,?\J+FQ,$`#Y9UGJS1/E_QU6QX_*C8XB.,?SI:7+U[B@H
MG4T:M+\H^?-3^<%WY;_@66DHI3R9_799=)*N*AB:A2?__.W]Q4S%XS2;3.-L
ME+P+&!P=_5+DX^1#<GU4_OOIP^EW#02P+P.(<79U?QL7=_%/H_SNI"QX8O+Q
M.+[,BX#68Z)NBB0IS3()DI0"_7Q;)->_OAO=IT]!?T@`PZ#4_F\UU:9?[Y-?
MWTW2N_MQT/]D.P'O[M+IK'6579D\FP8*!'JE20,A:ZMV*FAVE623I/RB23Y.
MKTI>ZWA<FNCB-DFFDT]9_'"5AD_K!=^XJ=TH<AX7`=W;9)J.XG&'6JULMV\5
M+Z;A[Y(M9]?N7P_I].MV]JIO;C"%)F?7)I[<^G'^94L2-FMR2,7.[I-BYNKG
M??SNODAN0X7@ED[#&'27O,\G'>K<ZMLZA*,:-\.WN^#.IE]/LW*`G(E4IUR3
MNAV*ZN(B*T?K$I+SI+@(OT[J1%Q7IV?1;#*-TW'MF-*@ZC""?DR>I@_U3K=Y
M"SV+_3&^'-</V?4U.Q1SWF4_QD_U<JTHVH\@FUFWMF*G0CX&YY$7#0*O%47[
M$:1AIWV[1J]B-39B3<5^A&S6(=^LT*%0O\7%YZ!X:/TB&3T4Z;0!Q=;5Z5FT
MAJ1K4+5G09M9N+YFAV+^GGPY+_*KAU']%'-%T7X$49-),ILAOD_CRW0\`R!\
M%F*EJX:F;M58/\H\_S$NYO/SS;5HT$H_XC>C[)L5.A3JK+B)L_3/670<S*GC
M21KB__,BF01_V"C>;M["H&*?AWE-D^S)YBUUJ,:')`P[#_5"OBS7@P@->\\;
MQ?L3J&%TL;Y6#^(UZ\*K2W<HSFSJ<)N/KY)B,L^_!!+;Y'):)UEMQ2&$G/]I
M1+Q-VAA"]->_V%:1VA8W5NMYIE[.]<F2FS+9\SZ^3%[TJ57UQD7Q7;5R=4"6
MJP.0S719U5J'4OZ>3+L5]&6#'<H:IO%I?N6RCJ%=W6SG<E],XZ)CK-]JN$/9
M/X:>DG0K]>LFNY0WG\;CCN5]U60W\K8@P_2UB`TL?_\LTGH?2BW*EFUVL[8W
M_]80#R3957(U7T4,WSO.1ZN4FREV'4\N9]H]3(YOXO@^(`/Q23*>3JI/2I>.
MCP%<+)/^;?%Q]#R:_)9<GX>6SV/*LVN?9G$V2N/QM[R[NIQ,BWBT'('')7B_
MO@N21IVV'PD&%',<*&@M%T(SA`T3`G.&/7&$?@_=N%QDSHO*8KUA][T=PW0L
MNYG);=/):)Q/'HJDC.IT^/+/:Q#:H)6(28>H5\)[QXFUWED%*QPP9+@.A^?<
M5<7H*"_"V/WK._CN*/SF.BF*Q="X9OE\QN#'I+C,7[B=N!B]Z@/?5UV4.+F?
MK2(>CV[3\7(MIMQ<L%/FY$-9):"P]"4G+YU)=RZFX1+[0&YFC3S?$&W@3C9J
M)^+82N48L31811!GK+0+PVA!C-J5VVB@0S//L4E#$2#<@)*0QDL.N#9<RPH-
MK@@<RGE,7T4L7;N.GECRRD7T"/]`7J+E?I:!O,:SK1I+'W^>3](9`^N=19/J
MD2!6,F.0\@C2\#/B2"K(G6:4"P;Y;GS$(EU=K^/W!2.H&<'&*A#&-J&=Y);C
M2AO+@#^D`*%;\^8=XOJL\_;,$/-0E%`U)LJ+\I%4DJ#@\K0!0!C+(>:\TDN9
MPPHHVYIT)3.V`W((@I3;P,IQ*?Q3)N<>X_%LI)J:N"B^AI'J?^/Q0[(NNFA2
M/U+4$BR\H``:Q`CQT(!*;\?U`1*HM>5?A@\]X#L$K]:M\*^@T:KB44!+EZ$6
M,$9PKZ"RQ%5:887:L@8=/FLZ@'.0T6DTRA\"G3\DHR10.XC[>S)=8+!ND%I3
M+7*.(HU<^$]BA)G@1*M*2\`Q:TD:?/BDZ1#6(<A3[6WZ&J1<0Y;GQ2*/I7"`
M*\^A$1X03X"OM`CA'VI)#G+XY-@"QB'(<#:]38KO-%Z7;7Y5.")`>F8(#9-N
M8;RQWNIOOI%ATI(8]/")L368@T^#FDY_(HD=%D0;:+6D"$G#634K-,A!UY(4
M;.-4V*O%L/VFQ#8H#L&&\R*_3XKIU_-Q/#]/$0+K^S)%L'XD65<M0IQJI0&B
MWAJ`*>50VX66E@J@#R]6W7J*W"&>0[#&IUDZ3=ZGC\G5:3!4=I.&"&D.Q7K>
MK*\886$PHI(A%$95[!`SMH(O^$UJ#B]@W9HYG2(Z<'CR>YZ--HE0OI6/K&`A
MX"(6(H`\,2+@5L7@E@`L#R]ZW9HI70`Y7(!2&YE$/M`WC)\8*"8`%`YJ`"O)
ME9)M)S`;QZE#A20=Y6$WQ&T(BS\_89!=74SST>?O=T_6)^N;-A%I9Z!WPC$*
MC+,LX&5TI3W7K:>]>QF<]+K>TQ/B`_.M^7+0VY4BX!WBQ(6IGA+`6(N!)I6&
M$+JV`>]>IO2[-_O;O-H.YR&SMN?QUS))V#Q?^WV%"$L%`%`(4*&Q00(#L@3+
M8=4VG-EW!K4V\!OIVJU0'2SX?0U`7?C[ND8DG?9":.X1QEYB0JF6RTFA16T3
M,GLYCO7`F&Y@W<U@M=$@%3EA(&=>ZEFD2(0%B%4:6<7:$F7C.77_87(/--D:
MST$8DF<W'Y/B[GV:)6?7)A@D7<N1%<4C'5RD0A18;#!7WDN%1:65`+;M-JA]
M=R<]A3#;([R>-Z^/G)6?+)S:XLO/+L?IS?R&'_<T&C^4E]@M.'R>%\\/[3[C
M2)MF(HH,H\X":ZD.\U%>KGE4FC&KVTZI]C)KUQMW!D!^X-&JV3`5080L@H8H
M:HU7`&$OS$('!X!N.SYMG,D;='SJ?>JT(:R#;*^K/V&QV9;]R$'"C)5(6J,D
M@\A342W*.>+-<!G`WO?G]TZ=[F`>@DJO`3C-%AYRX1K5=%JDEP^S?5\?\S+?
M'50*@`=1;DZS8+!DTB3IT^T711A`K0S`PG`!L;)"P&IVX73XW5"KZ#_T2+D7
MMMD-RULQ=JFA1X*&(%0"J1#ST"'%V7)(<+3MQIZ]3#+MBARU'&UIC:$&Z#R;
MB5R[U?U%T:B<SN@0<=H2)TX5,@@NM>&N]KSQC\VMS8VZ8OC=`L\AV/&AO*DD
M2ZZJBRW5:/1P]S`N#\#9Y#H=K<TYU%>.("`F@&<L"7$&!Y@36NV4<]R+MH<M
M]S(#T0.#.D=X-R/<1B-;1"`&!&--&`@@(6<56_82YTGM<>4?)[?9`V.VQG.0
MLS-IEA>ST7L^(J_AQ\NBD89"<(,0`RZ0W3/(6)5Q<Y(Z.Y1'Z7]ZN"?1SI86
M^'%FCKW/&"..E==4622L\H!H2`3[YJMQVWCJA_!L>Q*I#V"W?=A<M<6FJ@A!
M"93B5`C!*/&80XF7F2'(VGI8OG\L'3)WVP76^W8;QIIW4`[H:@P;(C$),=?*
M(>NEEA`M+D;1B%I7FY#N6?/9%:5-=)P5C!"7GG,'K((.J\`Q24BEC;=&##6G
M'R)^ZM*XKT:6+5`=)B9:"'@Q2K*X2'/UE*Y;DEE9/J)(.B$\!4(SH;4%%"SA
MP4`<(ELV-.A;O-@"QD'HL1#O4S:Y3T;I=9I<V?PN3E?M'ZBM$V'O!2DGJ-8;
MZ0B2G(!*/^15VR,^^TR3=O9]R9:.$!W4H90;8$[#CXV\R;)PZ%$L!#K2(J6E
MXDXR;EFE$<2N+4?V<N+>K2MIB^'`RPN_YR$>W&"-X5OY2"FDG-+,P=FA>^V=
M<Y5>A)&VVT7V=*&AO5G?7F!H#>;`))E=ECY1#]/;O$C__':AWGJJO*P5!6U$
MF'HAZ"$'NMRR">A"1ZP$&\R9_+B$V1+2G=#F=#)YV(PR\QJ1<%XH0*'Q!`"B
M++:45[HY.-R2PH].EU9P[H0J9P_3\OGA,M.W"5^>58L(`]0P!AR$.`1XW$+N
MEUIRV#9;NY>GD?LD37M,=Y?O:OHZ[O!IKI;[AQK4CS@7(DQ<!*?8><RHE'RQ
ML`-"!,%JCPOL5Z(+(&L!1L9((C14%N+J""QPF+7>1[K/<])NK+L^T[49K(-.
M3.<*E\\>Y]ELSVO#C->J>A'Q0#HC&,/2`4BU-G2IIPPP'B!]-C3P6SSI`,XA
M:/-"S-KLU\KR$98BA$+8*X84$$)CC'"EEX5FL(M?!Z3)=O;-NT=UX`#SMZ0,
M)9I%E?.RD1-$,>E\"'>H0>7"@D.5/H:RP=X<&"*4W-*B;T>3K;#<Q2;*6H*L
MKA!Q%295BEEOJ"9:$NB=KC3S7-?>P?\C)36Z94DG@`Y!E=4;3&H)LZY:!)$5
MEAKA).)*2D,1!\L!F]JVYT_V,KG1+6TZA/5'6($Q4&#/E-=`.V,-$I*[2B-H
MS>&NP&P=TK;%<`A6G&:C(HDGB4WF_YYFKR>!'P+#?5Y\B8MUV=,-6XH04P*%
MJ,\BC3RG$&A&*BP(@H.]LC(@GUH0X=4]TWV"_._=MM]V;1*(&23*466!)E81
MPY>]GK/6[FYC>MZ_\:!JUR3MC5G];*K=S#P_ZB*"4A!(R;EC7`/,.!>N"DV\
MYJ+M(L+&8^ZAD;!#T`?SF?/5,_M0E#UE9H_9@OU,?AW/5B#N[I-L$K]QCTO[
MQB+ID#38EDLO`C*#L:$5S)ZW?^!J+^<(@_K!/LVP0V+.^U17S%S76D0<X%@`
M:@D2`&EMO%,5)DR0P2Y][C^*W#$Q.[3"SEUF^;NS^\4U2DDQ2B=K]X5LW%9$
MA?96&X490(@RQ82I5LN\@Z)M4F4OWTO9"X?9@15VE\"K$/0!VXMXG)Q=SX_&
M5.%Q[91GFV8CSYQU'++092'U`@"B0[BC/-1,6@[:#NZ;/^-R,!YT0',,YDH_
M)/</Q>BV]/RO>E^=ZUQ7-[+82:_"-VLCB`CSN-!5JTY*L&[K*IN?%Y1S^F7)
M3;EUYR`(V#7JNV;9//9H2;-YY0@!##`2&%$AI>.:*5DM_'G#0=L=&>+?/.L0
M]B&(=E[DU^GT?3Y91ZAOA2)NN0S=PPE,F%8((6!9I0'%%+0DCOSKCH^MP?UW
M?OI;`A013LM71[VE!A#./"5VF:42MNVF=`C:Y09==D`N;6CK_*CI:8VMXJX\
MLD@%)XHQNUS%\B#X_+8<;+E(<B@<[!#S/=@#/SF[+I]G]^/\RV1O]L$O)=IL
M^_NK:A$P%(1(1F%`H!!,6\V%PHA`)$SX<4?7.Y0O4P=1PT#[F`9<]==/D_(M
MP+/03^+R%E\UFJ:/\XM%ZO7?O+%(0HT8<1H9$B8:E!C#Y`(5JZ0?;&U_X!>U
MMJ#'RQ1"WYCO8Z0MO44TS#\YD51;PYSW?*&!8\@=U#G>/@W\=KB]&<)#<$1=
M_=_#9'[)^,?\0Q)BJ5$Z3@(Z8;#-[Y)2ZH]Y=[ZLCZ^+M)4\#/74!#2%@,;;
M,,>M4*6H[27*>[GS=D#>[H&MAN@!-@E6'J4SZX>?Q\F,!MF5NBOG&W_6+9HV
MJ1YY0:GU81;B5(@:D6<<J$IKYQ0[),^Z6]KDO5MG&$[.C3J'[&/\Y)[*Q=Y$
M)UERO?96YYJ:D="$2J@PUX8A)BTQDBUT]1JU?LY[#W<1[QD/NS3+('FXC7>/
MK-Z:@,(\F9HP"6?"(80I%K0:?;Q3YJ#.-^P5Y3JQQR!'.9]&20`F?EITAMD"
M[4KA5\"TAI!;M1LQ:C`+/9)QJ1V53%..*YPX5&T/_37?V#3@>M5>\79(LPTR
MPWH6:BSOLLQN3#Z9KF/ONFI1&<A[1L(\TG(*H4.$FTI+(UNOB>WE_J:](F>'
M5AF">Y^R(HG'Y051_XC3K(3J+#O-'I,%GFOH5U,SLI`3)[QB7BIH.8`A3JET
M11JT=8_-=RW]5=UCMX;9S1&W)2XFOD^G\;A!XJAY(Y&7H%RZEH98Z#VC4%)2
M(>!)ZYN?-KX!_2_G''NST6Y86KU@'V!-TL>:ZXN:5"_?WF!8`J2Y<UY[CQV`
ME=9,Z_[30#O=`[4]&6KYMC7FNV%:Z;^S8.KU\YFU]2)I'%),*(V@I4Q:)#A?
M!K[.]_]6UZ%SJSW8ZTGUQL/AKP58/#2]5'7]N\Z;-Q(1C9QR)@2MCEBFK1$.
M+$,'W_K4Q%ZF:GJD4._([RAH*Q]"+[=;S?5H]JKX)LU$2A'@C1&((D`9DLS9
M)=`V!+6]IUQVN--S``?6&?([Y-^WL'4R2=9.8)LU$`$GG'0<AK^0@%1IJI?I
M4*EAV_.+>[DM?=\G"]O;9Y`S9(U7X#O9TQ49X!676I+@!FQ`5P&^6)V4P'#=
MEJ%[^.S<@'L;>L-_APR<9X$ZVEVXIK$HP#U;KS18\("`I8"*"A'!2-MQ>B_W
MVPRYN[`[S`?971A_70PE:O2OA[1(@CJA^TR_GH_C;*JRJW)#]GU99-WNP\:-
M1-AR`SC22G.MA%+(6%8AP/0`%P(-.%+W29"7NQ/[LL!../A;7'Q.9D=#+I(0
MY]8-PXWJ1]A0'?R_L()C*X220.HEM+3UDYI[F5K9)?,Z`'^@;=6C)+F:5`?)
M0Q_Y+9Z6\GX]N]Z4@)NV%1F-`\1,.1Y0AI0`2E"%!S;U[UEV%@[V/DD>DHH]
MFV%(7^CSXKQ('M/\83+K5_,G,QLXP=45(Z@X"9V.&&V84<*'"9BL-'4$M3T5
MT'8CS,>#XEV7T.]DP#T-ELUNTM`Y:C,RM74C@PAUT#)DRZ>4)0.<DTI?(%#;
M*[2;;VOYBPRT6P*_7W/<3N:V40#382PYI-Y0#R!QE%<(<(+;SFDWOX5G5UF6
M/HC7&_X[9.!RSU<7698UC44HZ,T9P5)BQ!T3R!.W!%WZ@[KT<<@L2W>8#SW9
M^)#<+SSYV?7[-$O*D]W!BFO/@S2J'PD$0Q=7A@E,F5=:0(0KO3VS;0?>/;P+
MO$]2K)E4=`7]X//;#:]JK*T;A0D\0=AYC8&5_\_>E3:YK5O9?S3!OGS$FG*-
MM_)SDII/*+G%;C-1BQZIY6?/KQ]0$MEVMQ:2(D%*255>16H3%.[!`7`O<!=%
MJ,*JMN>]3^"G,GZPYM!DZP/X:05^'$"LE\"/`^\-@E'MD2T#L(P'3BL@?'W*
M:7#7:.))[KL)"9IR4,8X!?QP_YQHTA2K;\4JJC1_6S;>G$^^(SA*N%6$>:89
MMLAKPG:[!!%"^\X!'Q-TC1EKS>P1_L2G?<\)`*-2\9RZJ-F)WY'&P5I/RY@5
MJ#2RG%K,ZKL>Z*'Y=SB*&81R?2,_+4NX%PLX6"V8]XH;[Z-F(F"T^)X1L'SX
MV**QSV*&8-Y@^"=)GA=[KI;S\O_*Z^CO<;&.DVB7Z/2E(]D)#K9Y3;#2,F&A
M%(A2+;UQ4-D*!4<[%]UHO^4.SL)!3E\&Q'H\QJDXAU:KGW&ZG$N\W:A]P!@K
M9+6&F!FJL1&HMLF@473X739Q?:&$3+L,ZMNA&*7`0JBHU-PX``PITY_6<J.N
MED/KS31-BM`1"=8.Z"0I7#;?OBVV:,P6%1IOEO?%ZG$WF@U2;S9[0UG"-1KD
M7DO!RTFEG*DOJJ%WN"O))AER.PC%A@$ZU2I6]K8,+(D?G^_VEO,#NJ7-UW>+
M8KU990W8=^FK@V`&:*7*<"I!H07*^'I*6F^ZNLY/,NU:[PPZL`@F'(PD=NU.
ME`^KCU'OV7_YQ?W&YS^R^<Y!8N\W,8<GV-KA;4%B1ZAR'EG/D#4$<@8K3*3E
M76V,"=Z[I://@6)`PP[++U0=,<?W/G0E_FNIJA2/\2>_Q@;Y]^PYNFO<]-^[
M?M1];I;TXU"+X`F`7"&(L(2:08B5VQ<UP5PC?=999R!U*^J%ZT_9]VRY*8/J
M3JE5OS\9F"-10S3(1,7!1.K)J#A4\@!,.N?QG^(^=?&8OM2<+L(RB894)H<J
M`REV*1^;N`L=:Q*4=5`89($&S'"/$5"NDDX9W-49=Y*WYWTSI2=04U'FP_U?
MBV*^_J-8G'*X>/%D8`"6WG,(`Q--$>)Q-$LK60QA76^O)[F47#Z@!QC2'<PD
M)GVVK7.SC4\HHQ+BY[WTI[:;HXT"X("+\BK!@FBN0L\)K"04FG6NRC;)]:1W
MNO2&:PKF?(H#%7^G/,BR<;=<%-N8OO/D.=DN4$$$L!9X`12S4``)225G5)EO
MREFF=_[T"6T*"OTU6T8;8U&F3Y\_YLN\%#]:;-EY$IUI&;"2`D5S3@B"8/S/
M$R(K62WL7$RM]5W;5=*H7W!3$.GW+*HM0HA.-PR($<J`Y5X"9&W\@HRO)*4:
M=+6C)ID6MW<:]8KM&'95"WLJ`&,1]3;"3BC66!.)Z_V90GE#X3Z#*,D78)F"
M&74:E^>CKQ/D./!T\(!Z*JRW*)J8`A%#G:AD,AP-7Q7[>OEQ.9QI\HM5*9-W
MW6Q0./98D^"]T]Q`3SRA1AI&F=.5=-*0KIE))JD$]WTHTQ.H:2BSZ]IY=??%
MDT$Y)Z@S0"J*XPS03FM3:V!<I@ZAOS*"7()E&EY4ZUSI2&Z*95S\-G']>[Z1
MT=E]L<KJVC_9^EV^+%;;VL8[X>+Z^_M;=L5LWV5/7TMON28)^Q/V(F`-K0/8
M*^2I=%@`8^KE'#+2-8]U:SU[^-VQ?S9/=932S90VY<R.U<O2")<9<Z-:PB4!
MS`)<6R,6:7A3Y2>&X>"EF":*L6I5P)9`[*-"J;@QF#*(&6*TDH!#UE41FZ#6
MWC<G.H.8*/[D><533T^K_,MFFX_I<U$Z=,1%-"*WV%H<9Y7XUN\*4E)&H'`>
M21+-6V:@A7L\G*.F:SF1268([IM60Z.=G'U-F14H,C1.&^8A4]8RHYFJ#EU=
M&;O:D37R]I>B2W!,$K4^6RTC8\M0EFW\<@-WCF--`O&J#,7GS"#)O.?&ZYKM
MG'3.[0S!O\/104^HCL$9/5OG=RT(LWT^8.X@A8HP*H2U<354SM=K(^Y<DG*2
MOAV7#^X9MG2!=`RJV'RQ>3J9<^5(BV!%.7V(8`!CJJ&$L/:$<T9"WY$ND_3M
M&)PNW4!-09A_9/G#U]@U%7&>/63OMR[$'^ZWO5Y_V#RMGV;+>>FF<GZ?:ONJ
M0!4694H.[+W&G,=/J#JD=4+;SO[KDUR2^MZ_!D9[2MP[M]^U>D_@1G!G&?6$
M>PLM5M14GC&.B,Y1LY,DW7`DZ<C&+D,P(A7WZ_8K,=J3\=B;@L)6>J4,`0Y3
M:R'EH#HP<5IU-O4FN<^.3<>>!B&->\JK&)QHVGZX_SS[<=)3Y6BK((FU!A-`
M'2,4.RJIJ@[TG8>R<P6,UDQ+4B"M9]__OF!-$NUEB_AOV:[\QO)I>_E31W+^
MWIVSL5M'RDN>^H43FF+CM@$BZH"6!!"+"8W;A">>"8$YX\1`?_;.^]2D7&=W
M__50?/_+/,MW\S%^>#D-XY_"KG>?LH>M3^3RZ?WL\="U_;%'@];<"<6H5,Q!
M@15C`%0R<(JZ'OU.*#QS@/$L>@6U^4K=CA0FRKN:+=[$N?/CO[.?)UGQXMD@
M&2!1"J6MIXHRJKE@M02&)$MA>MVTN`S5_GE1B?LYOO\('7Y])%"+N7442Z*(
M4T1R*EW57^0Z9XR?4"&685EP`9C##?['*DN-C9K'&1;\]FP`B#ECC(H;K>1>
M"XU-#0%$(EVZL"NGPR6H]L\+%;LT+[OE%[-#-N.K9P)0935*(*%TL9>`<PQL
MU6,/25<>M/>-NE(>7(+F<.N"S]=WL\7_9+.5CW\Y=`U\XND@X\+F(53*"FT@
MEDIY7DG!F.E:0*Y]M,&5<J(?7(=FQV[E:LZ/7YX/BB.$C*?8*HP95-9Z]<QS
ME<YSZ288TAW9_CEB=M76GZE[6KDX]GB0UD@O25P(M5%:2D1PK1XC;KKZD#=W
M0[IRAO0$[%#VJ,\7V<K$_CP4J]/6Z&]/!@J$0Y)QH8'SCAAG44UO!TU7*Z2]
MG]&5TN)R3`<[H7C."=[D]J)9PV`T--Q(HY&37'%,C)&U0LU95Z>`]AY'UTV8
M'C%.<J!<N3.4/G652T/+@^3I><]A;IBFR&#"K76.(2%WOAC424K@V2#--!)^
MCLCJQ>F"#$?;!*$11\K+:`"3[:U'^74GH]*N^WR=XN7BY0-]QHFG*ZRC35&;
M/<WRQ?KZ9RJ(8T:D97&XD%!28EH-(,,*G65QPTNM3]E=L;S+%_D^B<'[N`6L
MRE=M,ZPLB\=\N?UVYGZKY6N"9L)@Z!F*5H8H,XL[["OI/'0WE6;V\B$NDB%]
M6C,[PJ'G+IQAR:L'`Y,0:TM*7W4,830S)955[Z`P-[%6#SML18_X3C<VQ!)D
ME7&,.&=]A`0)HRHYA/2=_3@FIH)?,(`G0T+:P==I$6BQ61SD.[7$QVXY`*1G
MJJS7(^JUD/&;\+Q.MQ!<CO#MNL)ZXZ+@T=KD3%HD-"ZSNN]Q(`S<C(?*)12X
MR-&U'<"C$>V87Z2:_W.SRP?0EG+GWQBD)C9:4%QPYI&TQ#@)*VR<U5VK?DS.
M#V9H\O4.]6W[6V-NH3:8(,J%T99S+2K;G5D,NKI?M7>\&2RT-M6:UQ/$8Q^/
ME,<ZF]GB]TY=X2D)E-XA:&&<Y1PQ#:44>(\Z%H"=#21HJ-P>.A6+\)U3=,\T
M"UQ9CSTF$!CAH/,<85;U7D)^4T4,+A_"8C!D4RS^:OF4S\O%(_^>_9'=;5;;
MJBWNQ]UB$Z?<+K71X[?-T]XL>`778[$YJ9'T\OX0P6<>$!\W2!/!DT136..&
M2#+E>'`SK#<"O4P).\(PC+:9?"[SDES_43M"''-I#->06T"H(K(RL06&YV,6
MAI'PC[NOV7Q3EE@_&(=?'A?L=)'M*#2Y,NOXQ@#*ZE$0":`1==Q[)U5U!B4D
M]<E*;HVZ334FR<N*!TE`3[($_))A;Y0Y7_]^JY*()UH%;1SC4?E@F#LCN01<
M[1V9)(UK[T415[W*V61ZGVH6!',"4`N,I4)XIZ))K"M)#>\>"#G%.=S+B!_+
M`'@YN*GGZ@1,O@%F+C?$$B6)<A1)8*2O'<Z@4JIU/;LCAM\O,#:T^8ZWB'TF
MC'+KA?&""(4!D)7;)*3$=8UZO[XYV'3LBB%P36'LV?UP/&<,+37_K>_;AV_;
MG+7N1[:ZR]<GLQ2U>$NPE@*AC',((XZBC>")J3"(_[N)1%>]\:!(A7.BI?Y[
M?$&QRD=3RW:__[/EXGZT5="2$&GC`&*O<%1].13[_91!"?399-G)Y&RFEAUO
M%J(A$2T)XZU@%G'CB9>VDC02JFO1C$E-VUY'_$`MA)[`33U7QW14['_*&N`T
M5A8[;3UFC"++K(+&E"E'$;=GC[('EK-TAWG*'M?;#"9E$;G5]TPMGK+5<EOW
MJXWP#5\5#7A($9&0"D4\(YIIZ2I$),0W<93:*S..3>UA`$^A!M8B?)K]^6X6
M>YS/%K^)<;HZQ;G&P6CBO2=:*88(@!8SSRJ),;FM[*;#T>$8[_K"/2G3?%G-
M\&LVWU;D;4VUXZV#!4A1`>+<+2TV%]5LSBN9A0`W5D8[-==Z`SXIV6)'&^Z8
M05H,A!646<*%Q\KCLN+=3@J`.M\A3,@#93SRM,=W)%UWW"/(OE5>!RUW#C`"
MB:"2$8;T_KB!.:3.QQ$W/H*L86Q\!'FL14!*>(<U<U)Q$LTL9BBL^JQ1YY#X
M:6L,EXQ=,02NG1SL:W'^^)HM[M_F]X?R(1QY,K#8.V$THG%%,98R![&K^L=-
MYU1+4W-Z[F.$#HUX9R0O&VFW7QJ;C_BK%@%):K;.V`0"&+<&#S6N^AO_E"S5
M[K6._*6()E7(_CY;;+8CU4;I?]4H..8Y9"!J(L`X+Z.(%-4<MZAKMO!)56?M
MFS6]PYI:1QO1F:M_W4P@QYU"-MI+A$LD,>/[.<JUE>?UG*%=NNJ^[W/L=/#A
M.OV*(!%'#D)`B:4&(^2MJ]+`E<O5367\[X4)1_VV>@4ZR:Q^-UO]*]L6C7MV
M01UM8N]KJ]KLRS:SS+;RZG.W&L[S9B\)VF+%`:;:.6DDQ9;1?:)DR3"RK4VR
MWE%XL]R+\#Q$KX19SDVVBO;R\O-JMHUI6J^S*'KK2\<A?C(@B"&7RH&H_GAK
ML$+<50A[W[DN]V27E;Z)=[26^ZCC--JJ-/8E:,K%26H8S09HL+$*>T`IK5Q'
M!.5:C)1[R<_R5:FJ9CLN10'>YK,O^6+;]W?9K*35_$-48J,\JY)RR_G[8KFJ
MOI9.S#O5\01(O?U&\)!CBEE9=DX8%?5S&DWP/894\ZYEU"=TCC$DL8II#$L*
MD[B63?_<2[+-=;K*_G>3+>]^JA_Y*=NX0>L0I12(<H0=4Z#,HDN`JV2V]+SO
M^/50<02>'&-J;^.1E(.'^FR+Q[B/-^'@\=8!$(0DC1J&X<*8./<58[7,$B5S
M'TO(P3X8<(Q=O2&=E%UOEM\V3^NWV?=L`=]EI?;5A%6O6P5/C"+.8@VY=YYR
MBPRJ9&1:WE2<5Z]C?HQ/%V,\%H]0)Q[M6P5CF5`01DM(2:^8X0S*6D9";ZJZ
M7VH>=<,X!8_>S?Y9K,K*-.L/]\<TUM-:5\,W!.<9\`P![R#PU$E",*FU""&[
M)H^<T)76=#2O8<9D(GP\JX,U?D=P6AE)##0,6<DY+J-V*_D!D<E<,8?G9.^,
M:,^X3IAWNHK_V_KS:CO-?KXOGK8'<+I8SM?/73FZ4;9I'IBRP"CH,1:`4XPT
M`+R21(C;NJP98'R+P2%/LF`5JZ>'V4.F9W?_RN;/'7ZS7F^RN?[Y<95_GSUE
M;AGG^+=5OCY!ODM?&32S#)1!FDH+0STN<UM5Z!!!DN6INVY")AZ&)&F,'DK%
MML'Z=[I!L(P0H9WPY5PSR&$`JMV!"2ZZ1L=,RL4D'<%Z`;G3!OFVF"T_%L7B
MS$;XXK$`G9:N[`01G&G`#%6H[IFS70]/6Y=^O.[A[P':)!O;9IG?Y=]FB^U.
M?'[3.O!X4,ANB\,8ID!9]A8"5U/91+0Z$J9UC<CK)DR/$"<]FKK`_'V;+[-M
M&,;`]Y/U[P0,D66..DJ]LX18).OC'F:AZ:H[3:C*\72.)\8<N23JUE:L6LI6
M_I%GVP8M./><.P\9E$I)#DV%.HO64++;]*0'M6F9\E)1ZWE,4G!P[VOTVI7P
M`.=>/1L`%A$2BR410&E/RHBV2IZXT=Q4C'*/HUOTB^MH#EXC>Y6G].\20$-E
MF4<4>J(Q=UQ65S**-3@"3J)#M=F5FSB:]O'ZH+%`WE$HH_Z*'91&8%LA9XR_
MN509?1/JM%*48DR2K"_OLS\_KHKYYNYIG`5%;]91`5BO3?'XI:PR4&8&:["$
MG&H6#&3*:\V=9)(J[RGP8A\]P+FV9^O<)Y.TG?]YLQ=$-8HB0Z0UT`HBN+&J
M8CCG4;.Z@5H\_9*@2(!RZJE\2!^/?]L\9O,QO<.'F.P"0.8EXQX"@QD!!IG]
MG1/3Q)N1-(3G2*>J\^HN;DGK?-MY_?.7;^<<O=N^*BAM`4)`"6<`T)&@CE9Q
M^-KXSL=ZU[8`-";&T2"U0?!.85T>Z/@9-Z$C+4(TJBP@$;FHK3COO1!:5+(!
M3I+5$AV>2\,-^Y$-YC*HQZ)1^7&596>]?,ZV#<#%W5EQ1IB5F"I3PEC)*QV[
MP66J\X@W8-`EV':ZI/S[K+Q5+Q:G[RA_?RI(KIVSC`OM%$7(05%G#]6<=DYX
M=B5CWG&,BK[P'&G-:');=*I9H-%8YDX1:^*L<-!3PJM$MEI[VM6BF:!OZIB;
M4%>\4[+J%T6OK/G[L,S_+YN_F4=D\_N\!&1O^.QFVOR@`?0F&CKW^3)_RM[F
MW\NO3[/E0UZW;6>'#-6+8*R+FBN4'@I>>IM$6Y968P"5/!MU?]4K90<JGK?B
M)S)4US==]IDZDDV,_>\%7I9],4`+KTG<W#`5K,+5`"5O:-F_@BG0;5"NC>RF
MB$\O'V*;ZM]2T?[`+P?('+("4PL$!UQ@CT"5%,T0K+N6,FWN]")W$V"9/<S*
M8FK_F0>7CU(G6ZNC"+/3(L1/ZSPR8E<V\\LB?]B=H!VSY=+V(D"N',84`DN)
MTQB6@<<5KDAWSO7?W)WUJMD__1&;\-Y09@S_,U\L#JX!IQ-T#_2+@3DJ.$,4
M(&LH@(`:XRML'79=[8'6OKK#Y_J>TB;0\["DO@;\]>-LM=JF2+^U^S_D(9``
M1;.+V;+`M*;`*400B+:8M^?KO=_>_9_A%BMM!`(.:ZDL@ECL$?'4_W][U];<
M-HZL?]+!_5)U7G"=2IV9.)5D=A]9&HNV52N3+DG.3O;7GZ8DRG9BB1)(D92R
M#Y/RV"")_OH#NM%H--`5A@[:$:/M_M]I>/=A]CY/P%`W[/CMVF2"4F,"\MYB
MK8D+@G-9]S]*GII;/T*^G$^U93?@]D:.Q@-#KUIE"D2')3\FDF+C%.+4N%H&
M%*^I0%R"WM[3?!)NO9P:FQ6SQ^?'YN-BK]MEEA.@NZ5>(D(M10R`J>60[IJ2
M`)*T]^,YL!;8]5/#X^_C./"Z7>8E%5%*!,(@X45D%MM:#DQ]ZAPPPF!L)QQH
M@=UE)0C92+C"BFG$HF8R,.WBSD+JF'H4982\Z,UYZ`;JRT\0X@K!J`O>,1X#
M<T%*OYLZ@^17<+].9QH_.4'H-&R3@M8WC_GM?/)8_OUI\J_#24(_M\P$F$W)
MC<><2:6<QS[N^J?3K[:[$-TGZJKL$M/^DL)4Q%8I<(Z$1,QIRP1CFWXY<)?H
M%9F0,^FZ%9Z7FA0FE'-`8ZF<X4Q13@F3M90"B=0HUP@K`@SI>*3BW=4VYY]/
M@$>Q^C3Y7IWN.V%G\NV#L`Q#UEI<W27LD#?"^*J$RZ;W6KOK3C9.4&+#+F(K
M=+OBAKF_7ZSW9M_VYI3]ZWVOR!SE&!9[V%27K).@N2"HE@AFXL8CA!=MD[KG
M2T<X=Y8\47Z?S*N=O/5:O[S;=N?F6[[X;5$NEY\6Y=ULM?R4+VXK)=[OO2.R
MBW=GA`AL9/35>6!!M0]1[D:/E>3\:3[7Q;5S*Z`/A^G+9`[]S[_EQ7-^.-_@
MAY89T5$8(XW6.C#+A7-1U;)(@U,-W2B+P'5*IVX`[7N'?\!2(.?8S)<*W-,@
M&->1.UBA:B^W%X0JQ4SSUO7PF_DG73=Y_.LRC(33QBE+I05B2R;,]JR8TBK$
M*W1@VQ&DQ:9^(N:]#/V;Q?VDF/UGH\9BNBXR<G/WZ=5[!YD+7G>K2@\LY[-I
MW<?7G;NYBZ#2XG8VF7^!WZQO=CAFTNCD_1DW1LA`L6!>$JL]3.3;F@U">BD:
M,TI'B-UI%42Z_E1&K==!<:159-P:&CVJSQ\JS]%5%;OKF8/EJ%0WDLGM$XA]
M.]3%NY<QR7G%'0Y!BL"BU=:)*(/!,EB!B,%HH.)'X+*:V]OR>9U##LYK`3_>
M;GJ^UNGWS;_'3&*GOBK3.F+LO7%,<1Y@+5"5`,.6Z6@QQ\WEH"['=>J9066O
MBNECW?WG$CS$L%S-'@&50UL3;QMFR$D;'8')W%LK3`R:T1JRR)-/:HWR:H=A
M2=8*^%Y"-_E])>GG_*E<K`?"B=/;4<]7M7(U`]DEB`O"1B(LJ>46V*9>;C/*
MJQZ&)=PY]-&+-[6-80WC*_V(VA'NS[Y',DYB8)9&I)DRUBBIS+:0%_5:Z,:K
M#_N1\+25V!%/9P:%@!1Q`1%8+&A*HS6UW,3Z5*,RRL55>^4W#-OV`/<Z:(<\
MI=7EV#6>1>*%EUQ+YV)0CGJ8%X5'*B`J!P_H!G!65]__.9OF'XJ[$E2Q.1FX
M5D($E@:`?%%,YNYYN2H?P8&O+I;:UM@LIE_RQ;?9[;8@]U$1WPZ_EREGO.?"
M1\$4EL8)3FV-+:?QBLYYM:?7WG#P<`KIPQG==O5FL>UH0Y+W>\TS"HXU5@1;
MS`B.7"`3Z%:JJ)7JS0SUF6@U""O*SI71(\5>R]V8^[WWF4P''25QT3A*5'#"
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MA(9EB.+($AXQ9;'N(24A-:E,_`*Z;@]G'XNS4]>QOQ]Q*BOYG9E'""N.)3(`
M-Q=5RK^M\?%"7=&ABG%%$OK2V`"9\<?$IM]_(I.8D"`X9DHB6UWZ'(W>RB8"
ML;UEU/8Q^?7`@,-I](FH)QG%W?C9SXUWVV66>$*]`U=,4&48O%G4+K?`FEX5
M(UKKI^P.R7&?J&',!D)D$`)YZ#NKDL&WLL@8DBN<C(H5+;78<(3F-`2'V&>M
M]H2?)_.W';G`[58E"&<!26TD5XYY1KQ8IZ%PKZ@,C>'S_VZW[O>^B`4LO0T,
M.ZO!NZ^.KM;8"L5ZFP<&W&X]FEZ];+>>II#>2BL>77=34PO&E9.HHK$H:FJT
MK_LON4_-X1LCH8;5_][BG*=IH#<&G52<4PJ0GGMG:>1>DU`9ZEH&L+A7=#`P
M06\'BG.>AMMX"S,B%E15Z0=AHCB5GLFPDT-J=$75>Y.T=[`PXVG8]<&!K_"E
MFSNS6%2R5D:XP9J\VS[34H2J]K7@DF$>B91.U7(IE5PY[Y<)M*5:EBZTT0?+
M7O6P$OYC64Q>?O,5?EJ"MU<=C&Z<BTY\4X8YBT)Q+3D/R&LKB8F[<>OQ%?D\
M+;E0]HES4ICM8W4:8PZ<*#<72[SJ8D4[5S["**L.8]0G.N\7^?JO_YRM'K["
MJV&@KH=D]<?)_--DL2I`*X=WL<[ZT8R`Y8@D"`RK&^R04RK(&C5.U155G3P;
MG\J1*BN)XG_,YCE8BP*\CM5#.8W/J^=%OK4IG_/;?/:TNKG[G-\_SRLB?/]8
MKL"&W!3FZ6E1?ILTY%5T\O+,6BDQN+S@#B-8@1,LUFDB%0K:,9I:FWV$IKX7
MR@ZAE,ZI65=7LY-E/KTIOE97-@%BIBB>811MG)YUC#:=H"=^(I,*$^^)<RQ0
M1ZB@V-L71.P55>L<G*;G5<VEG%K07&CFM8QT760#.13KI9W6'J>FJ8V0<.-:
M`G6@C,L[M:"<<`9K%3T3!C"C&+\,(:VNZ(*<=NH]^M3":8"VR1+8I=+_EH-O
M.;L];!(//I1Q;'6@G*&HH_64"$_J,:,E8E=T(*\#S;V3/]`)K+]>6IU31FMI
M&6?,:D-]"&P'.6!V_HMR?U%3UY?&DJ:W.L%AF]G0E`NUIWEF*/68$D>EDXX+
M1[4-=4]YP+W53AIWDMS1^BP[ASPM=+?.BRGOMD.B$F1WY>W>R-N!9S++C&31
M4X8"Q<9B!V/*8.@_YDIAU5BB8_R6KQN5E><!M.\$NNI:Y.7Q671U\\PXAI%D
M)&`MB$8*I`DOSH%-W:L<4;"J4YITB&4;&[(AZLW=+CR[K.*S[X9F8[GX*:K[
MH7C3](_)XE_Y_DL:SOG-C.$0!,46(<*H%"[J4,=:-.,ZE7\C"@IT/TV-2"$]
M!09N\WRZK`Q^->YN[J#CD^)^MKL;_G"$H.'AS!F%,7@)3$D0/`87>;U6-MS+
M5(=J5/7YSS()=HYMFRGQ<WY;WA?K<N&'0K%ALBCRZ9]/U35?#[/\VZRXWS5O
MF``[^$(6M/&1&H^PAQ^D(SC6H\O`CS:1:R<?Y;S`Z:Y_^'M->Q_PVHA.*P,B
M[;SD!'M*P'(X'<BV.)R(2I!&>WXAZ>XGW2G1\3<S9F-TTBNKJ6`N"$U\7;`\
M5L&2:XH`M"?:N1/?$]72R^3R!?X_?RCGH-]E@'7LZCOTW.=_K4Z<9_:8WC>O
M;(IGO=LXB_!2:1"36%"F,0+4M@4?E911-=:A.=-\L0*%OL'M8[G*3ZPG>NP[
M,FTDDLCIB)ARVG$*%JG&`)C46P;>V1W0EA3X<22?">!A1^;FOY12H^<;I)0)
M8X1&W%&,"#8(8VY(H(JC*AS?F(1WGD%:A>=N[ARP>[:*D]O9''K>=`YM[S-9
MD$2OZ]A*S`E'$FOLMC+"/]>0M-^%@LOSP-E'&*$2^$,!`C]O'(II_OBTOL`D
M7\S*:4-"2_/#&3865KO"PX*",8NPHC'4$C-*4_?\1D2@#K5>GAG>X0G5F+MR
MS.,9>+CP<<&P(DPBI&&UC+=2@Z]I4\OTC9!475+@)'8E(9U6_.O-B(FSN]6#
M>5S;=)B//^?+ZH:$Z>_EY"7K^N6'YWM8A<`K<4/EL.X^D85("5:::\\$=9@H
M0GV-"+'NBB[IZ98@Y2CTT<<,^)XA:#"D^Q[)9+0R8*LH0SYH+Y"SJ):.T^;`
MT?@W(L]G/CL"=2C*_%X-B$6CP6QZ-#,1$TT#QT)SX7C`!DQ%/4*QOZ*S0NT5
M?@2#6F";9!Z_/!=?%S#EV4G14,_XYY99"-QIQJ03Q#F/&(F&[02WR=/'A>@^
M355EEY#V[W&?M&1;CPZ&9*1.*A<9(Y1(39&N)1+&I=:+&5&R05]+M`0X^R?(
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M93`]HR"PPKI&`<,*];KW!\Y#M8[`3HKVGM*?*IO["VAN>;<IU`+/Y8L5N`.N
M+*;KC/"]AY<Z_DQFN&3$<_`T!'@)5@:#9(V,\"(U]_9"0HCI-!R!,OH/0*X/
M6.7+U>?)*O^RWNJ%*?VV4O]]7OUN4SYU5E0`'!VB/.6E&>'<6>R\E)CQ8$F4
MRM8($4RNZ&JX\\R:O4$_5G)N1F?'Y-R\-"-*16:)I#@R'R(U8%QJA(QWJ>2\
MD-7(,.1,@GXHG_*U2&:U<8=#<>JJ9<];,HU5!%^:2DDIYSH:I'9^M8/E82+]
M3KYJ[U+I=SZLA^+;G\7S,I_6'DAU8GJVJH96S/.7L70B^XYZ9T:KFJG!:1N$
M5E8@QN+.6#`L22(7Y:_,Q7,@/^S9D)__,+:3(EIQ0:/#P1!N!'-1NBJZ[ZB/
M`04]^&U':P3793B!#T]YL=R.F)<"H?;[2YMMW4[S[\EB>OP-1RV_D4EGG?+2
M>,21U$X3H>06PRAY\A6P(PJJ=4&@O<<Z^X6_ESH_E3=7]7(#6256652"-&Q*
M'WPN8X1:!^-?4,H0TC+HR@W<R*FHN:+2B`-PXZ>CBMUIHI=JBF^[V;BW_6[[
M#,'2PHD@3!0LJ&"")K:6"V3M[9QZ#PSK1K\_5C/L`-5>$B'`M2J+]7'<QLWM
MG]I6]V_0X&PPE$BKD,!"LEH>$DUOE7I[J6?83J,_YD&TQ+(/;GR=K3:%@::S
M;[-I50NFX?:D]]IG5%NOL*?*8L^DUUC86,ME-$D]!C?"S9_A;547&AB$657U
ML\_Y?`W3\F'V]+7<5/AHM%XGOBD+3C*IHR3.R.C!/T5<U%@$XQH7.9=CUUIR
MH8E9G>*<M`L9'I_FY?=\__V.[[3*@K$L4"4ILX09&R0.N.X7]<DU,R]!_UUI
MK.P*W5[V36:+_!94V.C<O&V8&<7`$B-)3$"(4*:K\;&5Q-IX11<!G9LGG0#<
M!U4V]A<^U^#FO&F7\<BM8]I8&@/6C+H8=@L$Y&VJ01EA4L'P[DT;Y'L)]B3C
M\B)9,?TTGQ1''7\ZQ^<R3YW&B(5(454#F7!8S^P<!*NN**L]D4T_AH>&5T(_
M"?'+U6)VN\JGQ\4*WFV?*4.<%0C\SD@)LPXF`+);+3-^1=[WL+3X*8&^O3)&
M,7_NPVRW"=EFMFQ\>68"P2P2+$F0VC,#/LPN1.,53\TZ&&%&UO"VOG=UI=4]
M^&E7]\@;8AH?S!3S5@9G+>,B,(:MB[SNO4,D-:U@E+'5/I5=GE$+_>PHPA3^
M.7]Z7MP^`!R?%N7]8O)HGE</Y6+VGWQJ'LOGXF#]YZ->D%%`,EI:!;8%#%RA
M0O1KR6&])G'L[1*:LU<V[9`$[U4Y[1KI`3@V]<^+67&_20E;PW5XZ[KIX<R;
M&(FVEGLB,-/2&2]JB1WXX)<?7>F76>TQ'II5_YC,GP^FZ#0]FYEHG316HV@B
M<BP8:^QN%#%_!8&8`3F5`O&H5PP;Z%XRL)<WJX=\\?5A4MRLRP<N?X-7K)8?
MF@];]M6%+`9F@G."6,T96`J*M=X-:*=3<\M&M/HX-\''J:E1CY/U/__(EZO=
M5(#/,1;>^4PFP$P)PSSWV`=+D).6UR@26$9>_A&3L?*]O3;ZX/3'LK@MBQ7@
M#*^^KT\O?"AN%SD(]'*QU:>U#NHQO&EU@,-M7INIJ*G1+%*K+!.!:%==7>HC
M0EB!"Y::$#6B<REGYFR/Z/?!T3]F!2SU7KIX\^_J2K^'V=/+*0;[?2/+`4J>
M\):,8L0YQ@0188BE%*R0-#A@YI1RE*4NK49T&N7,##P?V'T0;CN-+[^6V\MO
M7X;0E^>_EK/I;+*8Y=4E2.;N;C:?358'U_(IK\N\QH"\-2%ZI(Q0`(\!5*1"
MGBOJ4RO5J%^&@CV@GE;WH9P4U7VD][-O>3$KPM^P4`17`GZSQN+#<OE\(/YX
MZBLRXL%YIM@Q&;GP#`LIP8T.%K,@J4RNTJBOGD=G1KKI(-W__D_5^"^PU_`_
M_P]02P,$%`````@`>X@(1<;!&(5#"P``H&T``!$`'`!C<&EX+3(P,30P-C,P
M+GAS9%54"0`#.COE4SH[Y5-U>`L``00E#@``!#D!``#M76UOVS@2_G[`_0>=
MOUP+G&,[3KK7H.DBKPOCDCC(RW6_+6AI9!.52"U))?;]^AM2DBU9LF0ISM:%
M76RQLL1Y.#,/.1Q2I/KEUZGO62\@).7LM-4[Z+8L8#9W*!N?MIX?VV>/%X-!
MZ]>O?__;EW^TV[^?/]Q8E]P.?6#*NA!`%#C6*U43ZYL#\KOE"NY;W[CX3E_(
MORR7"Q^$-[.^P>B:>H@IV^T8RHJNIM(YD?8$?&(1I00=A0JN4>P27!)ZZK05
MLC]#XE&7@H.J>:!KSA1(/59$C$'=$1]D0&PX;4V4"DXZG=?7UP/4>82Z$.8$
M$R)\<F!SOW/8[1UU/_71:'0#DR=V0*?UI="P[QFIZ4AX!UR,L62WW]&/1T1"
M4IQQQD*_6,!1HJ-F`72P4!M+@:#V7*Y:*"N@"]`2Q2B3BC![KM@T9\AKWY3N
M??[\N6.>SHM*IZ@@PO8ZO]_>/!I&6TBP91F*J1]PH2R6H\8E<F1$0]D>$Q)H
MY_;;W5Z[WVM94<.XX391IGG&,L:*0L$.>$HF=]H+J`/4H65U:NHCN`=R0PH9
MK#=KI%G>E$8&JY%&92UIA3YY$?VKG<BU]:UV[_"-:BQZ6CTU$KF-J/&Y0X2M
MZ4;F;-6&:8#A@R@N9M?X>SW5/"$R*%<+$*WC9ZUC[]-;=#30#,8Z@*^O4UIJ
MLXK4<$PB\78%BJ/M.GJD)>\BP4VJTTR5-^B1YN38_'+69"0EH&L^KEFG!/M@
MS%\Z-@^9$K.U8UN17/*C45#+HH9"8!ID8`]KJ9,6G/]J+V`:*N0`K>V:1$9?
MO-TE,+4GM568"YFKMRM!V0M(55N-E%A\_795&*&V&8I[=3192$67[05`0STD
MM6MKD<CHBPUHH`)17X5$R%R5*4$8X\H@F7O)W2"@S.7Q+;RIQ_"39"!_`-<R
M^>I)/(J69[6=0/``A**87*6R=0,P$>">MO3$H)WD_7_8Q#O`/#@IDJL@FV*8
M\0I%[-`S9MPLE$P0=/P^;4GTMP>)\7^Y50ZX=:U"$<KH-AOED5%=HU`$O&VU
M)Q!0UQX4D3AI;M;V-,(3EK`H3O@NN(?.X0*A7N!L+,#,QF7+TJ6>'P;54V>C
MT"J8>=5)Y8OF]?6PU_UWK]NUVM8EE;;'92@`?V2@K`76E\XRP#)V*,$9LJ_F
M>ME#L71<I$QRJ5NO+YCM.<5R\=V$@G)F?)\J8_H9<RXX4Y2-,?7`9E6?G=50
M%0Q]+F1H#F=A;58&</=H8@XP%,<+R3WJZ(G4.?'T'/AQ`J#D,R.A0\VDK"YM
MZT.7T8@4XG^:QD?TM.E-AL48W4K#6S&^%55@?9A7\7'/[$KWWQ.<%*@)*(K*
MOR/-V7JJ.#_N]M[*N?4A4^6^#6A_S3TZ=*_^#*F:;;:'E\!7,'ZT=B]?%.&N
M%=6R[^JK>)!#]X+(R;7'7S<<S"NJJ*"[7Y]NJ?G6-5FFJCWG)80,,8DW:D9)
MDX\F3U``L](!0UKAALMW;`[U:J]H*8<-6\I"B3C12ZEA17I8'[0F'W>Y)25O
M3Y&H*\R$U6S`]&M2HUC==E&*5<9R=Y[DS5_FIBXU>Q&>E0+<-:*NB&#ZC;5N
ML?<@'M'W4)>@0HR*252_8!*5X"3]![$L`[8G1<`E*$*]VO/<,JA2BHZZ_:/N
MX=H461]BU)T+=24>?H*I"NO/?M9`K*:N7Y\Z*T;?4XA>>2(CK_ZR4@E2*67]
M;K]OIJ;K4A:![AQ348+U1*;UJ4F+5@Q.OQ0,3G%J9^1WV.MOBVRK@2H"VB]'
M^=Z19F0?PP;L!0W@HL%:>%JTHF<<%_:,N?@..[UA?E:`4-$5C@O2LA3*[B9B
M>5<VCE*K@*JIR:5=1=3L@Q3(9OE5'J`BK3HN2*LRE.QH(G5+Q'=LC&C[(]BA
MH*K!N%&(43&`'!8,(`L<:P&T)Z3QF%(&51'!#@L&ET)Z=G>8*?)NLV!6@E01
MU0X+HMH*FG8TOMW!Z[W@3FC7W[B3%BV/9O@G'\U0W$KD=]CK9U*"V5MS0\F(
M>J8UXKW0!Z=A6*L'7A[H>KV"0)=FSHJJ,&\)4I58<2V[&_Y2+*0OB8AVI[V=
MVS+4:E)S^7>&U,P/?);@[^E$AS0;Q/(`Y6-7KU<P=F5XV=4A:RC&A-'_&44P
MM)T32>70O4_959>;-1`KTO6B`2Z-:N*CP=7OQM/(>_:6?7W//=IDJVH-Y%(V
M]?&<?-=;CTWK0U+'SG7+!W@!%M:G;2Y7T<6."KI8(KNKOFZ812R+5TQVCPIR
MP`1B=S.")2<V7$-=@5+-2"Z!RS&RLZNGB2>:)6I+TA4K#$<%6=J"B1W-T,R[
M]PGW'!`RVB&,X_$EC%1=+E8#50P6GPH&BS38/Y.=RWHDUX![BF+/1G\;#2MK
M859$MD\%8TTI<3K<C=3'W1V'5GH]_V#3O*ZNH9KE7-2L8+GH\6ZP_J6S?,0Y
MOI,]"FT.0L>?1++(2"I!;'7:4B*$EFDH^NCH'V<V.LSA"FY!T]TRQ[E/6_G;
M5!^EU,=)(P`9(B)5H:[N-\'#X+1E/BAT0A7X+2LZ-AI]R^C$X3ZA;(`/M!4M
M*RH8@*#<>3(%G5#$$_5.7O>YKN>AI`RDO.#^B+)H7C<>"_/!D>?`%9RI>S*+
M#YU&=M03:6)C=,?G#!TF9LM&CJ+C4&B``(>J(MNCK]RHVJ8_@,W'.`,%9^!@
M6>I2K7N\PFMC?\`:2=%*[_R,I=+;]:D3[\L?CCPZCG;HEWCO?6O]N0C@,^)I
M"Q\(VL7=N"$-7T"@LE+>"^Y2I;<SVCJVC*',K0VP&O5([(Y!!%+6'YNZ)-NE
M2NS-%=PZYE=&S`OB.=SC(ALP<W=_7+Q<K;EQQ#6Q=<^<75-73<Y0P@$'Q^\'
MD/J\CG/#"9N?E%]<A.-0*OT=CB6S-PJYA3Z[!,9]:CZN=1:726PO?M2\(2,$
M!LAW,*'D'%#.IO7*;I^1R9;O^>;Q:*UCV;[J8EMHFA]X?`9+&5KN[A9VGLSD
M($?%BH?;1T!J]_6*9E5:XH<9E#9``)%P"='_!^S"?'M,Q8<RV3B5KZ5LJB7T
MCB.X`Z/B`;PIGXO-D*OX+"FQ#7Q&ZLVNILH,MH\3\-P;ZL*R`84EFAN0J+=!
M$U:KOB4JKVQ&_Q$4\QN/RZ7(7'!_"R;/-YB"#]ULOG9+IM0/_7,N!'_%EGE!
M`GRB9L\!9X^(*?771?4DS;T`H5`-?=*;9J:(FX?]>68".J^]Y]R36?[SM[>!
M?E1*7G,QIMB[*+N:VA,]T\0[)@\:X"0=<W9??R(S;<?Z(C^$MF8=]Y9Z.#/!
M6F]!3;AS':I00/R2)ED-.B=F*>Z)8T_&'.4,R2!>O-7FD:!\EO/-0FYA*E=F
MX`/80`,U=!]@K-=",7;?<45M&+*S(!#\A7CK>ZL.V!;ZZ8ZS[`?LA-"=1@OI
MCXKJ[YV!L"GQDHTIR73X&U63IPG^&#`%(EHEP>9!A&(@EEK;>U>R!?'JSKQ]
MX&[</_0P,U]?G+NAO$SSB$31.V,0[]`Z]$>8B]82BAYLWT1HZ(/M$9]/[\GW
M;(LL?+(%S6BH)B!N.!L_@?!3:\TXF'FA_F<LXCG-/1<16&Q.;;&?)VLQMB6;
M1I=8+'RTA5$VUG'^ENHW8/KCYEEKJ@IMKUUR.3P4W-^^Z*!?#3$]`XA>[+B+
MF*;7>%8NH]87^_$3\#A7B0:@H;OXLJP>8`O'5LR:<\/R@&6*1@>1Y,(O[UK'
MNXZ.:[T_6B1\^HVBKK@L+]0KM^#H*>29/:'P@CS.BR^Y;#.(/T]$G^]0*U[,
M6OUX^V)(?@?)"J/6*;B%YH7L2812G1.VE$`5/MG"$>I9/NG5X-#,RD`?)3OG
MS)&+DY-9L]8OOH6V_I<$@DJ^-'G-W?T+-8\V^D3_@@+^_#]02P$"'@,4````
M"`![B`A%ABRWKY.1``"#G`8`$0`8```````!````I($`````8W!I>"TR,#$T
M,#8S,"YX;6Q55`4``SH[Y5-U>`L``00E#@``!#D!``!02P$"'@,4````"`![
MB`A%,Q\_QR`/``#ER```%0`8```````!````I('>D0``8W!I>"TR,#$T,#8S
M,%]C86PN>&UL550%``,Z.^53=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M>X@(1>WHA+\'(```QW`!`!4`&````````0```*2!3:$``&-P:7@M,C`Q-#`V
M,S!?9&5F+GAM;%54!0`#.COE4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`'N("$7KRGFW2&@``$%"!0`5`!@```````$```"D@:/!``!C<&EX+3(P,30P
M-C,P7VQA8BYX;6Q55`4``SH[Y5-U>`L``00E#@``!#D!``!02P$"'@,4````
M"`![B`A%*)=V]Q\]``#KV0(`%0`8```````!````I($Z*@$`8W!I>"TR,#$T
M,#8S,%]P<F4N>&UL550%``,Z.^53=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`>X@(1<;!&(5#"P``H&T``!$`&````````0```*2!J&<!`&-P:7@M,C`Q
M-#`V,S`N>'-D550%``,Z.^53=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*&@(``#9S`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ORGANIZATION AND BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc. and its subsidiaries (the&#160;"Company" or "Cumberland") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland has both internal product development and commercial capabilities. The Company is focused on maximizing the commercial potential of its current brands, as well as expanding its product portfolio through select acquisitions and development of new product candidates.  Cumberland&#8217;s products are manufactured by third parties, which are overseen by the Company&#8217;s quality assurance professionals. The Company works closely with its distribution partners to ensure the delivery and availability of the Company's products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission, or the SEC, and omit certain information and footnote disclosure necessary to present the statements in accordance with U.S. generally accepted accounting principles. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total comprehensive income (loss) was comprised solely of net income (loss) for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Financial Accounting Standards Board (the "FASB") issued amended guidance in the form of a FASB Accounting Standards Update on "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity".  The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomes effective on January 1, 2015. Adoption is on a prospective basis. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued amended guidance in the form of a FASB Accounting Standards Update on, "Revenue from Contracts with Customers".  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process.  The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method by which we will adopt the standard in 2017.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Policies:</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual amounts could differ from those estimated at the time the condensed consolidated financial statements are prepared.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the  allowances for obsolescent or unmarketable inventory.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Operating Segments</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment, specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold.  Substantially all of the Company&#8217;s assets are located in the United States, and total revenues are primarily attributable to U.S.&#160;customers.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">17,660,367<span></span></td>
        <td class="nump">17,985,503<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">17,660,367<span></span></td>
        <td class="nump">17,985,503<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount per share of no-par value common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNoParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Financial Accounting Standards Board (the "FASB") issued amended guidance in the form of a FASB Accounting Standards Update on "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity".  The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomes effective on January 1, 2015. Adoption is on a prospective basis. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued amended guidance in the form of a FASB Accounting Standards Update on, "Revenue from Contracts with Customers".  The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process.  The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method by which we will adopt the standard in 2017.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual amounts could differ from those estimated at the time the condensed consolidated financial statements are prepared.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the  allowances for obsolescent or unmarketable inventory.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Operating Segments</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment, specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold.  Substantially all of the Company&#8217;s assets are located in the United States, and total revenues are primarily attributable to U.S.&#160;customers.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 04, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CUMBERLAND PHARMACEUTICALS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001087294<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,577,699<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of these marketable securities, by level within the fair value hierarchy, as of each period end:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:675px;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="200px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="62px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury notes and bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency issued mortgage-backed securities &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,896,871</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Agency notes and bonds &#8211; fixed rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,747,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SBA loan pools &#8211; variable rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds &#8211; VRDN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,895,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of marketable  securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,692,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,133,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,825,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,724,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EX1AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">$ 9,750,168<span></span></td>
        <td class="nump">$ 7,081,088<span></span></td>
        <td class="nump">$ 17,843,412<span></span></td>
        <td class="nump">$ 17,339,220<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
        <td class="nump">1,298,816<span></span></td>
        <td class="nump">1,154,833<span></span></td>
        <td class="nump">2,352,533<span></span></td>
        <td class="nump">2,263,468<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
        <td class="nump">3,930,082<span></span></td>
        <td class="nump">3,542,049<span></span></td>
        <td class="nump">7,544,013<span></span></td>
        <td class="nump">7,215,988<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">861,154<span></span></td>
        <td class="nump">1,386,904<span></span></td>
        <td class="nump">1,687,527<span></span></td>
        <td class="nump">2,835,622<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">2,140,249<span></span></td>
        <td class="nump">1,855,201<span></span></td>
        <td class="nump">4,037,466<span></span></td>
        <td class="nump">4,430,940<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
        <td class="nump">304,258<span></span></td>
        <td class="nump">282,645<span></span></td>
        <td class="nump">598,213<span></span></td>
        <td class="nump">407,695<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">8,534,559<span></span></td>
        <td class="nump">8,221,632<span></span></td>
        <td class="nump">16,219,752<span></span></td>
        <td class="nump">17,153,713<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
        <td class="nump">1,215,609<span></span></td>
        <td class="num">(1,140,544)<span></span></td>
        <td class="nump">1,623,660<span></span></td>
        <td class="nump">185,507<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">29,544<span></span></td>
        <td class="nump">48,982<span></span></td>
        <td class="nump">96,887<span></span></td>
        <td class="nump">141,359<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(12,278)<span></span></td>
        <td class="num">(20,700)<span></span></td>
        <td class="num">(24,481)<span></span></td>
        <td class="num">(38,435)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
        <td class="nump">1,232,875<span></span></td>
        <td class="num">(1,112,262)<span></span></td>
        <td class="nump">1,696,066<span></span></td>
        <td class="nump">288,431<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
        <td class="num">(523,339)<span></span></td>
        <td class="nump">463,408<span></span></td>
        <td class="num">(711,348)<span></span></td>
        <td class="num">(95,959)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
        <td class="nump">709,536<span></span></td>
        <td class="num">(648,854)<span></span></td>
        <td class="nump">984,718<span></span></td>
        <td class="nump">192,472<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
        <td class="nump">13,034<span></span></td>
        <td class="nump">9,836<span></span></td>
        <td class="nump">24,172<span></span></td>
        <td class="nump">23,219<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
        <td class="nump">722,570<span></span></td>
        <td class="num">(639,018)<span></span></td>
        <td class="nump">1,008,890<span></span></td>
        <td class="nump">215,691<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- basic (in USD per share)</a></td>
        <td class="nump">$ 0.04<span></span></td>
        <td class="num">$ (0.03)<span></span></td>
        <td class="nump">$ 0.06<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- diluted (in USD per share)</a></td>
        <td class="nump">$ 0.04<span></span></td>
        <td class="num">$ (0.03)<span></span></td>
        <td class="nump">$ 0.06<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
        <td class="nump">17,743,395<span></span></td>
        <td class="nump">18,405,522<span></span></td>
        <td class="nump">17,825,174<span></span></td>
        <td class="nump">18,580,891<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
        <td class="nump">18,025,913<span></span></td>
        <td class="nump">18,405,522<span></span></td>
        <td class="nump">18,093,391<span></span></td>
        <td class="nump">18,756,691<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
        <td class="nump">$ 709,536<span></span></td>
        <td class="num">$ (648,854)<span></span></td>
        <td class="nump">$ 984,718<span></span></td>
        <td class="nump">$ 192,472<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingAndMarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHAREHOLDERS&#8217; EQUITY AND DEBT</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May&#160;13, 2010, the Company announced a share repurchase program to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2011, April 2012 and January 2013, the Company's Board of Directors replaced the prior authorizations with new </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> authorizations for repurchases of the Company's outstanding common stock.  During the first six months of </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">340,436</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">676,551</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Grants </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first half of 2014, the Company issued approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">175,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted stock to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one year</font><font style="font-family:inherit;font-size:10pt;"> anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cumberland Emerging Technologies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company received approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Gloria for its participation in Cumberland Emerging Technologies ("CET"). As a result, Gloria received shares in CET and will have the first right to negotiate a license to CET developed products for the Chinese market. Prior to April 2014, Cumberland owned </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of CET, with the balance of the enterprise being owned by Vanderbilt University and the Tennessee Technology Development Corporation.  In connection with Gloria&#8217;s investment in CET, the Company also provided an additional investment in CET.  Cumberland contributed </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and provided </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> in loan foregiveness to CET in exchange for newly issued shares.   Upon completion of the additional investment by Gloria and Cumberland in April 2014, the Company&#8217;s ownership in CET is </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;">. As a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">New Debt Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, Cumberland entered into a Revolving Credit Loan Agreement (&#8220;Loan Agreement&#8221;) with SunTrust Bank. The new agreement replaced the August 2011 Fifth Amended and Restated Loan Agreement (the "Agreement") with its previous primary lender which was to expire on December 31, 2014.   There are no borrowings under the Loan Agreement at June 30, 2014 and it has a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year term expiring on June 26, 2017.  The Loan Agreement provides for an aggregate principal amount up to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">.  The initial revolving line of credit is up to </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;">, an increase from the </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> under the previous Agreement.  Similar to the previous Agreement, Cumberland has the ability to increase the borrowing amount up to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">, upon the satisfaction of certain conditions. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rate on the Loan Agreement is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.85%</font><font style="font-family:inherit;font-size:10pt;">.  In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;"> per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of the Company&#8217;s assets.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Loan Agreement, Cumberland is subject to certain financial covenants, including, but not limited to, maintaining an EBIT to Interest Expense Ratio and a Funded Debt Ratio, as such terms are defined in the Loan Agreement and that are determined on a quarterly basis.  The Company is in compliance with all covenants at June 30, 2014. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred no early termination penalties upon termination of the previous Agreement and incurred less than $0.1 million in deferred financing costs related to the new Loan Agreement, which will be amortized to interest expense using the effective interest method over the term of the Loan Agreement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Previous Debt Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2011 Fifth Amended and Restated Loan Agreement carried an interest rate of the LIBOR Daily Floating Rate plus an applicable margin, as defined by the agreement (</font><font style="font-family:inherit;font-size:10pt;">2.17%</font><font style="font-family:inherit;font-size:10pt;"> at December&#160;31, 2013). Interest and an unused line of credit fee (</font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per annum) were payable quarterly. There were no borrowings outstanding on the credit facility at December 31, 2013 or at any time during 2014.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the previous Agreement, the Company was subject to certain financial covenants including, but not limited to, maintaining a leverage ratio and interest coverage ratio, as defined in the Agreement.  In March&#160;2014 and May 2014, the previous Agreement was amended for certain provisions related to the aggregate ownership of the Company's common stock over 30% and certain other financial covenants.  As of March&#160;31, 2014 and December 31, 2013, the Company was in compliance with all covenants.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_EquityAndDebtAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVENTORIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor inventory on hand at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> had varying original expiration dates that began in the second quarter of 2014 and extend through January 2016. During 2013, the Company provided stability data to the Food and Drug Administration ("FDA") supporting that the Caldolor product expiration dates may be extended by up to a year.  In January 2014, the FDA notified the Company that it had approved its request to extend the original shelf life of the Caldolor 800mg vials from </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company has recognized cumulative charges for potential obsolescence and discontinuance losses, primarily for Caldolor, of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. If actual sales in future periods are less than projected sales, the Company may incur additional obsolescence losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient for Kristalose and maintains the inventory at the third-party manufacturer. As the ingredients are consumed in production, the value of the ingredients is transferred from raw materials to finished goods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, inventory was comprised of the following: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,228,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,697,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,996,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPGBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Marketable Securities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">$ 14,825,632<span></span></td>
        <td class="nump">$ 14,019,761<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. Treasury notes and bonds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">1,857,533<span></span></td>
        <td class="nump">2,829,809<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. Agency issued mortgage-backed securities &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">3,896,871<span></span></td>
        <td class="nump">3,049,754<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. Agency notes and bonds &#x2013; fixed rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">2,747,151<span></span></td>
        <td class="nump">1,496,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">SBA loan pools &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">1,489,077<span></span></td>
        <td class="nump">1,748,498<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Municipal bonds &#x2013; VRDN</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">4,835,000<span></span></td>
        <td class="nump">4,895,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">6,692,533<span></span></td>
        <td class="nump">7,724,809<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 | U.S. Treasury notes and bonds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">1,857,533<span></span></td>
        <td class="nump">2,829,809<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 | U.S. Agency issued mortgage-backed securities &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 | U.S. Agency notes and bonds &#x2013; fixed rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 | SBA loan pools &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 | Municipal bonds &#x2013; VRDN</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">4,835,000<span></span></td>
        <td class="nump">4,895,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">8,133,099<span></span></td>
        <td class="nump">6,294,952<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 | U.S. Treasury notes and bonds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 | U.S. Agency issued mortgage-backed securities &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">3,896,871<span></span></td>
        <td class="nump">3,049,754<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 | U.S. Agency notes and bonds &#x2013; fixed rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">2,747,151<span></span></td>
        <td class="nump">1,496,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 | SBA loan pools &#x2013; variable rate</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">1,489,077<span></span></td>
        <td class="nump">1,748,498<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 | Municipal bonds &#x2013; VRDN</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of marketable securities, by type</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TradingSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles the numerator and denominator used to calculate diluted earnings per share for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">722,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(639,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,743,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,025,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,405,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="441px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="102px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="103px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,825,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,580,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding &#8211; diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,093,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,756,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received notices during 2012 and 2013, that its Acetadote patents are being challenged on the basis of invalidity or non-infringement by others.&#160; The Company is continuing to seek additional claims to protect its intellectual property associated with Acetadote and have additional pending patent applications relating to Acetadote.  The Company continues to consider its legal options and intends to continue to vigorously defend and protect its Acetadote product and related intellectual property rights.&#160; Also see the discussion of the Company's Acetadote patent defense legal proceedings contained in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Part 1, Item 1, Business -Trademarks and Patents</font><font style="font-family:inherit;font-size:10pt;">, of the Company's Form 10-K for the year ended December&#160;31, 2013, which is incorporated by reference herein.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is unable to successfully defend the Acetadote patents and related intellectual property rights associated with its Acetadote product, its financial condition and results of operations could be adversely affected in the event of a loss of patent rights and lower sales volumes due to competition.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company has unrecognized net operating loss carryforwards generated from the exercise of nonqualified options of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;">. These benefits occurred as a result of the actual tax benefit realized upon an employee's exercise exceeding the cumulative book compensation charge associated with the awards and will be recognized in the year in which they are able to reduce current income taxes payable.  Accordingly, deferred tax assets are not recognized for these net operating loss carryforwards or credit carryforwards resulting from the exercise of nonqualified options.  The Company's utilization of these net operating loss carryforwards and a net operating loss in 2013 resulted in it paying minimal income taxes in each of the years 2009 through 2013.  The Company expects to pay minimal income taxes in 2014 through utilization of these net operating loss carryforwards.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COLLABORATIVE AGREEMENTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration (SBIR/STTR) grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from private sector investments and grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>New Products<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">NEW PRODUCTS</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEW PRODUCTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Omeclamox-Pak</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2013, the Company entered into an agreement with Pernix to distribute and promote Omeclamox-Pak. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:10pt;">) infection and duodenal ulcer disease. Under the terms of the agreement, the Company promotes the product to gastroenterologists across the United States and Pernix promotes the product through its specialty sales force focusing on select primary care physicians. The companies cooperate in the marketing and other activities needed to support the commercialization of the brand. The Company paid an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Pernix on October 29, 2013.  There are additional milestones at the first and second anniversary dates of the execution of the agreement totaling </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate. Royalty payments ranging from </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> based on tiered levels of gross profits are paid by Cumberland to Pernix.  The Company also makes royalty payments to Pernix to reflect their ongoing sales promotional efforts.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment that the Company paid to Pernix on October 29, 2013 is included in product and license rights and will be amortized over the remaining expected useful life of the acquired asset, currently the life of the agreement, which ends in June 2032.  Omeclamox-Pak contributed </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">  and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> in net revenues during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vaprisol</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 28, 2014, the Company acquired certain product rights, intellectual property and related assets of Vaprisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">  </sup></font><font style="font-family:inherit;font-size:10pt;">from Astellas. Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia.  The Company provided an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Astellas at closing. There is an additional milestone payment due forty-five days after the first anniversary date of the closing of the transaction of up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, dependent upon Cumberland achieving certain first year sales levels for the product.  Cumberland's acquisition of Vaprisol is accounted for as a business combination and the product is included in the results of operations since the acquisition date. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary allocation of the fair values of the assets acquired and liabilities assumed as of the acquisition date for Vaprisol:</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="569px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="95px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,990,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent consideration obligation represents the additional milestone payment discussed above.  Cumberland prepared the valuations of the contingent consideration obligation and the intangible assets utilizing significant unobservable inputs. As a result, the valuations are classified as Level 3 fair value measurements.  Vaprisol contributed </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> in net revenues during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The pro-forma effects of the acquisition on the condensed consolidated financial statements were not material for disclosure.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6996-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7000-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECDAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>New Products New Products - Narrative (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Omeclamox-Pak</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Omeclamox-Pak</div>
        </th>
        <th class="th">
          <div>Oct. 29, 2013

</div>
          <div>Omeclamox-Pak</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Vaprisol</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Vaprisol</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014

</div>
          <div>Vaprisol</div>
        </th>
        <th class="th">
          <div>Oct. 29, 2013

</div>
          <div>Minimum

</div>
          <div>Omeclamox-Pak</div>
        </th>
        <th class="th">
          <div>Oct. 29, 2013

</div>
          <div>Maximum

</div>
          <div>Omeclamox-Pak</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationUpfrontPayment', window );">Upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationAggregateUpfrontPayments', window );">Additional upfront payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage', window );">Royalty payments based on percentage over gross profits</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">$ 9,750,168<span></span></td>
        <td class="nump">$ 7,081,088<span></span></td>
        <td class="nump">$ 17,843,412<span></span></td>
        <td class="nump">$ 17,339,220<span></span></td>
        <td class="nump">$ 1,344,869<span></span></td>
        <td class="nump">$ 2,484,290<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,071,433<span></span></td>
        <td class="nump">$ 1,369,765<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationAggregateUpfrontPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination, Aggregate Upfront Payments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_BusinessCombinationAggregateUpfrontPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination, Upfront Payment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_BusinessCombinationUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, inventory was comprised of the following: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,228,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,697,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,996,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,722,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenues (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">$ 9,750,168<span></span></td>
        <td class="nump">$ 7,081,088<span></span></td>
        <td class="nump">$ 17,843,412<span></span></td>
        <td class="nump">$ 17,339,220<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Acetadote</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">3,063,819<span></span></td>
        <td class="nump">4,146,974<span></span></td>
        <td class="nump">5,784,905<span></span></td>
        <td class="nump">11,398,968<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Kristalose</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">3,559,313<span></span></td>
        <td class="nump">2,041,043<span></span></td>
        <td class="nump">6,935,370<span></span></td>
        <td class="nump">4,158,293<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Caldolor</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">626,684<span></span></td>
        <td class="nump">615,547<span></span></td>
        <td class="nump">1,129,082<span></span></td>
        <td class="nump">1,025,971<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenues</a></td>
        <td class="nump">$ 84,050<span></span></td>
        <td class="nump">$ 277,524<span></span></td>
        <td class="nump">$ 140,000<span></span></td>
        <td class="nump">$ 755,988<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_ProductsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EARAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
        <td class="nump">$ 984,718<span></span></td>
        <td class="nump">$ 192,472<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">800,231<span></span></td>
        <td class="nump">610,052<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">65,413<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">325,344<span></span></td>
        <td class="nump">305,199<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess tax benefit derived from exercise of stock options</a></td>
        <td class="num">(711,348)<span></span></td>
        <td class="num">(15,288)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
        <td class="nump">12,038<span></span></td>
        <td class="nump">12,038<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment losses</a></td>
        <td class="nump">181,950<span></span></td>
        <td class="nump">62,323<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities, net of effect of business combination:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(1,484,052)<span></span></td>
        <td class="nump">2,046,259<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="nump">136,039<span></span></td>
        <td class="nump">124,061<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
        <td class="nump">2,165,828<span></span></td>
        <td class="num">(1,707,560)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
        <td class="nump">109,244<span></span></td>
        <td class="nump">37,479<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
        <td class="num">(701,604)<span></span></td>
        <td class="nump">59,877<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
        <td class="nump">1,818,388<span></span></td>
        <td class="nump">1,792,325<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
        <td class="num">(48,239)<span></span></td>
        <td class="num">(69,119)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
        <td class="num">(3,254,903)<span></span></td>
        <td class="num">(4,371,508)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
        <td class="nump">2,267,082<span></span></td>
        <td class="nump">1,481,682<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Cash paid for acquisitions</a></td>
        <td class="num">(2,000,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
        <td class="num">(732,072)<span></span></td>
        <td class="num">(1,829,693)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investment activities</a></td>
        <td class="num">(3,768,132)<span></span></td>
        <td class="num">(4,788,638)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Net borrowings on line of credit</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(41,292)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess tax benefit derived from exercise of stock options</a></td>
        <td class="nump">711,348<span></span></td>
        <td class="nump">15,288<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit', window );">Sale of subsidiary shares to noncontrolling interest</a></td>
        <td class="nump">1,000,005<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
        <td class="num">(1,580,225)<span></span></td>
        <td class="num">(3,162,302)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump">131,128<span></span></td>
        <td class="num">(1,688,306)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
        <td class="num">(1,818,616)<span></span></td>
        <td class="num">(4,684,619)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">40,869,457<span></span></td>
        <td class="nump">54,349,381<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">39,050,841<span></span></td>
        <td class="nump">49,664,762<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Net change in unpaid additions to intangibles, property and equipment</a></td>
        <td class="nump">$ 450,781<span></span></td>
        <td class="nump">$ 249,633<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase (Decrease) in Current Operating Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_IncreaseDecreaseInCurrentOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForPreviousAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -Subparagraph c<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow resulting from the sale of an interest in a corporate unit during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfInterestInCorporateUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenues<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVENUES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s net revenues consisted of the following for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acetadote</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,063,819</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,974</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,784,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,398,968</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omeclamox-Pak</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,344,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristalose</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,559,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,041,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,935,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,158,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vaprisol</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626,684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,547</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,129,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,750,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081,088</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,843,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,339,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 10, the Company acquired rights to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> new products and both Omeclamox-Pak and Vaprisol contributed to Cumberland's net revenue during 2014. On October 28, 2013, Cumberland entered into an agreement with Pernix Therapeutics ("Pernix") to distribute and promote Omeclamox-Pak. Under the terms of the agreement, effective October 1, 2013, the Company began to record the revenue of this product and effective January 2014 Cumberland began distributing Omeclamox-Pak and promoting it to gastroenterologists across the United States.  On February 28, 2014, Cumberland entered into an agreement with Astellas Pharma US, Inc. ("Astellas") to acquire certain product rights, intellectual property and related assets of Vaprisol. The Company began selling Vaprisol in March 2014 and launched promotional efforts for the brand in May 2014.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2012, the Company entered into a settlement agreement with Paddock Laboratories, LLC ("Paddock") and Perrigo Company ("Perrigo") involving an Acetadote patent.  As part of the agreement, Cumberland supplies Perrigo with an Authorized Generic version of the Company's Acetadote product.  The Company's revenue generated by sales of it's Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">second quarter of 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> agreements for the registration and commercialization of Caldolor outside the United States and amended its agreement with Harbin Gloria Pharmaceuticals Co., Ltd ("Gloria") to extend Gloria's territory.  Earlier in </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> agreements with international partners for commercialization of certain of its products into additional international territories. As a result of these agreements, Cumberland recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of non-refundable up-front payments as other revenue in the consolidated statement of operations during the first half of </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the full year of 2013, the Company entered into a total of </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> new agreements and amended </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> agreement with international partners.  The agreements entered into during 2013 provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, will handle ongoing distribution and sales in the respective international territories.  The Company maintains responsibility for the intellectual property and product formulation.  Under the licensing agreements, Cumberland is entitled to receive additional milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company will recognize revenue for these substantive milestones using the milestone method. The 2013 agreements provide for up to  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone payments related to regulatory approvals and up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone payments related to total and annual product sales. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, Cumberland has not recognized any revenues related to milestones associated with the new agreements.  The Company is also entitled to receive royalties on future sales of the products under the agreements.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5BAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenues (Details Textual) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">6 Months Ended</th>
        <th class="th" colspan="3"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>product_line</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>agreement</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Acetadote, Generic</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Acetadote, Generic</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Acetadote, Generic</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Acetadote, Generic</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners

</div>
          <div>agreement</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners

</div>
          <div>agreement</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Maximum

</div>
          <div>Receipt of regulatory notice on approval</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Maximum

</div>
          <div>Payments based on total and annual product sales</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenuesTextualAbstract', window );"><strong>Revenues (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumberofProductLinesAcquired', window );">Number of product lines acquired</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Share of product revenue from generic sales</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.8<span></span></td>
        <td class="nump">$ 2.1<span></span></td>
        <td class="nump">$ 3.2<span></span></td>
        <td class="nump">$ 5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets', window );">Number of agreements with international partners for commercialization in international markets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Revenue recognized from license agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone', window );">Other revenues, milestone method, future revenue upon achieving milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.6<span></span></td>
        <td class="nump">$ 4.0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumberofProductLinesAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of Product Lines Acquired</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_NumberofProductLinesAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue, Number of Agreements with International Partners for Commercialization in International Markets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_RevenueNumberOfAgreementsWithInternationalPartnersForCommercializationInInternationalMarkets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognition, Milestone Method, Future Revenue Earned Upon Achieving MIlestone</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenuesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cpix_RevenuesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cpix_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>102</ContextCount>
  <ElementCount>142</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementOfEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Equity (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - New Products</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/NewProducts</Role>
      <ShortName>New Products</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationAndBasisOfPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - New Products (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/NewProductsTables</Role>
      <ShortName>New Products (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesDetailsTextual</Role>
      <ShortName>Inventories (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt  (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityAndDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - New Products Assets and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/NewProductsAssetsAndLiabilitiesAssumedDetails</Role>
      <ShortName>New Products Assets and Liabilities Assumed (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - New Products New Products - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/NewProductsNewProductsNarrativeDetails</Role>
      <ShortName>New Products New Products - Narrative (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_StockRepurchasedDuringPeriodValue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '2411403 - Disclosure - New Products New Products - Narrative (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 1003000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>cpix-20140630.xml</File>
    <File>cpix-20140630.xsd</File>
    <File>cpix-20140630_cal.xml</File>
    <File>cpix-20140630_def.xml</File>
    <File>cpix-20140630_lab.xml</File>
    <File>cpix-20140630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s net revenues consisted of the following for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acetadote</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,063,819</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,974</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,784,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,398,968</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omeclamox-Pak</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,344,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,484,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kristalose</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,559,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,041,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,935,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,158,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vaprisol</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,071,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626,684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,547</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,129,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,750,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081,088</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,843,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,339,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
